{
  "search_results": {
    "-count": "335",
    "query": "Prostate Cancer | United Kingdom | Studies with Male Participants",
    "study": [
      {
        "-rank": "1",
        "nct_id": "NCT03857477",
        "title": "The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.",
        "acronym": "BARCODE1",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Genetic",
              "#text": "Genetic SNP profiling"
            },
            {
              "-type": "Other",
              "#text": "Prostate cancer screening"
            },
            {
              "-type": "Procedure",
              "#text": "MRI Scan"
            },
            {
              "-type": "Procedure",
              "#text": "Prostate biopsy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Association of SNP genetic risk score with prostate biopsy results.",
            "Incidence and aggressiveness of PrCa in men within the top 10% of the genetic score.",
            "Association of the biomarker profile with genetic score and biopsy results.",
            "Use of genetic profiling to target prostate cancer screening in a clinical environment."
          ]
        },
        "sponsors": { "lead_sponsor": "Institute of Cancer Research, United Kingdom" },
        "gender": "Male",
        "min_age": "55 Years",
        "max_age": "69 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "4700",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Control",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "CCR5044" },
        "start_date": "March 14, 2019",
        "primary_completion_date": "March 1, 2020",
        "completion_date": "January 1, 2021",
        "study_first_posted": "February 28, 2019",
        "last_update_posted": "September 4, 2019",
        "locations": { "location": "Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03857477"
      },
      {
        "-rank": "2",
        "nct_id": "NCT01105338",
        "title": "Lycopene or Green Tea for Men at Risk of Prostate Cancer",
        "acronym": "ProDiet",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Behavioral",
              "#text": "Green tea drink"
            },
            {
              "-type": "Dietary Supplement",
              "#text": "green tea capsules"
            },
            {
              "-type": "Other",
              "#text": "Green tea placebo capsules"
            },
            {
              "-type": "Dietary Supplement",
              "#text": "Lycopene capsules"
            },
            {
              "-type": "Other",
              "#text": "Lycopene placebo capsules"
            },
            {
              "-type": "Other",
              "#text": "Tomato rich diet"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Serum lycopene and epigallocatechin-3-gallate (green tea) levels at 6 months following randomization",
            "Trial recruitment and randomization rates at each stage of the study",
            "Intervention tolerability (adverse event reporting during the six months of follow-up)",
            "Compliance (returned tablet counts and self-reported counts at 6 months)",
            "Trial retention (participants completing 6-month follow-up and questionnaires)",
            "PSA values at baseline and at 6 months",
            "Dietary compliance with recommendations (dietary questionnaire completed at 6 months and participant data reporting dietary change)",
            "Weight and body mass index at 1 and 6 months",
            "Blood pressure at 1 and 6 months",
            "Attitudes and views of men and their spouses about dietary modification and participation in long-term study (qualitative interviews conducted throughout the study)",
            "Anxiety, depression, and psychological state as measured by the Hospital Anxiety and Depression Scale and the Profile of Moods States",
            "Urinary symptoms as measured by the ICSmaleSF questionnaire (including voiding and incontinence scores, nocturia, frequency, and urinary-specific quality-of-life care data sources)"
          ]
        },
        "sponsors": { "lead_sponsor": "University of Bristol" },
        "gender": "Male",
        "min_age": "50 Years",
        "max_age": "69 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 2",
            "Phase 3"
          ]
        },
        "enrollment": "126",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Factorial Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "C11046/A10052",
            "ISRCTN-95931417"
          ]
        },
        "start_date": "August 2009",
        "primary_completion_date": "August 2010",
        "completion_date": "August 2010",
        "study_first_posted": "April 16, 2010",
        "last_update_posted": "January 23, 2018",
        "locations": { "location": "Southmead Hospital, Bristol, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01105338"
      },
      {
        "-rank": "3",
        "nct_id": "NCT01737242",
        "title": "UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies",
        "acronym": "UKGPCS",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "outcome_measures": { "outcome_measure": "To find genes which predispose to PrCa" },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": [
            "Cancer Research UK",
            "Royal Marsden NHS Foundation Trust"
          ]
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "26000",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Only",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": {
          "other_id": [
            "06/MRE02/4",
            "CCR0848"
          ]
        },
        "start_date": "January 1993",
        "primary_completion_date": "December 2022",
        "completion_date": "December 2022",
        "study_first_posted": "November 29, 2012",
        "last_update_posted": "September 4, 2019",
        "locations": { "location": "Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01737242"
      },
      {
        "-rank": "4",
        "nct_id": "NCT03658486",
        "title": "Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial",
        "acronym": "EXACT",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer Metastatic",
            "Castration-resistant Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "Exercise"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Feasibility - recruitment.",
            "Feasibility - adherence to the exercise intervention.",
            "Feasibility - attrition rates.",
            "Feasibility - safety / adverse events.",
            "Feasibility - patient experience.",
            "Anthropometric assessment.",
            "Hip and waist circumference analysis.",
            "Functional ability assessment.",
            "Physical fitness assessment.",
            "Objectively measure of physical activity levels.",
            "Perceived physical activity levels.",
            "Cancer-related fatigue by questionnaire.",
            "Quality of life will be measured using a questionnaire.",
            "Quality of life will be measured using questionnaires.",
            "Pain will be measured through a questionnaire."
          ]
        },
        "sponsors": {
          "lead_sponsor": "Queen's University, Belfast",
          "collaborator": "HSC Public Health Agency"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "30",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Other"
          ]
        },
        "other_ids": { "other_id": "B18/15" },
        "start_date": "February 19, 2019",
        "primary_completion_date": "October 2021",
        "completion_date": "October 2021",
        "study_first_posted": "September 5, 2018",
        "last_update_posted": "April 5, 2019",
        "locations": { "location": "Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03658486"
      },
      {
        "-rank": "5",
        "nct_id": "NCT01132599",
        "title": "Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Withdrawn"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Dietary Supplement",
              "#text": "C-11 choline"
            },
            {
              "-type": "Radiation",
              "#text": "18F-fluoromethylcholine"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Identification of a true 5% difference in lesion detection using 18F-fluoromethylcholine versus C-11 choline",
            "Identification of a true 5% difference in lesion detection between the best early-phase scanning, using either the 18F-fluoromethylcholine and C-11 choline, and late-phase scanning using 18F-fluoromethylcholine",
            "Causality of each adverse event to C-11 choline and 18F-fluoromethylcholine and adverse event severity according to NCI CTCAE version 4.0"
          ]
        },
        "sponsors": { "lead_sponsor": "Cancer Research UK" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "0",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000674024",
            "CRUK-CR0701-21",
            "EUDRACT-2008-004828-23"
          ]
        },
        "start_date": "May 2010",
        "primary_completion_date": "June 2011",
        "study_first_posted": "May 28, 2010",
        "last_update_posted": "February 28, 2012",
        "locations": { "location": "St. Thomas' Hospital, London, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01132599"
      },
      {
        "-rank": "6",
        "nct_id": "NCT01193855",
        "title": "Dutasteride in Treating Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "dutasteride"
            },
            {
              "-type": "Drug",
              "#text": "gadolinium-chelate"
            },
            {
              "-type": "Other",
              "#text": "active surveillance"
            },
            {
              "-type": "Procedure",
              "#text": "diffusion-weighted magnetic resonance imaging"
            },
            {
              "-type": "Procedure",
              "#text": "functional magnetic resonance imaging"
            },
            {
              "-type": "Procedure",
              "#text": "prostate biopsy"
            },
            {
              "-type": "Procedure",
              "#text": "ultrasound imaging"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "The change in volume of foci of prostate cancer (PC) as assessed by T2-weighted (T2w) MRI between baseline and 6 months",
            "The change in volume of PC as determined by gadolinium-enhanced (GE) MRI and diffusion-weighted (DW) MRI at 6 months",
            "The change in volume of PC as determined by T2w MRI, GE MRI, and DW MRI at 3 months",
            "The changes in MR characteristics of PC (perfusion, cell density) between baseline and 6 months",
            "The change in volume of PC as assessed by HistoScan transrectal ultrasound (TRUS) between baseline and 6 months",
            "The association between the measured PC volumes on MRI with the measured PC volumes on TRUS at baseline and 6 months",
            "The association between the measured changes in PC volume using MRI vs TRUS at baseline and 6 months",
            "The association of PC volume change with qualitative changes seen on TRUS between baseline and 6 months",
            "The association between MR changes in volume and characteristics with histological features as seen on 6-month biopsy (Gleason score and sum, number of cores involved, cancer core length)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University College London Hospitals",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "42",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Masking: Double",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000684018",
            "UCL-09-0221",
            "EUDRACT-2009-012405-18",
            "EU-21067"
          ]
        },
        "start_date": "June 2010",
        "primary_completion_date": "January 2012",
        "study_first_posted": "September 2, 2010",
        "last_update_posted": "August 26, 2013",
        "locations": { "location": "University College of London Hospitals, London, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01193855"
      },
      {
        "-rank": "7",
        "nct_id": "NCT00758173",
        "title": "Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Genetic",
              "#text": "polymorphism analysis"
            },
            {
              "-type": "Other",
              "#text": "laboratory biomarker analysis"
            },
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Acquisition of epidemiological information and biological material",
            "Identification of novel cancer susceptibility genes",
            "Estimation of the age and sex-specific risks associated with variants in predisposition genes",
            "Evaluation interactions between polymorphisms in predisposition genes and potential lifestyle risk factors"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Cancer Research UK",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "74 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "2000",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "other_ids": {
          "other_id": [
            "CDR0000589199",
            "MREC-SEARCH-PROSTATE"
          ]
        },
        "start_date": "February 2008",
        "study_first_posted": "September 23, 2008",
        "last_update_posted": "August 26, 2013",
        "locations": { "location": "University of Cambridge Cancer Research UK, Cambridge, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00758173"
      },
      {
        "-rank": "8",
        "nct_id": "NCT00967889",
        "title": "Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Genetic",
              "#text": "gene expression analysis"
            },
            {
              "-type": "Genetic",
              "#text": "protein analysis"
            },
            {
              "-type": "Other",
              "#text": "biologic sample preservation procedure"
            },
            {
              "-type": "Other",
              "#text": "laboratory biomarker analysis"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Molecular pathology and mechanisms of disease progression",
            "Development of novel treatment strategies for patients with advanced prostate cancer",
            "Evaluation of novel markers and treatment and epidemiological approaches"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Cancer Research UK",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "other_ids": {
          "other_id": [
            "CRUK-ProMPT",
            "CDR0000638974",
            "EU-20919"
          ]
        },
        "start_date": "January 2002",
        "primary_completion_date": "June 2011",
        "study_first_posted": "August 28, 2009",
        "last_update_posted": "August 12, 2013",
        "locations": { "location": "Cancer Research UK at Cambridge Research Institute, Cambridge, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00967889"
      },
      {
        "-rank": "9",
        "nct_id": "NCT03365297",
        "title": "Therapeutics in Active Prostate Cancer Surveillance",
        "acronym": "TAPS01",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Apalutamide"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Physiological Response",
            "Patient Reported Outcomes",
            "Adverse Events"
          ]
        },
        "sponsors": {
          "lead_sponsor": "CCTU- Cancer Theme",
          "collaborator": [
            "Janssen-Cilag Ltd.",
            "Cambridge University Hospitals NHS Foundation Trust"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "10",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "TAPS01",
            "2017-001700-29"
          ]
        },
        "start_date": "June 5, 2018",
        "primary_completion_date": "September 5, 2019",
        "completion_date": "June 5, 2020",
        "study_first_posted": "December 7, 2017",
        "last_update_posted": "June 6, 2018",
        "locations": { "location": "Cambridge University Hospitals NHS Foundation Trust/Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03365297"
      },
      {
        "-rank": "10",
        "nct_id": "NCT01950143",
        "title": "Effect of Sulforaphane on Prostate CAncer PrEvention",
        "acronym": "ESCAPE",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Dietary Supplement",
              "#text": "Standard broccoli soup"
            },
            {
              "-type": "Dietary Supplement",
              "#text": "Beneforte broccoli soup"
            },
            {
              "-type": "Dietary Supplement",
              "#text": "Beneforte extra broccoli soup"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "global gene expression",
            "metabolite concentration"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Quadram Institute Bioscience",
          "collaborator": [
            "Prostate Cancer Foundation",
            "Biotechnology and Biological Sciences Research Council"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "61",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Prevention"
          ]
        },
        "other_ids": {
          "other_id": [
            "IFR01-2013",
            "14482"
          ]
        },
        "start_date": "August 2013",
        "primary_completion_date": "October 2016",
        "completion_date": "October 31, 2017",
        "study_first_posted": "September 25, 2013",
        "last_update_posted": "March 29, 2018",
        "locations": { "location": "Norfolk and Norwich University Hospital, Norwich, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01950143"
      },
      {
        "-rank": "11",
        "nct_id": "NCT01098331",
        "title": "Implant Radiation Therapy or Surgery in Treating Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "counseling intervention"
            },
            {
              "-type": "Other",
              "#text": "educational intervention"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            },
            {
              "-type": "Procedure",
              "#text": "therapeutic conventional surgery"
            },
            {
              "-type": "Radiation",
              "#text": "iodine I 125"
            },
            {
              "-type": "Radiation",
              "#text": "palladium Pd 103"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Proportion of patients consenting to the treatment randomization",
            "Feasibility of randomization in terms of average accrual rate per center during the last 6 months of recruitment",
            "Decisional quality post-treatment",
            "Compliance with allocated treatment",
            "Clinical failure",
            "PSA relapse",
            "Patient-reported quality of life",
            "Toxicity"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University Hospital Southampton NHS Foundation Trust",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "400",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Masking: None (Open Label)"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000668741",
            "USCTU-SABRE1",
            "ISRCTN88144169",
            "EU-21018",
            "CRUK-CTAAC-C328/A8692",
            "NCRN-11061813"
          ]
        },
        "start_date": "May 2009",
        "primary_completion_date": "November 2011",
        "study_first_posted": "April 2, 2010",
        "last_update_posted": "February 21, 2011",
        "locations": { "location": "Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01098331"
      },
      {
        "-rank": "12",
        "nct_id": "NCT01492270",
        "title": "Imaging for Significant Prostate Cancer Risk Evaluation",
        "acronym": "PICTURE",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Procedure",
              "#text": "Prostate HistoScanning"
            },
            {
              "-type": "Procedure",
              "#text": "Multi-parametric MRI"
            },
            {
              "-type": "Procedure",
              "#text": "Transperineal prostate mapping biopsy"
            },
            {
              "-type": "Procedure",
              "#text": "Image guided biopsies"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of men who could avoid repeat biopsy as determined by the Negative predictive value and specificity of mp-MRI for Clinically significant disease.",
            "Number of men who could avoid repeat biopsy as determined by the negative predictive value and specificity of Prostate HistoScanning for Clinically significant disease.",
            "Proportion of men correctly identified as having no cancer on Imaging (mp-MRI and Prostate HistoScanning)",
            "Number of men correctly identified by Imaging (mp-MRI and Prostate HistoScanning) to have CLINICALLY SIGNIFICANT disease",
            "Test- retest reproducibility of Prostate HistoScanningâ„¢.",
            "Proportion of patients with correct disease risk stratification using MRI/US guided biopsies as determined by sensitivity and specificity",
            "Number of patients with bothersome Lower Urinary tract symptoms following Transperineal Template Mapping biopsy",
            "Number of patients with worsened erectile function compared to baseline following Transperineal Template Mapping biopsy"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University College London Hospitals",
          "collaborator": "Advanced Medical Diagnostics s.a."
        },
        "gender": "Male",
        "min_age": "20 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "126",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "11/LO/1657" },
        "start_date": "December 2011",
        "primary_completion_date": "July 2013",
        "completion_date": "July 2013",
        "study_first_posted": "December 14, 2011",
        "last_update_posted": "December 30, 2011",
        "locations": { "location": "University College London Hospitals, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01492270"
      },
      {
        "-rank": "13",
        "nct_id": "NCT00987675",
        "title": "High-Intensity Focused Ultrasound Ablation in Treating Patients With Progressive Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "pharmacological study"
            },
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            },
            {
              "-type": "Procedure",
              "#text": "assessment of therapy complications"
            },
            {
              "-type": "Procedure",
              "#text": "high-intensity focused ultrasound ablation"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Side effects and patient-reported quality of life after treatment as measured by IPSS, IPSS-QOL, ICS, FACT-P, and IIEF-5 questionnaires at baseline, 6 weeks, and 3, 6, 9 and 12 months",
            "Success of treatment as demonstrated by the absence of cancer at 6 months",
            "PSA kinetics after completion of treatment",
            "Proportion of patients requiring androgen blockade at 12 months"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University College London Hospitals",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "26",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": { "study_design": "Primary Purpose: Treatment" },
        "other_ids": {
          "other_id": [
            "CDR0000650138",
            "UCLH-09-H0714-7"
          ]
        },
        "start_date": "July 2009",
        "primary_completion_date": "July 2011",
        "study_first_posted": "October 1, 2009",
        "last_update_posted": "August 26, 2013",
        "locations": { "location": "University College Hospital, London, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00987675"
      },
      {
        "-rank": "14",
        "nct_id": "NCT00967954",
        "title": "Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "antiandrogen therapy"
            },
            {
              "-type": "Drug",
              "#text": "releasing hormone agonist therapy"
            },
            {
              "-type": "Genetic",
              "#text": "DNA analysis"
            },
            {
              "-type": "Genetic",
              "#text": "RNA analysis"
            },
            {
              "-type": "Genetic",
              "#text": "comparative genomic hybridization"
            },
            {
              "-type": "Genetic",
              "#text": "gene expression analysis"
            },
            {
              "-type": "Other",
              "#text": "laboratory biomarker analysis"
            },
            {
              "-type": "Procedure",
              "#text": "diffusion-weighted magnetic resonance imaging"
            },
            {
              "-type": "Procedure",
              "#text": "magnetic resonance spectroscopic imaging"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Identification of molecular and pathophysiological changes",
            "Functional imaging as a non-invasive tool to measure treatment response",
            "Development of clinical models to predict tumor response"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Cancer Research UK",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "120",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000639017",
            "CRUK-CHIRRP",
            "EU-20920"
          ]
        },
        "start_date": "September 2008",
        "primary_completion_date": "August 2013",
        "study_first_posted": "August 28, 2009",
        "last_update_posted": "January 10, 2014",
        "locations": { "location": "Cancer Research UK at Cambridge Research Institute, Cambridge, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00967954"
      },
      {
        "-rank": "15",
        "nct_id": "NCT03967080",
        "title": "Adaptive Radiotherapy for High-risk Prostate Cancer Using Multiparametric MRI",
        "acronym": "ARPC-MRI",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "outcome_measures": {
          "outcome_measure": [
            "Reproducability of DW-MRI",
            "Reproducibility of DCE-MRI",
            "MP-MRI Response Correlation",
            "Assessment of adapted dosimetry",
            "Assessment of cell kill",
            "Tumour response prediction"
          ]
        },
        "sponsors": { "lead_sponsor": "East and North Hertfordshire NHS Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "15",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "RD2018-46" },
        "start_date": "February 5, 2019",
        "primary_completion_date": "March 31, 2020",
        "completion_date": "September 30, 2020",
        "study_first_posted": "May 30, 2019",
        "last_update_posted": "June 21, 2019",
        "locations": { "location": "East and North Hertfordshire NHS Trust, Northwood, Middlesex, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03967080"
      },
      {
        "-rank": "16",
        "nct_id": "NCT01177865",
        "title": "Study of Treatment Choice in Patients With Localized Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "informational intervention"
            },
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Preferences for, and trade-offs between, the attributes of pre-treatment evaluation with general anaesthetic biopsies and post-treatment frequency of biopsies",
            "Treatment choice in respect to risks to sexual function and urinary function, return to normal activities, aim to treat the whole gland or only cancer areas or important cancer areas, retreatment rate, and mortality rate",
            "Correlation between attributes important to men and baseline demographics, functional status, and disease risk characteristics"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University College London Hospitals",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "min_age": "45 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "432",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": { "study_design": "Primary Purpose: Health Services Research" },
        "other_ids": {
          "other_id": [
            "CDR0000682206",
            "UCL-COMPARE",
            "EU-21055"
          ]
        },
        "start_date": "September 2010",
        "primary_completion_date": "September 2012",
        "study_first_posted": "August 9, 2010",
        "last_update_posted": "August 26, 2013",
        "locations": { "location": "University College of London Hospitals, London, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01177865"
      },
      {
        "-rank": "17",
        "nct_id": "NCT01006564",
        "title": "Multifunctional Magnetic Resonance (MR) for Radiotherapy Planning in Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "Imaging Investigations (not radiation)"
            },
            {
              "-type": "Other",
              "#text": "Other"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Comparison of dose distributions produced by rival radiotherapy plans judged using radiobiological model predictions of Tumour Control Probability (TCP) and Normal Tissue Complication Probability (NTCP).",
            "Comparison of reproducibility of registration algorithms for mapping functional MR data acquired before hormone therapy to MR anatomical data acquired after hormone therapy and prior to radiotherapy.",
            "Comparison of reproducibility of registration of functional and MR data with computed tomography (CT) data using gold seed registration, assessing reproducibility and positioning issues.",
            "Comparison of image quality, registration reproducibility and gland distortion of internal and external imaging coils for MRI image acquisition and registration of the prostate.",
            "Comparison of dose distributions produced by rival radiotherapy plans judged using three standard dose-volume constraints for targets and normal tissues and careful examination of the 3D dose distribution."
          ]
        },
        "sponsors": {
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborator": "Institute of Cancer Research, United Kingdom"
        },
        "gender": "Male",
        "min_age": "16 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "30",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "CCR3121" },
        "start_date": "March 2009",
        "primary_completion_date": "June 2011",
        "completion_date": "June 2011",
        "study_first_posted": "November 3, 2009",
        "last_update_posted": "November 3, 2009",
        "locations": { "location": "Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01006564"
      },
      {
        "-rank": "18",
        "nct_id": "NCT00391950",
        "title": "Maintaining Bone Strength in Men With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Zoledronic acid"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Change in bone mineral density (BMD) at lumbar spine as assessed by dual energy x-ray absoptiometry (DEXA) scan",
            "To compare the effect of zoledronic acid 4 mg every 12 weeks versus every 24 weeks on:",
            "The percent change in BMD of the total hip following one year of therapy and the forearm following one year of therapy. This will be carried out at a limited number of centres.",
            "Quality of life following one year of therapy.",
            "Various biochemical markers of bone resorption (N-telopeptide, NTX, C-telopeptide, CTX, TRACP, PINP) and bone formation (bone alkaline phosphatase, BAP) during one year of therapy. This will be carried out at a limited number of centres.",
            "Percentage of and rate of vertebral and hip fractures.",
            "Safety and tolerability"
          ]
        },
        "sponsors": { "lead_sponsor": "Novartis" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "300",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CZOL446GGB12" },
        "start_date": "October 2006",
        "primary_completion_date": "May 2007",
        "study_first_posted": "October 25, 2006",
        "last_update_posted": "November 23, 2009",
        "locations": { "location": "Derby, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00391950"
      },
      {
        "-rank": "19",
        "nct_id": "NCT02935816",
        "title": "Localising Occult Prostate Cancer Metastases With Advanced Imaging TEchniques",
        "acronym": "LOCATE",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Radiation",
            "#text": "Whole body MRI"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "The investigator will measure and analyse sensitivity and specificity of WB-MRI compared to conventional multi-modality imaging for detection of regional lymph node distant metastasis.T",
            "Interobserver agreement for WB-MRI: Per-site and per-nodal staging assessment will be done by two radiologists separately and then in consensus. Kappa agreement statistic will be tested for the level of agreement for per-site and per-patient assessments.",
            "The investigator will investigate whether there would be any significant correlation between MRI quantitative parameters and the response following treatment.",
            "The investigator will evaluate using blood test differences between two groups",
            "The investigator will asses the Cost-effectiveness by comparing the direct and indirect costs of multi-modality imaging path versus WB-MRI path",
            "The investagator will measure sensitivity and specificity of WB-MRI compared to choline PET-CT for detection of regional lymph node distant metastasis. Analysis of sensitivity and specificity will be investigated on per-site basis and per-patient basis"
          ]
        },
        "sponsors": { "lead_sponsor": "University College, London" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "130",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Only",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "15/0047" },
        "start_date": "January 2015",
        "primary_completion_date": "January 2018",
        "completion_date": "January 2018",
        "study_first_posted": "October 18, 2016",
        "last_update_posted": "October 18, 2016",
        "locations": { "location": "Centre for Medical Imaging, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02935816"
      },
      {
        "-rank": "20",
        "nct_id": "NCT03061539",
        "title": "Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Nivolumab & Ipilimumab"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Composite response rate",
            "Overall survival",
            "Radiological progression free survival",
            "PSA progression free survival",
            "Change in patient reported outcome measures (NCI's PRO-CTCAE)",
            "Frequency and severity of adverse events"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University College, London",
          "collaborator": "Bristol-Myers Squibb"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "175",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CA209-935" },
        "start_date": "February 6, 2018",
        "primary_completion_date": "April 2019",
        "completion_date": "July 2024",
        "study_first_posted": "February 23, 2017",
        "last_update_posted": "March 13, 2019",
        "locations": { "location": "University College London Hospital, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03061539"
      },
      {
        "-rank": "21",
        "nct_id": "NCT03253978",
        "title": "SPORT High-Risk Trial Evaluating SABR in Prostate Cancer",
        "acronym": "SPORT",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Radiation",
            "#text": "Stereotatic Radiotherapy"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Adequate recruitment rate",
            "Acute toxicity of SABR",
            "Acute quality of life during and after SABR",
            "Number of SABR plans delivered as planned and on schedule",
            "Quantification of acute toxicity in each treatment group",
            "Late toxicity of SABR",
            "Late patient-reported quality of life",
            "Rate of PSA failure",
            "Prostate cancer-specific survival",
            "Overall survival"
          ]
        },
        "sponsors": { "lead_sponsor": "Belfast Health and Social Care Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "30",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "14190SJ-SS" },
        "start_date": "January 18, 2016",
        "primary_completion_date": "December 31, 2019",
        "completion_date": "December 31, 2028",
        "study_first_posted": "August 18, 2017",
        "last_update_posted": "August 21, 2018",
        "locations": { "location": "Belfast Health and Social Care Trust, Belfast, Co. Antrim, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03253978"
      },
      {
        "-rank": "22",
        "nct_id": "NCT02785627",
        "title": "Assessment of Bone Loss in Men Receiving Treatment for Prostate Cancer",
        "acronym": "ANTELOPE",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "Comprehensive bone health assessment"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Change in volumetric bone mineral density at the distal radius",
            "Characterisation of the microstructural pattern of bone loss in men receiving treatments for prostate cancer.",
            "Correlation of bone loss and microstructural change with biochemical markers of bone turnover, serum testosterone levels and changes in muscle strength and body composition.",
            "Characterisation of the microstructural pattern of bone loss at the spine (T12)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Prof Janet Brown",
          "collaborator": [
            "Sheffield Teaching Hospitals",
            "Weston Park Hospital Cancer Charity",
            "University of Sheffield"
          ]
        },
        "gender": "Male",
        "min_age": "50 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "90",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case Control",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "STH18645" },
        "start_date": "September 2016",
        "primary_completion_date": "March 2019",
        "completion_date": "September 2019",
        "study_first_posted": "May 30, 2016",
        "last_update_posted": "May 30, 2016",
        "locations": { "location": "Cancer Clinical Trials Centre, Sheffield, South Yorkshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02785627"
      },
      {
        "-rank": "23",
        "nct_id": "NCT02705846",
        "title": "Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations",
        "acronym": "GENPROS",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "outcome_measures": {
          "outcome_measure": [
            "Cause Specific Survival (CSS) will be measured in men with prostate cancer who carry a rare germline mutation and compared to CSS in non-carriers",
            "Biochemical progression free survival (bPFS) will be measured and compared between mutation carriers and non-carriers.",
            "Metastasis free survival (MFS) after radical treatment will be measured and compared between mutation carriers and non-carriers.",
            "Overall survival will be measured and compared between mutation carriers and non-carriers."
          ]
        },
        "sponsors": { "lead_sponsor": "Institute of Cancer Research, United Kingdom" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "1020",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Control",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": {
          "other_id": [
            "14/LO/0072",
            "CCR 4059"
          ]
        },
        "start_date": "September 2014",
        "primary_completion_date": "October 2019",
        "completion_date": "October 2019",
        "study_first_posted": "March 11, 2016",
        "last_update_posted": "September 4, 2019",
        "locations": { "location": "Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02705846"
      },
      {
        "-rank": "24",
        "nct_id": "NCT02404428",
        "title": "Utilizing MRI to Study the Effect of Sulforaphane on Prostate Cancer",
        "acronym": "ESCAPE-ING",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Dietary Supplement",
              "#text": "Standard broccoli soup"
            },
            {
              "-type": "Dietary Supplement",
              "#text": "Beneforte extra broccoli soup"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "tumor size/blood flow",
            "choline + creatine/citrate ratio",
            "citrate levels",
            "PSA levels",
            "GSTM1 genotype"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Quadram Institute Bioscience",
          "collaborator": "Cambridge University Hospitals NHS Foundation Trust"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "5",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)"
          ]
        },
        "other_ids": { "other_id": "IFR02/2014" },
        "start_date": "February 2015",
        "primary_completion_date": "September 2016",
        "completion_date": "September 2016",
        "study_first_posted": "March 31, 2015",
        "last_update_posted": "November 25, 2016",
        "locations": { "location": "Cambridge University Hospitals NHS Foundation Trust_Addenbrooke's Hospital, Cambridge, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02404428"
      },
      {
        "-rank": "25",
        "nct_id": "NCT02745496",
        "title": "Advanced Magnetic Resonance Imaging (MRI) in Men With Suspected Prostate Cancer",
        "acronym": "MULTIPROS",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Procedure",
              "#text": "TRUS Biopsy"
            },
            {
              "-type": "Procedure",
              "#text": "TRUS/FUSION Biopsy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of prostate cancers detected by MP-MRI when compared to gold standard prostatectomy specimen",
            "Number of clinically significant cancers detected by MP-MRI when compared to gold standard prostatectomy specimen",
            "Number of cancer detected in each randomised group, namely intervention group (TRUS/FUSION biopsy) versus standard of care (TRUS biopsy)",
            "Number of significant cancer detected in each randomised group, namely intervention group (TRUS/FUSION biopsy) versus standard of care (TRUS biopsy)",
            "Safety outcomes(death, post biopsy pain, bleeding, sepsis and hospitalization) of intervention (biopsy) in each of the two randomised groups.",
            "Comparison of MRI negative standard of care TRUS guided biopsies with MRI positive TRUS histopathology to facilitate analysis of diagnostic accuracy of MRI in men suspected with target condition."
          ]
        },
        "sponsors": {
          "lead_sponsor": "University of Dundee",
          "collaborator": [
            "NHS Tayside",
            "Prostate Cancer UK",
            "Tayside Clinical Trials Unit",
            "Health Informatics Centre",
            "Chief Scientist Office of the Scottish Government"
          ]
        },
        "gender": "Male",
        "min_age": "40 Years",
        "max_age": "75 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "600",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "MULTIPROS Study" },
        "start_date": "December 2014",
        "primary_completion_date": "July 2020",
        "completion_date": "December 2020",
        "study_first_posted": "April 20, 2016",
        "last_update_posted": "May 1, 2019",
        "locations": { "location": "Ninewells Hospital and Medical School, Dundee, Tayside, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02745496"
      },
      {
        "-rank": "26",
        "nct_id": "NCT02689271",
        "title": "CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr",
        "acronym": "INNOVATE",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "MRI"
          }
        },
        "outcome_measures": { "outcome_measure": "Diagnostic accuracy of VERDICT MRI" },
        "sponsors": { "lead_sponsor": "University College, London" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "365",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "15/0692" },
        "start_date": "April 2016",
        "primary_completion_date": "March 2019",
        "completion_date": "March 2020",
        "study_first_posted": "February 23, 2016",
        "last_update_posted": "May 4, 2018",
        "locations": { "location": "University College London Hospital, Camden, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02689271"
      },
      {
        "-rank": "27",
        "nct_id": "NCT00989105",
        "title": "Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "immunohistochemistry staining method"
            },
            {
              "-type": "Other",
              "#text": "laboratory biomarker analysis"
            },
            {
              "-type": "Other",
              "#text": "pharmacological study"
            },
            {
              "-type": "Procedure",
              "#text": "computed tomography"
            },
            {
              "-type": "Procedure",
              "#text": "magnetic resonance imaging"
            },
            {
              "-type": "Procedure",
              "#text": "single photon emission computed tomography"
            },
            {
              "-type": "Radiation",
              "#text": "technetium Tc 99m demobesin-4"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Causality of each adverse events as assessed by NCI CTCAE v. 3.0",
            "Biodistribution of radioactivity of 99mTc DB4 by gamma-camera imaging",
            "Pharmacokinetics of 99mTc DB4 in blood and urine and assessment of decline over 6 hours",
            "Performance of 99mTc DB4 gamma-camera imaging compared with conventional imaging (CT scan and/or MRI)",
            "Levels of expression in gastrin-releasing peptide in prostate tumor samples and lymph node specimens"
          ]
        },
        "sponsors": { "lead_sponsor": "Cancer Research UK" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "8",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000650867",
            "UKM-ICRF-CR0402-11",
            "CRUK-CR0402-11",
            "EUDRACT-2007-005324-32",
            "EU-20981"
          ]
        },
        "start_date": "June 2009",
        "primary_completion_date": "December 2011",
        "completion_date": "December 2011",
        "study_first_posted": "October 2, 2009",
        "last_update_posted": "February 28, 2012",
        "locations": { "location": "Saint Bartholomew's Hospital, London, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00989105"
      },
      {
        "-rank": "28",
        "nct_id": "NCT02409212",
        "title": "Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer",
        "acronym": "PANTERA",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Behavioral",
              "#text": "Aerobic exercise training"
            },
            {
              "-type": "Behavioral",
              "#text": "Placebo surveillance and written exercise guidelines"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Feasibility as measured by rate of recruitment",
            "Feasibility as measured by Intervention adherence"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Sheffield Teaching Hospitals NHS Foundation Trust",
          "collaborator": [
            "Sheffield Hallam University",
            "University of Sheffield",
            "Queen Mary University of London",
            "University College London Hospitals",
            "Institute of Cancer Research, United Kingdom"
          ]
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "50",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "STH 18624" },
        "start_date": "May 2015",
        "primary_completion_date": "December 2018",
        "completion_date": "December 2018",
        "study_first_posted": "April 6, 2015",
        "last_update_posted": "January 30, 2019",
        "locations": { "location": "Sheffield Teaching Hospitals NHS Trust, Sheffield, South Yorkshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02409212"
      },
      {
        "-rank": "29",
        "nct_id": "NCT02721784",
        "title": "Serial mpMRI (Multi Parametric Magnetic Resonance Imaging) Scanning in Prostate Cancer After Androgen Deprivation Therapy and RadioTherapy",
        "acronym": "SMART",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Device",
              "#text": "mpMRI/VERDICT"
            },
            {
              "-type": "Radiation",
              "#text": "External Beam Radiotherapy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Measurement of changes in MRI ADC value",
            "Measurement of changes in mpMRI tumour volume (cubic centimetres)",
            "Measurement of changes in enhancement measured as a transfer constant (KTrans) value"
          ]
        },
        "sponsors": { "lead_sponsor": "University College, London" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "10",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "15/0342" },
        "start_date": "June 2016",
        "primary_completion_date": "January 2018",
        "completion_date": "January 2018",
        "study_first_posted": "March 29, 2016",
        "last_update_posted": "October 26, 2016",
        "locations": { "location": "Urology Research Group, London, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02721784"
      },
      {
        "-rank": "30",
        "nct_id": "NCT01842438",
        "title": "A Couple Support Intervention for Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Behavioral",
            "#text": "Behavioral: psychosexual intervention"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "EPIC (Expanded Prostate Cancer Index Composite), Sexual Bother Subscale",
            "HADS (Hospital Anxiety and Depression Scale)",
            "SCORE15 (Systemic Core Outcome Measure)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University of Stirling",
          "collaborator": "Prostate Cancer UK"
        },
        "gender": "All",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "86",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Single (Outcomes Assessor)",
            "Primary Purpose: Supportive Care"
          ]
        },
        "other_ids": { "other_id": "03979" },
        "start_date": "October 2012",
        "primary_completion_date": "July 2015",
        "completion_date": "August 2015",
        "study_first_posted": "April 29, 2013",
        "results_first_posted": "June 22, 2016",
        "last_update_posted": "June 5, 2017",
        "locations": { "location": "Western General Hospital, Edinburgh, Lothian, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01842438"
      },
      {
        "-rank": "31",
        "nct_id": "NCT02618161",
        "title": "Timing of HDR With EBRT in Localised Prostate Cancer,Toxicity and Quality of Life Assessment",
        "acronym": "THEPCA",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Radiation",
              "#text": "HDR Brachytherapy"
            },
            {
              "-type": "Radiation",
              "#text": "External beam Radiotherapy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Prospective assessment of genitourinary toxicities according to the treatment sequence of HDR Brachytherapy and EBRT",
            "Biochemical response and survival",
            "Gastrointestinal toxicities according to the treatment sequence of HDR Brachytherapy and EBRT",
            "Radiotherapy Planning Challenges including Image Guided Radiotherapy"
          ]
        },
        "sponsors": { "lead_sponsor": "Southend University Hospital Foundation NHS Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "100",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Single (Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "P0845" },
        "start_date": "September 2014",
        "primary_completion_date": "September 2017",
        "completion_date": "September 2018",
        "study_first_posted": "December 1, 2015",
        "last_update_posted": "April 27, 2017",
        "locations": { "location": "Southend University Hospital NHS Foundation trust, Westcliff on sea, Essex, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02618161"
      },
      {
        "-rank": "32",
        "nct_id": "NCT02499848",
        "title": "Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "PRX302"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "safety and tolerability of a single injection of PRX302 in all patients will be assessed by recording Adverse Event assessments over 24 weeks",
            "To evaluate the potential efficacy of PRX302 by â€¢ Transperineal targeted biopsy performed of the treated area at 24 weeks post-treatment"
          ]
        },
        "sponsors": { "lead_sponsor": "Sophiris Bio Corp" },
        "gender": "Male",
        "min_age": "40 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "18",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "PRX302-2-07" },
        "start_date": "July 2015",
        "primary_completion_date": "June 2016",
        "completion_date": "June 2016",
        "study_first_posted": "July 16, 2015",
        "last_update_posted": "July 27, 2016",
        "locations": { "location": "UCLH, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02499848"
      },
      {
        "-rank": "33",
        "nct_id": "NCT02349347",
        "title": "A Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles in Patients With Castration-resistant Prostate Cancer (CRPC)",
        "acronym": "MEL-CAP",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Melphalan"
            },
            {
              "-type": "Drug",
              "#text": "Lenograstim"
            }
          ]
        },
        "outcome_measures": { "outcome_measure": "Progression free survival (PFS) rate at 6 months according to PCWG2 criteria" },
        "sponsors": { "lead_sponsor": "Queen Mary University of London" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "39",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "MEL-CAP" },
        "start_date": "December 2012",
        "primary_completion_date": "November 2017",
        "study_first_posted": "January 28, 2015",
        "last_update_posted": "January 28, 2015",
        "locations": { "location": "St Bartholomews Hospital, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02349347"
      },
      {
        "-rank": "34",
        "nct_id": "NCT01726894",
        "title": "Focal Therapy for Localised Prostate Cancer Using Irreversible Electroporation",
        "acronym": "Nano",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "Irreversible Electroporation"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety Profile",
            "Sexual Side Effects",
            "Continence side effect",
            "Rectal side effects",
            "Cancer Control"
          ]
        },
        "sponsors": { "lead_sponsor": "University College London Hospitals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "20",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)"
          ]
        },
        "other_ids": { "other_id": "12/0399" },
        "start_date": "October 2013",
        "primary_completion_date": "August 2015",
        "study_first_posted": "November 15, 2012",
        "last_update_posted": "June 18, 2014",
        "locations": { "location": "University College London Hospitals, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01726894"
      },
      {
        "-rank": "35",
        "nct_id": "NCT03934164",
        "title": "Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO",
        "acronym": "MAESTRO",
        "status": {
          "-open": "Y",
          "#text": "Not yet recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Metastatic Prostate Cancer",
            "Castration-resistant Prostate Cancer"
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of molecular aberrations in diagnostic archive and fresh mCRPC tissue",
            "Quantify the association between molecular aberrations and baseline prognostic characteristics",
            "Changes in molecular aberrations",
            "Safety - Review of biopsy-related adverse events: occurrence of at least one grade 3 or 4 event",
            "Time to development of CRPC",
            "Overall Survival (OS)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": "Prostate Cancer UK"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "600",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Other",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "ICR-CTSU/2016/10059" },
        "start_date": "June 2019",
        "primary_completion_date": "March 2024",
        "completion_date": "March 2025",
        "study_first_posted": "May 1, 2019",
        "last_update_posted": "May 1, 2019",
        "locations": { "location": "The Royal Marsden NHSFT, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03934164"
      },
      {
        "-rank": "36",
        "nct_id": "NCT00997464",
        "title": "An Exploration of Genetic Testing for Prostate Cancer Susceptibility",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "outcome_measures": {
          "outcome_measure": [
            "Whether cancer worry changes between the two time-points (measured using the Impact of Event Scale)",
            "Why are men interested/ not interested in seeking genetic profiling for prostate cancer, and what might be the uptake of such testing?",
            "What are the expectations of this testing from the perspective of the user, what are the perceived benefits and limitations of testing and how do these change through the testing process",
            "Is there a relationship between a family history of cancer, cancer worry, and a persons intention to seek genetic testing?",
            "How would the information provided by such a test be used by the individual and the family and how could this impact upon the healthcare system"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborator": "Institute of Cancer Research, United Kingdom"
        },
        "gender": "Male",
        "min_age": "40 Years",
        "max_age": "69 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "200",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "CCR3200" },
        "start_date": "August 2009",
        "primary_completion_date": "February 2011",
        "completion_date": "February 2011",
        "study_first_posted": "October 19, 2009",
        "last_update_posted": "October 19, 2009",
        "locations": { "location": "Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00997464"
      },
      {
        "-rank": "37",
        "nct_id": "NCT03017417",
        "title": "A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer",
        "acronym": "COMRADE",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "Exercise Intervention"
            },
            {
              "-type": "Other",
              "#text": "standard of care"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of participants recruited who complete the intervention",
            "Number of participants who show improvement in the Physical function assessments",
            "number of participants who show improvement from treatment as shown by a DEXA scan",
            "number of participants who show an increase in Muscle hypertrophy following intervention assessment",
            "number of participants who show increases in Muscle Strength following intervention assessment",
            "number of participants who show a higher score on Quality of life assessments following intervention",
            "number of participants who adhere to the Diet diaries"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Sheffield Teaching Hospitals NHS Foundation Trust",
          "collaborator": "Sheffield Hallam University"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "31",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Health Services Research"
          ]
        },
        "other_ids": { "other_id": "STH19598" },
        "start_date": "February 8, 2017",
        "primary_completion_date": "June 2020",
        "completion_date": "June 2020",
        "study_first_posted": "January 11, 2017",
        "last_update_posted": "August 7, 2018",
        "locations": { "location": "Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03017417"
      },
      {
        "-rank": "38",
        "nct_id": "NCT02955082",
        "title": "The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment",
        "acronym": "BARCODE2",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Hormone Refractory Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Carboplatin"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Treatment Response",
            "Biochemical Treatment Response",
            "Overall survival of men with mCRPC and germline DNA repair gene mutations",
            "Progression-free survival of men with mCRPC and germline DNA repair gene mutations",
            "Incidence of germline DNA repair gene mutations in a population of mCRPC cases",
            "Cause specific survival",
            "Radiographic progression free survival",
            "Time to radiographic progression",
            "PSA objective responses"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": [
            "Royal Marsden NHS Foundation Trust",
            "European Research Council",
            "Colchester Hospital University NHS Foundation Trust",
            "Imperial College Healthcare NHS Trust",
            "Dartford and Gravesham NHS Foundation Trust",
            "Medway NHS Foundation Trust",
            "Southend University Hospital Foundation NHS Trust",
            "Great Ormond Street Hospital for Children NHS Foundation Trust",
            "Maidstone & Tunbridge Wells NHS Trust",
            "East and North Hertfordshire NHS Trust",
            "Royal Free Hampstead NHS Trust",
            "The Whittington Hospital NHS Trust",
            "Luton and Dunstable Hospital NHS Foundation Trust",
            "Buckinghamshire Healthcare NHS Trust",
            "Chelsea and Westminster NHS Foundation Trust",
            "Frimley Park Hospital NHS Trust",
            "North Middlesex University Hospital NHS Trust",
            "Whipps Cross University NHS Trust",
            "Barts & The London NHS Trust",
            "Heatherwood and Wexham Park Hospitals NHS Foundation Trust"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "450",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CCR4520" },
        "start_date": "May 25, 2017",
        "primary_completion_date": "September 30, 2020",
        "completion_date": "April 25, 2022",
        "study_first_posted": "November 4, 2016",
        "last_update_posted": "September 4, 2019",
        "locations": { "location": "Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02955082"
      },
      {
        "-rank": "39",
        "nct_id": "NCT02125175",
        "title": "BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer",
        "acronym": "BIOPROP20",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Radiation",
            "#text": "Hypofractionated IMRT boost Radiotherapy"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Acute bladder and bowel toxicity (NCI CTCAE v 4.0 and RTOG) at 18 weeks after the commencement of radiotherapy treatment",
            "The success rate of producing dose painted IMRT plans which fulfill the dose-volume constraints as specified for the prostate and for the normal tissues",
            "Late bladder and bowel toxicity (NCI CTCAE v4) at 2 years"
          ]
        },
        "sponsors": { "lead_sponsor": "The Clatterbridge Cancer Centre NHS Foundation Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "55",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "RDD547" },
        "start_date": "January 2014",
        "primary_completion_date": "September 2018",
        "completion_date": "September 2019",
        "study_first_posted": "April 29, 2014",
        "last_update_posted": "May 14, 2019",
        "locations": { "location": "The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02125175"
      },
      {
        "-rank": "40",
        "nct_id": "NCT03506997",
        "title": "Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer",
        "acronym": "PERSEUS1",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Castration-resistant Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Pembrolizumab"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "To evaluate tumour response",
            "Radiological progression-free survival (rPFS)",
            "Time to radiological progression",
            "Progression free survival",
            "Time to PSA progression",
            "Duration of PSA response",
            "Overall survival",
            "Safety and tolerability defined by CTC-AE, V 4.0 criteria."
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": "Merck Sharp & Dohme Corp."
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "100",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "ICR-CTSU/2016/10060",
            "2017-000931-15"
          ]
        },
        "start_date": "November 27, 2018",
        "primary_completion_date": "September 1, 2023",
        "completion_date": "September 1, 2025",
        "study_first_posted": "April 24, 2018",
        "last_update_posted": "December 24, 2018",
        "locations": { "location": "The Royal Marsden Hospital, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03506997"
      },
      {
        "-rank": "41",
        "nct_id": "NCT01168141",
        "title": "Window Study of ZD4054 in Metastatic Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Metastasis"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "ZD4054"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Changes in tissue biomarkers",
            "Changes in blood-borne biomarkers",
            "Changes in imaging biomarkers"
          ]
        },
        "sponsors": {
          "lead_sponsor": "The Christie NHS Foundation Trust",
          "collaborator": "AstraZeneca"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "30",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Basic Science"
          ]
        },
        "other_ids": { "other_id": "08_CLPHA_54" },
        "start_date": "July 2009",
        "primary_completion_date": "September 2010",
        "completion_date": "September 2010",
        "study_first_posted": "July 23, 2010",
        "last_update_posted": "July 23, 2010",
        "locations": { "location": "The Christie NHS Foundation Trust, Manchester, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01168141"
      },
      {
        "-rank": "42",
        "nct_id": "NCT01907009",
        "title": "A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).",
        "acronym": "MEL-CAP",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Castrate Resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Melphalan"
            },
            {
              "-type": "Drug",
              "#text": "Lenograstim"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "To determine the efficacy of intensified intravenous Melphalan with autologous whole blood stem cell transplantation in patients with castration resistant prostate cancer using progression free survival.",
            "To determine weather early falls (two weeks)in circulating tumor cells (CTC)predict the progression free survival",
            "To assess the changes in prostate specific antigen pre and post treament",
            "To study progression free survival and overall survival",
            "To assess the effect of this schedule in reintroduction of hormone senstivity",
            "To study the Quality of life."
          ]
        },
        "sponsors": { "lead_sponsor": "Barts & The London NHS Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 2",
            "Phase 3"
          ]
        },
        "enrollment": "39",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "MEL-CAP" },
        "start_date": "January 2013",
        "primary_completion_date": "January 2016",
        "completion_date": "September 2017",
        "study_first_posted": "July 24, 2013",
        "last_update_posted": "September 9, 2015",
        "locations": { "location": "St Batholowmew's Hospital NHS, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01907009"
      },
      {
        "-rank": "43",
        "nct_id": "NCT01233557",
        "title": "Biomarkers of Bone Resorption in Metastatic Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Prostate Cancer" },
        "sponsors": { "lead_sponsor": "University of Aberdeen" },
        "gender": "Male",
        "min_age": "40 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "40",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Only",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "10/S0802/36" },
        "start_date": "September 2010",
        "primary_completion_date": "August 2014",
        "completion_date": "August 2014",
        "study_first_posted": "November 3, 2010",
        "last_update_posted": "November 5, 2015",
        "locations": { "location": "Aberdeen Royal Infirmary, Aberdeen, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01233557"
      },
      {
        "-rank": "44",
        "nct_id": "NCT00988130",
        "title": "High-Intensity Focused Ultrasound Focal Ablation in Treating Patients With Progressive Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Sexual Dysfunction"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "laboratory biomarker analysis"
            },
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            },
            {
              "-type": "Procedure",
              "#text": "assessment of therapy complications"
            },
            {
              "-type": "Procedure",
              "#text": "high-intensity focused ultrasound ablation"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Total proportion of men with erectile dysfunction and/or incontinence",
            "Quality of life",
            "Success of index lesion ablation with HIFU at 6 months",
            "Prostate-specific antigen kinetics",
            "Proportion of men requiring androgen blockade at 12 months"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University College London Hospitals",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "26",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000652331",
            "UCL-09-H0714-7",
            "EU-20977"
          ]
        },
        "start_date": "July 2009",
        "study_first_posted": "October 1, 2009",
        "last_update_posted": "August 26, 2013",
        "locations": { "location": "University College Hospital - London, London, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00988130"
      },
      {
        "-rank": "45",
        "nct_id": "NCT02424448",
        "title": "Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate Cancer",
        "acronym": "BIOMETHS",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration Resistant Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "Biopsies, blood and urine samples"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of formalin fixed cancer tissue samples evaluable for immunohistochemical analysis",
            "Baseline levels of biomarkers in formalin fixed cancer tissue samples",
            "Intra-lesion temporal variability between formalin fixed cancer tissue samples",
            "Intra-lesion spatial variability between formalin fixed cancer tissue samples",
            "Percentage of frozen cancer tissue samples evaluable for biomarker analysis",
            "Baseline levels of biomarkers in frozen cancer tissue samples",
            "Intra-lesion temporal variability between frozen cancer tissue samples",
            "Intra-lesion spatial variability between frozen cancer tissue samples"
          ]
        },
        "sponsors": {
          "lead_sponsor": "The Christie NHS Foundation Trust",
          "collaborator": "AstraZeneca"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "6",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "CFTSp063 / 12_DOG04_145" },
        "start_date": "December 2014",
        "primary_completion_date": "July 2016",
        "completion_date": "July 2016",
        "study_first_posted": "April 23, 2015",
        "last_update_posted": "July 26, 2016",
        "locations": { "location": "The Christie NHS Foundation Trust, Manchester, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02424448"
      },
      {
        "-rank": "46",
        "nct_id": "NCT03702439",
        "title": "Prostate Cancer Screening Trial Using Imaging",
        "acronym": "PROSTAGRAM",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Neoplasm" },
        "outcome_measures": {
          "outcome_measure": [
            "The proportion of men with a positive MRI defined by a score of 3 or greater",
            "The proportion of men with screen-positive prostate ultrasound defined by a score of 3 or greater",
            "The proportion of participants within each MRI score or US score of 1, 2, 3, 4 or 5",
            "An evaluation of proportion of participants across each MRI and US score with no cancer, insignificant cancer and significant cancer with each test.",
            "A comparison of the proportion of participants with a positive result for each screening test. A comparison of the proportion of men subsequently diagnosed with a clinically significant prostate cancer as defined by pre-specified histological definition",
            "Comparison of different testing combinations in terms of biopsy rates, detection of insignificant cancer and significant cancers"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Imperial College London",
          "collaborator": "Imperial College Healthcare NHS Trust"
        },
        "gender": "Male",
        "min_age": "50 Years",
        "max_age": "69 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "364",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Other",
            "Time Perspective: Cross-Sectional"
          ]
        },
        "other_ids": { "other_id": "18HH4595" },
        "start_date": "October 10, 2018",
        "primary_completion_date": "December 12, 2020",
        "completion_date": "January 1, 2021",
        "study_first_posted": "October 11, 2018",
        "last_update_posted": "December 12, 2018",
        "locations": { "location": "Imperial College Healthcare NHS Trust, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03702439"
      },
      {
        "-rank": "47",
        "nct_id": "NCT02375035",
        "title": "Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer",
        "acronym": "CAMPROBE",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Prostate Biopsy"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "CAMPROBE"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Pain score assessment of CAMPROBE biopsy procedure",
            "Patient reported adverse events related to CAMPROBE biopsy",
            "Patient perception and acceptance of CAMPROBE biopsy",
            "Deterioration in urinary function after CAMPROBE biopsy",
            "Deterioration in sexual function after CAMPROBE biopsy"
          ]
        },
        "sponsors": { "lead_sponsor": "Cambridge University Hospitals NHS Foundation Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "85 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "50",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": { "study_design": "Time Perspective: Prospective" },
        "other_ids": { "other_id": "AO93224" },
        "start_date": "January 2015",
        "primary_completion_date": "December 2015",
        "completion_date": "September 2019",
        "study_first_posted": "March 2, 2015",
        "last_update_posted": "March 2, 2015",
        "locations": { "location": "Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02375035"
      },
      {
        "-rank": "48",
        "nct_id": "NCT01664728",
        "title": "An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Glucocorticoid"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of participants with serum prostate specific antigen (PSA) decline according to PSA Working Group criteria",
            "Overall survival",
            "Number of participants with adverse events",
            "Time to disease progression",
            "Time to prostate specific antigen progression",
            "Objective tumor response by Response Evaluation Criteria in Solid Tumors (RECIST)"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Research & Development, LLC" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "54",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR016912",
            "COU-AA-001EXT",
            "2006-006755-12"
          ]
        },
        "start_date": "April 2007",
        "primary_completion_date": "February 2009",
        "completion_date": "September 2012",
        "study_first_posted": "August 14, 2012",
        "last_update_posted": "April 19, 2013",
        "locations": { "location": "Sutton, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01664728"
      },
      {
        "-rank": "49",
        "nct_id": "NCT03238170",
        "title": "MR-simulation in Radiotherapy for Prostate Cancer",
        "acronym": "FIMRA-P",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Cancer of the PROSTATE" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "MRI scan"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Standard Operating Procedure (SOP) for MRI-simulation for prostate patients",
            "Clinical Protocol for in-direct MRI planning for prostate",
            "Clinical Protocol for direct MRI-only planning for prostate"
          ]
        },
        "sponsors": { "lead_sponsor": "Guy's and St Thomas' NHS Foundation Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "20",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "215681" },
        "start_date": "March 1, 2017",
        "primary_completion_date": "August 31, 2020",
        "completion_date": "August 31, 2020",
        "study_first_posted": "August 3, 2017",
        "last_update_posted": "August 5, 2019",
        "locations": { "location": "Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03238170"
      },
      {
        "-rank": "50",
        "nct_id": "NCT02294903",
        "title": "Focal Prostate Radiofrequency Ablation",
        "acronym": "ProRAFT",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "Coiled Bipolar Radiofrequency Ablation"
          }
        },
        "outcome_measures": { "outcome_measure": "Cancer control outcome" },
        "sponsors": { "lead_sponsor": "Trod Medical N.V." },
        "gender": "Male",
        "min_age": "40 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "20",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "TM-105" },
        "start_date": "March 2015",
        "primary_completion_date": "April 2018",
        "completion_date": "May 30, 2018",
        "study_first_posted": "November 19, 2014",
        "last_update_posted": "April 24, 2018",
        "locations": { "location": "University College London Hospitals, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02294903"
      },
      {
        "-rank": "51",
        "nct_id": "NCT03326440",
        "title": "Virtual Environment Radiotherapy to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer",
        "acronym": "VERT",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Carcinoma" },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "VERT system"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Volume of bladder measurement in cm3",
            "Does increased compliance translate into reduced side effects from RT."
          ]
        },
        "sponsors": { "lead_sponsor": "University Hospitals of North Midlands NHS Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "340",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Other"
          ]
        },
        "other_ids": { "other_id": "772" },
        "start_date": "August 2015",
        "primary_completion_date": "July 2019",
        "completion_date": "July 2019",
        "study_first_posted": "October 31, 2017",
        "last_update_posted": "October 31, 2017",
        "locations": { "location": "University Hospitals of North Midlands, Royal Stoke University Hospital, City General Site, Newcaslte Road, Stoke on Trent, Staffordshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03326440"
      },
      {
        "-rank": "52",
        "nct_id": "NCT00363285",
        "title": "Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "gonadotrophin releasing hormone"
            },
            {
              "-type": "Drug",
              "#text": "cyproterone acetate"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Time to loss of androgen-dependence, based on serum prostate-specific antigen (PSA) failure according to protocol definition",
            "Time to treatment failure (subjective or objective progression)",
            "Quality of life",
            "Survival",
            "Side effects",
            "First and total therapy-free intervals in patients treated with intermittent cyproterone acetate"
          ]
        },
        "sponsors": {
          "lead_sponsor": "St. Bartholomew's Hospital",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "max_age": "79 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "900",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000495321",
            "SEUG-9901",
            "BARTS-SEUK-9901",
            "MREC-04/5/006",
            "BARTS-P/02/203",
            "EU-20630"
          ]
        },
        "start_date": "January 2003",
        "study_first_posted": "August 15, 2006",
        "last_update_posted": "August 26, 2013",
        "locations": {
          "location": [
            "Saint Bartholomew's Hospital, London, England, United Kingdom",
            "Scarborough General Hospital, Scarborough, England, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00363285"
      },
      {
        "-rank": "53",
        "nct_id": "NCT00551044",
        "title": "Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Bicalutamide"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Quality of life (using Rand 36-Item Health Survey SF-36)",
            "Renal & liver function tests, PSA, testosterone, estradiol",
            "Body Mass Index, arm anthropometry (mid-upper arm circumference and triceps skin fold thickness), dynamometry (quadriceps muscle strength)",
            "Bone turnover markers (bone-specific alkaline phosphatase, N-terminal propeptide of type I collagen, C-telopeptide crosslinks of type I collagen, urine N-telopeptide of tyoe I collagen corrected for creatinine",
            "Peripheral bone densitometry of non-dominant forearm"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Wirral University Teaching Hospital NHS Trust",
          "collaborator": "AstraZeneca"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "42",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "96/02" },
        "start_date": "August 2003",
        "completion_date": "August 2005",
        "study_first_posted": "October 30, 2007",
        "last_update_posted": "October 30, 2007",
        "locations": { "location": "Wirral University Teaching Hospitals NHS Trust, Upton, Wirral, Merseyside, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00551044"
      },
      {
        "-rank": "54",
        "nct_id": "NCT00261456",
        "title": "The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer in BRCA1 and BRCA2 Carriers" },
        "interventions": {
          "intervention": [
            {
              "-type": "Behavioral",
              "#text": "PSA test"
            },
            {
              "-type": "Procedure",
              "#text": "Prostate Biopsy"
            }
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": [
            "Cancer Research UK",
            "Royal Marsden NHS Foundation Trust",
            "Ronald and Rita McAulay Foundation"
          ]
        },
        "gender": "Male",
        "min_age": "40 Years",
        "max_age": "69 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "1700",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Control",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": {
          "other_id": [
            "05/MRE07/25",
            "CCR2598"
          ]
        },
        "start_date": "October 2005",
        "primary_completion_date": "December 2019",
        "completion_date": "December 2024",
        "study_first_posted": "December 5, 2005",
        "last_update_posted": "September 4, 2019",
        "locations": { "location": "Cancer Genetics Unit, Royal Marsden Hospital, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00261456"
      },
      {
        "-rank": "55",
        "nct_id": "NCT00473512",
        "title": "A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate MTD"
            },
            {
              "-type": "Drug",
              "#text": "Dexamethasone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12",
            "Number of Participants With Objective Tumor Response",
            "Duration of Prostate Specific Antigen (PSA) Response",
            "Duration of Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)",
            "Time to Disease Progression",
            "Overall Survival"
          ]
        },
        "sponsors": { "lead_sponsor": "Cougar Biotechnology, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "54",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR016909",
            "COU-AA-001"
          ]
        },
        "start_date": "November 2005",
        "primary_completion_date": "November 2008",
        "completion_date": "November 2008",
        "study_first_posted": "May 15, 2007",
        "results_first_posted": "August 29, 2013",
        "last_update_posted": "March 27, 2014",
        "locations": { "location": "Sutton, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00473512"
      },
      {
        "-rank": "56",
        "nct_id": "NCT02390063",
        "title": "Vaccination in Prostate Cancer (VANCE)",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "ChAdOx1.5T4"
            },
            {
              "-type": "Biological",
              "#text": "MVA.5T4"
            },
            {
              "-type": "Drug",
              "#text": "Cyclophosphamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Vaccine safety and immunogenicity",
            "Cellular and humoral immune response with CHAMVA",
            "Cellular and humoral immune response with MVA",
            "PSA level change secondary to vaccination",
            "MRI or Gleason score change secondary to vaccination",
            "Regulatory T-cell response"
          ]
        },
        "sponsors": { "lead_sponsor": "University of Oxford" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "40",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Factorial Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "VANCE01" },
        "start_date": "June 2015",
        "primary_completion_date": "May 15, 2018",
        "completion_date": "May 15, 2019",
        "study_first_posted": "March 17, 2015",
        "last_update_posted": "January 8, 2019",
        "locations": {
          "location": [
            "University of Oxford, Oxford, United Kingdom",
            "Royal Hallamshire Hospital, Sheffield, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02390063"
      },
      {
        "-rank": "57",
        "nct_id": "NCT04046653",
        "title": "Accumulation of Dietary Bioactives and Prostate Cancer",
        "acronym": "ADaPT",
        "status": {
          "-open": "N",
          "#text": "Enrolling by invitation"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Dietary Supplement",
              "#text": "Allin"
            },
            {
              "-type": "Dietary Supplement",
              "#text": "Sulforaphane"
            },
            {
              "-type": "Dietary Supplement",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Concentration of sulforaphane, alliin and their metabolites in prostate tissue as measured by mass spectrometry",
            "2. Concentration of sulforaphane, alliin and their metabolites in in the transitional and peripheral zones of the prostate as measured by mass spectrometry",
            "Urinary excretion of Sulforaphane and Alliin metabolites",
            "4. Changes in global gene expression in prostate tissue as measured using next generation sequencing",
            "Microbiome profile",
            "Number of participants with glutathione S-transferase M1 (GSTM1) genotype null and positive"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Quadram Institute Bioscience",
          "collaborator": "Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "40",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Prevention"
          ]
        },
        "other_ids": { "other_id": "QIB01/2019" },
        "start_date": "July 3, 2019",
        "primary_completion_date": "February 2020",
        "completion_date": "May 2020",
        "study_first_posted": "August 6, 2019",
        "last_update_posted": "August 6, 2019",
        "locations": { "location": "Quadram Institute Bioscience, Norwich, Norfolk, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT04046653"
      },
      {
        "-rank": "58",
        "nct_id": "NCT02022371",
        "title": "Prostate Cancer Genomic Heterogeneity",
        "acronym": "PROGENY",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "PROSTATE CANCER" },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "Targeted biopsies of the prostate"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Tumour heterogeneity",
            "Clonal origin of secondary tumours",
            "Relationship of tumours to metastases",
            "Identifying genomic signature of tumour DNA in blood",
            "Genomic signature changes in tumour DNA in blood when drug resistance develops",
            "Relationship of tumour genomics with imaging"
          ]
        },
        "sponsors": { "lead_sponsor": "University College London Hospitals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "50",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "13/0244" },
        "start_date": "September 2014",
        "primary_completion_date": "June 2016",
        "completion_date": "June 2016",
        "study_first_posted": "December 27, 2013",
        "last_update_posted": "May 10, 2017",
        "locations": { "location": "University College London Hospitals, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02022371"
      },
      {
        "-rank": "59",
        "nct_id": "NCT00561262",
        "title": "High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            },
            {
              "-type": "Procedure",
              "#text": "high-intensity focused ultrasound ablation"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Feasibility",
            "Adverse events",
            "Patient acceptability as assessed by Assessment of Cancer Therapy - Prostate (FACT-P), International Prostate Symptom Score (IPSS) , IPSS-Quality of Life, Continence Questionnaire, and 15-Item International Index of Erectile Function",
            "Side effect profile",
            "Measurement of prostate-specific antigen (PSA) kinetics including time to PSA nadir",
            "Exclusion of cancer on MRI at 2-7 days and at 6 months",
            "Transrectal ultrasound biopsies at 6 months",
            "Need for secondary or adjuvant treatment for prostate cancer following therapy"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University College London Hospitals",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "max_age": "79 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "60",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": { "study_design": "Primary Purpose: Treatment" },
        "other_ids": {
          "other_id": [
            "CDR0000574367",
            "UCLCTC-UCLH-HEMI-HIFU",
            "EU-20774",
            "ISRCTN25145525"
          ]
        },
        "start_date": "May 2006",
        "primary_completion_date": "October 2009",
        "completion_date": "April 2011",
        "study_first_posted": "November 20, 2007",
        "last_update_posted": "August 26, 2013",
        "locations": { "location": "University College of London Hospitals, London, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00561262"
      },
      {
        "-rank": "60",
        "nct_id": "NCT02324998",
        "title": "Study of Olaparib (Â± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy",
        "acronym": "CaNCaP03",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Olaparib"
            },
            {
              "-type": "Drug",
              "#text": "Degarelix"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Determination of PARP Inhibition",
            "Incidence and Severity of Adverse Events",
            "Feasibility of treatment approach",
            "Clinical benefit rate"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Cambridge University Hospitals NHS Foundation Trust",
          "collaborator": "AstraZeneca"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "73 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "20",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Other"
          ]
        },
        "other_ids": {
          "other_id": [
            "CaNCaP03",
            "2014-004417-86"
          ]
        },
        "start_date": "December 2016",
        "primary_completion_date": "May 2019",
        "completion_date": "May 2019",
        "study_first_posted": "December 24, 2014",
        "last_update_posted": "August 29, 2019",
        "locations": { "location": "Addenbrooke's Hospital, Cambridge University Hospitals Foundation Trust,, Cambridge, Cambridgeshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02324998"
      },
      {
        "-rank": "61",
        "nct_id": "NCT02064608",
        "title": "Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer",
        "acronym": "CaNCaP02",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "AZD2014"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "To measure the amount of inhibition (percentage change from baseline) in mTORC1 and mTORC2 signalling in tumour samples from men with early, high-risk prostate cancer after AZD2014 treatment",
            "To determine the incidence of adverse events due to AZD2014 given prior to radical prostatectomy",
            "To determine the severity of adverse events due to AZD2014 prior to radical prostatectomy"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Cambridge University Hospitals NHS Foundation Trust",
          "collaborator": "AstraZeneca"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "23",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CANCAP02",
            "2014-000214-56"
          ]
        },
        "start_date": "October 2014",
        "primary_completion_date": "December 2016",
        "completion_date": "June 2018",
        "study_first_posted": "February 17, 2014",
        "last_update_posted": "July 17, 2019",
        "locations": { "location": "Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02064608"
      },
      {
        "-rank": "62",
        "nct_id": "NCT02049190",
        "title": "Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Metastatic Prostate Cancer",
            "Androgen-independent Prostate Cancer",
            "Recurrent Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "onapristone"
            },
            {
              "-type": "Drug",
              "#text": "abiraterone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Dose limiting toxicities related to onapristone or the combination of onapristone and abiraterone utilizing a day 57 safety cut off and based on CTCAE v4",
            "Response to onapristone or the combination of onapristone and abiraterone",
            "Safety and tolerability of extended-release onapristone tablets BID",
            "PK of onapristone, mono-demethylated onapristone and other metabolites in plasma and urine"
          ]
        },
        "sponsors": { "lead_sponsor": "Arno Therapeutics" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "75",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "ARN-AR18-CT-102" },
        "start_date": "February 2014",
        "primary_completion_date": "July 2017",
        "completion_date": "December 2017",
        "study_first_posted": "January 30, 2014",
        "last_update_posted": "June 24, 2015",
        "locations": { "location": "Inst of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02049190"
      },
      {
        "-rank": "63",
        "nct_id": "NCT02121639",
        "title": "Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy",
        "acronym": "ProCAID",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "AZD5363"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Phase I:Determination of a suitable dose of AZD5363",
            "Phase II: Progression free survival",
            "Phase I: Safety and tolerability profiles",
            "Phase I: AZD5363 pharmacokinetics Area Under Curve (AUC) Time Frame: predose, 2, 4, 8, 24,144 hours post-dose",
            "Phase II: Bone Pain",
            "Phase II: Progression Free Survival",
            "Phase II: Biochemical (PSA) response rates according to PCWG2 criteria",
            "Phase II: Safety and tolerability profiles using CTCAE version 4.03"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University Hospital Southampton NHS Foundation Trust",
          "collaborator": [
            "AstraZeneca",
            "Cancer Research UK"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "168",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "RHMCAN0935" },
        "start_date": "January 29, 2014",
        "primary_completion_date": "October 31, 2019",
        "completion_date": "February 2, 2020",
        "study_first_posted": "April 23, 2014",
        "last_update_posted": "August 9, 2019",
        "locations": { "location": "Southampton General Hospital, Southampton, Hampshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02121639"
      },
      {
        "-rank": "64",
        "nct_id": "NCT01852864",
        "title": "Degarelix Before Radical Prostatectomy",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "240mg degarelix s.c. injection"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "proliferative index defined by immunohistochemistry for ki67",
            "Gene expression levels measured by microarray"
          ]
        },
        "sponsors": { "lead_sponsor": "University of Cambridge" },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Early Phase 1" },
        "enrollment": "40",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Basic Science"
          ]
        },
        "other_ids": { "other_id": "11/H0311/2" },
        "start_date": "July 2011",
        "primary_completion_date": "July 2015",
        "completion_date": "December 2015",
        "study_first_posted": "May 14, 2013",
        "last_update_posted": "December 16, 2014",
        "locations": { "location": "Cambridge University Hopital NHS Trust, Cambridge, Cambridgeshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01852864"
      },
      {
        "-rank": "65",
        "nct_id": "NCT03158922",
        "title": "The BARCODE 1 Study",
        "acronym": "BARCODE1Pilot",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Genetic",
              "#text": "Genetic SNP profiling"
            },
            {
              "-type": "Other",
              "#text": "Prostate cancer screening"
            },
            {
              "-type": "Procedure",
              "#text": "Prostate biopsy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Association of SNP genetic risk score with prostate biopsy results.",
            "Incidence and aggressiveness of PrCa in men within the top 10% of the genetic score.",
            "Association of the biomarker profile with genetic score and biopsy results.",
            "Use of genetic profiling to target prostate cancer screening in a clinical environment."
          ]
        },
        "sponsors": { "lead_sponsor": "Institute of Cancer Research, United Kingdom" },
        "gender": "Male",
        "min_age": "55 Years",
        "max_age": "69 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "329",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Control",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "CCR4130" },
        "start_date": "April 29, 2016",
        "primary_completion_date": "April 14, 2018",
        "completion_date": "April 29, 2021",
        "study_first_posted": "May 18, 2017",
        "last_update_posted": "September 4, 2019",
        "locations": { "location": "Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03158922"
      },
      {
        "-rank": "66",
        "nct_id": "NCT02712684",
        "title": "Cancer Diagnosis by Multiparametric UltraSound of the Prostate",
        "acronym": "CADMUS",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "multiparametric MRI. Multi-parametric ultrasound"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "To determine the overall agreement in identifying lesions to biopsy between mp-USS and mp-MRI in men who require a prostate biopsy. Then compare agreement in proportion of men diagnosed with clinically significant prostate cancer on biopsy.",
            "To compare the overall agreement in proportion of men diagnosed with other thresholds of clinically significant prostate cancer on biopsy",
            "To determine the detection of clinically significant cancer (using all of the pre-specified definitions based on histology) by using the combination of these two imaging techniques versus either modality alone",
            "To determine whether the order in which the targeted biopsies are carried out, either to the same target (present on both scans) or different targets impacts on detection of clinically significant cancer",
            "To compare, in those men who go on to radical prostatectomy, the mp-MRI, mp-USS and histology from targeted biopsy with the whole mount specimen obtained at surgery.",
            "To create an inception cohort of men, consented for long-term follow-up and linkage, providing the potential for further translational and clinical studies",
            "To determine rates of adverse events, resource utilization and impact of each test on health-related quality-of-life (using EQ-5D-5L questionnaire) which would allow modelling of overall cost-effectiveness of one strategy compared to the other."
          ]
        },
        "sponsors": { "lead_sponsor": "University College, London" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "500",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "15/0473" },
        "start_date": "July 2015",
        "primary_completion_date": "May 2017",
        "completion_date": "July 2017",
        "study_first_posted": "March 18, 2016",
        "last_update_posted": "August 9, 2016",
        "locations": { "location": "University College London Hospitals, London,, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02712684"
      },
      {
        "-rank": "67",
        "nct_id": "NCT03211052",
        "title": "A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone",
        "acronym": "NEPTUNE",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "TAK-700 and LHRH agonist"
            },
            {
              "-type": "Procedure",
              "#text": "prostatectomy"
            }
          ]
        },
        "outcome_measures": { "outcome_measure": "3 year biochemical progression free survival (PSA)" },
        "sponsors": {
          "lead_sponsor": "Centre of Experimental Medicine",
          "collaborator": [
            "Millennium Pharmaceuticals, Inc.",
            "Queen Mary University of London"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "16",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "008285QM" },
        "start_date": "February 18, 2013",
        "primary_completion_date": "June 2, 2015",
        "completion_date": "June 2, 2015",
        "study_first_posted": "July 7, 2017",
        "last_update_posted": "July 7, 2017",
        "locations": { "location": "St Bartholomew's Hospital, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03211052"
      },
      {
        "-rank": "68",
        "nct_id": "NCT02511665",
        "title": "Metformin And Longevity",
        "acronym": "METAL",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Metformin"
            },
            {
              "-type": "Radiation",
              "#text": "PET-MRI Scan"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": { "outcome_measure": "Assessment of the difference in expression levels of markers of the FASN/AMPK pathway pre and post treatment between the placebo and metformin arms." },
        "sponsors": {
          "lead_sponsor": "Guy's and St Thomas' NHS Foundation Trust",
          "collaborator": "King's College London"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 4" },
        "enrollment": "185",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Basic Science"
          ]
        },
        "other_ids": { "other_id": "METAL" },
        "start_date": "July 2015",
        "primary_completion_date": "July 2017",
        "completion_date": "July 2017",
        "study_first_posted": "July 30, 2015",
        "last_update_posted": "July 30, 2015",
        "locations": { "location": "Guy's Hospital, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02511665"
      },
      {
        "-rank": "69",
        "nct_id": "NCT04081428",
        "title": "Using Breath, Cell Free DNA and Image Analysis to PRedIct Normal TissUe and Tumour Response During Prostate Cancer SBRT",
        "acronym": "PRINToUT",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Radiotherapy Side Effects",
            "Volatile Organic Compounds",
            "DNA Damage"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Radiation",
            "#text": "Stereotactic Body Radiotherapy"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Measurement of the relative change in Gas Chromatography Ion Mobility Spectra (GC-IMS) of Volatile Organic Compounds (VOC's) from breath samples of men with prostate cancer treated with prostate stereotactic body radiotherapy (SBRT)",
            "Measurement of the relative change in normal tissue and tumour cell free DNA (cfDNA) released into the blood of men with prostate cancer treated with prostate stereotactic body radiotherapy (SBRT)",
            "Measurement of the true rectal wall delivered radiation dose compared to planned dose during the prostate SBRT for each patient",
            "Measurement of SBRT treatment related acute and late normal tissue toxicity",
            "Measurement of SBRT treatment related quality of life"
          ]
        },
        "sponsors": { "lead_sponsor": "NHS Lothian" },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "12",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "AC18048" },
        "start_date": "October 11, 2018",
        "primary_completion_date": "October 11, 2019",
        "completion_date": "October 11, 2021",
        "study_first_posted": "September 9, 2019",
        "last_update_posted": "September 9, 2019",
        "locations": { "location": "Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Mid Lothian, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT04081428"
      },
      {
        "-rank": "70",
        "nct_id": "NCT01691976",
        "title": "Mild Cognitive Impairment in Men Following Androgen Deprivation",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Oestrogen Patches"
            },
            {
              "-type": "Drug",
              "#text": "LHRHa"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Objective evaluation of mild cognitive impairment on parietal fMRI signals",
            "Objective evaluation of mild cognitive impairment on non-parietal fMRI signals",
            "Electroencephalographic evaluation of mild cognitive impairment",
            "Subjective evaluation of mild cognitive impairment by CANTAB",
            "Subjective evaluation of mild cognitive impairment by ADAS-cog"
          ]
        },
        "sponsors": { "lead_sponsor": "Imperial College London" },
        "gender": "Male",
        "min_age": "50 Years",
        "max_age": "90 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "10",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)"
          ]
        },
        "other_ids": { "other_id": "CRO2017" },
        "start_date": "October 2012",
        "primary_completion_date": "September 2013",
        "completion_date": "March 2014",
        "study_first_posted": "September 25, 2012",
        "last_update_posted": "October 17, 2012",
        "locations": { "location": "Imperial College Healthcare NHS Trust, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01691976"
      },
      {
        "-rank": "71",
        "nct_id": "NCT02033447",
        "title": "Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate:A Phase 0 Study in Men",
        "acronym": "MAGNABLATE I",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "Magnetic Nanoparticle Injection"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants with Adverse Events as a Measure of Safety and Tolerability",
            "The anatomical distribution of magnetic nanoparticles"
          ]
        },
        "sponsors": { "lead_sponsor": "University College London Hospitals" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Early Phase 1" },
        "enrollment": "12",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Other"
          ]
        },
        "other_ids": {
          "other_id": [
            "13/0257",
            "National Institute for Health"
          ]
        },
        "start_date": "December 2013",
        "primary_completion_date": "January 2015",
        "completion_date": "January 2015",
        "study_first_posted": "January 10, 2014",
        "last_update_posted": "May 10, 2017",
        "locations": { "location": "University College London Hospital, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02033447"
      },
      {
        "-rank": "72",
        "nct_id": "NCT02543905",
        "title": "The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment",
        "acronym": "PROFILE",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Prostate Biopsy",
            "Genetic Counselling",
            "Genetic Markers"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "Prostate MRI and Biopsy"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "The association of specific genetic profiles and biomarkers to predict outcome of prostate screening in men at higher genetic risk",
            "The incidence and aggressiveness of prostate cancer in men at higher genetic risk.",
            "The association of Diffusion Weighted MRI (DW-MRI) findings with prostate biopsy results.",
            "The incidence of abnormal imaging (using 3D ultrasound combined with shear wave elastography) and correlation with biopsy outcome.",
            "The association of biological sample biomarker profiles with prostate biopsy result",
            "The association of quantitative imaging biomarkers with prostate biopsy result"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": [
            "Royal Marsden NHS Foundation Trust",
            "University of Cambridge",
            "University of Oxford",
            "Queen Mary University of London"
          ]
        },
        "gender": "Male",
        "min_age": "40 Years",
        "max_age": "69 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "700",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "CCR4045" },
        "start_date": "April 2015",
        "primary_completion_date": "February 2021",
        "completion_date": "April 2025",
        "study_first_posted": "September 7, 2015",
        "last_update_posted": "September 4, 2019",
        "locations": { "location": "Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02543905"
      },
      {
        "-rank": "73",
        "nct_id": "NCT02061345",
        "title": "PET Imaging in MCI Following ADT for PCa",
        "status": {
          "-open": "N",
          "#text": "Suspended"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Mild Cognitive Impairment"
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "PET biomarker uptake",
            "PET biomarker volume of distribution"
          ]
        },
        "sponsors": { "lead_sponsor": "Imperial College London" },
        "gender": "Male",
        "min_age": "50 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "12",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case Control",
            "Time Perspective: Cross-Sectional"
          ]
        },
        "other_ids": { "other_id": "13HH0558" },
        "start_date": "April 2014",
        "primary_completion_date": "December 2016",
        "completion_date": "December 2016",
        "study_first_posted": "February 12, 2014",
        "last_update_posted": "August 15, 2016",
        "locations": { "location": "Imperial College Healthcare NHS Trust, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02061345"
      },
      {
        "-rank": "74",
        "nct_id": "NCT00337155",
        "title": "BAY88-8223, Dose Finding Study in Patients With HRPC",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Neoplasm Metastasis"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Radium-223 dichloride (BAY88-8223)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Proportion of participants in each dose group with a confirmed PSA response",
            "The maximum percent decrease in PSA level compared to baseline",
            "Time to PSA Progression",
            "Bone-ALP response (classified as for PSA response) and decrease in bone-ALP level compared to baseline",
            "Total number of SRE per patient",
            "Pain Assessment and analgesic consumption",
            "Time to death from first treatment",
            "Time to Skeletal Related Events (SRE)",
            "Adverse events, blood chemistry and haematological toxicity"
          ]
        },
        "sponsors": { "lead_sponsor": "Bayer" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "122",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "15304",
            "2005-003680-22",
            "BC1-04"
          ]
        },
        "start_date": "May 2006",
        "primary_completion_date": "December 2008",
        "completion_date": "December 2009",
        "study_first_posted": "June 15, 2006",
        "last_update_posted": "December 24, 2014",
        "locations": { "location": "Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00337155"
      },
      {
        "-rank": "75",
        "nct_id": "NCT01584258",
        "title": "Prostate Advances in Comparative Evidence",
        "acronym": "PACE",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Procedure",
              "#text": "Laproscopic Prostatectomy"
            },
            {
              "-type": "Radiation",
              "#text": "Conventionally Fractionated Prostate Radiotherapy"
            },
            {
              "-type": "Radiation",
              "#text": "Prostate SBRT"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Biochemical progression-free survival",
            "Toxicity assessment for surgical and SBRT arm",
            "Toxicity assessment for conventionally fractionated and SBRT arm",
            "Patient reported outcomes and quality of life assessment for all treatment arms",
            "Disease-specific and overall survival",
            "Progression-free survival",
            "Commencement of androgen deprivation therapy"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborator": "The Institute of Cancer Research, Sutton, Surrey, UK"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1716",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "ACCP003" },
        "start_date": "April 2012",
        "primary_completion_date": "September 2021",
        "completion_date": "September 2026",
        "study_first_posted": "April 24, 2012",
        "last_update_posted": "April 27, 2015",
        "locations": {
          "location": [
            "Mount Vernon Cancer Centre, London, Surrey, United Kingdom",
            "Royal Marsden NHS Foundation Trust, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01584258"
      },
      {
        "-rank": "76",
        "nct_id": "NCT02388308",
        "title": "Evaluation of Clarity Ultrasound Guidance for Prostate Therapy",
        "acronym": "Clarity-Pro",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "Clarity ultrasound"
          }
        },
        "outcome_measures": { "outcome_measure": "Prostate position (measured in millimeters) measured using Clarity ultrasound and implanted fiducial markers" },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": "Royal Marsden NHS Foundation Trust"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "61",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "4267" },
        "start_date": "May 15, 2015",
        "primary_completion_date": "June 18, 2018",
        "completion_date": "June 18, 2018",
        "study_first_posted": "March 17, 2015",
        "last_update_posted": "June 19, 2018",
        "locations": { "location": "The Royal Marsden, Sutton, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02388308"
      },
      {
        "-rank": "77",
        "nct_id": "NCT02632669",
        "title": "Hemi-Ablative Prostate Brachytherapy",
        "acronym": "HAPpy",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostatic Neoplasms",
            "Cancer of the Prostate"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Radiation",
            "#text": "Hemi gland focal LDR brachytherapy"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Treatment related Urinary toxicity (symptoms) as recorded by the IPSS questionnaire score.",
            "Treatment related Quality of Life (QoL) due to urinary symptoms as recorded by the Quality of Life (QoL) component of the IPSS questionnaire score.",
            "Treatment related bowel toxicity (symptoms) as recorded by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) questionnaire (30 PR 25) score.",
            "Treatment related adverse events on Erectile function as recorded by the International Index of Erectile Function 5 (IIEF 5) questionnaire score.",
            "To evaluate tumor control of hemigland focal brachytherapy"
          ]
        },
        "sponsors": { "lead_sponsor": "Royal Surrey County Hospital NHS Foundation Trust" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "31",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "R&D12oncn0015" },
        "start_date": "November 2013",
        "primary_completion_date": "April 2018",
        "completion_date": "June 2018",
        "study_first_posted": "December 17, 2015",
        "last_update_posted": "April 11, 2018",
        "locations": { "location": "Royal Surrey NHS Foundation Trust, Guildford, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02632669"
      },
      {
        "-rank": "78",
        "nct_id": "NCT01194648",
        "title": "Focal Therapy for Prostate Cancer Using HIFU",
        "acronym": "INDEX",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Male Erectile Disorder",
            "Prostate Cancer",
            "Therapy-related Toxicity",
            "Urinary Incontinence"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            },
            {
              "-type": "Procedure",
              "#text": "assessment of therapy complications"
            },
            {
              "-type": "Procedure",
              "#text": "high-intensity focused ultrasound ablation"
            },
            {
              "-type": "Procedure",
              "#text": "multiparametric magnetic resonance imaging"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            },
            {
              "-type": "Procedure",
              "#text": "transperineal prostate biopsy"
            },
            {
              "-type": "Procedure",
              "#text": "transrectal prostate biopsy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Conversion to radical therapy and/or requiring systemic therapy and/or developing metastases and/or dying of prostate cancer",
            "rate of erectile dysfunction",
            "time to return of erectile function",
            "rate of urinary incontinence (pad free, leak free and pad-free alone)",
            "time to return of continence (pad free, leak free and pad-free alone)",
            "rate of loss of ejaculation",
            "rate of loss of orgasm",
            "rate of pain during intercourse",
            "number of men using phosphodiesterase-5 inhibitors to maintain erectile function",
            "rate of lower urinary tract symptoms",
            "rate of bowel toxicity",
            "anxiety levels",
            "general health related quality of life",
            "proportion of men achieving trifecta status at 12 months",
            "proportion of men achieving trifecta status at 24 months",
            "rate of secondary prostate cancer intervention (prostatectomy, radiotherapy, androgen ablation, whole-gland HIFU or cryosurgery)",
            "risk factors for failure defined as a) presence of any cancer and b) clinically significant cancer at study end",
            "biochemical (PSA) kinetics including determining the optimal biochemical definition of failure",
            "describe composite outcomes of failure",
            "Cost-effectiveness"
          ]
        },
        "sponsors": { "lead_sponsor": "University College, London" },
        "gender": "Male",
        "max_age": "90 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "354",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000684020",
            "9945"
          ]
        },
        "start_date": "June 29, 2011",
        "primary_completion_date": "December 2028",
        "completion_date": "June 2029",
        "study_first_posted": "September 3, 2010",
        "last_update_posted": "April 20, 2018",
        "locations": { "location": "University College London, London, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01194648"
      },
      {
        "-rank": "79",
        "nct_id": "NCT01883128",
        "title": "FOcal RECurrent Assessment and Salvage Treatment",
        "acronym": "FORECAST",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Progression of Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Device",
              "#text": "Whole Body MRI"
            },
            {
              "-type": "Procedure",
              "#text": "Focal Salvage Therapy"
            },
            {
              "-type": "Procedure",
              "#text": "MRI Targeted biopsies"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Accuracy of whole body MRI in identifying distant disease",
            "Can multiparametric MRI accurately detect localised recurrent prostate cancer"
          ]
        },
        "sponsors": { "lead_sponsor": "University College London Hospitals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "177",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: Single (Investigator)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "1R01CA135089" },
        "start_date": "April 2014",
        "primary_completion_date": "October 2019",
        "completion_date": "October 2019",
        "study_first_posted": "June 21, 2013",
        "last_update_posted": "May 10, 2017",
        "locations": {
          "location": [
            "Hampshire Hospitals NHS Trust, London, United Kingdom",
            "University College London Hospitals, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01883128"
      },
      {
        "-rank": "80",
        "nct_id": "NCT02380027",
        "title": "PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not?",
        "acronym": "PRECISION",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Neoplasm" },
        "interventions": {
          "intervention": [
            {
              "-type": "Device",
              "#text": "MRI"
            },
            {
              "-type": "Procedure",
              "#text": "MRI-targeted biopsy"
            },
            {
              "-type": "Procedure",
              "#text": "TRUS-biopsy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Proportion of men with clinically significant detected",
            "Proportion of men in MRI arm who avoid biopsy",
            "Proportion of men with MRI score 3, 4 or 5 who have no clinically significant cancer detected",
            "Proportion of men who go on to definitive treatment for prostate cancer",
            "Cancer core length of the most involved biopsy core (maximum cancer core length)",
            "Proportion of men with post-biopsy adverse events",
            "EQ-5D-5L Quality of Life scores",
            "Proportion of men undergoing Radical prostatectomy who have Gleason grade upgrading",
            "Cost per diagnosis of cancer",
            "Proportion of men with clinically insignificant detected"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University College, London",
          "collaborator": [
            "National Institute for Health Research, United Kingdom",
            "University Hospital, Lille",
            "Radboud University",
            "London North West Healthcare NHS Trust",
            "Royal Free Hospital NHS Foundation Trust",
            "Sunnybrook Health Sciences Centre",
            "University College London Hospitals",
            "University Ghent",
            "Helsinki University Central Hospital",
            "Jewish General Hospital",
            "University of Roma La Sapienza",
            "GÃ¶teborg University",
            "Erasmus Medical Center",
            "Hunter Holmes Mcguire Veteran Affairs Medical Center",
            "University Hospital Heidelberg",
            "University Hospital, Aachen",
            "Hampshire Hospitals NHS Foundation Trust",
            "The Princess Alexandra Hospital NHS Trust, United Kingdom",
            "San Raffaele University Hospital, Italy",
            "M.D. Anderson Cancer Center",
            "University Hospital Southampton NHS Foundation Trust",
            "University of Oulu",
            "The Whittington Hospital NHS Trust",
            "University Hospital of Cologne",
            "Mayo Clinic",
            "Centro de Urologia Argentina",
            "Weill Medical College of Cornell University",
            "University of Chicago",
            "University Hospital, Bordeaux"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "500",
        "funded_bys": {
          "funded_by": [
            "Other",
            "U.S. Fed"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Single (Outcomes Assessor)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "DRF-2014-07-146" },
        "start_date": "January 2016",
        "primary_completion_date": "December 31, 2017",
        "completion_date": "December 31, 2017",
        "study_first_posted": "March 5, 2015",
        "last_update_posted": "May 1, 2018",
        "locations": { "location": "University College Hospitals, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02380027"
      },
      {
        "-rank": "81",
        "nct_id": "NCT03321864",
        "title": "Capture of Prostatic Trans-rectal Ultrasound Scans for Research",
        "acronym": "CAPTURE",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Prostate Neoplasm"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "Transrectal ultrasound scan of prostate"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Prostate size",
            "Prostate location"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Cambridge University Hospitals NHS Foundation Trust",
          "collaborator": "University of Cambridge"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "100 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "150",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Basic Science"
          ]
        },
        "other_ids": {
          "other_id": [
            "A094516",
            "228575"
          ]
        },
        "start_date": "January 1, 2018",
        "primary_completion_date": "December 31, 2022",
        "completion_date": "December 31, 2022",
        "study_first_posted": "October 26, 2017",
        "last_update_posted": "January 14, 2019",
        "locations": { "location": "Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03321864"
      },
      {
        "-rank": "82",
        "nct_id": "NCT00946543",
        "title": "Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Radiation",
              "#text": "hypofractionated radiation therapy"
            },
            {
              "-type": "Radiation",
              "#text": "intensity-modulated radiation therapy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Late RTOG radiotherapy toxicity as assessed at 6, 12, 18, and 24 months and then annually thereafter",
            "Overall survival",
            "Local control",
            "PSA control",
            "Acute side effects as assessed weekly by the RTOG scoring system",
            "Quality of life",
            "Patterns of recurrence"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "198",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": { "study_design": "Primary Purpose: Treatment" },
        "other_ids": {
          "other_id": [
            "CDR0000601695",
            "RMNHS-1766",
            "EU-20869"
          ]
        },
        "start_date": "March 2000",
        "primary_completion_date": "March 2010",
        "study_first_posted": "July 27, 2009",
        "last_update_posted": "August 26, 2013",
        "locations": {
          "location": [
            "Institute of Cancer Research - Chelsea, London, England, United Kingdom",
            "Institute of Cancer Research - Sutton, Sutton, England, United Kingdom",
            "Royal Marsden - Surrey, Sutton, England, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00946543"
      },
      {
        "-rank": "83",
        "nct_id": "NCT00667537",
        "title": "PK in Pts With HRPC & Skeletal Metastes",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Radium-223 chloride (XofigoÂ®, BAY88-8223) injection"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Estimation of whole-body retention of radioactivity at each imaging time post-injection",
            "Estimation of the individual organ uptake/retention of radioactivity at each time-point post injection",
            "Estimate retention of administered radioactivity in blood",
            "Estimation of elimination of radioactivity in urine and faeces",
            "Calculation of estimated absorbed radiation dose to target organs",
            "Pharmacokinetics",
            "Comparison of the biodistribution and dosimetry after the first and second injection",
            "Prostate specific antigen (PSA) response",
            "Survival",
            "Adverse events",
            "Laboratory variables; serum biochemistry and haematology",
            "Vital signs",
            "ECG (12 leads)",
            "Physical examination"
          ]
        },
        "sponsors": { "lead_sponsor": "Bayer" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "6",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Basic Science"
          ]
        },
        "other_ids": {
          "other_id": [
            "15302",
            "2006-006101-88",
            "BC1-05"
          ]
        },
        "start_date": "July 2007",
        "primary_completion_date": "December 2008",
        "completion_date": "December 2008",
        "study_first_posted": "April 28, 2008",
        "last_update_posted": "December 14, 2015",
        "locations": { "location": "Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00667537"
      },
      {
        "-rank": "84",
        "nct_id": "NCT03658525",
        "title": "Prostate Radiotherapy Integrated With Simultaneous MRI (The PRISM Study)",
        "acronym": "PRISM",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "MR LINAC"
          }
        },
        "outcome_measures": { "outcome_measure": "The proportion of patients in whom the imaging and treatment on the MR Linac (i.e. total time on the treatment couch) can be completed within 1 hour on 90% of fractions as assessed by the radiotherapy timing sheet." },
        "sponsors": { "lead_sponsor": "Royal Marsden NHS Foundation Trust" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "30",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CCR4888" },
        "start_date": "August 7, 2018",
        "primary_completion_date": "August 2020",
        "completion_date": "August 2023",
        "study_first_posted": "September 5, 2018",
        "last_update_posted": "September 7, 2018",
        "locations": { "location": "Royal Marsden - Surrey, Sutton, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03658525"
      },
      {
        "-rank": "85",
        "nct_id": "NCT03609528",
        "title": "CamPROBE: Developing a Safer and Simple Device for Local Anaesthetic Transperineal Prostate Biopsies",
        "acronym": "CamPROBE",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "CamPROBE"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Incidence of Infection",
            "Patient reported pain score",
            "Biological functions post biopsy",
            "Patient willingness to have a repeat biopsy"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Cambridge University Hospitals NHS Foundation Trust",
          "collaborator": "University of Cambridge"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "40",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "CamPROBE" },
        "start_date": "February 15, 2019",
        "primary_completion_date": "June 30, 2020",
        "completion_date": "June 30, 2021",
        "study_first_posted": "August 1, 2018",
        "last_update_posted": "March 13, 2019",
        "locations": { "location": "Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03609528"
      },
      {
        "-rank": "86",
        "nct_id": "NCT03851211",
        "title": "Prolaris Enhanced Risk Stratification - an ecONomic and clinicAL Evaluation",
        "acronym": "PERSONAL",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "outcome_measures": {
          "outcome_measure": [
            "Prolaris test outcome received via report.",
            "Treatment counselling"
          ]
        },
        "sponsors": { "lead_sponsor": "The Leeds Teaching Hospitals NHS Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "100 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "100",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "UR17/104867" },
        "start_date": "February 21, 2019",
        "primary_completion_date": "October 30, 2020",
        "completion_date": "October 30, 2020",
        "study_first_posted": "February 22, 2019",
        "last_update_posted": "February 28, 2019",
        "locations": { "location": "St James's University Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03851211"
      },
      {
        "-rank": "87",
        "nct_id": "NCT02821728",
        "title": "Sulphate Accumulation in Prostate",
        "acronym": "SAP",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Dietary Supplement",
              "#text": "Dietary intervention"
            },
            {
              "-type": "Other",
              "#text": "Normal diet"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Sulphate level",
            "ADP",
            "Redox status of phosphatase proteins"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Quadram Institute Bioscience",
          "collaborator": "Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "18",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Prevention"
          ]
        },
        "other_ids": { "other_id": "IFR01/2016" },
        "start_date": "April 2016",
        "primary_completion_date": "December 2016",
        "completion_date": "April 2017",
        "study_first_posted": "July 4, 2016",
        "last_update_posted": "June 2, 2017",
        "locations": { "location": "Institute of Food Research, Norwich, Norfolk, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02821728"
      },
      {
        "-rank": "88",
        "nct_id": "NCT03011606",
        "title": "Robotic Surgery After Focal Ablation Therapy",
        "acronym": "RAFT",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "Robotic Surgery"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety profile of surgery: This will be quantified using the Clavien-Dindo classification of complications (I-V)",
            "Toxicity profile prior to surgery",
            "Toxicity profile following surgery",
            "Oncological outcome"
          ]
        },
        "sponsors": { "lead_sponsor": "Queen Mary University of London" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "24",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "9211QM" },
        "start_date": "February 2016",
        "primary_completion_date": "December 2019",
        "completion_date": "January 2020",
        "study_first_posted": "January 5, 2017",
        "last_update_posted": "August 22, 2017",
        "locations": { "location": "Guys and St Thomas' Hospital, London, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03011606"
      },
      {
        "-rank": "89",
        "nct_id": "NCT03025633",
        "title": "Explaining the Invisible Using the PEARL System",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "PEARL"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Clinically significant reduction in the number of CBCT rescans due to protocol non-compliance (resulting from both rectum and bladder non-conformances).",
            "Statistically significant difference in bladder volume compliance between the two groups.",
            "A statistically significant reduction in treatment-related anxiety in patients, to be assessed using pre-treatment questionnaires.",
            "Increased understanding of patients, as perceived by them, regarding the radiotherapy treatment procedure in terms of accurate positioning and need for preparation (rectum/bladder management)."
          ]
        },
        "sponsors": { "lead_sponsor": "Hull and East Yorkshire Hospitals NHS Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "155",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Supportive Care"
          ]
        },
        "other_ids": { "other_id": "HullEastYorkshireNHS" },
        "start_date": "November 2016",
        "primary_completion_date": "February 2018",
        "completion_date": "February 2018",
        "study_first_posted": "January 19, 2017",
        "last_update_posted": "July 15, 2019",
        "locations": { "location": "Hull and East Yorkshire Hospitals NHS Trust, Hull, East Yorkshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03025633"
      },
      {
        "-rank": "90",
        "nct_id": "NCT02145494",
        "title": "The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife",
        "acronym": "SPARC",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Radiation",
            "#text": "Radiotherapy"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Acute genitourinary(GU) toxicity",
            "Acute gastrointestinal (GI) toxicity",
            "Late GI and GU toxicity",
            "Patient reported outcomes i.e. IPSS, IIEF-5 and EQ5-D",
            "Biochemical relapse-free survival"
          ]
        },
        "sponsors": { "lead_sponsor": "Royal Marsden NHS Foundation Trust" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "20",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "13/LO/0109",
            "CCR 3923"
          ]
        },
        "start_date": "June 2013",
        "primary_completion_date": "December 2015",
        "completion_date": "December 2018",
        "study_first_posted": "May 23, 2014",
        "last_update_posted": "May 23, 2014",
        "locations": { "location": "Royal Marsden NHS Foundation trust, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02145494"
      },
      {
        "-rank": "91",
        "nct_id": "NCT02055716",
        "title": "Sulforadex in Healthy Human Males MAD",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Sulforadex"
            },
            {
              "-type": "Drug",
              "#text": "alpha-cyclodextrin"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of participants with adverse events",
            "Area under the plasma concentration versus time curve (AUC) of sulforaphane"
          ]
        },
        "sponsors": { "lead_sponsor": "Evgen Pharma" },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "45 Years",
        "age_groups": { "age_group": "Adult" },
        "phases": { "phase": "Phase 1" },
        "enrollment": "18",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "EVG002N" },
        "start_date": "January 2014",
        "primary_completion_date": "April 2014",
        "completion_date": "May 2014",
        "study_first_posted": "February 5, 2014",
        "last_update_posted": "February 10, 2015",
        "locations": { "location": "Richmond Pharmacology Limited, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02055716"
      },
      {
        "-rank": "92",
        "nct_id": "NCT03815942",
        "title": "VAccination in Early and ADvanced Prostate caNCEr",
        "acronym": "ADVANCE",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Intermediate Risk Prostate Cancer",
            "Castration-resistant Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "ChAdOx1-MVA 5T4 vaccine"
            },
            {
              "-type": "Drug",
              "#text": "Nivolumab Infusion [Opdivo]"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety - incidence of treatment-related adverse events.",
            "Efficacy - measure composite response rate defined as one of the following: 1) change in circulating tumour DNA, 2) change in serum PSA",
            "Evaluate immune responses to the vaccine antigen in the periphery",
            "Evaluate immune cell subsets in the prostate secondary to treatment (for surgical cohort)",
            "Evaluate progression-free survival following study treatment (for advanced metastatic cancer cohort)",
            "Evaluate overall survival following study treatment (for advanced metastatic cancer cohort)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University of Oxford",
          "collaborator": "Vaccitech Limited"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "36",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "ADVANCE" },
        "start_date": "December 10, 2018",
        "primary_completion_date": "December 10, 2020",
        "completion_date": "May 10, 2021",
        "study_first_posted": "January 24, 2019",
        "last_update_posted": "February 8, 2019",
        "locations": {
          "location": [
            "Cancer Institute, University College London, London, United Kingdom",
            "Department of Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom",
            "Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03815942"
      },
      {
        "-rank": "93",
        "nct_id": "NCT01842750",
        "title": "The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study",
        "acronym": "BRAD",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "Endorectal Balloon insertion"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Tolerability",
            "rectal volume",
            "Assessment of planning target volume (PTV) coverage",
            "Rectal wall sparing",
            "Acute toxicity"
          ]
        },
        "sponsors": { "lead_sponsor": "The Christie NHS Foundation Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "10",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)"
          ]
        },
        "other_ids": { "other_id": "11_RADIO_101" },
        "start_date": "August 2013",
        "primary_completion_date": "December 2014",
        "study_first_posted": "April 30, 2013",
        "last_update_posted": "July 30, 2014",
        "locations": { "location": "Christie Hospital NHS Foundation Trust, Manchester, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01842750"
      },
      {
        "-rank": "94",
        "nct_id": "NCT00520052",
        "title": "Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Osteoporosis" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "zoledronic acid"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "axial and peripheral bone mineral density",
            "serum and urine bone turnover markers"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Wirral University Teaching Hospital NHS Trust",
          "collaborator": "Novartis"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "58",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "57/03" },
        "start_date": "August 2003",
        "completion_date": "August 2005",
        "study_first_posted": "August 23, 2007",
        "last_update_posted": "August 23, 2007",
        "locations": { "location": "Wirral Hospitals Universirt NHS Trust, Upton, Wirral, Merseyside, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00520052"
      },
      {
        "-rank": "95",
        "nct_id": "NCT01337518",
        "title": "A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Suspended"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasm" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "EZN-4176"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Determine the Maximum Tolerated Dose (MTD) of EZN-4176 administered as a weekly 1-hour IV infusion.",
            "Determine the recommended Phase 2 dose of EZN-4176"
          ]
        },
        "sponsors": { "lead_sponsor": "Enzon Pharmaceuticals, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "150",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "EZN-4176-01" },
        "start_date": "March 2011",
        "primary_completion_date": "December 2013",
        "completion_date": "December 2013",
        "study_first_posted": "April 19, 2011",
        "last_update_posted": "December 18, 2012",
        "locations": {
          "location": [
            "Memorial Sloan-Kettering Cancer Center, New York, New York, United States",
            "Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01337518"
      },
      {
        "-rank": "96",
        "nct_id": "NCT01948362",
        "title": "Sulforadex in Healthy Volunteers SAD",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Stage, Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Sulforadex"
            },
            {
              "-type": "Drug",
              "#text": "Alpha cyclodextrin"
            }
          ]
        },
        "outcome_measures": { "outcome_measure": "Safety" },
        "sponsors": { "lead_sponsor": "Evgen Pharma" },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "45 Years",
        "age_groups": { "age_group": "Adult" },
        "phases": { "phase": "Phase 1" },
        "enrollment": "29",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "EVG001N" },
        "start_date": "November 2012",
        "primary_completion_date": "February 2013",
        "completion_date": "February 2013",
        "study_first_posted": "September 23, 2013",
        "last_update_posted": "September 23, 2013",
        "locations": { "location": "Richmond Pharmacology, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01948362"
      },
      {
        "-rank": "97",
        "nct_id": "NCT02978014",
        "title": "A Trial Assessing Post-Operative Use of ProSpare, a Rectal Obturator in Prostate Cancer Radiotherapy",
        "acronym": "POPS",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "ProSpare"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "EPIC Bowel Scores for Bowel, Urinary and Sexual domains",
            "Quality of Life measures",
            "Dosimetric analysis"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborator": "Institute of Cancer Research, United Kingdom"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "245",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CCR 4359" },
        "start_date": "February 8, 2017",
        "primary_completion_date": "October 2020",
        "completion_date": "October 2023",
        "study_first_posted": "November 30, 2016",
        "last_update_posted": "November 28, 2018",
        "locations": { "location": "The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02978014"
      },
      {
        "-rank": "98",
        "nct_id": "NCT00536653",
        "title": "Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Osteoporosis" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Bicalutamide and Calcium/ Vitamin D supplementation"
            },
            {
              "-type": "Drug",
              "#text": "LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation"
            },
            {
              "-type": "Drug",
              "#text": "LHRH agonists (Goserelin acetate)"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Peripheral Forearm bone mineral density",
            "Fractures of the thoracolumbar spine"
          ]
        },
        "sponsors": { "lead_sponsor": "Wirral University Teaching Hospital NHS Trust" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "618",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Prevention"
          ]
        },
        "other_ids": { "other_id": "55/99" },
        "start_date": "October 1999",
        "completion_date": "January 2007",
        "study_first_posted": "September 28, 2007",
        "last_update_posted": "September 28, 2007",
        "locations": { "location": "Wirral University Hospitals NHS Trust, Upton, Wirral, Merseyside, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00536653"
      },
      {
        "-rank": "99",
        "nct_id": "NCT02151097",
        "title": "PRIME - PRostate Imaging for Margin Evaluation",
        "acronym": "PRIME",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "outcome_measures": {
          "outcome_measure": [
            "Margin status of prostatectomy specimen as determined by the LightPathTM Imaging System",
            "The agreement between margin status as determined by CLI and histopathology"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Lightpoint Medical Limited",
          "collaborator": [
            "University College London Hospitals",
            "University College, London"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "7",
        "funded_bys": {
          "funded_by": [
            "Industry",
            "Other"
          ]
        },
        "study_types": "Observational",
        "study_designs": { "study_design": "Time Perspective: Prospective" },
        "other_ids": { "other_id": "LPM-003" },
        "start_date": "November 2014",
        "primary_completion_date": "June 2016",
        "completion_date": "June 2016",
        "study_first_posted": "May 30, 2014",
        "last_update_posted": "June 23, 2016",
        "locations": { "location": "University College Hospital London, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02151097"
      },
      {
        "-rank": "100",
        "nct_id": "NCT00600535",
        "title": "A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Stage 1 Group 1: abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Stage 1 Group 2: abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Stage 2: abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Stage 3: abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Stage 3: glucocorticoid"
            },
            {
              "-type": "Drug",
              "#text": "Stage 4: abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Stage 4: glucocorticoid"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Mean plasma concentrations of abiraterone",
            "Maximum plasma concentrations of abiraterone",
            "Time to reach the maximum plasma concentration of abiraterone",
            "Area under the plasma-concentration-time curve from time 0 to the last quantifiable concentration of abiraterone",
            "Area under the plasma-concentration-time curve from time 0 to infinite time of abiraterone",
            "Elimination half-life of abiraterone",
            "Steady state trough concentration of abiraterone",
            "Number of participants affected by an adverse event",
            "Number of patients with serum prostate specific antigen (PSA) decline according to PSA Working Group criteria",
            "Number of patients with circulating tumor cells isolated from peripheral blood samples defined by cell counts",
            "Number of patients with circulating tumor cells isolated from peripheral blood samples defined by molecular characterization"
          ]
        },
        "sponsors": { "lead_sponsor": "Cougar Biotechnology, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "31",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR016933",
            "COU-AA-BE"
          ]
        },
        "start_date": "July 2007",
        "primary_completion_date": "March 2012",
        "completion_date": "March 2012",
        "study_first_posted": "January 25, 2008",
        "last_update_posted": "April 17, 2013",
        "locations": {
          "location": [
            "Los Angeles, California, United States",
            "Glasgow, United Kingdom",
            "Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00600535"
      },
      {
        "-rank": "101",
        "nct_id": "NCT03832803",
        "title": "Less to Hold - A Comparison of Bladder Toxicities (Side Effects) in Patients Undergoing Prostate Radiotherapy Between Patients Treated With Empty Bladder and Those on a Drinking Protocol.",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Radiotherapy Side Effect"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Behavioral",
              "#text": "Empty bladder"
            },
            {
              "-type": "Behavioral",
              "#text": "Full bladder"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Change in IPSS score",
            "Change in LENT SOMA score",
            "Bowel and bladder DVH"
          ]
        },
        "sponsors": { "lead_sponsor": "Lancashire Teaching Hospitals NHS Foundation Trust" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "50",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Other"
          ]
        },
        "other_ids": { "other_id": "2113" },
        "start_date": "March 1, 2017",
        "primary_completion_date": "March 1, 2018",
        "completion_date": "January 25, 2019",
        "study_first_posted": "February 6, 2019",
        "last_update_posted": "February 6, 2019",
        "locations": { "location": "Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03832803"
      },
      {
        "-rank": "102",
        "nct_id": "NCT02123888",
        "title": "Simultaneous CBCT Acquisition During Arc Radiotherapy",
        "acronym": "SCART",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Lung Cancer"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Radiation",
            "#text": "Cone Beam Computed Tomography"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Equivalence of image quality",
            "Quantify inter-observer variation",
            "Quantify impact on treatment times."
          ]
        },
        "sponsors": {
          "lead_sponsor": "Sally Falk",
          "collaborator": "The Christie NHS Foundation Trust"
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "75",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)"
          ]
        },
        "other_ids": { "other_id": "10_RADIO_94" },
        "start_date": "June 2011",
        "primary_completion_date": "December 2015",
        "completion_date": "December 2015",
        "study_first_posted": "April 28, 2014",
        "last_update_posted": "February 9, 2015",
        "locations": { "location": "The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02123888"
      },
      {
        "-rank": "103",
        "nct_id": "NCT00561314",
        "title": "High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Sexual Dysfunction",
            "Urinary Incontinence"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            },
            {
              "-type": "Procedure",
              "#text": "biopsy"
            },
            {
              "-type": "Procedure",
              "#text": "high-intensity focused ultrasound ablation"
            },
            {
              "-type": "Procedure",
              "#text": "magnetic resonance imaging"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Feasibility, patient acceptability and side effect profile of high-intensity focal ultrasound ablation as determined by adverse events",
            "Patient acceptability, urinary symptoms, and erectile function as assessed by Functional Assessment of Cancer Treatment-Prostate (FACT-P); Item International Index of Erectile Dysfunction (IIEF-15); International Prostate Symptom Score (IPSS); I ...",
            "Effectiveness of high-intensity focal ultrasound ablation to control prostate cancer as determined by time to PSA nadir, MRI at 10-20 days and again at 6 months, biopsies of treated areas at 6 months, and by recording the need for secondary or adjuva ..."
          ]
        },
        "sponsors": {
          "lead_sponsor": "University College London Hospitals",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "min_age": "45 Years",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "33",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": { "study_design": "Primary Purpose: Treatment" },
        "other_ids": {
          "other_id": [
            "CDR0000574344",
            "UCLCTC-UCLH-FOCAL-HIFU",
            "EU-20773"
          ]
        },
        "start_date": "July 2007",
        "primary_completion_date": "February 2009",
        "completion_date": "January 2012",
        "study_first_posted": "November 20, 2007",
        "last_update_posted": "August 26, 2013",
        "locations": {
          "location": [
            "Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom",
            "University College of London Hospitals, London, England, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00561314"
      },
      {
        "-rank": "104",
        "nct_id": "NCT03151512",
        "title": "UNDISTORT Correction of Distortions in Diffusion MRI V1.0",
        "acronym": "UNDISTORT",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "MR Image Distortion Correction",
            "Prostate Cancer"
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Dice similarity score to assess distortions",
            "Radiological scoring of image quality",
            "Diffusion coefficient consistency"
          ]
        },
        "sponsors": { "lead_sponsor": "University College, London" },
        "gender": "All",
        "min_age": "18 Years",
        "max_age": "120 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "155",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "16/0128" },
        "start_date": "March 29, 2017",
        "primary_completion_date": "January 2020",
        "completion_date": "March 2020",
        "study_first_posted": "May 12, 2017",
        "last_update_posted": "May 12, 2017",
        "locations": { "location": "University College London Hospital, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03151512"
      },
      {
        "-rank": "105",
        "nct_id": "NCT03617588",
        "title": "68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer",
        "acronym": "PRONOUNCED",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Gallium-68 THP-PSMA"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Change in patient management",
            "Treatment Emergent Adverse Events [Safety and tolerability]"
          ]
        },
        "sponsors": { "lead_sponsor": "Theragnostics Ltd" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "51",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "THERAG0001" },
        "start_date": "June 18, 2018",
        "primary_completion_date": "June 12, 2019",
        "completion_date": "June 12, 2019",
        "study_first_posted": "August 6, 2018",
        "last_update_posted": "June 26, 2019",
        "locations": {
          "location": [
            "St Bartholomew's Hospital (PIC), London, United Kingdom",
            "Royal Free Hospital (PIC), London, United Kingdom",
            "Guy's and St Thomas' Hospital (PIC), London, United Kingdom",
            "University College Hospital London, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03617588"
      },
      {
        "-rank": "106",
        "nct_id": "NCT03436485",
        "title": "Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer",
        "acronym": "CYPIDES",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer Metastatic" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "ODM-208"
          }
        },
        "outcome_measures": { "outcome_measure": "Maximum tolerated dose (MTD)" },
        "sponsors": { "lead_sponsor": "Orion Corporation, Orion Pharma" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "156",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "3124001" },
        "start_date": "March 19, 2018",
        "primary_completion_date": "May 2021",
        "completion_date": "May 2021",
        "study_first_posted": "February 16, 2018",
        "last_update_posted": "May 17, 2019",
        "locations": {
          "location": [
            "Helsinki University Central Hospital, Helsinki, Finland",
            "Institut Gustave Roussy, Villejuif, France",
            "The Christie NHS Foundation Trust, Manchester, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03436485"
      },
      {
        "-rank": "107",
        "nct_id": "NCT02341677",
        "title": "SmartTarget: BIOPSY",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostatic Neoplasms",
            "Diagnostic Techniques and Procedures"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "SmartTarget - Biopsy"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Cancer Detection",
            "Targeting Efficiency (core length, grade)",
            "Clinical Usability (length of procedure, generation time, re-registration rate, failure rate)",
            "Quality of Life"
          ]
        },
        "sponsors": { "lead_sponsor": "University College, London" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "134",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "14/0044" },
        "start_date": "November 2014",
        "primary_completion_date": "September 2016",
        "completion_date": "September 2016",
        "study_first_posted": "January 19, 2015",
        "last_update_posted": "January 31, 2019",
        "locations": { "location": "University College London, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02341677"
      },
      {
        "-rank": "108",
        "nct_id": "NCT03317990",
        "title": "Evaluating the Effects of Frozen Section Technology on Oncological and Functional Outcomes at Radical Prostatectomy.",
        "acronym": "NSAFEPROOF",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "NeuroSAFE procedure"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Recruitment rates",
            "Study acceptability",
            "Short term oncological and functional outcome (compound outcome)",
            "Health economics"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University College, London",
          "collaborator": [
            "North Bristol NHS Trust",
            "Sheffield Teaching Hospitals NHS Foundation Trust",
            "University College London Hospitals",
            "NHS Greater Glasgow and Clyde"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "75 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "100",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Single (Participant)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "220262" },
        "start_date": "April 9, 2018",
        "primary_completion_date": "March 2021",
        "completion_date": "March 2021",
        "study_first_posted": "October 23, 2017",
        "last_update_posted": "August 13, 2019",
        "locations": {
          "location": [
            "North Bristol NHS Trust, Bristol, United Kingdom",
            "NHS Greater Glasgow & Clyde, Glasgow, United Kingdom",
            "University College London Hospital, London, United Kingdom",
            "Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03317990"
      },
      {
        "-rank": "109",
        "nct_id": "NCT00459654",
        "title": "A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Neoplasm Metastasis"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Radium-223 dichloride (BAY88-8223)"
            },
            {
              "-type": "Drug",
              "#text": "Saline"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Time to occurrence of Skeletal-related Events (SRE)",
            "Relative change (%) in bone-ALP levels from baseline to 4 weeks after last injection",
            "Number of SREs per patient",
            "Changes in the levels of biochemical markers of bone formation",
            "Change in Prostate Specific Antigen (PSA)",
            "Change in pain level",
            "Changes in analgesic use during study period",
            "Changes in Edmonton Symptom Assessment Scale (ESAS) from baseline",
            "Overall survival",
            "Adverse events",
            "Clinical laboratory tests including haematology, renal and liver function parameters"
          ]
        },
        "sponsors": { "lead_sponsor": "Bayer" },
        "gender": "Male",
        "min_age": "40 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "64",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "15280",
            "BC1-02"
          ]
        },
        "start_date": "February 2004",
        "primary_completion_date": "May 2006",
        "completion_date": "May 2007",
        "study_first_posted": "April 12, 2007",
        "last_update_posted": "June 25, 2014",
        "locations": {
          "location": [
            "LinkÃ¶ping, Sweden",
            "Sundsvall, Sweden",
            "Nottingham, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00459654"
      },
      {
        "-rank": "110",
        "nct_id": "NCT01352208",
        "title": "Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Castrate Resistant Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "ASP9521"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "To evaluate the safety and tolerability, based on the frequency and severity of Adverse Events (AEs), laboratory assessments, vital signs, electrocardiograms (ECGs) and clinical observations",
            "Decline in Prostate-specific antigen (PSA)"
          ]
        },
        "sponsors": { "lead_sponsor": "Astellas Pharma Inc" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "13",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "9521-CL-0002",
            "2010-023382-22"
          ]
        },
        "start_date": "March 2011",
        "primary_completion_date": "September 2012",
        "completion_date": "September 2012",
        "study_first_posted": "May 11, 2011",
        "last_update_posted": "March 24, 2014",
        "locations": {
          "location": [
            "Site 131, Antwerp, Belgium",
            "Site: 121, Villejuif, France",
            "Site:109, Glasgow, United Kingdom",
            "Site: 101, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01352208"
      },
      {
        "-rank": "111",
        "nct_id": "NCT00474383",
        "title": "An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Glucocorticoid"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12",
            "Percentage of Participants With Confirmed Prostate Specific Antigen (PSA) Response",
            "Percentage of Participants With Confirmed Objective Tumor Response as Per Response Evaluation Criteria in Solid Tumors (RECIST)",
            "Time to PSA Progression",
            "Duration of PSA Response",
            "Progression Free Survival Time",
            "Overall Survival",
            "Shift From Baseline in Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score at Post-dose (Week 148)"
          ]
        },
        "sponsors": { "lead_sponsor": "Cougar Biotechnology, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "47",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR016915",
            "COU-AA-003",
            "COU-AA-003EXT"
          ]
        },
        "start_date": "November 2006",
        "primary_completion_date": "August 2011",
        "completion_date": "August 2011",
        "study_first_posted": "May 16, 2007",
        "results_first_posted": "August 15, 2013",
        "last_update_posted": "May 12, 2014",
        "locations": {
          "location": [
            "San Francisco, California, United States",
            "New York, New York, United States",
            "Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00474383"
      },
      {
        "-rank": "112",
        "nct_id": "NCT00848601",
        "title": "Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Non-Hodgkins Lymphoma"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "SGI-1776"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "MTD & DLT",
            "Response rate, pharmacokinetics, PSA response, renal elimination and pharmacodynamic effects on biomarker modulation."
          ]
        },
        "sponsors": {
          "lead_sponsor": "Astex Pharmaceuticals",
          "collaborator": "Astex Pharmaceuticals, Inc."
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "14",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)"
          ]
        },
        "other_ids": { "other_id": "SGI-1776-01" },
        "start_date": "February 2009",
        "primary_completion_date": "October 2010",
        "completion_date": "October 2010",
        "study_first_posted": "February 20, 2009",
        "last_update_posted": "December 2, 2011",
        "locations": {
          "location": [
            "UCLA, Los Angeles, California, United States",
            "Cancer Therapy Research Center, San Antonio, Texas, United States",
            "Royal Marsden Hospital, Sutton, England, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00848601"
      },
      {
        "-rank": "113",
        "nct_id": "NCT03067051",
        "title": "Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Recurrent Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Verteporfin"
            },
            {
              "-type": "Device",
              "#text": "SpectraCure P18 System"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of participants with treatment related adverse events as assesses by CTCAE v4.0 related to protocol therapy.",
            "Damage to the periprostatic tissues including the rectal wall mediated by PDT",
            "Performance of SpectraCure P18 system",
            "Adequacy of effectiveness"
          ]
        },
        "sponsors": { "lead_sponsor": "SpectraCure AB" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "36",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Sequential Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "SPC11-01-110" },
        "start_date": "March 21, 2017",
        "primary_completion_date": "December 31, 2019",
        "completion_date": "December 31, 2020",
        "study_first_posted": "March 1, 2017",
        "last_update_posted": "May 13, 2019",
        "locations": {
          "location": [
            "Keith Cengel, Philadelphia, Pennsylvania, United States",
            "Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03067051"
      },
      {
        "-rank": "114",
        "nct_id": "NCT01682772",
        "title": "TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer",
        "acronym": "TOPARP",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Adenocarcinoma of the Prostate" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Olaparib"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Response rate to Olaparib",
            "Radiographic progression free survival",
            "Progression free survival",
            "Time to PSA Progression",
            "CTC count conversion rate",
            "Duration of PSA response",
            "Number of participants with grade 3 or 4 adverse events as a measure of safety and tolerability.",
            "Time to radiographic progression",
            "Overall survival",
            "PSA objective response"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": "Royal Marsden NHS Foundation Trust"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "148",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "ICR-CTSU/2011/10030",
            "2011-000601-49",
            "CRUK/C12540/A12354",
            "ISRCTN15124653",
            "ISS22810018"
          ]
        },
        "start_date": "July 2012",
        "primary_completion_date": "March 2019",
        "completion_date": "February 2020",
        "study_first_posted": "September 11, 2012",
        "last_update_posted": "August 15, 2019",
        "locations": {
          "location": [
            "Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",
            "University College Hospital London, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01682772"
      },
      {
        "-rank": "115",
        "nct_id": "NCT02998567",
        "title": "Combination Study of Guadecitabine and Pembrolizumab.",
        "acronym": "HyPeR",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Castration-Resistant Prostatic Cancer",
            "Non Small Cell Lung Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Guadecitabine"
            },
            {
              "-type": "Drug",
              "#text": "Pembrolizumab"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Establish maximum tolerated dose (MTD)",
            "Measure Adverse Events according to CTCAE v4.0",
            "Pharmacodynamic profile of guadecitabine in combination with pembrolizumab.",
            "Pharmacodynamic studies in guadecitabine in combination with pembrolizumab."
          ]
        },
        "sponsors": {
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborator": [
            "Astex Pharmaceuticals",
            "Merck Sharp & Dohme Corp.",
            "Institute of Cancer Research, United Kingdom"
          ]
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "35",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Health Services Research"
          ]
        },
        "other_ids": { "other_id": "CCR4420" },
        "start_date": "January 26, 2017",
        "primary_completion_date": "December 2019",
        "completion_date": "December 2019",
        "study_first_posted": "December 20, 2016",
        "last_update_posted": "October 18, 2018",
        "locations": {
          "location": [
            "Rpyal Marsden Hospital, Sutton, Surrey, United Kingdom",
            "UCLH, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02998567"
      },
      {
        "-rank": "116",
        "nct_id": "NCT01162395",
        "title": "Open Label Prostate Cancer Study",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "AZD3514"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "To investigate the safety and tolerability of AZD3514 when given orally to patients with CRPC.",
            "To define the MTD, if possible, a lower biologically-effective dose(s) or maximum feasible dose (if decided by the Safety Review Committee (SRC) and AstraZeneca).",
            "To characterise the PK of AZD3514 after a single oral dose and at steady state after multiple oral doses.",
            "To obtain an assessment of the activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate on the circulating levels of prostate-specific antigen (PSA).",
            "To obtain a preliminary assessment of the anti-tumour activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate by evaluation of counts of Circulating Tumour Cells (CTCs).",
            "To investigate safety, tolerability, MTD (and/or biologically-effective dose(s) or maximum feasible dose) and PK of AZD3514 and abiraterone when administered in combination, in patients who have not received prior treatment with abiraterone acetate",
            "To compare the PK of AZD3514 monotherapy in patients who have been fed or fasted before the administration of study treatment",
            "To investigate the effect of AZD3514 on biomarkers of AR expression in paired pre- and post-dose tumour biopsies."
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "Male",
        "min_age": "20 Years",
        "max_age": "130 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "64",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "D3760C00001",
            "2010-020232-19",
            "IND 111707"
          ]
        },
        "start_date": "August 2010",
        "primary_completion_date": "March 2013",
        "completion_date": "October 2015",
        "study_first_posted": "July 14, 2010",
        "last_update_posted": "January 12, 2016",
        "locations": {
          "location": [
            "Research Site, Portland, Oregon, United States",
            "Research Site, Amsterdam, Netherlands",
            "Research Site, Glasgow, United Kingdom",
            "Research Site, Manchester, United Kingdom",
            "Research Site, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01162395"
      },
      {
        "-rank": "117",
        "nct_id": "NCT02344017",
        "title": "Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer",
        "acronym": "DUALIDES",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "ODM-204"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety and tolerability assessed by incidence of adverse events",
            "Safety and tolerability assessed by vitals signs and 12-lead ECG",
            "Safety and tolerability assessed by laboratory assessments",
            "Pharmacokinetic profile assessed by plasma peak concentration (Cmax)",
            "Pharmacokinetic profile assessed by area under the concentration-time curve (AUC)",
            "Pharmacokinetic profile assessed by time to reach peak concentration (tmax)",
            "Preliminary antitumour activity assessed by prostate specific antigen (PSA) response",
            "Preliminary antitumour activity assessed by response in soft and bone tissues",
            "Pharmacodynamic profile assessed by hormone and circulating tumour cell measurements"
          ]
        },
        "sponsors": { "lead_sponsor": "Orion Corporation, Orion Pharma" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "75",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "3116001" },
        "start_date": "February 2015",
        "primary_completion_date": "January 2019",
        "completion_date": "January 2019",
        "study_first_posted": "January 22, 2015",
        "last_update_posted": "February 15, 2019",
        "locations": {
          "location": [
            "Helsinki University Central Hospital, Helsinki, Finland",
            "Institut Gustave Roussy, Villejuif, France",
            "P. Stradins Clinical University Hospital, Riga, Latvia",
            "Velindre Cancer Centre, Cardiff, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02344017"
      },
      {
        "-rank": "118",
        "nct_id": "NCT01511536",
        "title": "Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Cabazitaxel XRP6258"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone 5 mg"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Phase 1: Maximally Tolerated Dose (MTD) of Cabazitaxel in Combination With Abiraterone Acetate",
            "Phase 2: Percentage of Participants With Prostate Specific Antigen (PSA) Response",
            "Phase 2: Objective Progression Free Survival (PFS)",
            "Phase 2: PSA Progression Free Survival",
            "Phase 2: Percentage of Participants With Objective Response",
            "Phase 2: Overall Survival",
            "Phase 2: Pharmacokinetic of Cabazitaxel : Maximum Plasma Concentration Observed (Cmax)",
            "Phase 2: Pharmacokinetic of Cabazitaxel : Area Under the Plasma Concentration Versus Time Curve (AUC)",
            "Phase 2: Pharmacokinetic of Cabazitaxel : Terminal Half-life (t 1/2z)",
            "Phase 2: Pharmacokinetic of Cabazitaxel : Total Plasma Clearance (CL)",
            "Phase 2: Pharmacokinetic of Cabazitaxel : Volume of Distribution at Steady State (Vss)",
            "Phase 2: Pharmacokinetic of Abiraterone : Maximum Plasma Concentration Observed (Cmax)",
            "Phase 2: Pharmacokinetic of Abiraterone : First Time to Reach Cmax (Tmax)",
            "Phase 2: Pharmacokinetic of Abiraterone : Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC 0-24)",
            "Phase 2: Pharmacokinetic of Abiraterone : Concentration Observed Just Before Treatment Administration During Repeated Dosing at Steady State (Ctrough ss)"
          ]
        },
        "sponsors": { "lead_sponsor": "Sanofi" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "38",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "TCD12128",
            "2011-001506-96",
            "U1111-1121-6324"
          ]
        },
        "start_date": "March 2012",
        "primary_completion_date": "July 2014",
        "completion_date": "December 2014",
        "study_first_posted": "January 18, 2012",
        "results_first_posted": "November 4, 2015",
        "last_update_posted": "July 28, 2016",
        "locations": {
          "location": [
            "Investigational Site Number 840001, San Francisco, California, United States",
            "Investigational Site Number 840002, New Haven, Connecticut, United States",
            "Investigational Site Number 250001, Villejuif, France",
            "Investigational Site Number 826001, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01511536"
      },
      {
        "-rank": "119",
        "nct_id": "NCT02042885",
        "title": "A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Salivary Gland Cancer",
            "Endometrial Cancer",
            "Squamous Cell Carcinoma of the Cervix",
            "Breast Cancer",
            "Ovarian Cancer"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "OPB-111001"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Maximum tolerated dose / Recommended Phase 2 dose; Tolerability",
            "Pharmacokinetic parameters for OPB-111001 and its metabolites",
            "Assessment of antitumor activity as defined by Response Evaluation Criteria in Solid Tumours (RECIST)",
            "Prostate-specific antigen (PSA) response in patients with prostate cancer",
            "Cancer antigen 125 (CA 125) response in patients with ovarian cancer",
            "Time to treatment failure"
          ]
        },
        "sponsors": { "lead_sponsor": "Otsuka Novel Products GmbH" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "79",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "314-12-401",
            "2013-001249-15"
          ]
        },
        "start_date": "January 2014",
        "primary_completion_date": "February 2015",
        "completion_date": "February 2015",
        "study_first_posted": "January 23, 2014",
        "last_update_posted": "October 20, 2015",
        "locations": {
          "location": [
            "The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, Sutton, Surrey, United Kingdom",
            "NIHR/Wellcome Trust Imperial CRF/Imperial College Healthcare NHS Trust, Imperial Centre for Translational and Experimental Medicine (L-Block), Hammersmith Hospital, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02042885"
      },
      {
        "-rank": "120",
        "nct_id": "NCT02566772",
        "title": "Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration Resistant Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "TAS3681"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of participants with dose limiting toxicity",
            "Number of patients with adverse events and significant ECG abnormalities",
            "Prostate Specific Antigen (PSA) response",
            "Maximum concentration of TAS3681 in plasma",
            "Time to reach maximum concentration of TAS3681",
            "Area under the concentration-time curve of TAS3681",
            "Terminal half-life time of TAS3681",
            "Accumulation ratio of TAS3681",
            "Tumor response as per RECIST 1.1 and PCWG3"
          ]
        },
        "sponsors": { "lead_sponsor": "Taiho Oncology, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "200",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "TO-TAS3681-101",
            "2015-002745-55"
          ]
        },
        "start_date": "March 2016",
        "primary_completion_date": "September 2021",
        "completion_date": "September 2021",
        "study_first_posted": "October 2, 2015",
        "last_update_posted": "May 30, 2019",
        "locations": {
          "location": [
            "Univeristy of California Davis Comprehensive Cancer Center, Sacramento, California, United States",
            "Sarah Cannon Research Institute, Sarasota, Florida, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "The Christie Clinic, Manchester, Greater Manchester, United Kingdom",
            "Institute of Cancer Research, Sutton, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02566772"
      },
      {
        "-rank": "121",
        "nct_id": "NCT03568656",
        "title": "Study to Evaluate CCS1477 in Advanced Tumours",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Metastatic Castration-Resistant Prostate Cancer",
            "Advanced Solid Tumors"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "CCS1477"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Incidence of treatment-related adverse events",
            "Laboratory assessments",
            "PSA response",
            "CTC response",
            "Objective response rate (ORR)",
            "Radiological progression-free survival (rPFS)",
            "AUC of CCS1477",
            "Cmax of CCS1477"
          ]
        },
        "sponsors": { "lead_sponsor": "CellCentric Ltd." },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "120",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Sequential Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CCS1477-01" },
        "start_date": "July 23, 2018",
        "primary_completion_date": "January 2020",
        "completion_date": "December 2021",
        "study_first_posted": "June 25, 2018",
        "last_update_posted": "June 20, 2019",
        "locations": {
          "location": [
            "Belfast City Hospital, Belfast, United Kingdom",
            "Leicester Royal Infirmary, Leicester, United Kingdom",
            "Freeman Hospital, Newcastle, United Kingdom",
            "Royal Marsden Hospital, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03568656"
      },
      {
        "-rank": "122",
        "nct_id": "NCT02655952",
        "title": "Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Metastatic Breast Cancer",
            "Metastatic Colon Cancer",
            "Metastatic Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Foxy-5"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Presence of Dose Limiting Toxicities (DLTs).",
            "Genome wide mRNA gene expression in tumour biopsies and blood (buffy coat)",
            "Wnt-5a protein expression and hematoxylin-eosin (HE) staining of tumour biopsies",
            "Numbers of circulating tumour cells (CTCs) in blood",
            "Maximum tolerated dose (MTD)",
            "Area under the plasma concentration curve (AUC) of Foxy-5",
            "Bioavailability (F) of Foxy-5",
            "Half life (TÂ½) of Foxy-5",
            "Absorption rate Constant (tmax) of Foxy-5",
            "Volume of distribution (V) of Foxy-5",
            "Clearance (C) of Foxy-5",
            "Extraction Ratio (E) of Foxy-5",
            "Hepatic and Renal Clearance of Foxy-5"
          ]
        },
        "sponsors": { "lead_sponsor": "WntResearch AB" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "17",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "SMR-3164" },
        "start_date": "April 2016",
        "primary_completion_date": "October 2017",
        "completion_date": "October 2017",
        "study_first_posted": "January 14, 2016",
        "last_update_posted": "December 28, 2018",
        "locations": {
          "location": [
            "Clinical Research Department, Oncology, Rigshospitalet, Copenhagen, Denmark",
            "Onkologisk Afdeling R, Herlev Hospital, Herlev, Denmark",
            "Odense University Hospital, Odense, Denmark",
            "NCCC, Freeman Hospital, Newcastle, Newcastle Upon Tyne, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02655952"
      },
      {
        "-rank": "123",
        "nct_id": "NCT03673787",
        "title": "A Trial of Ipatasertib in Combination With Atezolizumab",
        "acronym": "IceCAP",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Solid Tumor",
            "Glioblastoma Multiforme",
            "Prostate Cancer Metastatic"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "ipatasertib"
            },
            {
              "-type": "Drug",
              "#text": "Atezolizumab"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "To identify a maximum tolerated dose in Phase I",
            "To determine the number and type of treatment-related adverse events of the two drug combination as assessed by CTCAE v4.0",
            "Determination of changes in immune-cell population in blood and plasma, using Fluorescence-Activated Cell Sorting (FACS)",
            "To assess the tumour microenvironment by immunophenotyping"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": "Hoffmann-La Roche"
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "51",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Health Services Research"
          ]
        },
        "other_ids": { "other_id": "CCR4720" },
        "start_date": "August 13, 2018",
        "primary_completion_date": "July 2020",
        "completion_date": "November 2020",
        "study_first_posted": "September 17, 2018",
        "last_update_posted": "September 17, 2018",
        "locations": { "location": "Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03673787"
      },
      {
        "-rank": "124",
        "nct_id": "NCT03327662",
        "title": "Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer",
        "acronym": "CTC-STOP",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Adenocarcinoma of the Prostate" },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "Active CTC Assessment"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "CTC-guided switch rates",
            "CTC effects on chemotherapy",
            "Toxicity burden assessment",
            "Brief Pain Inventory",
            "The Functional Assessment of Cancer Therapy-Prostate (FACT-P)",
            "EuroQoL Five Dimensions (EQ-5D)",
            "Progression Free Survival",
            "Radiographic Progression Free Survival (rPFS)",
            "Time to First Symptomatic Skeletal Related Event (SSRE)",
            "Time to CTC Progression",
            "Circulating Tumour Cells (CTC) counts",
            "Prostate Specific Antigen (PSA) Counts",
            "Rate of CTC Response",
            "Rate of Pain response",
            "Health Economic assessment"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": [
            "Prostate Cancer UK",
            "University of Twente",
            "Sanofi",
            "Janssen, LP",
            "Menarini Group"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1178",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "ICR-CTSU/2015/10054" },
        "start_date": "January 11, 2017",
        "primary_completion_date": "January 2021",
        "completion_date": "January 2022",
        "study_first_posted": "October 31, 2017",
        "last_update_posted": "October 31, 2017",
        "locations": {
          "location": [
            "The Royal Marsden Hospital, Sutton, Surrey, United Kingdom",
            "Velindre Cancer Centre, Cardiff, United Kingdom",
            "Western General Hospital, Edinburgh, United Kingdom",
            "University College London Hospital, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03327662"
      },
      {
        "-rank": "125",
        "nct_id": "NCT00706498",
        "title": "Phase II Study of BI 2536 in Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "BI 2536"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "PSA response rate at 12 weeks according to Prostate Specific Antigen Working Group (PSAWG) criteria.",
            "PSA response duration",
            "Time to PSA progression assessed at 24 weeks",
            "Overall objective response using RECIST criteria (complete response [CR] or partial response [PR]) in patients with measurable disease",
            "Time to death",
            "Time to overall progression",
            "Progression free survival",
            "Overall survival",
            "Duration of overall response (RECIST)",
            "BI 2536 plasma concentrations",
            "Incidence and intensity of AEs, with grading according to the US National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, version 3.0)",
            "Number of patients with changes in laboratory safety parameters"
          ]
        },
        "sponsors": { "lead_sponsor": "Boehringer Ingelheim" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "20",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "1216.19" },
        "start_date": "September 2006",
        "primary_completion_date": "February 2008",
        "study_first_posted": "June 27, 2008",
        "last_update_posted": "May 16, 2014",
        "locations": {
          "location": [
            "1216.19.4407 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom",
            "1216.19.4405 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom",
            "1216.19.4402 Boehringer Ingelheim Investigational Site, Headington, United Kingdom",
            "1216.19.4406 The Christie NHS Foundation Trust, Manchester, United Kingdom",
            "1216.19.4404 Boehringer Ingelheim Investigational Site, Newcastle Upon Tyne, United Kingdom",
            "1216.19.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00706498"
      },
      {
        "-rank": "126",
        "nct_id": "NCT03103152",
        "title": "A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression",
        "acronym": "PROVENT",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "High dose Aspirin & Vitamin D"
            },
            {
              "-type": "Drug",
              "#text": "High dose Aspirin, Vitamin D placebo"
            },
            {
              "-type": "Drug",
              "#text": "Low dose Aspirin , Vitamin D"
            },
            {
              "-type": "Drug",
              "#text": "Low dose Aspirin, Vitamin D placebo"
            },
            {
              "-type": "Drug",
              "#text": "Aspirin Placebo, Vitamin D"
            },
            {
              "-type": "Drug",
              "#text": "Aspirin placebo, Vitamin D placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Rate of patient recruitment to a randomised chemoprevention study in men enrolled on an Active Surveillance programme for prostate cancer. Number accrued per month.",
            "Response to treatment as determined by serial multi-parametric magnetic resonance imaging (MRI) of the prostate. New lesion present or existing lesion + or - in size.",
            "Biochemical disease progression.",
            "Histological disease progression. Increase in Gleason score or MCCL",
            "Toxicity and/or allergy to both aspirin and Vitamin D3; Symptoms of Aspirin or Vit D toxicity."
          ]
        },
        "sponsors": {
          "lead_sponsor": "Queen Mary University of London",
          "collaborator": [
            "Barts and the London School of Medicine and Dentistry",
            "Cancer Research UK"
          ]
        },
        "gender": "Male",
        "min_age": "16 Years",
        "max_age": "100 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 2",
            "Phase 3"
          ]
        },
        "enrollment": "104",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Factorial Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Prevention"
          ]
        },
        "other_ids": { "other_id": "isrctn91422391" },
        "start_date": "December 2016",
        "primary_completion_date": "August 2019",
        "completion_date": "October 2019",
        "study_first_posted": "April 6, 2017",
        "last_update_posted": "April 9, 2019",
        "locations": {
          "location": [
            "Darent Valley Hospital, Dartford, United Kingdom",
            "University Hospital of Wales, London, United Kingdom",
            "University Hospital UHCW NHS Trust, London, United Kingdom",
            "St Bartholomews Hospital London, Bart's and the London school of Medicine, London, United Kingdom",
            "University College Hospital London, London, United Kingdom",
            "Homerton Hospital, London, United Kingdom",
            "Southampton General Hospital, Southampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03103152"
      },
      {
        "-rank": "127",
        "nct_id": "NCT02968784",
        "title": "Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "ExAblate MRgFUS"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "The primary efficacy endpoint in this trial measured with whole-gland extended imaging-guided mapping biopsy, is Response scored dichotomously; success vs. failure",
            "Adverse events",
            "Percent of patients with negative biopsy",
            "Quality of Life - urinary symptoms - IPSS questionnaire score",
            "Quality of Life - urinary continence - ICIQ-SF questionnaire score",
            "Quality of Life - sexual function - IIEF-15 questionnaire score",
            "Prostate Specific Antigen (PSA)"
          ]
        },
        "sponsors": { "lead_sponsor": "InSightec" },
        "gender": "Male",
        "min_age": "50 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "68",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "PCa006" },
        "start_date": "June 2016",
        "primary_completion_date": "June 2022",
        "completion_date": "June 2022",
        "study_first_posted": "November 21, 2016",
        "last_update_posted": "August 20, 2019",
        "locations": {
          "location": [
            "Toronto General Hospital, Toronto, Ontario, Canada",
            "Shanghai Jiaotong University No.1 Hospital, Shanghai, HongKou District, China",
            "Changhai Hospital of Shanghai, Shanghai, Shanghai, China",
            "Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",
            "St. Mary's Hospital, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02968784"
      },
      {
        "-rank": "128",
        "nct_id": "NCT02991911",
        "title": "A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer",
        "acronym": "MEDI3726",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration Resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "MEDI3726 Post-Chemo"
            },
            {
              "-type": "Biological",
              "#text": "MEDI3726 Pre-Chemo"
            },
            {
              "-type": "Biological",
              "#text": "MEDI3726 & Enzalutamide Combo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Occurrence of adverse events (AEs)",
            "Occurrence of serious adverse events (SAEs)",
            "Occurrence of dose-limiting toxicities (DLTs)",
            "Number of patients with changes in laboratory parameters from baseline",
            "Number of patients with changes in vital signs from baseline",
            "Number of patients with changes in electrocardiogram (ECG) results from baseline",
            "Response Evaluation Criteria in Solid Tumors (RECIST) response",
            "PSA50 response",
            "Circulating Tumor Cell (CTC) response",
            "Safety and tolerability of MEDI3726 in combination with Enzalutamide",
            "MEDI3726 plasma concentrations for pharmacokinetics (PK)",
            "MEDI3726 maximum observed concentration for PK",
            "MEDI3726 area under the concentration-time curve for PK",
            "MEDI3726 clearance for PK",
            "MEDI3726 terminal half-life for PK",
            "Number and percentage of subjects who develop anti-drug antibodies (ADAs)"
          ]
        },
        "sponsors": { "lead_sponsor": "MedImmune LLC" },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "100 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "33",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Sequential Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "D9320C00001" },
        "start_date": "January 6, 2017",
        "primary_completion_date": "October 1, 2019",
        "completion_date": "October 1, 2019",
        "study_first_posted": "December 14, 2016",
        "last_update_posted": "July 4, 2019",
        "locations": {
          "location": [
            "Research Site, New Haven, Connecticut, United States",
            "Research Site, Sarasota, Florida, United States",
            "Research Site, Norfolk, Virginia, United States",
            "Research Site, Chur, Switzerland",
            "Research Site, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02991911"
      },
      {
        "-rank": "129",
        "nct_id": "NCT00959023",
        "title": "Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "laboratory biomarker analysis"
            },
            {
              "-type": "Other",
              "#text": "medical chart review"
            },
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Prostate cancer (PC) predisposition (PCP) genes",
            "Association of PCP genes with disease and treatment parameters",
            "Association of PCP with environmental factors",
            "Family history of PC",
            "Relative risk of developing PC",
            "Increased risk relatives of PC patients are to develop cancers other than PC",
            "Markers of PC that are associated with PCP genes",
            "Specific tumor genetic profile correlated with PCP genes"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "21000",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "other_ids": {
          "other_id": [
            "CDR0000636371",
            "ICR-UKGPCS",
            "EU-20909"
          ]
        },
        "start_date": "June 1993",
        "study_first_posted": "August 14, 2009",
        "last_update_posted": "August 26, 2013",
        "locations": {
          "location": [
            "William Harvey Hospital, Ashford-Kent, England, United Kingdom",
            "Tameside General Hospital, Ashton-Under-Lyne, England, United Kingdom",
            "Stoke Mandeville Hospital, Aylesbury-Buckinghamshire, England, United Kingdom",
            "North Devon District Hospital, Barnstaple, England, United Kingdom",
            "Furness General Hospital, Barrow in Furness, England, United Kingdom",
            "Basildon University Hospital, Basildon, England, United Kingdom",
            "Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom",
            "Royal United Hospital, Bath, England, United Kingdom",
            "Primrose Centre at Bedford Hospitals NHS Trust, Bedford, England, United Kingdom",
            "Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom",
            "City Hospital - Birmingham, Birmingham, England, United Kingdom",
            "Good Hope Hospital, Birmingham, England, United Kingdom",
            "Birmingham Heartlands Hospital, Birmingham, England, United Kingdom",
            "Royal Blackburn Hospital, Blackburn, England, United Kingdom",
            "Blackpool Victoria Hospital, Blackpool, England, United Kingdom",
            "Pilgrim Hospital, Boston, England, United Kingdom",
            "Royal Bournemouth Hospital, Bournemouth, England, United Kingdom",
            "Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom",
            "Southmead Hospital, Bristol, England, United Kingdom",
            "Frenchay Hospital, Bristol, England, United Kingdom",
            "Bristol Royal Infirmary, Bristol, England, United Kingdom",
            "Broomfield Hospital, Broomfield, England, United Kingdom",
            "Burnley General Hospital, Burnley, England, United Kingdom",
            "Queen's Hospital, Burton-upon-Trent, England, United Kingdom",
            "Addenbrooke's Hospital, Cambridge, England, United Kingdom",
            "Kent and Canterbury Hospital, Canterbury, England, United Kingdom",
            "St. Helier Hospital, Carshalton, England, United Kingdom",
            "Countess of Chester Hospital, Chester, England, United Kingdom",
            "Colchester General Hospital, Colchester, England, United Kingdom",
            "Castle Hill Hospital, Cottingham, England, United Kingdom",
            "Walsgrave Hospital, Coventry, England, United Kingdom",
            "Mid Cheshire Hospitals Trust- Leighton Hopsital, Crewe, England, United Kingdom",
            "Mayday University Hospital, Croydon, England, United Kingdom",
            "Darent Valley Hospital, Dartford Kent, England, United Kingdom",
            "Derbyshire Royal Infirmary, Derby, England, United Kingdom",
            "Royal Derby Hospital, Derby, England, United Kingdom",
            "Dorset County Hospital, Dorchester, England, United Kingdom",
            "Russells Hall Hospital, Dudley, England, United Kingdom",
            "Eastbourne District General Hospital, Eastbourne, England, United Kingdom",
            "Birmingham Women's Hospital, Edgbaston, England, United Kingdom",
            "Epsom General Hospital, Epsom, Surrey, England, United Kingdom",
            "Royal Devon and Exeter Hospital, Exeter, England, United Kingdom",
            "Royal Bolton Hospital, Farnworth, England, United Kingdom",
            "Frimley Park Hospital, Frimley, England, United Kingdom",
            "Grantham and District Hospital, Grantham, Lincolnshire, England, United Kingdom",
            "Diana Princess of Wales Hospital, Grimsby, England, United Kingdom",
            "Harrogate District Hospital, Harrogate, England, United Kingdom",
            "Wycombe General Hospital, High Wycombe, England, United Kingdom",
            "Princess Royal Hospital at Hull and East Yorkshire NHS Trust, Hull, England, United Kingdom",
            "Ipswich Hospital, Ipswich, England, United Kingdom",
            "Kidderminster Hospital, Kidderminster Worcestershire, England, United Kingdom",
            "Royal Albert Edward Infirmary, Lancanshire, England, United Kingdom",
            "Royal Lancaster Infirmary, Lancaster, England, United Kingdom",
            "Leeds General Infirmary, Leeds, England, United Kingdom",
            "Cookridge Hospital, Leeds, England, United Kingdom",
            "Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom",
            "Leicester Royal Infirmary, Leicester, England, United Kingdom",
            "Leicester General Hospital, Leicester, England, United Kingdom",
            "Lincoln County Hospital, Lincoln, England, United Kingdom",
            "Royal Liverpool University Hospital, Liverpool, England, United Kingdom",
            "Royal London Hospital, London, England, United Kingdom",
            "Whipps Cross Hospital, London, England, United Kingdom",
            "Saint Bartholomew's Hospital, London, England, United Kingdom",
            "Guy's Hospital, London, England, United Kingdom",
            "Hammersmith Hospital, London, England, United Kingdom",
            "Middlesex Hospital, London, England, United Kingdom",
            "St. Mary's Hospital, London, England, United Kingdom",
            "Charing Cross Hospital, London, England, United Kingdom",
            "Macclesfield District General Hospital, Macclesfield, England, United Kingdom",
            "Maidstone Hospital, Maidstone, England, United Kingdom",
            "Christie Hospital, Manchester, England, United Kingdom",
            "Clatterbridge Centre for Oncology, Merseyside, England, United Kingdom",
            "James Cook University Hospital, Middlesbrough, England, United Kingdom",
            "Milton Keynes General Hospital, Milton Keynes, England, United Kingdom",
            "Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom",
            "Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom",
            "Norfolk and Norwich University Hospital, Norwich, England, United Kingdom",
            "Kings Mill Hospital, Nottinghamshire, England, United Kingdom",
            "Nottingham City Hospital, Nottingham, England, United Kingdom",
            "George Eliot Hospital, Nuneaton, England, United Kingdom",
            "Churchill Hospital, Oxford, England, United Kingdom",
            "Peterborough Hospitals Trust, Peterborough, England, United Kingdom",
            "Derriford Hospital, Plymouth, England, United Kingdom",
            "Dorset Cancer Centre, Poole Dorset, England, United Kingdom",
            "Rosemere Cancer Centre at Royal Preston Hospital, Preston, England, United Kingdom",
            "Berkshire Cancer Centre at Royal Berkshire Hospital, Reading, England, United Kingdom",
            "Alexandra Healthcare NHS, Redditch, Worcestershire, England, United Kingdom",
            "Queens Hospital, Romford, England, United Kingdom",
            "Conquest Hospital, Saint Leonards-on-Sea, England, United Kingdom",
            "Hope Hospital, Salford, England, United Kingdom",
            "Salisbury District Hospital, Salisbury, England, United Kingdom",
            "Scarborough General Hospital, Scarborough, England, United Kingdom",
            "Scunthorpe General Hospital, Scunthorpe, England, United Kingdom",
            "Royal Shrewsbury Hospital, Shrewsbury, England, United Kingdom",
            "Wexham Park Hospital, Slough, Berkshire, England, United Kingdom",
            "Solihull Hospital, Solihull, England, United Kingdom",
            "Southampton General Hospital, Southampton, England, United Kingdom",
            "Southport and Formby District General Hospital, Southport, England, United Kingdom",
            "Staffordshire General Hospital, Stafford, England, United Kingdom",
            "Lister Hospital, Stevenage, England, United Kingdom",
            "Stirling Royal Infirmary, Stirling, England, United Kingdom",
            "Stepping Hill Hospital, Stockport, England, United Kingdom",
            "Kingston Hospital, Surrey, England, United Kingdom",
            "East Surrey Hospital, Surrey, England, United Kingdom",
            "Royal Marsden - Surrey, Sutton, England, United Kingdom",
            "Great Western Hospital, Swindon, England, United Kingdom",
            "Taunton and Somerset Hospital, Taunton, England, United Kingdom",
            "Torbay Hospital, Torquay, England, United Kingdom",
            "Hillingdon Hospital, Uxbridge, England, United Kingdom",
            "Warwick Hospital, Warwick, England, United Kingdom",
            "Sandwell General Hospital, West Bromwich, England, United Kingdom",
            "Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, England, United Kingdom",
            "New Cross Hospital, Wolverhampton, England, United Kingdom",
            "Worthing Hospital, Worthing, England, United Kingdom",
            "Yeovil District Hospital, Yeovil, England, United Kingdom",
            "Cancer Care Centre at York Hospital, York, England, United Kingdom",
            "Belfast City Hospital Trust Incorporating Belvoir Park Hospital, Belfast, Northern Ireland, United Kingdom",
            "Downe Hospital, Downpatrick, Northern Ireland, United Kingdom",
            "Altnagelvin Area Hospital, Londonderry, Northern Ireland, United Kingdom",
            "Craigavon Area Hospital, Portadown, Craigavon, Northern Ireland, United Kingdom",
            "Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom",
            "Ayr Hospital, Ayr, Scotland, United Kingdom",
            "Falkirk and District Royal Infirmary, Falkirk, Scotland, United Kingdom",
            "Western Infirmary, Glasgow, Scotland, United Kingdom",
            "Pinderfields General Hospital, Wakefield, Scotland, United Kingdom",
            "Princess of Wales Hospital, Bridgend, Wales, United Kingdom",
            "Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom",
            "University Hospital of Wales, Cardiff, Wales, United Kingdom",
            "Royal Gwent Hospital, Newport Gwent, Wales, United Kingdom",
            "Glan Clwyd Hospital, Rhyl, Denbighshire, Wales, United Kingdom",
            "Singleton Hospital, Swansea, Wales, United Kingdom",
            "Queen Victoria Hospital, Morecambe, United Kingdom",
            "Edith Cavell Hospital, Peterborough, United Kingdom",
            "Southlands Hospital, Shoreham-by-Sea, United Kingdom",
            "Princess Anne Hospital, Southampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00959023"
      },
      {
        "-rank": "130",
        "nct_id": "NCT03724747",
        "title": "Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration Resistant Prostate Cancer (mCRPC)" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "BAY 2315497 Injection"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Maximum tolerated dose (MTD) of BAY 2315497 injection",
            "Recommended dose for further clinical development of BAY 2315497 injection",
            "Maximum observed concentration (Cmax) of thorium",
            "Area under the curve from time of dosing to 42 days after dosing [AUC(0-42)] days of thorium",
            "Cmax of radium",
            "AUC(0-42) days of radium",
            "Cmax of total antibody",
            "AUC(0-42) days of total antibody"
          ]
        },
        "sponsors": { "lead_sponsor": "Bayer" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "111",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Sequential Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "19445",
            "2018-001490-25"
          ]
        },
        "start_date": "December 18, 2018",
        "primary_completion_date": "September 23, 2022",
        "completion_date": "November 18, 2022",
        "study_first_posted": "October 30, 2018",
        "last_update_posted": "September 9, 2019",
        "locations": {
          "location": [
            "Tulane Medical Center, New Orleans, Louisiana, United States",
            "Memorial Sloan-Kettering Cancer Center, New York, New York, United States",
            "HUS, Meilahden sairaala, Helsinki, Finland",
            "SkÃ¥nes Universitetssjukhus, Lund, Sweden",
            "Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03724747"
      },
      {
        "-rank": "131",
        "nct_id": "NCT00392535",
        "title": "Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Radiation",
              "#text": "conventional radiotherapy 74 Gy delivered in 37 fractions"
            },
            {
              "-type": "Radiation",
              "#text": "hypofractionated radiation therapy 60 Gy in 20 fractions"
            },
            {
              "-type": "Radiation",
              "#text": "hypofractionated radiation therapy 57 Gy in 19 fractions"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Time to biochemical or clinical failure",
            "Disease-free survival",
            "Overall survival",
            "Development of metastases",
            "Recommencement of hormonal treatment for disease recurrence",
            "Acute and late side-effects"
          ]
        },
        "sponsors": { "lead_sponsor": "Institute of Cancer Research, United Kingdom" },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "120 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "3216",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000510112",
            "ICR-CTSU-CHHIP-2006-10007",
            "ISRCTN97182923",
            "EU-20646"
          ]
        },
        "start_date": "October 18, 2002",
        "primary_completion_date": "September 8, 2015",
        "completion_date": "June 17, 2021",
        "study_first_posted": "October 26, 2006",
        "last_update_posted": "February 27, 2019",
        "locations": {
          "location": [
            "Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom",
            "Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom",
            "Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom",
            "West Suffolk Hospital, Bury St. Edmunds, England, United Kingdom",
            "Addenbrooke's Hospital, Cambridge, England, United Kingdom",
            "Countess of Chester Hospital, Chester, England, United Kingdom",
            "Walsgrave Hospital, Coventry, England, United Kingdom",
            "Eastbourne District General Hospital, Eastbourne, England, United Kingdom",
            "St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford, England, United Kingdom",
            "Ipswich Hospital, Ipswich, England, United Kingdom",
            "Clatterbridge Centre for Oncology, Liverpool, England, United Kingdom",
            "Saint Bartholomew's Hospital, London, England, United Kingdom",
            "Royal Marsden - London, London, England, United Kingdom",
            "Christie Hospital, Manchester, England, United Kingdom",
            "Norfolk and Norwich University Hospital, Norwich, England, United Kingdom",
            "Whiston Hospital, Prescot, England, United Kingdom",
            "Rosemere Cancer Centre at Royal Preston Hospital, Preston, England, United Kingdom",
            "Halton Hospital, Runcorn, England, United Kingdom",
            "Cancer Research Centre at Weston Park Hospital, Sheffield, England, United Kingdom",
            "Southport and Formby District General Hospital, Southport, England, United Kingdom",
            "Royal Marsden - Surrey, Sutton, England, United Kingdom",
            "Warrington Hospital NHS Trust, Warrington, England, United Kingdom",
            "Worthing Hospital, Worthing, England, United Kingdom",
            "Belfast City Hospital Trust, Belfast, Northern Ireland, United Kingdom",
            "Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom",
            "Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00392535"
      },
      {
        "-rank": "132",
        "nct_id": "NCT03763253",
        "title": "Adjuvant Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms",
        "acronym": "IP2-ATLANTA",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Metastatic Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Combination Product",
              "#text": "Standard of Care"
            },
            {
              "-type": "Procedure",
              "#text": "Minimally Invasive Ablative Therapy (MIAT)"
            },
            {
              "-type": "Procedure",
              "#text": "Radical Therapy (Prostatectomy or Radiotherapy)"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Prostate cancer on post-standard of care prostate biopsy.",
            "Safety (Adverse Events)",
            "Progression-free survival (PFS)",
            "Urinary side effects",
            "Sexual side effects",
            "Rectal side effects",
            "Progression (Biochemical / Radiological / Clinical)",
            "Health-related quality-of-life"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Imperial College London",
          "collaborator": "Wellcome Trust"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "918",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Factorial Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "18HH4804" },
        "start_date": "April 10, 2019",
        "primary_completion_date": "March 1, 2023",
        "completion_date": "March 1, 2024",
        "study_first_posted": "December 4, 2018",
        "last_update_posted": "July 23, 2019",
        "locations": {
          "location": [
            "Wexham Park Hospital, Frimley Health NHS Foundation Trust, Frimley, Surrey, United Kingdom",
            "The Royal United Hospital, Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom",
            "Wirral University Teaching Hospital, Wirral University Teaching Hospital NHS Foundation Trust, Birkenhead, United Kingdom",
            "University Hospital Coventry, University Hospitals Coventry & Warwickshire NHS Trust (UHCW), Coventry, United Kingdom",
            "Royal Devon and Exeter NHS Trust, Exeter, United Kingdom",
            "West Middlesex University Hospital, Isleworth, United Kingdom",
            "Cambridge Queen Elizabeth hospital, Kings Lynn, King's Lynn, United Kingdom",
            "Guy's and St Thomas Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, Chelsea Research Centre, London, United Kingdom",
            "Imperial College Healthcare NHS Trust, London, United Kingdom",
            "Northwick Park, London North West Healthcare NHS Trust, London, United Kingdom",
            "Freeman Hospital, Newcastle, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom",
            "Norfolk and Norwich University Hospital, Norfolk & Norwich University Hospital NHS Foundation Trust, Norwich, United Kingdom",
            "Southampton General Hospital, University Hospital Southampton NHS Foundation Trust (UHS), Southampton, United Kingdom",
            "Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust, Sunderland, United Kingdom",
            "Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03763253"
      },
      {
        "-rank": "133",
        "nct_id": "NCT03072238",
        "title": "Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer",
        "acronym": "IPATential150",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Ipatasertib"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Investigator-Assessed Radiographic Progression-Free Survival (rPFS)",
            "Time to Pain Progression",
            "Time to Initiation of Cytotoxic Chemotherapy",
            "Overall Survival",
            "Time to Function Deterioration",
            "Time to Prostate-Specific Antigen (PSA) Progression",
            "Time to First Opioid Use",
            "Time to Symptomatic Skeletal Event (SSE)",
            "Objective Response Rate (ORR)",
            "PSA Response Rate",
            "Investigator-Assessed rPFS in Participants With PTEN-Loss Tumors by Next-Generation Sequencing (NGS)",
            "Plasma concentration of ipatasertib",
            "Plasma concentration of abiraterone"
          ]
        },
        "sponsors": { "lead_sponsor": "Hoffmann-La Roche" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1100",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CO39303" },
        "start_date": "June 30, 2017",
        "primary_completion_date": "May 12, 2020",
        "completion_date": "October 11, 2023",
        "study_first_posted": "March 7, 2017",
        "last_update_posted": "August 26, 2019",
        "locations": {
          "location": [
            "Ironwood Cancer & Research Centers, Chandler, Arizona, United States",
            "Mayo Clinic Arizona, Scottsdale, Arizona, United States",
            "City of Hope, Duarte, California, United States",
            "UCSD Moores Cancer Center, La Jolla, California, United States",
            "Kaiser Permanente San Diego - Los Angeles, Los Angeles, California, United States",
            "USC Norris Cancer Center, Los Angeles, California, United States",
            "USC/Westside Cancer Ctr, Los Angeles, California, United States",
            "UC Irvine Medical Center, Orange, California, United States",
            "Stanford University, Palo Alto, California, United States",
            "Pacific Hematology Oncology Assocociates, San Francisco, California, United States",
            "University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States",
            "University of Connecticut Health Center, Farmington, Connecticut, United States",
            "Yale Cancer Center, New Haven, Connecticut, United States",
            "Georgetown University Medical Center, Washington, District of Columbia, United States",
            "Lynn Cancer Institute/Boca Raton Regional Hospital, Boca Raton, Florida, United States",
            "Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States",
            "Northside Hospital, Atlanta, Georgia, United States",
            "Northwest Medical Specialists, Arlington Heights, Illinois, United States",
            "Illinois Cancer Care, Peoria, Illinois, United States",
            "Associates in Oncology/Hematology P.C., Rockville, Maryland, United States",
            "Tufts Medical Center, Boston, Massachusetts, United States",
            "Massachusetts General Hospital, Boston, Massachusetts, United States",
            "Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",
            "Dana-Farber Cancer Institute, Boston, Massachusetts, United States",
            "University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",
            "Karmanos Cancer Institute.., Detroit, Michigan, United States",
            "HCA Midwest Division, Kansas City, Missouri, United States",
            "Urology Cancer Center & GU Research Network, Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States",
            "Hackensack Univ Medical Center; John Theurer Cancer Ctr, Hackensack, New Jersey, United States",
            "New York Oncology Hematology, P.C., Albany, New York, United States",
            "Columbia University Medical Center, New York, New York, United States",
            "Cleveland Clinic, Cleveland, Ohio, United States",
            "Fairview Hospital, Cleveland, Ohio, United States",
            "Good Samaritan North Health Center, Dayton, Ohio, United States",
            "Cleveland Clinic Cancer Center- Hillcrest, Mayfield Heights, Ohio, United States",
            "Northwest Cancer Specialists, P.C., Tigard, Oregon, United States",
            "Andrews and Patel Associates Hematology/Oncology, Camp Hill, Pennsylvania, United States",
            "Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",
            "Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",
            "Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States",
            "UPMC Cancer Pavillion; Hillman Cancer Pavillion, Pittsburgh, Pennsylvania, United States",
            "Rhode Island Hospital, Providence, Rhode Island, United States",
            "Charleston Hematology Oncology, Charleston, South Carolina, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "UT Southwestern Medical Center, Dallas, Texas, United States",
            "Simmons Cancer Center - Fort Worth, Fort Worth, Texas, United States",
            "Texas Oncology - Memorial City, Houston, Texas, United States",
            "Huntsman Cancer Institute, Salt Lake City, Utah, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "Madigan Army Medical Center, Tacoma, Washington, United States",
            "Macquarie University Hospital, Sydney, New South Wales, Australia",
            "Adelaide Cancer Centre, Kurralta Park, South Australia, Australia",
            "Monash Medical Centre; Oncology, Clayton, Victoria, Australia",
            "Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia",
            "Eastern Health; GU - Oncology, Melbourne, Victoria, Australia",
            "LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung fÃ¼r Onkologie, Graz, Austria",
            "Ordensklinikum Linz Elisabethinen; Abteilung fÃ¼r Urologie und Andrologie, Linz, Austria",
            "Landeskrankenhaus Salzburg; UniversitÃ¤tsklinik fÃ¼r Urologie und Andrologie der PMU, Salzburg, Austria",
            "UZ Gent, Gent, Belgium",
            "AZ Groeninge, Kortrijk, Belgium",
            "CHU Sart-Tilman, LiÃ¨ge, Belgium",
            "Hospital Luxemburgo; Oncologia, Belo Horizonte, MG, Brazil",
            "Liga Norte Riograndense Contra O Cancer; Centro De Pesquisa ClÃ­nica, Natal, RN, Brazil",
            "Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil",
            "Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil",
            "BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada",
            "Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada",
            "Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada",
            "Sunnybrook Research Institute, Toronto, Ontario, Canada",
            "Princess Margaret Cancer Center, Toronto, Ontario, Canada",
            "McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada",
            "Hopital Sacre-Coeur Research Centre, Montreal, Quebec, Canada",
            "CHU de QuÃ©bec - UniversitÃ© Laval - HÃ´tel-Dieu de QuÃ©bec, QuÃ©bec, Quebec, Canada",
            "Peking University First Hospital, Beijing City, China",
            "Beijing Friendship Hospital Affiliated of Capital University of Medical Science, Beijing Shi, China",
            "Peking University Third Hospital, Beijing, China",
            "Beijing Cancer Hospital, Beijing, China",
            "Beijing Hospital of Ministry of Health, Beijing, China",
            "Chongqing Cancer Hospital, Chongqing, China",
            "The Second Affiliated Hospital of Zhejiang University College, Hangzhou, China",
            "Jiangsu Cancer Hospital, Nanjing, China",
            "Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China",
            "Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai City, China",
            "Fudan University Shanghai Cancer Center, Shanghai, China",
            "Zhongshan Hospital Fudan University, Shanghai, China",
            "The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China",
            "Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China",
            "First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China",
            "Clinica CIMCA, San Jose, Costa Rica",
            "ICIMED Instituto de InvestigaciÃ³n en Ciencias MÃ©dicas, San Jose, Costa Rica",
            "Aarhus Universitetshospital, Urologisk Afd. K, Aarhus N, Denmark",
            "Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark",
            "ICO Paul Papin; Oncologie Medicale., Angers, France",
            "Hopital Saint Andre; Oncologie 2, Bordeaux, France",
            "Centre Francois Baclesse; Oncologie, Caen, France",
            "Centre Jean Perrin, Clermont Ferrand, France",
            "Hopital Louis Pasteur; Medecine B, Colmar, France",
            "CHD VendÃ©e, La Roche Sur Yon, France",
            "Hopital Claude Huriez; Urologie, Lille, France",
            "Centre Leon Berard, Lyon, France",
            "Institut Paoli Calmettes; Oncologie Medicale, Marseille, France",
            "Institut rÃ©gional du Cancer Montpellier, Montpellier, France",
            "Centre Antoine Lacassagne, Nice, France",
            "Institut de cancerologie du Gard, Nimes, France",
            "Institut Curie; Oncologie Medicale, Paris, France",
            "APHP - Hospital Saint Louis, Paris, France",
            "Institut Mutualiste Montsouris; Oncologie, Paris, France",
            "CHU Poitiers, Poitiers, France",
            "Institut Jean Godinot; Oncologie Medicale, Reims CEDEX, France",
            "Hopital d'Instruction des Armees de Begin, Saint-Mande, France",
            "Hopital Foch; Oncologie, Suresnes, France",
            "Institut de CancÃ©rologie de Lorraine, Vandoeuvre-Les-Nancy, France",
            "Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France",
            "CharitÃ© - UniversitÃ¤tsmedizin Berlin; CC 8: Chirurgische Medizin; Klinik fÃ¼r Urologie, Berlin, Germany",
            "Universitaetsklinikum Freiburg; Urology, Freiburg, Germany",
            "Martini-Klinik am UKE GmbH, Hamburg, Germany",
            "Urologikum Hamburt MVZ, Standort Alstertal, Hamburg, Germany",
            "Universitaetsklinikum Muenster; Urology, Muenster, Germany",
            "Studienpraxis Urologie, NÃ¼rtingen, Germany",
            "Urologische Gemeinschaftspraxis - URONEUM, Reutlingen, Germany",
            "UniversitÃ¤tsklinikum TÃ¼bingen; Klinik fÃ¼r Urologie, TÃ¼bingen, Germany",
            "Kliniken Nordoberpfalz; Klinikum Weiden; Klinik fÃ¼r Urologie, Andrologie und Kinderurologie, Weiden, Germany",
            "Urologisches Zentrum Euregio; Urologische Praxis am Wasserturm, WÃ¼rselen, Germany",
            "Alexandras Hospital; Dept. of Clin. Therapeutics, Athens Uni School of Medicine, Athens, Greece",
            "IASO General Hospital of Athens, Athens, Greece",
            "University Hospital of Patras Medical Oncology, Patras, Greece",
            "Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece",
            "Semmelwies University of Medicine; Urology Dept., Budapest, Hungary",
            "Orszagos Onkologiai Intezet; \"C\" BelgyÃ³gyÃ¡szati-OnkolÃ³giai Ã©s Klinikai FarmakolÃ³giai OsztÃ¡ly, Budapest, Hungary",
            "Uzsoki Utcai Korhaz, Budapest, Hungary",
            "Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen, Hungary",
            "B-A-Z County Hospital, Miskolc, Hungary",
            "Cork University Hospital, Cork, Ireland",
            "Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital; Oncology Day Unit, Dublin, Ireland",
            "Mater Misericordiae Uni Hospital; Oncology, Dublin, Ireland",
            "Mater Private Hospital, Dublin, Ireland",
            "Soroka Medical Center; Oncology Dept, Beer Sheva, Israel",
            "Rambam Health Care Campus; Oncology, Haifa, Israel",
            "Meir Medical Center; Oncology, Kfar-Saba, Israel",
            "Belinson Medical Center, Division of Oncology, Petach Tikva, Israel",
            "Chaim Sheba medical center, Oncology division, Ramat Gan, Israel",
            "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico, Napoli, Campania, Italy",
            "I.R.S.T Srl IRCCS; Oncologia Medica, Meldola, Emilia-Romagna, Italy",
            "A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, Italy",
            "Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica, Roma, Lazio, Italy",
            "A.O. Istituti Ospitalieri - Cremona; S.C. Oncologia, Cremona, Lombardia, Italy",
            "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy",
            "A.O. San Carlo Borromeo; U.O.C. Oncologia, Milano, Lombardia, Italy",
            "Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy",
            "Ospedale Area Aretina Nord; U.O.C. Oncologia, Arezzo, Toscana, Italy",
            "Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy",
            "Ospedale di Trento-Presidio Ospedaliero Santa Chiara; Oncologia Medica, Trento, Trentino-Alto Adige, Italy",
            "Nagoya University Hospital, Aichi, Japan",
            "Hirosaki University Hospital, Aomori, Japan",
            "National Cancer Center East, Chiba, Japan",
            "Toho University Sakura Medical Center, Chiba, Japan",
            "Gunma University Hospital, Gunma, Japan",
            "National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan",
            "Kanazawa University Hospital, Ishikawa, Japan",
            "Yokohama City University Medical Center, Kanagawa, Japan",
            "Kitasato University Hospital, Kanagawa, Japan",
            "Kochi Medical School Hospital, Kochi, Japan",
            "Kumamoto University Hospital, Kumamoto, Japan",
            "University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan",
            "Niigata University Medical & Dental Hospital, Niigata, Japan",
            "Kindai University Hospital, Osaka, Japan",
            "Toranomon Hospital, Tokyo, Japan",
            "Nippon Medical School Hospital, Tokyo, Japan",
            "The Cancer Institute Hospital of JFCR, Tokyo, Japan",
            "Keio University Hospital, Tokyo, Japan",
            "Kyorin University Hospital, Tokyo, Japan",
            "Yamaguchi University Hospital, Yamaguchi, Japan",
            "National Cancer Center, Gyeonggi-do, Korea, Republic of",
            "Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of",
            "Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",
            "Asan Medical Center - Oncology, Seoul, Korea, Republic of",
            "Gangnam Severance Hospital, Seoul, Korea, Republic of",
            "Samsung Medical Center, Seoul, Korea, Republic of",
            "Health Pharma Professional Research, CD Mexico, Mexico CITY (federal District), Mexico",
            "Centro Medico Culiacan SA de CV; Consultorio Medico 303 B, Culiacan, Sinaloa, Mexico",
            "Medical Care & Research, MÃ©rida, Yucatan, Mexico",
            "Consultorio de Especialidad en Urologia Privado, Durango, Mexico",
            "Hospital Angeles Mocel, Mexico City, Mexico",
            "Sykehuset Ã˜stfold Kalnes; Onkologisk seksjon, GrÃ¥lum, Norway",
            "Akershus universitetssykehus HF, LÃ¸renskog, Norway",
            "Medical University of Bialystok; Oncology clinic, Bialystok, Poland",
            "SPZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarawskiego, Opole, Poland",
            "Szpital Sw. Elzbiety - Mokotowskie Centrum Medyczne Sp. z o.o., Warszawa, Poland",
            "Centrum onkologii Instytutu im. Marii Sklodowskiej-Curie; Klinika Nowotworow Ukladu Moczowego, Warszawa, Poland",
            "Dolnoslaskie Centrum Onkologii, WrocÅ‚aw, Poland",
            "Woj. Wielospec. Centrum Onkologii i Traumatologii, ÅÃ³dÅº, Poland",
            "HUC; Servico de Urologia e Transplantacao Renal, Coimbra, Portugal",
            "Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal",
            "IPO do Porto; Servico de Oncologia Medica, Porto, Portugal",
            "SBEI HPE \"The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova\"of MoH of RF, Sankt-peterburg, Leningrad, Russian Federation",
            "Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation",
            "Altai Regional Oncological Center, Barnaul, Russian Federation",
            "Blokhin Cancer Research Center; Urological Dept, Moscow, Russian Federation",
            "Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation",
            "P.A. Herzen Oncological Inst. ; Oncology, Moscow, Russian Federation",
            "Privolzhsk Regional Medical Center, Nizhny Novgorod, Russian Federation",
            "Institute of Oncology Ljubljana, Ljubljana, Slovenia",
            "Institut Catala dÂ´Oncologia Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain",
            "Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain",
            "Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain",
            "Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain",
            "Hospital Universitario Reina Sofia; Servicio de Oncologia, CÃ³rdoba, Cordoba, Spain",
            "Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain",
            "Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain",
            "Hospital Clinic i Provincial; Servicio de UrologÃ­a, Barcelona, Spain",
            "Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, Spain",
            "Hospital General Universitario Gregorio MaraÃ±on; Servicio de Oncologia, Madrid, Spain",
            "Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain",
            "Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain",
            "Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain",
            "Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain",
            "Hospital Universitario de Salamanca; Servicio de UrologÃ­a, Salamanca, Spain",
            "Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain",
            "KAOHSIUNG MEDICAL UNI CHUNG-HO HOSPITAL; Dept. Of Urology, Kaohsiung, Taiwan",
            "China Medical University Hospital; Urology, Taichung, Taiwan",
            "Taichung Veterans General Hospital; Division of Urology, Taichung, Taiwan",
            "Chang Gung Memorial Hospital-LinKou; Urology, Taoyuan, Taiwan",
            "Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand",
            "Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand",
            "Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand",
            "Maharaj Nakorn Chiangmai Hospital; Department of Surgery/ Urology unit, Chiangmai, Thailand",
            "Royal Blackburn Hospital, Blackburn, United Kingdom",
            "Addenbrookes Nhs Trust; Oncology Clinical Trials Unit, Cambridge, United Kingdom",
            "Leicester Royal Infirmary, Leicester, United Kingdom",
            "The Christie NHS Foundation Trust, Manchester, United Kingdom",
            "James Cook Uni Hospital, Middlesborough, United Kingdom",
            "Mount Vernon & Watford Trust Hospital; Dept. of Clinical Oncology, Northwood, United Kingdom",
            "Royal Marsden Hospital; Institute of Cancer Research, Sutton, United Kingdom",
            "Royal Wolverhampton hospital; McHale Building, Wolverhampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03072238"
      },
      {
        "-rank": "134",
        "nct_id": "NCT01685190",
        "title": "A Study of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer",
        "acronym": "PIVOTAL",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Radiation",
              "#text": "Prostate alone IMRT"
            },
            {
              "-type": "Radiation",
              "#text": "Prostate and pelvis IMRT"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Acute lower GI RTOG toxicity at week 18 of follow-up.",
            "Ability to deliver 60Gy in 37 fractions to the pelvis using the varying radiotherapy planning techniques and delivery systems at the participating centres.",
            "Late (1 and 2 year) toxicity",
            "Patient Reported Outcomes",
            "Biochemical progression free survival",
            "Time to local progression",
            "Time to distant metastases",
            "Overall survival"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": "Cancer Research UK"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "124",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "ICR-CTSU/2010/10025",
            "CRUK/10/022",
            "ISRCTN48709247"
          ]
        },
        "start_date": "June 2011",
        "primary_completion_date": "December 2013",
        "completion_date": "December 2019",
        "study_first_posted": "September 14, 2012",
        "last_update_posted": "January 4, 2019",
        "locations": {
          "location": [
            "Queen Elizabeth, Birmingham, United Kingdom",
            "Addenbrooke's Hospital, Cambridge, United Kingdom",
            "Velindre Hospital, Cardiff, United Kingdom",
            "Ipswich, Ipswich, United Kingdom",
            "Clatterbridge Centre for Oncology, Liverpool, United Kingdom",
            "Royal Marsden NHSFT, London, United Kingdom",
            "Freeman Hospital, Newcastle, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01685190"
      },
      {
        "-rank": "135",
        "nct_id": "NCT01020448",
        "title": "Effect of Triptorelin (DecapeptylÂ®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer",
        "acronym": "Triptocare",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Triptorelin (DecapeptylÂ®)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA",
            "PCA3 Score Expressed as a Ratio of PCA3 mRNA Over PSA mRNA",
            "TMPRSS2-ERG Score (Expressed as a Ratio of T2-ERG mRNA Over PSA mRNA)",
            "Proportion of Patients Medically Castrated (i.e. With Serum Testosterone Levels of <50 ng/dL)",
            "PSA Level",
            "Safety, Assessed Through the Collection of Adverse Events (AEs)"
          ]
        },
        "sponsors": { "lead_sponsor": "Ipsen" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "339",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": {
          "other_id": [
            "8-79-52014-168",
            "2009-012786-58"
          ]
        },
        "start_date": "November 2009",
        "primary_completion_date": "November 2011",
        "completion_date": "June 2013",
        "study_first_posted": "November 25, 2009",
        "results_first_posted": "July 15, 2015",
        "last_update_posted": "January 30, 2019",
        "locations": {
          "location": [
            "HÃ´pital Erasme, Brussels, Belgium",
            "UZ Brussels, Brussels, Belgium",
            "UCL Saint-Luc, Brussels, Belgium",
            "UZ Antwerpen, Edegem, Belgium",
            "UZ Leuven, Leuven, Belgium",
            "CHU de LiÃ¨ge, LiÃ¨ge, Belgium",
            "Fredericia Sygehus, Fredericia, Denmark",
            "Frederiksbergs Hospital, Frederiksberg, Denmark",
            "Herlev University Hospital, Herlev, Denmark",
            "Odense Universitets hospital, Odense, Denmark",
            "Clinique RhÃ´ne Durance, Avignon, France",
            "HÃ´pital Pellegrin, Bordeaux, France",
            "CHU Henri Mondor, CrÃ©teil, France",
            "CHU Michalon, Grenoble, France",
            "Chru Lille, Lille, France",
            "HÃ´pital Nord, Marseille, France",
            "Clinique Beau Soleil, Montpellier, France",
            "Private practice, Nancy, France",
            "CHU Nantes, Nantes, France",
            "CHU Pasteur, Nice, France",
            "HÃ´pital Val de GrÃ¢ce, Paris, France",
            "Institut Mutualiste Monsouris, Paris, France",
            "HÃ´pital Henry Gabrielle, Saint Genis Laval, France",
            "HÃ´pital Foch, Suresnes, France",
            "CHU Toulouse, Toulouse, France",
            "IRCCS Fondazione S. Raffaele del Monte Tabor, Milano, Italy",
            "AOU San Luigi Gonzaga, Torino, Italy",
            "P.Stradins Clinical University Hospital, Riga, Latvia",
            "Center of Oncology, Riga, Latvia",
            "Medical University Clinics, Kaunas, Lithuania",
            "University Hospital, Klaipeda, Lithuania",
            "University Oncological Institute, Vilnius, Lithuania",
            "Ziekenhuis Amstelland, Amstelveen, Netherlands",
            "Academisch Medisch Centrum, Amsterdam, Netherlands",
            "Diaconessenhuis, Leiden, Netherlands",
            "Antonius Ziekenhuis, Sneek, Netherlands",
            "Medical Center, Arad, Romania",
            "Oncology Institute, Bucharest, Romania",
            "Sc E-Uro Srl, Cluj Napoca, Romania",
            "Oncomed, Timisoara, Romania",
            "Hospital Valle HebrÃ³n, Barcelona, Spain",
            "Hospital Clinic, Barcelona, Spain",
            "Hospital de Basurto, Bilbao, Spain",
            "Hospital Juan Canalejo, CoruÃ±a, Spain",
            "Hospital General Universitario, Madrid, Spain",
            "Hospital 12 de Octubre, Madrid, Spain",
            "Hospital Infanta SofÃ­a, Madrid, Spain",
            "Instituto de OncologÃ­a, Valencia, Spain",
            "Bristol Royal Infirmary, Bristol, United Kingdom",
            "Addenbrookes Hospital, Cambridge, United Kingdom",
            "University Hospital Wales, Cardiff, United Kingdom",
            "University Hospital Coventry, Coventry, United Kingdom",
            "Derby City Hosptial, Derby, United Kingdom",
            "Royal Devon and Exeter Hospital, Exeter, United Kingdom",
            "Falkirk & District Royal Infirmary, Falkirk, United Kingdom",
            "Leicester General Hospital, Leicester, United Kingdom",
            "Freeman Hospital, Newcastle upon Tyne, United Kingdom",
            "Nottingham City Hospital, Nottingham, United Kingdom",
            "Lister Hospital, Stevenage, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01020448"
      },
      {
        "-rank": "136",
        "nct_id": "NCT00316927",
        "title": "Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "acetylsalicylic acid"
            },
            {
              "-type": "Drug",
              "#text": "dexamethasone"
            },
            {
              "-type": "Drug",
              "#text": "diethylstilbestrol"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Prostate-specific antigen (PSA) response",
            "Overall response",
            "Quality of life",
            "Progression-free and overall survival"
          ]
        },
        "sponsors": {
          "lead_sponsor": "St. Bartholomew's Hospital",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "260",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "BARTS-DAVDAS",
            "CDR0000472404",
            "EU-20610",
            "ISRCTN13255144"
          ]
        },
        "start_date": "December 2002",
        "completion_date": "April 2007",
        "study_first_posted": "April 21, 2006",
        "last_update_posted": "June 26, 2013",
        "locations": {
          "location": [
            "Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom",
            "Burnley General Hospital, Burnley, England, United Kingdom",
            "Kent and Canterbury Hospital, Canterbury, England, United Kingdom",
            "Eastbourne District General Hospital, Eastbourne, England, United Kingdom",
            "Whipps Cross Hospital, London, England, United Kingdom",
            "Saint Bartholomew's Hospital, London, England, United Kingdom",
            "Chelsea Westminster Hospital, London, England, United Kingdom",
            "Maidstone Hospital, Maidstone, England, United Kingdom",
            "Milton Keynes General Hospital, Milton Keynes, England, United Kingdom",
            "Churchill Hospital, Oxford, England, United Kingdom",
            "Oldchurch Hospital, Romford, England, United Kingdom",
            "Torbay Hospital, Torquay Devon, England, United Kingdom",
            "Weston General Hospital, Weston-super-Mare, England, United Kingdom",
            "Worthing Hospital, Worthing, England, United Kingdom",
            "Cancer Care Centre at York Hospital, York, England, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00316927"
      },
      {
        "-rank": "137",
        "nct_id": "NCT01212991",
        "title": "A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer",
        "acronym": "PREVAIL",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Radiographic Progression-free Survival",
            "Time to First Skeletal-related Event",
            "Time to Initiation of Cytotoxic Chemotherapy",
            "Time to Prostate-specific Antigen (PSA) Progression",
            "Percentage of Patients With Prostate Specific Antigen (PSA) Response â‰¥ 50%",
            "Best Overall Soft Tissue Response"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Pfizer",
          "collaborator": [
            "Astellas Pharma Inc",
            "Medivation LLC, a wholly owned subsidiary of Pfizer Inc."
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1718",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Masking: Triple (Participant, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "MDV3100-03",
            "2010-020821-41",
            "C3431003"
          ]
        },
        "start_date": "September 2010",
        "primary_completion_date": "September 2013",
        "completion_date": "February 2019",
        "study_first_posted": "October 1, 2010",
        "results_first_posted": "October 16, 2014",
        "last_update_posted": "August 7, 2019",
        "locations": {
          "location": [
            "University of Alabama at Birmingham, Birmingham, Alabama, United States",
            "University of Alabama at Birmingham, Birmingham, Alabama, United States",
            "The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States",
            "The University of Arizona Cancer Certer-North Campus, Tucson, Arizona, United States",
            "Cancer Center Oncology Medical Group, La Mesa, California, United States",
            "Keck Hospital of USC, Los Angeles, California, United States",
            "LAC&USC Medical Center, Los Angeles, California, United States",
            "USC/Norris Comprehensive Cancer Center / Investigational Drug Services, Los Angeles, California, United States",
            "USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States",
            "Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services, Los Angeles, California, United States",
            "UCLA Clark Urology Clinic, Los Angeles, California, United States",
            "North County Oncology Medical Clinic, Inc, Oceanside, California, United States",
            "UC Davis Medical Center, Sacramento, California, United States",
            "University of California Davis Comprehensive Cancer Center, Sacramento, California, United States",
            "Medical Oncology Associates-SD, San Diego, California, United States",
            "Sharp Memorial Hospital Investigational Pharmacy, San Diego, California, United States",
            "Sharp Rees-Stealy, San Diego, California, United States",
            "Stanford University Medical Center, Stanford, California, United States",
            "Anschutz Cancer Center Pavilion Pharmacy, Aurora, Colorado, United States",
            "University of Colorado Hospital, Anschutz Cancer Pavilion, Aurora, Colorado, United States",
            "Lynn Cancer Institute Center for Hematology Oncology, Boca Raton, Florida, United States",
            "Northwestern Medical Faculty Foundation, Chicago, Illinois, United States",
            "Northwestern Memorial Hospital, Chicago, Illinois, United States",
            "Jewish Hospital & St. Mary's Healthcare, Inc., Louisville, Kentucky, United States",
            "Brigham & Women's Hospital, Boston, Massachusetts, United States",
            "Beth Israel Deaoness Medical Center, Boston, Massachusetts, United States",
            "Dana Farber Cancer Institute, Boston, Massachusetts, United States",
            "Karmanos Cancer Institute, Detroit, Michigan, United States",
            "Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States",
            "Mayo Clinic, Rochester, Minnesota, United States",
            "Barnes-Jewish West County Hospital, Creve Coeur, Missouri, United States",
            "BJH Pharmacy, Saint Louis, Missouri, United States",
            "Barnes-Jewish Hospital, Saint Louis, Missouri, United States",
            "Washington University School of Medicine, Saint Louis, Missouri, United States",
            "Barnes-Jewish St. Peters Hospital, Saint Peters, Missouri, United States",
            "Nebraska Methodist Hospital, Omaha, Nebraska, United States",
            "The Mount Sinai Medical Center, New York, New York, United States",
            "Memorial Sloan-Kettering Cancer Center, New York, New York, United States",
            "Cancer Centers of North Carolina, Cary, North Carolina, United States",
            "Levine Cancer Institute, Charlotte, North Carolina, United States",
            "Levine Cancer Institute - Main, Charlotte, North Carolina, United States",
            "Levine Cancer Institute - Southpark, Charlotte, North Carolina, United States",
            "Levine Cancer Institute - University, Charlotte, North Carolina, United States",
            "Levine Cancer Institute - Ballantyne, Charlotte, North Carolina, United States",
            "Duke University Medical Center, Durham, North Carolina, United States",
            "Investigational Chemotherapy Services, Durham, North Carolina, United States",
            "Cancer Centers of North Carolina, Raleigh, North Carolina, United States",
            "Portland VA Medical Center Laboratory, Portland, Oregon, United States",
            "Abramson Cancer Center of the University of Pennsylvania at Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States",
            "UPMC Presbyterian, Pittsburgh, Pennsylvania, United States",
            "UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",
            "Hematology / Oncology MUSC Hollings Cancer Center, Charleston, South Carolina, United States",
            "Medical University of South Carolina - Urology Services, Charleston, South Carolina, United States",
            "MUSC Department of Radiology, Charleston, South Carolina, United States",
            "MUSC Urology Ambulatory Care, Charleston, South Carolina, United States",
            "MUSC Hematology / Oncology Medical Specialty Associates, East Cooper Medical Arts Center 3rd Floor, Mount Pleasant, South Carolina, United States",
            "MUSC Urology Medical Specialty Associates, East Cooper Medical Arts Center 3rd Floor, Mount Pleasant, South Carolina, United States",
            "UT Southwestern Medical Center at Dallas, Dallas, Texas, United States",
            "Virginia Oncology Associates, Hampton, Virginia, United States",
            "Virginia Oncology Associates, Newport News, Virginia, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "Virginia Oncology Associates, Virginia Beach, Virginia, United States",
            "Seattle Cancer Care Alliance, Seattle, Washington, United States",
            "University of Washington Medical Center, Seattle, Washington, United States",
            "University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",
            "Concord Repatriation General Hospital, Concord, New South Wales, Australia",
            "St George Private Hospital, Kogarah, New South Wales, Australia",
            "Lismore Base Hospital, Lismore Cancer Care and Haematology Unit, Lismore, New South Wales, Australia",
            "Liverpool Hospital, Liverpool, New South Wales, Australia",
            "North Coast Cancer Institute, Port Macquarie, New South Wales, Australia",
            "Prince of Wales Hospital, Randwick, New South Wales, Australia",
            "Royal North Shore Hospital, Department of Medical Oncology, St Leonards, New South Wales, Australia",
            "Sydney Adventist Hospital, Sydney, New South Wales, Australia",
            "Australian Clinical Trials Pty Ltd, Wahroonga, New South Wales, Australia",
            "SAN Pathology, Wahroonga, New South Wales, Australia",
            "SAN Radiology, Wahroonga, New South Wales, Australia",
            "Calvary Mater Newcastle, Waratah, New South Wales, Australia",
            "Westmead Hospital, Westmead, New South Wales, Australia",
            "Heart Care Partners, Auchenflower, Queensland, Australia",
            "Icon Cancer Care Wesley, Auchenflower, Queensland, Australia",
            "River City Pharmacy, Auchenflower, Queensland, Australia",
            "Icon Cancer Care Chermside, Chermside, Queensland, Australia",
            "University of Queensland Centre for Clinical Research (UQCCR), Herston, Queensland, Australia",
            "Nuclear Medicine and Imaging Department, Herston, Queensland, Australia",
            "Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia",
            "Icon Cancer Foundation, South Brisbane, Queensland, Australia",
            "Mater Private Cardiology, South Brisbane, Queensland, Australia",
            "Adelaide Cancer Centre, Kurralta Park, South Australia, Australia",
            "APHS Pharmacy, Kurralta Park, South Australia, Australia",
            "Ashford Cancer Centre Research, Kurralta park, South Australia, Australia",
            "Cancer Care SA Pty Ltd, Kurralta Park, South Australia, Australia",
            "Bendigo Health, Bendigo Hospital, Bendigo, Victoria, Australia",
            "Bendigo Health Medical Imaging, Bendigo, Victoria, Australia",
            "Eastern Health, Box Hill, Victoria, Australia",
            "MIA Box Hill Radiology, Box Hill, Victoria, Australia",
            "Oncology Eastern Clinical Research Unit (ECRU), Box Hill, Victoria, Australia",
            "Pharmacy Department, Box Hill, Victoria, Australia",
            "Cabrini Hospital Brighton, Brighton, Victoria, Australia",
            "Monash Health Translation Precinct, Clayton, Victoria, Australia",
            "Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia",
            "Barwon Health, Geelong Hospital, Geelong, Victoria, Australia",
            "Austin Hospital, Heidelberg, Victoria, Australia",
            "Cabrini Hospital Malvern, Malvern,, Victoria, Australia",
            "Cabrini Radiology, Malvern, Victoria, Australia",
            "MDI Chemer, Malvern, Victoria, Australia",
            "Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",
            "Sunshine Hospital, St Albans, Victoria, Australia",
            "Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria",
            "Ordination Dr. Fink, Salzburg, Austria",
            "Salzburger Universitatsklinikum, Salzburg, Austria",
            "Medizinische Universitaet Wien, Wien, Austria",
            "Cliniques Universitaires Saint-Luc, Brussels, Belgium",
            "AZ Sint-Lucas, Ghent, Belgium",
            "Jessaziekenhuis, Hasselt, Belgium",
            "AZ Groeninge, Campus KL, Kortrijk, Belgium",
            "UZ Leuven - University Hospital Gasthuisberg, Leuven, Belgium",
            "Centre Hospitalier Universitaire de Liege-Urologie, Liege, Belgium",
            "Alberta Health Services - Cancer Care, Tom Baker Cancer Centre, Calgary, Alberta, Canada",
            "Tom Baker Cancer Centre - Holy Cross Site, Calgary, Alberta, Canada",
            "Cross Cancer Institute, Edmonton, Alberta, Canada",
            "British Columbia Cancer Agency, Sindi Ahluwalia Hawkins, Centre for the Southern Interior, Kelowna, British Columbia, Canada",
            "Vancouver Prostate Centre, Vancouver, British Columbia, Canada",
            "Vancouver Island Health Authority-Royal Jubilee Hospital Medical Imaging, Victoria, British Columbia, Canada",
            "British Columbia Cancer Agency - Vancouver Island Centre, Victoria, British Columbia, Canada",
            "Manitoba Prostate Centre, Winnipeg, Manitoba, Canada",
            "QEII Health Sciences Centre, Nova Scotia Cancer Centre., Halifax, Nova Scotia, Canada",
            "QEII Health Sciences Centre, Halifax, Nova Scotia, Canada",
            "QEII Health Sciences Centre, Halifax, Nova Scotia, Canada",
            "Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada",
            "London RegCancer Program, London Health Sciences Centre, London, Ontario, Canada",
            "The Ottawa Hospital Cancer Centre, General Campus, Ottawa, Ontario, Canada",
            "The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada",
            "Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",
            "Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada",
            "CHU de Quebec - L'Hotel-Dieu de Quebec, Quebec, Canada",
            "Centre de recherche clinique el evaluative en oncologie (CRCEO), Quebec, Canada",
            "Aalborg Hospital Nord, Aalborg, Denmark",
            "Aarhus Universitetshospital, Aarhus N, Denmark",
            "Rigshospitalet, Copenhagen, Denmark",
            "Frederiksberg Hospital, Frederiksberg, Denmark",
            "Herlev Hospital, Herlev, Denmark",
            "Roskilde Sygehus, Roskilde, Denmark",
            "Docrates Clinic, Helsinki, Finland",
            "Helsinki University Central Hospital, Helsinki, Finland",
            "Oulu University Hospital, Oulu, Finland",
            "Tampere University Hospital, Tampere, Finland",
            "Hopital Civil, Strasbourg, Alsace, France",
            "Centre Eugene Marquis-Service d'Oncologie Medicale, Rennes cedex, Bretagne, France",
            "Institut Bergonie, Bordeaux, Nouvelle Aquitaine, France",
            "ICO Paul Papin, Angers, France",
            "Clinique Rhone Durance, Avignon, France",
            "Institut Bergonie, Bordeaux, France",
            "CHD Vendee, La Roche sur Yon Cedex, France",
            "Centre Jean Bernard - Clinique Victor Hugo, Le Mans, France",
            "Centre Leon Berard, Lyon, France",
            "Hopital Europeen Georges Pompidou, Paris Cedex 15, France",
            "Institut Curie, Paris, France",
            "Groupe Hospitalier La Pitie Salpetriere, Paris, France",
            "Centre de Recherche Clinique, Saint Herblain Cedex, France",
            "HIA Begin, Service de Medecine Interne et Oncologie, Saint-Mande, France",
            "Institut de Cancerologie Lucien Neuwirth, Saint-Priest en Jarez, France",
            "Clinique Pasteur, Toulouse, France",
            "Institut Gustave Roussy, Villejuif, France",
            "Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany",
            "GeschÃ¤ftsstelle der Ethik-Kommission des Landes Berlin, Berlin, Germany",
            "Charite-Universitaetsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany",
            "Staedtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany",
            "Universitaetsklinikum Carl Gustav Carus Dresden an der, Dresden, Germany",
            "Martini-Klinik am UKE Gmbh, Hamburg, Germany",
            "Urologikum Hamburg, Hamburg, Germany",
            "Universitaetsklinikum Heidelberg, Klinik Fuer Urologie, Heidelberg, Germany",
            "Universitaetsklinikum des Saarlandes, Homburg/Saar, Germany",
            "Universitaetsklinikum Mannheim, Klinik fuer Urologie, Mannheim, Germany",
            "Universitaetsklinikum Muenster, Muenster, Germany",
            "Universitaetsklinikum Tuebingen, Universitaetsklinik fuer Urologie, Tuebingen, Germany",
            "Universitaetsklinikum Ulm, Ulm, Germany",
            "Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden In Der Oberpfalz, Germany",
            "Soroka University Medical Center, Beer Sheva, Israel",
            "Assaf Harofe Medical Center, Beer Yaakov, Israel",
            "Bnai Zion Medical Center, Haifa, Israel",
            "Rabin Medical Center, Petach Tikva, Israel",
            "The Chaim Sheba Medical Center, Ramat Gan, Israel",
            "Azienda Socio Sanitaria Territoriale di Cremona, Cremona, CR, Italy",
            "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy",
            "Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, TO, Italy",
            "Azienda USL8-Presidio Ospedaliero S.Donato, Arezzo, Italy",
            "Farmacia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy",
            "Struttura Complessa di Oncologia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy",
            "UO di Radiologia, Azienda Socio Sanitaria Territoriale de Cremona, Cremona, Italy",
            "Ospedale G.B. Morgagni, Forli, Italy",
            "Azienda Ospedaliera San. Camillo Forlanini, Rome, Italy",
            "Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan",
            "Yokohama City University Hospital, Yokohama-shi, Kanagawa-ken, Japan",
            "Tohoku University Hospital, Sendai-Shi, Miyagi, Japan",
            "Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan",
            "Kindai University Hospital, Osaka-sayama, Osaka, Japan",
            "Osaka International Cancer Institute, Osaka-shi, Osaka, Japan",
            "Osaka University Hospital, Suita-shi, Osaka, Japan",
            "Tokushima University Hospital, Tokushima-shi, Tokushima, Japan",
            "Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan",
            "Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan",
            "Cancer Institute Hospital, Koutou-ku, Tokyo, Japan",
            "Kyorin University Hospital, Mitaka-shi, Tokyo, Japan",
            "Showa University Hospital, Shinagawa-ku, Tokyo, Japan",
            "Keio University Hospital, Shinjyuku-ku, Tokyo, Japan",
            "Yamaguchi University Hospital, Ube-shi, Yamaguchi, Japan",
            "Chiba Cancer Center, Chiba, Japan",
            "Kyoto University Hospital, Kyoto, Japan",
            "Niigata University Medical and Dental Hospital, Niigata, Japan",
            "Osaka City University Hospital, Osaka, Japan",
            "Jikei University Hospital, Tokyo, Japan",
            "Yamagata Prefectural Central Hospital, Yamagata, Japan",
            "National Cancer Center, Goyang, Gyeonggi-do, Korea, Republic of",
            "Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",
            "Chonnam National University Hwasun Hospital, Hwasun-eup, Hwasun-gun, Jeonnam, Korea, Republic of",
            "Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of",
            "Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of",
            "Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",
            "Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",
            "Klaipeda University Hospital, Klaipeda, Lithuania",
            "Division of Oncourology, National Cancer Institute, Vilnius, Lithuania",
            "Vrije Universiteit Medical Center, Department of Medical Oncology, Amsterdam, Netherlands",
            "Catharina Ziekenhuis, Eindhoven, Netherlands",
            "University Medical Center Groningen, Department of Urology, Groningen, Netherlands",
            "UMC St. Radboud, Nijmegen, Netherlands",
            "EMC Instytut Medyczny S.A., Wroclaw, Dolnoslaskie, Poland",
            "Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Tramatologii im. M.Kopernika w Lodzi, Lodz, Lodzkie, Poland",
            "Apteka Szpitalna, Gdansk, Pomorskie, Poland",
            "Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie, Poland",
            "Niepubliczny Zaklad Opieki Zdrowotnej, Myslowice, Slaskie, Poland",
            "Wielkopolskie Centrum Onkologii, Poznan, Wielkopolskie, Poland",
            "Russian Academy of Medical Sciences Institution, Moscow, Russian Federation",
            "State Educational Institution of Higher Professional Education, St-Petersburg, Russian Federation",
            "State healthcare institute, St-Petersburg, Russian Federation",
            "North-Western State Medical University named after I.I.Mechnikov of the Ministry of Healthcare, St.-Petersburg, Russian Federation",
            "Department of Urology, National University Hospital, Singapore, Singapore",
            "Singapore General Hospital, Singapore, Singapore",
            "Fakultna nemocnica s poliklinikou F.D. Roosevelta B. bystrica, Banska Bystrica, Slovakia",
            "CUIMED s.r.o., Bratislava, Slovakia",
            "Univerzitna Nemocnica Martin, Martin, Slovakia",
            "UROEXAM, spol. s r.o. urologicka ambulancia, Nitra, Slovakia",
            "Poliklinika Sekcov, wesper, s.r.o., Presov, Slovakia",
            "UROCENTRUM MILAB s.r.o., Presov, Slovakia",
            "Hospital Universitario German Trias i Pujol, Badalona, Barcelona, Spain",
            "Althaia Xarxa Asistencial Manresa, Manresa, Barcelona, Spain",
            "Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain",
            "ClÃ­nica Universidad de Navarra, Pamplona, Navarra, Spain",
            "Complejo Hospitalario Universitario A Coruna, A Coruna, Spain",
            "Hospital del Mar, Barcelona, Spain",
            "Hospital Vall d'Hebron, Barcelona, Spain",
            "Hospital Clinic i Provincial, Barcelona, Spain",
            "Hospital Universitario Ramon y Cajal, Madrid, Spain",
            "Hospital Madrid Norte Sanchinarro, Madrid, Spain",
            "Corporacio Sanitaria Parc Tauli, Sabadell(Barcelona), Spain",
            "Sahlgrenska University Hospital, Gothenburg, Sweden",
            "Skane University Hospital, Malmo, Sweden",
            "Orebro University Hospital, Orebro, Sweden",
            "Karolinska University Hospital Solna, Stockholm, Sweden",
            "Umea University Hospital, Umea, Sweden",
            "Bishops Wood Hospital, Northwood, Middlesex, United Kingdom",
            "Mount Vernon Hospital, Northwood, Middlesex, United Kingdom",
            "Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom",
            "Royal Marsden Hospital, Sutton, Surrey, United Kingdom",
            "Northern Centre for Cancer Care, Newcastle Upon Tyne, Tyne and Wear, United Kingdom",
            "Velindre Cancer Centre, Cardiff, Wales, United Kingdom",
            "Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, Merseyside, United Kingdom",
            "Clinical Investigations and Research Unit, Royal Sussex County Hospital, Brighton, East Sussex, United Kingdom",
            "University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom",
            "Edinburgh Cancer Centre, Edinburgh, United Kingdom",
            "University College London Hospital NHS Trust, London, United Kingdom",
            "Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",
            "Imperial College Healthcare NHS Trust, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01212991"
      },
      {
        "-rank": "138",
        "nct_id": "NCT02236637",
        "title": "A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "outcome_measures": {
          "outcome_measure": [
            "Sequencing of treatment initiation, termination, and duration",
            "Clinical Benefit",
            "Medical Resource Utilization",
            "European Quality of Life-5 Dimensions, 5 Levels Questionnaire (EQ-5D-(5L))",
            "Functional Assessment of Cancer Therapy - Prostate Cancer (FACT-P)",
            "Overall Survival",
            "Radiologic Assessment",
            "Prior prostate cancer treatment",
            "Reason for start and rationale for choice of treatment",
            "Reason for treatment discontinuation"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Pharmaceutica N.V., Belgium" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "3049",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR100857",
            "212082PCR4001"
          ]
        },
        "start_date": "June 14, 2013",
        "primary_completion_date": "July 9, 2018",
        "completion_date": "July 9, 2018",
        "study_first_posted": "September 10, 2014",
        "last_update_posted": "November 14, 2018",
        "locations": {
          "location": [
            "Salzburg, Austria",
            "Vienna, Austria",
            "Aalst, Belgium",
            "Antwerpen, Belgium",
            "Bonheiden, Belgium",
            "Brasschaat, Belgium",
            "Brugge, Belgium",
            "Edegem, Belgium",
            "Gent, Belgium",
            "Kortrijk, Belgium",
            "LiÃ¨ge, Belgium",
            "Oostende, Belgium",
            "Ottignies, Belgium",
            "Roeselare, Belgium",
            "Turnhout, Belgium",
            "Angers, France",
            "Avignon Cedex 9, France",
            "Brest, France",
            "BÃ©ziers, France",
            "Gap, France",
            "Hyeres, France",
            "La Tronche, France",
            "Marseille, France",
            "Metz, France",
            "Montpellier, France",
            "Nancy, France",
            "Paris, France",
            "Perigueux, France",
            "Pierre Benite Cedex, France",
            "Pringy, France",
            "Reims Cedex, France",
            "Rennes Cedex 09, France",
            "Saint Mande, France",
            "St Gregoire Cedex, France",
            "St Quentin Cedex, France",
            "Toulouse, France",
            "Tours Cedex, France",
            "Augsburg, Germany",
            "Bad Saarow, Germany",
            "Bautzen, Germany",
            "Berlin, Germany",
            "Braunschweig, Germany",
            "Chemnitz, Germany",
            "Duisburg, Germany",
            "Erkrath, Germany",
            "Frankfurt, Germany",
            "Hamburg, Germany",
            "Holzminden, Germany",
            "Jena, Germany",
            "Kiel, Germany",
            "Kirchheim, Germany",
            "NÃ¼rtingen, Germany",
            "Remscheid, Germany",
            "Reutlingen, Germany",
            "Rostock, Germany",
            "Schwerin, Germany",
            "Sindelfingen, Germany",
            "TÃ¼bingen, Germany",
            "Ulm, Germany",
            "Weiden, Germany",
            "Wilhelmshaven, Germany",
            "WÃ¼rselen, Germany",
            "Beer Sheva, Israel",
            "Beer Yaakov, Israel",
            "Haifa, Israel",
            "Holon, Israel",
            "Tel-Aviv, Israel",
            "Luxembourg, Luxembourg",
            "Niederkorn, Luxembourg",
            "Bydgoszcz, Poland",
            "Gdansk, Poland",
            "Krakow, Poland",
            "Lodz, Poland",
            "Opole, Poland",
            "PoznaÃ±, Poland",
            "Warsaw, Poland",
            "Warszawa, Poland",
            "Braga, Portugal",
            "Coimbra, Portugal",
            "Evora, Portugal",
            "Lisboa, Portugal",
            "Porto, Portugal",
            "Setubal, Portugal",
            "Ekaterinbourg, Russian Federation",
            "Moscow N/A, Russian Federation",
            "Obninsk, Russian Federation",
            "Omsk, Russian Federation",
            "Rostov-On-Don, Russian Federation",
            "St.-Petersburg, Russian Federation",
            "Ufa, Russian Federation",
            "Celje, Slovenia",
            "Ljubljana, Slovenia",
            "Slovenj Gradec, Slovenia",
            "Asturias, Spain",
            "Barakaldo Vizcaya, Spain",
            "Barcelona, Spain",
            "Bilbao Vizcaya, Spain",
            "Girona, Spain",
            "La CoruÃ±a, Spain",
            "Langreo, Spain",
            "Palma De Mallorca, Spain",
            "Pontevedra, Spain",
            "Sabadell, Spain",
            "Salamanca, Spain",
            "Santiago De Compostela, Spain",
            "Valladolid, Spain",
            "Zaragoza, Spain",
            "BorÃ¥s, Sweden",
            "GÃ¶teborg, Sweden",
            "MalmÃ¶, Sweden",
            "Stockholm, Sweden",
            "UmeÃ¥, Sweden",
            "VÃ¤sterÃ¥s, Sweden",
            "VÃ¤xjÃ¶, Sweden",
            "Ã–rebro, Sweden",
            "Ã–stersund, Sweden",
            "Aarau, Switzerland",
            "Winterthur, Switzerland",
            "Ankara, Turkey",
            "Edirne, Turkey",
            "Istanbul, Turkey",
            "Izmir, Turkey",
            "Kayseri, Turkey",
            "Kocaeli, Turkey",
            "Turkey, Turkey",
            "Ashton Under Lyne, United Kingdom",
            "Barnstaple, United Kingdom",
            "Blackburn, United Kingdom",
            "Bournemouth, United Kingdom",
            "Bradford, United Kingdom",
            "Brighton Sussex, United Kingdom",
            "Burton, United Kingdom",
            "Crewe, United Kingdom",
            "Huddersfield, United Kingdom",
            "Lancaster, United Kingdom",
            "Leeds Yorks, United Kingdom",
            "London, United Kingdom",
            "N/a N/a, United Kingdom",
            "Plymouth, United Kingdom",
            "Scunthorpe, United Kingdom",
            "Steeton, United Kingdom",
            "Stoke On Trent, United Kingdom",
            "Taunton, United Kingdom",
            "Torquay, United Kingdom",
            "Wakefield, United Kingdom",
            "Wigan, United Kingdom",
            "York, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02236637"
      },
      {
        "-rank": "139",
        "nct_id": "NCT01867710",
        "title": "Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abiraterone Acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone 5 mg twice daily"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone 5 mg once daily"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone 2.5 mg twice daily"
            },
            {
              "-type": "Drug",
              "#text": "Dexamethasone 0.5 mg once daily"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of Participants Experiencing Neither of the 2 Mineralocorticoid Excess Toxicity During the First 24 Weeks of Treatment",
            "Percentage of Participants With Confirmed Prostate Specific Antigen (PSA) Response Rate [Greater Than or Equal to (>=) 50 Percent (%) Decline From Baseline] at Week 12",
            "Change From Baseline to Endpoint in Brief Pain Inventory- Short Form (BPI-SF) Score: Worst Pain",
            "Change From Baseline to Endpoint in Brief Pain Inventory- Short Form (BPI-SF) Score: Pain Intensity Subscale",
            "Change From Baseline to Endpoint in Brief Pain Inventory- Short Form (BPI-SF) Score: Pain Interference Subscale",
            "Change From Baseline to Endpoint in EuroQol-5 Dimension-5 Level (EQ-5D-5L): Index Score",
            "Change From Baseline to Endpoint in EuroQol-5 Dimension-5 Level (EQ-5D-5L): EQ-VAS",
            "Change From Baseline to Endpoint in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire Score",
            "Progression-Free Survival (PFS)",
            "Time to Prostate-Specific Antigen (PSA) Progression",
            "Objective Response Rate (ORR)",
            "Time to Opiate Use for Cancer-related Pain",
            "Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by 1 Point",
            "Overall Survival",
            "Time to Next Prostate Cancer Therapy"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Pharmaceutica N.V., Belgium" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "164",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR100916",
            "2012-004331-23",
            "212082PCR2023"
          ]
        },
        "start_date": "July 16, 2013",
        "primary_completion_date": "April 20, 2015",
        "completion_date": "June 5, 2018",
        "study_first_posted": "June 4, 2013",
        "results_first_posted": "May 11, 2016",
        "last_update_posted": "July 4, 2019",
        "locations": {
          "location": [
            "Aalst, Belgium",
            "Brussels, Belgium",
            "Gent, Belgium",
            "Hasselt, Belgium",
            "Kortrijk, Belgium",
            "Leuven, Belgium",
            "Hannover, Germany",
            "MÃ¼lheim, Germany",
            "NÃ¼rtingen, Germany",
            "TÃ¼bingen, Germany",
            "Budapest, Hungary",
            "Miskolc, Hungary",
            "Birmingham, United Kingdom",
            "Glasgow, United Kingdom",
            "London, United Kingdom",
            "Sutton, United Kingdom",
            "Whitchurch, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01867710"
      },
      {
        "-rank": "140",
        "nct_id": "NCT03706365",
        "title": "A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abemaciclib"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone Acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Progression Free Survival (rPFS)",
            "Time to Prostate-Specific Antigen (PSA) Progression",
            "Objective Response Rate (ORR): Percentage of Participants with a Complete Response (CR) or Partial Response (PR)",
            "Duration of Response (DOR)",
            "Overall Survival (OS)",
            "Time to Symptomatic Progression",
            "Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib",
            "PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567",
            "PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726",
            "PK: Mean Steady State Exposure of Abiraterone Acetate"
          ]
        },
        "sponsors": { "lead_sponsor": "Eli Lilly and Company" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "180",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "16598",
            "I3Y-MC-JPCM",
            "2016-004276-21"
          ]
        },
        "start_date": "November 27, 2018",
        "primary_completion_date": "September 15, 2021",
        "completion_date": "February 14, 2024",
        "study_first_posted": "October 16, 2018",
        "last_update_posted": "August 19, 2019",
        "locations": {
          "location": [
            "University of Arizona Cancer Center, Phoenix, Arizona, United States",
            "Mayo Clinic Hospital, Phoenix, Arizona, United States",
            "The University of Arizona Cancer Center, Tucson, Arizona, United States",
            "St. Bernards Medical Center, Jonesboro, Arkansas, United States",
            "Comprehensive Blood and Cancer Center, Bakersfield, California, United States",
            "St. Joseph Heritage Healthcare, Fullerton, California, United States",
            "University of California - San Diego, La Jolla, California, United States",
            "UCLA Medical Center, Los Angeles, California, United States",
            "TRIO - Translational Research in Oncology-US, Inc., Los Angeles, California, United States",
            "Pacific Cancer Care, Monterey, California, United States",
            "Rocky Mountain Cancer Center, Lone Tree, Colorado, United States",
            "Yale University School of Medicine, New Haven, Connecticut, United States",
            "Millennium Oncology, Hollywood, Florida, United States",
            "Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States",
            "Northside Hospital Cancer Institute, Marietta, Georgia, United States",
            "Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States",
            "Norton Cancer Institute, Louisville, Kentucky, United States",
            "Maryland Oncology Hematology, P.A., Rockville, Maryland, United States",
            "Massachusetts General Hospital, Boston, Massachusetts, United States",
            "Southcoast Centers for Cancer Care, Fairhaven, Massachusetts, United States",
            "University of Minnesota Hospital, Minneapolis, Minnesota, United States",
            "Research Medical Center, Kansas City, Missouri, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "New York Oncology Hematology, P.C, Albany, New York, United States",
            "Associated Medical Professionals of NY, Syracuse, New York, United States",
            "Mission SECU Cancer Center, Asheville, North Carolina, United States",
            "Oklahoma Cancer Specialists & Research Institute, LLC, Tulsa, Oklahoma, United States",
            "Northwest Cancer Specialists PC, Tigard, Oregon, United States",
            "University of Tennessee Medical Center, Knoxville, Tennessee, United States",
            "Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States",
            "Southwestern Medical Center - Dallas, Dallas, Texas, United States",
            "Texas Oncology Fort Worth, Fort Worth, Texas, United States",
            "Texas Oncology-Memorial City, Houston, Texas, United States",
            "Scott & White Memorial Hospital & Clinic, Temple, Texas, United States",
            "US Oncology, The Woodlands, Texas, United States",
            "Texas Oncology Cancer Care and Research Center, Waco, Texas, United States",
            "University of Utah School of Medicine, Salt Lake City, Utah, United States",
            "University of Vermont Medical Center, Burlington, Vermont, United States",
            "Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia",
            "Southside Cancer Care Centre, Kogarah, New South Wales, Australia",
            "Macquarie University Hospital, Macquarie Park, New South Wales, Australia",
            "Prince of Wales Hospital, Randwick, New South Wales, Australia",
            "St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia",
            "Finsen Institute, Copenhagen, Denmark",
            "NÃ¦stved Sygehus, NÃ¦stved, Denmark",
            "Studienpraxis Urologie, NÃ¼rtingen, Baden-WÃ¼rttemberg, Germany",
            "UniversitÃ¤tsklinikum MÃ¼nster, MÃ¼nster, Nordrhein-Westfalen, Germany",
            "UniversitÃ¤tsklinikum TÃ¼bingen, TÃ¼bingen, Germany",
            "Samsung Medical Center, Seoul, Korea, Korea, Republic of",
            "Seoul National University Hospital, Seoul, Korea, Republic of",
            "Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Canisius-Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands",
            "Erasmus Medisch Centrum, Rotterdam, South Holland, Netherlands",
            "St. Antonius Ziekenhuis, locatie Nieuwegein, Utrecht, Netherlands",
            "Puerto Rico Hematology/Oncology Group, Bayamon, Puerto Rico",
            "Centrul de Oncologie Sf. Nectarie SRL, Craiova, Dolj, Romania",
            "S.C. R.T.C. Radiology Therapeutic Center S.R.L., Otopeni, Ilfov, Romania",
            "SC Gral Medical SRL, Bucuresti, Romania",
            "Sp Clinic Judetean de Urgenta Sf.Apostol Andrei Constanta, Constanta, Romania",
            "Hospital Clinico Universitario Virgen de la Victoria, Malaga, Andalucia, Spain",
            "Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain",
            "Hospital Universitari Vall d'Hebron, Barcelona, Spain",
            "Hospital Clinic I Provincial, Barcelona, Spain",
            "Hospital General Universitario Gregorio MaraÃ±on, Madrid, Spain",
            "Hospital Universitario Ramon y Cajal, Madrid, Spain",
            "Hospital Universitario 12 de Octubre, Madrid, Spain",
            "Derriford Hospital, Plymouth, Devon, United Kingdom",
            "University College Hospital - London, London, Greater London, United Kingdom",
            "Charing Cross Hospital, Chelsea, London, United Kingdom",
            "Northampton General Hospital, Northampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03706365"
      },
      {
        "-rank": "141",
        "nct_id": "NCT00819247",
        "title": "The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Degarelix"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With Testosterone <0.5 Nanogram/Milliliter",
            "Number of Participants With Testosterone < 0.5 Nanogram/Milliliter at All Visits Between Weeks 4-24",
            "Number of Participants Not Meeting a Testosterone Withdrawal Criterion Between Weeks 4-24",
            "Number of Participants Who Met the Withdrawl Criteria for Prostate-specific Antigen",
            "Number of Participants With Normal Prostate-specific Antigen Levels During the Study",
            "The Number of Participants With Abnormal Liver Function Tests",
            "Percentage Change in Vital Signs and Body Weight"
          ]
        },
        "sponsors": { "lead_sponsor": "Ferring Pharmaceuticals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "129",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "FE200486 CS02" },
        "start_date": "March 2001",
        "primary_completion_date": "May 2002",
        "completion_date": "August 2002",
        "study_first_posted": "January 8, 2009",
        "results_first_posted": "March 31, 2009",
        "last_update_posted": "May 20, 2011",
        "locations": {
          "location": [
            "Ayr Hospital, Ayr, United Kingdom",
            "Bristol Royal Infirmary, Bristol, United Kingdom",
            "Southmead Hospital, Bristol, United Kingdom",
            "St. Richards Hospital, Chichester, United Kingdom",
            "Glan Clwyd Hospital, Denbighshire, United Kingdom",
            "Ninewells Hospital, Dundee, United Kingdom",
            "Southern General Hospital, Glasgow, United Kingdom",
            "Leicester General Hospital, Leicester, United Kingdom",
            "Chelsea and Westminster Hospital, London, United Kingdom",
            "Kings College Hospital, London, United Kingdom",
            "St. Bartholemews Hospital, London, United Kingdom",
            "Derriford Hospital, Plymouth, United Kingdom",
            "Lister Hospital, Stevenage, United Kingdom",
            "Stirling Royal Infirmary, Stirling, United Kingdom",
            "Morriston Hospital, Swansea, United Kingdom",
            "Pindersfields General Hospital, Wakefield, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00819247"
      },
      {
        "-rank": "142",
        "nct_id": "NCT02525068",
        "title": "A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC",
        "acronym": "RE-AKT",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Adenocarcinoma of the Prostate" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "AZD5363"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Phase I: Type, frequency, severity, seriousness and relatedness of adverse events",
            "Phase I: Laboratory abnormalities will be assessed according to NCI CTCAE v4",
            "Randomised phase II: Best overall tumour response",
            "Phase II expansion: Best overall tumour response",
            "Phase I and phase II expansion only - Pharmacokinetic (PK) assay analyses",
            "Phase I - Antitumour activity of the combination",
            "Randomised phase II and phase II expansion - Overall survival and radiographic progression free survival",
            "Maximum PSA decline and circulating tumour cell (CTC) fall",
            "Pain Palliation - Randomised phase II only",
            "Number of Adverse events will be graded according to NCI-CTCAE v4"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Institute of Cancer Research, United Kingdom",
          "collaborator": "Royal Marsden NHS Foundation Trust"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "136",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "ICRâ€CTSU/2012/10037",
            "2013-004091-34",
            "CRUKE/12/050",
            "ISRCTN17168679",
            "ISS53630011"
          ]
        },
        "start_date": "December 2014",
        "primary_completion_date": "December 31, 2019",
        "completion_date": "March 2020",
        "study_first_posted": "August 17, 2015",
        "last_update_posted": "August 8, 2018",
        "locations": { "location": "Royal Marsden Hospital, Sutton, Surrey, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT02525068"
      },
      {
        "-rank": "143",
        "nct_id": "NCT03732820",
        "title": "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration-resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "olaparib"
            },
            {
              "-type": "Drug",
              "#text": "abiraterone acetate"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiological progression free survival (rPFS)",
            "Time to first subsequent anticancer therapy or death (TFST)",
            "Time to pain progression (TTPP)",
            "Overall survival (OS)",
            "Time to opiate use",
            "Time to a Symptomatic Skeletal-Related Event (SSRE)",
            "Circulating Tumour Cells (CTC) conversion",
            "Time to second progression or death (PFS2)",
            "Brief Pain Inventory-Short Form (BPI-SF)",
            "Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P)",
            "Homologous Recombination Repair (HRR) gene status",
            "Maximum plasma concentration at steady state [Cmax,ss]",
            "Time to maximum plasma concentration at steady state (Cmax,ss) [tmax,ss]",
            "Minimum plasma concentration at steady state [Cmin,ss]",
            "Partial area under the concentration-time curve in 0-8 h [AUC0-8])",
            "Partial area under the concentration-time curve [AUC0-8])",
            "Number of adverse events",
            "Vital signs-blood pressure",
            "Vital signs-pulse rate",
            "Vital signs-body temperature",
            "ECG",
            "Change in Albumin (g/L)",
            "Change in Alkaline phosphatase (U/L)",
            "Change in Aspartate aminotransferase (U/L)",
            "Change in Amylase (U/L)",
            "Change in Alanine aminotransferase (U/L)",
            "Change in Total bilirubin (Î¼mol/L)",
            "Change in Direct bilirubin",
            "Change in Calcium (mmol/L)",
            "Change in Chloride (mmol/L)",
            "Change in Creatinine (Î¼mol/L)",
            "Change in Gamma glutamyltransferase (U/L)",
            "Change in Fasting gucose (mmol/L)",
            "Change in Lactate dehydrogenase (U/L)",
            "Change in Magnesium (mmol/L)",
            "Change in Potassium (mmol/L)",
            "Change in Phosphorus ((mmol/L)",
            "Change in Sodium (mmol/L)",
            "Change in Carbon dioxide (mEq/L )",
            "Change in Total protein (g/L)",
            "Change in Urea or blood urea nitrogen, depending on the local practice (mmol/L)",
            "Change in absolute neutrophil count (/L)",
            "Change in absolute lymphocyte count (/L)",
            "Change in haemoglobin (g/L)",
            "Change in platelet count with differential (/L)",
            "Change in total white blood cell count with differential(/L)",
            "Change in red blood cell count (/l)",
            "Change in Haematocrit (%)",
            "Change in Mean Cell Volume (fL)",
            "Urinalysis:change in blood",
            "Urinalysis: Change in protein",
            "Urinalysis: change in glucose"
          ]
        },
        "sponsors": {
          "lead_sponsor": "AstraZeneca",
          "collaborator": "Merck Sharp & Dohme Corp."
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "99 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "720",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "D081SC00001",
            "2018-002011-10"
          ]
        },
        "start_date": "October 31, 2018",
        "primary_completion_date": "April 13, 2021",
        "completion_date": "August 17, 2022",
        "study_first_posted": "November 7, 2018",
        "last_update_posted": "August 7, 2019",
        "locations": {
          "location": [
            "Research Site, Homewood, Alabama, United States",
            "Research Site, Anchorage, Alaska, United States",
            "Research Site, Tucson, Arizona, United States",
            "Research Site, Tucson, Arizona, United States",
            "Research Site, Clovis, California, United States",
            "Research Site, La Jolla, California, United States",
            "Research Site, Los Angeles, California, United States",
            "Research Site, Los Angeles, California, United States",
            "Research Site, Sacramento, California, United States",
            "Research Site, San Diego, California, United States",
            "Research Site, Denver, Colorado, United States",
            "Research Site, Norwich, Connecticut, United States",
            "Research Site, Lisle, Illinois, United States",
            "Research Site, Jeffersonville, Indiana, United States",
            "Research Site, New Orleans, Louisiana, United States",
            "Research Site, Towson, Maryland, United States",
            "Research Site, Detroit, Michigan, United States",
            "Research Site, Grand Rapids, Michigan, United States",
            "Research Site, Saint Louis, Missouri, United States",
            "Research Site, Bozeman, Montana, United States",
            "Research Site, Omaha, Nebraska, United States",
            "Research Site, Paramus, New Jersey, United States",
            "Research Site, Brooklyn, New York, United States",
            "Research Site, Fresh Meadows, New York, United States",
            "Research Site, Lake Success, New York, United States",
            "Research Site, Mineola, New York, United States",
            "Research Site, Rochester, New York, United States",
            "Research Site, Syracuse, New York, United States",
            "Research Site, White Plains, New York, United States",
            "Research Site, Durham, North Carolina, United States",
            "Research Site, Middleburg Heights, Ohio, United States",
            "Research Site, Portland, Oregon, United States",
            "Research Site, Philadelphia, Pennsylvania, United States",
            "Research Site, Charleston, South Carolina, United States",
            "Research Site, Myrtle Beach, South Carolina, United States",
            "Research Site, San Antonio, Texas, United States",
            "Research Site, Seattle, Washington, United States",
            "Research Site, Wheeling, West Virginia, United States",
            "Research Site, Milwaukee, Wisconsin, United States",
            "Research Site, Box Hill, Australia",
            "Research Site, Darlinghurst, Australia",
            "Research Site, Greenslopes, Australia",
            "Research Site, Herston, Australia",
            "Research Site, Kingswood, Australia",
            "Research Site, Kurralta Park, Australia",
            "Research Site, St Albans, Australia",
            "Research Site, Waratah, Australia",
            "Research Site, Brussels, Belgium",
            "Research Site, Brussels, Belgium",
            "Research Site, Gent, Belgium",
            "Research Site, LiÃ¨ge, Belgium",
            "Research Site, Belo Horizonte, Brazil",
            "Research Site, Curitiba, Brazil",
            "Research Site, Fortaleza, Brazil",
            "Research Site, Porto Alegre, Brazil",
            "Research Site, Porto Alegre, Brazil",
            "Research Site, Rio de Janeiro, Brazil",
            "Research Site, Sao Paulo, Brazil",
            "Research Site, Sao Paulo, Brazil",
            "Research Site, SÃ£o JosÃ© do Rio Preto, Brazil",
            "Research Site, Calgary, Alberta, Canada",
            "Research Site, Edmonton, Alberta, Canada",
            "Research Site, Kelowna, British Columbia, Canada",
            "Research Site, Toronto, CA, Canada",
            "Research Site, Halifax, Nova Scotia, Canada",
            "Research Site, London, Ontario, Canada",
            "Research Site, Toronto, Ontario, Canada",
            "Research Site, Greenfield Park, Quebec, Canada",
            "Research Site, Montreal, Quebec, Canada",
            "Research Site, Montreal, Quebec, Canada",
            "Research Site, Santiago, Chile",
            "Research Site, Santiago, Chile",
            "Research Site, Temuco, Chile",
            "Research Site, ViÃ±a del Mar, Chile",
            "Research Site, Beijing, China",
            "Research Site, Beijing, China",
            "Research Site, Beijing, China",
            "Research Site, Beijing, China",
            "Research Site, Changsha, China",
            "Research Site, Changsha, China",
            "Research Site, Chengdu, China",
            "Research Site, ChongQing, China",
            "Research Site, Hangzhou, China",
            "Research Site, Hangzhou, China",
            "Research Site, Hangzhou, China",
            "Research Site, Nanchang, China",
            "Research Site, Nanjing, China",
            "Research Site, Shanghai, China",
            "Research Site, Shanghai, China",
            "Research Site, Shanghai, China",
            "Research Site, Xi'an, China",
            "Research Site, Xiamen, China",
            "Research Site, Brno, Czechia",
            "Research Site, Hradec Kralove, Czechia",
            "Research Site, Praha 5, Czechia",
            "Research Site, Praha, Czechia",
            "Research Site, Angers Cedex 01, France",
            "Research Site, BESANCON Cedex, France",
            "Research Site, Caen Cedex 05, France",
            "Research Site, Marseille, France",
            "Research Site, Pierre Benite, France",
            "Research Site, Quimper Cedex, France",
            "Research Site, Toulouse Cedex 3, France",
            "Research Site, Vandoeuvre les Nancy, France",
            "Research Site, Bergisch Gladbach, Germany",
            "Research Site, Bremen, Germany",
            "Research Site, Duisburg, Germany",
            "Research Site, Freiburg im Breisgau, Germany",
            "Research Site, Hannover, Germany",
            "Research Site, Heinsberg, Germany",
            "Research Site, KÃ¶ln, Germany",
            "Research Site, Mettmann, Germany",
            "Research Site, NÃ¼rnberg, Germany",
            "Research Site, NÃ¼rtingen, Germany",
            "Research Site, Ulm, Germany",
            "Research Site, Milano, Italy",
            "Research Site, Milano, Italy",
            "Research Site, Napoli, Italy",
            "Research Site, Orbassano, Italy",
            "Research Site, Pavia, Italy",
            "Research Site, Roma, Italy",
            "Research Site, Trento, Italy",
            "Research Site, Bunkyo-ku, Japan",
            "Research Site, Hirakata-shi, Japan",
            "Research Site, Kashihara-shi, Japan",
            "Research Site, Kawagoe-shi, Japan",
            "Research Site, Kita-gun, Japan",
            "Research Site, Kyoto-shi, Japan",
            "Research Site, Maebashi-shi, Japan",
            "Research Site, Nagoya-shi, Japan",
            "Research Site, Osaka-shi, Japan",
            "Research Site, Osaka-shi, Japan",
            "Research Site, Osakasayama-shi, Japan",
            "Research Site, Sagamihara-shi, Japan",
            "Research Site, Sakura-shi, Japan",
            "Research Site, Shinjuku-ku, Japan",
            "Research Site, Toon-shi, Japan",
            "Research Site, Yokohama-shi, Japan",
            "Research Site, Daegu, Korea, Republic of",
            "Research Site, Goyang-si, Korea, Republic of",
            "Research Site, Seoul, Korea, Republic of",
            "Research Site, Seoul, Korea, Republic of",
            "Research Site, Seoul, Korea, Republic of",
            "Research Site, Seoul, Korea, Republic of",
            "Research Site, Hilversum, Netherlands",
            "Research Site, Nijmegen, Netherlands",
            "Research Site, Tilburg, Netherlands",
            "Research Site, Bratislava, Slovakia",
            "Research Site, Nitra, Slovakia",
            "Research Site, Presov, Slovakia",
            "Research Site, Sala, Slovakia",
            "Research Site, Trencin, Slovakia",
            "Research Site, Barcelona, Spain",
            "Research Site, Barcelona, Spain",
            "Research Site, Gerona, Spain",
            "Research Site, Madrid, Spain",
            "Research Site, Malaga, Spain",
            "Research Site, Sevilla, Spain",
            "Research Site, Adana, Turkey",
            "Research Site, Ankara, Turkey",
            "Research Site, Ankara, Turkey",
            "Research Site, Istanbul, Turkey",
            "Research Site, Izmir, Turkey",
            "Research Site, Karsiyaka, Turkey",
            "Research Site, Blackburn, United Kingdom",
            "Research Site, Guildford, United Kingdom",
            "Research Site, Manchester, United Kingdom",
            "Research Site, Sheffield, United Kingdom",
            "Research Site, Southampton, United Kingdom",
            "Research Site, Swansea, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03732820"
      },
      {
        "-rank": "144",
        "nct_id": "NCT00003290",
        "title": "Radiation Therapy in Treating Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "gonadotrophin releasing hormone"
            },
            {
              "-type": "Radiation",
              "#text": "radiation therapy"
            }
          ]
        },
        "sponsors": {
          "lead_sponsor": "Medical Research Council",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "800",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000066222",
            "MRC-RT01",
            "EU-98005"
          ]
        },
        "start_date": "January 1998",
        "completion_date": "August 2004",
        "study_first_posted": "April 23, 2003",
        "last_update_posted": "December 4, 2013",
        "locations": {
          "location": [
            "Groote Schuur Hospital, Cape Town, Cape Town, South Africa",
            "University of Birmingham, Birmingham, England, United Kingdom",
            "Bristol Royal Hospital for Children, Bristol, England, United Kingdom",
            "Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom",
            "Derbyshire Royal Infirmary, Derby, England, United Kingdom",
            "Cookridge Hospital, Leeds, England, United Kingdom",
            "University Hospitals of Leicester, Leicester, England, United Kingdom",
            "Middlesex Hospital- Meyerstein Institute, London, England, United Kingdom",
            "Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom",
            "Clatterbridge Centre for Oncology NHS Trust, Merseyside, England, United Kingdom",
            "Newcastle General Hospital, Newcastle Upon Tyne, England, United Kingdom",
            "Mount Vernon Hospital, Northwood, England, United Kingdom",
            "Norfolk & Norwich Hospital, Norwich, England, United Kingdom",
            "Oxford Radcliffe Hospital, Oxford, England, United Kingdom",
            "Royal Marsden Hospital, Sutton, England, United Kingdom",
            "Southend NHS Trust Hospital, Westcliff-On-Sea, England, United Kingdom",
            "Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom",
            "Beatson Oncology Centre, Glasgow, Scotland, United Kingdom",
            "Royal Preston Hospital, Preston, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00003290"
      },
      {
        "-rank": "145",
        "nct_id": "NCT01578655",
        "title": "Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer",
        "acronym": "AFFINITY",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "cabazitaxel"
            },
            {
              "-type": "Drug",
              "#text": "prednisone"
            },
            {
              "-type": "Drug",
              "#text": "custirsen sodium"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Survival in the intent-to-treat population",
            "Survival in the poor-prognosis patient population",
            "Progression-free survival at Day 140"
          ]
        },
        "sponsors": { "lead_sponsor": "Achieve Life Sciences" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "630",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "OGX-011-12" },
        "start_date": "August 2012",
        "primary_completion_date": "July 2016",
        "completion_date": "July 2016",
        "study_first_posted": "April 17, 2012",
        "last_update_posted": "October 12, 2016",
        "locations": {
          "location": [
            "Prostate Oncology Specialists, Marina Del Rey, California, United States",
            "University of California Davis Medical Center, Sacramento, California, United States",
            "Sharp Health Care, San Diego, California, United States",
            "California Pacific Medical Center Research Institute, San Francisco, California, United States",
            "Rocky Mountain Cancer Center, Boulder, Colorado, United States",
            "Hartford Hospital, Hartford, Connecticut, United States",
            "Smilow Cancer Hospital at Yale New Haven Hospital, New Haven, Connecticut, United States",
            "The Center for Hematology-Oncology, Boca Raton, Florida, United States",
            "Florida Cancer Specialists, Fort Myers, Florida, United States",
            "Florida Cancer Specialists, Inverness, Florida, United States",
            "H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",
            "Georgia Cancer Specialists, P.C., Marietta, Georgia, United States",
            "Cancer Center of Kansas, Wichita, Kansas, United States",
            "Boston University Medical Center, Boston, Massachusetts, United States",
            "University of Michigan Health System, Ann Arbor, Michigan, United States",
            "Karmanos Cancer Institute, Detroit, Michigan, United States",
            "Washington University School of Medicine, St. Louis, Missouri, United States",
            "Urology Cancer Center and GU Research Network, Omaha, Nebraska, United States",
            "Albert Einstein Medical Center, Bronx, New York, United States",
            "Monter Cancer Center, Lake Success, New York, United States",
            "SUNY Upstate Medical University, Syracuse, New York, United States",
            "Blumenthal Cancer Center, Charlotte, North Carolina, United States",
            "Cancer Centers of North Carolina, Raleigh, North Carolina, United States",
            "Oncology Hematology Care, Inc., Blue Ash, Ohio, United States",
            "The Mark H. Zangmeister Center, Columbus, Ohio, United States",
            "Oregon Health and Science University, Portland, Oregon, United States",
            "South Carolina Oncology Associates, Columbia, South Carolina, United States",
            "Cancer Centers of the Carolinas, Greenville, South Carolina, United States",
            "Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States",
            "The West Clinic, Memphis, Tennessee, United States",
            "Tennessee Oncology, PLLC, Nashville, Tennessee, United States",
            "Texas Oncology, PA, Dallas, Texas, United States",
            "Utah Cancer Specialists, Salt Lake City, Utah, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "Virginia Cancer Institute, Richmond, Virginia, United States",
            "The Canberra Hospital, Garran, Australian Capital Territory, Australia",
            "Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia",
            "St George Public Hospital, Kogarah, New South Wales, Australia",
            "Royal North Shore Hospital, Saint Leonards, New South Wales, Australia",
            "Westmead Hospital, Westmead, New South Wales, Australia",
            "Haematology and Oncology Clinics of Australia, Brisbane, Queensland, Australia",
            "The Queen Elizabeth Hospital, Woodville South, South Australia, Australia",
            "Royal Hobart Hospital, Hobart, Tasmania, Australia",
            "Box Hill Hospital, Box Hill, Victoria, Australia",
            "Austin Health, Heidelberg, Victoria, Australia",
            "Epworth Healthcare, Richmond, Victoria, Australia",
            "Cross Cancer Institute, Edmonton, Alberta, Canada",
            "British Columbia Cancer Agency, Vancouver, British Columbia, Canada",
            "Juravinski Cancer Centre, Hamilton, Ontario, Canada",
            "London Health Sciences Center, London, Ontario, Canada",
            "R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa, Oshawa, Ontario, Canada",
            "The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada",
            "Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",
            "CHUM-Hospital Notre-Dame, MontrÃ©al, Quebec, Canada",
            "KrajskÃ¡ nemo. T.Bati, a. s., ZlÃ­n, Severomoravsky Kraj, Czech Republic",
            "Fakultni nemo Hradec KrÃ¡lovÃ©, Hradec KrÃ¡lovÃ©, Czech Republic",
            "KrajskÃ¡ nemocnice Liberec a.s., Liberec, Czech Republic",
            "University Hospital Olomouc, Olomouc, Czech Republic",
            "Centre FranÃ§ois Baclesse, Caen cedex 05, Basse-Normandie, France",
            "Institut Jean-Godinot, Reims, Champagne-Ardenne, France",
            "HÃ´pital Saint Louis, Paris, Ile de France, France",
            "Institut Curie, Paris Cedex 05, Ile-de-France, France",
            "Institut Gustave Roussy, Villejuif, Ile-de-France, France",
            "Institut de CancÃ©rologie de l'Ouest - RenÃ© Gauducheau, Saint Herblain, Pays de la Loire, France",
            "Centre Hospitalier Universitaire de Poitiers HÃ´pital de la MilÃ©trie, Poitiers Cedex, Poitou-Charentes, France",
            "Centre Antoine Lacassagne, Nice Cedex 2, Provence Alpes Cote d'Azur, France",
            "Centre LÃ©on BÃ©rard, Lyon cÃ©dex 08, Rhone-Alpes, France",
            "Institut Paoli Calmettes, Marseille, France",
            "PÃ¡ndy KÃ¡lmÃ¡n Megyei KÃ³rhÃ¡z, Gyula, Bekes, Hungary",
            "Borsod AbaÃºj ZemplÃ©n Megyei KÃ³rhÃ¡z Ã©s Egyetemi OktatÃ³ KÃ³rhÃ¡z, Miskolc, Borsod-Abauj-Zemplen, Hungary",
            "Szegedi TudomÃ¡nyegyetem, OnkoterÃ¡piÃ¡s Klinika, Szeged, Csongrad, Hungary",
            "OrszÃ¡gos OnkolÃ³giai IntÃ©zet, Budapest, Hungary",
            "Semmelweis Egyetem ÃltalÃ¡nos OrvostudomÃ¡nyi Kar, Budapest, Hungary",
            "Sverdlovsk Reg Clin Hosp#1, Ekaterinburg, Ural, Russian Federation",
            "Volgograd Regional Oncological Dispensary, Volzhskiy, Volgograd, Russian Federation",
            "S Inst Hlth Altay Reg Onc Disp, Barnaul, Russian Federation",
            "Ivanovo Reg Oncology Centre, Ivanovo, Russian Federation",
            "Cancer Research Center na NN Blokhin, Moscow, Russian Federation",
            "Hertzen Rsrch Inst of Oncology, Moscow, Russian Federation",
            "Russian Research Center of Radiology, Moscow, Russian Federation",
            "Urology Research Institute, Moscow, Russian Federation",
            "State Healthcare Inst Omsk Reg, Omsk, Russian Federation",
            "Petrov Research Oncology Institute, Saint Petersburg, Russian Federation",
            "Saint Petersburg City Oncological Dispensary, Saint Petersburg, Russian Federation",
            "Stavropol Reg Oncology Ctr, Stavropol, Russian Federation",
            "Cancer Research UK, Birmingham, England, United Kingdom",
            "Addenbrookes Hospital Cambridge, Cambridge, England, United Kingdom",
            "U of Surrey Post Grad Med, Guildford, England, United Kingdom",
            "Christie Hospital NHS Foundation Trust, Manchester, England, United Kingdom",
            "Nottingham City Hospital NHS Trust, Nottingham, England, United Kingdom",
            "The Royal Marsden Hospital, Surrey, England, United Kingdom",
            "Musgrove Park Hospital, Taunton, England, United Kingdom",
            "Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral, England, United Kingdom",
            "Beatson Cancer Centre, Glasgow, Glasgow, Scotland, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01578655"
      },
      {
        "-rank": "146",
        "nct_id": "NCT02960022",
        "title": "A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "prednisone"
            }
          ]
        },
        "outcome_measures": { "outcome_measure": "Number of participants with adverse events" },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Global Development, Inc.",
          "collaborator": [
            "Pfizer",
            "Astellas Pharma Inc"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "470",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "9785-CL-0123",
            "2016-001694-32"
          ]
        },
        "start_date": "December 22, 2016",
        "primary_completion_date": "July 2021",
        "completion_date": "July 2021",
        "study_first_posted": "November 9, 2016",
        "last_update_posted": "April 8, 2019",
        "locations": {
          "location": [
            "Site US10052, Anchorage, Alaska, United States",
            "Site US10011, Tucson, Arizona, United States",
            "Site US10040, Los Angeles, California, United States",
            "Site US10009, Los Angeles, California, United States",
            "Site US10008, San Bernardino, California, United States",
            "Site US10042, San Diego, California, United States",
            "Site US10028, Stanford, California, United States",
            "Site US10001, Aurora, Colorado, United States",
            "Site US10017, Denver, Colorado, United States",
            "Site US10050, Washington, District of Columbia, United States",
            "Site US10049, Daytona Beach, Florida, United States",
            "Site US10048, Jacksonville, Florida, United States",
            "Site US10002, Chicago, Illinois, United States",
            "Site US10007, Jeffersonville, Indiana, United States",
            "Site US10029, Towson, Maryland, United States",
            "Site US10032, Saint Louis, Missouri, United States",
            "Site US10023, Omaha, Nebraska, United States",
            "Site US10004, Hackensack, New Jersey, United States",
            "Site US10024, Garden City, New York, United States",
            "Site US10055, New York, New York, United States",
            "Site US10059, New York, New York, United States",
            "Site US10053, Syracuse, New York, United States",
            "Site US10030, Chapel Hill, North Carolina, United States",
            "Site US10062, Charlotte, North Carolina, United States",
            "Site US10020, Concord, North Carolina, United States",
            "Site US10031, Greensboro, North Carolina, United States",
            "Site US10046, Winston-Salem, North Carolina, United States",
            "Site US10035, Cincinnati, Ohio, United States",
            "Site US10022, Springfield, Oregon, United States",
            "Site US10027, Lancaster, Pennsylvania, United States",
            "Site US10005, Pittsburgh, Pennsylvania, United States",
            "Site US10018, Charleston, South Carolina, United States",
            "Site US10003, Myrtle Beach, South Carolina, United States",
            "Site US10041, Nashville, Tennessee, United States",
            "Site US10010, Dallas, Texas, United States",
            "Site US10034, Houston, Texas, United States",
            "Site US10043, Houston, Texas, United States",
            "Site US10014, Norfolk, Virginia, United States",
            "Site US10015, Virginia Beach, Virginia, United States",
            "Site US10038, Seattle, Washington, United States",
            "Site US10021, Madison, Wisconsin, United States",
            "Site AR54003, Cordorba, Argentina",
            "Site AR54002, Tucuman, Argentina",
            "Site AU61001, Tweed Heads, New South Wales, Australia",
            "Site AU61006, Ashford, Australia",
            "Site AU61009, Malvern, Australia",
            "Site AU61008, South Brisbane, Australia",
            "Site AU61004, Westmead, Australia",
            "Site BE32002, Kortrijk, West-Vlaanderen, Belgium",
            "Site BE32004, Brussels, Belgium",
            "Site BE32005, Gent, Belgium",
            "Site BE32007, Hasselt, Belgium",
            "Site BE32008, Leuven, Belgium",
            "Site BE32001, Liege, Belgium",
            "Site BE32003, Turnhout, Belgium",
            "Site CA15003, Kingston, Ontario, Canada",
            "Site CA15001, Granby, Quebec, Canada",
            "Site CA15011, Montreal, Canada",
            "Site CL56004, IX Region, Chile",
            "Site CL56002, Santiago, Chile",
            "Site CL56001, Vina del Mar, Chile",
            "Site CZ42002, Olomouc, Czechia",
            "Site CZ42003, Praha 2, Czechia",
            "Site CZ42001, Praha 6, Czechia",
            "Site DK45002, Aalborg, Nordjylland, Denmark",
            "Site DK45003, Aarhus, Denmark",
            "Site DK45001, Copenhagen, Denmark",
            "Site DK45004, Herlev, Denmark",
            "Site FL35802, Tampere, Finland",
            "Site FR33008, La Roche sur Yon, France",
            "Site FR33010, Lille, France",
            "Site FR33002, Lyon Cedex 3, France",
            "Site FR33006, Nimes, France",
            "Site FR33003, Paris, France",
            "Site FR33017, Paris, France",
            "Site FR33001, Saint Herblain, France",
            "Site FR33004, Villejuif, France",
            "Site GE99501, Tbilisi, Georgia",
            "Site DE49004, NÃ¼rtingen, Baden-WÃ¼rttemberg, Germany",
            "Site DE49007, Waldshut-Tiengen, Baden-WÃ¼rttemberg, Germany",
            "Site DE49006, Mannheim, DE, Germany",
            "Site DE49001, Duisburg, NRW, Germany",
            "Site DE49010, Bonn, Germany",
            "Site DE49003, Hamburg, Germany",
            "Site DE49013, Hamburg, Germany",
            "Site IL97202, Peth Tikva, Israel",
            "Site IL97204, Ramat-Gan, Israel",
            "Site IL97203, Tzrifin Beer Yakov, Israel",
            "Site IT39001, Arezzo, Italy",
            "Site IT39004, Cremona, Italy",
            "Site IT39002, Forli, Italy",
            "Site IT39005, Roma, Italy",
            "Site KR82005, Seongnam-si, Korea, Republic of",
            "Site KR82001, Seoul, Korea, Republic of",
            "Site KR82002, Seoul, Korea, Republic of",
            "Site KR82003, Seoul, Korea, Republic of",
            "Site KR82004, Seoul, Korea, Republic of",
            "Site MD37301, Chisinau, Moldova, Republic of",
            "Site NZ64001, Hamilton, New Zealand",
            "Site PL48002, Gdansk, Poland",
            "Site PL48001, Myslowice, Poland",
            "Site PL48004, Pozman, Poland",
            "Site PL48003, Wroclaw, Poland",
            "Site RU70001, Moscow, Russian Federation",
            "Site RU70003, St. Petersburg, Russian Federation",
            "Site SK10223, Bratislava, Slovakia",
            "Site ZA27001, George, South Africa",
            "Site ES34003, Barcelona, Spain",
            "Site ES34004, Barcelona, Spain",
            "Site ES34001, Madrid, Spain",
            "Site ES34005, Pamplona, Spain",
            "Site GB44009, Bebington, United Kingdom",
            "Site GB44003, Belfast, United Kingdom",
            "Site GB44004, Bristol, United Kingdom",
            "Site GB44005, Cardiff, United Kingdom",
            "Site GB44002, Glasgow, United Kingdom",
            "Site GB44006, London, United Kingdom",
            "Site GB44007, Manchester, United Kingdom",
            "Site GB44008, Northwood, United Kingdom",
            "Site GB44001, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02960022"
      },
      {
        "-rank": "147",
        "nct_id": "NCT01188187",
        "title": "Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer",
        "acronym": "SYNERGY",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Custirsen"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Drug",
              "#text": "Dexamethasone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Kaplan-Meier Estimates for Time to Death (Overall Survival)",
            "Percentage of Participants Who Were Alive Without Event At Day 140",
            "Percentage of Participants with Adverse Events"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Achieve Life Sciences",
          "collaborator": "Teva Pharmaceutical Industries"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1022",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "OGX-011-11 TRANSFERRED" },
        "start_date": "November 2010",
        "primary_completion_date": "February 2014",
        "completion_date": "June 2014",
        "study_first_posted": "August 25, 2010",
        "last_update_posted": "October 14, 2016",
        "locations": {
          "location": [
            "Teva Investigational Site 100, Birmingham, Alabama, United States",
            "Teva Investigational Site 086, Los Angeles, California, United States",
            "Teva Investigational Site 263, Los Angeles, California, United States",
            "Teva Investigational Site 093, Marina del Rey, California, United States",
            "Teva Investigational Site 097, San Diego, California, United States",
            "Teva Investigational Site 090, Fort Collins, Colorado, United States",
            "Teva Investigational Site 106, Fort Myers, Florida, United States",
            "Teva Investigational Site 094, Port St. Lucie, Florida, United States",
            "Teva Investigational Site 096, Atlanta, Georgia, United States",
            "Teva Investigational Site 103, Baton Rough, Louisiana, United States",
            "Teva Investigational Site 098, Ann Arbor, Michigan, United States",
            "Teva Investigational Site 112, Detroit, Michigan, United States",
            "Teva Investigational Site 032, Rochester, Minnesota, United States",
            "Teva Investigational Site 204, Las Vegas, Nevada, United States",
            "Teva Investigational Site 107, Cincinnati, Ohio, United States",
            "Teva Investigational Site 266, Greensboro, South Carolina, United States",
            "Teva Investigational Site 102, Myrtle Beach, South Carolina, United States",
            "Teva Investigational Site 084, Memphis, Tennessee, United States",
            "Teva Investigational Site 101, Nashville, Tennessee, United States",
            "Teva Investigational Site 116, San Antonio, Texas, United States",
            "Teva Investigational Site 059, Tyler, Texas, United States",
            "Teva Investigational Site 063, Tyler, Texas, United States",
            "Teva Investigational Site 047, Newport, Virginia, United States",
            "Teva Investigational Site 104, Norfolk, Virginia, United States",
            "Teva Investigational Site 029, Seattle, Washington, United States",
            "Teva Investigational Site 862, Bonheiden, Belgium",
            "Teva Investigational Site 860, Brussels, Belgium",
            "Teva Investigational Site 864, Edegem, Belgium",
            "Teva Investigational Site 863, Gent, Belgium",
            "Teva Investigational Site 002, Calgary, Alberta, Canada",
            "Teva Investigational Site 023, Edmonton, Alberta, Canada",
            "Teva Investigational Site 118, Abbotsford, British Columbia, Canada",
            "Teva Investigational Site 007, Surrey, British Columbia, Canada",
            "Teva Investigational Site 001, Vancouver, British Columbia, Canada",
            "Teva Investigational Site 085, Victoria, British Columbia, Canada",
            "Teva Investigational Site 024, Winnipeg, Manitoba, Canada",
            "Teva Investigational Site 028, Halifax, Nova Scotia, Canada",
            "Teva Investigational Site 025, Hamilton, Ontario, Canada",
            "Teva Investigational Site 108, Kingston, Ontario, Canada",
            "Teva Investigational Site 091, Oshawa, Ontario, Canada",
            "Teva Investigational Site 003, Ottawa, Ontario, Canada",
            "Teva Investigational Site 004, Toronto, Ontario, Canada",
            "Teva Investigational Site 087, Toronto, Ontario, Canada",
            "Teva Investigational Site 026, Montreal, Quebec, Canada",
            "Teva Investigational Site 027, Montreal, Quebec, Canada",
            "Teva Investigational Site 551, Angers Cedex 9, France",
            "Teva Investigational Site 552, Avignon, France",
            "Teva Investigational Site 553, Grenoble, France",
            "Teva Investigational Site 555, La Roche-sur-Yon Cedex, France",
            "Teva Investigational Site 557, Marseille, France",
            "Teva Investigational Site 558, Nice Cedex 2, France",
            "Teva Investigational Site 560, Paris Cedex 05, France",
            "Teva Investigational Site 559, Paris Cedex 15, France",
            "Teva Investigational Site 561, Saint Herblain Cedex, France",
            "Teva Investigational Site 566, Saint-Brieuc Cedex, France",
            "Teva Investigational Site 562, Saint-Priest-en-Jarez Cedex, France",
            "Teva Investigational Site 563, Toulouse, France",
            "Teva Investigational Site 564, Vandoeuvre-les-Nancy Cedex, France",
            "Teva Investigational Site 550, Villejuif, France",
            "Teva Investigational Site 607, Aachen, Germany",
            "Teva Investigational Site 609, Berlin, Germany",
            "Teva Investigational Site 613, Berlin, Germany",
            "Teva Investigational Site 604, Darmstadt, Germany",
            "Teva Investigational Site 612, Dresden, Germany",
            "Teva Investigational Site 618, Greifswald, Germany",
            "Teva Investigational Site 600, Hannover, Germany",
            "Teva Investigational Site 606, Heidelberg, Germany",
            "Teva Investigational Site 615, Heinsberg, Germany",
            "Teva Investigational Site 611, Homburg/Saar, Germany",
            "Teva Investigational Site 617, Kempen, Germany",
            "Teva Investigational Site 608, Marburg, Germany",
            "Teva Investigational Site 616, Meiningen, Germany",
            "Teva Investigational Site 614, Muenchen, Germany",
            "Teva Investigational Site 601, Muenster, Germany",
            "Teva Investigational Site 602, Nuertingen, Germany",
            "Teva Investigational Site 603, Stuttgart, Germany",
            "Teva Investigational Site 610, Tuebingen, Germany",
            "Teva Investigational Site 605, Wuppertal, Germany",
            "Teva Investigational Site 691, Budapest, Hungary",
            "Teva Investigational Site 694, Budapest, Hungary",
            "Teva Investigational Site 692, Debrecen, Hungary",
            "Teva Investigational Site 697, Debrecen, Hungary",
            "Teva Investigational Site 696, Gyor, Hungary",
            "Teva Investigational Site 698, Miskolc, Hungary",
            "Teva Investigational Site 699, Nyiregyhaza, Hungary",
            "Teva Investigational Site 693, Szeged, Hungary",
            "Teva Investigational Site 695, Veszprem, Hungary",
            "Teva Investigational Site 506, Jerusalem, IL, Israel",
            "Teva Investigational Site 507, Haifa, Israel",
            "Teva Investigational Site 505, Petach Tikva, Israel",
            "Teva Investigational Site 502, Ramat Gan, Israel",
            "Teva Investigational Site 503, Tel Aviv, Israel",
            "Teva Investigational Site 501, Zrifin, Israel",
            "Teva Investigational Site 753, Arezzo, Italy",
            "Teva Investigational Site 758, Catanzaro, Italy",
            "Teva Investigational Site 760, Cesena (FC), Italy",
            "Teva Investigational Site 752, Genova, Italy",
            "Teva Investigational Site 755, Lugo (Ravenna), Italy",
            "Teva Investigational Site 759, Meldola (FC), Italy",
            "Teva Investigational Site 763, Milano, Italy",
            "Teva Investigational Site 754, Napoli, Italy",
            "Teva Investigational Site 756, Napoli, Italy",
            "Teva Investigational Site 761, Rimini, Italy",
            "Teva Investigational Site 750, Roma, Italy",
            "Teva Investigational Site 762, Roma, Italy",
            "Teva Investigational Site 764, Rozzano (MI), Italy",
            "Teva Investigational Site 765, Verona, Italy",
            "Teva Investigational Site 404, Cheongju,Chungbuk, Korea, Republic of",
            "Teva Investigational Site 401, Goyang-si Gyeonggi-do, Korea, Republic of",
            "Teva Investigational Site 400, Seoul, Korea, Republic of",
            "Teva Investigational Site 402, Seoul, Korea, Republic of",
            "Teva Investigational Site 403, Seoul, Korea, Republic of",
            "Teva Investigational Site 406, Seoul, Korea, Republic of",
            "Teva Investigational Site 405, Yangsan-si, Korea, Republic of",
            "Teva Investigational Site 851, Amsterdam, Netherlands",
            "Teva Investigational Site 852, Rotterdam, Netherlands",
            "Teva Investigational Site 853, Sittard-Geleen, Netherlands",
            "Teva Investigational Site 803, Barcelona, Spain",
            "Teva Investigational Site 808, Barcelona, Spain",
            "Teva Investigational Site 809, Barcelona, Spain",
            "Teva Investigational Site 816, Dos Hermanas, Spain",
            "Teva Investigational Site 814, El Palmar, Spain",
            "Teva Investigational Site 807, Guadalajara, Spain",
            "Teva Investigational Site 800, Madrid, Spain",
            "Teva Investigational Site 801, Madrid, Spain",
            "Teva Investigational Site 806, Madrid, Spain",
            "Teva Investigational Site 813, Madrid, Spain",
            "Teva Investigational Site 815, Manresa, Spain",
            "Teva Investigational Site 810, Murcia, Spain",
            "Teva Investigational Site 811, Palma de Mallorca, Spain",
            "Teva Investigational Site 805, Pamplona, Spain",
            "Teva Investigational Site 804, Sabadell - Barcelona, Spain",
            "Teva Investigational Site 802, Valencia, Spain",
            "Teva Investigational Site 704, Brighton, United Kingdom",
            "Teva Investigational Site 701, Cambridge, United Kingdom",
            "Teva Investigational Site 709, Coventry, United Kingdom",
            "Teva Investigational Site 705, Guildford, Surrey, United Kingdom",
            "Teva Investigational Site 703, Manchester, United Kingdom",
            "Teva Investigational Site 700, Surrey, United Kingdom",
            "Teva Investigational Site 710, Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01188187"
      },
      {
        "-rank": "148",
        "nct_id": "NCT00036543",
        "title": "A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Atrasentan"
          }
        },
        "outcome_measures": { "outcome_measure": "The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression" },
        "sponsors": { "lead_sponsor": "Abbott" },
        "gender": "Male",
        "min_age": "19 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1000",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "M00-211" },
        "start_date": "May 2001",
        "study_first_posted": "May 13, 2002",
        "last_update_posted": "August 15, 2006",
        "locations": {
          "location": [
            "Urology Centers Of Alabama, Homewood,, Alabama, United States",
            "Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States",
            "Advanced Clinical Trials, Tucson, Arizona, United States",
            "Arkansas Urologial Associates, PA, Little Rock, Arkansas, United States",
            "Robin V. Smith, MD, Chula Vista, California, United States",
            "Urology Associate Of Central California, Fresno,, California, United States",
            "South Valley Medical Plaza, Gilroy, California, United States",
            "San Diego Urology Center, La Mesa, California, United States",
            "UCLA School Of Medicine, Los Angeles,, California, United States",
            "UCLA School of Medicine, Los Angeles, California, United States",
            "Hillcrest Urological Medical Group, Inc., San Diego, California, United States",
            "Urology Associates Of San Luis Obispo, San Luis Obispo,, California, United States",
            "Pacific Clinical Research, Santa Monica, California, United States",
            "Western Clinical Research, Inc., Torrance,, California, United States",
            "Urology Associate, Pc, Denver,, Colorado, United States",
            "South Fl Medical Research, Aventura, Florida, United States",
            "Clinical Physiology Associates, Fort Myers, Florida, United States",
            "Advanced Research Institute, New Port Richey, Florida, United States",
            "Urology Treatment Center, Sarasota,, Florida, United States",
            "Southeastern Urological Center, P.A., Tallahassee, Florida, United States",
            "Winship Cancer Institute Emory University, Atlanta,, Georgia, United States",
            "Sandy Springs Urology, Atlanta, Georgia, United States",
            "Atlanta Va Medical Center, Decatur, Georgia, United States",
            "Dreyer Medical Clinic, Aurora, Illinois, United States",
            "Weiss Memorial Hospital, Chicago,, Illinois, United States",
            "Progressive Care, S.C., Chicago, Illinois, United States",
            "Evanston Hospital Kellogg Cancer Center, Evanston, Illinois, United States",
            "Welborn Clinic, Evansville, Indiana, United States",
            "Urologic Associates, Pc, Davenport, Iowa, United States",
            "Iowa Urology, Des Moines, Iowa, United States",
            "Kansas University Medical Center, Kansas City,, Kansas, United States",
            "Ochsner Clinic, Department of Urology, New Orleans, Louisiana, United States",
            "Regional Urology, Shreveport, Louisiana, United States",
            "LSUHSC, Shreveport, Louisiana, United States",
            "Johns Hopkins Oncology Center, Baltimore, Maryland, United States",
            "Mid Atlantic Clinical Research, Rockville, Maryland, United States",
            "Michigan Institute Of Urology, Pc, St. Clair Shores, Michigan, United States",
            "Lakeside Urology, PC, St. Joseph, Michigan, United States",
            "Mayo Clinic, Rochester, Minnesota, United States",
            "The Medical Oncology Group, Gulfport,, Mississippi, United States",
            "St. Joseph Oncology, St. Joseph, Missouri, United States",
            "Washington University, St. Louis, Missouri, United States",
            "Billings Oncology Associates, Billings,, Montana, United States",
            "Nevada Urology Associate, Reno, Nevada, United States",
            "Albany Medical Center South Clinical Campus, Albany, New York, United States",
            "Albert Einstein College of Medicine, Bronx, New York, United States",
            "HemOnCare, PC, Brooklyn, New York, United States",
            "Beth Israel Medical Center, New York, New York, United States",
            "NYU Medical Center, New York, New York, United States",
            "Nyack Hospital, Nyack, New York, United States",
            "Rochester General Hospital, Rochester, New York, United States",
            "St. Vincent's Medical Center - Staten Island, Staten Island,, New York, United States",
            "The University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States",
            "Blumenthal Cancer Center, Charlotte, North Carolina, United States",
            "The Urology Center, Greensboro,, North Carolina, United States",
            "Urologic Specialists Of Oklahoma, Inc., Tulsa,, Oklahoma, United States",
            "Oregon Urology Specialists, Eugene, Oregon, United States",
            "Urologic Associates of Allentown, Allentown, Pennsylvania, United States",
            "Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",
            "Urological Associates Of Lancaster, Lancaster, Pennsylvania, United States",
            "Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States",
            "University Of Pittsburgh, Pittsburgh, Pennsylvania, United States",
            "Center for Urologic Care, West Reading,, Pennsylvania, United States",
            "Vanderbilt University Medical Center, Nashville,, Tennessee, United States",
            "Urology Associates, Nashville, Tennessee, United States",
            "Dept of Veteran's Affairs North Texas Healthcare System, Dallas, Texas, United States",
            "Ntouch Research Corporation, Dallas, Texas, United States",
            "Uthscsa, San Antonio, Texas, United States",
            "Scott & White Memorial Hospital, Temple,, Texas, United States",
            "Anthony Middleton, M.D., Salt Lake City,, Utah, United States",
            "Western Urological Clinic, Salt Lake City, Utah, United States",
            "University Of Vermont, Burlington,, Vermont, United States",
            "Virginia Urology Center, Richmond,, Virginia, United States",
            "Jeffrey Frankel, M.D., Seattle,, Washington, United States",
            "Seattle Urological Associates, Seattle, Washington, United States",
            "University Of Washington School Of Medicine, Seattle, Washington, United States",
            "Madigan Army Medical Center, Tacoma,, Washington, United States",
            "Midwest Research Specialists, LLC, Milwaukee, Wisconsin, United States",
            "Medical College of Wisconsin, Milwaukee, Wisconsin, United States",
            "Wyoming Research Foundation, Cheyenne, Wyoming, United States",
            "St Vincent's Clinic, Darlinghurst, New South Wales, Australia",
            "Prince Of Wales Hospital, Randwick, New South Wales, Australia",
            "Westmead Public Hospital, Westmead, New South Wales, Australia",
            "Royal Brisbane Hospital, Herston, Queensland, Australia",
            "Repatriation General Hospital, Daws Park, South Australia, Australia",
            "Peter Maccallum Cancer Institute, East Melbourne, Victoria, Australia",
            "Bayside Urology, Mentone, Victoria, Australia",
            "Royal Melbourne Hospital, Parkville, Victoria, Australia",
            "Hollywood Specialist Centre, Nedlands, Western Australia, Australia",
            "Princess Alexandra Hospital, Woolloongabba, Australia",
            "Universitatsklinik Innsbruck, Innsbruck, Austria",
            "Urologische Abteilung, Linz, Austria",
            "Landesklinik fur Urologie und Andrologie, Salzburg, Austria",
            "A.Z. Middelheim, Antwerpen, Belgium",
            "AZ Middelheim, Antwerpen, Belgium",
            "A Z St Jan, Brugge, Belgium",
            "University Hospital Erasme, Bruxelles, Belgium",
            "Uz Gent, Gent, Belgium",
            "Virga Jesse Hospital, Hasselt, Belgium",
            "C.H.U. Liege, Liege, Belgium",
            "St-Elisabeth Ziekenhuis, Turnhout, Belgium",
            "Tom Baker Cancer Center, Calgary,, Alberta, Canada",
            "Cross Cancer Institute, Edmonton,, Alberta, Canada",
            "Wilson Urology, Kelowna, British Columbia, Canada",
            "Dr. Cal Andreou, Surrey, British Columbia, Canada",
            "Vancouver Hospital & Health Sciences Centre, Vancouver, British Columbia, Canada",
            "Dr. P. J. Pommerville, Inc., Victoria, British Columbia, Canada",
            "Dr. Gary Steinhoff, Clinical Research, Victoria, British Columbia, Canada",
            "Abbott Clinic, Winnipeg, Manitoba, Canada",
            "Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada",
            "Valley Professional Centre, Kentville, Nova Scotia, Canada",
            "The Male Health Centres, Barrie, Ontario, Canada",
            "Burlington Professional Centre, Burlington, Ontario, Canada",
            "The Urology Resource Centre, Burlington, Ontario, Canada",
            "Kingston General Hospital, Kingston, Ontario, Canada",
            "Probidity Medical Research, Kitchener, Ontario, Canada",
            "London Health Sciences Centre, London, Ontario, Canada",
            "Quest Clinical Trials, Markham, Ontario, Canada",
            "Walk-In Clinic, North Bay, Ontario, Canada",
            "Jack Barkin, M.D., North York, Ontario, Canada",
            "The Male Health Centres, Oakville, Ontario, Canada",
            "Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",
            "Service Radio-Oncologie, Chus, Fleurimont,, Quebec, Canada",
            "Hopital Notre-Dame, Montreal, Quebec, Canada",
            "Royal Victoria Hospital, Montreal, Quebec, Canada",
            "Ultramed, Pointe Claire, Quebec, Canada",
            "Chuq Pavillon Hotel-Dieu, Quebec, Canada",
            "Hopital De Pontchaillou, Rennes, Cedex, France",
            "Hopital De Rangueil, Toulouse, Cedex, France",
            "CHU HÃ´pital CÃ´te De Nacre, Caen, France",
            "HÃ´pital Henri Mondor, Creteil, France",
            "CHU de BicÃªtre, Kremlin Bicetre, France",
            "Hopital Bichat Claude Bernard, Paris, France",
            "HÃ´pital Foch, Suresnes, France",
            "Krankenhaus Am Urban, Berlin, Germany",
            "Allgemeines Krankenhaus Urologie, Celle, Germany",
            "UniversitÃ¤tsklinikum Carl Gustav Carus an der, Dresden, Germany",
            "UniversitÃ¤tsklinikum Urologie, Essen, Germany",
            "UniversitÃ¤tsklinkum, Freiburg, Germany",
            "Allgemeines Krankenhaus Barmbek, Hamburg, Germany",
            "Klinik Und Poliklinik fÃ¼r Urologie und Kinder, Homburg / Saar, Germany",
            "Universitutsklinikum Lubeck Urologie, LuBECK, Germany",
            "UniversitÃ¤tsklinikum Mannheim, Mannheim, Germany",
            "Urologische Klinik Und Poliklinik Grosshadern, Munchen, Germany",
            "Klinikum Rechts Der Isar, Munchen, Germany",
            "UniversitÃ¤tsklinikum, Munster, Germany",
            "StÃ¤dtische Kliniken, Urologie, Offenbach, Germany",
            "Universitat Ulm, ULM, Germany",
            "Klinikum Wuppertal GmbH, Wuppertal, Germany",
            "'Alexandra' Hospital, Athens, Greece",
            "Pe.Pa.G.N.I Hospital, Heraklion, Greece",
            "G. Genimatas Hospital, Thessaloniki, Greece",
            "Tallaght Hospital, Dublin, Ireland",
            "St Vincent'S Hospital, Dublin, Ireland",
            "Mater Misericordiae Hospital, Dublin, Ireland",
            "Clinica Urologica I - UniversitÃ  di Bari, Bari, Italy",
            "Istituto Nazionale per la Ricerca sul Cancro -IST, Genoa, Italy",
            "Istituto Europeo di Oncologia, Milan, Italy",
            "Clinica Urologica - UniversitÃ  Di Milano, Milan, Italy",
            "Istituto di Urologia, Padova, Italy",
            "Policlinico G. B. Rossi, Verona, Italy",
            "Amc, Amsterdam, Netherlands",
            "Rijnstate Hospital, Arnhem, Netherlands",
            "Medisch Spectrun Twente, Enschede, Netherlands",
            "Atrium Heerlen, Heerlen, Netherlands",
            "University Hospital Maastricht, Maastricht, Netherlands",
            "University Hospital Rotterdam, Rotterdam, Netherlands",
            "St Franciscus Gasthuis, Rotterdam, Netherlands",
            "University Hospital Utrecht, Utrecht, Netherlands",
            "Canterbury Urology Research Trust, Christchurch, New Zealand",
            "Promed Urology Ltd., Tauranga, New Zealand",
            "Katedra I Klinika Urologi AM, Gdansk, Poland",
            "Katedra i Klinika Urologii - Akademia Medyczna w Gdansku, Gdansk, Poland",
            "Samodzielny Publiczny Zaklad Opieki, Katowice, Poland",
            "Szpital Kliniczny Dzieciatka Jezus, Warszawa, Poland",
            "Akademia Medyczna we Wroclawiu, Wroclaw, Poland",
            "Mediclinic Hospital, Petermaritzburg, 3201, South Africa",
            "Constantiaberg Medi-Clinic, Cape Town, South Africa",
            "University Of Stellenbosch, Cape Town, South Africa",
            "University Of Natal - Nelson R Mandela School of Medicine, Durban, South Africa",
            "Kenridge St Joseph Wingl, Parktown, South Africa",
            "Medi-Clinic Hospital, Pietermaritzburg, South Africa",
            "Medical Centre, Pietermaritzburg, South Africa",
            "Pretoria Urology Hospital, Pretoria, South Africa",
            "Pretoria Academic Hospital, Pretoria, South Africa",
            "Fundacion Puigvert, Barcelona, Spain",
            "Hospital Vall D'Hebron, Barcelona, Spain",
            "Hospital de Galdakao, Galdakao-Vizcaya, Spain",
            "Hospital Juan Canalejo, La Coruna, Spain",
            "Hospital Gregorio Maranon, Madrid, Spain",
            "Clinica Puerta De Hierro, Madrid, Spain",
            "Hospital 12 De Octubre, Madrid, Spain",
            "Hospital Carlos Haya, Malaga, Spain",
            "Hospital Marques De Valdecilla, Santander, Spain",
            "Instituto Valenciano De Oncologia, Valencia, Spain",
            "Sahlgrenska University Hospital, Gothenburg, Sweden",
            "Helsingborg Hospital, Helsingborg, Sweden",
            "Linkoping University Hospital, Linkoping, Sweden",
            "Lund University Hospital, Lund, Sweden",
            "Malmo University Hospital MAS, Malmo, Sweden",
            "Orebro Regional Hospital, Orebro, Sweden",
            "Karolinska Hospital, Stockholm, Sweden",
            "Umea University Hospital, Umea, Sweden",
            "Uppsala University Hospital, Uppsala, Sweden",
            "Zentrum fur Onkologie, HÃ¤matologie und, Aarau, Switzerland",
            "Inselspital, UniversitÃ¤t Bern, Bern, Switzerland",
            "Chefarzt Urologische Klinik - UniversitÃ¤tsspital ZÃ¼rich, ZÃ¼rich, Switzerland",
            "Royal Devon And Exeter Hospital, Exeter,, Devon, United Kingdom",
            "Lister Hospital, Stevenage, Hertfordshire, United Kingdom",
            "Northwick Park Hospital, Harrow, Middlesex, United Kingdom",
            "Western General Hospital, Edinburgh,, Scotland, United Kingdom",
            "Taunton And Somerset Hospital, Taunton, Somerset, United Kingdom",
            "The Institute Of Cancer Research - Royal Marsden Hospital, Sutton, Surrey, United Kingdom",
            "St Lukes Hospital, Bradford, West Yorkshire, United Kingdom",
            "Clatterbridge Centre For Oncology, Bebington, Wirral, United Kingdom",
            "Aberdeen Royal Infirmary, Aberdeen, United Kingdom",
            "Institute Of Cancer Studies - University of Birmingham, Birmingham, United Kingdom",
            "Royal Sussex County Hospital, Brighton, United Kingdom",
            "Southmead Hospital, Bristol, United Kingdom",
            "Addenbrookes Hospital, Cambridge, United Kingdom",
            "St Richard'S Hospital, Chichester, United Kingdom",
            "Leighton Hospital, Crewe, United Kingdom",
            "Gartnavel General Hospital, Glasgow, United Kingdom",
            "Glasgow Royal Infirmary, Glasgow, United Kingdom",
            "Freeman Hospital, High Heaton, United Kingdom",
            "St Batholomew'S Hospital, London, United Kingdom",
            "Royal Free Hospital, London, United Kingdom",
            "Clinical Research Centre - St Georges Hospital, London, United Kingdom",
            "Nottingham City Hospital, Nottingham, United Kingdom",
            "Derriford Hospital, Plymouth, United Kingdom",
            "Hope Hospital, Salford, United Kingdom",
            "Royal Hallamshire Hospital, Sheffield, United Kingdom",
            "Southampton General, Southampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00036543"
      },
      {
        "-rank": "149",
        "nct_id": "NCT00988208",
        "title": "Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer",
        "acronym": "Mainsail",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Lenalidomide"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival (OS)",
            "Progression-Free Survival (PFS)",
            "Percentage of Participants With an Objective Response According to Response Evaluation Criteria in Solid Tumors - RECIST Version 1.1 Criteria",
            "Number of Participants With Treatment Emergent Adverse Events (AEs)",
            "Percentage of Participants Who Received Post-Study Therapies",
            "Percentage of Participants With Secondary Primary Malignancies During the Course of the Trial",
            "Time to Onset of Secondary Primary Malignancies"
          ]
        },
        "sponsors": { "lead_sponsor": "Celgene" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1059",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CC-5013-PC-002",
            "EudraCT Number 2008-007969-23"
          ]
        },
        "start_date": "November 11, 2009",
        "primary_completion_date": "January 13, 2012",
        "completion_date": "November 28, 2016",
        "study_first_posted": "October 2, 2009",
        "results_first_posted": "September 5, 2013",
        "last_update_posted": "April 4, 2018",
        "locations": {
          "location": [
            "Hematology Oncology Associates, Phoenix, Arizona, United States",
            "Northern AZ Hematology and Oncology Assoc, Sedona, Arizona, United States",
            "Arizona Oncology, Tucson, Arizona, United States",
            "City of Hope Cancer Center, Duarte, California, United States",
            "Southwest Cancer Center - Escondido, Escondido, California, United States",
            "Scripps Cancer Center - Clinical Research, La Jolla, California, United States",
            "VA Long Beach Healthcare System, Long Beach, California, United States",
            "The Angeles Clinc and Research Institute, Los Angeles, California, United States",
            "University of Southern California, Los Angeles, California, United States",
            "Prostate Oncology Specialists, Marina Del Rey, California, United States",
            "Stanford University Medical Center, Stanford, California, United States",
            "Rocky Mountain Cancer Centers-Colorado Springs Circle, Colorado Springs, Colorado, United States",
            "Washington Cancer Institute, Washington, District of Columbia, United States",
            "Melbourne Internal Medicine Associates, Melbourne, Florida, United States",
            "Advanced Medical Specialties, Miami, Florida, United States",
            "Florida Cancer Institute - New Hope, New Port Richey, Florida, United States",
            "Ocala Oncology Center, Ocala, Florida, United States",
            "Cancer Centers of Florida, P.A.- West Gore Street, Orlando, Florida, United States",
            "South Florida Oncology - Hematology, Tamarac, Florida, United States",
            "Palm Beach Cancer Institute, LLC, West Palm Beach, Florida, United States",
            "Cancer Care and Hematology Specialists of Chicagoland, Niles, Illinois, United States",
            "Lutheran General Hospital, Park Ridge, Illinois, United States",
            "Indiana University Health, Indianapolis, Indiana, United States",
            "Hematology and Oncology Specialist, LLC, Metairie, Louisiana, United States",
            "Maryland Oncology Hematology PA, Columbia, Maryland, United States",
            "Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States",
            "Missouri Cancer Associates, Columbia, Missouri, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "Summit Medical Group Overlook Oncology Center, Berkeley Heights, New Jersey, United States",
            "Hematology-Oncology Associates of NNJ, P, Morristown, New Jersey, United States",
            "Hematology Oncology Associates of South Jersey, Mount Holly, New Jersey, United States",
            "New York Oncology Hematology P.C., Albany, New York, United States",
            "Columbia Univ Medical Center, New York, New York, United States",
            "Weill Cornell Medical College Dr. Feldman's Office, New York, New York, United States",
            "New Bern Cancer Care, New Bern, North Carolina, United States",
            "Cancer Centers of North Carolina, Raleigh, North Carolina, United States",
            "Mid Dakota Clinic, PC, Bismarck, North Dakota, United States",
            "Oncology Hematology Care, Inc., Cincinnati, Ohio, United States",
            "Northwest Cancer Specialists-Tualatin, Tualatin, Oregon, United States",
            "Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States",
            "South Carolina Oncology Associates, PA, Columbia, South Carolina, United States",
            "Cancer Center of the Carolinas, Greer, South Carolina, United States",
            "Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States",
            "Cookeville Regional Medical Center, Cookeville, Tennessee, United States",
            "Sarah Cannon Research Institute UK, Nashville, Tennessee, United States",
            "Texas Oncology, P.A.-Amarillo, Amarillo, Texas, United States",
            "Texas Oncology-Arlington South, Arlington, Texas, United States",
            "Texas Oncology, PA, Austin, Texas, United States",
            "Baylor Sammons Cancer Center, Dallas, Texas, United States",
            "Texas Oncology, P.A.-Fort Worth, Fort Worth, Texas, United States",
            "Longview Cancer Center, Longview, Texas, United States",
            "Allison Cancer Center, Midland, Texas, United States",
            "Texas Oncology, P.A. - Paris, Paris, Texas, United States",
            "Southlake Oncology, Southlake, Texas, United States",
            "Texas Oncology, P.A. - Tyler, Tyler, Texas, United States",
            "Texas Oncology Deke Slayton Cancer Center, Webster, Texas, United States",
            "Texas Oncology-Texoma Cancer Center, Wichita Falls, Texas, United States",
            "Veterans Education and Research Association of Northern New England, Inc., White River Junction, Vermont, United States",
            "Cancer Outreach Associates, Abingdon, Virginia, United States",
            "Fairfax Northern Virginia Hematology Oncology, Fairfax, Virginia, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "Virginia Cancer Institute, Richmond, Virginia, United States",
            "Oncology and Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, United States",
            "Columbia Basin Hematology and Oncology, Kennewick, Washington, United States",
            "VA Puget Sound HCS Seattle Division, Seattle, Washington, United States",
            "Evergreen Hematology and Oncology, Spokane, Washington, United States",
            "Royal Adelaide Hospital, Adelaide, South Australia, Australia",
            "Royal Melbourne Hospital, Parkville, Victoria, Australia",
            "Flinders Medical Centre, Bedford Park, Australia",
            "Chris O'Brien Lifehouse, Camperdown, Australia",
            "Sir Charles Gairdner Hospital, Nedlands, Australia",
            "Port Macquarie Base Hospital, Port Macquarie, Australia",
            "Redcliffe Hospital, Redcliffe, Australia",
            "Royal North Shore Hospital, St Leonards, Australia",
            "Newcastle Calvary Mater Hospital, Waratah, Australia",
            "Westmead Hospital, Westmead, Australia",
            "Border Medical Oncology, Wodonga, Australia",
            "The Queen Elizabeth Hospital, Woodville South, Australia",
            "Princess Alexandra Hospital, Woolloongabba, Australia",
            "Medical University of Graz, Graz, Austria",
            "Landeskrankenhaus Salzburg, Salzburg, Austria",
            "Krankenhaus der Barmherzigen Brueder, Vienna, Austria",
            "Medizinische Universitat Wien, Vienna, Austria",
            "ZNA Middelheim, Antwerpen, Belgium",
            "Hopital Erasme, Brussels, Belgium",
            "Edith Cavell Clinic, Bruxelles, Belgium",
            "AZ Groeninge, Kortrijk, Belgium",
            "UZ Leuven, Leuven, Belgium",
            "AZ Nikolaas, Sint-Niklaas, Belgium",
            "The Health Institute for Men CMX Research Inc, Toronto, Ontario, Canada",
            "Les Urologues Specialises, Montreal, Quebec, Canada",
            "Krajska zdravotni, a.s. Nemocnice Chomutov, o.z., Chomutov, Czechia",
            "Fakultni nemocnice Motol, Prague 5, Czechia",
            "Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad La, Usti Nad Labem, Czechia",
            "Arhus Universitets hospital, Aarhus C, Denmark",
            "Herlev Hospital, Herlev, Denmark",
            "Rigshospitalet University Hospital, Kobenhavn, Denmark",
            "Odense Universitetshospital, Odense C, Denmark",
            "CRLCC Paul Papin, Angers 49, France",
            "Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest, Bordeaux, France",
            "Centre Georges Francois Leclerc, Dijon Cedex, France",
            "Clinique Victor Hugo, Le Mans, France",
            "Centre Oscar Lambret, Lille 59, France",
            "Centre Leon Berard, Lyon, France",
            "Clinique de Valdegour, Nimes, France",
            "CHU de Poitiers, Poitiers Cedex, France",
            "Centre Eugene Marquis, Rennes Cedex, France",
            "CRLCC Centre Rene Gauducheau, Saint Herblain 44, France",
            "Institut de Cancerologie de la Loire, Saint Priest En Jaroz, France",
            "Hopital Civil de Strasbourg, Strasbourg, France",
            "CHRU Hopital Bretonneau, Tours Cedex, France",
            "Institut Gustave Roussy, Villejuif, France",
            "Vivantes Klinikum am Urban, Berlin, Germany",
            "Medizinisches Zentrum Bonn-Friedensplatz, Bonn, Germany",
            "Diakonissenkrankenhaus Dessau gGmbH, Dessau-Rosslau, Germany",
            "Universitaetsklinikum Duesseldorf, Duesseldorf, Germany",
            "Krankenhaus Nordwest, Frankfurt a.M., Germany",
            "Onkologische Praxis Freiburg, Freiburg, Germany",
            "Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, Germany",
            "IORC- Innovation Onkologie Research and Consulting GmbH, Hamburg, Germany",
            "Praxis fuer Haematologie und Onkologie Koblenz, Koblenz, Germany",
            "Vituro GmbH & Co KG, Leipzig, Germany",
            "TU MÃ¼nchen - Klinikum rechts der Isar, MÃ¼nchen, Germany",
            "Universitaetsklinikum Muenster, MÃ¼nster, Germany",
            "University-Hospital TÃ¼bingen, Tuebingen, Germany",
            "Universitatsklinikum Ulm, Ulm, Germany",
            "Alexandra General Hospital of Athens, Athens, Greece",
            "Agioi Anargyroi Hospital, Athens, Greece",
            "University Hospital of Larissa, Larissa, Greece",
            "Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece",
            "Fovarosi Onkirmanyzat Peterfy S.Utcai Korhaz-Rend.Int es Baleseti Kozp., Budapest, Hungary",
            "Fovarosi Onkormanyzat Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest, Hungary",
            "Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary",
            "Pecsi Tudomanyegytem Altalanos Orvostudomanyi Kar, Pecs, Hungary",
            "The Soroka University Medical Center, Beer Sheva, Israel",
            "Rambam Health Care Campus, Haifa, Israel",
            "Rabin Medical Center, Petach Tikva, Israel",
            "Assaf Harofeh Medical Center, Zerifin, Israel",
            "Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy",
            "Ordine Mauriziano, Candiolo, Italy",
            "Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, Italy",
            "Ospedale Vito Fazzi, Lecce, Italy",
            "Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.), Meldola, Italy",
            "Ospedale di Mirano, Mirano (VE), Italy",
            "Azienda Ospedaliero Universitaria Pisana, Pisa, Italy",
            "Ospedale degli Infermi di Rimini, Rimini, Italy",
            "Azienda Ospedaliera San Camillo Forlanini, Roma, Italy",
            "Azienda Ospedaliero-Universitaria Santa Maria della Miserico, Udine, Italy",
            "Hospital Angeles Lindavista, D.f, Df, Mexico",
            "Consultorio de Especialidad en Urologia Privado, Durango, DGO, Mexico",
            "Hospital Fatima, Sinaloa, SIN, Mexico",
            "Consultorio Privado- Dr Jose Arturo Rodriguez Rivera, Zapopan, JAL, Mexico",
            "VU University Medical Center VU Medisch Centrum, Amsterdam, Netherlands",
            "Ziekenhuis Rijnstate, Arhem, Netherlands",
            "Amphia Ziekenhuis Molengracht, Breda, Netherlands",
            "HagaZiekenhuis, Den Haag, Netherlands",
            "Gemini Ziekenhuis, Den Helder, Netherlands",
            "Albert Schweitzer Ziekenhuis Amstelwijck, Dordrecht, Netherlands",
            "Catharina Ziekenhuis, Eindhoven, Netherlands",
            "Medisch Centrum Leeuwarden, Leeuwarden, Netherlands",
            "Leids Universitair Medisch Centrum, Leiden, Netherlands",
            "Academisch Ziekenhuis Maastricht, Maastricht, Netherlands",
            "St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands",
            "Erasmus Medical Center, Rotterdam, Netherlands",
            "Erasmus Medisch Centrum, Rotterdam, Netherlands",
            "Twee Steden Ziekenhuis Tilburg, Tilburg, Netherlands",
            "VieCuri Medisch Centrum Venlo, Venlo, Netherlands",
            "Isala Klinieken, Zwolle, Netherlands",
            "Uniwersyteckie Centrum Kliniczne, Gdansk, Poland",
            "Regionalny Osrodek Onkologiczny WSS im. M. Kopernika, Lodz, Poland",
            "ZOZ MSWiA z Warminsko- Mazurskim Centrum Onkologii, Olsztyn, Poland",
            "NZOZ Olsztynski Osr. Onkologiczny Kopernik Sp.z o.o, Olsztyn, Poland",
            "SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku, Rybnik, Poland",
            "Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie, Warszawa, Poland",
            "4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ, Wroclaw, Poland",
            "Moscow Oncology Clinical Dispensary 1, Moscow, Russian Federation",
            "Medical Radiology Research Centre RAMS, Obninsk, Russian Federation",
            "State Institution of Heath Omsk Regional Oncology Dispensary, Omsk, Russian Federation",
            "Russian Scientific Center for Radiology and Surgical Technol, St. Petersburg, Pesochny Vlg Saint Petersburg, Russian Federation",
            "NSHI Dorozhnaya Clinical Hospital of OAO Russian Railways, Rostov-on-Don, Russian Federation",
            "Oncology Dispensary 2 of Krasnodar Region, Sochi, Russian Federation",
            "Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation",
            "Groote Schuur Hospital, Cape Town, W Cape, South Africa",
            "The Oncology Centre Durban, Durban, KZ-Natal, South Africa",
            "Westridge Medical Centre, Durban, KZ-Natal, South Africa",
            "Netcare Oncology and Interventional Centre, Goodwood, W Cape, South Africa",
            "Dr. H. Malan, Polokwane, South Africa",
            "Pretoria Urology Hospital, Pretoria, South Africa",
            "Hospital del Mar, Barcelona, Spain",
            "Hospital DurÃ¡n i Reynals - Instituto CatalÃ n de OncologÃ¬a ICO, Hospitalet de Llobregat, Barcelona, Spain",
            "Hospital Arnau de Vilanova, LÃ©rida, Spain",
            "Hospital 12 de Octobre, Madrid, Spain",
            "HCU Virgen de la Victoria, Malaga, Spain",
            "Clinica Universitaria de Navarra, Pamplona, Spain",
            "Hospital Mutua de Terrassa, Terrassa (Barcelona), Spain",
            "Hospital Clinico Universitario de Valencia, Valencia, Spain",
            "Hospital Universitario Miguel Servet, Zaragoza, Spain",
            "Lanssjukhuset Ryhov, JÃ¶nkÃ¶ping, Sweden",
            "Norrlands Universitetssjukhus, UmeÃ¥, Sweden",
            "Centrallasarettet Vasteras, VÃ¤sterÃ¥s, Sweden",
            "Clatterbridge Centre for Oncology NHS Trust, Bebington, Wirral, United Kingdom",
            "Addenbrookes Hospital, Cambridge, United Kingdom",
            "Royal Surrey County Hospital, Guildford, United Kingdom",
            "Guy's and St Thomas' Hospital - London, London, United Kingdom",
            "St George's Hospital, London, United Kingdom",
            "Royal Marsden Hospital, London, United Kingdom",
            "Christie NHS Trust Hospital, Manchester, United Kingdom",
            "Nottingham City Hospital, Nottingham, United Kingdom",
            "Northern Lincolnshire and Goole Hospitals NHS Foundation Trust, Scunthorpe, United Kingdom",
            "Royal Marsden Hospital, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00988208"
      },
      {
        "-rank": "150",
        "nct_id": "NCT02730338",
        "title": "INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer",
        "acronym": "INTERVAL",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer Metastatic" },
        "interventions": {
          "intervention": [
            {
              "-type": "Behavioral",
              "#text": "High intensity aerobic and resistance training"
            },
            {
              "-type": "Behavioral",
              "#text": "Psychosocial support"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Disease Progression",
            "Symptomatic Skeletal Related Events (SSE)",
            "Opiate Use",
            "Analgesic Use",
            "Biomarker analysis",
            "Quality of Life",
            "Physical Function",
            "Pain"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Movember Foundation",
          "collaborator": [
            "University of California, San Francisco",
            "Edith Cowan University",
            "King's College London",
            "Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM)",
            "Epworth Foundation"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "866",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "GAP4" },
        "start_date": "January 2016",
        "primary_completion_date": "October 2024",
        "completion_date": "October 2024",
        "study_first_posted": "April 6, 2016",
        "last_update_posted": "June 28, 2019",
        "locations": {
          "location": [
            "Cedars Sinai Medical Centre, Los Angeles, California, United States",
            "UCSF, San Francisco, California, United States",
            "UC Denver, Denver, Colorado, United States",
            "University of Minnesota, Minneapolis, Minnesota, United States",
            "Oregon Health & Science University, Portland, Oregon, United States",
            "Fred Hutchinson Cancer Centre, Seattle, Washington, United States",
            "Australian Prostate Cncr Research Centre, Brisbane, Queensland, Australia",
            "GenesisCare Wesley, Brisbane, Queensland, Australia",
            "University of Queensland, Brisbane, Queensland, Australia",
            "Epworth Hospital, Melbourne, Victoria, Australia",
            "Victoria University / Sunshine Hospital, Melbourne, Victoria, Australia",
            "Edith Cowan University, Perth, Western Australia, Australia",
            "University of Alberta, Edmonton, Alberta, Canada",
            "QEII Cancer Centre / Dalhousie University, Halifax, Nova Scotia, Canada",
            "Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Centre Hospitalier de l'UniversitÃ© de MontrÃ©al (CRCHUM), Montreal, Canada",
            "West China Hospital of Sichuan University, Chengdu, China",
            "German Sport University Cologne, Cologne, Germany",
            "Trinity University, Dublin, Ireland",
            "Erasmus MC, Rotterdam, Netherlands",
            "University of Surrey, Guildford, Surrey, United Kingdom",
            "University of Bath / Bath Royal United Hospital, Bath, United Kingdom",
            "Queen's University Belfast, Belfast, United Kingdom",
            "University of Glasgow, Glasgow, United Kingdom",
            "Kings College London, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02730338"
      },
      {
        "-rank": "151",
        "nct_id": "NCT01226576",
        "title": "Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Localized Low-Intermediate Risk Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "MRgFUS Treatment"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety and initial Effectiveness",
            "Safety",
            "Effectiveness",
            "QOL"
          ]
        },
        "sponsors": { "lead_sponsor": "InSightec" },
        "gender": "Male",
        "min_age": "50 Years",
        "max_age": "75 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "8",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "PCa004" },
        "start_date": "October 2010",
        "primary_completion_date": "December 2018",
        "completion_date": "December 2018",
        "study_first_posted": "October 22, 2010",
        "last_update_posted": "March 13, 2019",
        "locations": {
          "location": [
            "University Health Network, Toronto, Ontario, Canada",
            "Sheba Medical Center, Tel Hashomer, Israel",
            "Sapienza University Hospital, Rome, Italy",
            "National Cancer Center Singapore, Singapore, Singapore",
            "St. Mary's Hospital, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01226576"
      },
      {
        "-rank": "152",
        "nct_id": "NCT00974311",
        "title": "Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy",
        "acronym": "AFFIRM",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Castration-Resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Radiographic Progression-free Survival",
            "Time to First Skeletal-related Event",
            "Percentage of Participants Who Were Responders for Functional Assessment of Cancer Therapy-Prostate (FACT-P)",
            "Time to Prostate-specific Antigen (PSA) Progression",
            "Percentage of Participants With Pain Palliation",
            "Percentage of Participants With Prostate Specific Antigen (PSA) Response",
            "Percentage of Participants With Soft-tissue Objective Response",
            "European Quality of Life Five-Domain (EQ-5D) Scale",
            "Percentage of Participants With Circulating Tumor Cell (CTC) Conversion"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Pfizer",
          "collaborator": [
            "Astellas Pharma Inc",
            "Medivation LLC, a wholly owned subsidiary of Pfizer Inc."
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1199",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CRPC2",
            "2009-013174-41",
            "C3431010"
          ]
        },
        "start_date": "September 30, 2009",
        "primary_completion_date": "September 15, 2011",
        "completion_date": "November 2, 2017",
        "study_first_posted": "September 10, 2009",
        "results_first_posted": "October 30, 2012",
        "last_update_posted": "December 11, 2018",
        "locations": {
          "location": [
            "University of Alabama at Birmingham, Birmingham, Alabama, United States",
            "University of Alabama at Birmingham, Birmingham, Alabama, United States",
            "Mayo Clinic Hospital, Phoenix, Arizona, United States",
            "Premiere Oncology of Arizona, Scottsdale, Arizona, United States",
            "Mayo Clinic Arizona, Scottsdale, Arizona, United States",
            "Tower Cancer Research Foundation, Tower Hematology Oncology Medical Group, Beverly Hills, California, United States",
            "USC Westside Prostate Cancer Center, Beverly Hills, California, United States",
            "City of Hope, Duarte, California, United States",
            "Cancer Center Oncology Medical Group, La Mesa, California, United States",
            "LAC & USC Medical Center, Los Angeles, California, United States",
            "USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States",
            "Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",
            "UCLA, Los Angeles, California, United States",
            "c/o Prostate Oncology Specialist, Inc., Marina Del Rey, California, United States",
            "North County Oncology Medical Clinic, Inc,, Oceanside, California, United States",
            "Medical Oncology Associates - SD, San Diego, California, United States",
            "Sharp Memorial Hospital Investigational Pharmacy, San Diego, California, United States",
            "Sharp Rees-Stealy, San Diego, California, United States",
            "UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States",
            "City of Hope Medical Group, South Pasadena, California, United States",
            "Stanford Hospital and Clinics Research Pharmacy, Stanford, California, United States",
            "Stanford University Medical Center, Stanford, California, United States",
            "Research Pharmacist, Aurora, Colorado, United States",
            "University of Colorado Denver, Anschutz Cancer Pavilion, Aurora, Colorado, United States",
            "C/O: Thomas Ferencz R.Ph., BCOP, New Haven, Connecticut, United States",
            "Yale University School of Med, New Haven, Connecticut, United States",
            "George Washington University-Medical Faculty Associates, Washington, District of Columbia, United States",
            "Palm Beach Cancer Institute, Atlantis, Florida, United States",
            "Palm Beach Cancer Institute, Palm Beach Gardens, Florida, United States",
            "Palm Beach Cancer Institute, Wellington, Florida, United States",
            "Palm Beach Cancer Institute, West Palm Beach, Florida, United States",
            "Peachtree Hematology-Oncology Consultants, P.C., Atlanta, Georgia, United States",
            "University of Chicago Medical Center, Chicago, Illinois, United States",
            "University of Chicago, Chicago, Illinois, United States",
            "The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",
            "The Johns Hopkins Hospital, Baltimore, Maryland, United States",
            "Massachusetts General Hospital (MGH), Boston, Massachusetts, United States",
            "Brigham & Women's Hospital (BWH), Boston, Massachusetts, United States",
            "Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",
            "Dana-Farber Cancer Institute, Boston, Massachusetts, United States",
            "Karmanos Cancer Institute, Detroit, Michigan, United States",
            "Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States",
            "Mayo Clinic, Rochester, Minnesota, United States",
            "Siteman Cancer Center-West County, Creve Coeur, Missouri, United States",
            "Barnes-Jewish Hospital, Saint Louis, Missouri, United States",
            "Washington University School of Medicine, Saint Louis, Missouri, United States",
            "Siteman Cancer Center, Saint Peters, Missouri, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "Nevada Cancer Institute, an affiliate of the UC San Diego Health System, Las Vegas, Nevada, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "New Mexico Oncology Hematology Consultants, Ltd., Albuquerque, New Mexico, United States",
            "Roswell Park Cancer Institute, Buffalo, New York, United States",
            "Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States",
            "Memorial Sloan-Kettering Cancer Center, New York, New York, United States",
            "Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States",
            "Duke University Medical Center, Durham, North Carolina, United States",
            "Pharmaceutical Research Services, Durham, North Carolina, United States",
            "Portland VA Medical Center, Portland, Oregon, United States",
            "UPMC Cancer Centers, McKeesport, Pennsylvania, United States",
            "Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",
            "Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",
            "University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",
            "UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States",
            "VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States",
            "Hollings Cancer Center, Charleston, South Carolina, United States",
            "Medical University of South Carolina (MUSC), Charleston, South Carolina, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Grand Strand Urology, Myrtle Beach, South Carolina, United States",
            "Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States",
            "Tennessee Oncology, PLLC, Dickson, Tennessee, United States",
            "Tennessee Oncology, PLLC, Franklin, Tennessee, United States",
            "Tennessee Oncology, PLLC, Gallatin, Tennessee, United States",
            "Tennessee Oncology, PLLC, Hermitage, Tennessee, United States",
            "Tennessee Oncology, PLLC, Lebanon, Tennessee, United States",
            "Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States",
            "Tennessee Oncology, PLLC, Nashville, Tennessee, United States",
            "The Sarah Cannon Research Institute, Nashville, Tennessee, United States",
            "Tennessee Oncology, PLLC, Nashville, Tennessee, United States",
            "Tennessee Oncology, PLLC, Nashville, Tennessee, United States",
            "Tennessee Oncology, PLLC, Nashville, Tennessee, United States",
            "Vanderbilt University Medical Center, Nashville, Tennessee, United States",
            "Tennessee Oncology, PLLC, Smyrna, Tennessee, United States",
            "Parkland Health and Hospital System, Dallas, Texas, United States",
            "Texas Oncology, Sammons Cancer Center, Dallas, Texas, United States",
            "UT Southwestern Medical Center at Dallas, Dallas, Texas, United States",
            "Virginia Oncology Associates, Chesapeake, Virginia, United States",
            "Virginia Oncology Associates, Hampton, Virginia, United States",
            "Virginia Cancer Institute, Mechanicsville, Virginia, United States",
            "Virginia Cancer Institute, Midlothian, Virginia, United States",
            "Virginia Oncology Associates, Newport News, Virginia, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "Virginia Cancer Institute, Richmond, Virginia, United States",
            "Virginia Cancer Institute, Richmond, Virginia, United States",
            "Virginia Oncology Associates, Virginia Beach, Virginia, United States",
            "Virginia Oncology Associates, Williamsburg, Virginia, United States",
            "Seattle Cancer Care Alliance, Seattle, Washington, United States",
            "University of Washington Medical Center, Seattle, Washington, United States",
            "University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",
            "Instituto Medico de Asistencia e Investigaciones S.A (IMAI Research), Buenos Aires, AR, Argentina",
            "Instituto Oulton, Cordoba, Provincia DE Cordoba, Argentina",
            "Clinica Universitaria Privada Reina Fabiola, Cordoba, Provincia DE Cordoba, Argentina",
            "Policlinico Neuquen, Neuquen, Provincia DE Neuquen, Argentina",
            "Policlinico Modelo de Cipolletti, Cipolletti, Provincia DE RIO Negro, Argentina",
            "Instituto de Investigaciones Clinicas Cipolletti, Cipolletti, Provincia DE RIO Negro, Argentina",
            "Sanatorio Mapaci, Rosario, Provincia DE Santa FE, Argentina",
            "Instituto de Oncologia y Especialidades Medicas, Rosario, Provincia DE Santa FE, Argentina",
            "Hospital Italiano Garibaldi, Rosario, Provincia DE Santa FE, Argentina",
            "Centro de Diagnostico Dr. Enrique Rossi, Ciudad Autonoma de Buenos Aires, Argentina",
            "Centro de Diagnostico Dr. Enrique Rossi, Ciudad Autonoma de Buenos Aires, Argentina",
            "North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia",
            "Sydney Cancer Centre, Concord, New South Wales, Australia",
            "Mid North Coast Diagnostic Imaging, Port Macquarie, New South Wales, Australia",
            "Port Macquarie Base Hospital Pharmacy, Port Macquarie, New South Wales, Australia",
            "Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia",
            "Prince of Wales Hospital, Department of Medical Oncology, Randwick, New South Wales, Australia",
            "The Tweed Hospital, Tweed Heads, New South Wales, Australia",
            "PRP Diagnostic Imaging, Wentworthville, New South Wales, Australia",
            "Sydney West Cancer Trials Centre, Department of Medical Oncology, Westmead, New South Wales, Australia",
            "River City Pharmacy, Auchenflower, Queensland, Australia",
            "Heart Care Partners, Auchenflower, Queensland, Australia",
            "Icon Cancer Care Wesley, Auchenflower, Queensland, Australia",
            "Icon Cancer Care Chermside, Chermside, Queensland, Australia",
            "Southern X-Ray Chermside, Chermside, Queensland, Australia",
            "Cancer Care Services, Herston, Queensland, Australia",
            "Icon Cancer Foundation, Milton, Queensland, Australia",
            "Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia",
            "Mater Private Cardiology, South Brisbane, Queensland, Australia",
            "Queensland X-Ray, South Brisbane, Queensland, Australia",
            "XRadiology, Toowong, Queensland, Australia",
            "Department of Medical Oncology, Adelaide, South Australia, Australia",
            "Royal Hobart Hospital, Hobart, Tasmania, Australia",
            "St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia",
            "Peninsula Oncology Centre, Frankston, Victoria, Australia",
            "Austin Hospital, Heidelberg, Victoria, Australia",
            "Sir Charles Gairdner Hospital, Department of Medical Oncology, Nedlands, Western Australia, Australia",
            "60 Eleanor St, Footscray, Australia",
            "Western Hospital, Footscray, Australia",
            "The Royal Melbourne Hospital, Victoria, Australia",
            "Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria",
            "ISOTOPIX Ambulatorium fuer, Vienna, Austria",
            "Medical University of Vienna, Vienna, Austria",
            "Cliniques Universitaires Saint- Luc, Brussels, Belgium",
            "AZ Sint- Lucas, Ghent, Belgium",
            "VZW Jessa Ziekenhuis, Hasselt, Belgium",
            "AZ Groeninge - Campus Kennedylaan, Kortrijk, Belgium",
            "AZ Groeninge - Campus Sint Maarten, Kortrijk, Belgium",
            "University Hospital Gasthuisberg, Leuven, Belgium",
            "H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium",
            "Tom Baker Cancer Centre, Calgary, Alberta, Canada",
            "Tom Baker Cancer Centre - Holy Cross Site, Calgary, Alberta, Canada",
            "Cross Cancer Institute, Edmonton, Alberta, Canada",
            "British Columbia Cancer Agency, Centre for the Southern Interior, Kelowna, British Columbia, Canada",
            "B.C. Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada",
            "British Columbia Cancer Agency - Vancouver Island Centre, Victoria, British Columbia, Canada",
            "QEII Health Sciences Centre, Halifax, Nova Scotia, Canada",
            "QEII Health Sciences Centre, Halifax, Nova Scotia, Canada",
            "QEII Health Sciences Centre, Halifax, Nova Scotia, Canada",
            "Juravinski Cancer Centre, Hamilton, Ontario, Canada",
            "London Regional Cancer Program, London, Ontario, Canada",
            "Princess Margaret Hospital, Toronto, Ontario, Canada",
            "Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada",
            "The Urology Specialists., Montreal, Quebec, Canada",
            "Imagerie medicale de la Capitale, Quebec, Canada",
            "CHU de Quebec, Quebec, Canada",
            "Centre de rechereche clinique et evaluative en oncologie, Quebec, Canada",
            "Hospital San Jose, Santiago, Chile",
            "Instituto Nacional del Cancer, Santiago, Chile",
            "Centro Investigacion Clinica del Sur, Temuco, Chile",
            "Instituto Oncologico, Vina del Mar, Chile",
            "Centre Paul Papin, Angers Cedex 9, France",
            "Institut Bergonie, Bordeaux cedex, France",
            "Centre Regional Francois Baclesse de lutte contre le cancer, Caen Cedex, France",
            "Centre hospitalier de Cannes, Cannes Cedex, France",
            "CHU Henri Mondor, Creteil, France",
            "Centre Hospitalier Intercommunal Frejus-Saint Raphael, Frejus Cedex, France",
            "Centre hospitalier departemental Vendee, LA Roche sur Yon, France",
            "Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France",
            "Centre Leon Berard, Lyon Cedex 08, France",
            "Groupement Hospitalier Edouard Herriot - Pavillon V, Lyon Cedex 3, France",
            "Institut Paoli Calmettes, Marseille, France",
            "Institut Curie, Paris, France",
            "Hopital Europeen Georges Pompidou, Paris, France",
            "Centre Hospitalier Lyon sud, Pierre Benite, France",
            "CHU La Miletrie, Poitiers Cedex, France",
            "Institut Jean Godinot, Reims Cedex, France",
            "Centre Hospitalier, Saint Etienne Cedex 2, France",
            "Institut de Cancerologie de la Loire, Saint Priest en Jarez, France",
            "Centre d'Investigation Clinique, (CIE3), Saint-Etienne CEDEX 2, France",
            "Centre Rene Gauducheau, SAINT-HERBLAIN Cedex, France",
            "Hopital Foch, Suresnes Cedex, France",
            "Institut Gustave Roussy, Villejuif, France",
            "Universitaetsklinikum Aachen, Aachen, Germany",
            "Charite - Universitaetsmedizin Berlin-Campus Benjamin Franklin, Berlin, Germany",
            "Gemeinschaftspraxis Fuer Nuklearmedizin, Berlin, Germany",
            "Radiologische Gemeinschaftspraxis, Berlin, Germany",
            "FacharztzentrumInnere Medizin, Berlin, Germany",
            "Praxis Dr. Wolfgang Hoelzer, Berlin, Germany",
            "Staedtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany",
            "Technical University Dresden, Dresden, Germany",
            "Martini-Klinik am UKE GmbH, Hamburg, Germany",
            "Roentgenpraxis, Hamburg, Germany",
            "Urologische Gemeinschaftspraxis Poppenbuettel, Hamburg, Germany",
            "Medizinische Hochschule Hannover - Klinik fuer Urologie und Urologische Onkologie, Hannover, Germany",
            "Medizinische Hochschule Hannover, Hannover, Germany",
            "Universitaetsklinikum Heidelberg, Heidelberg, Germany",
            "Universitaetsklinikum Mannheim, Mannheim, Germany",
            "Universitaetsklinikum Muenster, Klinik fuer Klinische Radiologie, Muenster, Germany",
            "Universitaetsklinikum Muenster, Klinik und Poliklinik fuer Nuklearmedizin, Muenster, Germany",
            "Universitaetsklinikum Muenster, Klinik und Poliklinik fuer Urologie, Muenster, Germany",
            "Abt.f.Diagnostische u. Interventionelle Radiologie, Tuebingen, Germany",
            "Klinik fuer Urologie, Tuebingen, Germany",
            "Nuklearmedizin, Tuebingen, Germany",
            "Azienda Ospedaliero-Universitaria di Modena Policlinico, Via Del Pozzo 71, Modena, Italy",
            "Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, TO, Italy",
            "Azienda Ospedaliera \"Istituti Ospitalieri\" di Cremona, Cremona, Italy",
            "Azienda Ospedaliera San Camillo Forlanini, Rome, Italy",
            "VU Medisch Centrum, Amsterdam, Netherlands",
            "UMC St. Radboud, Nijmegen, Netherlands",
            "Erasmus MC, Rotterdam, Netherlands",
            "Uniwersyteckie Centrum Kliniczne, Gdansk, Poland",
            "Regionalny Szpital Specjalistyczny im. Dr. Wladyslawa Bieganskiego, Grudziadz, Poland",
            "Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Regionalny Osrodek Onkologiczny, Lodz, Poland",
            "Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland",
            "Wojewodzki szpital specjalistyczny im. Janusza Korczaka, Slupsk, Poland",
            "Hopelands Cancer Centre, Durban, South Africa",
            "GVI Oncology, Port Elizabeth, South Africa",
            "Sandton Oncology Centre, Sandton, South Africa",
            "Hospital Universitario Germans Trias i Pujol, Badalona, Spain",
            "Hospital del Mar, Barcelona, Spain",
            "Radiodiagnostic Cetir Clinica Pilar, Barcelona, Spain",
            "Hospital Santa Creu i Sant Pau, Barcelona, Spain",
            "Hospital Vall d'Hebron, Barcelona, Spain",
            "Hospital Madrid Norte Sanchinarro, Madrid, Spain",
            "Clinica Universidad de Navarra, Pamplona, Spain",
            "Bishops Wood Hospital, Northwood, Middlesex, United Kingdom",
            "Mount Vernon Hospital, Northwood, Middlesex, United Kingdom",
            "The Royal Marsden Hospital, Sutton, Surrey, United Kingdom",
            "Belfast City Hospital, Belfast, United Kingdom",
            "Cancer Centre, Birmingham, United Kingdom",
            "Bristol Haematology & Oncology Centre, Bristol, United Kingdom",
            "Bristol Royal Infirmary, Bristol, United Kingdom",
            "Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",
            "The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom",
            "University College Hospital, London, United Kingdom",
            "Hammersmith Hospital, London, United Kingdom",
            "The Christie NHS Foundation Trust, Manchester, United Kingdom",
            "Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom",
            "Churchill Hospital, Oxford, United Kingdom",
            "The Manor Hospital Oxford, Oxford, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00974311"
      },
      {
        "-rank": "153",
        "nct_id": "NCT03511664",
        "title": "Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer",
        "acronym": "VISION",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "177Lu-PSMA-617"
            },
            {
              "-type": "Other",
              "#text": "Best supportive/best standard of care"
            }
          ]
        },
        "outcome_measures": { "outcome_measure": "Overall Survival" },
        "sponsors": { "lead_sponsor": "Endocyte" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "750",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "PSMA-617-01" },
        "start_date": "May 23, 2018",
        "primary_completion_date": "August 2020",
        "completion_date": "May 2021",
        "study_first_posted": "April 30, 2018",
        "last_update_posted": "August 27, 2019",
        "locations": {
          "location": [
            "HonorHealth Institute, Scottsdale, Arizona, United States",
            "University of Arizona Cancer Center, Tucson, Arizona, United States",
            "VA Greater Los Angeles Healthcare System, Los Angeles, California, United States",
            "UCLA, Los Angeles, California, United States",
            "Stanford University, Palo Alto, California, United States",
            "UCSF Medical Center at Mission Bay, San Francisco, California, United States",
            "University of Colorado Denver, Aurora, Colorado, United States",
            "Yale Cancer Center, Clinical Trials Office, New Haven, Connecticut, United States",
            "Washington DC VA Medical Center, Nuclear Medicine Service, Washington, District of Columbia, United States",
            "H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",
            "Northwestern University, Chicago, Illinois, United States",
            "Parkview Cancer Institute, Fort Wayne, Indiana, United States",
            "IU Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States",
            "University of Iowa Hospitals and Clinics Cancer Center Research, Iowa City, Iowa, United States",
            "Iowa VA Medical Center, Iowa City, Iowa, United States",
            "Norton Cancer Institute, Louisville, Kentucky, United States",
            "Tulane Cancer Center, New Orleans, Louisiana, United States",
            "University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States",
            "Chesapeake Urology Research Associates, Towson, Maryland, United States",
            "Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",
            "The Lank Center for Genitourinary Oncology, Boston, Massachusetts, United States",
            "VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States",
            "University of Michigan Medical Center, Division of Nuclear Medicine, Ann Arbor, Michigan, United States",
            "Karmanos Cancer Center, Detroit, Michigan, United States",
            "Mayo Clinic, Rochester, Minnesota, United States",
            "John Cochran St. Louis Veterans Medical Center, Saint Louis, Missouri, United States",
            "Washington University School of Medicine, Saint Louis, Missouri, United States",
            "St. Louis University Hospital, Saint Louis, Missouri, United States",
            "GU Research Network/ Urology Cancer Center, Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "Regional Cancer Care Associates, East Brunswick, New Jersey, United States",
            "New Mexico Oncology & Hematology Consultants, Albuquerque, New Mexico, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States",
            "Duke University School of Medicine, Duke Cancer Institute, Durham, North Carolina, United States",
            "Precision Cancer Research/ Dayton Physicians Network, Kettering, Ohio, United States",
            "Oregon Health and Science University Nuclear Medicine Department, Portland, Oregon, United States",
            "Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States",
            "Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Dallas VA Research Organization, Dallas, Texas, United States",
            "UT Southwestern Medical Center, Dallas, Texas, United States",
            "Excel Diagnostics & Nuclear Oncology Center, Houston, Texas, United States",
            "UVA Cancer Care, Charlottesville, Virginia, United States",
            "Swedish Cancer Institute, Seattle, Washington, United States",
            "Cliniques Universitaires Saint Luc, Brussels, Belgium",
            "Institut Jules Bordet, Brussels, Belgium",
            "University Hospitals Leuven, Campus Gasthuisberg, Department of Nuclear Medicine, Leuven, Belgium",
            "BC Cancer - Vancouver, Vancouver, British Columbia, Canada",
            "London Health Sciences Centre, Division of Nuclear Medicine, London, Ontario, Canada",
            "The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada",
            "Odette Cancer Centre, Toronto, Ontario, Canada",
            "CHUM - Hotel Dieu Hospital, MontrÃ©al, Quebec, Canada",
            "Jewish General Hospital, MontrÃ©al, Quebec, Canada",
            "Hotel Dieu Hospital in Quebec, QuÃ©bec, Quebec, Canada",
            "Aalborg University Hospital Klinik Kirurgi-KrÃ¦ft Clinical Research Unit Department of Oncology, Aalborg, Denmark",
            "Aarhus Universitetshospital, Aarhus, Denmark",
            "Rigshospitalet - University Hospital Copenhagen, Department of Oncology, Copenhagen, Denmark",
            "Bergonie Institute, Bordeaux, France",
            "Center Jean Perrin, Clermont-Ferrand, France",
            "Leon Berard Center, Lyon, France",
            "Centre d'Investigations et de Recherche Clinique en Oncologie Hospital SAINT-LOUIS, Paris, France",
            "Tenon Hospital, Paris, France",
            "Institute Claudius Regaud, Toulouse Cancer Research Center, Toulouse, France",
            "Gustave Roussy Oncology Institute, Villejuif, France",
            "The Netherlands Cancer Institute, Amsterdam, Netherlands",
            "St. Antonius Hospital, Nieuwegein, Netherlands",
            "Radboud University Medical Center, Nijmegen, Netherlands",
            "Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",
            "VA Caribbean Healthcare System, San Juan, Puerto Rico",
            "Sahlgrenska University Hospital, Department of Oncology, Gothenburg, Sweden",
            "Skane University Hospital, Lund, Sweden",
            "Karolinska University Hospital, Stockholm, Sweden",
            "Norrlands Universitetssjukhus, UmeÃ¥, Sweden",
            "Uppsala University Hospital, Department of Oncology, Uppsala, Sweden",
            "Institute of Cancer Research, Sutton, Surrey, United Kingdom",
            "Bristol Hematology & Oncology Center, Bristol, United Kingdom",
            "Beatson West of Scotland Cancer Center, Glasgow, United Kingdom",
            "Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom",
            "University College London Hospitals NHS Foundation Trust, London, United Kingdom",
            "Royal Free London NHS Foundation Trust Royal Free Hospital, London, United Kingdom",
            "Guy's Hospital, London, United Kingdom",
            "St Bartholomew's Hospital, West Smithfield, London, United Kingdom",
            "University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03511664"
      },
      {
        "-rank": "154",
        "nct_id": "NCT00268476",
        "title": "Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy",
        "acronym": "STAMPEDE",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Celecoxib"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Prednisolone"
            },
            {
              "-type": "Drug",
              "#text": "ADT"
            },
            {
              "-type": "Drug",
              "#text": "Zoledronic Acid"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone"
            },
            {
              "-type": "Radiation",
              "#text": "Radiotherapy to the prostate"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Metformin"
            },
            {
              "-type": "Drug",
              "#text": "Transdermal Oestradiol"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall survival",
            "Failure-free survival",
            "Cost effectiveness by EuroQol",
            "Quality of life (QOL) by EORTC QOL Questionnaire C30 and prostate specific 25-item",
            "Number of participants with treatment-related side effects as assessed by CTCAE v4.0",
            "Skeletal related events",
            "Biochemical failure",
            "Progression-free survival",
            "Lymph node progression",
            "Distant metastases",
            "Treatment for progression",
            "Disease-specific survival",
            "Non-prostate cancer death",
            "Metabolic effects"
          ]
        },
        "sponsors": { "lead_sponsor": "Medical Research Council" },
        "gender": "Male",
        "max_age": "120 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 2",
            "Phase 3"
          ]
        },
        "enrollment": "12200",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000455008",
            "MRC-STAMPEDE",
            "EU-205102",
            "PR08",
            "ISRCTN78818544",
            "2004-000193-31"
          ]
        },
        "start_date": "July 8, 2005",
        "primary_completion_date": "September 2024",
        "completion_date": "September 2024",
        "study_first_posted": "December 22, 2005",
        "last_update_posted": "November 7, 2018",
        "locations": {
          "location": [
            "Kantonsspital Graubuenden, Chur, Graubunden, Switzerland",
            "Lausanne Centre Hospitalier Universitaire, Lausanne, Vaud, Switzerland",
            "Winterthur Hospital, Winterthur, Zurich, Switzerland",
            "Hirslanden Klinik Aarau, Aarau, Switzerland",
            "Universitaetsspital-Basel, Basel, Switzerland",
            "Inselspital Bern, Berne, Switzerland",
            "Liestal Hospital, Liestal, Switzerland",
            "Kantonsspital - St. Gallen, St. Gallen, Switzerland",
            "UniversitaetsSpital Zuerich, Zurich, Switzerland",
            "City Hospital Triemli, Zurich, Switzerland",
            "Berkshire Cancer Centre at Royal Berkshire Hospital, Reading, Berkshire, United Kingdom",
            "Royal Bolton Hospital, Farnworth, Bolton, United Kingdom",
            "Wycombe General Hospital, High Wycombe, Buckinghamshire, United Kingdom",
            "Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom",
            "Broomfield Hospital, Broomfield, Chelmsford, United Kingdom",
            "Countess of Chester Hospital, Chester, Chesire, United Kingdom",
            "James Cook University Hospital, Middlesbrough, County Durham, United Kingdom",
            "Cumberland Infirmary, Carlisle, Cumbria, United Kingdom",
            "North Devon District Hospital, Barnstaple, Devon, United Kingdom",
            "Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom",
            "Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom",
            "Dorset County Hospital, Dorchester, Dorset, United Kingdom",
            "Poole Hospital, Poole, Dorset, United Kingdom",
            "Castle Hill Hospital, Cottingham, East Riding Of Yorkshire, United Kingdom",
            "Eastbourne District General Hospital, Eastbourne, East Sussex, United Kingdom",
            "Conquest Hospital, Saint Leonards-on-Sea, East Sussex, United Kingdom",
            "William Harvey Hospital, Ashford, England, United Kingdom",
            "Stoke Mandeville Hospital, Aylesbury, England, United Kingdom",
            "Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom",
            "City Hospital (Birmingham), Birmingham, England, United Kingdom",
            "Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom",
            "Burnley General Hospital, Burnley, England, United Kingdom",
            "Queen's Hospital, Burton-upon-Trent, England, United Kingdom",
            "West Suffolk Hospital, Bury St. Edmunds, England, United Kingdom",
            "Mid Cheshire Hospitals Trust- Leighton Hopsital, Crewe, England, United Kingdom",
            "Darlington Memorial, Darlington, England, United Kingdom",
            "Derbyshire Royal Infirmary, Derby, England, United Kingdom",
            "Doncaster Royal Infirmary, Doncaster, England, United Kingdom",
            "Russells Hall Hospital, Dudley, England, United Kingdom",
            "University Hospital of North Durham, Durham, England, United Kingdom",
            "Gloucestershire Royal Hospital, Gloucester, England, United Kingdom",
            "Hereford County Hospital, Hereford, England, United Kingdom",
            "Kidderminster Hospital, Kidderminster, England, United Kingdom",
            "Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom",
            "Glenfield Hospital, Leicester, England, United Kingdom",
            "Royal Liverpool University Hospital, Liverpool, England, United Kingdom",
            "University Hospital Aintree, Liverpool, England, United Kingdom",
            "Helen Rollason Cancer Care Centre at North Middlesex Hospital, London, England, United Kingdom",
            "Guy's Hospital, London, England, United Kingdom",
            "St. Mary's Hospital, London, England, United Kingdom",
            "UCL Cancer Institute, London, England, United Kingdom",
            "University College of London Hospitals, London, England, United Kingdom",
            "Withington Hospital, Manchester, England, United Kingdom",
            "Royal Shrewsbury Hospital, Shrewsbury, England, United Kingdom",
            "Stepping Hill Hospital, Stockport, England, United Kingdom",
            "Sunderland Royal Hospital, Sunderland, England, United Kingdom",
            "Torbay Hospital, Torquay, England, United Kingdom",
            "Warrington Hospital NHS Trust, Warrington, England, United Kingdom",
            "West Cumberland Hospital, Whitehaven, England, United Kingdom",
            "Royal Albert Edward Infirmary, Wigan, England, United Kingdom",
            "Worcester Royal Hospital, Worcester, England, United Kingdom",
            "Worthing Hospital, Worthing, England, United Kingdom",
            "Princess Alexandra Hospital, Harlow, Essex, United Kingdom",
            "Queen's Hospital, Romford, Essex, United Kingdom",
            "Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, Essex, United Kingdom",
            "South West Wales Cancer Institute At Singleton Hospital, Swansea, Glamorgan, United Kingdom",
            "Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom",
            "St. Bartholomews Hospital, London, Greater London, United Kingdom",
            "Queen Elizabeth Hospital - Woolwich, London, Greater London, United Kingdom",
            "St. George's Hospital, London, Greater London, United Kingdom",
            "Charing Cross Hospital, London, Greater London, United Kingdom",
            "Christie Hospital, Manchester, Greater Manchester, United Kingdom",
            "Royal Oldham Hospital, Oldham, Greater Manchester, United Kingdom",
            "Southampton General Hospital, Southampton, Hampshire, United Kingdom",
            "Lister Hospital, Stevenage, Hertfordshire, United Kingdom",
            "Raigmore Hospital, Inverness, Highland, United Kingdom",
            "St. Mary's Hospital, Newport, Isle Of Wight, United Kingdom",
            "Airedale General Hospital, Steeton, Keighley, United Kingdom",
            "Kent and Canterbury Hospital, Canterbury, Kent, United Kingdom",
            "Mid Kent Oncology Centre at Maidstone Hospital, Maidstone, Kent, United Kingdom",
            "Queen Elizabeth The Queen Mother Hospital, Margate, Kent, United Kingdom",
            "Beatson Institute for Cancer Research - Glasgow, Glasgow, Lanarkshire, United Kingdom",
            "Rosemere Cancer Centre at Royal Preston Hospital, Preston, Lancashire, United Kingdom",
            "Southport and Formby District General Hospital, Southport, Merseyside, United Kingdom",
            "Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, Middlesex, United Kingdom",
            "Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Midlothian, United Kingdom",
            "Freeman Hospital, Newcastle, Newcastle-upon-Tyne, United Kingdom",
            "Scarborough General Hospital, Scarborough, North Yorkshire, United Kingdom",
            "Centre for Cancer Research and Cell Biology at Queen's University Belfast, Belfast, Northern Ireland, United Kingdom",
            "Nottingham City Hospital, Nottingham, Nottinghamshire, United Kingdom",
            "King's Mill Hospital, Sutton-in-Ashfield, Nottinghamshire, United Kingdom",
            "Churchill Hospital, Oxford, Oxfordshire, United Kingdom",
            "Queen Alexandra Hospital, Cosham, Portsmouth, United Kingdom",
            "Ayr Hospital, Ayr, Scotland, United Kingdom",
            "Royal United Hospital, Bath, Somerset, United Kingdom",
            "Bristol Haematology and Oncology Centre, Bristol, Somerset, United Kingdom",
            "Musgrove Park Hospital, Taunton, Somerset, United Kingdom",
            "Weston General Hospital, Weston Super Mare, Somerset, United Kingdom",
            "Yeovil District Hospital, Yeovil, Somerset, United Kingdom",
            "Cancer Research Centre at Weston Park Hospital, Sheffield, South Yorkshire, United Kingdom",
            "Royal Stoke University Hospital, Stoke-on-Trent, Staffordshire, United Kingdom",
            "Ipswich Hospital, Ipswich, Suffolk, United Kingdom",
            "St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom",
            "Royal Marsden - Sutton, Sutton, Surrey, United Kingdom",
            "Northern Centre for Cancer Treatment at Newcastle General Hospital, Newcastle-Upon-Tyne, Tyne & Wear, United Kingdom",
            "South Tyneside District Hospital, South Shields, Tyne & Wear, United Kingdom",
            "Bronglais General Hospital, Aberystwyth, Wales, United Kingdom",
            "Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom",
            "Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom",
            "Good Hope Hospital, Sutton Coldfield, West Midlands, United Kingdom",
            "Bradford Royal Infirmary, Bradford, West Yorkshire, United Kingdom",
            "Huddersfield Royal Infirmary, Huddersfield, West Yorkshire, United Kingdom",
            "Great Western Hospital, Swindon, Wiltshire, United Kingdom",
            "Clatterbridge Centre for Oncology, Bebington, Wirral, United Kingdom",
            "Barnet General Hospital, Barnet, United Kingdom",
            "Colchester General Hospital, Colchester, United Kingdom",
            "Forth Valley Hospital, Larbert, United Kingdom",
            "Lincoln Hospital, Lincoln, United Kingdom",
            "North Tees Hospital, Stockton-on-Tees, United Kingdom",
            "New Cross Hospital, Wolverhampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00268476"
      },
      {
        "-rank": "155",
        "nct_id": "NCT00626548",
        "title": "A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer",
        "acronym": "ENTHUSE M0",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "ZD4054"
            },
            {
              "-type": "Drug",
              "#text": "Palcebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Progression Free Survival",
            "Health Related Quality of Life",
            "Time to Prostate-specific Antigen (PSA) Progression",
            "Time to Symptomatic Progression"
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "2577",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "D4320C00015" },
        "start_date": "January 2008",
        "primary_completion_date": "January 2011",
        "completion_date": "May 2011",
        "study_first_posted": "February 29, 2008",
        "results_first_posted": "June 1, 2012",
        "last_update_posted": "September 3, 2012",
        "locations": {
          "location": [
            "Research Site, Tucson, Arizona, United States",
            "Research Site, Greenbrae, California, United States",
            "Research Site, Los Angeles, California, United States",
            "Research Site, San Diego, California, United States",
            "Research Site, San Francisco, California, United States",
            "Research Site, Denver, Colorado, United States",
            "Research Site, Norwich, Connecticut, United States",
            "Research Site, Washington, District of Columbia, United States",
            "Research Site, Boca Raton, Florida, United States",
            "Research Site, Miami, Florida, United States",
            "Research Site, Ocala, Florida, United States",
            "Research Site, Port St. Lucie, Florida, United States",
            "Research Site, Atlanta, Georgia, United States",
            "Research Site, Macon, Georgia, United States",
            "Research Site, Kansas City, Kansas, United States",
            "Research Site, New Orleans, Louisiana, United States",
            "Research Site, Baltimore, Maryland, United States",
            "Research Site, Rockville, Maryland, United States",
            "Research Site, Minneapolis, Minnesota, United States",
            "Research Site, Lincoln, Nebraska, United States",
            "Research Site, Las Vegas, Nevada, United States",
            "Research Site, Brooklyn, New York, United States",
            "Research Site, Chapel Hill, North Carolina, United States",
            "Research Site, Bismarck, North Dakota, United States",
            "Research Site, Canton, Ohio, United States",
            "Research Site, Cincinnati, Ohio, United States",
            "Research Site, Philadelphia, Pennsylvania, United States",
            "Research Site, Pittsburgh, Pennsylvania, United States",
            "Research Site, Charleston, South Carolina, United States",
            "Research Site, Mystle Beach, South Carolina, United States",
            "Research Site, Raleigh, South Carolina, United States",
            "Research Site, Memphis, Tennessee, United States",
            "Research Site, Nashville, Tennessee, United States",
            "Research Site, San Antonio, Texas, United States",
            "Research Site, Burlington, Vermont, United States",
            "Research Site, Seattle, Washington, United States",
            "Research Site, Wenatchee, Washington, United States",
            "Research Site, Milwaukee, Wisconsin, United States",
            "Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina",
            "Research Site, Rosario, Santa Fe, Argentina",
            "Research Site, Santa Fe, Argentina",
            "Research Site, Darlinghurst, New South Wales, Australia",
            "Research Site, Hornsby, New South Wales, Australia",
            "Research Site, Westmead, New South Wales, Australia",
            "Research Site, Wollongong, New South Wales, Australia",
            "Research Site, Wodonga, Victoria, Australia",
            "Research Site, Nedlands, Western Australia, Australia",
            "Research Site, Sydney, Australia",
            "Research Site, Graz, Austria",
            "Research Site, Innsbruck, Austria",
            "Research Site, Wels, Austria",
            "Research Site, (Wilrijk) Antwerpen, Belgium",
            "Research Site, Brussels, Belgium",
            "Research Site, Edegem, Belgium",
            "Research Site, Gent, Belgium",
            "Research Site, Kortrijk, Belgium",
            "Research Site, Leuven, Belgium",
            "Research Site, Liege, Belgium",
            "Research Site, Goiania, Goias, Brazil",
            "Research Site, Belo Horizonte, Minas Gerais, Brazil",
            "Research Site, Curitiba, Parana, Brazil",
            "Research Site, Londrina, PR, Brazil",
            "Research Site, Porto Alegre, Rio Grande do Sul, Brazil",
            "Research Site, Rio de Janeiro, RJ, Brazil",
            "Research Site, Santo Andre, Sao Paulo, Brazil",
            "Research Site, Sao Paulo, Brazil",
            "Research Site, Calgary, Alberta, Canada",
            "Research Site, Edmonton, Alberta, Canada",
            "Research Site, Vancouver, British Columbia, Canada",
            "Research Site, Victoria, British Columbia, Canada",
            "Research Site, Winnipeg, Manitoba, Canada",
            "Research Site, Burlington, Ontario, Canada",
            "Research Site, Hamilton, Ontario, Canada",
            "Research Site, Kingston, Ontario, Canada",
            "Research Site, Kitchener, Ontario, Canada",
            "Research Site, London, Ontario, Canada",
            "Research Site, North York, Ontario, Canada",
            "Research Site, Oakville, Ontario, Canada",
            "Research Site, Toronto, Ontario, Canada",
            "Research Site, Greenfeild Park, Quebec, Canada",
            "Research Site, Montreal, Quebec, Canada",
            "Research Site, Point-Claire, Quebec, Canada",
            "Research Site, Quebec City, Quebec, Canada",
            "Research Site, Sherbrooke, Quebec, Canada",
            "Research Site, La Serena, Chile",
            "Research Site, Santiago, Chile",
            "Research Site, Temuco, Chile",
            "Research Site, Vina del Mar, Chile",
            "Research Site, Nanjing, Jiangsu, China",
            "Research Site, Hangzhou, Zhejiang, China",
            "Research Site, Beijing, China",
            "Research Site, Chongqing, China",
            "Research Site, Guangzhou City, China",
            "Research Site, Hubei, China",
            "Research Site, Jiangsu, China",
            "Research Site, Shanghai, China",
            "Research Site, Shanxi, China",
            "Research Site, Tianjin, China",
            "Research Site, Zejiang, China",
            "Research Site, Bogota, Colombia",
            "Research Site, Medellin, Colombia",
            "Research Site, Brno, Czech Republic",
            "Research Site, Hradec Kralove, Czech Republic",
            "Research Site, Jablonec nad Nisou, Czech Republic",
            "Research Site, Kromeriz, Czech Republic",
            "Research Site, Olomouc, Czech Republic",
            "Research Site, Prague 2, Czech Republic",
            "Research Site, Prague 4, Czech Republic",
            "Research Site, Prague 6, Czech Republic",
            "Research Site, Praha, Czech Republic",
            "Research Site, Usti nad Labem, Czech Republic",
            "Research Site, Aalborg, Denmark",
            "Research Site, Frederiksberg, Denmark",
            "Research Site, Herlev, Denmark",
            "Research Site, Holstebro, Denmark",
            "Research Site, Kobenhavn, Denmark",
            "Research Site, Odense, Denmark",
            "Research Site, Roskilde, Denmark",
            "Research Site, Helsinki, Finland",
            "Research Site, Joensuu, Finland",
            "Research Site, Oulu, Finland",
            "Research Site, Seinajoki, Finland",
            "Research Site, Tampere, Finland",
            "Research Site, Caen cedex, France",
            "Research Site, Creteil, France",
            "Research Site, Lille, France",
            "Research Site, Lyon cedex 03, France",
            "Research Site, Lyon, France",
            "Research Site, Marseille, France",
            "Research Site, Montpellier, France",
            "Research Site, Orleans Cedex, France",
            "Research Site, Paris, France",
            "Research Site, Pierre Benite cedex, France",
            "Research Site, Poitiers Cedex, France",
            "Research Site, Reims cedex, France",
            "Research Site, Reims, France",
            "Research Site, Rennes cedex 9, France",
            "Research Site, Rouen, France",
            "Research Site, Suresnes, France",
            "Research Site, Toulouse, France",
            "Research Site, Vandoeuvre-les-Nancy cedex, France",
            "Research Site, Villejuif, France",
            "Research Site, Augsburg, Germany",
            "Research Site, Bad Ems, Germany",
            "Research Site, Berlin, Germany",
            "Research Site, Bonn, Germany",
            "Research Site, Borken, Germany",
            "Research Site, Chemnitz, Germany",
            "Research Site, Emmendingen, Germany",
            "Research Site, Fuerth, Germany",
            "Research Site, Gelsenkirchen-Buer, Germany",
            "Research Site, Germering, Germany",
            "Research Site, Goettingen, Germany",
            "Research Site, Holzminden, Germany",
            "Research Site, Kirchheim/Teck, Germany",
            "Research Site, Leipzig, Germany",
            "Research Site, Lubeck, Germany",
            "Research Site, Mannheim, Germany",
            "Research Site, Muehlacker, Germany",
            "Research Site, Muehlheim an der Ruhr, Germany",
            "Research Site, Muenchen-Planegg, Germany",
            "Research Site, Muenchen, Germany",
            "Research Site, Muenster, Germany",
            "Research Site, Reutlingen, Germany",
            "Research Site, Rostock, Germany",
            "Research Site, Tuebingen, Germany",
            "Research Site, Waltshut-Tiengen, Germany",
            "Research Site, Wuppertal, Germany",
            "Research Site, Budapest, Hungary",
            "Research Site, Debrecen, Hungary",
            "Research Site, Gyor, Hungary",
            "Research Site, Miskolc, Hungary",
            "Research Site, Nyiregyhaza, Hungary",
            "Research Site, Szeged, Hungary",
            "Research Site, Szekesfehervar, Hungary",
            "Research Site, Ahmedabad, Gujarat, India",
            "Research Site, Nadiad, Gujarat, India",
            "Research Site, Kochi, Kerala, India",
            "Research Site, Pune, Maharashtra, India",
            "Research Site, Chennai, Tamil Nadu, India, India",
            "Research Site, Lucknow, Uttar Pradesh, India",
            "Research Site, Kolkota, West Bengal, India",
            "Research Site, New Delhi, India",
            "Research Site, Dublin 7, Ireland",
            "Research Site, Dublin 8, Ireland",
            "Research Site, Dublin, Ireland",
            "Research Site, Be'er Sheva, Israel",
            "Research Site, Be'er-Ya'akov, Israel",
            "Research Site, Haifa, Israel",
            "Research Site, Holon, Israel",
            "Research Site, Jeruslaem, Israel",
            "Research Site, Petah-Tikva, Israel",
            "Research Site, Tel-HaShomer - Ramat Gan, Israel",
            "Research Site, Ancona, Italy",
            "Research Site, Bari, Italy",
            "Research Site, Bergamo, Italy",
            "Research Site, Bologna, Italy",
            "Research Site, Catania, Italy",
            "Research Site, Como, Italy",
            "Research Site, Firenze, Italy",
            "Research Site, Genova, Italy",
            "Research Site, Messina, Italy",
            "Research Site, Milano, Italy",
            "Research Site, Pisa, Italy",
            "Research Site, Rome, Italy",
            "Research Site, Terni, Italy",
            "Research Site, Varese, Italy",
            "Research Site, Hirosaki-City, Aomori, Japan",
            "Research Site, Chiba-City, Chiba, Japan",
            "Research Site, Narashino-city, Chiba, Japan",
            "Research Site, Matsuyama-City, Ehime, Japan",
            "Research Site, Fukuoka-City, Fukuoka, Japan",
            "Research Site, Maebashi-City, Gunma, Japan",
            "Research Site, Otake-City, Hiroshima, Japan",
            "Research Site, Sapporo-City, Hokkaido, Japan",
            "Research Site, Kobe-City, Hyogo, Japan",
            "Research Site, Ibaraki-machi, Ibaraki, Japan",
            "Research Site, Mito-City, Ibaraki, Japan",
            "Research Site, Tsukuba-City, Ibaraki, Japan",
            "Research Site, Kita-gun, Kagawa, Japan",
            "Research Site, Sagamihara-City, Kanagawa, Japan",
            "Research Site, Kamigyo-ku, Kyoto, Japan",
            "Research Site, Kyoto-City, Kyoto, Japan",
            "Research Site, Sendai-City, Miyagi, Japan",
            "Research Site, Ueda-City, Nagano, Japan",
            "Research Site, Kashihara, Nara, Japan",
            "Research Site, Oita-City, Oita, Japan",
            "Research Site, Kurashiki, Okayama, Japan",
            "Research Site, Osaka-City, Osaka, Japan",
            "Research Site, Osaka-Sayama-City, Osaka, Japan",
            "Research Site, Suita-City, Osaka, Japan",
            "Research Site, Wako-City, Saitama, Japan",
            "Research Site, Hamamatsu-city, Shizuoka, Japan",
            "Research Site, Sunto-gun, Shizuoka, Japan",
            "Research Site, Bunkyo-ku, Tokyo, Japan",
            "Research Site, Fuchu_city, Tokyo, Japan",
            "Research Site, Itabashi-Ku, Tokyo, Japan",
            "Research Site, Meguro-ku, Tokyo, Japan",
            "Research Site, Minato-Ku, Tokyo, Japan",
            "Research Site, Mitaka-City, Tokyo, Japan",
            "Research Site, Shinjuku-ku, Tokyo, Japan",
            "Research Site, Kyoto, Japan",
            "Research Site, Nagasaki, Japan",
            "Research Site, Bundang-Gu, Seongnam-si, Gyeonggi-do, Korea, Republic of",
            "Research Site, Seo-gu, Pusan, Korea, Republic of",
            "Research Site, Gangnam-gu, Seoul, Korea, Republic of",
            "Research Site, Seodaemun-gu, Seoul, Korea, Republic of",
            "Research Site, Seongbuk-gu, Seoul, Korea, Republic of",
            "Research Site, Songpa-gu, Seoul, Korea, Republic of",
            "Research Site, Liepaja, Latvia",
            "Research Site, Riga, Latvia",
            "Research Site, Distrito Federal, Ciudad de Mexico, Mexico",
            "Research Site, Mexico DF, Distrito Federal, Mexico",
            "Research Site, Amsterdam, Netherlands",
            "Research Site, Arnhem, Netherlands",
            "Research Site, Eindhoven, Netherlands",
            "Research Site, Hertogenbosch, Netherlands",
            "Research Site, Nijmegen, Netherlands",
            "Research Site, Rotterdam, Netherlands",
            "Research Site, Tilburg, Netherlands",
            "Research Site, Tonsberg, Norway",
            "Research Site, Trondheim, Norway",
            "Research Site, Arequipa, Peru",
            "Research Site, Bellavista, Peru",
            "Research Site, Jesus Maria, Peru",
            "Research Site, Lima, Peru",
            "Research Site, Gdynia, Poland",
            "Research Site, Kielce, Poland",
            "Research Site, Koscierzyna, Poland",
            "Research Site, Szczecin, Poland",
            "Research Site, Warszawa, Poland",
            "Research Site, Wroclaw, Poland",
            "Research Site, Coimbra, Portugal",
            "Research Site, Porto, Portugal",
            "Research Site, Timisoara, Timis, Romania",
            "Research Site, Bucuresti, Romania",
            "Research Site, Cluj-Napoca, Romania",
            "Research Site, Omsk, Omsk region, Russian Federation",
            "Research Site, Izhevsk, Russia, Russian Federation",
            "Research Site, Tomsk, Tomsk Region, Russian Federation",
            "Research Site, Barnaul, Russian Federation",
            "Research Site, Kursk, Russian Federation",
            "Research Site, Moscow, Russian Federation",
            "Research Site, Sochi, Russian Federation",
            "Research Site, St.Petersburg, Russian Federation",
            "Research Site, Voronezh, Russian Federation",
            "Research Site, Belgrade, Serbia",
            "Research Site, Nis, Serbia",
            "Research Site, Novi Sad, Serbia",
            "Research Site, Observatory, Cape Town, South Africa",
            "Research Site, Tygerberg, Cape Town, South Africa",
            "Research Site, Overport, Durban, South Africa",
            "Research Site, Parktown, Johannesburg, South Africa",
            "Research Site, Pietermaritzburg, South Africa",
            "Research Site, Pretoria, South Africa",
            "Research Site, Elche, Alicante, Spain",
            "Research Site, Barakaldo, Bizkaia, Spain",
            "Research Site, Bilbao, Vizcaya, Spain",
            "Research Site, A Corunna, Spain",
            "Research Site, Barcelona, Spain",
            "Research Site, Madrid, Spain",
            "Research Site, Sevilla, Spain",
            "Research Site, Valencia, Spain",
            "Research Site, Gothenburg, Sweden",
            "Research Site, Helsingborg, Sweden",
            "Research Site, Jonkoping, Sweden",
            "Research Site, Orebro, Sweden",
            "Research Site, Stockholm, Sweden",
            "Research Site, Uppsala, Sweden",
            "Research Site, Aarau, Switzerland",
            "Research Site, CH-4031 Basel, Switzerland",
            "Research Site, Locarno, Switzerland",
            "Research Site, Zuerich, Switzerland",
            "Research Site, Taipei, Taiwan",
            "Research Site, Ankara, Turkey",
            "Research Site, Istanbul, Turkey",
            "Research Site, Izmir, Turkey",
            "Research Site, Reading, Berkshire, United Kingdom",
            "Research Site, Cottingham, East Yorkshire, United Kingdom",
            "Research Site, Stevenage, Hertfordshire, United Kingdom",
            "Research Site, Maidstone, Kent, United Kingdom",
            "Research Site, Guildford, Surrey, United Kingdom",
            "Research Site, Cambridge, United Kingdom",
            "Research Site, Coventry, United Kingdom",
            "Research Site, Glasgow, United Kingdom",
            "Research Site, Huddersfield, United Kingdom",
            "Research Site, Liverpool, United Kingdom",
            "Research Site, London, United Kingdom",
            "Research Site, Manchester, United Kingdom",
            "Research Site, Newcastle upon Tyne, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00626548"
      },
      {
        "-rank": "156",
        "nct_id": "NCT00887198",
        "title": "Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Radiographic Progression-free Survival (rPFS)",
            "Time to Opiate Use for Prostate Cancer Pain",
            "Time to Initiation of Cytotoxic Chemotherapy",
            "Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point",
            "Time to Prostate-specific Antigen (PSA) Progression",
            "Number of Participants With Treatment Emergent Adverse Events",
            "Mean Plasma Concentrations of Abiraterone",
            "Maximum Plasma Concentrations of Abiraterone",
            "Area Under the Plasma Concentration-time Curve From Time 0 to Time the Last Quantifiable Concentration of Abiraterone (AUC[0-infinity])",
            "Elimination Half-Life (t1/2)"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Research & Development, LLC" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1088",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR016927",
            "COU-AA-302",
            "2008-008004-41"
          ]
        },
        "start_date": "April 28, 2009",
        "primary_completion_date": "March 31, 2014",
        "completion_date": "May 25, 2017",
        "study_first_posted": "April 23, 2009",
        "results_first_posted": "April 9, 2015",
        "last_update_posted": "June 25, 2018",
        "locations": {
          "location": [
            "Birmingham, Alabama, United States",
            "Tucson, Arizona, United States",
            "Bellflower, California, United States",
            "Los Angeles, California, United States",
            "Marina Del Rey, California, United States",
            "Sacramento, California, United States",
            "San Diego, California, United States",
            "San Francisco, California, United States",
            "Stanford, California, United States",
            "Aurora, Colorado, United States",
            "New Haven, Connecticut, United States",
            "Boca Raton, Florida, United States",
            "Fort Myers, Florida, United States",
            "Gainesville, Florida, United States",
            "Atlanta, Georgia, United States",
            "Honolulu, Hawaii, United States",
            "Kansas City, Kansas, United States",
            "Metairie, Louisiana, United States",
            "New Orleans, Louisiana, United States",
            "Baltimore, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Dearborn, Michigan, United States",
            "Saint Louis Park, Minnesota, United States",
            "Saint Louis, Missouri, United States",
            "Billings, Montana, United States",
            "Omaha, Nebraska, United States",
            "Las Vegas, Nevada, United States",
            "East Syracuse, New York, United States",
            "New Hyde Park, New York, United States",
            "New York, New York, United States",
            "Syracuse, New York, United States",
            "Durham, North Carolina, United States",
            "Raleigh, North Carolina, United States",
            "Canton, Ohio, United States",
            "Cleveland, Ohio, United States",
            "Portland, Oregon, United States",
            "Philadelphia, Pennsylvania, United States",
            "Pittsburgh, Pennsylvania, United States",
            "Columbia, South Carolina, United States",
            "Myrtle Beach, South Carolina, United States",
            "Chattanooga, Tennessee, United States",
            "Nashville, Tennessee, United States",
            "Dallas, Texas, United States",
            "Houston, Texas, United States",
            "San Antonio, Texas, United States",
            "Norfolk, Virginia, United States",
            "Seattle, Washington, United States",
            "Madison, Wisconsin, United States",
            "Adelaide, Australia",
            "Camperdown, Australia",
            "Footscray, Australia",
            "Frankston, Australia",
            "Garran, Australia",
            "Geelong, Australia",
            "Heidelberg, Australia",
            "Herston, Australia",
            "Hornsby, Australia",
            "Kogarah, Australia",
            "Kurralta Park, Australia",
            "Lismore, Australia",
            "Liverpool, Australia",
            "Malvern, Australia",
            "Parkville, Australia",
            "Perth, Australia",
            "South Brisbane, Australia",
            "Southport, Australia",
            "Subiaco, Australia",
            "Aalst, Belgium",
            "Antwerpen, Belgium",
            "Gent, Belgium",
            "Hasselt, Belgium",
            "Leuven Belgie, Belgium",
            "Roeselare, Belgium",
            "Calgary, Alberta, Canada",
            "Edmonton, Alberta, Canada",
            "Kelowna, British Columbia, Canada",
            "Vancouver, British Columbia, Canada",
            "Victoria, British Columbia, Canada",
            "Hamilton, Ontario, Canada",
            "London, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Montreal, Quebec, Canada",
            "London, Canada",
            "Quebec, Canada",
            "Caen, France",
            "Clichy, France",
            "Dijon Cedex, France",
            "La Roche Sur Yon, France",
            "Lyon Cedex 03, France",
            "Lyon, France",
            "Montpellier, France",
            "Paris Cedex 15, France",
            "Tours, Cedex 9, France",
            "Villejuif, France",
            "Aachen, Germany",
            "Berlin, Germany",
            "Braunschweig, Germany",
            "Dresden, Germany",
            "DÃ¼sseldorf, Germany",
            "Hamburg, Germany",
            "Hannover, Germany",
            "Homburg, Germany",
            "Kempen, Germany",
            "Leipzig, Germany",
            "Muenchen, Germany",
            "MÃ¼nster, Germany",
            "Wuppertal, Germany",
            "Athens, Greece",
            "Larisa, Greece",
            "Amsterdam, Netherlands",
            "Heerlen, Netherlands",
            "Nijmegen, Netherlands",
            "Rotterdam, Netherlands",
            "Barcelona, Spain",
            "CoruÃ±a, Spain",
            "Madrid, Spain",
            "Oviedo, Spain",
            "Santander N/A, Spain",
            "Santiago De Compostela, Spain",
            "GÃ¶teborg, Sweden",
            "MalmÃ¶ N/A, Sweden",
            "Stockholm, Sweden",
            "Uppsala, Sweden",
            "VÃ¤xjÃ¶, Sweden",
            "Birmingham, United Kingdom",
            "Cambridge, United Kingdom",
            "Glasgow, United Kingdom",
            "Leeds, United Kingdom",
            "London, United Kingdom",
            "Manchester, United Kingdom",
            "Newcastle Upon Tyne, United Kingdom",
            "Oxford, United Kingdom",
            "Sutton, United Kingdom",
            "Whitchurch, United Kingdom",
            "Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00887198"
      },
      {
        "-rank": "157",
        "nct_id": "NCT03085095",
        "title": "A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer",
        "acronym": "HERO",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Relugolix"
            },
            {
              "-type": "Drug",
              "#text": "Leuprolide Acetate"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Sustained Castration Rate",
            "Castration Rate by Visit",
            "Profound Castration Rate",
            "Prostate-specific antigen (PSA) response rate by PCWG3 criteria",
            "PSA response rate",
            "Time to PSA progression",
            "Quality of life (QoL) total score and each subdomain score",
            "Time to castration resistance",
            "Composite of safety as measure of safety and tolerability",
            "Pharmacokinetics of relugolix",
            "Serum concentrations of luteinizing hormone, follicle-stimulating hormone, dihydrotestosterone, sex hormone binding globulin",
            "Testosterone recovery"
          ]
        },
        "sponsors": { "lead_sponsor": "Myovant Sciences GmbH" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1100",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "MVT-601-3201",
            "2017-000160-15"
          ]
        },
        "start_date": "April 18, 2017",
        "primary_completion_date": "December 15, 2019",
        "completion_date": "July 31, 2020",
        "study_first_posted": "March 21, 2017",
        "last_update_posted": "September 5, 2019",
        "locations": {
          "location": [
            "Homewood, Homewood, Alabama, United States",
            "Anchorage, Anchorage, Alaska, United States",
            "Tucson, Tucson, Arizona, United States",
            "Orange, Orange, California, United States",
            "San Diego, San Diego, California, United States",
            "Denver, Denver, Colorado, United States",
            "Pompano Beach, Pompano Beach, Florida, United States",
            "Jeffersonville, Jeffersonville, Indiana, United States",
            "Des Moines, Des Moines, Iowa, United States",
            "Wichita, Wichita, Kansas, United States",
            "Towson, Towson, Maryland, United States",
            "Troy, Troy, Michigan, United States",
            "Omaha, Omaha, Nebraska, United States",
            "Las Vegas, Las Vegas, Nevada, United States",
            "Brick, Brick, New Jersey, United States",
            "Lawrenceville, Lawrenceville, New Jersey, United States",
            "Albuquerque, Albuquerque, New Mexico, United States",
            "Albany, Albany, New York, United States",
            "Brooklyn, Brooklyn, New York, United States",
            "Garden City, Garden City, New York, United States",
            "New York, New York, New York, United States",
            "Plainview, Plainview, New York, United States",
            "Poughkeepsie, Poughkeepsie, New York, United States",
            "Syracuse, Syracuse, New York, United States",
            "Durham, Durham, North Carolina, United States",
            "Greensboro, Greensboro, North Carolina, United States",
            "Winston-Salem, Winston-Salem, North Carolina, United States",
            "Cincinnati, Cincinnati, Ohio, United States",
            "MiddleBurg Heights, Middleburg Heights, Ohio, United States",
            "Toledo, Toledo, Ohio, United States",
            "Oklahoma City, Oklahoma City, Oklahoma, United States",
            "Lancaster, Lancaster, Pennsylvania, United States",
            "Myrtle Beach, Myrtle Beach, South Carolina, United States",
            "Nashville, Nashville, Tennessee, United States",
            "Dallas, Dallas, Texas, United States",
            "San Antonio, San Antonio, Texas, United States",
            "Virginia Beach, Virginia Beach, Virginia, United States",
            "Camperdown, Camperdown, New South Wales, Australia",
            "Darlinghurst, Darlinghurst, New South Wales, Australia",
            "Tweed Heads, Tweed Heads, New South Wales, Australia",
            "Wahroonga, Wahroonga, New South Wales, Australia",
            "Westmead, Westmead, New South Wales, Australia",
            "Cairns, Cairns, Queensland, Australia",
            "Redcliffe, Redcliffe, Queensland, Australia",
            "Geelong, Geelong, Victoria, Australia",
            "Herston, Herston, Australia",
            "Linz, Linz, Austria",
            "Salzburg, Salzburg, Austria",
            "Edegem, Edegem, Antwerpen, Belgium",
            "Gent, Gent, Oost-Vlaanderen, Belgium",
            "Leuven, Leuven, Vlaams Brabant, Belgium",
            "Brussels, Brussels, Belgium",
            "Kortrijk, Kortrijk, Belgium",
            "Itabuna, Itabuna, Bahia, Brazil",
            "Salvador, Salvador, Bahia, Brazil",
            "Salvador, Salvador, Bahia, Brazil",
            "Curitiba, Curitiba, ParanÃ¡, Brazil",
            "Teresina, Teresina, PiauÃ­, Brazil",
            "Natal, Natal, Rio Grande Do Norte, Brazil",
            "IjuÃ­, IjuÃ­, Rio Grande Do Sul, Brazil",
            "Passo Fundo, Passo Fundo, Rio Grande Do Sul, Brazil",
            "Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",
            "Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",
            "Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",
            "Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",
            "Joinville, Joinville, Santa Catarina, Brazil",
            "SÃ£o JosÃ© Do Rio Preto, SÃ£o JosÃ© Do Rio Preto, Sao Paulo, Brazil",
            "SÃ£o Paulo, SÃ£o Paulo, Brazil",
            "Calgary, Calgary, Alberta, Canada",
            "Vancouver, Vancouver, British Columbia, Canada",
            "Halifax, Halifax, Nova Scotia, Canada",
            "Hamilton, Hamilton, Ontario, Canada",
            "London, London, Ontario, Canada",
            "Montreal, MontrÃ©al, Quebec, Canada",
            "Sherbrooke, Sherbrooke, Quebec, Canada",
            "Toronto, Toronto, Quebec, Canada",
            "Quebec, Quebec, Canada",
            "Nanjing, Nanjing, Jiangsu, China",
            "Changchun, Chang chun, Jilin, China",
            "Shanghai, Shanghai, Shanghai, China",
            "Taiyuan, Taiyuan, Shanxi, China",
            "Beijing, Beijing, China",
            "Chongqing, Chongqing, China",
            "Shanghai, Shanghai, China",
            "Alborg, Aalborg, Nordjylland, Denmark",
            "Aarhus, Aarhus, Denmark",
            "Copenhagen, Copenhagen, Denmark",
            "Herlev, Herlev, Denmark",
            "Vejle, Vejle, Denmark",
            "Helsinki, Helsinki, Finland",
            "Seinajoki, SeinÃ¤joki, Finland",
            "Tampere, Tampere, Finland",
            "Turku, Turku, Finland",
            "Strasbourg, Strasbourg, Bas-Rhin, France",
            "Marseille, Marseille, Bouches-du-RhÃ´ne, France",
            "Lille, Lille, Nord, France",
            "Pierre Benite, Pierre-BÃ©nite, Rhone, France",
            "Creteil, CrÃ©teil, Val De Marne, France",
            "Creteil, CrÃ©teil, Val-de-Marne, France",
            "Hyeres, HyÃ¨res, France",
            "Lyon, Lyon, France",
            "Nimes, NÃ®mes, France",
            "Poitiers, Poitiers, France",
            "Emmendingen, Emmendingen, Baden-Wurttemberg, Germany",
            "Planegg, Planegg, Bayern, Germany",
            "Braunschweig, Braunschweig, Niedersachsen, Germany",
            "Braunschweig, Braunschweig, Niedersachsen, Germany",
            "Dresden, Dresden, Germany",
            "Hamburg, Hamburg, Germany",
            "Lubeck, LÃ¼beck, Germany",
            "Munster, MÃ¼nster, Germany",
            "Meldola, Meldola, Emilia-Romagna, Italy",
            "Rome, Rome, Lazio, Italy",
            "Cremona, Cremona, Lombardia, Italy",
            "Candiolo, Candiolo, Piemonte, Italy",
            "Orbassano, Orbassano, Piemonte, Italy",
            "Arezzo, Arezzo, Toscana, Italy",
            "Milano, Milano, Italy",
            "Pavia, Pavia, Italy",
            "Kanazawa-shi, Kanazawa-shi, Isikawa, Japan",
            "Sendai, Sendai, Miyagi, Japan",
            "Sendai, Sendai, Miyagi, Japan",
            "Suita, Suita, Osaka, Japan",
            "Osaka-sayama City, ÅŒsaka-sayama, Osaka, Japan",
            "Fukuoka, Fukuoka, Japan",
            "Hiroshima, Hiroshima, Japan",
            "Hiroshima, Hiroshima, Japan",
            "Kita-gun, Kita, Japan",
            "Kyoto, Kyoto, Japan",
            "Maebashi-shi, Maebashi, Japan",
            "Nagasaki-shi, Nagasaki, Japan",
            "Osaka, Osaka, Japan",
            "Sapporo, Sapporo, Japan",
            "Tokyo, Tokyo, Japan",
            "Tokyo, Tokyo, Japan",
            "Ube-shi, Ube, Japan",
            "Yokohama City, Yokohama, Japan",
            "ÅŒsaka-sayama, ÅŒsaka-sayama, Ã”saka, Japan",
            "Goyang-Si, Goyang-si, Gyeonggido, Korea, Republic of",
            "Busan, Busan, Korea, Republic of",
            "Hwasun-gun, Hwasun, Korea, Republic of",
            "Hwasun-gun, Hwasun, Korea, Republic of",
            "Seongnam, Seongnam, Korea, Republic of",
            "Seoul, Seoul, Korea, Republic of",
            "Seoul, Seoul, Korea, Republic of",
            "Seoul, Seoul, Korea, Republic of",
            "Seoul, Seoul, Korea, Republic of",
            "Seoul, Seoul, Korea, Republic of",
            "Eindhoven, Eindhoven, Noord Brabant, Netherlands",
            "Amsterdam, Amsterdam, Noord Holland, Netherlands",
            "Maastricht, Maastricht, Netherlands",
            "Sneek, Sneek, Netherlands",
            "Hamilton, Hamilton, Northland, New Zealand",
            "Dunedin, Dunedin, South Island, New Zealand",
            "Canterbury, Christchurch, New Zealand",
            "Tauranga, Tauranga, New Zealand",
            "Wroclaw, WrocÅ‚aw, Dolnoslaskie, Poland",
            "Gdynia, Gdynia, Lubelskie, Poland",
            "Lublin, Lublin, Lubelskie, Poland",
            "Siedlce, Siedlce, Mazowieckie, Poland",
            "Warszawa, Warszawa, Mazowieckie, Poland",
            "Gdynia, Gdynia, Poland",
            "Gdynia, Gdynia, Poland",
            "Katowice, Katowice, Poland",
            "Bratislava, Bratislava, Slovakia",
            "Kosice, KoÅ¡ice, Slovakia",
            "Martin, Martin, Slovakia",
            "Nitra, Nitra, Slovakia",
            "Poprad, Poprad, Slovakia",
            "Presov, PreÅ¡ov, Slovakia",
            "Trencin, TrenÄÃ­n, Slovakia",
            "Sula, Å ula, Slovakia",
            "A Coruna, A CoruÃ±a, A Coruna, Spain",
            "Oviedo, Oviedo, Asturias, Spain",
            "Barcelona, Barcelona, Spain",
            "Barcelona, Barcelona, Spain",
            "Madrid, Madrid, Spain",
            "Madrid, Madrid, Spain",
            "Sabadell, Sabadell, Spain",
            "Salamanca, Salamanca, Spain",
            "Santiago de Compostela, Santiago de Compostela, Spain",
            "Valencia, Valencia, Spain",
            "Orebro, Ã–rebro, Orebro Ian, Sweden",
            "Malmo, MalmÃ¶, Skane Ian, Sweden",
            "Stockholm, Stockholm, Sodermandlands Ian, Sweden",
            "Stockholm, Stockholm, Sodermanlands Ian, Sweden",
            "Uppsala, Uppsala, Sweden",
            "Kaohsiung, Kaohsiung, Taiwan",
            "Taipei, Taipei, Taiwan",
            "Taipei, Taipei, Taiwan",
            "Taipei, Taipei, Taiwan",
            "Wirral, Wirral, Cheshire, United Kingdom",
            "Glasgow, Glasgow, Glasgow City, United Kingdom",
            "Scunthorpe, Scunthorpe, North Lincolnshire, United Kingdom",
            "Aberdeen, Aberdeen, United Kingdom",
            "Nottingham, Nottingham, United Kingdom",
            "Plymouth, Plymouth, United Kingdom",
            "Wrexham, Wrexham, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03085095"
      },
      {
        "-rank": "158",
        "nct_id": "NCT02495974",
        "title": "European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)",
        "acronym": "PREMISE",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration Resistant Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "enzalutamide"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Time to treatment failure (TTF)",
            "Time to prostate specific antigen (PSA) progression",
            "PSA response",
            "Time to disease progression",
            "Overall Survival (France only)",
            "Treatment duration",
            "Reason for initiation of treatment with enzalutamide",
            "Reason for enzalutamide discontinuation",
            "Subsequent anti-neoplastic therapy for mCRPC",
            "Time to opiate use",
            "Pain assessed by Brief Pain Inventory Short Form (BPI-SF)",
            "Quality of life of participants assessed using EQ-5D-5L",
            "Quality of life of participants assessed using FACT-P",
            "Number of participants hospitalized",
            "Number of visits to health care professionals",
            "Safety assessed by reported adverse events",
            "Safety assessed by modification of treatment with enzalutamide as a response to adverse events",
            "Number of Deaths"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Europe Ltd.",
          "collaborator": [
            "Medivation, Inc.",
            "Astellas Pharma Inc"
          ]
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "1763",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Only",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "9785-MA-1002" },
        "start_date": "September 8, 2015",
        "primary_completion_date": "February 8, 2019",
        "completion_date": "February 8, 2019",
        "study_first_posted": "July 13, 2015",
        "last_update_posted": "May 1, 2019",
        "locations": {
          "location": [
            "Site AT43001, Bregenz, Austria",
            "Site AT43005, Innsbruck, Austria",
            "Site AT43006, Linz, Austria",
            "Site AT43004, Wien, Austria",
            "Site BL32003, Bonheiden, Antwerpen, Belgium",
            "Site BL32004, Brasschaat, Antwerpen, Belgium",
            "Site BL32007, Haine-Saint-Paul, Hainaut, Belgium",
            "Site BL32008, Aalst, Oost-Vlaanderen, Belgium",
            "Site BL32009, Gent, Oost-Vlaanderen, Belgium",
            "Site BL32010, Sint-Niklaas, Oost-Vlaanderen, Belgium",
            "Site BL32013, Leuven, Vlaams Brabant, Belgium",
            "Site BL32005, Kortrijk, West-Vlaanderen, Belgium",
            "Site BL32001, Brussels, Belgium",
            "Site BL32011, Bruxelles, Belgium",
            "Site BL32012, Hasselt, Belgium",
            "Site BG35903, Plovdiv, Bulgaria",
            "Site BG35901, Sofia, Bulgaria",
            "Site CZ42004, Brno, Czechia",
            "Site CZ42007, Jihlava, Czechia",
            "Site CZ42003, Novy Jicin, Czechia",
            "Site CZ42001, Praha, Czechia",
            "Site CZ42006, Praha, Czechia",
            "Site DK45003, Aalborg, Denmark",
            "Site DK45004, Aarhus, Denmark",
            "Site DK45002, Copenhagen, Denmark",
            "Site DK45001, Herlev, Denmark",
            "Site FR33015, Colmar, Alsace, France",
            "Site FR33003, Strasbourg, Alsace, France",
            "Site FR33017, Bordeaux, Aquitaine, France",
            "Site FR33051, Bordeaux, Aquitaine, France",
            "Site FR33018, Bordeaux, Aquitaine, France",
            "Site FR33022, Clermont Ferrand, Auvergne, France",
            "Site FR33006, Aix en Provence, Bouches-du-RhÃ´ne, France",
            "Site FR33027, Marseille, Bouches-du-RhÃ´ne, France",
            "Site FR33041, Marseille, Bouches-du-RhÃ´ne, France",
            "Site FR33069, Saint-Martin-Boulogne, Boulogne-sur-Mer, France",
            "Site FR33043, Sens, Bourgogne, France",
            "Site FR33026, Brest Cedex 2, Bretagne, France",
            "Site FR33004, Saint GrÃ©goire, Bretagne, France",
            "Site FR33025, Vannes, Bretagne, France",
            "Site FR33010, Reims Cedex, Champagne-Ardenne, France",
            "Site FR33067, Dijon, CÃ´te-d'Or, France",
            "Site FR33062, Longjumeau, Essonne, France",
            "Site FR33033, Evreux, Eure, France",
            "Site FR33002, Quimper, FinistÃ¨re, France",
            "Site FR33040, Toulouse, Haute-Garonne, France",
            "Site FR33049, Gap, Hautes-Alpes, France",
            "Site FR33042, Suresnes, Hauts-de-Seine, France",
            "Site FR33020, Tours, Indre-et-Loire, France",
            "Site FR33060, Grenoble, IsÃ¨re, France",
            "Site FR33050, BÃ©zier, Languedoc-Roussillon, France",
            "Site FR33066, OrlÃ©ans, Loiret, France",
            "Site FR33016, Saint-Priest-en-Jarez, Loire, France",
            "Site FR33061, VandÅ“uvre-lÃ¨s-Nancy, Lorraine, France",
            "Site FR33065, Agen, Lot-et-Garonne, France",
            "Site FR33019, Angers, Maine-et-Loire, France",
            "Site FR33007, Nancy, Meurthe-et-Moselle, France",
            "Site FR33059, Albi, Midi-PyrÃ©nÃ©es, France",
            "Site FR33039, Lille, Nord-Pas-de-Calais, France",
            "Site FR33021, Coudekerque-Branche Cedex, Nord, France",
            "Site FR33063, Beauvais, Oise, France",
            "Site FR33070, Amiens, Picardie, France",
            "Site FR33044, Saint Quentin Cedex, Picardie, France",
            "Site FR33028, Clermont Ferrand Cedex 1, Puy-de-DÃ´me, France",
            "Site FR33035, Bayonne, PyrÃ©nÃ©es-Atlantiques, France",
            "Site FR33009, Valence, RhÃ´ne-Alpes, France",
            "Site FR33012, Lyon Cedex 9, RhÃ´ne, France",
            "Site FR33030, Lyon, RhÃ´ne, France",
            "Site FR33058, Chalon-Sus-Saone, SaÃ´ne-et-Loire, France",
            "Site FR33008, Amiens, Somme, France",
            "Site FR33032, Amiens, Somme, France",
            "Site FR33014, CrÃ©teil, Val-de-Marne, France",
            "Site FR33037, Saint MandÃ©, Val-de-Marne, France",
            "Site FR33011, Toulon, Var, France",
            "Site FR33001, Avignon Cedex 9, Vaucluse, France",
            "Site FR33046, Arras, France",
            "Site FR33054, HyÃ¨res, France",
            "Site FR33038, La ChaussÃ©e-Saint-Victor, France",
            "Site FR33057, Paris, France",
            "Site FR33034, Paris, France",
            "Site FR33029, Paris, France",
            "Site FR33064, Paris, France",
            "Site DE49001, NÃ¼rtingen, Baden-WÃ¼rttemberg, Germany",
            "Site DE49016, Wiesbaden, Hessen, Germany",
            "Site DE49003, LÃ¼neburg, Niedersachsen, Germany",
            "Site DE49011, Soltau, Niedersachsen, Germany",
            "Site DE49013, Bonn, Nordrhein-Westfalen, Germany",
            "Site DE49009, Bernburg, Sachsen-Anhalt, Germany",
            "Site DE49012, Chemnitz, Sachsen, Germany",
            "Site DE49015, Kiel, Schleswig-Holstein, Germany",
            "Site DE49005, KÃ¶ln, Germany",
            "Site DE49006, Rostock, Germany",
            "Site DE49014, Wuppertal, Germany",
            "Site DE49010, WÃ¼rselen, Germany",
            "Site GC30001, Kifisia, Attiki, Greece",
            "Site GC30013, Athens, Greece",
            "Site GC30007, Athens, Greece",
            "Site GC30005, Athens, Greece",
            "Site GC30010, Athens, Greece",
            "Site GC30003, Athens, Greece",
            "Site GC30004, Ioannina, Greece",
            "Site GC30006, Ioannina, Greece",
            "Site GC30012, Larissa, Greece",
            "Site GC30008, Thessaloniki, Greece",
            "Site GC30002, Thessaloniki, Greece",
            "Site GC30011, Thessaloniki, Greece",
            "Site HU36006, Debrecen, HajdÃº-Bihar, Hungary",
            "Site HU36002, Budapest, Hungary",
            "Site HU36001, Budapest, Hungary",
            "Site HU36005, Szeged, Hungary",
            "Site HU36003, Szombathely, Hungary",
            "Site IR35304, Dublin, Ireland",
            "Site IR35302, Dublin, Ireland",
            "Site IR35305, Dublin, Ireland",
            "Site IR35306, Dublin, Ireland",
            "Site IT39001, Meldola, ForlÃ¬, Italy",
            "Site IT39010, Lecco, Lombardia, Italy",
            "Site IT39009, Rozzano, Milano, Italy",
            "Site IT39002, Aviano, Pordenone, Italy",
            "Site IT39013, Candiolo, Torino, Italy",
            "Site IT39011, Mirano, Venezia, Italy",
            "Site IT39005, Bari, Italy",
            "Site IT39012, Catania, Italy",
            "Site IT39006, Firenze, Italy",
            "Site IT39004, Milano, Italy",
            "Site IT39017, Milano, Italy",
            "Site IT39003, Modena, Italy",
            "Site IT39007, Napoli, Italy",
            "Site IT39018, Novara, Italy",
            "Site IT39008, Padova, Italy",
            "Site IT39015, Palermo, Italy",
            "Site IT39014, Pisa, Italy",
            "Site IT39016, Reggio Emilia, Italy",
            "Site NL31006, Arnhem, Netherlands",
            "Site NL31007, Breda, Netherlands",
            "Site NL31003, Den Haag, Netherlands",
            "Site NL31005, Doetinchem, Netherlands",
            "Site NL31008, Helmond, Netherlands",
            "Site NL31001, Hilversum, Netherlands",
            "Site NL31004, Hoofddorp, Netherlands",
            "Site NL31010, Nieuwegein, Netherlands",
            "Site NL31011, Zwolle, Netherlands",
            "Site PT35101, Porto, Portugal",
            "Site SV38501, Ljubljana, Slovenia",
            "Site ES34007, Zaragoza, AragÃ³n, Spain",
            "Site ES34012, Zaragoza, AragÃ³n, Spain",
            "Site ES34008, Guadalajara, Castilla La Mancha, Spain",
            "Site ES34009, Toledo, Castilla La Mancha, Spain",
            "Site ES34013, Barcelona, CataluÃ±a, Spain",
            "Site ES34011, Lleida, CataluÃ±a, Spain",
            "Site ES34010, Reus, CataluÃ±a, Spain",
            "Site ES34004, Badajoz, Extremadura, Spain",
            "Site ES34006, CÃ¡ceres, Extremadura, Spain",
            "Site ES34005, A CoruÃ±a, Galicia, Spain",
            "Site ES34016, Lugo, Galicia, Spain",
            "Site ES34003, Orense, Galicia, Spain",
            "Site ES34001, Santiago de Compostela, Galicia, Spain",
            "Site ES34017, Vigo, Galicia, Spain",
            "Site GB44001, Aberdeen, Aberdeenshire, United Kingdom",
            "Site GB44012, Torquay, Devon, United Kingdom",
            "Site GB44025, Poole, Dorset, United Kingdom",
            "Site GB44026, Blackburn, Lancashire, United Kingdom",
            "Site GB44011, Preston, Lancashire, United Kingdom",
            "Site GB44004, Boston, Lincolnshire, United Kingdom",
            "Site GB44002, Lincoln, Lincolnshire, United Kingdom",
            "Site GB44008, Berkshire, Slough, United Kingdom",
            "Site GB44013, Weston-super-Mare, Somerset, United Kingdom",
            "Site GB44007, Treliske, Truro, United Kingdom",
            "Site GB44009, Swindon, Wiltshire, United Kingdom",
            "Site GB44005, Worcester, Worcestershire, United Kingdom",
            "Site GB44023, Birmingham, United Kingdom",
            "Site GB44010, Brighton, United Kingdom",
            "Site GB44016, Derby, United Kingdom",
            "Site GB44020, Guildford, United Kingdom",
            "Site GB44022, Inverness-shire, United Kingdom",
            "Site GB44024, Leicester, United Kingdom",
            "Site GB44003, London, United Kingdom",
            "Site GB44017, Newcastle upon Tyne, United Kingdom",
            "Site GB44015, Norfolk, United Kingdom",
            "Site GB44006, Reading, United Kingdom",
            "Site GB44014, Taunton, United Kingdom",
            "Site GB44018, Wolverhampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02495974"
      },
      {
        "-rank": "159",
        "nct_id": "NCT02987543",
        "title": "Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration-resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "olaparib"
            },
            {
              "-type": "Drug",
              "#text": "enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "enzalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Change in radiographic progression free survival (rPFS)",
            "Confirmed Objective Response Rate (ORR) by BICR",
            "Time to Pain progression",
            "Overall Survival (OS)",
            "rPFS",
            "AEs/SAEs and Collection of clinical chemistry/hematology parameters"
          ]
        },
        "sponsors": {
          "lead_sponsor": "AstraZeneca",
          "collaborator": [
            "Merck Sharp & Dohme Corp.",
            "Foundation Medicine, Inc.",
            "Myriad Genetics, Inc."
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "130 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "340",
        "funded_bys": {
          "funded_by": [
            "Industry",
            "Other"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "D081DC00007" },
        "start_date": "February 6, 2017",
        "primary_completion_date": "June 4, 2019",
        "completion_date": "February 5, 2021",
        "study_first_posted": "December 9, 2016",
        "last_update_posted": "September 6, 2019",
        "locations": {
          "location": [
            "Research Site, Anchorage, Alaska, United States",
            "Research Site, Tucson, Arizona, United States",
            "Research Site, Tucson, Arizona, United States",
            "Research Site, Duarte, California, United States",
            "Research Site, San Diego, California, United States",
            "Research Site, Santa Barbara, California, United States",
            "Research Site, Washington, District of Columbia, United States",
            "Research Site, Tampa, Florida, United States",
            "Research Site, Atlanta, Georgia, United States",
            "Research Site, Chicago, Illinois, United States",
            "Research Site, Jeffersonville, Indiana, United States",
            "Research Site, New Orleans, Louisiana, United States",
            "Research Site, Baltimore, Maryland, United States",
            "Research Site, Towson, Maryland, United States",
            "Research Site, Omaha, Nebraska, United States",
            "Research Site, Las Vegas, Nevada, United States",
            "Research Site, Albany, New York, United States",
            "Research Site, Bronx, New York, United States",
            "Research Site, Brooklyn, New York, United States",
            "Research Site, Syracuse, New York, United States",
            "Research Site, Durham, North Carolina, United States",
            "Research Site, Salisbury, North Carolina, United States",
            "Research Site, Gahanna, Ohio, United States",
            "Research Site, Oklahoma City, Oklahoma, United States",
            "Research Site, Springfield, Oregon, United States",
            "Research Site, Tualatin, Oregon, United States",
            "Research Site, Charleston, South Carolina, United States",
            "Research Site, Charleston, South Carolina, United States",
            "Research Site, Myrtle Beach, South Carolina, United States",
            "Research Site, Germantown, Tennessee, United States",
            "Research Site, Nashville, Tennessee, United States",
            "Research Site, San Antonio, Texas, United States",
            "Research Site, Salt Lake City, Utah, United States",
            "Research Site, Salt Lake City, Utah, United States",
            "Research Site, Spokane, Washington, United States",
            "Research Site, Wheeling, West Virginia, United States",
            "Research Site, Buenos Aires, Argentina",
            "Research Site, Buenos Aires, Argentina",
            "Research Site, Buenos Aires, Argentina",
            "Research Site, Caba, Argentina",
            "Research Site, La Rioja, Argentina",
            "Research Site, Rosario, Argentina",
            "Research Site, Adelaide, Australia",
            "Research Site, Box Hill, Australia",
            "Research Site, Clayton, Australia",
            "Research Site, Greenslopes, Australia",
            "Research Site, Herston, Australia",
            "Research Site, Macquarie University, Australia",
            "Research Site, Melbourne, Australia",
            "Research Site, Nedlands, Australia",
            "Research Site, Randwick, Australia",
            "Research Site, Waratah, Australia",
            "Research Site, Graz, Austria",
            "Research Site, Linz, Austria",
            "Research Site, Salzburg, Austria",
            "Research Site, Wien, Austria",
            "Research Site, Wien, Austria",
            "Research Site, Barretos, Brazil",
            "Research Site, Belo Horizonte, Brazil",
            "Research Site, Curitiba, Brazil",
            "Research Site, FlorianÃ³polis, Brazil",
            "Research Site, Passo Fundo, Brazil",
            "Research Site, Porto Alegre, Brazil",
            "Research Site, Porto Alegre, Brazil",
            "Research Site, Recife, Brazil",
            "Research Site, Ribeirao Preto, Brazil",
            "Research Site, Rio de Janeiro, Brazil",
            "Research Site, Santo Andre, Brazil",
            "Research Site, SÃ£o JosÃ© do Rio Preto, Brazil",
            "Research Site, SÃ£o Paulo, Brazil",
            "Research Site, SÃ£o Paulo, Brazil",
            "Research Site, Edmonton, Alberta, Canada",
            "Research Site, Kelowna, British Columbia, Canada",
            "Research Site, Vancouver, British Columbia, Canada",
            "Research Site, Hamilton, Ontario, Canada",
            "Research Site, Oakville, Ontario, Canada",
            "Research Site, Toronto, Ontario, Canada",
            "Research Site, Toronto, Ontario, Canada",
            "Research Site, Chicoutimi, Quebec, Canada",
            "Research Site, Montreal, Quebec, Canada",
            "Research Site, Montreal, Quebec, Canada",
            "Research Site, Saskatoon, Saskatchewan, Canada",
            "Research Site, Quebec, Canada",
            "Research Site, Beijing, China",
            "Research Site, Beijing, China",
            "Research Site, Beijing, China",
            "Research Site, Beijing, China",
            "Research Site, Beijing, China",
            "Research Site, Changsha, China",
            "Research Site, Changsha, China",
            "Research Site, Chengdu, China",
            "Research Site, Chongqing, China",
            "Research Site, ChongQing, China",
            "Research Site, Guang Zhou, China",
            "Research Site, Hangzhou, China",
            "Research Site, Hangzhou, China",
            "Research Site, Nanjing, China",
            "Research Site, Shanghai, China",
            "Research Site, Shanghai, China",
            "Research Site, Shanghai, China",
            "Research Site, Shanghai, China",
            "Research Site, Shanghai, China",
            "Research Site, Shenyang, China",
            "Research Site, Suzhou, China",
            "Research Site, Wuhan, China",
            "Research Site, Xi'an, China",
            "Research Site, Xiamen, China",
            "Research Site, Odense C, Denmark",
            "Research Site, BESANCON Cedex, France",
            "Research Site, Bordeaux Cedex, France",
            "Research Site, Caen, France",
            "Research Site, Lille, France",
            "Research Site, Lyon Cedex 08, France",
            "Research Site, Marseille cedex 09, France",
            "Research Site, Montpellier, France",
            "Research Site, Paris, France",
            "Research Site, Poitiers Cedex, France",
            "Research Site, Saint Herblain, France",
            "Research Site, Toulouse Cedex 09, France",
            "Research Site, Vandoeuvre les Nancy, France",
            "Research Site, Villejuif, France",
            "Research Site, Bergisch Gladbach, Germany",
            "Research Site, Berlin, Germany",
            "Research Site, Bremen, Germany",
            "Research Site, Duisburg, Germany",
            "Research Site, DÃ¼sseldorf, Germany",
            "Research Site, Hamburg, Germany",
            "Research Site, Heidelberg, Germany",
            "Research Site, Holzminden, Germany",
            "Research Site, Jena, Germany",
            "Research Site, KÃ¶ln, Germany",
            "Research Site, Magdeburg, Germany",
            "Research Site, NÃ¼rnberg, Germany",
            "Research Site, NÃ¼rtingen, Germany",
            "Research Site, TÃ¼bingen, Germany",
            "Research Site, Wuppertal, Germany",
            "Research Site, Haifa, Israel",
            "Research Site, Jerusalem, Israel",
            "Research Site, Kfar Saba, Israel",
            "Research Site, Petach-Tikva, Israel",
            "Research Site, Ramat Gan, Israel",
            "Research Site, Zerifin, Israel",
            "Research Site, Ancona, Italy",
            "Research Site, Arezzo, Italy",
            "Research Site, Bari, Italy",
            "Research Site, Brescia, Italy",
            "Research Site, Meldola, Italy",
            "Research Site, Milano, Italy",
            "Research Site, Milano, Italy",
            "Research Site, Modena, Italy",
            "Research Site, Napoli, Italy",
            "Research Site, Trento, Italy",
            "Research Site, Bunkyo-ku, Japan",
            "Research Site, Bunkyo-ku, Japan",
            "Research Site, Bunkyo-ku, Japan",
            "Research Site, Fukuoka, Japan",
            "Research Site, Hirosaki-shi, Japan",
            "Research Site, Kanazawa-shi, Japan",
            "Research Site, Kashihara-shi, Japan",
            "Research Site, Kashiwa, Japan",
            "Research Site, Kawagoe-shi, Japan",
            "Research Site, Kita-gun, Japan",
            "Research Site, Koto-ku, Japan",
            "Research Site, Kyoto-shi, Japan",
            "Research Site, Maebashi-shi, Japan",
            "Research Site, Matsuyama-shi, Japan",
            "Research Site, Minato-ku, Japan",
            "Research Site, Mitaka-shi, Japan",
            "Research Site, Miyazaki-shi, Japan",
            "Research Site, Nagasaki-shi, Japan",
            "Research Site, Nagoya-shi, Japan",
            "Research Site, Nagoya-shi, Japan",
            "Research Site, Osaka-shi, Japan",
            "Research Site, Osaka-shi, Japan",
            "Research Site, Osakasayama-shi, Japan",
            "Research Site, Sagamihara-shi, Japan",
            "Research Site, Sakura-shi, Japan",
            "Research Site, Sapporo-shi, Japan",
            "Research Site, Shinjuku-ku, Japan",
            "Research Site, Suita-shi, Japan",
            "Research Site, Sunto-gun, Japan",
            "Research Site, Yokohama-shi, Japan",
            "Research Site, Busan, Korea, Republic of",
            "Research Site, Daegu, Korea, Republic of",
            "Research Site, Goyang-si, Korea, Republic of",
            "Research Site, Gwangju, Korea, Republic of",
            "Research Site, Seoul, Korea, Republic of",
            "Research Site, Seoul, Korea, Republic of",
            "Research Site, Seoul, Korea, Republic of",
            "Research Site, Seoul, Korea, Republic of",
            "Research Site, Seoul, Korea, Republic of",
            "Research Site, Amsterdam, Netherlands",
            "Research Site, Hilversum, Netherlands",
            "Research Site, Leiden, Netherlands",
            "Research Site, Nijmegen, Netherlands",
            "Research Site, Tilburg, Netherlands",
            "Research Site, Zwolle, Netherlands",
            "Research Site, LÃ¸renskog, Norway",
            "Research Site, Barcelona, Spain",
            "Research Site, Gerona, Spain",
            "Research Site, Madrid, Spain",
            "Research Site, Madrid, Spain",
            "Research Site, Malaga, Spain",
            "Research Site, Oviedo, Spain",
            "Research Site, Sevilla, Spain",
            "Research Site, GÃ¶teborg, Sweden",
            "Research Site, Solna, Sweden",
            "Research Site, Changhua City, Taiwan",
            "Research Site, Kaohsiung, Taiwan",
            "Research Site, Kaohsiung, Taiwan",
            "Research Site, Taichung, Taiwan",
            "Research Site, Taichung, Taiwan",
            "Research Site, Tainan, Taiwan",
            "Research Site, Taipei, Taiwan",
            "Research Site, Taipei, Taiwan",
            "Research Site, Taoyuan City, Taiwan",
            "Research Site, Adana, Turkey",
            "Research Site, Ankara, Turkey",
            "Research Site, Ankara, Turkey",
            "Research Site, Ankara, Turkey",
            "Research Site, Edirne, Turkey",
            "Research Site, Istanbul, Turkey",
            "Research Site, Istanbul, Turkey",
            "Research Site, Karsiyaka, Turkey",
            "Research Site, London, United Kingdom",
            "Research Site, London, United Kingdom",
            "Research Site, Manchester, United Kingdom",
            "Research Site, Romford, United Kingdom",
            "Research Site, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02987543"
      },
      {
        "-rank": "160",
        "nct_id": "NCT00992186",
        "title": "A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Carlumab"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of Participants With Composite Response",
            "Percentage of Participants With Objective Tumor Response",
            "Progression-Free Survival (PFS)",
            "Overall Survival (OS)",
            "Percentage of Participants With Prostate Specific Antigen (PSA) Response",
            "Percentage of Participants With Urinary Crosslinked N-Telopeptide of Type I Collagen (NTx) Response",
            "Percentage of Participants With Pain Response",
            "Time to Radiologic Response",
            "Duration of Radiologic Response",
            "Minimum Observed Serum Concentration (Cmin)",
            "Maximum Observed Serum Concentration (Cmax)",
            "Area Under the Serum Concentration Versus Time Curve Between 0 And 14 Days (AUC 0-14d)",
            "Half-life (t1/2)"
          ]
        },
        "sponsors": { "lead_sponsor": "Centocor Research & Development, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "46",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR015907",
            "2009-011251-48",
            "CNTO888PCR2001"
          ]
        },
        "start_date": "September 2009",
        "primary_completion_date": "July 2011",
        "completion_date": "July 2011",
        "study_first_posted": "October 9, 2009",
        "results_first_posted": "May 20, 2013",
        "last_update_posted": "June 24, 2013",
        "locations": {
          "location": [
            "Orange City, Florida, United States",
            "Ann Arbor, Michigan, United States",
            "Charleston, South Carolina, United States",
            "Antwerpen, Belgium",
            "Bruxelles, Belgium",
            "Wilrijk, Belgium",
            "Moscow, Russian Federation",
            "St Petersburg, Russian Federation",
            "St-Petersburg, Russian Federation",
            "Birmingham, United Kingdom",
            "Guildford, United Kingdom",
            "Leeds, United Kingdom",
            "Southampton, United Kingdom",
            "Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00992186"
      },
      {
        "-rank": "161",
        "nct_id": "NCT02914873",
        "title": "SPCG17: Prostate Cancer Active Surveillance Trigger Trial",
        "acronym": "PCASTT",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "Active surveillance"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Progression-free survival",
            "Cumulative incidence of pT3 at radical prostatectomy specimens",
            "Cumulative incidence of metastases",
            "Cumulative number of treatments with curative intent (mainly radical prostatectomies or local radiotherapy)",
            "Cumulative incidence of switch to watchful waiting",
            "Quality of life"
          ]
        },
        "sponsors": { "lead_sponsor": "Uppsala University" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "2000",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "SPCG-17" },
        "start_date": "October 2016",
        "primary_completion_date": "December 2030",
        "completion_date": "December 2030",
        "study_first_posted": "September 26, 2016",
        "last_update_posted": "June 18, 2019",
        "locations": {
          "location": [
            "Helsinki University Hospital, Helsinki, Finland",
            "Oslo University Hospital, Oslo, Norway",
            "St Olavs University Hospital, Trondheim, Norway",
            "Hospital of Vestfold, TÃ¸nsberg, Norway",
            "Ã…lesund Regional Hospital, Ã…lesund, Norway",
            "Sahlgrenska University Hospital, GÃ¶teborg, Sweden",
            "LinkÃ¶ping University Hospital, LinkÃ¶ping, Sweden",
            "Sunderby Regional Hospital, LuleÃ¥, Sweden",
            "Sundsvall Regional Hospital, Sundsvall, Sweden",
            "University Hospital of UmeÃ¥, UmeÃ¥, Sweden",
            "Akademiska University Hospital, Uppsala, Sweden",
            "VÃ¤xjÃ¶ Hospital, VÃ¤xjÃ¶, Sweden",
            "University Hospital of Ã–rebro, Ã–rebro, Sweden",
            "Epsom Hospital, Epsom, United Kingdom",
            "Guy's Hospital, London, United Kingdom",
            "King's College Hospital, London, United Kingdom",
            "Royal Marsden Hospital, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02914873"
      },
      {
        "-rank": "162",
        "nct_id": "NCT01995513",
        "title": "Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients",
        "acronym": "PLATO",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone"
            },
            {
              "-type": "Drug",
              "#text": "Placebo for Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Progression Free Survival (PFS)",
            "Time to Prostate Specific Antigen (PSA) Progression",
            "Prostate Specific Antigen (PSA) Response Rate",
            "Objective Response Rate (ORR)",
            "Rate of Pain Progression",
            "Time to First Use of New Antineoplastic Therapy for Prostate Cancer",
            "Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score",
            "Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Social/Family Well-Being Domain Scores",
            "Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Emotional Well-Being Domain Scores",
            "Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Functional Well-Being Domain Scores",
            "Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Prostate Cancer Domain Scores",
            "Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Physical Well-Being Domain Scores",
            "Time to Degradation of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Pfizer",
          "collaborator": [
            "Astellas Pharma Inc",
            "Medivation LLC, a wholly owned subsidiary of Pfizer Inc."
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 4" },
        "enrollment": "509",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "MDV3100-10",
            "2013-000722-54",
            "C3431013",
            "PLATO, C3431013"
          ]
        },
        "start_date": "October 22, 2013",
        "primary_completion_date": "November 15, 2016",
        "completion_date": "May 31, 2024",
        "study_first_posted": "November 26, 2013",
        "results_first_posted": "November 17, 2017",
        "last_update_posted": "August 8, 2019",
        "locations": {
          "location": [
            "Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",
            "Brigham & Women's Hospital, Boston, Massachusetts, United States",
            "Dana Farber Cancer Institute, Boston, Massachusetts, United States",
            "Urology of Virginia, PLLC, Virginia Beach, Virginia, United States",
            "Regional Imaging Border, Albury, New South Wales, Australia",
            "Terry White Chemist, Albury, New South Wales, Australia",
            "Concord Cancer Centre, Medical Oncology Department, Concord, New South Wales, Australia",
            "Epic Pharmacy Lismore, Lismore, New South Wales, Australia",
            "Macquarie University Hospital Pharmacy, North Ryde, New South Wales, Australia",
            "Macquarie University, North Ryde, New South Wales, Australia",
            "Epic Pharmacy Port Macquarie base hospital, Port Macquarie, New South Wales, Australia",
            "Port Macquarie Base Hospital,North Coast Cancer Institute, Port Macquarie, New South Wales, Australia",
            "North Shore Radiology and Nuclear Medicine, St Leonards, New South Wales, Australia",
            "Royal North Shore Hospital, St Leonards, New South Wales, Australia",
            "Sydney Adventist Hospital, Sydney, New South Wales, Australia",
            "Northern NSW Local Health District, Tweed Heads, New South Wales, Australia",
            "Pharmacy Department, The Tweed Hospital, Tweed Heads, New South Wales, Australia",
            "Queensland Diagnostic Imaging, Tweed Heads, New South Wales, Australia",
            "Sydney Adventist Hospital, Wahroonga, New South Wales, Australia",
            "Westmead Hospital, Westmead, New South Wales, Australia",
            "Icon Cancer Care Wesley, Auchenflower, Queensland, Australia",
            "River City Pharmacy - APHS, Auchenflower, Queensland, Australia",
            "Icon Cancer Care Chermside, Chermside, Queensland, Australia",
            "Gold Coast Radiology PTY LTD, Hope Island, Queensland, Australia",
            "Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia",
            "Icon Cancer Care, South Brisbane, Queensland, Australia",
            "South Coast Radiology, Tugun, Queensland, Australia",
            "Adelaide Cancer Centre, Kurralta Park, South Australia, Australia",
            "Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia",
            "Cancer Care SA Pty Ltd, Kurralta Park, South Australia, Australia",
            "Tenpharm Pty Ltd trading as EPIC Pharmacy Tennyson, Kurralta Park, South Australia, Australia",
            "Box Hill Hospital, Box Hill, Victoria, Australia",
            "Monash Medical Centre, Clayton, Victoria, Australia",
            "Cabrini Health - Cabrini Hospital, Malvern, Victoria, Australia",
            "Border Medical Oncology, Wodonga, Victoria, Australia",
            "Algemeen Ziekenhuis Groeninge, Kortrijk, West-vlaanderen, Belgium",
            "Cliniques universitaires saint-Luc, Bruxelles, Belgium",
            "Universitaire Ziekenhuizen Leuven, Leuven, Belgium",
            "Rigshospitalet CPC 7521, Copenhagen, Norrebro, Denmark",
            "Arhus Universitetshospital, Arhus N, Denmark",
            "Rigshospitalet, Copenhagen, Denmark",
            "Frederiksberg Hospital, Frederiksberg, Denmark",
            "Helsingin yliopistollinen keskussairaala, Meilahden sairaala, Helsinki, Finland",
            "Oulun yliopistollinen sairaala, Oulu, Finland",
            "Tampereen yliopistollinen Sairaala, Tampere, Finland",
            "Institut Gustave Roussy - Service d'Urologie, Villejuif Cedex, France",
            "Farmacia, Azienda Ospedaliera \"Istituti Ospitalieri\" di Cremona, Cremona, Italy",
            "Medicina Nucleare, Azienda Ospedaliera \"Istituti Ospitalieri\" di Cremona, Cremona, Italy",
            "Servizio di Radiologia, Azienda Ospedaliera \"Istituti Ospitalieri\" di Cremona, Cremona, Italy",
            "U.O di Oncologia-Presidio Ospedaliero di Cremona-Istituti Ospitalieri di Cremona, Cremona, Italy",
            "Laboratorio Farmaci Antiblastici, Meldola (FC), Italy",
            "U.O. Oncologia Medica, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura, Meldola (FC), Italy",
            "UO Radiologia, Meldola (FC), Italy",
            "Farmacia Ospedaliera, A.O.U. San Luigi Gonzaga, Orbassano TO, Italy",
            "SCDU Oncologia Medica II Pad, A.O.U. San Luigi Gonzaga, Orbassano TO, Italy",
            "SCDU Radiodiagnostica, A.O.U. San Luigi Gonzaga, Orbassano TO, Italy",
            "SS Medicina Nucleare, A.O.U. San Luigi Gonzaga, Orbassano TO, Italy",
            "Farmacia, Ospedale Forlanini, Roma, Italy",
            "Azienda Ospedaliera S. Camillo Forlanini, UOC per il governo clinico in Oncologia Medica, Roma, Italy",
            "UOC Radiologia, Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy",
            "Fakultna nemocnica s poliklinikou F.D. Roosevelta, Banska Bystrica, Slovakia",
            "Institut nuklearnej a molekularnej mediciny, Banska Bystrica, Slovakia",
            "Fakultna nemocnica s poliklinikou F.D. Roosevelta, Banska Bystrica, Slovakia",
            "Bratislavske radiodiagnosticke centrum,a.s., Bratislava, Slovakia",
            "CUIMED, s.r.o., urologicka ambulancia, Bratislava, Slovakia",
            "Univerzitna nemocnica martin, Martin, Slovakia",
            "Jessenius-diagnosticke centrum, a.s., Nitra, Slovakia",
            "Uroexam, spol. s r.o., Urologicka ambulancia, Nitra, Slovakia",
            "IZOTOPCENTRUM, s.r.o., Nitra, Slovakia",
            "GAMMALAB, spol.s r.o., Oddelenie nuklearnej mediciny, Trnava, Slovakia",
            "CO Badalona-Instituto Germans Trias i Pujol, Badalona, Barcelona, Spain",
            "ALTAHIA, Xarxa Assistencial Universitaria de Manresa, Manresa, Barcelona, Spain",
            "Hospital Universitari Parc Tauli, Sabadell, Barcelona, Spain",
            "Hospital Universitario Son Espases, Palma, Islas Baleares, Spain",
            "Hospital del Mar, Barcelona, Spain",
            "Hospital Clinic de Barcelona, Barcelona, Spain",
            "Hospital Universitario Madrid Sanchinarro, Madrid, Spain",
            "Urologmottagningen, Goteborg, Sweden",
            "Urologiska kliniken, Malmo, Sweden",
            "Oriola, Molnlycke, Sweden",
            "Apoteket AB Kliniska Provningar Molnlycke, Molnlycke, Sweden",
            "Rontgenkliniken, Orebro, Sweden",
            "Urologmottagningen, Orebro, Sweden",
            "East and North Hertfordshire NHS Trust, Northwood, Middlesex, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",
            "Velindre NHS Trust, Cardiff, United Kingdom",
            "University College Hospitals NHS Trust, London, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, London, United Kingdom",
            "University College London Hospitals NHS Foundation Trust, London, United Kingdom",
            "Oxford University Hospitals NHS Trust, Oxford, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01995513"
      },
      {
        "-rank": "163",
        "nct_id": "NCT00268892",
        "title": "Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Degarelix"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight",
            "Liver Function Tests"
          ]
        },
        "sponsors": { "lead_sponsor": "Ferring Pharmaceuticals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 2",
            "Phase 3"
          ]
        },
        "enrollment": "278",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "FE200486 CS15A" },
        "start_date": "January 2006",
        "primary_completion_date": "September 2009",
        "completion_date": "December 2009",
        "study_first_posted": "December 23, 2005",
        "results_first_posted": "December 6, 2010",
        "last_update_posted": "December 24, 2010",
        "locations": {
          "location": [
            "UZ Gasthuisberg Leuven, Leuven, Belgium",
            "Helsinki University Hospital, Maria Hospital, Building 11, Helsinki, Finland",
            "Central Hospital, North Karelian, Joensuu, Finland",
            "Oulu University Hospital, Oulu, Finland",
            "Tampere University Hospital, Tampere, Finland",
            "FÃ©dÃ©ration d'Urologie et NÃ©phrologie, BP69 HÃ´pital Pasteur, Nice, France",
            "Gemeinschaftspraxis Dres Effert und Benedic, Aachen, Germany",
            "Clinical Center Novi Sad, Clinic of Urology, Novi Sad, Montenegro",
            "Academic Medical Center, Urology, Amsterdam, Netherlands",
            "St. Elisabeth Hospital, Tilburg, Netherlands",
            "\"Centrul Medical Privat\" Prof. Dr. Ioiart Ioan\", Arad, Romania",
            "Clinical Hospital \"Prof. Dr. Theodor Burghele\", Urology Department, Bucharest, Romania",
            "University CF Hospital No. 2, Bucharest, Romania",
            "Andros Clinic, St. Petersburg, Russian Federation",
            "City Hospital #15, St. Petersburg, Russian Federation",
            "City Hospital #26, St. Petersburg, Russian Federation",
            "Pavlov State Medical University, Outpatient Diagnostic Center affiliated with the Urology Department, St. Petersburg, Russian Federation",
            "Pavlov State Medical University, Urology Department, St. Petersburg, Russian Federation",
            "Clinical Center of Serbia, Institute of Urology and Nephrology, Belgrade, Serbia",
            "Mount Vernon Cancer Centre, Marie Cuire Research Wing, Northwood, Middlesex, United Kingdom",
            "Castle Hill Hospital, Hull, North Humberside, United Kingdom",
            "Ward 13, NHS Forth Valley Acute Operating Division, Falkirk and District Royal Infirmary, Majors Loans, Falkirk, United Kingdom",
            "Level 7, Urology Research Unit, Derriford Hospital, Plymouth, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00268892"
      },
      {
        "-rank": "164",
        "nct_id": "NCT00673205",
        "title": "(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer",
        "acronym": "Capri",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Non-Metastatic Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Bicalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Time to clinical progression",
            "Tolerability in terms of adverse events and laboratory parameters",
            "Survival",
            "Time to treatment failure",
            "Prostate-specific antigen"
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "3588",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "D6876C00024",
            "7054IL/0024"
          ]
        },
        "start_date": "September 1995",
        "primary_completion_date": "August 2008",
        "completion_date": "August 2008",
        "study_first_posted": "May 7, 2008",
        "last_update_posted": "December 10, 2010",
        "locations": {
          "location": [
            "Research Site, Wooloongabba, Queensland, Australia",
            "Research Site, East Melbourne, Victoria, Australia",
            "Research Site, Graz, Austria",
            "Research Site, Linz, Austria",
            "Research Site, Mistelbach, Austria",
            "Research Site, Oberwart, Austria",
            "Research Site, St. Polten, Austria",
            "Research Site, Antwerpen, Belgium",
            "Research Site, Brugge, Belgium",
            "Research Site, Brussels, Belgium",
            "Research Site, Gent, Belgium",
            "Research Site, Kortrijk, Belgium",
            "Research Site, Leuven, Belgium",
            "Research Site, Mons, Belgium",
            "Research Site, Oostende, Belgium",
            "Research Site, Seraing, Belgium",
            "Research Site, Brno, Czech Republic",
            "Research Site, Hradec Kralove, Czech Republic",
            "Research Site, Olomouc, Czech Republic",
            "Research Site, Praha 4, Czech Republic",
            "Research Site, Praha 5, Czech Republic",
            "Research Site, Berlin, Germany",
            "Research Site, Bonn, Germany",
            "Research Site, Dresden, Germany",
            "Research Site, Freiburg, Germany",
            "Research Site, Heidelberg, Germany",
            "Research Site, Jena, Germany",
            "Research Site, Lubeck, Germany",
            "Research Site, Ludenscheid, Germany",
            "Research Site, Mannheim, Germany",
            "Research Site, Munchen, Germany",
            "Research Site, Regensburg, Germany",
            "Research Site, Sigmaringen, Germany",
            "Research Site, Budapest, Hungary",
            "Research Site, Miskolc, Hungary",
            "Research Site, Nyiregyhaza, Hungary",
            "Research Site, Dublin 4, Ireland",
            "Research Site, Dublin 7, Ireland",
            "Research Site, Haifa, Israel",
            "Research Site, Petach Tikva, Israel",
            "Research Site, Tel-aviv, Israel",
            "Research Site, Tel-hashomer, Israel",
            "Research Site, Bari, BA, Italy",
            "Research Site, Bergamo, BG, Italy",
            "Research Site, Belluno, BL, Italy",
            "Research Site, Bologna, BO, Italy",
            "Research Site, Brescia, BS, Italy",
            "Research Site, Como, CO, Italy",
            "Research Site, Cesena, FO, Italy",
            "Research Site, Anagni, FR, Italy",
            "Research Site, Carpi, MO, Italy",
            "Research Site, Fidenza, PR, Italy",
            "Research Site, Siena, SI, Italy",
            "Research Site, Torino, TO, Italy",
            "Research Site, Treviso, TV, Italy",
            "Research Site, Udine, UD, Italy",
            "Research Site, Varese, VA, Italy",
            "Research Site, Dolo, VE, Italy",
            "Research Site, Portogruaro, VE, Italy",
            "Research Site, Roma, Italy",
            "Research Site, Mexico, Mexico",
            "Research Site, Amsterdam, Netherlands",
            "Research Site, Breda, Netherlands",
            "Research Site, Capelle A/d Ijssel, Netherlands",
            "Research Site, Eindhoven, Netherlands",
            "Research Site, Enschede, Netherlands",
            "Research Site, Gouda, Netherlands",
            "Research Site, Heerlen, Netherlands",
            "Research Site, Maastricht, Netherlands",
            "Research Site, Nijmegen, Netherlands",
            "Research Site, Roosendaal, Netherlands",
            "Research Site, Rotterdam, Netherlands",
            "Research Site, Spijkenisse, Netherlands",
            "Research Site, Utrecht, Netherlands",
            "Research Site, Warszawa, Poland",
            "Research Site, Wroclaw, Poland",
            "Research Site, Almada, Portugal",
            "Research Site, Coimbra, Portugal",
            "Research Site, Lisboa, Portugal",
            "Research Site, Porto, Portugal",
            "Research Site, Vila Nova de Gaia, Portugal",
            "Research Site, Somerset West, Cape Town, South Africa",
            "Research Site, Bloemfontein, South Africa",
            "Research Site, Cape Town, South Africa",
            "Research Site, Durban, South Africa",
            "Research Site, George, South Africa",
            "Research Site, Johannesburg, South Africa",
            "Research Site, Pietermarizberg, South Africa",
            "Research Site, Pretoria, South Africa",
            "Research Site, Granada, Andalucia, Spain",
            "Research Site, Malaga, Andalucia, Spain",
            "Research Site, Sevilla, Andalucia, Spain",
            "Research Site, Oviedo, Asturias, Spain",
            "Research Site, Guadalajara, Castilla La Mancha, Spain",
            "Research Site, Salamanca, Castilla Leon, Spain",
            "Research Site, Badalona(barcelona), Cataluna, Spain",
            "Research Site, Barcelona, Cataluna, Spain",
            "Research Site, Hospitalet de Llobregat(barcel, Cataluna, Spain",
            "Research Site, Alcala de Henares, Comunidad de Madrid, Spain",
            "Research Site, Getafe, Comunidad de Madrid, Spain",
            "Research Site, Madrid, Comunidad de Madrid, Spain",
            "Research Site, San Juan(alicante), Comunidad Valenciana, Spain",
            "Research Site, Valencia, Comunidad Valenciana, Spain",
            "Research Site, A Coruna, Galicia, Spain",
            "Research Site, Vigo(pontevedra), Galicia, Spain",
            "Research Site, Pamplona, Navarra, Spain",
            "Research Site, Bilbao, Pais Vasco, Spain",
            "Research Site, Reading, Berkshire, United Kingdom",
            "Research Site, Colchester, Essex, United Kingdom",
            "Research Site, Barnet, Hertfordshire, United Kingdom",
            "Research Site, Tooting, London, United Kingdom",
            "Research Site, Belfast, Northern Ireland, United Kingdom",
            "Research Site, Taunton, Somerset, United Kingdom",
            "Research Site, Gwent, South Wales, United Kingdom",
            "Research Site, Eastbourne, Sussex, United Kingdom",
            "Research Site, Birmingham, West Midlands, United Kingdom",
            "Research Site, Bolton, United Kingdom",
            "Research Site, Bristol, United Kingdom",
            "Research Site, Cardiff, United Kingdom",
            "Research Site, Cleveland, United Kingdom",
            "Research Site, Edinburgh, United Kingdom",
            "Research Site, Falkirk, United Kingdom",
            "Research Site, Hull, United Kingdom",
            "Research Site, Kent, United Kingdom",
            "Research Site, Leeds, United Kingdom",
            "Research Site, London, United Kingdom",
            "Research Site, Manchester, United Kingdom",
            "Research Site, Plymouth, United Kingdom",
            "Research Site, Sheffield, United Kingdom",
            "Research Site, Shrewsbury, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00673205"
      },
      {
        "-rank": "165",
        "nct_id": "NCT03151629",
        "title": "Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)",
        "acronym": "IRONMAN",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "Standard of Care"
          }
        },
        "outcome_measures": { "outcome_measure": "Practice Patterns" },
        "sponsors": { "lead_sponsor": "Prostate Cancer Clinical Trials Consortium" },
        "gender": "Male",
        "min_age": "21 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "5000",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "c16-170" },
        "start_date": "May 1, 2017",
        "primary_completion_date": "June 2022",
        "completion_date": "June 2024",
        "study_first_posted": "May 12, 2017",
        "last_update_posted": "September 10, 2019",
        "locations": {
          "location": [
            "University of Alabama-Birmingham, Birmingham, Alabama, United States",
            "University of California - Los Angeles, Los Angeles, California, United States",
            "University of California San Diego, San Diego, California, United States",
            "Emory Winship Cancer Institute, Atlanta, Georgia, United States",
            "Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States",
            "University of Chicago, Chicago, Illinois, United States",
            "Tulane University, New Orleans, Louisiana, United States",
            "Tulane University, New Orleans, Louisiana, United States",
            "Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States",
            "Chesapeake Urology Associates, Towson, Maryland, United States",
            "Dana-Farber Cancer Institute, Boston, Massachusetts, United States",
            "University of Michigan, Ann Arbor, Michigan, United States",
            "Karmanos Cancer Institute, Detroit, Michigan, United States",
            "Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States",
            "Columbia University Medical Center, New York, New York, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "Weill Cornell Medical Center, New York, New York, United States",
            "University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",
            "Duke University, Durham, North Carolina, United States",
            "Oregon Health & Science University Hospital, Portland, Oregon, United States",
            "Thomas Jefferson University, Philadelphia, Pennsylvania, United States",
            "Baylor College of Medicine, Houston, Texas, United States",
            "University of Virginia, Charlottesville, Virginia, United States",
            "University of Washington Medical Center, Seattle, Washington, United States",
            "University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",
            "St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia",
            "Macquarie University, Sydney, New South Wales, Australia",
            "Westmead Hospital, Sydney, New South Wales, Australia",
            "Redland Hospital, Cleveland, Queensland, Australia",
            "Princess Alexandra Hospital, Woolloongabba, Queensland, Australia",
            "Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia",
            "Australian Prostate Centre, Melbourne N., Australia",
            "Australian Urology Associates, Melbourne, Australia",
            "Hospital BeneficÃªncia Portuguesa, Bela Vista, SÃ£o Paulo, Brazil",
            "Centro de Pesquisa em Oncologia, Porto Alegre, Brazil",
            "BC Cancer Agency, Vancouver, British Columbia, Canada",
            "Juravinski Cancer Centre, Hamilton, Ontario, Canada",
            "Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada",
            "Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM), MontrÃ©al, Quebec, Canada",
            "CHU de QuÃ©bec-UniversitÃ© Laval, QuÃ©bec, Quebec, Canada",
            "Beacon Hospital, Dublin, Leinster, Ireland",
            "St. Vincent's University Hospital, Dublin, Ireland",
            "Vall d'Hebron Institute of Oncology, Barcelona, Catalunya, Spain",
            "Skane University Hospital, MalmÃ¶, Skane, Sweden",
            "Orebro University Hospital, Ã–rebro, Sweden",
            "Kantonsspital GraubÃ¼nden, Chur, Switzerland",
            "Kantonsspital St. Gallen, Saint Gallen, Switzerland",
            "University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom",
            "Guys St Thomas NHS Foundation Trust, London, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, London, United Kingdom",
            "The Christie NHS Foundation Trust, Manchester, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03151629"
      },
      {
        "-rank": "166",
        "nct_id": "NCT00116753",
        "title": "A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Degarelix"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With Testosterone Level <=0.5 ng/mL From Day 28 Until the End of the Study",
            "Number of Participants With Testosterone Level <=0.5 ng/mL After the Dose at Day 28 Until the End of the Study",
            "Number of Participants With Testosterone <=0.5 ng/mL at Day 28",
            "Liver Function Tests",
            "Number of Participants With Markedly Abnormal Change in Vital Signs and Body Weight as Compared to Baseline"
          ]
        },
        "sponsors": { "lead_sponsor": "Ferring Pharmaceuticals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "460",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "FE200486 CS15" },
        "start_date": "January 2005",
        "primary_completion_date": "November 2006",
        "completion_date": "November 2006",
        "study_first_posted": "July 1, 2005",
        "results_first_posted": "December 10, 2010",
        "last_update_posted": "December 10, 2010",
        "locations": {
          "location": [
            "Urology Centers of Alabama, Homewood, Alabama, United States",
            "Medical Affiliationed Research Center, Huntsville, Alabama, United States",
            "Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States",
            "Advanced Urology Medical Center, Anaheim, California, United States",
            "Center for Urological Research, La Mesa, California, United States",
            "South Orange County Medical Research Center, Laguna Woods,, California, United States",
            "West Coast Clinical Research, Tarzana, California, United States",
            "Western Clinical Research, Torrance, California, United States",
            "Urology Research Option, Aurora, Colorado, United States",
            "South Florida Medical Research, Aventura, Florida, United States",
            "SW Florida Urological Associates, Fort Myers, Florida, United States",
            "RT Services, Inc, Ft Myers, Florida, United States",
            "Regional Urology, Shreveport, Louisiana, United States",
            "Mississippi Urology Clinic, Jackson, Mississippi, United States",
            "University of Missouri, Urology, Deptof Surgery, Columbia, Missouri, United States",
            "Kansas City Urology Care, Kansas City, Missouri, United States",
            "Northeast Urology Research, Concord, North Carolina, United States",
            "The Urology Center, Greensboro, North Carolina, United States",
            "State College Urologic Association, State College, Pennsylvania, United States",
            "Grand Strand Urology, Myrtle Beach, South Carolina, United States",
            "Urology Association of Northern Texas, Fort Worth, Texas, United States",
            "Urology San Antonio Research, San Antonio, Texas, United States",
            "Seatle Urology Research Centre, Seattle, Washington, United States",
            "UZ Gasthuisberg Leuven, Leuven, Belgium",
            "Southern Interior Medical Research Corp, Kelowna, British Columbia, Canada",
            "Andreou Researce, Surrey, British Columbia, Canada",
            "Can-Med Clinical Research Inc., Victoria, British Columbia, Canada",
            "The Male/Female Health Centres and Research, Barrie, Ontario, Canada",
            "Brantford Urology Research, Brantford, Ontario, Canada",
            "North Bay Hospital, North Bay, Ontario, Canada",
            "The Male/Female Health Centres and Research, Oakville, Ontario, Canada",
            "The Male Health Center, Toronto, Ontario, Canada",
            "Helsinki University Hospital, Maria Hospital, Dept Urology, Helsinki, Finland",
            "Central Hospital, North Karelian, Dept. of Urology, Joensuu, Finland",
            "Oulu University Hospital, Department of Surgery Division of Urology, Oys, Finland",
            "Tampere University Hospital, Dept. of Urology, Tampere, Finland",
            "Clinical Center of Serbia Institute of Urology and Nephrology, Belgrade, Former Serbia and Montenegro",
            "Clinical Center Novi Sad, Clinic of Urology Hajduk, Novi Sad, Former Serbia and Montenegro",
            "Centre Hospitalier DÃ©partemental des Oudairies, Chirurgie Urologie, La Roche-sur-Yon, France",
            "FÃ©dÃ©ration d'Urologie et NÃ©phrologie, Nice, France",
            "Gemeinschaftspraxis Dres Effert und Benedic, Aachen, Germany",
            "Klinik fuer Urologie, Vivantes Klinikum Am Urban, Berlin, Germany",
            "Academic Medical Center, Urology, Amsterdam, Netherlands",
            "St. Elisabeth Hospital, Tilburg, Netherlands",
            "Centrul Medical Privat, Arad, Romania",
            "Clinical Hospital \"Prof. Dr. Theodor Burghele\", Urology Department, Bucharest, Romania",
            "University CF Hospital No.2, Urology Clinic, Bucharest, Romania",
            "Andros Clinic, Saint Petersburg, Russian Federation",
            "City Hospital #15, Saint Petersburg, Russian Federation",
            "City Hospital #26, Saint Petersburg, Russian Federation",
            "Pavlov State Medical University, Outpatient Diagnostic Center affiliated with the Urology Department, Saint Petersburg, Russian Federation",
            "Pavlov State Medical University, Urology Department, Saint Petersburg, Russian Federation",
            "Ward 10, NHS Forth Valley Acute Operating Division, Falkirk and District Royal Infirmary, Falkirk, United Kingdom",
            "Mount Vernon Cancer Centre, Marie Curie Research Wing, Middlesex, United Kingdom",
            "Castle Hill Hospital, Dept. Urology, North Humberside, United Kingdom",
            "Level 7, Urology Research Unit, Derriford Hospital, Plymouth, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00116753"
      },
      {
        "-rank": "167",
        "nct_id": "NCT02135445",
        "title": "Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "TAK-385"
            },
            {
              "-type": "Drug",
              "#text": "Degarelix"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of Participants With Effective Castration Rate Over 25 Weeks",
            "Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Signs",
            "Number of Participants With TEAEs Related to Physical Findings",
            "Number of Participants With TEAEs Related to 12-lead Electrocardiogram (ECG) Findings",
            "Number of Participants With TEAEs Categorized Into Investigations Related to Chemistry, Hematology or Urinalysis",
            "Number of Participants Reporting One or More TEAEs and Serious Adverse Events (SAEs)",
            "Average Percent Change in Prostate Size",
            "Time to Achieve Effective Castration",
            "Time to Achieve Profound Castration",
            "Estimated Time to Testosterone Recovery (TTR)",
            "Percentage of Participants Who Have Recovered to Baseline Value of Testosterone",
            "Percentage of Participants Who Have Recovered to >280 ng/dL Testosterone",
            "Number of Participants With PSA Response of >=50% and >=90% Reduction",
            "Percent Change From Baseline in Serum PSA Concentration",
            "PSA Nadir",
            "Serum PSA Concentration",
            "Plasma Concentrations of TAK-385",
            "Serum Luteinizing Hormone (LH) Level",
            "Serum Follicle-Stimulating Hormone (FSH) Level",
            "Serum Sex Hormone-Binding Globulin (SHBG) Level",
            "Percent Change From Baseline in Aging Male's Symptoms (AMS) Total Scale Score",
            "Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Score",
            "Change From Baseline in 25-item Prostate Cancer-specific Questionnaire Supplement (EORTC QLQ-PR25) Score"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Millennium Pharmaceuticals, Inc.",
          "collaborator": "Takeda"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "103",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "C27003 Merge to Takeda",
            "U1111-1152-9537",
            "2013-005002-53",
            "14/LO/1052"
          ]
        },
        "start_date": "June 2014",
        "primary_completion_date": "December 2015",
        "completion_date": "December 2015",
        "study_first_posted": "May 12, 2014",
        "results_first_posted": "April 13, 2017",
        "last_update_posted": "April 13, 2017",
        "locations": {
          "location": [
            "Birmingham, Alabama, United States",
            "San Diego, California, United States",
            "Denver, Colorado, United States",
            "Bradenton, Florida, United States",
            "Daytona Beach, Florida, United States",
            "Fort Lauderdale, Florida, United States",
            "Fort Myers, Florida, United States",
            "Plantation, Florida, United States",
            "Jeffersonville, Indiana, United States",
            "Wichita, Kansas, United States",
            "Shreveport, Louisiana, United States",
            "Omaha, Nebraska, United States",
            "Syracuse, New York, United States",
            "Columbus, Ohio, United States",
            "Eugene, Oregon, United States",
            "Myrtle Beach, South Carolina, United States",
            "Dallas, Texas, United States",
            "San Antonio, Texas, United States",
            "Virginia Beach, Virginia, United States",
            "Brighton, East Sussex, United Kingdom",
            "Manchester, Greater Manchester, United Kingdom",
            "Wirral, Merseyside, United Kingdom",
            "Taunton, Somerset, United Kingdom",
            "Sutton, Surrey, United Kingdom",
            "Birmingham, West Midlands, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02135445"
      },
      {
        "-rank": "168",
        "nct_id": "NCT03748641",
        "title": "A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer",
        "acronym": "MAGNITUDE",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Niraparib"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone Acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Progression Free Survival (rPFS)",
            "Overall survival (OS)",
            "Time to Chronic Opioid Use",
            "Time to Pain Progression",
            "Time to Initiation of Cytotoxic Chemotherapy",
            "Observed Plasma Concentrations of Niraparib",
            "Observed Trough Plasma Concentrations of Abiraterone",
            "Number of Participants with Treatment-Emergent Adverse events (TEAEs)",
            "Number of Participants with Treatment-Emergent Adverse events by Severity",
            "Number of Participants with Laboratory Abnormalities as Measure of Safety"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Research & Development, LLC" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1000",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR108534",
            "2017-003364-12",
            "64091742PCR3001"
          ]
        },
        "start_date": "January 25, 2019",
        "primary_completion_date": "July 21, 2022",
        "completion_date": "February 25, 2025",
        "study_first_posted": "November 21, 2018",
        "last_update_posted": "August 22, 2019",
        "locations": {
          "location": [
            "Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States",
            "Kaiser Permanente, Riverside, California, United States",
            "San Bernardino Urological Associates, San Bernardino, California, United States",
            "University of California San Francisco, San Francisco, California, United States",
            "Kaiser Permanente Medical Center, Vallejo, California, United States",
            "Urology Associates of Denver, Englewood, Colorado, United States",
            "Foothills Urology - Golden Off, Golden, Colorado, United States",
            "VA Connecticut Healthcare, West Haven, Connecticut, United States",
            "Bay Pines VA Healthcare System, Bay Pines, Florida, United States",
            "Advanced Urology Institute, Daytona Beach, Florida, United States",
            "University of Florida, Jacksonville, Florida, United States",
            "Veterans Affairs Medical Ctr, Hines, Illinois, United States",
            "University of Kansas Medical Center, Kansas City, Kansas, United States",
            "Norton Healthcare, Louisville, Kentucky, United States",
            "Rcca Md, Llc, Bethesda, Maryland, United States",
            "Chesapeake Urology Research Associates, Towson, Maryland, United States",
            "Massachusetts General, Boston, Massachusetts, United States",
            "Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States",
            "Adult Pediatric Urology & Urogynecology, P.C, Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "Delaware Valley Urology, LLC, Mount Laurel, New Jersey, United States",
            "Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg, New York, New York, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "Upstate Cancer Center, Syracuse, New York, United States",
            "Lancaster Urology, Lancaster, Pennsylvania, United States",
            "VA Pittsburgh, Pittsburgh, Pennsylvania, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "University of Texas MD Anderson Cancer Center, Houston, Texas, United States",
            "Utah Cancer Specialists, Salt Lake City, Utah, United States",
            "Salem VA Medical Center, Salem, Virginia, United States",
            "Urology of Virginia, PLCC, Virginia Beach, Virginia, United States",
            "NorthWest Medical Specialties, PLLC, Tacoma, Washington, United States",
            "Hospital Aleman, Buenos Aires, Argentina",
            "Hospital Italiano de Buenos Aires, C.a.b.a., Argentina",
            "FundaciÃ³n CENIT para la InvestigaciÃ³n en Neurociencias, Capital Federal, Argentina",
            "Centro de Urologia (CDU), Ciudad Automoma Buenos Aires, Argentina",
            "CEMIC Saavedra, Ciudad Autonoma Buenos Aires, Argentina",
            "Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Cordoba, Argentina",
            "Hospital Privado - Centro Medico de Cordoba, Cordoba, Argentina",
            "Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Argentina",
            "Hospital Privado de Comunidad, Mar del Plata, Argentina",
            "Centro de Investigacion Pergamino SA, Pergamino, Argentina",
            "Sanatorio Britanico de Rosario, Rosario, Argentina",
            "Sanatorio Parque, Rosario, Argentina",
            "ARS MÃ©dica, San Salvador de Jujuy, Argentina",
            "Royal Adelaide Hospital, Adelaide, Australia",
            "Pindara Private Hospital, Benowa, Australia",
            "Sunshine Coast University Hospital, Birtinya, Australia",
            "Princess Alexandra Hospital, Brisbane, Australia",
            "Chris O'Brien Lifehouse, Camperdown, Australia",
            "St. Vincent's Hospital Sydney, Darlinghurst, Australia",
            "Royal Hobart Hospital, Hobart, Australia",
            "Macquarie University, Macquarie University, Australia",
            "Cabrini Health, Malvern, Australia",
            "Peter MacCallum Cancer Centre, Melbourne, Australia",
            "Fiona Stanley Hospital, Murdoch, Australia",
            "Hollywood Private Hospital, Nedlands, Australia",
            "Prince Of Wales Hospital, Randwick, Australia",
            "Sydney Adventist Hospital, Wahroonga, Australia",
            "Wollongong Private Hospital, Wollongong, Australia",
            "OLV Ziekenhuis Aalst, Aalst, Belgium",
            "ZNA Middelheim, Antwerpen, Belgium",
            "Grand HÃ´pital de Charleroi, site Notre Dame, Charleroi, Belgium",
            "AZ Maria Middelares, Gent, Belgium",
            "Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium",
            "Hospital Do Cancer De Barretos - Fundacao Pio Xii, Barretos, Brazil",
            "PERSONAL - Oncologia de PrecisÃ£o e Personalizada, Belo Horizonte, Brazil",
            "Hospital SÃ­rio Libanes Unidade Brasilia, Brasilia, Brazil",
            "CIONC - Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil",
            "Hospital AraÃºjo Jorge da AssociaÃ§Ã£o de Combate ao CÃ¢ncer em GoiÃ¡s, GoiÃ¢nia, Brazil",
            "Hospital de Caridade de Ijui - CACON, Ijui, Brazil",
            "ClÃ­nica de Neoplasias Litoral Ltda., Itajai, Brazil",
            "Instituto Joinvilense De Hematologia e Oncologia, Joinville, Brazil",
            "Centro de Tratamento de cÃ¢ncer Medradius, MaceiÃ³, Brazil",
            "Liga Norte Riograndense Contra O Cancer, Natal, Brazil",
            "Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil",
            "Instituto Nacional do Cancer - INCA, Rio de Janeiro, Brazil",
            "Hospital UniversitÃ¡rio Pedro Ernesto, Rio de Janeiro, Brazil",
            "Instituto COI de Pesquisa, Educacao e Gestao, Rio de Janeiro, Brazil",
            "Hospital Santa Isabel, Salvador, Brazil",
            "CEPHO - Faculdade de Medicina do ABC, Santo AndrÃ©, Brazil",
            "Santa Casa de Misericordia de SÃ£o Paulo, Sao Paulo, Brazil",
            "Instituto de Ensino E Pesquisa Sao Lucas, Sao Paulo, Brazil",
            "ICESP - INSTITUTO DO CANCER DO ESTADO DE SAO PAULO OCTAVIO FRIAS de OLIVEIRA, Sao Paulo, Brazil",
            "Fundacao Antonio Prudente, Sao Paulo, Brazil",
            "IBCC Instituto Brasileiro de Controle do Cancer, Sao Paulo, Brazil",
            "IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado, Sorocaba, Brazil",
            "Instituto de AssistÃªncia MÃ©dica ao Servidor PÃºblico Estadual - HSPE-FMO, SÃ£o Paulo, Brazil",
            "Instituto do Cancer De Tres Lagoas, TrÃªs Lagoas, Brazil",
            "Instituto do Cancer De Tres Lagoas, TrÃªs Lagoas, Brazil",
            "MHAT Deva Maria, Burgas, Bulgaria",
            "UMHAT 'Dr. Georgi Stranski', EAD, Pleven, Bulgaria",
            "Complex Oncology Center - Plovdiv EOOD, Plovdiv, Bulgaria",
            "Specialized Hospital for Active Treatment in Oncology EAD, Sofia, Bulgaria",
            "SHATOD 'Dr. Marko Antonov Markov', Varna, Bulgaria",
            "Comprehensive Cancer Center, Vratsa, Bulgaria",
            "Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada",
            "British Columbia Cancer Agency (BCCA) - Vancouver Centre, Vancouver, British Columbia, Canada",
            "British Columbia Cancer Agency - Vancouver Island Centre, Victoria, British Columbia, Canada",
            "McMaster Institute of Urology, Hamilton, Ontario, Canada",
            "Cancer Centre of Southeastern Ontario (Kingston Regional Cancer Centre), Kingston, Ontario, Canada",
            "Sunnybrook Health Sciences Center, Toronto, Ontario, Canada",
            "University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Centre de Recherche du CHUM, Montreal, Quebec, Canada",
            "Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada",
            "Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China",
            "Peking University First Hospital, Beijing, China",
            "Beijing Friendship Hospital, Beijing, China",
            "Beijing Cancer Hospital of Peking University, Beijing, China",
            "Peking University Third Hospital, Beijing, China",
            "Beijing Hospital, BeiJing, China",
            "Sichuan Provincial People's Hospital, Chengdu, China",
            "Southwest Hospital, The Third Military Medical University, Chongqing, China",
            "Chongqing Cancer hospital, Chongqing, China",
            "Fujian Medical University Union Hospital, Fuzhou, China",
            "Sun Yat-Sen Memorial Hospital Sun Yat-sen University, Guangzhou, China",
            "Guangzhou First Municipal People's Hospital, GuangZhou, China",
            "The First Affiliated hospital of Anliui Medical University, Hefei, China",
            "Nanjing Drum Tower Hospital, Nanjing, China",
            "Jiangsu Cancer Hospital, Nanjing, China",
            "Drug clinical trial ethics committee of Ningbo First Hospital, Ningbo, China",
            "Fudan University Shanghai Cancer Center, Shanghai, China",
            "Shanghai Zhongshan Hospital, ShangHai, China",
            "Huashan Hospital Fudan University, Shanghai, China",
            "ShangHai Huadong Hospital, ShangHai, China",
            "Renji Hospital, Shanghai Jiaotong University School of Medicine, ShangHai, China",
            "The Fifth People's Hospital of Shanghai, Fudan University, ShangHai, China",
            "The First Affiliated Hospital of Soochow University, Suzhou, China",
            "Tianjin Medical University Cancer Hospital, Tianjin, China",
            "The Central Hospital of Wuhan, Wuhan, China",
            "Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China",
            "Wuxi People's Hospital, Wuxi, China",
            "First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China",
            "Fakultni nemocnice Hradec Kralove, Hradec KrÃ¡love, Czechia",
            "KrajskÃ¡ nemocnice Liberec, Liberec, Czechia",
            "Uromedical Center s.r.o., Olomouc, Czechia",
            "Multiscan s.r.o., Pardubice, Czechia",
            "Fakultni nemocnice Plzen, Urologicka klinika, Plzen, Czechia",
            "Urologicka klinika 1.LF UK a VFN, Praha 2, Czechia",
            "Thomayerova nemocnice, Onkologicka klinika, Praha 4, Czechia",
            "CHRU De Besancon, Besancon, France",
            "Institut BergoniÃ©, Bordeaux, France",
            "Centre Jean Perrin, Clermont Ferrand, France",
            "Centre Leon BÃ©rard, Lyon, France",
            "Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France",
            "Polyclinique de Gentilly, Nancy, France",
            "Centre Antoine Lacassagne, Nice Cedex 2, France",
            "Hopital Europeen Georges-Pompidou, Paris Cedex 15, France",
            "Institut de CancÃ©rologie de l'Ouest (ICO), Saint Herblain, France",
            "HIA Begin, Saint Mande, France",
            "HÃ´pitaux Universitaire de Strasbourg -CHU, Strasbourg, France",
            "Charite - Universitatsmedizin Berlin (CCM), Berlin, Germany",
            "StÃ¤dtisches Klinikum Braunschweig gGmbH - Standort Salzdahlumer, Braunschweig, Germany",
            "Urologicum Duisburg, Duisburg, Germany",
            "UniversitÃ¤tsklinikum des Saarlandes, Homburg, Germany",
            "Klinik und Poliklinik fÃ¼r Urologie, KÃ¶ln, Germany",
            "UniversitÃ¤tsklinikum Otto-von-Guericke-UniversitÃ¤t Magdeburg, Magdeburg, Germany",
            "Universitaetsklinikum Muenster, Muenster, Germany",
            "Studienpraxis Urologie Drs. Feyerabend, Nuertingen, Germany",
            "Semmelweis Egyetem, UrolÃ³gia Klinika, Budapest, Hungary",
            "OrszÃ¡gos OnkolÃ³giai IntÃ©zet, C BelgyÃ³gyÃ¡szati-OnkolÃ³giai Ã©s Klinikai FarmakolÃ³giai OsztÃ¡ly, Budapest, Hungary",
            "Szent JÃ¡nos KÃ³rhÃ¡z Ã©s Ã‰szak-budai EgyesÃ­tett KÃ³rhÃ¡zak, Budapest, Hungary",
            "Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary",
            "BÃ©kÃ©s Megyei KÃ¶zponti KÃ³rhÃ¡z PÃ¡ndy KÃ¡lmÃ¡n TagkÃ³rhÃ¡z, Gyula, Hungary",
            "Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Nyiregyhaza, Hungary",
            "Uro-Clin Kft., PÃ©cs, Hungary",
            "Szegedi Tudomanyegyetem, Szeged, Hungary",
            "Markusovszky Egyetemi Oktatokorhaz, Szombathely, Hungary",
            "Asaf Harofe Medical Center, Beer Yaakov, Israel",
            "Rambam Health Care Campus, Haifa, Israel",
            "Rabin Medical Center, Petah Tikva, Israel",
            "Sheba Medical Center Tel Hashomer, Ramat Gan, Israel",
            "AUSL Romagna - Ospedale di Faenza, Faenza, Italy",
            "Ospedale San Raffaele, Milano, Italy",
            "ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy",
            "Oncologia Medica A - Ist Naz Tumori G Pascale, Napoli, Italy",
            "Istituto Oncologico Veneto Iov Irccs Padova, Padova, Italy",
            "Oncologia Medica - Azienda Ospedaliero Universitaria Di Parma, Parma, Italy",
            "Ospedale S. Maria Della Misericordia Centro Operativo Studi Clinici SC Oncologia Medica, Perugia, Italy",
            "Azienda Ospedaliero Universitaria Pisana, Pisa, Italy",
            "Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",
            "Campus Bio-Medico di Roma, Roma, Italy",
            "Azienda Ospedaliera S. Maria Terni, Terni, Italy",
            "A.O.U. CittÃ  della Salute e della Scienza, Torino, Italy",
            "Ospedale Santa Chiara Trento, Trento, Italy",
            "Pusan National University Hospital., Busan, Korea, Republic of",
            "Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of",
            "Keimyung University Dongsan Hospital, Daegu, Korea, Republic of",
            "Chungnam National University Hospital, Daejeon, Korea, Republic of",
            "National Cancer Center, Goyang-Si, Korea, Republic of",
            "Chonnam National University Hospital, Gwangju, Korea, Republic of",
            "Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of",
            "Seoul National University Hospital, Seoul, Korea, Republic of",
            "Severance Hospital, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Gangnam Severance Hospital, Seoul, Korea, Republic of",
            "Samsung Medical Center, Seoul, Korea, Republic of",
            "Seoul St. Mary's Hospital, Seoul, Korea, Republic of",
            "Ajou University Hospital, Suwon, Korea, Republic of",
            "Hospital Pulau Pinang, George Town, Malaysia",
            "Hospital Sultan Ismail, Johor Bahru, Malaysia",
            "Hospital Likas, Kota Kinabalu, Malaysia",
            "Hospital Kuala Lumpur, Kuala Lumpur, Malaysia",
            "University Malaya Medical Centre, Kuala Lumpur, Malaysia",
            "Sarawak General Hospital, Kuching, Malaysia",
            "iBiomed Research Unit, Aguascalientes, Mexico",
            "Mexico Centre for Clinical Research, S.A. de C.V., Ciudad de Mexico, Mexico",
            "Consultorio de Especialidad en Urologia Privado, Durango, Mexico",
            "Centro Medico Nacional Siglo XXI IMSS, Mexico, Mexico",
            "Avix Investigacion Clinica, S.C., Monterrey, Mexico",
            "Consultorio Privado, Zapopan, Mexico",
            "NKI-AVL, Amsterdam, Amsterdam, Netherlands",
            "Universitair Medisch Centrum Groningen, Groningen, Netherlands",
            "Atrium Medisch Centrum - Parkstad, Heerlen, Netherlands",
            "MC Haaglanden Lok Antoniushove - Afd.Interne - INT, Leidschendam, Netherlands",
            "St. Antonius Ziekenhuis (St. Antonius Hospital), Nieuwegein, Netherlands",
            "Canisius-Wilhelminaziekenhuis, Nijmegen, Netherlands",
            "Erasmus MC, Rotterdam, Netherlands",
            "Szpital Uniwersytecki NR 1 IM. Dr. Antoniego Jurasza, Bydgoszcz, Poland",
            "Centrum Onkologii im. Prof. F. Lukaszczyka, Bydgoszcz, Poland",
            "Uniwersyteckie Centrum Kliniczne, GdaÅ„sk, Poland",
            "Szpitale Pomorskie Sp. z o.o., Gdynia, Poland",
            "Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland",
            "Wielkopolskie Centrum Onkologii, Poznan, Poland",
            "Urologica Praktyka Lekarska Adam Marcheluk, Siedlce, Poland",
            "Pomorski Uniwersytet Medyczny w Szczecinie, Szczecin, Poland",
            "Szpital Åšw. ElÅ¼biety Mokotowskie Centrum Medyczne, Warszawa, Poland",
            "Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie, Warszawa, Poland",
            "Dolnoslaskie Centrum Onkologii, WrocÅ‚aw, Poland",
            "Hospitais da universidade de Coimbra, Coimbra, Portugal",
            "Instituto PortuguÃªs de Oncologia de Coimbra Francisco Gentil, EPE, Coimbra, Portugal",
            "Centro Hospitalar Lisboa Norte, EPE/Hosp. Santa Maria, Lisboa, Portugal",
            "Champalimaud Foundation Champalimaud Centre, Lisbon, Portugal",
            "H. Santo AntÃ³nio - Centro Hospitalar do Porto, Porto, Portugal",
            "VA Caribbean Healthcare System, San Juan, Puerto Rico",
            "Altai Regional Oncology Dispensary, Barnaul, Russian Federation",
            "Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation",
            "Naval Clinical Hospital, Kaliningrad, Russian Federation",
            "State Health Establishment Kursk Regional Oncology Dispensary, Kursk, Russian Federation",
            "Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation",
            "Moscow City Clinical Hospital # 62, Moscow, Russian Federation",
            "Clinical Diagnostic Centre of Nizhny Novgorod Region, Nizhny Novgorod, Russian Federation",
            "Clinical Oncology Dispensary, Omsk, Russian Federation",
            "LLC Novaya Clinica, Pyatigorsk, Russian Federation",
            "Pyatigorsk Regional Oncology Dispensary, Pyatigorsk, Russian Federation",
            "Private Medical Institution Euromedservice, Saint Petersburg, Russian Federation",
            "Leningrad Regional Oncology Dispensary, Saint-Petersburg, Russian Federation",
            "Russian Scientific Center of Radiology and Surgical Technologies, Saint-Petersburg, Russian Federation",
            "Republican Oncology Dispensary, Saransk, Russian Federation",
            "Oncologic Dispensary No.2, Sochi, Russian Federation",
            "Tambov Regional Oncology Clinical Dispansary, Tambov, Russian Federation",
            "Tomsk Cancer Research Institute, Tomsk, Russian Federation",
            "Medical-sanitary unit 'Neftyanik', Tyumen, Russian Federation",
            "Vologda Regional Oncological Dispensary, Vologda, Russian Federation",
            "Clinresco Centres Pty Ltd, Johannesburg, South Africa",
            "Clinical Research Unit, Pretoria, South Africa",
            "East Rand Urology Research Unit, Vosloorus, South Africa",
            "Hosp. Del Mar, Barcelona, Spain",
            "Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain",
            "Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain",
            "Hospital Juan Canalejo, CoruÃ±a, Spain",
            "Hosp. de Jerez de La Frontera, Jerez de la Frontera, Spain",
            "Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain",
            "Hosp. Univ. Ramon Y Cajal, Madrid, Spain",
            "Hosp. Clinico San Carlos, Madrid, Spain",
            "Hosp. Virgen de La Victoria, MÃ¡laga, Spain",
            "Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcon, Spain",
            "Corporacio Sanitari Parc Tauli, Sabadell, Spain",
            "Hosp. Univ. Marques de Valdecilla, Santander, Spain",
            "Hosp. Univ. I Politecni La Fe, Valencia, Spain",
            "SÃ¶dersjukhuset, Stockholm, Sweden",
            "Karolinska Universitetssjukhuset Solna, Stockholm, Sweden",
            "Akademiska Sjukhuset, Uppsala, Sweden",
            "Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan",
            "China Medical University Hospital, Taichung, Taiwan",
            "Taichung Veterans General Hospital, Taichung, Taiwan",
            "Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan",
            "Chi Mei Medical Center - Yong Kang, Tainan, Taiwan",
            "National Taiwan University Hospital, Taipei, Taiwan",
            "Taipei Veterans General Hospital, Taipei, Taiwan",
            "Chang Gung Memorial Hospital, Taoyuan, Taiwan",
            "Cukurova University, Faculty of Medicine, Adana, Turkey",
            "Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey",
            "Ankara Sehir Hastanesi, Ankara, Turkey",
            "Akdeniz University Medical Faculty, Antalya, Turkey",
            "Trakya University Medical Faculty, Edirne, Turkey",
            "Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey",
            "Bakirkoy Training and Research Hospital, Istanbul, Turkey",
            "Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey",
            "IzmÄ±r Medical Park Hospital, Izmir, Turkey",
            "Kocaeli University Medical Faculty, Kocaeli, Turkey",
            "Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council', Cherkasy, Ukraine",
            "Dnipropetrovsk State Medical Academy, Dnipropetrovk State Clinical Hospital NA Mechnikov I.I., Dnipo, Ukraine",
            "Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council, Dnipro, Ukraine",
            "Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4, Dnipro, Ukraine",
            "Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine",
            "Municipal non-profit enterprise 'Regional Center of Oncology', Khakhiv, Ukraine",
            "Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval, Kharkiv, Ukraine",
            "State Institution National Cancer Institute, Kyiv, Ukraine",
            "State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center, Kyiv, Ukraine",
            "Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital', Lviv, Ukraine",
            "Ukrainian Medical Stomatological Academy, Poltava, Ukraine",
            "Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal, Uzhgorod, Ukraine",
            "Zaporizhzhia medical Academy of postgraduate education, Zaporizhzhia Regoinal Clinical Hospital, Zaporizhzhya, Ukraine",
            "Royal Blackburn Hospital, Blackburn, United Kingdom",
            "Bristol Haematology and Oncology Centre, Bristol, United Kingdom",
            "Royal Lancaster Infirmary, Lancaster, United Kingdom",
            "UCL Cancer Institute, London, United Kingdom",
            "Royal Shrewsbury Hospital, Shrewsbury, United Kingdom",
            "Torbay Hospital-Devon, Torquay, United Kingdom",
            "Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",
            "New Cross Hospital, Wolverhampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03748641"
      },
      {
        "-rank": "169",
        "nct_id": "NCT00554229",
        "title": "A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases",
        "acronym": "ENTHUSE M1",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "ZD4054"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Progression Free Survival",
            "Time to Use of Opiates",
            "Incidence of Skeletal Related Events",
            "Bone Metastases Formation",
            "Health Related Quality of Life",
            "Time to Prostate-specific Antigen (PSA) Progression",
            "Time to Pain Progression",
            "Time to Initiation of Chemotherapy",
            "Pharmacokinetic Characteristics of ZD4054"
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "896",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "D4320C00014",
            "2007-003227-20"
          ]
        },
        "start_date": "November 2007",
        "primary_completion_date": "July 2010",
        "completion_date": "August 2011",
        "study_first_posted": "November 6, 2007",
        "results_first_posted": "May 31, 2012",
        "last_update_posted": "February 8, 2016",
        "locations": {
          "location": [
            "Research Site, Tucson, Arizona, United States",
            "Research Site, Greenbrae, California, United States",
            "Research Site, Los Angeles, California, United States",
            "Research Site, Palm Springs, California, United States",
            "Research Site, San Mateo, California, United States",
            "Research Site, Norwich, Connecticut, United States",
            "Research Site, Washington, District of Columbia, United States",
            "Research Site, Gainsville, Florida, United States",
            "Research Site, Port St.Lucie, Florida, United States",
            "Research Site, Des Moines, Iowa, United States",
            "Research Site, Canton, Ohio, United States",
            "Research Site, Pittsburgh, Pennsylvania, United States",
            "Research Site, Nashville, Tennessee, United States",
            "Research Site, Salt Lake City, Utah, United States",
            "Research Site, Burlington, Vermont, United States",
            "Research Site, Norfolk, Virginia, United States",
            "Research Site, Seattle, Washington, United States",
            "Research Site, Wheeling, West Virginia, United States",
            "Research Site, Milwaukee, Wisconsin, United States",
            "Research Site, Buenos Aires, Buenos Aires Province, Argentina",
            "Research Site, Santa Fe, Santa Fe Province, Argentina",
            "Research Site, Hornsby, New South Wales, Australia",
            "Research Site, St Leonards, New South Wales, Australia",
            "Research Site, Redcliffe, Queensland, Australia",
            "Research Site, Ashford, South Australia, Australia",
            "Research Site, Subiaco, Western Australia, Australia",
            "Research Site, Graz, Austria",
            "Research Site, Wels, Austria",
            "Research Site, Brussels, Belgium",
            "Research Site, Gent, Belgium",
            "Research Site, Kortrijk, Belgium",
            "Research Site, Leuven, Belgium",
            "Research Site, Fortaleza, Ceara, Brazil",
            "Research Site, Goiania, Goias, Brazil",
            "Research Site, Belo Horizonte, Minas Gerais, Brazil",
            "Research Site, Curitiba, Parana, Brazil",
            "Research Site, Porto Alegre, Rio Grande do Sul, Brazil",
            "Research Site, Ribeirao Preto, Sao Paulo, Brazil",
            "Research Site, Santo Andre, Sao Paulo, Brazil",
            "Research Site, Sao Paulo, Brazil",
            "Research Site, Calgary, Alberta, Canada",
            "Research Site, Edmonton, Alberta, Canada",
            "Research Site, Vancouver, British Columbia, Canada",
            "Research Site, Kentville, Nova Scotia, Canada",
            "Research Site, Barrie, Ontario, Canada",
            "Research Site, Burlington, Ontario, Canada",
            "Research Site, Hamilton, Ontario, Canada",
            "Research Site, Kitchener, Ontario, Canada",
            "Research Site, London, Ontario, Canada",
            "Research Site, Mississauga, Ontario, Canada",
            "Research Site, North York, Ontario, Canada",
            "Research Site, Oakville, Ontario, Canada",
            "Research Site, Ottawa, Ontario, Canada",
            "Research Site, Toronto, Ontario, Canada",
            "Research Site, Granby, Quebec, Canada",
            "Research Site, Laval, Quebec, Canada",
            "Research Site, Montreal, Quebec, Canada",
            "Research Site, Point-Claire, Quebec, Canada",
            "Research Site, Quebec City, Quebec, Canada",
            "Research Site, Quebec, Canada",
            "Research Site, Haidian District, Beijing, China",
            "Research Site, Xi Cheng District, Beijing, China",
            "Research Site, Xicheng District, Beijing, China",
            "Research Site, Wuhan, Hubei, China",
            "Research Site, Nanjing, Jiangsu, China",
            "Research Site, Pudong New Area, Shanghai, China",
            "Research Site, Shanghai, Shanghai, China",
            "Research Site, Xuhui District, Shanghai, China",
            "Research Site, Xi'an, Shanxi, China",
            "Research Site, Prague 4, Prague, Czech Republic",
            "Research Site, Prague 6, Prague, Czech Republic",
            "Research Site, Brno, Czech Republic",
            "Research Site, Olomouc, Czech Republic",
            "Research Site, Usti nad Labem, Czech Republic",
            "Research Site, Aalborg, Denmark",
            "Research Site, Aarhus, Denmark",
            "Research Site, Herlev, Denmark",
            "Research Site, Kobenhavn, Denmark",
            "Research Site, Joensuu, Finland",
            "Research Site, Kajaanintie, Finland",
            "Research Site, Tampere, Finland",
            "Research Site, Montpellier, France",
            "Research Site, Paris, France",
            "Research Site, Poitiers Cedex, France",
            "Research Site, Suresnes, France",
            "Research Site, Toulouse, France",
            "Research Site, Villejuif, France",
            "Research Site, Planegg, Muenchen, Germany",
            "Research Site, Kirchheim, Teck, Germany",
            "Research Site, Augsburg, Germany",
            "Research Site, Bad Gegeberg, Germany",
            "Research Site, Berlin, Germany",
            "Research Site, Emmendingen, Germany",
            "Research Site, Leipzig, Germany",
            "Research Site, Luebeck, Germany",
            "Research Site, Mannheim, Germany",
            "Research Site, Muenchen, Germany",
            "Research Site, Reutlingen, Germany",
            "Research Site, Hong Kong, Hong Kong",
            "Research Site, Shatin, Hong Kong",
            "Research Site, Tuen Mun, Hong Kong",
            "Research Site, Budapest, Hungary",
            "Research Site, Debrecen, Hungary",
            "Research Site, Miskolc, Hungary",
            "Research Site, Nyiregyhaza, Hungary",
            "Research Site, Szeged, Hungary",
            "Research Site, Rohini, Delhi, India",
            "Research Site, Trivandrum, Kerala, India",
            "Research Site, Bhopal, Madhya Pradesh, India",
            "Research Site, Mumbai, Maharashtra, India",
            "Research Site, Chandigarh, Punjab, India",
            "Research Site, Ludhiana, Punjab, India",
            "Research Site, Bikaner, Rajasthan, India",
            "Research Site, Jaipur, Rajasthan, India",
            "Research Site, Kolkota, West Bengal, India",
            "Research Site, Gujarat, India",
            "Research Site, New Delhi, India",
            "Research Site, Milan, Italy",
            "Research Site, Rome, Italy",
            "Research Site, Asahi-City, Chiba, Japan",
            "Research Site, Chiba-City, Chiba, Japan",
            "Research Site, Narashino-city, Chiba, Japan",
            "Research Site, Matsuyama-City, Ehime, Japan",
            "Research Site, Fukuoka-City, Fukuoka, Japan",
            "Research Site, Maebashi-City, Gunma, Japan",
            "Research Site, Otake-City, Hiroshima, Japan",
            "Research Site, Sapporo-City, Hokkaido, Japan",
            "Research Site, Kobe-City, Hyogo, Japan",
            "Research Site, Tsukuba-City, Ibaraki, Japan",
            "Research Site, Kita-gun, Kagawa, Japan",
            "Research Site, Sagamihara-City, Kanagawa, Japan",
            "Research Site, Kyoto-City, Kyoto, Japan",
            "Research Site, Sendai-City, Miyagi, Japan",
            "Research Site, Oita-City, Oita, Japan",
            "Research Site, Osaka-City, Osaka, Japan",
            "Research Site, Osaka-Sayama-City, Osaka, Japan",
            "Research Site, Suita-City, Osaka, Japan",
            "Research Site, Wako-City, Saitama, Japan",
            "Research Site, Hamamatsu-city, Shizuoka, Japan",
            "Research Site, Sunto-gun, Shizuoka, Japan",
            "Research Site, Bunkyo-ku, Tokyo, Japan",
            "Research Site, Fuchu_city, Tokyo, Japan",
            "Research Site, Itabashi-Ku, Tokyo, Japan",
            "Research Site, Meguro-ku, Tokyo, Japan",
            "Research Site, Mitaka-City, Tokyo, Japan",
            "Research Site, Shinjuku-ku, Tokyo, Japan",
            "Research Site, Nagasaki, Japan",
            "Research Site, Heungduk-gu Cheongju, Chungbuk, Korea, Republic of",
            "Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of",
            "Research Site, Seo-gu, Pusan, Korea, Republic of",
            "Research Site, Gangnam-gu, Seoul, Korea, Republic of",
            "Research Site, Songpa-gu, Seoul, Korea, Republic of",
            "Research Site, Metepec, Estado de Mexico, Mexico",
            "Research Site, Distrito Federal Ciudad, Mexico",
            "Research Site, Mexico City, Mexico",
            "Research Site, Amsterdam, Netherlands",
            "Research Site, Eindhoven, Netherlands",
            "Research Site, Groningen, Netherlands",
            "Research Site, Nijmegen, Netherlands",
            "Research Site, Bialystok, Poland",
            "Research Site, Koscierzyna, Poland",
            "Research Site, Krakow, Poland",
            "Research Site, Rzeszow, Poland",
            "Research Site, Warszawa, Poland",
            "Research Site, Wroclaw, Poland",
            "Research Site, Coimbra, Portugal",
            "Research Site, Lisboa, Portugal",
            "Research Site, Porto, Portugal",
            "Research Site, Stary Oskol, Belgorodskaya region, Russian Federation",
            "Research Site, Barnaul, Russian Federation",
            "Research Site, Izhevsk, Russian Federation",
            "Research Site, Kursk, Russian Federation",
            "Research Site, Moscow, Russian Federation",
            "Research Site, Sochi, Russian Federation",
            "Research Site, St. Petersgurg, Russian Federation",
            "Research Site, Voronezh, Russian Federation",
            "Research Site, Belgrade, Serbia",
            "Research Site, Nis, Serbia",
            "Research Site, Novi Sad, Serbia",
            "Research Site, Singapore, Singapore",
            "Research Site, Tygerberg, Cape Town, South Africa",
            "Research Site, Bloemfontein, South Africa",
            "Research Site, Pietermaritzburg, South Africa",
            "Research Site, Port Elizabeth, South Africa",
            "Research Site, Goteborg, Sweden",
            "Research Site, Gothenburg, Sweden",
            "Research Site, Stockholm, Sweden",
            "Research Site, Basel, Switzerland",
            "Research Site, Bern, Switzerland",
            "Research Site, Locarno, Switzerland",
            "Research Site, Sursee, Switzerland",
            "Research Site, Kaohsiung, Taiwan",
            "Research Site, Taipei, Taiwan",
            "Research Site, Taoyuan, Taiwan",
            "Research Site, Reading, Berkshire, United Kingdom",
            "Research Site, Cambridge, Cambridgeshire, United Kingdom",
            "Research Site, Maidstone, Kent, United Kingdom",
            "Research Site, Huddersfield, Yorkshire, United Kingdom",
            "Research Site, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00554229"
      },
      {
        "-rank": "170",
        "nct_id": "NCT03081481",
        "title": "Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "PRX302"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]",
            "Proportion of patients with an absence of clinically significant prostate cancer in the targeted area at 24 weeks post-administration of PRX302, as determined by a transperineal targeted biopsy [Efficacy]"
          ]
        },
        "sponsors": { "lead_sponsor": "Sophiris Bio Corp" },
        "gender": "Male",
        "min_age": "40 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "38",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "PRX302-2-08" },
        "start_date": "June 7, 2017",
        "primary_completion_date": "November 28, 2018",
        "completion_date": "April 5, 2019",
        "study_first_posted": "March 16, 2017",
        "last_update_posted": "April 10, 2019",
        "locations": {
          "location": [
            "Vantage Health, Ocala, Florida, United States",
            "Chesapeake Urology Associates, Baltimore, Maryland, United States",
            "New York Urology Associates, New York, New York, United States",
            "Baylor Scott & White Memorial Hospital and Clinic, Temple, Texas, United States",
            "Princess Alexandra Hospital, Harlow, United Kingdom",
            "Imperial College, London, United Kingdom",
            "University College Hospital (UCLH), London, United Kingdom",
            "University Hospital Southampton, Southampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03081481"
      },
      {
        "-rank": "171",
        "nct_id": "NCT01234311",
        "title": "A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "tasquinimod"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": { "outcome_measure": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer" },
        "sponsors": { "lead_sponsor": "Active Biotech AB" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1245",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "10TASQ10" },
        "start_date": "March 2011",
        "primary_completion_date": "February 2015",
        "completion_date": "August 2015",
        "study_first_posted": "November 4, 2010",
        "last_update_posted": "October 21, 2015",
        "locations": {
          "location": [
            "Tucson, Arizona, United States",
            "Oxnard, California, United States",
            "Santa Monica, California, United States",
            "Santa Rosa, California, United States",
            "Wellington, Florida, United States",
            "Atlanta, Georgia, United States",
            "Meridian, Idaho, United States",
            "Melrose Park, Illinois, United States",
            "Park Ridge, Illinois, United States",
            "Jeffersonville, Indiana, United States",
            "Baltimore, Maryland, United States",
            "Rockville, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Jefferson City, Missouri, United States",
            "Las Vegas, Nevada, United States",
            "Hackensack, New Jersey, United States",
            "Lawrenceville, New Jersey, United States",
            "Buffalo, New York, United States",
            "Poughkeepsie, New York, United States",
            "Concord, North Carolina, United States",
            "Durham, North Carolina, United States",
            "Raleigh, North Carolina, United States",
            "Springfield, Oregon, United States",
            "Bala Cynwyd, Pennsylvania, United States",
            "Lancaster, Pennsylvania, United States",
            "Pittsburgh, Pennsylvania, United States",
            "Myrtle Beach, South Carolina, United States",
            "Nashville, Tennessee, United States",
            "Dallas, Texas, United States",
            "Salt Lake, Utah, United States",
            "Fairfax, Virginia, United States",
            "Norfolk, Virginia, United States",
            "Salem, Virginia, United States",
            "Burien, Washington, United States",
            "Ciudad Autonoma de Buenos Aires, Argentina",
            "Santa Rosa, Argentina",
            "Venado Tuerto, Argentina",
            "Camperdown, New South Wales, Australia",
            "Coffs Harbour, New South Wales, Australia",
            "Darlinghurst, New South Wales, Australia",
            "Tweed Heads, New South Wales, Australia",
            "Richmond, Victoria, Australia",
            "Subiaco, Western Australia, Australia",
            "Bruxelles, Belgium",
            "Gent, Belgium",
            "Kortrijk, Belgium",
            "Liege, Belgium",
            "Botucatu, Sao Paulo, Brazil",
            "Cachoeiro de Itapemirim - ES, Brazil",
            "Curitiba, Parana, Brazil",
            "Florianopolis, Brazil",
            "Juiz de Fora, Minas Gerais, Brazil",
            "Mogi das Cruzes, Sao Paulo, Brazil",
            "Natal, Rio Grande do Norte, Brazil",
            "Passo Fundo, Brazil",
            "Porto Alegre, RS, Brazil",
            "Rio de Janeiro, Brazil",
            "Salvador/BA, Brazil",
            "Sao Paulo, Brazil",
            "Volta Redonda - RJ, Brazil",
            "Pleven, Bulgaria",
            "Plovdiv, Bulgaria",
            "Sofia, Bulgaria",
            "Varna, Bulgaria",
            "Kelowna, British Columbia, Canada",
            "Victoria, British Columbia, Canada",
            "Brantford, Ontario, Canada",
            "North York, Ontario, Canada",
            "Oakville, Ontario, Canada",
            "Santiago, Chile",
            "Temuco, Chile",
            "Vina del Mar, Chile",
            "Beijing, China",
            "Chengdu, China",
            "Shanghai, China",
            "Shantou, China",
            "Wuhan, China",
            "Bogota, Colombia",
            "Cali, Colombia",
            "Novy Jicin, Czech Republic",
            "Olomouc, Czech Republic",
            "Praha 2, Czech Republic",
            "Praha 5, Czech Republic",
            "Usti nad Labem, Czech Republic",
            "Tartu, Estonia",
            "Angers, France",
            "Cannes, France",
            "Marseille, France",
            "Montpellier, France",
            "Paris, France",
            "Pierre Benite, France",
            "Rennes, France",
            "Suresnes, France",
            "Dresden, Germany",
            "Hamburg, Germany",
            "Koln, Germany",
            "Mannheim, Germany",
            "Marburg, Germany",
            "Munchen, Germany",
            "Munster, Germany",
            "Nurtingen, Germany",
            "Tubingen, Germany",
            "Weiden, Germany",
            "Athens, Greece",
            "Patras, Greece",
            "Thessaloniki, Greece",
            "Pune, India",
            "Beer-Sheva, Israel",
            "Haifa, Israel",
            "Jerusalem, Israel",
            "Petach Tikva, Israel",
            "Ramat-Gan, Israel",
            "Tel-Aviv, Israel",
            "Zerifin, Israel",
            "Cremona, Italy",
            "Lecco, Italy",
            "Meldola, Italy",
            "Milano, Italy",
            "Padova, Italy",
            "Ravenna, Italy",
            "Roma, Italy",
            "Torino, Italy",
            "Gwangju, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Liepaja, Latvia",
            "Riga, Latvia",
            "Beirut, Lebanon",
            "Bsalim, Lebanon",
            "Kaunas, Lithuania",
            "Vilnius, Lithuania",
            "Chihuahua, Chih., Mexico",
            "Culiacan, Sinaloa, Mexico",
            "Leon, GTO, Mexico",
            "Puebla, Mexico",
            "Zapopan, Jalisco, Mexico",
            "Amsterdam, Netherlands",
            "Groningen, Netherlands",
            "Leiden, Netherlands",
            "Nijmegen, Netherlands",
            "Tilburg, Netherlands",
            "Christchurch, New Zealand",
            "Nelson, New Zealand",
            "Palmerston North, New Zealand",
            "Tauranga, New Zealand",
            "Panama, Panama",
            "Arequipa, Peru",
            "Bialystok, Poland",
            "Lodz, Poland",
            "Myslowice, Poland",
            "Poznan, Poland",
            "Warszawa, Poland",
            "Wroclaw, Poland",
            "Baia Mare, Romania",
            "Bucharest, Romania",
            "Cluj-Napoca, Romania",
            "Craiova, Romania",
            "Ploiesti, Romania",
            "Suceava, Romania",
            "Timisoara, Romania",
            "Ekaterinburg, Russian Federation",
            "Moscow, Russian Federation",
            "Novosibirsk, Russian Federation",
            "Omsk, Russian Federation",
            "St. Petersburg, Russian Federation",
            "Vladimir, Russian Federation",
            "Bratislava, Slovakia",
            "Trencin, Slovakia",
            "Sevilla, Andalucia, Spain",
            "Zaragoza, Aragon, Spain",
            "Oviedo, Asturias, Spain",
            "Santander, Cantabria, Spain",
            "Sabadell, Cataluna, Spain",
            "Alcorcon, Madrid, Communidad de, Spain",
            "Pamplona, Navarra, Spain",
            "Barcelona, Spain",
            "San Sebastian de los Reyes, Spain",
            "Valencia, Spain",
            "GÃ¶teborg, Sweden",
            "Karlstad, Sweden",
            "Stockholm, Sweden",
            "Kaohsiung, Taiwan",
            "Taichung, Taiwan",
            "Taipei, Taiwan",
            "Taoyuan, Taiwan",
            "Istanbul, Turkey",
            "Chernivtsi, Ukraine",
            "Dnipropetrovsk, Ukraine",
            "Donetsk, Ukraine",
            "Ivano-Frankivsk, Ukraine",
            "Kharkiv, Ukraine",
            "Kyiv, Ukraine",
            "Lutsk, Ukraine",
            "Lviv, Ukraine",
            "Odesa, Ukraine",
            "Uzhgorod, Ukraine",
            "Zaporizhzhya, Ukraine",
            "Birmingham, United Kingdom",
            "Chichester, United Kingdom",
            "Leeds, United Kingdom",
            "London, United Kingdom",
            "Northwood, United Kingdom",
            "Nottingham, United Kingdom",
            "Oxford, United Kingdom",
            "Scunthorpe, United Kingdom",
            "Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01234311"
      },
      {
        "-rank": "172",
        "nct_id": "NCT00554918",
        "title": "Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Metastatic Cancer",
            "Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "prednisolone"
            },
            {
              "-type": "Drug",
              "#text": "zoledronic acid"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            },
            {
              "-type": "Radiation",
              "#text": "strontium chloride Sr 89"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety",
            "Toxicity and tolerability of docetaxel and zoledronic acid",
            "Toxicity and tolerability of docetaxel and strontium chloride Sr 89",
            "Toxicity and tolerability of docetaxel, zoledronic acid, and strontium chloride Sr 89",
            "Health Care economic analysis",
            "Changes in bone mineral density",
            "Median time to disease progression",
            "Pain progression-free survival (PFS)",
            "PSA PFS",
            "Pain response",
            "Overall survival",
            "Quality of life"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University Hospital Birmingham",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "300",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CRUK-TRAPEZE-2100",
            "CDR0000574585",
            "EUDRACT-2004-002295-41",
            "EU-20782",
            "ISRCTN12808747",
            "SANOFI-AVENTIS-CRUK-TRAPEZE-21",
            "NOVARTIS-CRUK-TRAPEZE-2100"
          ]
        },
        "start_date": "February 2005",
        "primary_completion_date": "December 2008",
        "completion_date": "June 2013",
        "study_first_posted": "November 7, 2007",
        "last_update_posted": "August 7, 2013",
        "locations": {
          "location": [
            "Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom",
            "Gloucestershire Oncology Centre at Cheltenham General Hospital, Cheltenham, England, United Kingdom",
            "Gloucestershire Royal Hospital, Gloucester, England, United Kingdom",
            "Ipswich Hospital, Ipswich, England, United Kingdom",
            "Mid Kent Oncology Centre at Maidstone Hospital, Maidstone, England, United Kingdom",
            "Christie Hospital, Manchester, England, United Kingdom",
            "Royal Marsden - Surrey, Sutton, England, United Kingdom",
            "Walsall Manor Hospital, Walsall, England, United Kingdom",
            "Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom",
            "Ayr Hospital, Ayr, Scotland, United Kingdom",
            "Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom",
            "Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom",
            "Crosshouse Hospital, Kilmarnock, Scotland, United Kingdom",
            "Wishaw General Hospital, Wishaw, Scotland, United Kingdom",
            "Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom",
            "Glan Clwyd Hospital, Rhyl, Denbighshire, Wales, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00554918"
      },
      {
        "-rank": "173",
        "nct_id": "NCT01234350",
        "title": "A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "outcome_measures": {
          "outcome_measure": [
            "Incidence Rate of Adverse Events of Special Interest (AESI): Cardiovascular Events",
            "Incidence Rate of AESI: Decreased Bone Density",
            "Incidence Rate of AESI: Glucose Intolerance or Type 2 Diabetes Mellitus (T2DM)",
            "Change in Hepatic Enzymes",
            "Change in Serum Glucose",
            "Number and Classification of New Adverse Drug Reactions (ADRs)",
            "Long Term Evaluation of Clinical Evolution of Prostate Cancer",
            "Changes in Testosterone Levels",
            "All-cause of Mortality"
          ]
        },
        "sponsors": { "lead_sponsor": "Ferring Pharmaceuticals" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "1493",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "FE200486 CS39" },
        "start_date": "January 2011",
        "primary_completion_date": "March 27, 2018",
        "completion_date": "March 27, 2018",
        "study_first_posted": "November 4, 2010",
        "results_first_posted": "May 20, 2019",
        "last_update_posted": "June 25, 2019",
        "locations": {
          "location": [
            "Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium",
            "Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg, Antwerpen, Belgium",
            "AZ Sint-Jan AV, Brugge, Belgium",
            "HÃ´pitaux IRIS Sud, Bruxelles, Belgium",
            "UniversitÃ© Catholique de Louvain, Bruxelles, Belgium",
            "HÃ´pital Erasme, Bruxelle, Belgium",
            "AZ Sint-Blasius, Dendermonde, Belgium",
            "AZ Jan Palfijn, Gent, Belgium",
            "AZ Maria Middelares, Gent, Belgium",
            "AZ Sint-Lucas, Gent, Belgium",
            "UZ Gent, Gent, Belgium",
            "Regionaal Ziekenhuis Jan Yperman VZW, Ieper, Belgium",
            "AZ Groeninge - Campus Sint-Maarten, Kortrijk, Belgium",
            "CHU de LiÃ¨ge, LiÃ¨ge, Belgium",
            "Centre Hospitalier Universitaire Ambroise ParÃ©, Mons, Belgium",
            "AZ Damiaan, Oostende, Belgium",
            "AZ-Sint-Elizabeth VZW, Zottegem, Belgium",
            "Aalborg Sygehus, Aalborg, Denmark",
            "Fredericia Hospital, Sygehus Lillebaelt, Fredericia, Denmark",
            "Herlev Hospital, Herlev, Denmark",
            "Holstebro Sygehus, Holstebro, Denmark",
            "Rigshospitalet, Kobenhavn, Denmark",
            "Regionhospitalet Viborg, Viborg, Denmark",
            "Docrates clinic, Helsinki, Finland",
            "Pohjois-Karjalan keskussairaala, Joensuu, Finland",
            "SeinÃ¤joen keskussairaala, SeinÃ¤joki, Finland",
            "Tampereen yliopistollinen sairaala, Tampere, Finland",
            "Turun yliopistollinen keskussairaala, Turku, Finland",
            "Peijaksen sairaala, Vantaa, Finland",
            "CHRU Angers, Angers, France",
            "Centre Hospitalier d'Athis Mons site Caron, Athis Mons, France",
            "Hopital Tenon, Aubervilliers, France",
            "Clinique Rhone Durance, Avignon, France",
            "CHU Saint-Jacques, BesanÃ§on, France",
            "Centre Hospitalier Laennec, Clermont Ferrand, France",
            "Chu Gabriel Montpied, Clermont-Ferrand, France",
            "Ramsay Sante, Evry, France",
            "Groupement hospitalier Edouard Herriot, Lyon, France",
            "Cabinet MÃ©dical 65 prado, Marseille, France",
            "CHU Nord, Marseille, France",
            "Hopital de la Conception, Marseille, France",
            "Polyclinique Saint-Jean, Melun, France",
            "Clinique du Pont de Chaume, Montauban, France",
            "Clinique Beausoleil, Montpellier, France",
            "Centre d'Urologie de Nancy, Nancy, France",
            "HÃ´pital Max Fourestier, Nanterre, France",
            "Centre Hospitalier Georges Renon, Niort, France",
            "Groupe hospitalo-universitaire Caremeau, NÃ®mes, France",
            "Hopital Tenon, Paris, France",
            "Clinique du Ter, Ploemeur, France",
            "Clinic De L'Europe, Pontoise, France",
            "Hopital Pontchaillou, Rennes, France",
            "Clinique Saint Michel, Toulon, France",
            "Clinique St Jean Languedoc, Toulouse, France",
            "Hopital Bretonneau, Tours, France",
            "CHU Brabois, Vandoeuvre les Nancy, France",
            "Gemeinschaftspraxis Dres Effert und Benedic, Aachen, Germany",
            "Praxis Dr. Schlichter, Bad Bergzabern, Germany",
            "Praxis Dr. Markus Hentschel, Bautzen, Germany",
            "Praxis Dr. Richter, Bonn, Germany",
            "Urologie im Schlosscarree, Braunschweig, Germany",
            "Praxis Dr. Ahmad Haider, Bremerhaven, Germany",
            "Praxis Dr. Krieger, Chemnitz, Germany",
            "Urologie Chemnitz, Chemnitz, Germany",
            "Gemeinschaftspraxis fur Urologie, Dachau, Germany",
            "Klinikpraxis fur Urologie, Dinslaken, Germany",
            "Praxis Dr. SchÃ¶nfelder, Hamburg, Germany",
            "Gemeinschaftspraxis Urologie, Kiel, Germany",
            "Urologische Gemeinschaftspraxis, Kiel, Germany",
            "Gemeinshaftspraxis Rudolph & WÃ¶rner, Kirchheim, Germany",
            "Praxis Dr. Thomas Harms, Koln, Germany",
            "Vituro, Leipzig, Germany",
            "Praxis Alexander von Keitz, Marburg, Germany",
            "Praxis Dr. Peczat, Nienburg, Germany",
            "Studienzentrum MÃ¼nchen-Planegg, Planegg, Germany",
            "Urologische Gemeinschaftspraxis, Reutlingen, Germany",
            "Praxis Dr. Jan Franz, Tostedt, Germany",
            "Praxis fur Urologie, Wuppertal, Germany",
            "\"Agios Savas\" Anticancer-Oncology Hospital of Athens, Athens, Greece",
            "\"G. Gennimtas\" General Hospital of Athens, Athens, Greece",
            "\"Laiko\" General Hospital of Athens, Athens, Greece",
            "Amalia Fleming General Hospital of Athens, Athens, Greece",
            "Errikos Dynan Hospital of Athens, Athens, Greece",
            "Eurokliniki Hospital of Athens, Athens, Greece",
            "Evaggelismos General Hospital, Athens, Greece",
            "General Hospital of Athens \"Ag. Olga\" - Konstantopouleion, Athens, Greece",
            "Ippokrateio Hospital of Athens, Athens, Greece",
            "Korgialenio-Benakio, Athens, Greece",
            "Pe. Pa.G.N:I Hospital, Heraklion, Greece",
            "General hospital of Kalamata, Kalamata, Greece",
            "IASO General Hospital, Kalamata, Greece",
            "University Hospital of Larissa, Larissa, Greece",
            "Aghios Andreas General Hospital of Patras, Patras, Greece",
            "University General Hospital of Patras, Patras, Greece",
            "General Hospital of Piraeus \"Tzanneio\", Piraeus, Greece",
            "\"G. Gennimtas\" General Hospital of Thessaloniki, Thessaloniki, Greece",
            "2nd IKA-ETAM \"Panagia\" General Hospital of Thessaloniki, Thessaloniki, Greece",
            "Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece",
            "General Hospital of Volos \"Achillopouleio\", Volos, Greece",
            "Azarka Zsuzsanna Ã©s TÃ¡rsa Bt, Budapest, Hungary",
            "UROFOR Bt, Debrecen, Hungary",
            "Kiskunhalasi Semmelweis KÃ³rhÃ¡z Kht., Kiskunhalas, Hungary",
            "Miskolci Semmelweis IgnÃ¡c EgÃ©szsÃ©gÃ¼gyi KÃ¶zpont Ã©s Egyetemi OktatÃ³ KÃ³rhÃ¡z Nonprofit Kft, Miskolc, Hungary",
            "Uro-Clin Kft, PÃ©cs, Hungary",
            "FEjÃ©r Megyei Szent GyÃ¶rgy KÃ³rhaz, SzÃ©kesfehÃ©rvÃ¡r, Hungary",
            "Beacon Hospital, Dublin, Ireland",
            "Beaumont Hospital, Dublin, Ireland",
            "University College Hospital, Galway, Ireland",
            "Medical Consulting Center S.r.l., Avellino, Italy",
            "Azienda Sanitaria Regionale del Molise (ASREM), Campobasso, Italy",
            "Azienda Ospedaliera Mater Domini di Catanzaro, Catanzaro, Italy",
            "Azienda Ospedaliera Carlo Poma, Mantova, Italy",
            "Ospedale Luigi Sacco, Milano, Italy",
            "Azienda Ospedaliera Monaldi, Napoli, Italy",
            "Azienda Sanitaria Locale Salerno, Nocera Inferiore, Italy",
            "Ospedale Santa Maria delle Croci, Ravenna, Italy",
            "Azienda Ospedaliera \"Bianchi-Melacrino-Morelli\", Reggio Calabria, Italy",
            "Istituto Nazionale Tumori \"Regina Elena\", Roma, Italy",
            "Azienda Ospedaliera Universitaria OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy",
            "ASL 4 di Teramo, Teramo, Italy",
            "Ospedale \"San Pio da Pietrelcina\", Vasto, Italy",
            "AMC, Amsterdam, Netherlands",
            "MC Haaglanden, Den Haag, Netherlands",
            "Catharina ziekenhuis, Eindhoven, Netherlands",
            "Groene Hart Ziekenhuis, Gouda, Netherlands",
            "Diaconessenhuis Leiden, Leiden, Netherlands",
            "Vestre Viken HF, Sykehuset Asker og Baerum, Asker, Norway",
            "Haukeland Universitetssykehus, Bergen, Norway",
            "Helse Nordmore og Romsdal HF, Kristiansund Sykehus, Kristiansund, Norway",
            "Olso Universitetssykehus HF, Radiumhospitalet, Oslo, Norway",
            "Oslo Universitetssykehus, Aker, Oslo, Norway",
            "Clinica de Santo Antonio, Lisboa, Portugal",
            "Hospital Militar, Lisboa, Portugal",
            "Hospital Santa Maria, Lisboa, Portugal",
            "VEBMED, s.r.o., Bosany, Slovakia",
            "CUIMED, s.r.o., Bratislava, Slovakia",
            "Nemocnica Svateho Michala, a.s., Bratislava, Slovakia",
            "Univerzitna nemocnica Bratislava, Bratislava, Slovakia",
            "URO clinic, s.r.o., Bratislava, Slovakia",
            "Poliklinika Galanta, Galanta, Slovakia",
            "MEDICONA s.r.o., Kosice, Slovakia",
            "UROCENTRUM LEVICE, s.r.o., Levice, Slovakia",
            "Poliklinika Malacky, Malacky, Slovakia",
            "Univerzitna nemocnica Martin, Martin, Slovakia",
            "UROEXAM, spol. s r.o., Nitra, Slovakia",
            "CENTRUM UROLOGIE Povazska Bystrica s.r.o, Povazska Bystrica, Slovakia",
            "MILAB, s.r.o., Presov, Slovakia",
            "UROCENTRUM SALA, s.r.o., Sala, Slovakia",
            "Nemocnica s poliklinikou Skalica, a.s., Skalica, Slovakia",
            "M & M & M, s.r.o., Topolcany, Slovakia",
            "PRIVATNA UROLOGICKA AMBULANCIA s.r.o., Trencin, Slovakia",
            "UROREX, s.r.o., Vrable, Slovakia",
            "UniversitÃ¤tsspital Basel, Basel, Switzerland",
            "Urozentrum ZÃ¼rich, Zurich, Switzerland",
            "Homerton University Hospital, London, United Kingdom",
            "Kings College Hospital, London, United Kingdom",
            "Royal Marsden Hospital, London, United Kingdom",
            "Whipps Cross Hospital, London, United Kingdom",
            "East Surrey Hospital, Redhill, United Kingdom",
            "Sunderland Royal Hospital, Sunderland, United Kingdom"
          ]
        },
        "study_documents": {
          "study_document": [
            {
              "label": "Study Protocol",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/50/NCT01234350/Prot_000.pdf"
            },
            {
              "label": "Statistical Analysis Plan",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/50/NCT01234350/SAP_001.pdf"
            }
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01234350"
      },
      {
        "-rank": "174",
        "nct_id": "NCT01322490",
        "title": "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer",
        "acronym": "Prospect",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer Metastatic" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "PROSTVAC-V"
            },
            {
              "-type": "Biological",
              "#text": "PROSTVAC-F"
            },
            {
              "-type": "Drug",
              "#text": "GM-CSF"
            },
            {
              "-type": "Other",
              "#text": "GM-CSF Placebo"
            },
            {
              "-type": "Biological",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Number of Subjects Alive Without Event at 6 Months"
          ]
        },
        "sponsors": { "lead_sponsor": "Bavarian Nordic" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1297",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "BNIT-PRV-301" },
        "start_date": "November 28, 2011",
        "primary_completion_date": "September 25, 2017",
        "completion_date": "December 15, 2017",
        "study_first_posted": "March 24, 2011",
        "results_first_posted": "August 8, 2019",
        "last_update_posted": "September 4, 2019",
        "locations": {
          "location": [
            "Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States",
            "Scottsdale Healthcare, Scottsdale, Arizona, United States",
            "Alta Bates Summit Medical Center, Berkeley, California, United States",
            "Cedars-Sinai Medical Center, Los Angeles, California, United States",
            "Prostate Oncology Specialists, Inc., Marina Del Rey, California, United States",
            "Desert Hematology-Oncology, Rancho Mirage, California, United States",
            "San Bernardino Urological Associates, San Bernardino, California, United States",
            "San Diego Clinical Trials, San Diego, California, United States",
            "Sharp Memorial Hospital, San Diego, California, United States",
            "VA San Diego Healthcare System, San Diego, California, United States",
            "Stanford Advanced Medical Center, Stanford, California, United States",
            "University of Colorado, Aurora, Colorado, United States",
            "The Urology Center of Colorado, Denver, Colorado, United States",
            "Washington Cancer Institute, Washington, District of Columbia, United States",
            "South Florida Medical Research, Aventura, Florida, United States",
            "Manatee Medical Research Institute, LLC, Bradenton, Florida, United States",
            "Florida Urology Physicians, Fort Myers, Florida, United States",
            "Lakeland Regional Cancer Center, Lakeland, Florida, United States",
            "Pinellas Urology, Inc., Saint Petersburg, Florida, United States",
            "James A Haley Veteran Affairs Medical Center, Tampa, Florida, United States",
            "Palm Beach Cancer Institute, West Palm Beach, Florida, United States",
            "North Idaho Urology, Coeur d'Alene, Idaho, United States",
            "Jesse Brown VA, Chicago, Illinois, United States",
            "First Urology PSC, Jeffersonville, Indiana, United States",
            "Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States",
            "The Iowa Clinic, PC Iowa Urology, West Des Moines, Iowa, United States",
            "Tulane University, New Orleans, Louisiana, United States",
            "Ochsner Cancer Institute, New Orleans, Louisiana, United States",
            "Maryland Prostate Center, Baltimore, Maryland, United States",
            "Greater Baltimore Medical Center, Baltimore, Maryland, United States",
            "Union Memorial Hospital, Baltimore, Maryland, United States",
            "Walter Reed Army Medical Center, Bethesda, Maryland, United States",
            "National Cancer Institute - Center for Cancer Research, Bethesda, Maryland, United States",
            "Myron Murdock M.D. LLC, Greenbelt, Maryland, United States",
            "Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",
            "Dana Farber Cancer Institute, Boston, Massachusetts, United States",
            "Mayo Clinic, Rochester, Minnesota, United States",
            "Kansas City VA Medical Center, Kansas City, Missouri, United States",
            "GU Research Network, LLC, Omaha, Nebraska, United States",
            "Nebraska Cancer Specialists, Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "VA Sierra Nevada HealthCare System, Reno, Nevada, United States",
            "Delaware Valley Urology LLC - Westhampton, Mount Laurel, New Jersey, United States",
            "The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",
            "Brooklyn Urology Research Group, Brooklyn, New York, United States",
            "University Urology Associates, New York, New York, United States",
            "Hudson Valley Urology, P.C., Poughkeepsie, New York, United States",
            "Presbyterian Hospital Center for Cancer Research, Charlotte, North Carolina, United States",
            "Northeast Urology Research, Concord, North Carolina, United States",
            "Regional Cancer Care PA, Durham, North Carolina, United States",
            "Durham VA Medical Center, Durham, North Carolina, United States",
            "W.G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina, United States",
            "St. Alexius Medical Center, Bismarck, North Dakota, United States",
            "Gabrail Cancer Center, Canton, Ohio, United States",
            "University of Cincinnati Medical Center, Cincinnati, Ohio, United States",
            "University Hospitals Case Medical Center, Cleveland, Ohio, United States",
            "Cleveland Clinic Foundation, Cleveland, Ohio, United States",
            "Columbus Urology Research, Columbus, Ohio, United States",
            "Willamette Valley Cancer Center, Springfield, Oregon, United States",
            "Urologic Consultants of Southeaster PA LLP, Bala-Cynwyd, Pennsylvania, United States",
            "Urological Associates Of Lancaster, Lancaster, Pennsylvania, United States",
            "Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",
            "UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States",
            "Mount Nittany Medical Center, State College, Pennsylvania, United States",
            "Ralph H Johnson VAMC, Charleston, South Carolina, United States",
            "WJB Dorn VA Medical Center, Columbia, South Carolina, United States",
            "Greenville Hospital System, Greenville, South Carolina, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "University of TN Medical Center, Knoxville, Tennessee, United States",
            "The West Clinic, P.C., Memphis, Tennessee, United States",
            "James H. Quillen Veterans Affairs Medical Center, Mountain Home, Tennessee, United States",
            "Urology Associates, PC, Nashville, Tennessee, United States",
            "Urology Clinics of North Texas, Dallas, Texas, United States",
            "Mary Crowley Cancer Research Center, Dallas, Texas, United States",
            "Central Texas Veterans Health Care System, Temple, Texas, United States",
            "Scott and White Memorial Hospital, Temple, Texas, United States",
            "Salt Lake Research, Salt Lake City, Utah, United States",
            "University of Utah, Salt Lake City, Utah, United States",
            "White River Junction Veterans Affairs Medical Center, White River Junction, Vermont, United States",
            "Virginia Oncology Associates PC, Norfolk, Virginia, United States",
            "Virginia Mason Medical Center, Seattle, Washington, United States",
            "Madigan Army Medical Center, Tacoma, Washington, United States",
            "The Schiffler Cancer Center, Wheeling, West Virginia, United States",
            "Medical College of Wisconsin, Milwaukee, Wisconsin, United States",
            "Sydney Haematology and Oncology Clinic, St Leonards, New South Wales, Australia",
            "Calvary Mater Newcastle, Waratah, New South Wales, Australia",
            "Redcliffe Hospital, Redcliffe, Queensland, Australia",
            "Royal Adelaide Hospital, Adelaide, South Australia, Australia",
            "Austin Hospital, Heidelberg, Victoria, Australia",
            "Monash Medical Centre - Moorabbin Campus, Bentleigh East, Australia",
            "Barwon Health, Geelong, Australia",
            "St John of God Hospital, Subiaco, Australia",
            "Border Medical Oncology, Wodonga, Australia",
            "Princess Alexandra Hospital, Woolloongabba, Australia",
            "Ziekenhuisnetwerk Antwerpen - AZ Middelheim, Antwerp, Belgium",
            "Cliniques Universitaires Saint-Luc, Brussels, Belgium",
            "Institut Jules Bordet, Bruxelles, Belgium",
            "AZ Maria Middelares, Gent, Belgium",
            "UZ Leuven, Leuven, Belgium",
            "H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium",
            "Southern Interior Medical Research Inc., Kelowna, British Columbia, Canada",
            "Capital District Health Authority, Halifax, Nova Scotia, Canada",
            "Brantford Urology Research, Brantford, Ontario, Canada",
            "Cambridge Memorial Hospital, Cambridge, Ontario, Canada",
            "St. Josephs Healthcare Hamilton Research Ethics Board, Hamilton, Ontario, Canada",
            "Queen's University at Kingston, Kingston, Ontario, Canada",
            "London Health Sciences Centre, London, Ontario, Canada",
            "The Female/Male Health Centres, Oakville, Ontario, Canada",
            "Princess Margaret Hospital, Toronto, Ontario, Canada",
            "Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada",
            "Centre Hospitalier Universitaire de Quebec Hotel Dieu, Quebec, Canada",
            "Aalborg Sygehus, Aalborg, Denmark",
            "Rigshospitalet, Copenhagen, Denmark",
            "Frederiksberg Hospital, Frederiksberg, Denmark",
            "Herlev Hospital, Herlev, Denmark",
            "Holstebro Sygehus, Holstebro, Denmark",
            "StorstrÃ¸mmens Sygehus NÃ¦stved, NÃ¦stved, Denmark",
            "Skejby Sygehus, Ã…rhus N, Denmark",
            "East Tallinn Central Hospital, Tallinn, Estonia",
            "North Estonia Medical Centre Foundation, Tallinn, Estonia",
            "Tartu University Hospital, Tartu, Estonia",
            "Centre Paul Papin, Angers, France",
            "Centre Hospitalier DÃ©partemental La Roche sur Yon, LuÃ§on, Montaigu - Les Oudaries, La Roche Sur Yon, France",
            "Centre LÃ©on BÃ©rard - Centre rÃ©gional de lutte contre le cancer RhÃ´ne-Alpes, Lyon, France",
            "Centre d'Oncologie de Gentilly, Nancy, France",
            "HIA du Val de GrÃ¢ce, Paris, France",
            "Institut Curie, Paris, France",
            "Fondation HÃ´pital Saint-Joseph, Paris, France",
            "Institut Mutualiste Montsouris, Paris, France",
            "Centre Hospitalier Lyon Sud, Pierre Benite, France",
            "Institut Jean Godinot - Centre de lutte contre le cancer, Reims, France",
            "Clinique Armoricaine de Radiologie, Saint Brieuc, France",
            "HÃ´pital Bretonneau, Tours, France",
            "Centre Alexis Vautrin - Centre RÃ©gional de lutte contre le cancer de Lorraine, Vandoeuvre les Nancy, France",
            "Stadtisches Klinikum Muchen GmbH, Munich, Bavaria, Germany",
            "UniversitÃ¤tsklinikum Bonn, Bonn, Germany",
            "UniversitÃ¤tsklinikum Essen, Essen, Germany",
            "Klinikum der Johann-Wolfgang-Goethe-UniversitÃ¤t Frankfurt am Main, Frankfurt, Germany",
            "Chirurgische UniversitÃ¤tsklinik Freiburg, Freiburg, Germany",
            "Martini-Klinik am UKE GmbH, Hamburg, Germany",
            "Klinikum der Friedrich-Schiller-UniversitÃ¤t Jena, Jena, Germany",
            "UniversitÃ¤tsmedizin der JGU Mainz, Mainz, Germany",
            "Klinikum der Philipps-UniversitÃ¤t Marburg, Marburg, Germany",
            "Studienpraxis Urologie, Reutlingen, Germany",
            "UniversitÃ¤tsklinikum TÃ¼bingen, TÃ¼bingen, Germany",
            "Universitatsklinikum Ulm, Ulm, Germany",
            "UniversitÃ¤tsklinikum Ulm, Ulm, Germany",
            "UniversitÃ¤tsklinikum WÃ¼rzburg, WÃ¼rzburg, Germany",
            "Landspitali University Hospital, Reykjavik, Iceland",
            "Soroka University Medical Center, Beer Sheva, Israel",
            "Bnei Zion Medical Center, Haifa, Israel",
            "Rambam Medical Center, Haifa, Israel",
            "Edith Wolfson Medical Center, Holon, Israel",
            "Hadassah University Hospital Ein Kerem, Jerusalem, Israel",
            "The Chaim Sheba Medical Center, Ramat-Gan, Israel",
            "Assaf Harofe Medical Center, Tzrifin, Israel",
            "NKI-AVL, Amsterdam, Netherlands",
            "VUMC, Amsterdam, Netherlands",
            "Academisch Ziekenhuis Maastricht, Maastricht, Netherlands",
            "Radboudumc, Nijmegen, Netherlands",
            "Erasmus MC, Rotterdam, Netherlands",
            "AMEDS CENTRUM Sp. z o.o., Grodzisk Mazowiecki, Poland",
            "Urologica Praktyka Lekarska Adam Marcheluk, Siedlce, Poland",
            "Szpital sw Elzbiety - Mokotowskie Centrum Medyczne Sp. z o. o., Warsaw, Poland",
            "Miedzyleski Szpital Specjalistyczny w Warszawie, Warsaw, Poland",
            "Klinika Urologii i Onkologii Urologicznej, Uniwersytecki Szpital Kliniczny we WrocÅ‚awiu, Wroclaw, Poland",
            "Ponce School of Medicine, Ponce, Puerto Rico",
            "Alliance for Research and Knowledge, San Juan, Puerto Rico",
            "Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation",
            "Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk, Russian Federation",
            "Kazan State Medical University, Kazan, Russian Federation",
            "Moscow Research Oncology Institute n.a. P.A.Gertsen, Moscow, Russian Federation",
            "Clinical Oncology Dispensary, Omsk, Russian Federation",
            "Orel Oncology Center, Orel, Russian Federation",
            "Orenburg Regional Clinical Oncology Center, Orenburg, Russian Federation",
            "St. Petersburg Medical Academy of Postgraduate Education, St. Petersburg, Russian Federation",
            "St. Petersburg State Medical University n.a. I.P. Pavlov, St. Petersburg, Russian Federation",
            "City Hospital #15, St. Petersburg, Russian Federation",
            "\"Orkli\" LLC, St. Petersburg, Russian Federation",
            "\"Clinic Andros\" LLC, St.Petersburg, Russian Federation",
            "Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation",
            "Regional Clinical Oncology Center, Vladimir, Russian Federation",
            "Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation",
            "Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain",
            "Hospital 12 de Octubre, Madrid, Madrid, Communidad De, Spain",
            "Clinica Universitaria de Navarra, Pamplona, Navarra, Spain",
            "Hospital Nuestra SeÃ±ora de Sonsoles, Avila, Spain",
            "Hospital del Mar, Barcelona, Spain",
            "Hospital Vall DÂ´Hebron, Barcelona, Spain",
            "Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",
            "Hospital Universitario Reina Sofia, CÃ³rdoba, Spain",
            "Hospital General Universitario de Elche, Elche, Spain",
            "Hospital General Universitario Gregorio MaraÃ±on, Madrid, Spain",
            "MD Anderson International Espana, Madrid, Spain",
            "Centro Integral OncolÃ³gico Clara Campal, Madrid, Spain",
            "Hospital Universitario FundaciÃ³n AlcorcÃ³n, Madrid, Spain",
            "Hospital Universitario Puerta de Hierro, Majadahonda, Spain",
            "Althaia: Xarxa Assistencial de Manresa, Manresa, Spain",
            "Hospital General Carlos Haya, MÃ¡laga, Spain",
            "Hospital Son Espases, Palma de Mallorca, Spain",
            "FundaciÃ³n Hospital Manacor, Palma de Mallorca, Spain",
            "Clinica Universitaria de Navarra, Pamplona, Spain",
            "CorporaciÃ³ Sanitaria Parc TaulÃ­, Sabadell, Spain",
            "Hospital Virgen del Rocio, Sevilla, Spain",
            "Hospital Mutua de Terrassa, Terrassa, Spain",
            "Hospital Universitario Miguel Servet, Zaragoza, Spain",
            "Bristol Haematology & Oncology Centre, Bristol, UK, United Kingdom",
            "University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, United Kingdom",
            "Velindre Hospital, Cardiff, United Kingdom",
            "Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom",
            "University of Surrey, Guildford, United Kingdom",
            "Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, United Kingdom",
            "St Bartholomews Hospital, London, United Kingdom",
            "The Royal Marsden, London, United Kingdom",
            "St Mary's Hospital, London, United Kingdom",
            "Christie Hospital, Manchester, United Kingdom",
            "Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth, United Kingdom",
            "University of Southampton, Southampton, United Kingdom",
            "Royal Marsden Hospital, Sutton, United Kingdom",
            "The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom"
          ]
        },
        "study_documents": {
          "study_document": [
            {
              "label": "Statistical Analysis Plan",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/90/NCT01322490/SAP_000.pdf"
            },
            {
              "label": "Study Protocol",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/90/NCT01322490/Prot_001.pdf"
            }
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01322490"
      },
      {
        "-rank": "175",
        "nct_id": "NCT01972217",
        "title": "Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Metastatic Castration-resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Olaparib"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone or prednisolone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Part A: Percentage of Patients Experiencing Adverse Events (AEs)",
            "Part A: Number of Patients With Dose Limiting Toxicities (DLTs)",
            "Part B: Median Radiological Progression-Free Survival (rPFS) Time",
            "Part B: Percentage of Patients With Progression Events or Death (rPFS)",
            "Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)",
            "Part A PK: Abiraterone Cmax,ss",
            "Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)",
            "Part A PK: Abiraterone Tmax,ss",
            "Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)",
            "Part A PK: Abiraterone Cmin,ss",
            "Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)",
            "Part A PK: Abiraterone AUCss",
            "Part B: Percentage of Patients Experiencing AEs",
            "Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels",
            "Part B: Percentage of Patients With PSA Responses",
            "Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level",
            "Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])",
            "Median Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)",
            "Part B: Median Overall Survival (OS)",
            "Part B: Median Time to Second Progression or Death (PFS2)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "AstraZeneca",
          "collaborator": "Merck Sharp & Dohme Corp."
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "130 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "158",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "D081DC00008",
            "UVA97934"
          ]
        },
        "start_date": "April 1, 2014",
        "primary_completion_date": "September 22, 2017",
        "completion_date": "December 31, 2019",
        "study_first_posted": "October 30, 2013",
        "results_first_posted": "October 2, 2018",
        "last_update_posted": "July 9, 2019",
        "locations": {
          "location": [
            "Research Site, San Diego, California, United States",
            "Research Site, Lake Success, New York, United States",
            "Research Site, Edegem, Belgium",
            "Research Site, LiÃ¨ge, Belgium",
            "Research Site, Wilrijk, Belgium",
            "Research Site, London, Ontario, Canada",
            "Research Site, Greenfield Park, Quebec, Canada",
            "Research Site, Montreal, Quebec, Canada",
            "Research Site, Brno, Czechia",
            "Research Site, Brno, Czechia",
            "Research Site, Liberec, Czechia",
            "Research Site, Angers, France",
            "Research Site, Dijon, France",
            "Research Site, LYON cedex 08, France",
            "Research Site, Lecce, Italy",
            "Research Site, Mirano, Italy",
            "Research Site, Napoli, Italy",
            "Research Site, Parma, Italy",
            "Research Site, Pisa, Italy",
            "Research Site, Arnhem, Netherlands",
            "Research Site, Maastricht, Netherlands",
            "Research Site, Nijmegen, Netherlands",
            "Research Site, GdaÅ„sk, Poland",
            "Research Site, Warszawa, Poland",
            "Research Site, Ivanovo, Russian Federation",
            "Research Site, Moscow, Russian Federation",
            "Research Site, Moscow, Russian Federation",
            "Research Site, St. Petersburg, Russian Federation",
            "Research Site, Badalona, Spain",
            "Research Site, CÃ³rdoba, Spain",
            "Research Site, Gerona, Spain",
            "Research Site, L'Hospitalet de Llobregat, Spain",
            "Research Site, Madrid, Spain",
            "Research Site, Palma de Mallorca, Spain",
            "Research Site, Valencia, Spain",
            "Research Site, Cardiff, United Kingdom",
            "Research Site, Exeter, United Kingdom",
            "Research Site, Manchester, United Kingdom",
            "Research Site, Plymouth, United Kingdom",
            "Research Site, Torquay, United Kingdom",
            "Research Site, Westcliff-on-Sea, United Kingdom"
          ]
        },
        "study_documents": {
          "study_document": [
            {
              "label": "Study Protocol",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/17/NCT01972217/Prot_000.pdf"
            },
            {
              "label": "Statistical Analysis Plan",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/17/NCT01972217/SAP_001.pdf"
            }
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01972217"
      },
      {
        "-rank": "176",
        "nct_id": "NCT01193244",
        "title": "Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Orteronel"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Progression-free Survival (rPFS)",
            "Overall Survival",
            "Percentage of Participants Achieving 50 Percent Reduction From Baseline in Prostate Specific Antigen (PSA50) Response at Week 12",
            "Percentage of Participants With Favorable Circulating Tumor Cell Count (CTC) Levels at Week 12",
            "Time to Pain Progression",
            "Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)",
            "Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to (>=) Grade 3",
            "Number of Participants With TEAEs Related to Vital Signs",
            "Number of Participants With TEAEs Related to Weight",
            "Number of Participants With Worst Change From Baseline in Eastern Co-operative Oncology Group (ECOG) Performance Status",
            "Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings",
            "Worst Change From Baseline Over Time in Cardiac Ejection Fraction",
            "Number of Participants With TEAEs Categorized Into Investigations Related to Chemistry, Hematology or Coagulation",
            "Percentage of Participants With Skeletal Related Events (SRE)",
            "Time to SRE",
            "Percentage of Participants Achieving PSA50 Response at Any Time During the Study",
            "Percentage of Participants Achieving 90 Percent Reduction From Baseline in Prostate Specific Antigen (PSA90 Response) at Week 12",
            "Percentage of Participants Achieving PSA90 Response at Any Time During the Study",
            "Time to PSA Progression",
            "Time to Docetaxel Chemotherapy",
            "Time to Subsequent Antineoplastic Therapy",
            "Percentage of Participants With Objective Response",
            "Time to Deterioration in Global Health Status"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Millennium Pharmaceuticals, Inc.",
          "collaborator": "Takeda"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1560",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "C21004",
            "2010-018661-35",
            "0991413276",
            "10/H0406/75",
            "U1111-1181-0387"
          ]
        },
        "start_date": "October 1, 2010",
        "primary_completion_date": "January 1, 2014",
        "completion_date": "April 7, 2016",
        "study_first_posted": "September 1, 2010",
        "results_first_posted": "May 17, 2017",
        "last_update_posted": "May 17, 2017",
        "locations": {
          "location": [
            "Anchorage, Alaska, United States",
            "Tucson, Arizona, United States",
            "Duarte, California, United States",
            "Highland, California, United States",
            "Orange, California, United States",
            "Sacramento, California, United States",
            "San Francisco, California, United States",
            "Aurora, Colorado, United States",
            "Denver, Colorado, United States",
            "Deerfield Beach, Florida, United States",
            "Fort Myers, Florida, United States",
            "Jacksonville, Florida, United States",
            "Orlando, Florida, United States",
            "Port St Lucie, Florida, United States",
            "Jeffersonville, Indiana, United States",
            "Kansas City, Kansas, United States",
            "New Orleans, Louisiana, United States",
            "Baltimore, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Lansing, Michigan, United States",
            "Duluth, Minnesota, United States",
            "Corinth, Mississippi, United States",
            "Columbia, Missouri, United States",
            "Jefferson City, Missouri, United States",
            "Omaha, Nebraska, United States",
            "Las Vegas, Nevada, United States",
            "Hackensack, New Jersey, United States",
            "East Syracuse, New York, United States",
            "New York, New York, United States",
            "Durham, North Carolina, United States",
            "Raleigh, North Carolina, United States",
            "Kettering, Ohio, United States",
            "Tualatin, Oregon, United States",
            "Hershey, Pennsylvania, United States",
            "Lancaster, Pennsylvania, United States",
            "Philadelphia, Pennsylvania, United States",
            "Piitsburgh, Pennsylvania, United States",
            "Charleston, South Carolina, United States",
            "Columbia, South Carolina, United States",
            "Chattanooga, Tennessee, United States",
            "Nashville, Tennessee, United States",
            "Amarillo, Texas, United States",
            "Bedford, Texas, United States",
            "Dallas, Texas, United States",
            "Denton, Texas, United States",
            "Tyler, Texas, United States",
            "Salt Lake City, Utah, United States",
            "Norfolk, Virginia, United States",
            "Garran, Australia",
            "Hobart, Australia",
            "Kurralta Park, Australia",
            "Nedlands, Australia",
            "Perth, Australia",
            "Redcliffe, Australia",
            "Wodonga, Australia",
            "Graz, Austria",
            "Linz, Austria",
            "Wien, Austria",
            "Minsk, Belarus",
            "Edegem, Belgium",
            "Hasselt, Belgium",
            "Kortrijk, Belgium",
            "Leuven, Belgium",
            "Namur, Belgium",
            "Bairro Nazare - Salvador, Brazil",
            "Barretos/sp, Brazil",
            "Belo Horizonte, Brazil",
            "Campinas, Brazil",
            "Caxias Do Sul, Brazil",
            "Curitiba, Brazil",
            "Fortaleza/ce, Brazil",
            "Ijui, Brazil",
            "Joinville, Brazil",
            "Lajeado - Rs, Brazil",
            "Piracicaba - Sp, Brazil",
            "Porto Alegre- Rs, Brazil",
            "Porto Alegre/rs, Brazil",
            "Ribeirao Preto - Sp, Brazil",
            "Rio de Janeiro Rj, Brazil",
            "Rio de Janeiro, Brazil",
            "Santo Andre, Brazil",
            "Sao Jose Do Rio Preto, Brazil",
            "Sao Jose Dos Campos, Brazil",
            "Sao Paulo, Brazil",
            "Sorocaba - Sp, Brazil",
            "Plovdiv, Bulgaria",
            "Sofia, Bulgaria",
            "Varna, Bulgaria",
            "Kelowna, British Columbia, Canada",
            "Burlington, Ontario, Canada",
            "Hamilton, Ontario, Canada",
            "London, Ontario, Canada",
            "Owen Sound, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Montreal, Quebec, Canada",
            "Pointe Claire, Quebec, Canada",
            "Quebec City, Quebec, Canada",
            "Sherbrooke, Quebec, Canada",
            "Las Condes, Chile",
            "Santiago, Chile",
            "Temuco, Chile",
            "Valparaiso, Chile",
            "Cali, Colombia",
            "Hradec Kralove, Czech Republic",
            "Praha 4, Czech Republic",
            "Praha 5, Czech Republic",
            "Joensuu, Finland",
            "Oulu, Finland",
            "Seinajoki, Finland",
            "Tampere, Finland",
            "Angers, France",
            "Bordeaux, France",
            "Caen, France",
            "Creteil, France",
            "La Roche Sur Yon, France",
            "Lyon, France",
            "Marseille, France",
            "Nancy, France",
            "Nantes, France",
            "Paris Cedex 13, France",
            "Paris Cedex 14, France",
            "Paris, France",
            "Poitiers, France",
            "Saint-etienne, France",
            "Villejuif, France",
            "Braunschweig, Germany",
            "Dresden, Germany",
            "Hamburg, Germany",
            "Hannover, Germany",
            "Kassel, Germany",
            "Kempen, Germany",
            "Nurtingen, Germany",
            "Tubingen, Germany",
            "Wuppertal, Germany",
            "Athens, Greece",
            "Heraklion Crete, Greece",
            "Larissa, Greece",
            "Patras, Greece",
            "Thessaloniki, Greece",
            "Kowloon, Hong Kong",
            "Shatin, Hong Kong",
            "Dublin, Ireland",
            "Galway, Ireland",
            "Haifa, Israel",
            "Holon, Israel",
            "Jerusalem, Israel",
            "Petach Tikva, Israel",
            "Ramat-gan, Israel",
            "Tel Aviv, Israel",
            "Zerifin, Israel",
            "Aviano, Italy",
            "Novara, Italy",
            "Roma, Italy",
            "Torino, Italy",
            "Chiba-city, Japan",
            "Chiba, Japan",
            "Fukuoka, Japan",
            "Hamamatsu City, Japan",
            "Hokkaido, Japan",
            "Kanazawa, Japan",
            "Kita-gun, Japan",
            "Maebashi-city, Japan",
            "Mito-city, Japan",
            "Osaka-city, Japan",
            "Osaka, Japan",
            "Sakura City, Japan",
            "Sayama, Japan",
            "Sendai City, Japan",
            "Shimizucho Sunto-gun, Japan",
            "Suntou-gun, Japan",
            "Tokyo, Japan",
            "Yamagata City, Japan",
            "Yokohama City, Japan",
            "Yufu-city, Japan",
            "Riga, Latvia",
            "Kaunas, Lithuania",
            "Klaipeda, Lithuania",
            "Vilnius, Lithuania",
            "Durango Durango, Mexico",
            "Mexico City Distrito Federal, Mexico",
            "Zapopan Jalisco, Mexico",
            "Amsterdam, Netherlands",
            "Arnhem, Netherlands",
            "Breda, Netherlands",
            "Eindhoven, Netherlands",
            "Heerlen, Netherlands",
            "Nieuwegein, Netherlands",
            "Nijmegen, Netherlands",
            "Rotterdam, Netherlands",
            "Auckland, New Zealand",
            "Christchurch, New Zealand",
            "Dunedin, New Zealand",
            "Takapuna, New Zealand",
            "Tauranga, New Zealand",
            "Lima, Peru",
            "Bielsko-biala, Poland",
            "Wroclaw, Poland",
            "Liepaja, Portugal",
            "Lisboa, Portugal",
            "Porto, Portugal",
            "San Juan, Puerto Rico",
            "Bucharest, Romania",
            "Cluj-napoca, Romania",
            "Moscow, Russian Federation",
            "St Petersburg, Russian Federation",
            "Singapore, Singapore",
            "Nitra, Slovakia",
            "Presov, Slovakia",
            "Trencin, Slovakia",
            "Zilina, Slovakia",
            "Cape Town, South Africa",
            "Durban, South Africa",
            "George, South Africa",
            "Port Elizabeth, South Africa",
            "Barcelona, Spain",
            "La Coruna, Spain",
            "Madrid, Spain",
            "Majadahonda, Spain",
            "Pamplona, Spain",
            "Sevilla, Spain",
            "Valencia, Spain",
            "Goteborg, Sweden",
            "Stockholm, Sweden",
            "Uppsala, Sweden",
            "Aarau, Switzerland",
            "Lausanne, Switzerland",
            "Winterthur, Switzerland",
            "Zurich, Switzerland",
            "Taichung, Taiwan",
            "Taipei, Taiwan",
            "Dnipropetrovsk, Ukraine",
            "Donetsk, Ukraine",
            "Kyiv, Ukraine",
            "Zaporizhzhya, Ukraine",
            "Aberdeen, United Kingdom",
            "Belfast, United Kingdom",
            "Bristol, United Kingdom",
            "Cottingham, United Kingdom",
            "Coventry, United Kingdom",
            "Glasgow, United Kingdom",
            "London, United Kingdom",
            "Manchester, United Kingdom",
            "Northwood, United Kingdom",
            "Preston, United Kingdom",
            "Southampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01193244"
      },
      {
        "-rank": "177",
        "nct_id": "NCT01308580",
        "title": "Cabazitaxel at 20 mg/mÂ² Compared to 25 mg/mÂ² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer",
        "acronym": "PROSELICA",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Cabazitaxel (XRP6258)"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone (or Prednisolone)"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival (OS)",
            "Progression Free Survival (PFS)",
            "Time to Tumor Progression",
            "Percentage of Participants With Overall Objective Tumor Response",
            "Time to PSA Progression",
            "Percentage of Participants With PSA Response",
            "Time to Pain Progression",
            "Percentage of Participants With Pain Response",
            "Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of Health Related Quality of Life (HRQoL)",
            "Change From Baseline in FACT-P:Total Score as a Measure of HRQoL",
            "Percentage of Participants With FACT-P Total Score Response",
            "Time to Definitive Deterioration of Score by 10% From Baseline on FACT-P Sub-Scales",
            "Time to Definitive Deterioration of ECOG PS Score From Baseline",
            "Time to Definitive Weight Loss by 5% and 10% From Baseline",
            "Time to First Definitive Consumption of Narcotic Medication",
            "Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)",
            "Plasma Clearance (CL) for Cabazitaxel",
            "Plasma Steady State Volume of Distribution (Vss) for Cabazitaxel"
          ]
        },
        "sponsors": { "lead_sponsor": "Sanofi" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1200",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "EFC11785",
            "2010-022163-35"
          ]
        },
        "start_date": "April 2011",
        "primary_completion_date": "August 2015",
        "completion_date": "August 2015",
        "study_first_posted": "March 4, 2011",
        "results_first_posted": "October 11, 2016",
        "last_update_posted": "April 17, 2017",
        "locations": {
          "location": [
            "Investigational Site Number 840002, Muscle Shoals, Alabama, United States",
            "Investigational Site Number 840004, Hot Springs, Arkansas, United States",
            "Investigational Site Number 840008, Anaheim, California, United States",
            "Investigational Site Number 840010, La Jolla, California, United States",
            "Investigational Site Number 840001, San Bernardino, California, United States",
            "Investigational Site Number 840021, Stamford, Connecticut, United States",
            "Investigational Site Number 840023, Jacksonville, Florida, United States",
            "Investigational Site Number 840013, Lakeland, Florida, United States",
            "Investigational Site Number 840003, Port St. Lucie, Florida, United States",
            "Investigational Site Number 840007, New Orleans, Louisiana, United States",
            "Investigational Site Number 840014, Baltimore, Maryland, United States",
            "Investigational Site Number 840005, Rockville, Maryland, United States",
            "Investigational Site Number 840017, St Louis Park, Minnesota, United States",
            "Investigational Site Number 840011, Jackson, Mississippi, United States",
            "Investigational Site Number 840016, Lincoln, Nebraska, United States",
            "Investigational Site Number 840015, East Orange, New Jersey, United States",
            "Investigational Site Number 840024, Raleigh, North Carolina, United States",
            "Investigational Site Number 840020, Akron, Ohio, United States",
            "Investigational Site Number 840006, Pawtucket, Rhode Island, United States",
            "Investigational Site Number 840025, Chattanooga, Tennessee, United States",
            "Investigational Site Number 840012, Corpus Christi, Texas, United States",
            "Investigational Site Number 032002, Buenos Aires, Argentina",
            "Investigational Site Number 032001, Rosario, Argentina",
            "Investigational Site Number 032003, Salta, Argentina",
            "Investigational Site Number 032004, Santa Fe, Argentina",
            "Investigational Site Number 036014, Adelaide, Australia",
            "Investigational Site Number 036013, Bankstown, Australia",
            "Investigational Site Number 036010, Box Hill, Australia",
            "Investigational Site Number 036012, Camperdown, Australia",
            "Investigational Site Number 036008, Coffs Harbour, Australia",
            "Investigational Site Number 036001, Concord, Australia",
            "Investigational Site Number 036015, Elizabeth Vale, Australia",
            "Investigational Site Number 036009, Fitzroy, Australia",
            "Investigational Site Number 036007, Garran, Australia",
            "Investigational Site Number 036005, Heidelberg West, Australia",
            "Investigational Site Number 036002, Malvern, Australia",
            "Investigational Site Number 036006, South Brisbane, Australia",
            "Investigational Site Number 036016, Subiaco, Australia",
            "Investigational Site Number 036003, Wahroonga, Australia",
            "Investigational Site Number 036004, Wodonga, Australia",
            "Investigational Site Number 056007, Antwerpen, Belgium",
            "Investigational Site Number 056008, Brussel, Belgium",
            "Investigational Site Number 056001, Bruxelles, Belgium",
            "Investigational Site Number 056002, Bruxelles, Belgium",
            "Investigational Site Number 056009, Charleroi, Belgium",
            "Investigational Site Number 056003, Gent, Belgium",
            "Investigational Site Number 056012, Godinne, Belgium",
            "Investigational Site Number 056016, Haine-Saint-Paul, Belgium",
            "Investigational Site Number 056005, Hasselt, Belgium",
            "Investigational Site Number 056010, Libramont, Belgium",
            "Investigational Site Number 056013, LiÃ¨ge, Belgium",
            "Investigational Site Number 056011, Ottignies, Belgium",
            "Investigational Site Number 056004, Roeselare, Belgium",
            "Investigational Site Number 056006, Turnhout, Belgium",
            "Investigational Site Number 076016, Fortaleza, Brazil",
            "Investigational Site Number 076012, Ijui, Brazil",
            "Investigational Site Number 076015, Mogi Das Cruzes, Brazil",
            "Investigational Site Number 076014, Porto Alegre, Brazil",
            "Investigational Site Number 076010, Rio De Janeiro, Brazil",
            "Investigational Site Number 076007, Salvador, Brazil",
            "Investigational Site Number 076003, Sao Jose Do Rio Preto, Brazil",
            "Investigational Site Number 076009, Sao Paulo, Brazil",
            "Investigational Site Number 076001, Sao Paulo, Brazil",
            "Investigational Site Number 076013, Sao Paulo, Brazil",
            "Investigational Site Number 076008, Sao Paulo, Brazil",
            "Investigational Site Number 076002, Sao Paulo, Brazil",
            "Investigational Site Number 124002, Greenfield Park, Canada",
            "Investigational Site Number 124001, Oshawa, Canada",
            "Investigational Site Number 124003, Ottawa, Canada",
            "Investigational Site Number 124005, Owen Sound, Canada",
            "Investigational Site Number 152005, Santiago, Chile",
            "Investigational Site Number 152004, Santiago, Chile",
            "Investigational Site Number 152002, Santiago, Chile",
            "Investigational Site Number 152001, ViÃ±a Del Mar, Chile",
            "Investigational Site Number 250005, Avignon Cedex 9, France",
            "Investigational Site Number 250008, Hyeres, France",
            "Investigational Site Number 250001, La Roche Sur Yon, France",
            "Investigational Site Number 250002, Nantes Cedex 2, France",
            "Investigational Site Number 250004, Nimes, France",
            "Investigational Site Number 250010, Paris, France",
            "Investigational Site Number 250009, Reims Cedex, France",
            "Investigational Site Number 250007, Reims, France",
            "Investigational Site Number 250006, Saint Brieuc Cedex, France",
            "Investigational Site Number 250011, Toulouse Cedex 03, France",
            "Investigational Site Number 250003, Toulouse Cedex 09, France",
            "Investigational Site Number 276003, Aachen, Germany",
            "Investigational Site Number 276007, Dresden, Germany",
            "Investigational Site Number 276004, DÃ¼sseldorf, Germany",
            "Investigational Site Number 276001, Erlangen, Germany",
            "Investigational Site Number 276011, Hamburg, Germany",
            "Investigational Site Number 276005, Hamburg, Germany",
            "Investigational Site Number 276010, Homburg, Germany",
            "Investigational Site Number 276006, MÃ¼nchen, Germany",
            "Investigational Site Number 276012, NÃ¼rtingen, Germany",
            "Investigational Site Number 276008, TÃ¼bingen, Germany",
            "Investigational Site Number 276002, Wuppertal, Germany",
            "Investigational Site Number 348001, Budapest, Hungary",
            "Investigational Site Number 348005, Budapest, Hungary",
            "Investigational Site Number 348004, Budapest, Hungary",
            "Investigational Site Number 348006, Miskolc, Hungary",
            "Investigational Site Number 348003, PÃ©cs, Hungary",
            "Investigational Site Number 410003, Seongnam, Korea, Republic of",
            "Investigational Site Number 410002, Seoul, Korea, Republic of",
            "Investigational Site Number 410004, Seoul, Korea, Republic of",
            "Investigational Site Number 410005, Seoul, Korea, Republic of",
            "Investigational Site Number 410001, Seoul, Korea, Republic of",
            "Investigational Site Number 528005, Arnhem, Netherlands",
            "Investigational Site Number 528003, Blaricum, Netherlands",
            "Investigational Site Number 528004, Hoofddorp, Netherlands",
            "Investigational Site Number 528002, Nijmegen, Netherlands",
            "Investigational Site Number 528001, Zwolle, Netherlands",
            "Investigational Site Number 604003, Arequipa, Peru",
            "Investigational Site Number 604006, Lima, Peru",
            "Investigational Site Number 604001, Lima, Peru",
            "Investigational Site Number 604007, Lima, Peru",
            "Investigational Site Number 604002, Lima, Peru",
            "Investigational Site Number 604004, Lima, Peru",
            "Investigational Site Number 604005, Lima, Peru",
            "Investigational Site Number 616006, Lubin, Poland",
            "Investigational Site Number 616002, Olsztyn, Poland",
            "Investigational Site Number 616001, Rybnik, Poland",
            "Investigational Site Number 616005, Siedlce, Poland",
            "Investigational Site Number 616004, Torun, Poland",
            "Investigational Site Number 642005, Alba Iulia, Romania",
            "Investigational Site Number 642006, Baia Mare, Romania",
            "Investigational Site Number 642009, Bucuresti, Romania",
            "Investigational Site Number 642008, Bucuresti, Romania",
            "Investigational Site Number 642001, Cluj Napoca, Romania",
            "Investigational Site Number 642003, Cluj Napoca, Romania",
            "Investigational Site Number 642004, Cluj Napoca, Romania",
            "Investigational Site Number 642002, Cluj Napoca, Romania",
            "Investigational Site Number 642012, Focsani, Romania",
            "Investigational Site Number 642007, Hunedoara, Romania",
            "Investigational Site Number 642013, Onesti, Romania",
            "Investigational Site Number 643009, Ekaterinburg, Russian Federation",
            "Investigational Site Number 643007, Moscow, Russian Federation",
            "Investigational Site Number 643005, Moscow, Russian Federation",
            "Investigational Site Number 643004, Moscow, Russian Federation",
            "Investigational Site Number 643006, Moscow, Russian Federation",
            "Investigational Site Number 643008, Obninsk, Russian Federation",
            "Investigational Site Number 643001, St.Petersburg, Russian Federation",
            "Investigational Site Number 643010, St.Petersburg, Russian Federation",
            "Investigational Site Number 643003, Tula, Russian Federation",
            "Investigational Site Number 710003, Cape Town, South Africa",
            "Investigational Site Number 710002, Durban, South Africa",
            "Investigational Site Number 710005, Johannesburg, South Africa",
            "Investigational Site Number 710004, Johannesburg, South Africa",
            "Investigational Site Number 710001, Pretoria, South Africa",
            "Investigational Site Number 724003, Badalona, Spain",
            "Investigational Site Number 724001, Barcelona, Spain",
            "Investigational Site Number 724002, Madrid, Spain",
            "Investigational Site Number 724008, Madrid, Spain",
            "Investigational Site Number 724006, MÃ¡laga, Spain",
            "Investigational Site Number 724005, Palma De Mallorca, Spain",
            "Investigational Site Number 724004, Sabadell, Spain",
            "Investigational Site Number 724007, Sevilla, Spain",
            "Investigational Site Number 158002, Taiching, Taiwan",
            "Investigational Site Number 158003, Tainan, Taiwan",
            "Investigational Site Number 158001, Taipei, Taiwan",
            "Investigational Site Number 788004, Sfax, Tunisia",
            "Investigational Site Number 788003, Sousse, Tunisia",
            "Investigational Site Number 788002, Tunis, Tunisia",
            "Investigational Site Number 792003, Antalya, Turkey",
            "Investigational Site Number 792001, Bornova, Turkey",
            "Investigational Site Number 792002, Istanbul, Turkey",
            "Investigational Site Number 826002, Birmingham, United Kingdom",
            "Investigational Site Number 826004, Colchester, United Kingdom",
            "Investigational Site Number 826005, Glasgow, United Kingdom",
            "Investigational Site Number 826006, Guildford, United Kingdom",
            "Investigational Site Number 826007, Manchester, United Kingdom",
            "Investigational Site Number 826003, Newcastle Upon Tyne, United Kingdom",
            "Investigational Site Number 826001, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01308580"
      },
      {
        "-rank": "178",
        "nct_id": "NCT01485861",
        "title": "Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Coralie in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abiraterone"
            },
            {
              "-type": "Drug",
              "#text": "Apitolisib"
            },
            {
              "-type": "Drug",
              "#text": "Ipatasertib"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Drug",
              "#text": "Prednisolone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Phase Ib: Percentage of Participants With Dose Limiting Toxicity (DLTs)",
            "Phase Ib: Percentage of Participants by Nature of DLTs",
            "Phase Ib: Recommended Phase II Dose (RP2D) of Ipatasertib",
            "Phase II: Percentage of Participants With Radiographic Progression (as Assessed by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) or Death - Intent to Treat (ITT) Population",
            "Phase II: Radiographic Progression Free Survival as Assessed by RECIST 1.1 - ITT Population",
            "Phase II: Percentage of Participants With Radiographic Progression (as Assessed by RECIST 1.1) or Death in Participants With Institute of Cancer Research (ICR) Phosphatase and Tensin Homolog (PTEN) Loss",
            "Phase II: Radiographic Progression Free Survival (as Assessed by RECIST 1.1) in Participants With ICR PTEN Loss",
            "Phase II: Percentage of Participants Who Died - ITT Population",
            "Phase II: Overall Survival - ITT Population",
            "Phase II: Percentage of Participants Who Died in Participants With ICR PTEN Loss",
            "Phase II: Overall Survival in Participants With ICR PTEN Loss",
            "Phase II: Percentage of Participants With Prostate-Specific Antigen (PSA) Progression (as Assessed by Prostate Cancer Working Group 2 Criteria) - ITT Population",
            "Phase II: Time to PSA Progression (as Assessed by Prostate Cancer Working Group 2 Criteria) - ITT Population",
            "Phase II: Percentage of Participants With PSA Progression (as Assessed by Prostate Cancer Working Group 2 Criteria) in Participants With ICR PTEN Loss",
            "Phase II: Time to PSA Progression (as Assessed by Prostate Cancer Working Group 2 Criteria) in Participants With ICR PTEN Loss",
            "Phase II: Percentage of Participants With PSA Response - ITT Population",
            "Phase II: Percentage of Participants With PSA Response in Participants With ICR PTEN Loss",
            "Phase II: Percentage of Participants With Objective Response as Assessed by RECIST 1.1 - ITT Population",
            "Phase II: Percentage of Participants With Objective Response (as Assessed by RECIST 1.1) in Participants With ICR PTEN Loss",
            "Phase II: Duration of Tumor Response, as Assessed by RECIST 1.1 - ITT Population",
            "Phase II: Percentage of Participants With Circulating Tumor Cells (CTC) Reduction Response - ITT Population",
            "Phase II: Percentage of Participants With CTC Reduction Response in Participants With ICR PTEN Loss",
            "Phase II: Percentage of Participants With CTC Conversion - ITT Population",
            "Phase II: Percentage of Participants With CTC Conversion in Participants With ICR PTEN Loss",
            "Phase II: Percentage of Participants With Pain Progression - ITT Population",
            "Phase II: Time to Pain Progression - ITT Population",
            "Phase II: Percentage of Participants With Pain Progression in Participants With ICR PTEN Loss",
            "Phase II: Time to Pain Progression in Participants With ICR PTEN Loss",
            "Phase Ib: Maximum Plasma Concentration (Cmax) (in nanograms per milliliter [ng/mL]) of Ipatasertib and Apitolisib When Co-Administered With Abiraterone",
            "Phase Ib: Time to Cmax (tmax) (in hours) of Ipatasertib and Apitolisib When Co-Administered With Abiraterone",
            "Phase Ib: Area Under The Concentration Time Curve From Time 0 to 24 Hours (AUC0-24) (in ng/mL*hours) of Ipatasertib and Apitolisib When Co-Administered With Abiraterone",
            "Phase Ib: Total Body Clearance (CL/F) of Ipatasertib When Co-Administered With Abiraterone",
            "Phase Ib: Accumulation Ratio of Ipatasertib When Co-Administered With Abiraterone",
            "Cmax of G-037720 (Metabolite of Ipatasertib)",
            "tmax of G-037720 (Metabolite of Ipatasertib)",
            "Phase Ib: AUC0-24 of G-037720 (Metabolite of Ipatasertib)",
            "Phase Ib: Accumulation Ratio of G-037720 (Metabolite of Ipatasertib)",
            "Phase Ib: Cmax of Abiraterone When Co-Administered With Ipatasertib or Apitolisib",
            "Phase Ib: tmax of Abiraterone When Co-Administered With Ipatasertib or Apitolisib",
            "Phase Ib: AUC0-24 of Abiraterone When Co-Administered With Ipatasertib or Apitolisib",
            "Phase Ib: Plasma Half-Life of Abiraterone When Co-Administered With Ipatasertib or Apitolisib",
            "Phase Ib: Accumulation Ratio of Abiraterone When Co-Administered With Ipatasertib or Apitolisib"
          ]
        },
        "sponsors": { "lead_sponsor": "Genentech, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "273",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "GO27983",
            "2011-004126-10"
          ]
        },
        "start_date": "January 11, 2012",
        "primary_completion_date": "September 1, 2015",
        "completion_date": "July 31, 2019",
        "study_first_posted": "December 6, 2011",
        "last_update_posted": "August 1, 2019",
        "locations": {
          "location": [
            "HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States",
            "Pacific Hematology Oncology Assocociates, San Francisco, California, United States",
            "Florida Cancer Specialists - Fort Myers (New Hampshire Ct), Fort Myers, Florida, United States",
            "Florida Cancer Specialists., Saint Petersburg, Florida, United States",
            "Florida Cancer Specialists; Sarasota, Sarasota, Florida, United States",
            "Kaiser Permanente Medical Ctr, Honolulu, Hawaii, United States",
            "Johns Hopkins Univ; Bunting Blaustein Cancer Center, Baltimore, Maryland, United States",
            "Karmanos Cancer Institute, Detroit, Michigan, United States",
            "North Shore Hem Onc Associates, East Setauket, New York, United States",
            "Weill Cornell Medical College, New York, New York, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States",
            "Masarykuv onkologicky ustav, Brno, Czechia",
            "Fakultni nemocnice Hradec Kralove; I. interni klinika,Oddeleni invazivni kardiologie, Hradec Kralove, Czechia",
            "Urocentrum Praha s.r.o., Praha 2, Czechia",
            "Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia",
            "Fakultni Thomayerova Nemocnice; Revmatologicke Oddeleni, Praha, Czechia",
            "ICO Paul Papin; Oncologie Medicale., Angers, France",
            "Centre Hospitalier Departemental Les Oudairies, La Roche Sur Yon, France",
            "Centre LÃ©on BÃ©rard - Centre rÃ©gional de lutte contre le cancer RhÃ´ne-Alpes, Lyon, France",
            "Hia Du Val De Grace, Paris, France",
            "Institut Curie; Oncologie Medicale, Paris, France",
            "GH Paris Saint Joseph; Hopital De Jour Oncologie, Paris, France",
            "Hopital d'Instruction des Armees de Begin, Saint-Mande, France",
            "Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France",
            "Alexandras Hospital; Dept. of Clin. Therapeutics, Athens Uni School of Medicine, Athens, Greece",
            "Sotiria Hospital, Athens, Greece",
            "General Oncology Hospital Kifissias \"Oi Agioi Anargyroi\", Athens, Greece",
            "Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece",
            "University Hospital of Larissa; Oncology, Larissa, Greece",
            "University Hospital of Patras Medical Oncology, Patras, Greece",
            "Metropolitan Hospital; 2Nd Oncology Clinic, Piraeus, Greece",
            "IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy",
            "Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica, Roma, Lazio, Italy",
            "Azienda Ospedaliera Istituti Ospitalieri, Cremona, Lombardia, Italy",
            "Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy",
            "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy",
            "Ospedale S. Donato; Divisione Di Reumatologia, Arezzo, Toscana, Italy",
            "Het Nederlands Kanker Inst, Amsterdam, Netherlands",
            "Vu Medisch Centrum; Afdeling Longziekten, Amsterdam, Netherlands",
            "MC Haaglanden; Oncologie, Den Haag, Netherlands",
            "UMC St Radboud, Nijmegen, Netherlands",
            "Sint Franciscus Gasthuis; Inwendige Geneeskunde, Rotterdam, Netherlands",
            "Sf. Constantin Hospital; Oncology, Brasov, Romania",
            "Prof. Dr. Th. Burghele Clin Urology Hosp, Bucharest, Romania",
            "Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania",
            "Institute of Oncology \"Prof. Dr. I. Chiricuta\", Cluj-Napoca, Romania",
            "ONCOMED - Medical Centre, Timisoara, Romania",
            "Municipal Hosp Turdal; Oncology, Turda, Romania",
            "Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain",
            "Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain",
            "Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain",
            "Clinica Universitaria de Navarra, Pamplona, Navarra, Spain",
            "Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain",
            "Hospital General Universitario Gregorio MaraÃ±on, Madrid, Spain",
            "Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain",
            "Hospital Madrid Norte Sanchinarro, Madrid, Spain",
            "Hospital Clinico Universitario Virgen de la Victoria, Malaga, Spain",
            "Queen Elizabeth Hospital; Centre for Clinical Haematology, Birmingham, United Kingdom",
            "Gartnavel General Hospital, Glasgow, United Kingdom",
            "St. James University Hospital; Pharmacy Department, Leeds, United Kingdom",
            "Sarah Cannon Research Institute, London, United Kingdom",
            "The Royal Marsden Hospital, Sutton, United Kingdom",
            "The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01485861"
      },
      {
        "-rank": "179",
        "nct_id": "NCT00133224",
        "title": "Docetaxel in Combination With GVAX Â® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "Immunotherapy allogeneic GM-CSF secreting cellular vaccine"
            },
            {
              "-type": "Drug",
              "#text": "Chemotherapy (docetaxel and prednisone)"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Survival",
            "Time to disease progression. Time to pain progression."
          ]
        },
        "sponsors": { "lead_sponsor": "Cell Genesys" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "408",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "G-0034",
            "VITAL-2"
          ]
        },
        "start_date": "July 2005",
        "primary_completion_date": "August 2008",
        "completion_date": "June 2009",
        "study_first_posted": "August 23, 2005",
        "last_update_posted": "September 23, 2008",
        "locations": {
          "location": [
            "Alaska Clinical Research Center, Anchorage, Alaska, United States",
            "St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States",
            "Loma Linda University, Loma Linda, California, United States",
            "Onocology Care Medical Associates, Los Angeles, California, United States",
            "Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States",
            "San Bernardino Urology Associates, San Bernardino, California, United States",
            "Kaiser Permanente Medical Group Dept. of Oncology Research, San Diego, California, United States",
            "Sharp Healthcare, San Diego, California, United States",
            "California Pacific Medical Center, San Francisco, California, United States",
            "UCSF Mt. Zion Cancer Center, San Francisco, California, United States",
            "Cancer Research & Prevention Center, Soquel, California, United States",
            "Cancer Center and Department of Medicine, Aurora, Colorado, United States",
            "Mayo Clinic - Jacksonville, Jacksonville, Florida, United States",
            "Jupiter Hematology & Oncology Associates, Jupiter, Florida, United States",
            "Lakeland Regional Cancer Center, Lakeland, Florida, United States",
            "Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States",
            "Atlanta VA Medical Center, Atlanta, Georgia, United States",
            "Peachtree Hematology & Oncology Consultants, PC, Atlanta, Georgia, United States",
            "Emory Winship Cancer Institute, Atlanta, Georgia, United States",
            "Medical & Surgical Specialists, Galesburg, Illinois, United States",
            "James Graham Brown Cancer Center, Louisville, Kentucky, United States",
            "Frederick Memorial Hospital Regional Cancer Therapy Center, Frederick, Maryland, United States",
            "General Clinical Research Center University of Michigan, Ann Arbor, Michigan, United States",
            "Billings Clinic, Billings, Montana, United States",
            "Hematology & Oncology Consultants P.C., Omaha, Nebraska, United States",
            "Nevada Cancer Institute, Las Vegas, Nevada, United States",
            "Hackensack University Medical Center, Hackensack, New Jersey, United States",
            "New Mexico Oncology, Albuquerque, New Mexico, United States",
            "North Shore Hematology Oncology Associates P.C., East Setauket, New York, United States",
            "NYU Clinical Cancer Center, New York, New York, United States",
            "Presbyterian Hospital Center for Cancer Research, Charlotte, North Carolina, United States",
            "Gabrail Cancer Center, Canton, Ohio, United States",
            "Providence Portland Medical Center, Portland, Oregon, United States",
            "Kaiser Permanente Oncology/Hematology, Portland, Oregon, United States",
            "Cancer Centers of the Carolinas, Greenville, South Carolina, United States",
            "The West Clinic, Memphis, Tennessee, United States",
            "Center for Oncology Research & Treatment, PA, Dallas, Texas, United States",
            "Dallas Oncology Consultants, Dallas, Texas, United States",
            "Mary Crowley Medical Research Center, Dallas, Texas, United States",
            "Mobley Research Center, Houston, Texas, United States",
            "Northwest Cancer Center, Houston, Texas, United States",
            "Urology San Antonio Research, PA, San Antonio, Texas, United States",
            "Seattle Cancer Care Alliance, Univ. of Washington, Seattle, Washington, United States",
            "Ziekenhuis Netwerk Antwerpen - AZ Middelheim, Antwerpen, Belgium",
            "V.Z.W. Imelda Ziekenhuis, Bonheiden, Belgium",
            "AZ Groeninge, Kortrijk, Belgium",
            "CHU de LiÃ¨ge - HÃ´pital du Sart Tilman, LiÃ¨ge, Belgium",
            "Heilig-Hartziekenhuis Campus Wilgenstraat, Roeselare, Belgium",
            "Regionaal Ziekenhuis Sint Trudo, Sint Truiden, Belgium",
            "Centre Hospitalier de L'Universite de Montreal, Montreal, Quebec, Canada",
            "Centre Hospitalier Universite de Sherbrooke, Sherbrooke, Quebec, Canada",
            "Centre Regional de lutte contre le cancer Paul Papin, Angers, France",
            "Centre Francois Baclesse, Caen, France",
            "Institut Jean Godinot, Oncologie Medicale, Cedex, France",
            "Centre Jean Perrin Centre RÃ©gional de lutte contre le cancer d'Auvergne, Clermont-Ferrand, France",
            "Centre Rene Gauducheau - Site Hospitalier Nord, Nantes, France",
            "Centre Antoine Lacassagne - Centre Regional de lutte contre le cancer, Nice, France",
            "CHU Saint Louis, Paris, France",
            "Hopital Saint Joseph Site Saint Michel, Paris, France",
            "Hopital Cochin, Paris, France",
            "CHU Poitiers, Poitiers, France",
            "Centre Hospitalier Rene Dubos, Pontoise, France",
            "Clinique Armoricaine de Radiology, Saint Brieuc, France",
            "Hopital Civil, Strasbourg, France",
            "CHU Bretonneau, Tours, France",
            "Centre Alexis Vautrin, Vandoeuvre les Nancy, France",
            "Universitatsklinikum Aachen, Aachen, Germany",
            "Charite Campus Mitte, Berlin, Germany",
            "Krankenhaus Am Urban, Berlin, Germany",
            "Universitatsklinikum Carl Gustav Carus An Der, Dresden, Germany",
            "Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt am Main, Germany",
            "Urologische Klinik und Poliklinik der Johannes Gutenberg Universitat Mainz, Mainz, Germany",
            "Klinikum Mannheim, Mannheim, Germany",
            "Urologische Klinik und Poliklinik, Munchen, Germany",
            "Istituto Nazionale dei Tumori, Milano, Italy",
            "Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy",
            "Fondazione San Raffaele del Monte Tabor, Milan, Italy",
            "Istituto Europeo di Oncologia, Milan, Italy",
            "Azienda Ospedaliero Universitaria di Modena, Modena, Italy",
            "Azienda Ospedaliera Maggiore della Carita, Novarra, Italy",
            "Azienda Ospedaliera di Parma, Parma, Italy",
            "Azienda Ospedaliero Universitaria (A.O.U.) Pisana-Ospedale S. Chiara, Pisa, Italy",
            "Azienda Ospedaliera San Camillo Forlanini, Roma, Italy",
            "Presidio Ospedaliero di Sassari-Ospedale SS. Anunziata, Sassari, Italy",
            "A.S.O. San Giovanni Battista di Torino, Turin, Italy",
            "VU Medisch Centrum, Amsterdam, Netherlands",
            "Academisch Centrum, Amsterdam, Netherlands",
            "Universitair Medisch Centrum Groningen, Groningen, Netherlands",
            "Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Bialystok, Poland",
            "Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Bytom, Poland",
            "Katedra i Klinika Onkologii i Radioterapli, Gdansk, Poland",
            "Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Katowice, Poland",
            "Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie Oddzial w Krakowie, Krakow, Poland",
            "Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland",
            "Samodzielny Publiczny Szpital Kliniczny nr 1 Przemienienia Panskiego AM w Poznaniu, Poznan, Poland",
            "Wojewodzki Szpital Specjalistyczny w Siedlcach, Siedlce, Poland",
            "Wojewodzki Szpital Specjalistyczny Oddzial Urologii, Slupsk, Poland",
            "Szpital Kliniczny Dzieciatka Jezus - Centrum Leczenia Obrazen, Warszawa, Poland",
            "Centrum Onkologii Instytut im. Marii Sklodowskiej- Curie, Warszawa, Poland",
            "Universitetssjukhuset i Lund, Lund, Sweden",
            "University Hospital MAS (UMAS), Malmo, Sweden",
            "Akademiska Sjukhuset i Uppsala, Uppsala, Sweden",
            "Addenbrookes Hospital, Cambridge, United Kingdom",
            "Royal Surrey County Hospital, Guildford, United Kingdom",
            "St. James University Hospital, Leeds, United Kingdom",
            "Lincoln County Hospital, Lincoln, United Kingdom",
            "Royal Marsden Hospital, London, United Kingdom",
            "Department of Oncology Hammersmith Hospital, London, United Kingdom",
            "Christie Hospital Manchester, Manchester, United Kingdom",
            "Mount Vernon Hospital, Middlesex, United Kingdom",
            "Nottingham City Hospital, Nottingham, United Kingdom",
            "Rosemere Cancer Centre, Royal Preston Hospital, Preston, United Kingdom",
            "Scunthorpe General Hospital, Dept of Oncology, Scunthorpe, United Kingdom",
            "Royal Marsden Academic Urology Unit, Sutton, United Kingdom",
            "Clatterbridge Centre For Oncology, Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00133224"
      },
      {
        "-rank": "180",
        "nct_id": "NCT02663908",
        "title": "A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease",
        "acronym": "PRONOUNCE",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Leuprolide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Time from randomization to the first confirmed (adjudicated) occurrence of the composite Major Adverse Cardiovascular Event (MACE) endpoint",
            "Time from randomization to occurrence of myocardial infarction (fatal, non-fatal)",
            "Time from randomization to occurrence of stroke (fatal, non-fatal)",
            "Time from randomization to occurrence of unstable angina requiring hospitalization (fatal, non-fatal)",
            "Time from randomization to death due to any cause",
            "Time from randomization to cardiovascular-related death"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Ferring Pharmaceuticals",
          "collaborator": [
            "Memorial Sloan Kettering Cancer Center",
            "Duke Clinical Research Institute"
          ]
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "900",
        "funded_bys": {
          "funded_by": [
            "Industry",
            "Other"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Single (Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "000108" },
        "start_date": "April 2016",
        "primary_completion_date": "July 2021",
        "completion_date": "July 2021",
        "study_first_posted": "January 26, 2016",
        "last_update_posted": "July 16, 2019",
        "locations": {
          "location": [
            "Urology Center of Alabama PC, Birmingham, Alabama, United States",
            "Alaska Clinical Research Center, Anchorage, Alaska, United States",
            "Arizona Institute of Urology, Tucson, Arizona, United States",
            "Urological Associates of Southern Arizona, Tucson, Arizona, United States",
            "Urology Associates, PA, Little Rock, Arkansas, United States",
            "Pacific Cancer Medical Center, Inc., Anaheim, California, United States",
            "San Diego Clinical Trials, La Mesa, California, United States",
            "Clinical Trials Research, Lincoln, California, United States",
            "Tower Urology Medical Group, Los Angeles, California, United States",
            "University of California, Irvine Medical Center, Orange, California, United States",
            "Urology Associates of the Central Coast, San Luis Obispo, California, United States",
            "Skyline Urology, Torrance, California, United States",
            "Innovative Clinical Research Institute, Whittier, California, United States",
            "Urology Center of Colorado, Denver, Colorado, United States",
            "Yale University, New Haven, Connecticut, United States",
            "Urologic Surgeons of Washington, Washington, District of Columbia, United States",
            "Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States",
            "San Marcus Research Clinic Inc, Miami, Florida, United States",
            "Clinical Research Center of Florida, Pompano Beach, Florida, United States",
            "Florida Urology Partners, Tampa, Florida, United States",
            "G. Patsias, M.D., PA, Wellington, Florida, United States",
            "Comprehensive Urologic Care, Lake Barrington, Illinois, United States",
            "Springfield Clinic LLP, Springfield, Illinois, United States",
            "Urology of Indiana LLC, Greenwood, Indiana, United States",
            "First Urology PSC, Jeffersonville, Indiana, United States",
            "Iowa Clinic, West Des Moines, Iowa, United States",
            "University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States",
            "Kansas City Urology Care, Lenexa, Kansas, United States",
            "Tulane University Health Sciences Center, New Orleans, Louisiana, United States",
            "Regional Urology, LLC, Shreveport, Louisiana, United States",
            "Mid-Atlantic Permanente Research Institute, Largo, Maryland, United States",
            "Chesapeake Urology Associates, P.A., Towson, Maryland, United States",
            "Michigan Institute of Urology, Troy, Michigan, United States",
            "Kansas City VA Medical Center, Kansas City, Missouri, United States",
            "Premier Urology Associates LLC, Lawrenceville, New Jersey, United States",
            "Delaware Valley Urology LLC Westhampton, Mount Laurel, New Jersey, United States",
            "Urology Group of New Mexico PC, Albuquerque, New Mexico, United States",
            "Albany Medical College, Albany, New York, United States",
            "Montefiore Medical Center PRIME, Bronx, New York, United States",
            "Advanced Urology Centers of New York Elmont Division, Elmont, New York, United States",
            "Manhattan Medical Research Practice PLLC, New York, New York, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "Premier Medical Group of the Hudson Valley, Newburgh, New York, United States",
            "Premier Medical Group, Poughkeepsie, New York, United States",
            "Carolina Clinical Trials Inc, Concord, North Carolina, United States",
            "Veterans Affairs Medical Center-Salisbury, NC, Salisbury, North Carolina, United States",
            "PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States",
            "The Carl and Edyth Lindner Center For Research and Education at The Christ Hospital, Cincinnati, Ohio, United States",
            "Signal Point Clinical Research Center, Dayton, Ohio, United States",
            "Clinical Research Solutions PC, Middleburg Heights, Ohio, United States",
            "University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States",
            "Oregon Urology Institute, Springfield, Oregon, United States",
            "Urologic Consultants of Southeaster PA LLP, Bala-Cynwyd, Pennsylvania, United States",
            "Lancaster Urology, Lancaster, Pennsylvania, United States",
            "University of Pennsylvania, Philadelphia, Pennsylvania, United States",
            "Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States",
            "Medical University of South Carolina (MUSC), Charleston, South Carolina, United States",
            "Erlanger Health System, Chattanooga, Tennessee, United States",
            "Urology Clinics of North Texas, Dallas, Texas, United States",
            "Urology of Virginia, Norfolk, Virginia, United States",
            "Virginia Urology Center, Richmond, Virginia, United States",
            "Seattle Urology Research Center, Burien, Washington, United States",
            "University of Washington School of Medicine, Seattle, Washington, United States",
            "Madigan Army Medical Center, Tacoma, Washington, United States",
            "Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, United States",
            "Okanagan Health Surgical Centre, Kelowna, British Columbia, Canada",
            "Vancouver Prostate Centre, Vancouver, British Columbia, Canada",
            "The Male Health Centre Euroscope Inc, Barrie, Ontario, Canada",
            "J. Giddens Medicine Professional Corporation, Brampton, Ontario, Canada",
            "St. Joseph's Lifecare Centre, Brantford, Ontario, Canada",
            "G. Kenneth Jansz Medicine Professional Corporation, Burlington, Ontario, Canada",
            "Urology Associates Urologic Medical Research, Kitchener, Ontario, Canada",
            "London Health Sciences Centre, London, Ontario, Canada",
            "Femalemale Health Centres, Oakville, Ontario, Canada",
            "Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Uro Laval, Laval, Quebec, Canada",
            "Jewish General Hospital / McGill University, MontrÃ©al, Quebec, Canada",
            "Fakultni nemocnice Olomouc, Olomouc, Czechia",
            "Fakultni nemocnice Ostrava, Ostrava, Czechia",
            "Multiscan s.r.o., Pardubice, Czechia",
            "Urocentrum Plzen, Plzen, Czechia",
            "Fakultni nemocnice v Motole, Praha, Czechia",
            "Proton Therapy Center Czech s.r.o., Praha, Czechia",
            "Oblastni nemocnice Pribram a.s., PÅ™Ã­bram, Czechia",
            "Krajska zdravotni a.s. - Masarykova nemocnice v Usti nad Labem o.z., ÃšstÃ­ Nad Labem, Czechia",
            "Institut Sainte Catherine, Avignon, France",
            "Groupe Hospitalier Pellegrin Tripode, Bordeaux, France",
            "HÃ´pital Henri Mondor, CrÃ©teil, France",
            "CHU de Grenoble - HÃ´pital Albert Michallon, Grenoble, France",
            "CH de Libourne- Hopital Robert Boulin, Libourne, France",
            "Hopital Claude Huriez - CHU Lille, Lille, France",
            "Hopital Edouard Herriot - CHU Lyon, Lyon, France",
            "Centre Hospitalier RÃ©gional Universitaire de Tours, Nantes, France",
            "Clinique Saint Jean Languedoc, Toulouse, France",
            "Urologische Gemeinschaftspraxis, Kirchheim Unter Teck, Baden Wuerttemberg, Germany",
            "Urologische Gemeinschaftspraxis, Herzogenaurach, Bayern, Germany",
            "Staedtisches Klinikum Braunschweig GmbH - Standort Salzdahlumer, Braunschweig, Niedersachsen, Germany",
            "Kliniken Maria Hilf GmbH, Moenchengladbach, Nordrhein Westfalen, Germany",
            "Praxisklinik Urologie Rhein Ruhr, MÃ¼lheim, Nordrhein Westfalen, Germany",
            "Facharztpraxis fÃ¼r Urologie, Lutherstadt Eisleben, Sachsen Anhalt, Germany",
            "Urologie am Nordplatz, Leipzig, Sachsen, Germany",
            "Gynaekologisches Zentrum Bonn-Friedensplatz, Bonn, Germany",
            "Studienpraxis Urologie, NÃ¼rtingen, Germany",
            "Athens Medical Center, Athens, Greece",
            "General Hospital of Athens \"Alexandra\", Athens, Greece",
            "T.Y.P.E.T. Hygeias Melathron Hospital, Athens, Greece",
            "University General Hospital of Heraklion, Heraklion, Greece",
            "University of Patras Medical School, Patras, Greece",
            "General Hospital Papageorgiou, ThessalonÃ­ki, Greece",
            "Swietokrzyskie Centrum Onkologii, Kielce, Poland",
            "Provita Profamilia, PiotrkÃ³w Trybunalski, Poland",
            "WroMedica, WrocÅ‚aw, Poland",
            "DERMED Centrum Medyczne Sp. z o.o., ÅÃ³dÅº, Poland",
            "CUIMED s.r.o., Bratislava, Slovakia",
            "Urocentrum Bratislava s.r.o., Bratislava, Slovakia",
            "Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovakia",
            "Nemocnica Kosice-Saca, a.s., KoÅ¡ice, Slovakia",
            "Zeleznicna nemocnica Kosice, KoÅ¡ice, Slovakia",
            "UROCENTRUM LEVICE s.r.o., Levice, Slovakia",
            "UROAMB s.r.o., LiptovskÃ½ MikulÃ¡Å¡, Slovakia",
            "Urobet s.r.o., Malacky, Slovakia",
            "Univerzitna nemocnica Martin, Martin, Slovakia",
            "Fakultna nemocnica Nitra, Nitra, Slovakia",
            "UROEXAM, spol. s r.o., Nitra, Slovakia",
            "MILAB s.r.o., PreÅ¡ov, Slovakia",
            "MIRAMED s.r.o, Rimavska Sobota, Slovakia",
            "UROCENTRUM SALA s.r.o., Sala, Slovakia",
            "Privatna Urologicka ambulancia, TrenÄÃ­n, Slovakia",
            "Fakultna nemocnica s poliklinikou Zilina, Å½ilina, Slovakia",
            "Prince Philip Hospital, Llanelli, Carmarthenshire, United Kingdom",
            "Charing Cross Hospital, London, Greater London, United Kingdom",
            "Scunthorpe General Hospital, Scunthorpe, Lincolnshire, United Kingdom",
            "St Peter's Hospital, Chertsey, Surrey, United Kingdom",
            "Royal Hallamshire Hospital, Sheffield, West Midlands, United Kingdom",
            "Royal Devon and Exeter Hospital (Wonford), Exeter, United Kingdom",
            "Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom",
            "Salford Royal, Salford, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02663908"
      },
      {
        "-rank": "181",
        "nct_id": "NCT00831233",
        "title": "Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Goserelin"
            },
            {
              "-type": "Drug",
              "#text": "Bicalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12",
            "Change From Baseline in Total IPSS at Weeks 4 and 8",
            "Change From Baseline in Maximum Urine Flow (Qmax) at Each Visit",
            "Change From Baseline in Residual Volume (Vresidual) at Each Visit",
            "Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12",
            "Number of Participants With Testosterone <=0.5 Nanograms/Milliliter at Each Visit",
            "Percentage Change From Baseline in Prostate-specific Antigen (PSA) Concentration at Each Visit",
            "Change From Baseline in Quality of Life (QoL) Related to Urinary Symptoms at Each Visit",
            "Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight",
            "Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables"
          ]
        },
        "sponsors": { "lead_sponsor": "Ferring Pharmaceuticals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "42",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "FE200486 CS28",
            "2008-004338-26"
          ]
        },
        "start_date": "April 2009",
        "primary_completion_date": "June 2010",
        "completion_date": "July 2010",
        "study_first_posted": "January 28, 2009",
        "results_first_posted": "August 26, 2011",
        "last_update_posted": "November 11, 2013",
        "locations": {
          "location": [
            "Facharztpraxis fÃ¼r Urologie, Bamberg, Germany",
            "Gemeinschaftspraxis, Borken, Germany",
            "UniversitÃ¤tsklinikum Dresden, Dresden, Germany",
            "Euromed Clinic, FÃ¼rth, Germany",
            "Urologische Gemeinschaftspraxis, Hamburg, Germany",
            "Gemeinschaftspraxis, KÃ¶ln, Germany",
            "VITURO Gesellschaft fÃ¼r Klinische Studien, Leipzig, Germany",
            "Klinikum Offenbach GmbH, Offenbach, Germany",
            "Urologische Klinik Planegg, Planegg, Germany",
            "Wuppertaler Gemeinschaftspraxis, Wuppertal, Germany",
            "Hospital Universitario Principe de Asturias, AlcalÃ¡ de Henares-Madrid, Spain",
            "Fundacion Hospital AlcorcÃ³n, Alcorcon, Spain",
            "FundaciÃ³n Puigvert, Barcelona, Spain",
            "Hospital de Basurto, Bilbao (Bizkaia), Spain",
            "Complejo Hospitalario Universitario A CoruÃ±a, CoruÃ±a, Spain",
            "Hospital universitario RamÃ³n y Cajal, Madrid, Spain",
            "Hospital Clinico Universitario S. Carlos, Madrid, Spain",
            "Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain",
            "Hospital Manacor, Manacor, Spain",
            "Hospital Universitario Central de Asturias, Oviedo, Spain",
            "Hospital Santiago de Compostela, Santiago de Compostela, Spain",
            "Hospital Virgen Macarena, Sevilla, Spain",
            "Hospital Xeral de Vigo, Vigo, Spain",
            "United Bristol Healthcare NHSTrust Bristol Royal Infirmary, Bristol, United Kingdom",
            "Falkirk and District Royal Infirmary, Falkirk, United Kingdom",
            "Southern General Hospital, Glasgow, United Kingdom",
            "Castle Hill Hospital, Hull, United Kingdom",
            "Whipps Cross University Hospital, London, United Kingdom",
            "The Royal Free Hospital, London, United Kingdom",
            "King's College Hospital, London, United Kingdom",
            "Derriford Hospital, Plymouth, United Kingdom",
            "Royal Hallamshire Hospital, Sheffield South, Sheffield, United Kingdom",
            "Sunderland Royal Hospital, Sunderland, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00831233"
      },
      {
        "-rank": "182",
        "nct_id": "NCT00833248",
        "title": "Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Goserelin"
            },
            {
              "-type": "Drug",
              "#text": "Bicalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set)",
            "Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Per Protocol Analysis Set)",
            "Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 4, 8, and 12",
            "Change From Baseline in Serum Testosterone Levels During the Study",
            "Change From Baseline in Serum Prostate-Specific Antigen (PSA) Levels During the Study",
            "Change From Baseline in Serum Oestradiol Levels During the Study",
            "Change From Baseline in Quality of Life (QoL) Related to Urinary Symptoms at Each Visit",
            "Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight",
            "Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables"
          ]
        },
        "sponsors": { "lead_sponsor": "Ferring Pharmaceuticals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "246",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "FE200486 CS30",
            "2008-005232-33"
          ]
        },
        "start_date": "April 2009",
        "primary_completion_date": "September 2011",
        "completion_date": "September 2011",
        "study_first_posted": "February 2, 2009",
        "results_first_posted": "September 27, 2012",
        "last_update_posted": "October 4, 2012",
        "locations": {
          "location": [
            "Alabama Research Center, Birmingham, Alabama, United States",
            "Urology Centers of Alabama, Homewood, Alabama, United States",
            "Alaska Urological Association, Anchorage, Alaska, United States",
            "Arizona Urologic Specialists, Tuscon, Arizona, United States",
            "Orange County Urology, Lagua Hills, California, United States",
            "Tri-Valley Urology Medical Group, Murrieta, California, United States",
            "Connecticut Clinical Research Center, Middlebury, Connecticut, United States",
            "South Florida Medical Research, Aventura, Florida, United States",
            "DCT -Celebration, LLC dba Discovery Clinical Trials, Celebration, Florida, United States",
            "Pinellas Urology Inc., St. Petersburg, Florida, United States",
            "Palm Beach Urology Associates, Wellington, Florida, United States",
            "Summit Research Institute, Bloomington, Indiana, United States",
            "Northeast Indiana Research, Fort Wayne, Indiana, United States",
            "Urology Center Research Institute, Englewood, New Jersey, United States",
            "Urology Group of New Mexico, Albuquerque, New Mexico, United States",
            "Premier Medical Group of Hudson, Columbia, New York, United States",
            "University Urology Associates, New York, New York, United States",
            "Urology Associates, Nashville, Tennessee, United States",
            "Urology of Virginia, Norfolk, Virginia, United States",
            "Hopital Jean Minjoz, Besancon, France",
            "Institut BergoniÃ©, Bordeaux Cedex, France",
            "Centre Francois Baclesse, Caen, France",
            "CHU Henri Mondor, Creteil, France",
            "Centre Oscar Lambret, Lille, France",
            "Centre Leon Berard, Lyon, France",
            "Hopital de la Timone, Marseille, Cedex 5, France",
            "CRLC Val d'Aurelle Oncology Radiotherapy, Montpellier, France",
            "HÃ´pital Tenon, Paris, France",
            "HÃ´pital Saint Louis, Radiotherapy Departement, Paris, France",
            "Clinique Francheville, Perigueux, France",
            "CHU La MilÃ©trie, Oncology Radiotherapy, Poitiers, France",
            "Centre de Lutte Contre le Cancer Nantes-Atlantique Centre RenÃ© Gauducheau, Saint Herblain Cedex, France",
            "Institut de CancÃ©rologie de la Loire, Saint Priest en Jarez, France",
            "Clinique Saint Brieuc, St Brieuc Cedex, France",
            "Centre Paul Strauss, Strassbourg, France",
            "Centre de radiologie Saint Louis, Toulon, France",
            "Clinique du Parc, Toulouse, France",
            "IGR, Villejuif, France",
            "CharitÃ©-UniversitÃ¤tsmedizin, Campus Benjamin Franklin Klinik fÃ¼r Urologie, Berlin, Germany",
            "StÃ¤dtisches Klinikum Braunschweig, Braunschweig, Germany",
            "UniversitÃ¤tsklinikum Dresden, Klinik und Poliklinik fÃ¼r Urologie, Dresden, Germany",
            "UniversitÃ¤tsklinikum Ulm, Klinik fÃ¼r Strahlentherapie und Radioonkologie, Ulm, Germany",
            "General University Hospital of Alexandroupolis, Alexandroupolis, Greece",
            "General Hospital of Athens, \"Sismanogleio\", University of Athens, Marouse, Athens, Greece",
            "University General Hospital of Loannina, Medical School, Loannina, Greece",
            "University General Hospital of Patras, Patras, Greece",
            "Albert Schweitzer Ziekenhuis, Ioc., Dordwijk, Dordrecht, Netherlands",
            "Groene Hart Ziekenhuis, urology, Gouda, Netherlands",
            "Franciscus Gasthuis, Dept. urology, Rotterdam, Netherlands",
            "Maastad Ziekenhuis, Ioc. Clara, Rotterdam, Netherlands",
            "Vlietland Ziekenhuis, Dept. urology, Schiedam, Netherlands",
            "St. Elisabeth Ziekenhuis Tilburg, Tilburg, Netherlands",
            "Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",
            "Hospital Universitari Vall dÂ´Hebron, Barcelona, Spain",
            "Hospital Universitario La Paz, Madrid, Spain",
            "FundaciÃ³n IVO, Valencia, Spain",
            "Kent Oncology Centre Maidstone Hospital, Maidstone, Kent, United Kingdom",
            "Mount Vernon Cancer Center, Northwood, Middlesex, United Kingdom",
            "Oncology Royal United Hospital Bath NHS Trust, Bath, United Kingdom",
            "Addenbrooke's Hospital, Oncology Centre, Cambridge, United Kingdom",
            "St. James' University Hospital, Leeds, United Kingdom",
            "The Royal Marsden NHS, Foundation Trust, London, United Kingdom",
            "Charing Cross Hospital, London, United Kingdom",
            "Northern Centre for Cancer Treatment, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom",
            "Southhampton General Hospital, Cancer Care Directorate, Southhampton Oncology Centre, Southhampton, United Kingdom",
            "Velindre Hospital, Cardiff University, Whitchurch, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00833248"
      },
      {
        "-rank": "183",
        "nct_id": "NCT00089856",
        "title": "GVAXÂ® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "Immunotherapy with allogeneic prostate vaccine"
            },
            {
              "-type": "Drug",
              "#text": "Chemotherapy (Taxotere and prednisone)"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Survival",
            "Bone pain and bone related events"
          ]
        },
        "sponsors": { "lead_sponsor": "Cell Genesys" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "626",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "G-0029",
            "(VITAL-1)"
          ]
        },
        "start_date": "July 2004",
        "primary_completion_date": "October 2008",
        "completion_date": "October 2008",
        "study_first_posted": "August 18, 2004",
        "last_update_posted": "November 5, 2008",
        "locations": {
          "location": [
            "Central Alabama Oncology, LLC, Alabaster, Alabama, United States",
            "Alaska Clinical Research Center, Anchorage, Alaska, United States",
            "Palo Verde Hematology/Oncology, Glendale, Arizona, United States",
            "Mayo Clinic Scottsdale, Scottsdale, Arizona, United States",
            "ACRC/Arizona Clinical Res. Ctr. Inc., Tuscon, Arizona, United States",
            "Arkansas Cancer Research Center, Little Rock, Arkansas, United States",
            "Compassionate Cancer Care Medical Group, Inc., Corona, California, United States",
            "Pacific Coast Hem Onc. Medical Group, Fountain Valley, California, United States",
            "California Cancer Care, Greenbrae, California, United States",
            "Center for Urological Research, La Mesa, California, United States",
            "Oncology Care Medical Associates, Montebello, California, United States",
            "UC Irvine Medical Center, Orange, California, United States",
            "San Bernardino Urological Associates, San Bernardino, California, United States",
            "Sharp Healthcare, San Diego, California, United States",
            "California Pacific Medical Center, San Francisco, California, United States",
            "Cancer Research & Prevention Center, Soquel, California, United States",
            "San Diego Cancer Center, Vista, California, United States",
            "Univ. of Colorado Health Science Center, Aurora, Colorado, United States",
            "Cancer Center of Colorado Springs, Colorado Springs, Colorado, United States",
            "The Hope Clinic, Bristol, Connecticut, United States",
            "Urology Center of Grove Hill, New Britain, Connecticut, United States",
            "Carl & Dorothy Bennett Cancer Center, Stamford, Connecticut, United States",
            "Boca Raton Community Hospital, Inc., Boca Raton, Florida, United States",
            "Michael and Dianne Bienes Comprehensive Cancer Center, Holy Cross Hospital, Fort Lauderdale, Florida, United States",
            "Integrated Community Oncology Network, Jacksonville, Florida, United States",
            "Oncology-Hematology Group of South Florida/Advanced Medical Specialists, Miami, Florida, United States",
            "Cancer Centers of Florida, Ocoee, Florida, United States",
            "Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States",
            "Urology Consultants, Safety Harbor, Florida, United States",
            "Atlanta VAMC, Atlanta, Georgia, United States",
            "Georgia Cancer Specialists, Atlanta, Georgia, United States",
            "Peachtree Hematology Oncology Consultants, PC, Atlanta, Georgia, United States",
            "Winship Cancer Institute, Emory University, Atlanta, Georgia, United States",
            "Central Georgia Cancer Care, P.C., Macon, Georgia, United States",
            "Straub Clinic & Hospital, Honolulu, Hawaii, United States",
            "University of Illinois at Chicago, Chicago, Illinois, United States",
            "Welborn Clinic Research Center, Evansville, Indiana, United States",
            "Fort Wayne Medical Oncology/Hematology Inc., Fort Wayne, Indiana, United States",
            "Louisiana Oncology Associates, Lafayette, Louisiana, United States",
            "Johns Hopkins University, Baltimore, Maryland, United States",
            "Frederick Memorial Hospital Regional Cancer Therapy Center, Frederick, Maryland, United States",
            "West Michigan Regional Cancer and Blood Center, Free Soil, Michigan, United States",
            "William Beaumont Hospital, Cancer Clinical Trials Office, Royal Oak, Michigan, United States",
            "Newland Medical Associates, P.C., Southfield, Michigan, United States",
            "Hematology Oncology Consultants, Inc., St. Louis, Missouri, United States",
            "Deaconess Billings Clinic, Billings, Montana, United States",
            "Hematology/Oncology Centers of the Northern Rockies, P.C., Billings, Montana, United States",
            "Omaha VA Medical Center, Omaha, Nebraska, United States",
            "Omaha VA Medical Center, Omaha, Nebraska, United States",
            "Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",
            "The Center for Cancer & Hematologic Disease, Cherry Hill, New Jersey, United States",
            "Hematology-Oncology Associates of Northern New Jersey, Morristown, New Jersey, United States",
            "Summit Medical Group/Overlook Oncology Center, Summit, New Jersey, United States",
            "Jacobi Medical Center, Bronx, New York, United States",
            "Columbia University Medical Center, New York, New York, United States",
            "SUNY Upstate Medical University, Syracuse, New York, United States",
            "Presbyterian Hospital/ Center for Cancer Research, Charlotte, North Carolina, United States",
            "Northwestern Carolina Hematology Oncology, PA, Hickory, North Carolina, United States",
            "Medcenter One Cancer Care / Odyssey Research, Bismarck, North Dakota, United States",
            "Dakota Cancer Institute, Fargo, North Dakota, United States",
            "Gabrail Cancer Center, Canton, Ohio, United States",
            "Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, Ohio, United States",
            "University of Oklahoma, Oklahoma City, Oklahoma, United States",
            "Providence Portland Medical Center, Portland, Oregon, United States",
            "Urologic Surgery PC, Bala Cynwyd, Pennsylvania, United States",
            "Medical Oncology Associates, Kingston, Pennsylvania, United States",
            "Lancaster Cancer Center, Ltd, Lancaster, Pennsylvania, United States",
            "Urological Associates of Lancaster, Lancaster, Pennsylvania, United States",
            "University of Pittsburgh Cancer Center, Pittsburgh, Pennsylvania, United States",
            "Charleston Hematology Oncology, Charleston, South Carolina, United States",
            "Memorial Health Care System, Chattanooga, Tennessee, United States",
            "The West Clinic, Memphis, Tennessee, United States",
            "The Don and Sybil Harrington Cancer Center, Amarillo, Texas, United States",
            "Mary Crowley Medical Research Center, Dallas, Texas, United States",
            "Center for Oncology Research and Treatment PA, Dallas, Texas, United States",
            "Urology Specialists and Associates, P.A., Dallas, Texas, United States",
            "Mobley Research Center, Houston, Texas, United States",
            "Urology San Antonio, San Antonio, Texas, United States",
            "Tyler Cancer Center, Tyler, Texas, United States",
            "Southwestern Oncology Research Department, Bennington, Vermont, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "Virginia Mason Medical Center Urology, Seattle, Washington, United States",
            "Seattle Cancer Care Alliance, Seattle, Washington, United States",
            "ZNA Middelheim, Antwerp, Belgium",
            "Imelda Ziekenhuis, Bonheiden, Belgium",
            "University Hospital Antwerp (UZA), Edegem, Belgium",
            "UZ Gent, Gent, Belgium",
            "Unversity Hospial Gent, Gent, Belgium",
            "Virga Jesse Ziekenhuis, Hasselt, Belgium",
            "AZ Groeninge, Kortrijk, Belgium",
            "Heilig Hartziekenhuis Roeselare Men, Roeselare, Belgium",
            "Regionaal Ziekenhuis Sint Trudo, Sint-Truiden, Belgium",
            "Princess Margaret Hospital, Toronto, Ontario, Canada",
            "CHUM Notre-Dam, Montreal, Quebec, Canada",
            "McGill University, Montreal, Quebec, Canada",
            "Ultra Med Inc., Pointe-Claire, Quebec, Canada",
            "Centre Hopitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",
            "Centre Paul Papin, Angers Cedex, France",
            "Centre Francois Baclesse, Caen Cedex 5, France",
            "Centre Georges Francois Leclerc, Dijon Cedex, France",
            "Centre Leon Berard Service de Cancerologie Medicale, Lyon Cedex, France",
            "Institut Paoli-Calmettes, Marseille, France",
            "Centre Rene Gauducheau, Nantes-Saint Herblain, France",
            "Institut Jean Godinot, Reims Cedex, France",
            "Centre Alexis Vautrin, Vandoeuvre les Nancy Cedex, France",
            "Universitatsklinikum Aachen Urologie, Aachen, Germany",
            "der Technischen Universitat Dresden, Dresden, Germany",
            "Universitatsklinik um Essen, Essen, Germany",
            "Universitatsklinik um des Saarlande, Homburg/Saar, Germany",
            "VU Medisch Centrum, Amsterdam, Netherlands",
            "University Medical Centre Groningen, Groningen, Netherlands",
            "University Hospital, Linkoping, Linkoping, Sweden",
            "University Hospital Lund, Lund, Sweden",
            "Akademiska University Hospital, Uppsala, Sweden",
            "Addenbrooke's Hospital, Cambridge, United Kingdom",
            "Beatson Oncology Centre, Glasgow, United Kingdom",
            "St. James's University Hospital, Leeds, United Kingdom",
            "Hammersmith Hospital, London, United Kingdom",
            "Mount Vernon Hospital, Middlesex, United Kingdom",
            "Newcastle General Hospital, Newcastle upon Tyne, United Kingdom",
            "Northampton General Hosptial, Northampton, United Kingdom",
            "Nottingham City Hospital, Nottingham, United Kingdom",
            "Oxford Cancer Centre, Churchill Hospital, Oxford, United Kingdom",
            "Scunthorpe General Hospital, Scunthorpe, United Kingdom",
            "Royal Hallamshire Hospital, Sheffield, United Kingdom",
            "Glan Clwyd Hospital, Wales, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00089856"
      },
      {
        "-rank": "184",
        "nct_id": "NCT00069745",
        "title": "Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Hormone Refractory Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Satraplatin"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "sponsors": { "lead_sponsor": "Agennix" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "GPC SAT3-03-01" },
        "start_date": "September 2003",
        "primary_completion_date": "January 2006",
        "completion_date": "March 2007",
        "study_first_posted": "October 6, 2003",
        "last_update_posted": "August 7, 2012",
        "locations": {
          "location": [
            "Birmingham Hematology and Oncology, Birmingham, Alabama, United States",
            "Birmingham Hematology and Oncology, Birmingham, Alabama, United States",
            "Hematology Oncology Associates, Phoenix, Arizona, United States",
            "Northern AZ Hematology & Oncology Assoc., Sedona, Arizona, United States",
            "Hematology Oncology Physicians/SMO, Tucson, Arizona, United States",
            "Arizona Cancer Center, Tuscon, Arizona, United States",
            "California Cancer Center, Fresno, California, United States",
            "Pacific Shores Medical Group, Long Beach, California, United States",
            "Division of Hematology - Oncology, Los Angeles, California, United States",
            "University of California Davis Cancer Center, Division of Hematology-Oncology, Sacramento, California, United States",
            "Sharp Healthcare - Clinical Oncology Research, San Diego, California, United States",
            "Rocky Mountain Cancer Center - Midtown, Denver, Colorado, United States",
            "Hartford Hospital, Hartford, Connecticut, United States",
            "DeQuattro Community Cancer Center, Manchester, Connecticut, United States",
            "Cancer Centers of Florida-Altamonte, Altamonte Springs, Florida, United States",
            "The Center for Hematology Oncology, Boca Raton, Florida, United States",
            "Innovative Medical Research of South Florida, Miami Shores, Florida, United States",
            "Hematology/Oncology Group of South Florida, Miami, Florida, United States",
            "Florida Cancer Institute, New Port Richey, Florida, United States",
            "Ocala Oncology Center, Ocala, Florida, United States",
            "South Florida Oncology & Hematology, Plantation, Florida, United States",
            "Hematology/Oncology Associates of Treasure Coast, Port St. Lucie, Florida, United States",
            "Oncology and Hematology Associates of West Broward P.A., Tamarac, Florida, United States",
            "Decatur Memorial Hospital, Decatur, Illinois, United States",
            "Northwest Medical Specialists, Niles, Illinois, United States",
            "North Shore Research Association, Skokie, Illinois, United States",
            "Central Indiana Cancer Centers, Fishers, Indiana, United States",
            "Indiana Hematology Oncology Consultants, Indianapolis, Indiana, United States",
            "Central Indiana Cancer Centers, Indianapolis, Indiana, United States",
            "Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa, United States",
            "Kansas City Cancer Centers - Southwest, Overland Park, Kansas, United States",
            "Louisiana Oncology Associates, Lafayette, Louisiana, United States",
            "LSU Health Science Center, Stanley S. Scott Cancer Center, New Orleans, Louisiana, United States",
            "Maine Center for Cancer Medicine & Blood Disorders, Scarborough, Maine, United States",
            "Berkshire Hematology Oncology, Pittsfield, Massachusetts, United States",
            "Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States",
            "Maplewood Cancer Center, Maplewood, Minnesota, United States",
            "Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States",
            "Missouri Cancer Associates, Columbia, Missouri, United States",
            "Capitol Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States",
            "St. Joseph Oncology, Inc., St. Joseph, Missouri, United States",
            "Hematology/Oncology Consultants, Inc., St. Louis, Missouri, United States",
            "Arch Medical Services, Inc., Washington, Missouri, United States",
            "Nebraska Methodist Hospital Cancer Center, Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "Nevada Cancer Institute, Las Vegas, Nevada, United States",
            "New Hampshire Oncology-Hematology PA, Hooksett, New Hampshire, United States",
            "Hematology Oncology Associates, Albuquerque, New Mexico, United States",
            "Lovelace Sandia Health Systems, Albuquerque, New Mexico, United States",
            "Veterans Affairs Medical Center, Albuquerque, New Mexico, United States",
            "The University of New Mexico, Albuquerque, New Mexico, United States",
            "New Mexico Cancer Care Associates, Santa Fe, New Mexico, United States",
            "Albany Regional Cancer Center, Albany, New York, United States",
            "New York Oncology Hematology, P.C., Albany, New York, United States",
            "Advanced Oncology Associates, Armonk, New York, United States",
            "Roswell Park Cancer Institute, Buffalo, New York, United States",
            "Interlakes Oncology Hematology, Canandaigua, New York, United States",
            "Columbia Presbyterian Medical Center, New York, New York, United States",
            "New York Oncology Hematology, Rexford, New York, United States",
            "VA Medical Center Syracuse, Syracuse, New York, United States",
            "Raleigh Hematology Oncology Clinic, Cary, North Carolina, United States",
            "Piedmont Hematology - Oncology, Winston - Salem, North Carolina, United States",
            "Dayton Oncology Hematology, Kettering, Ohio, United States",
            "Cancer Care Associates, Oklahoma City, Oklahoma, United States",
            "Cancer Care Associates, Tulsa, Oklahoma, United States",
            "Willamette Valley Cancer Center, Eugene, Oregon, United States",
            "Hematology and Oncology Associates of Northeastern PA / PC, Dunmore, Pennsylvania, United States",
            "University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States",
            "University of Pittsburgh Cancer Institute- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",
            "Charleston Cancer Center, Charleston, South Carolina, United States",
            "Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States",
            "Cancer Center of the Carolinas, Seneca, Seneca, South Carolina, United States",
            "The West Clinic, Memphis, Tennessee, United States",
            "Texas Cancer Center, Abilene, Texas, United States",
            "Texas Oncology, Arlington, Texas, United States",
            "Southwest Regional Cancer Center, Austin, Texas, United States",
            "Texas Oncology Cancer Center, Austin, Texas, United States",
            "Mamie McFaddin Ward Cancer Center, Beaumont, Texas, United States",
            "Texas Onoclogy PA - Bedford, Bedford, Texas, United States",
            "Texas Cancer Center at Medical City, Dallas, Texas, United States",
            "Texas Oncology, P.A., Dallas, Texas, United States",
            "The Texas Cancer Center, Dallas, Texas, United States",
            "TOPA Sammons Cancer Center, Dallas, Texas, United States",
            "Texas Cancer Center, Denton, Texas, United States",
            "El Paso Cancer Treatment Center, El Paso, Texas, United States",
            "San Antonio Tumor & Blood Clinic, Fredericksburg, Texas, United States",
            "Texas Oncology, P.A., Ft. Worth, Texas, United States",
            "Texas Oncology, P.A., Garland, Texas, United States",
            "Texas Oncology, P.A. - Irving, Irving, Texas, United States",
            "Lake Vista Cancer Center, Lewisville, Texas, United States",
            "Longview Cancer Center, Longview, Texas, United States",
            "S. Texas Cancer Center, McAllen, Texas, United States",
            "Texas Cancer Center of Mesquite, Mesquite, Texas, United States",
            "Allison Cancer Center, Midland, Texas, United States",
            "West Texas Cancer Center, Odessa, Texas, United States",
            "Hematology Oncology Associates of South Texas, San Antonio, Texas, United States",
            "Tyler Cancer Center, Tyler, Texas, United States",
            "Waco Cancer Care Research Center, Waco, Texas, United States",
            "Texas Oncology, P.A. - Deke Slayton Cancer Center, Webster, Texas, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "Onc and Hem Associates of SW VA, Inc., Salem, Virginia, United States",
            "Puget Sound Cancer Center - Edmonds, Edmonds, Washington, United States",
            "Cancer Care Northwest-North, Spokane, Washington, United States",
            "Northwest Cancer Specialists, Vancouver, Washington, United States",
            "Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States",
            "Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina",
            "Clinica Oncologica de Excelencia, Capital Federal, Buenos Aires, Argentina",
            "Policlinica Bancaria \"9 de Julio\" Av. Gaona 2197, Capital Federal, Buenos Aires, Argentina",
            "Hospital General de Agudos E. Tornu, Capital Federal, Buenos Aires, Argentina",
            "Salisbury Investigaciones Clinicas del Grupo CER S.A., Quilmes, Buenos Aires, Argentina",
            "Hospital Italiano Regional del Sur Dept. Oncology, Bahia Blanca, Argentina",
            "Grupo Plaza Dept. Oncology, Belen de Escobar, Argentina",
            "Instituto QuirÃºrgico del Callao, Buenos Aires, Argentina",
            "Instituto Alexander Fleming, Buenos Aires, Argentina",
            "Centro OncolÃ³gico LALCEC, Concepcion del Uruguay, Entre RÃ­os, Argentina",
            "Hospital Italiano de Cordoba Dept. Oncology, Cordoba, Argentina",
            "Unidad Oncologica del Neuquen, Neuquen, Argentina",
            "Caici Dept. Oncology, Rosario, Argentina",
            "Centro Oncologico Rosario, Rosario, Argentina",
            "Centro San Roque, San Miguel de TucumÃ¡n, TucumÃ¡n, Argentina",
            "Clinical Especializada ISIS, Santa Fe, Argentina",
            "AZ-VUB, Bruxelles, Belgium",
            "Institut Jules Bordet Service de ChimiothÃ©rapie, Bruxelles, Belgium",
            "Hopital Erasme, Bruxelles, Belgium",
            "UCLC St. Luc, Bruxelles, Belgium",
            "Sint Maartenziekenhuis, Kortrijk, Belgium",
            "Clinical Hospital Split Department of Oncology and Radiotherapy, Split, Croatia",
            "Clinical Hostpital Rebro Department of Oncology, Zagreb, Croatia",
            "Institut BergoniÃ©, Bordeaux Cedex, France",
            "Centre Georges FranÃ§ois Leclerc, Dijon, France",
            "HÃ´pital de La Tronche - CHU de Grenoble: Departement de cacerologie et d'hematologie, Grenoble Cedex 09, France",
            "Clinique du Mail Service d'Oncologie, Grenoble, France",
            "Centre Hospitalier DÃ©partemental, La Roche Sur Yon, France",
            "CHU de BicÃªtre, Le Kremlin Bicetre, France",
            "Chu Dupuytren, Limoges, France",
            "CRLC LÃ©on BÃ©rard, Lyon, France",
            "Centre Hospitalier Belfort-Montbeliard, Montbeliard, France",
            "CRLC Val d'Aurelle Paul-Lamarque, Montpellier, France",
            "Centre Antoine Lacassagne Oncologie medicale, Nice Cedex 2, France",
            "HÃ´pital Saint-Louis: Service de Radiotherapy, Paris, France",
            "HÃ´pital Tenon, Paris, France",
            "CHU de Poitiers, Poitiers, France",
            "Institut Jean , Service d'Oncologie, Reims, France",
            "Centre Eugene Marquis, Rennes Cedex, France",
            "Centre Alexis Vautrin, Vandoeuvre Les Nancy, France",
            "RWTH Aachen, Aachen, Germany",
            "Vivantes Krankenhaus am Urban, Berlin, Germany",
            "Fach- und Belegarzte fur Urologie, Berlin, Germany",
            "Diakonissenkrankenhaus Dessau gGmbH, Dessau, Germany",
            "UniversitÃ¤tsklinikum der Carl-Gustav-Carus UniversitÃ¤t, Dresden, Germany",
            "Stadtische Klinicen Frankfurt a.M. Hochst, Frankfurt a.M. Hochst, Germany",
            "EuromedClinic, FÃ¼rth, Germany",
            "Klinikum der medizinischen FakultÃ¤t der Martin-Luther-UniversitÃ¤t Halle-Wittenberg, Halle, Germany",
            "Niedergelassener Urologe, Hamburg, Germany",
            "Medizinische Hochschule, Hannover, Germany",
            "Marienhospital II, Herne, Germany",
            "Universitatklinikum Schleswig-Holstein, Lubeck, Germany",
            "Klinickum der Johannes-Gutenberg Universitat, Mainz, Germany",
            "Klinikum der Philipps - Universitat Marburg, Marburg, Germany",
            "Universitatklinikum Munster, Munster, Germany",
            "Klinikum rechts der Isar, MÃ¼nchen, Germany",
            "Klinik Bad Trissel, Oberaudorf, Germany",
            "Urologische Praxis, SaarbrÃ¼cken, Germany",
            "St. Margit Hospital, Budapest, Hungary",
            "St. Istvan Hospital, Budapest, Hungary",
            "National Institute of Oncology, Budapest, Hungary",
            "Pecs Medical University, Pecs, Hungary",
            "Soroka Medical Center, Beerhseva, Israel",
            "Rambam Medical Center, Haifa, Israel",
            "Hadassah University, Jerusalem, Israel",
            "Hospital Ein Kerem Asaf Harofeh Medical Center, Zerifin, Israel",
            "Istituto Nazionale per la Ricerca sul Cancro (IST), Genoa, Italy",
            "Universita degli Studi di Napoli Federico II-Nuovo Policlinico, Napoli, Italy",
            "A.S.O. San Luigi, Orbassano, Italy",
            "Azienda Ospedaliera di Padova, Padova, Italy",
            "A.O. San Camillo-Forlanini, Rome, Italy",
            "Istituto Clinico Humanitas: Dipartimento di Oncologia Medica ed Ematologia, Rozanno (MI), Italy",
            "Academic Hospital of the University of Amsterdam, Amsterdam, Netherlands",
            "Academisch Ziekenhuis Nijmegen: Urology Department, Nijmegen, Netherlands",
            "Streekziekenhuis Koningin : Dept. Urology, Winterswijk, Netherlands",
            "Essalud Dept. Oncology, Jesus Maria, Peru",
            "San Felipe (Oncomedical), Lima, Peru",
            "INEN Dept Onco-Hemato, Lima, Peru",
            "Oddzial Chemioterapii, Bialostocki Osrodek Onkologiczny, Bialystok, Poland",
            "Oddzial Onkologii I Radioterapii, Szpital Morski im. PCK, Gdynia, Poland",
            "Akademia Medyczna w Lodzi, Lodz, Poland",
            "Akademia Medyczna w Lublinie, Lublin, Poland",
            "Oddzial Radioterapii, Wielkopolskie Centrum Onkologii - Instytut, Poznan, Poland",
            "Akademia Medyczna w Szczecinie, Szczecin, Poland",
            "Klinika Nowotworow Ukladu Moczowego, Centrum Onkologii - Instytut, Warszawa, Poland",
            "Oddzial Chemioterapii, 4 Wojskowy Szpital Kliniczny, Wroclaw, Poland",
            "N.N Blokchin Cancer Research Centre, Moscow, Russian Federation",
            "Hertzen Research Institute of Oncology, Moscow, Russian Federation",
            "Medical Radilogical Research Center of Rams, Obninsk, Russian Federation",
            "Hospital de la Santa Creu i Sant Pau, Sevicio de OncologÃ­a MÃ©dica, Barcelona, Spain",
            "Hospital Clinic i Provincial, Sevicio de OncologÃ­a MÃ©dica, Barcelona, Spain",
            "Hospital Ramon y Cajal, Madrid, Spain",
            "Hospital ClÃ­nico San Carlos, Sevicio de OncologÃ­a MÃ©dica, Madrid, Spain",
            "Clinica Universitaria de Navarra, Sevicio de OncologÃ­a MÃ©dica, Pamplona, Spain",
            "Hospital Universitario MarquÃ©s de Valdecilla, Sevicio de OncologÃ­a MÃ©dica, Santander, Spain",
            "Instituto Valenciano de OncologÃ­a: Sevicio de OncologÃ­a MÃ©dica, Valencia, Spain",
            "Aberdeen Royal Infirmary, Aberdeen, United Kingdom",
            "CRUK Institute for Cancer Studies, Birmingham, United Kingdom",
            "Bristol Oncology Centre, Bristol, United Kingdom",
            "Beatson Oncology Center, Glasgow, United Kingdom",
            "Guy's hospital, London, United Kingdom",
            "St George's Healthcare Dept of Oncology, Tooting, London, United Kingdom",
            "St. Bartholomew's Hospital Dept. of Medical Oncology, London, United Kingdom",
            "Northern Centre for Cancer Treatment, Newcastle Upon Tyne, United Kingdom",
            "Lister Hospital Department of Urology, Stevenage Hertfordshire, United Kingdom",
            "Royal Marsden Hospital, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00069745"
      },
      {
        "-rank": "185",
        "nct_id": "NCT02116582",
        "title": "A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Metastatic Castration-Resistant Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Enzalutamide"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Progression-free Survival (rPFS)",
            "Overall Survival (OS)",
            "Percentage of Participants With a Prostate-specific Antigen (PSA) Response",
            "Time to PSA Progression",
            "Number of Participants With Adverse Events (AEs)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Europe B.V.",
          "collaborator": [
            "Medivation, Inc.",
            "Astellas Pharma Inc"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 4" },
        "enrollment": "215",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "9785-CL-0410",
            "2013-002271-17"
          ]
        },
        "start_date": "May 23, 2014",
        "primary_completion_date": "May 8, 2016",
        "completion_date": "September 29, 2017",
        "study_first_posted": "April 17, 2014",
        "results_first_posted": "June 8, 2017",
        "last_update_posted": "November 15, 2018",
        "locations": {
          "location": [
            "Site BE32001, Brussels, Flemish Brabant, Belgium",
            "Site BE32004, Gent, Belgium",
            "Site BE32007, Hasselt, Belgium",
            "Site BE32003, Kortrijk, Belgium",
            "Site BE32002, Liege, Belgium",
            "Site FR33015, Angers cedex 02, France",
            "Site FR33009, Caen Cedex 05, France",
            "Site FR33010, Creteil cedex, France",
            "Site FR33014, Le Mans, France",
            "Site FR33013, Lyon Cedex 3, France",
            "Site FR33003, Marseille CEDEX 9, France",
            "Site FR33008, Nantes Saint Herblain Cedex, France",
            "Site FR33002, Nimes, France",
            "Site FR33001, Paris cedex 15, France",
            "Site FR33011, Paris, France",
            "Site FR33007, Rennes, France",
            "Site FR33005, Suresnes, France",
            "Site FR33012, Villejiuf, France",
            "Site DE49005, Nuertingen, Baden-Wuerttemberg, Germany",
            "Site DE49015, Bergisch Gladbach, Northwest, Germany",
            "Site DE49017, Duisburg, NRW, Germany",
            "Site DE49014, Berlin, Germany",
            "Site DE49003, Berlin, Germany",
            "Site DE49009, Bonn, Germany",
            "Site DE49010, Dresden, Germany",
            "Site DE49016, Duesseldorf, Germany",
            "Site DE49004, Goettingen, Germany",
            "Site DE49001, Hamburg, Germany",
            "Site DE49008, Hamburg, Germany",
            "Site DE49007, Hannover, Germany",
            "Site DE49002, Heidelberg, Germany",
            "Site DE49012, Munster, Germany",
            "Site DE49006, Tubingen, Germany",
            "Site ES34004, Santiago de Compostela, A Coruna, Spain",
            "Site ES34009, Badalona, Spain",
            "Site ES34011, Barcelona, Spain",
            "Site ES34006, Barcelona, Spain",
            "Site ES34008, Barcelona, Spain",
            "Site ES34001, Madrid, Spain",
            "Site ES34003, Madrid, Spain",
            "Site ES34002, Madrid, Spain",
            "Site ES34010, Madrid, Spain",
            "Site GB44001, Sutton, Surrey, United Kingdom",
            "Site GB44004, Birmingham, United Kingdom",
            "Site GB44009, Brighton, United Kingdom",
            "Site GB44002, Glasgow, United Kingdom",
            "Site GB44007, London, United Kingdom",
            "Site GB44003, Northwood, Middlesex, United Kingdom",
            "Site GB44010, Plymouth, United Kingdom",
            "Site GB44006, Withington, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02116582"
      },
      {
        "-rank": "186",
        "nct_id": "NCT00617669",
        "title": "A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer",
        "acronym": "ENTHUSE M1C",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "ZD4054"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Progression Free Survival",
            "Incidence of Skeletal Related Events",
            "Time to Prostate-specific Antigen (PSA) Progression",
            "Time to Pain Progression",
            "Pain Response",
            "Health Related Quality of Life",
            "PSA Response"
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1494",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "D4320C00033" },
        "start_date": "January 2008",
        "primary_completion_date": "May 2011",
        "completion_date": "July 2011",
        "study_first_posted": "February 18, 2008",
        "results_first_posted": "May 31, 2012",
        "last_update_posted": "September 10, 2012",
        "locations": {
          "location": [
            "Research Site, Greenbrae, California, United States",
            "Research Site, San Diego, California, United States",
            "Research Site, Norwich, Connecticut, United States",
            "Research Site, Washington, District of Columbia, United States",
            "Research Site, Fort Myers, Florida, United States",
            "Research Site, Gainsville, Florida, United States",
            "Research Site, Ocala, Florida, United States",
            "Research Site, PORTUGALt St. Lucie, Florida, United States",
            "Research Site, Rockville, Maryland, United States",
            "Research Site, Minneapolis, Minnesota, United States",
            "Research Site, Lincoln, Nebraska, United States",
            "Research Site, Omaha, Nebraska, United States",
            "Research Site, Chapel Hill, North Carolina, United States",
            "Research Site, Durham, North Carolina, United States",
            "Research Site, Winston-Salem, North Carolina, United States",
            "Research Site, Canton, Ohio, United States",
            "Research Site, Cincinnati, Ohio, United States",
            "Research Site, Pittsburgh, Pennsylvania, United States",
            "Research Site, Charleston, South Carolina, United States",
            "Research Site, Chattanooga, Tennessee, United States",
            "Research Site, Nashville, Tennessee, United States",
            "Research Site, San Antonio, Texas, United States",
            "Research Site, Richmond, Virginia, United States",
            "Research Site, Seattle, Washington, United States",
            "Research Site, Milwaukee, Wisconsin, United States",
            "Research Site, Bahia Blanca, Buenos Aires, Argentina",
            "Research Site, Buenos Aires, Argentina",
            "Research Site, Santa Fe, Argentina",
            "Research Site, Darlinghurst, New South Wales, Australia",
            "Research Site, St Leonards, New South Wales, Australia",
            "Research Site, Wollongong, New South Wales, Australia",
            "Research Site, Redcliffe, Queensland, Australia",
            "Research Site, Ashford, South Australia, Australia",
            "Research Site, Footscray, Victoria, Australia",
            "Research Site, Wodonga, Victoria, Australia",
            "Research Site, Perth, Western Australia, Australia",
            "Research Site, Subiaco, Western Australia, Australia",
            "Research Site, Fortaleza, Ceara/ LA, Brazil",
            "Research Site, Goiania, Goias/ LA, Brazil",
            "Research Site, Goiania, Goias, Brazil",
            "Research Site, Belo Horizonte, Minas GERMANYais, Brazil",
            "Research Site, Curitiba, Parana/ Brazil, Brazil",
            "Research Site, Londrina, PR, Brazil",
            "Research Site, PORTUGALto Alegre, Rio Grande do Sul/ LA, Brazil",
            "Research Site, Rio de Janeiro, RJ, Brazil",
            "Research Site, Ribeirao Preto, Sao Paulo/ LA, Brazil",
            "Research Site, Santo Andre, Sao Paulo, Brazil",
            "Research Site, Sao Paulo, Brazil",
            "Research Site, Winnipeg, Manitoba, Canada",
            "Research Site, Halifax, Nova Scotia, Canada",
            "Research Site, London, Ontario, Canada",
            "Research Site, Toronto, Ontario, Canada",
            "Research Site, Quebec City, Quebec, Canada",
            "Research Site, Sherbrooke, Quebec, Canada",
            "Research Site, Brno, CZECHOSLOVAKIA Republic, Czech Republic",
            "Research Site, Jablonec nad Nisou, Czech Republic",
            "Research Site, Kromeriz, Czech Republic",
            "Research Site, Olomouc, Czech Republic",
            "Research Site, Prague 2, Czech Republic",
            "Research Site, Prague 6, Czech Republic",
            "Research Site, Usti nad Labem, Czech Republic",
            "Research Site, Helsinki, Finland",
            "Research Site, Joensuu, Finland",
            "Research Site, Seinajoki, Finland",
            "Research Site, La Roche sur Yon, FRANCEnce, France",
            "Research Site, Marseille, FRANCEnce, France",
            "Research Site, Paris, FRANCEnce, France",
            "Research Site, Reims, FRANCEnce, France",
            "Research Site, Villejuif, FRANCEnce, France",
            "Research Site, Paris, France",
            "Research Site, Saint Herblain, France",
            "Research Site, Hannover, GERMANYmany, Germany",
            "Research Site, Berlin, Germany",
            "Research Site, Bonn, Germany",
            "Research Site, Dresden, Germany",
            "Research Site, Emmendingen, Germany",
            "Research Site, Kirchheim-Teck, Germany",
            "Research Site, Leipzig, Germany",
            "Research Site, Luebeck, Germany",
            "Research Site, Muenster, Germany",
            "Research Site, Tuebingen, Germany",
            "Research Site, Wuppertal, Germany",
            "Research Site, Budapest, HUNGARYary, Hungary",
            "Research Site, Gyor, HUNGARYary, Hungary",
            "Research Site, Miskolc, HUNGARYary, Hungary",
            "Research Site, Ny Regyh Za, HUNGARYary, Hungary",
            "Research Site, Szeged, HUNGARYary, Hungary",
            "Research Site, Bangalore, Karnataka, India",
            "Research Site, Trivandrum, Kerala, India",
            "Research Site, Bhopal, Madhya Pradesh, India",
            "Research Site, Pune, Maharashtra, India",
            "Research Site, Bikaner, Rajasthan, India",
            "Research Site, Jaipur, Rajasthan, India",
            "Research Site, Vellore, Tamil Nadu, India",
            "Research Site, Kolkata, West Bengal, India",
            "Research Site, Kolkota, West Bengal, India",
            "Research Site, Delhi, India",
            "Research Site, New Delhi, India",
            "Research Site, Genoa, Italy",
            "Research Site, Lugo (RA), Italy",
            "Research Site, Rome, Italy",
            "Research Site, Cheongju, Chungbuk, Korea, Republic of",
            "Research Site, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, Republic of",
            "Research Site, Nowon-gu, Seoul, Korea, Republic of",
            "Research Site, Seodaemun-gu, Seoul, Korea, Republic of",
            "Research Site, Songpa-gu, Seoul, Korea, Republic of",
            "Research Site, Nijmegen, Netherlands",
            "Research Site, Cercado de Arequipa, Arequipa, Peru",
            "Research Site, Cercado, Arequipa, Peru",
            "Research Site, Callao, Peru",
            "Research Site, Lima, Peru",
            "Research Site, Lublin, POLANDand, Poland",
            "Research Site, Swidnica, POLANDand, Poland",
            "Research Site, Warszaa, POLANDand, Poland",
            "Research Site, Koscierzyna, Poland",
            "Research Site, Wroclaw, Poland",
            "Research Site, Coimbra, PORTUGALtugal, Portugal",
            "Research Site, PORTUGALto, PORTUGALtugal, Portugal",
            "Research Site, Bucharest, Romania",
            "Research Site, Sibiu, Romania",
            "Research Site, Timisoara, Romania",
            "Research Site, Barnaul, RUSSIAsia, Russian Federation",
            "Research Site, Izhevsk, RUSSIAsia, Russian Federation",
            "Research Site, Kursk, RUSSIAsia, Russian Federation",
            "Research Site, Sochi, RUSSIAsia, Russian Federation",
            "Research Site, Voronezh, RUSSIAsia, Russian Federation",
            "Research Site, Belgrade, SERBIAbia, Serbia",
            "Research Site, Beograd, SERBIAbia, Serbia",
            "Research Site, Nis, SERBIAbia, Serbia",
            "Research Site, Panorama, Cape Town, South Africa",
            "Research Site, TyGERberg, Cape Town, South Africa",
            "Research Site, Overport, Durban, South Africa",
            "Research Site, Bloemfontein, South Africa",
            "Research Site, PORt Elizabeth, South Africa",
            "Research Site, Madrid, Spain",
            "Research Site, Valencia, Spain",
            "Research Site, Stockholm, Sweden",
            "Research Site, Uppsala, Sweden",
            "Research Site, Aarau, Switzerland",
            "Research Site, Locarno, Switzerland",
            "Research Site, Sursee, Switzerland",
            "Research Site, Kaohsiung, TAIWANwan, Taiwan",
            "Research Site, TAIWANpei, TAIWANwan, Taiwan",
            "Research Site, Reading, Berkshire, United Kingdom",
            "Research Site, Westgate Road, Newcastle Upon Tyne, United Kingdom",
            "Research Site, London, United Kingdom",
            "Research Site, Manchester, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00617669"
      },
      {
        "-rank": "187",
        "nct_id": "NCT00861614",
        "title": "Study of Immunotherapy to Treat Advanced Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Ipilimumab"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival (OS)",
            "Overall Survival Rate",
            "Progression Free Survival (PFS)",
            "Pain Response",
            "Duration of Pain Response",
            "Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs, Immune-Related Adverse Events (irAE) and Immune-Mediated Adverse Reaction (imAR)",
            "Time to Onset of Grade 3 or 4 Immune-Related Adverse Event (irAE)",
            "Time to Resolution of Grade 3 or 4 Immune-Related Adverse Event (irAE)",
            "Time to Onset of Grade 3 to 5 Immune-Mediated Adverse Reaction (imAR)",
            "Time to Resolution of Grade 3 to 5 to Grade 0 Immune-Mediated Adverse Reactions (imARs) to Grade 0",
            "Number of Participants With Worst On-Study Hematology Common Toxicity Criteria (CTC) Grade and Shift From Baseline",
            "Number of Participants With Worst On-Study Liver Common Toxicity Criteria (CTC) Grade and Shift From Baseline",
            "Number of Participants With Worst On-Study Serum Chemistry Common Toxicity Criteria (CTC) Grade and Shift From Baseline",
            "Number of Participants With Worst On-Study Renal Function Common Toxicity Criteria (CTC) Grade and Shift From Baseline"
          ]
        },
        "sponsors": { "lead_sponsor": "Bristol-Myers Squibb" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "988",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CA184-043",
            "2008-003314-97"
          ]
        },
        "start_date": "May 2009",
        "primary_completion_date": "November 2012",
        "completion_date": "August 2015",
        "study_first_posted": "March 13, 2009",
        "results_first_posted": "March 16, 2016",
        "last_update_posted": "September 30, 2016",
        "locations": {
          "location": [
            "Southern Cancer Center, Mobile, Alabama, United States",
            "Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States",
            "Arizona Clinical Research Center, Inc., Tucson, Arizona, United States",
            "Highlands Oncology Group, P.A., Fayetteville, Arkansas, United States",
            "Marsha G. Fink, Md, Inc., Fountain Valley, California, United States",
            "Loma Linda University Cancer Center, Loma Linda, California, United States",
            "Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States",
            "Prostate Oncology Specialists, Inc., Marina Del Rey, California, United States",
            "Comprehensive Cancer Center, Palm Springs, California, United States",
            "Va San Diego Healthcare System, San Diego, California, United States",
            "Pacific Hematology Oncology Associates, San Francisco, California, United States",
            "Baptist Cancer Institute, Jacksonville, Florida, United States",
            "Orlando Health, Inc, Orlando, Florida, United States",
            "Suburban Hematology-Oncology Associates, Pc, Lawrenceville, Georgia, United States",
            "University Of Chicago, Chicago, Illinois, United States",
            "Cancer Care Specialists Of Central Illinois, Decatur, Illinois, United States",
            "Edward Cancer Center, Naperville, Illinois, United States",
            "Mid-Illinois Hematology & Oncology Associates, Ltd, Normal, Illinois, United States",
            "University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States",
            "Siouxland Hematology-Oncology Assoc., Llp, Sioux City, Iowa, United States",
            "Hutchinson Clinic, Pa, Hutchinson, Kansas, United States",
            "Kentucky Cancer Clinic, Hazard, Kentucky, United States",
            "The Bunting-Blaustein Cancer Research Building, Baltimore, Maryland, United States",
            "Frederick Memorial Hospital Regional Cancer Therapy Center, Frederick, Maryland, United States",
            "Dana Farber Cancer Institute, Boston, Massachusetts, United States",
            "Mayo Clinic, Rochester, Minnesota, United States",
            "Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States",
            "St Johns Medical Research Institute, Inc., Springfield, Missouri, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "Weill Cornell Medical College, New York, New York, United States",
            "Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States",
            "Gabrail Cancer Center, Canton, Ohio, United States",
            "University Of Cincinnati, Cincinnati, Ohio, United States",
            "Providence Portland Medical Center, Portland, Oregon, United States",
            "St. Luke'S Hospital & Health Network Laboratory, Bethlehem, Pennsylvania, United States",
            "Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States",
            "Associates In Hematology & Oncology, P.C., Upland, Pennsylvania, United States",
            "Musc Hollings Cancer Center, Charleston, South Carolina, United States",
            "Center For Oncology Research & Treatment, P.A., Dallas, Texas, United States",
            "The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States",
            "The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States",
            "Northwest Cancer Center, Houston, Texas, United States",
            "Huntsman Cancer Institute, Salt Lake City, Utah, United States",
            "Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States",
            "Local Institution, Caba, Buenos Aires, Argentina",
            "Local Institution, Capital Federal, Buenos Aires, Argentina",
            "Local Institution, Rosario, Santa Fe, Argentina",
            "Local Institution, Rosario, Santa Fe, Argentina",
            "Local Institution, San Miguel De Tucuman, Tucuman, Argentina",
            "Local Institution, San Miguel De Tucuman, Tucuman, Argentina",
            "Local Institution, Buenos Aires, Argentina",
            "Local Institution, Buenos Aires, Argentina",
            "Local Institution, Buenos Aires, Argentina",
            "Local Institution, Buenos Aires, Argentina",
            "Local Institution, Cordoba, Argentina",
            "Local Institution, Cordoba, Argentina",
            "Local Institution, La Rioja, Argentina",
            "Local Institution, Box Hill, Victoria, Australia",
            "Local Institution, Frankston, Victoria, Australia",
            "Local Institution, Heidelberg, Victoria, Australia",
            "Local Institution, Subiaco, Western Australia, Australia",
            "Local Institution, Salzburg, Austria",
            "Local Institution, Wien, Austria",
            "Local Institution, Brussels, Belgium",
            "Local Institution, Bruxelles, Belgium",
            "Local Institution, Bruxelles, Belgium",
            "Local Institution, Roeselare, Belgium",
            "Local Institution, Fortaleza, Ceara, Brazil",
            "Local Institution, Curitiba, Parana, Brazil",
            "Local Institution, Ijui, Rio Grande Do Sul, Brazil",
            "Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil",
            "Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil",
            "Local Institution, Curitiba, Sao Paulo, Brazil",
            "Local Institution, Divinopolis, Sao Paulo, Brazil",
            "Local Institution, Mogi Das Cruzes, Sao Paulo, Brazil",
            "Local Institution, Sao Paulo, Brazil",
            "Local Institution, Sao Paulo, Brazil",
            "Local Institution, Greenfield Park, Quebec, Canada",
            "Local Institution, Montreal, Quebec, Canada",
            "Local Institution, Temuco, Araucania, Chile",
            "Local Institution, Santiago - Independencia, Metropolitana, Chile",
            "Local Institution, Santiago De Chile, Metropolitana, Chile",
            "Local Institution, Santiago, Metropolitana, Chile",
            "Local Institution, Vi?a Del Mar, Valparaiso, Chile",
            "Local Institution, Monteria, Cordoba, Colombia",
            "Local Institution, Bogota, Colombia",
            "Local Institution, Brno, Czech Republic",
            "Local Institution, Hradec Kralove, Czech Republic",
            "Local Institution, Liberec, Czech Republic",
            "Local Institution, Aalborg, Denmark",
            "Local Institution, Aarhus, Denmark",
            "Local Institution, Herlev, Denmark",
            "Local Institution, Kobenhavn O, Denmark",
            "Local Institution, Odense C, Denmark",
            "Local Institution, Besancon Cedex, France",
            "Local Institution, Bordeaux, France",
            "Local Institution, Clermont-ferrand, France",
            "Local Institution, Marseille Cedex 20, France",
            "Local Institution, Pointe A Pitre, France",
            "Local Institution, Villejuif Cedex, France",
            "Local Institution, Berlin, Germany",
            "Local Institution, Bonn, Germany",
            "Local Institution, Eschweiler, Germany",
            "Local Institution, Mannheim, Germany",
            "Local Institution, Wuppertal, Germany",
            "Local Institution, Athens, Greece",
            "Local Institution, Budapest, Hungary",
            "Local Institution, Gyula, Hungary",
            "Local Institution, Kaposvar, Hungary",
            "Local Institution, Kecskemet, Hungary",
            "Local Institution, Dublin 7, Dublin, Ireland",
            "Local Institution, Tallaght, Dublin, Ireland",
            "Local Institution, Dublin, Ireland",
            "Local Institution, Beer Jacob, Israel",
            "Local Institution, Beer-sheva, Israel",
            "Local Institution, Haifa, Israel",
            "Local Institution, Tel Aviv, Israel",
            "Local Institution, Tel Hashomer, Israel",
            "Local Institution, Meldola (fc), Italy",
            "Local Institution, Milano, Italy",
            "Local Institution, Napoli, Italy",
            "Local Institution, Rimini, Italy",
            "Local Institution, Siena, Italy",
            "Local Institution, Sondrio, Italy",
            "Local Institution, Df, Distrito Federal, Mexico",
            "Local Institution, Mexico, Distrito Federal, Mexico",
            "Local Institution, Acapulco, Guerrero, Mexico",
            "Local Institution, Guadalajara, Jalisco, Mexico",
            "Local Institution, Cuernavaca, Morelos, Mexico",
            "Local Institution, Aguascalientes, Mexico",
            "Local Institution, Puebla, Mexico",
            "Local Institution, Amsterdam, Netherlands",
            "Local Institution, Mb Amsterdam, Netherlands",
            "Local Institution, Arequipa, Peru",
            "Local Institution, Lima, Peru",
            "Local Institution, Lima, Peru",
            "Local Institution, Lima, Peru",
            "Local Institution, Lima, Peru",
            "Local Institution, Olsztyn, Poland",
            "Ponce School Of Medicine, Ponce, Puerto Rico",
            "Local Institution, Bucharest, Romania",
            "Local Institution, Romania, Romania",
            "Local Institution, Suceava, Romania",
            "Local Institution, Moscow, Russian Federation",
            "Local Institution, Moscow, Russian Federation",
            "Local Institution, Moscow, Russian Federation",
            "Local Institution, Obninsk, Russian Federation",
            "Local Institution, St Petersburg, Russian Federation",
            "Local Institution, Barcelona, Spain",
            "Local Institution, Barcelona, Spain",
            "Local Institution, Benidorm-alicante, Spain",
            "Local Institution, Madrid, Spain",
            "Local Institution, Santiago De Compostela, Spain",
            "Local Institution, Valencia, Spain",
            "Local Institution, Chelmsford, Essex, United Kingdom",
            "Local Institution, Cardiff, Glamorgan, United Kingdom",
            "Local Institution, Manchester, Greater Manchester, United Kingdom",
            "Local Institution, Scunthorpe, Lincolnshire, United Kingdom",
            "Local Institution, Nottingham, Nottinghamshire, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00861614"
      },
      {
        "-rank": "188",
        "nct_id": "NCT03148795",
        "title": "A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Talazoparib"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Objective Response Rate (ORR)",
            "Time to objective response",
            "Duration of response",
            "Proportion of patients with prostate-specific antigen (PSA) response â‰¥ 50%",
            "Proportion of patients with conversion of circulating tumor cell (CTC) count",
            "Time to PSA progression",
            "Radiographic progression-free survival (PFS)",
            "Overall survival",
            "Patient-reported pain as assessed by the Brief Pain Inventory Short Form (BPI-SF)",
            "Patient-reported health-related quality of life as assessed by the European Quality of Life 5-Domain 5-Level Scale (EQ-5D-5L)",
            "Safety as assessed by percentage of patients with any Adverse Event (AE), AE leading to Study Drug Discontinuation, AE leading to death, Serious Adverse Event (SAE), AE related to study drug, SAE related to study drug",
            "Pharmacokinetics (PK) of talazoparib as assessed by trough plasma concentrations"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Pfizer",
          "collaborator": "Medivation, Inc."
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "100",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "MDV3800-06",
            "C3441006",
            "2016-002036-32"
          ]
        },
        "start_date": "July 4, 2017",
        "primary_completion_date": "September 29, 2020",
        "completion_date": "March 27, 2022",
        "study_first_posted": "May 11, 2017",
        "last_update_posted": "August 22, 2019",
        "locations": {
          "location": [
            "Arizona Oncology, Phoenix, Arizona, United States",
            "Arizona Oncology Associates, Tempe, Arizona, United States",
            "Sharp Chula Vista Outpatient Infusion Therapy Center, Chula Vista, California, United States",
            "South County Hematology/Oncology, Chula Vista, California, United States",
            "Sharp Rees-Steely, Chula Vista, California, United States",
            "City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States",
            "City of Hope Investigational Drug Service (IDS), Duarte, California, United States",
            "Cancer Center Oncology Medical Group, La Mesa, California, United States",
            "City of Hope-Antelope Valley, Lancaster, California, United States",
            "UC Irvine Health Investigational Drug Pharmacy, Orange, California, United States",
            "University of California, Irvine Medical Center, Orange, California, United States",
            "Medical Oncology Associates-SD, San Diego, California, United States",
            "Sharp Memorial Hospital, San Diego, California, United States",
            "Sharp Outpatient Infusion Therapy Center, San Diego, California, United States",
            "Sharp Rees-Stealy, San Diego, California, United States",
            "Providence Saint John's Health Center, Santa Monica, California, United States",
            "Piedmont Cancer Institute, PC, Atlanta, Georgia, United States",
            "Emory University Hospital, Atlanta, Georgia, United States",
            "Emory University, Atlanta, Georgia, United States",
            "The Emory Clinic, Atlanta, Georgia, United States",
            "Winship Cancer Institute, Emory University, Atlanta, Georgia, United States",
            "Piedmont Cancer Institute, PC, Fayetteville, Georgia, United States",
            "Siteman Cancer Center - West County, Creve Coeur, Missouri, United States",
            "Barnes-Jewish Hospital, Saint Louis, Missouri, United States",
            "Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States",
            "Washington University School of Medicine, Saint Louis, Missouri, United States",
            "Siteman Cancer Center - South County, Saint Louis, Missouri, United States",
            "Christian Hospital North East, Saint Louis, Missouri, United States",
            "Siteman Cancer Center - St. Peters, Saint Peters, Missouri, United States",
            "Weill Cornell Medical Cener - New York Presbyterian Hospital, New York, New York, United States",
            "Weill Cornell Medical Center-New York Presbyterian Hospital, New York, New York, United States",
            "New York-Presbyterian Hospital-Weill Cornell Medical Center, New York, New York, United States",
            "Carolinas Medical Center, Charlotte, North Carolina, United States",
            "Carolinas Medical Center Investigational Drug Services, Charlotte, North Carolina, United States",
            "Levine Cancer Institute, Charlotte, North Carolina, United States",
            "Carolinas Medical Center-Mercy, Charlotte, North Carolina, United States",
            "Carolinas HealthCare System-Pineville, Charlotte, North Carolina, United States",
            "Levine Cancer Institute-Pineville, Charlotte, North Carolina, United States",
            "Levine Cancer Institute-Southpark, Charlotte, North Carolina, United States",
            "Carolinas HealthCare System-University, Charlotte, North Carolina, United States",
            "Levine Cancer Institute-Mallard Creek, Charlotte, North Carolina, United States",
            "Levine Cancer Institute-University, Charlotte, North Carolina, United States",
            "Levine Cancer Institute-Ballantyne, Charlotte, North Carolina, United States",
            "Carolinas HealthCare System-NorthEast, Concord, North Carolina, United States",
            "Levine Cancer Institute-Concord, Concord, North Carolina, United States",
            "Levine Cancer Institute-Lincolnton, Lincolnton, North Carolina, United States",
            "Carolinas HealthCare System-Union, Monroe, North Carolina, United States",
            "Levine Cancer Institute-Monroe, Monroe, North Carolina, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Levine Cancer Institute-Rock Hill, Rock Hill, South Carolina, United States",
            "HOPE Cancer Center of East Texas, Tyler, Texas, United States",
            "Virginia Oncology Associates, Hampton, Virginia, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "Swedish Cancer Institute Edmonds Campus, Edmonds, Washington, United States",
            "Swedish Edmonds IDS Pharmacy, Edmonds, Washington, United States",
            "Swedish Cancer Institute Issaquah Campus, Issaquah, Washington, United States",
            "Swedish Issaquah IDS Pharmacy, Issaquah, Washington, United States",
            "Swedish Cancer Institute, Seattle, Washington, United States",
            "Swedish First Hill IDS Pharmacy, Seattle, Washington, United States",
            "Swedish Medical Center, Seattle, Washington, United States",
            "Froedtert Hospital IDS Pharmacy, Milwaukee, Wisconsin, United States",
            "Froedtert Hospital/Medical College of Wisconsin, Milwaukee, Wisconsin, United States",
            "Clinical Trials Pharmacy, Darlinghurst, New South Wales, Australia",
            "St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia",
            "Westmead Hospital, Northmead, New South Wales, Australia",
            "Westmead Hospital, Westmead, New South Wales, Australia",
            "Icon Cancer Care Wesley, Auchenflower, Queensland, Australia",
            "River City Pharmacy, Auchenflower, Queensland, Australia",
            "Liz Plummer Cancer Care Center, Cairns, Queensland, Australia",
            "Icon Cancer Care Chermside, Chermside, Queensland, Australia",
            "Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia",
            "Intergrated Clinical Oncology Network (ICON), South Brisbane, Queensland, Australia",
            "Ion Cancer Care, South Brisbane, Queensland, Australia",
            "Icon Cancer Care Southport, Southport, Queensland, Australia",
            "Box Hill Hospital, Box Hill, Victoria, Australia",
            "Eastern Health Pathology Service, Box Hill, Victoria, Australia",
            "Monash Medical Centre, Clayton, Victoria, Australia",
            "Frankston Hospital Pharmacy, Frankston, Victoria, Australia",
            "Peninsula Health, Frankston, Victoria, Australia",
            "Olivia Newton John Cancer Wellness and Research Centre, Heidelberg, Victoria, Australia",
            "Pharmacy Department, Heidelberg, Victoria, Australia",
            "Ordensklinikum Linz, Barmherzige Schwestern, Linz, Upper Austria, Austria",
            "Vinzenz Pathologieverbund, Linz, Upper Austria, Austria",
            "Ordensklinikum Linz, Elisabethinen, Linz, Upper Austria, Austria",
            "Paracelsus Medical University, SALK, Salzburg, Austria",
            "Uniklinikum Salzburg, Landeskrankenhaus, Salzburg, Austria",
            "AKH Wien, Vienna, Austria",
            "Allgemeines Krankenhaus der Stadt Wien, Sekretariat Onkologie, Innere Medizin 1, Vienna, Austria",
            "Isotopix-Ambulatorium fur Nuklearmedizin, Vienna, Austria",
            "Isotopiz-Ambulatorium fur Nuklearmedizin, Vienna, Austria",
            "Medical University of Vienna, Vienna, Austria",
            "Medical University of Vienna, Vienna, Austria",
            "Medizinische Universitat Wien, Klinisches Institut fur Pathologie, Vienna, Austria",
            "Medizinische Universitat Wien, Vienna, Austria",
            "Diagnosezentrum Meidling, Vienna, Austria",
            "Diagnosezentrum Meidling, Vienna, Austria",
            "Cliniques Universitaires Saint-Luc, Bruxelles, Belgium",
            "Algemeen Ziekenhuis Sint-Lucas, Gent, Belgium",
            "Universitaire Ziekenhuizen Leuven, Leuven, Belgium",
            "Hospital de Caridade de Ijui, Ijui, RIO Grande DO SUL, Brazil",
            "Hospital de Clinicas de Porto Alegre-HCPA, Porto Alegre, RS, Brazil",
            "Fundacao Pio XII-Hospital de Cancer de Barretos, Barretos, SAO Paulo, Brazil",
            "Fundacao Doutor Amaral Carvalho, Jau, SAO Paulo, Brazil",
            "Hopital Foch Service Oncologie, Suresnes, Cedex, France",
            "CHRU BesanÃ§on - HÃ´pital Jean Minjoz, Besancon Cedex, Doubs, France",
            "ICO-Site Paul Papin, Angers Cedex 02, France",
            "Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers cedex 02, France",
            "ICO-Site Paul Papin, Angers Cedex 2, France",
            "Institut Bergonie, Service d'Oncologie, Bordeaux cedex, France",
            "Institut Bergonie, Bordeaux cedex, France",
            "Center Hospitalier Departemental Les Oudairies, La Roche sur Yon, France",
            "Centre Hospitalier Departemental Les Oudairies, La Roche sur Yon, France",
            "Centre Jean Bernard - Clinique Victor Hugo, Le Mans Cedex 02, France",
            "Clinique Victor Hugo-Centre Jean Bernard, Le Mans Cedex 02, France",
            "Lbm Logic Bio Noirmoutiers, Noirmoutiers, France",
            "Labazur Alpes-Sud Var, Rocbaron, France",
            "Hopitaux Universitaires de Strasbourg HÃ´pital Civil, Strasbourg Cedex, France",
            "Hopital Civil, Strasbourg, France",
            "Hopital Foch, Suresnes, France",
            "Biorylis Talmont-Saint-Hilaire, Talmont-saint Hilaire, France",
            "Institut Gustave Roussy, Service Pharmacy, Villejuif cedex, France",
            "Institut Gustave-Roussy, Villejuif Cedex, France",
            "LABORATOIRE des VOSGES-BIOLIA, Wasselonne, France",
            "Medizinische Hochschule Hannover, Hannover, Germany",
            "Medizinische FakultÃ¤t Mannheim der UniversitÃ¤t Heidelberg, Mannheim, Germany",
            "Universitatsklinikum Munster, Munster, Germany",
            "Studienpraxis Urologie Drs. Feyerabend, Nuertingen, Germany",
            "Universitatsklinikum Tubingen, Tubingen, Germany",
            "Universitaetsklinikum Wuerzburg, Wuerzburg, Germany",
            "Orszagos Onkologiai Intezet, \"C\" Belgyogyaszati-Onkologiai ed Klinikal Farmakogogiai Osztaly, Budapest, Hungary",
            "Debreceni Egyetem, Debrecen, Hungary",
            "Szaboles Szatmar Bereg Megyei Korhzak es Egyetemi Oktato Korhaz, Nyiregyhaza, Hungary",
            "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forli - Cesena, Italy",
            "Magazzino Farmacia Oncologica-Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forli-cesena, Italy",
            "Azienda Ospedaliera San Camillo Forlanini, Roma, Rome, Italy",
            "Azienda Ospedaliero-Universitaria S. Luigi Gonzaga, Orbassano, Torino/piemonte, Italy",
            "AULSS3 Serenissima - Ospedale dell'Angelo - Oncologia Medica, Mestre, Venezia, Italy",
            "Servizio di Farmacia Ospedaliera-AULSS3 Serenissima-Ospedale dell'Angelo, Mestre, Venezia, Italy",
            "Azienda Socio Sanitaria Territoriale di Cremona (Istituti Ospitalieri di Cremona) U.O. Farmacia, Cremona, Italy",
            "Azienda Socio Sanitaria Territoriale di Cremona (Istituti Ospitalieri di Cremona), Cremona, Italy",
            "A.O.U. Policlinico di Modena, Modena, Italy",
            "IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Naples, Italy",
            "IOV - Istituto Oncologico Veneto IRCCS - U.O. Oncologia Medica 1, Padova, Italy",
            "IOV-Istituto Oncologico Veneto IRCCS-U.O. Oncologia Medica 1-SC Farmacia, Padova, Italy",
            "Azienda Ospedaliero Universitari di Parma - U.O. Oncologia Medica, Parma, Italy",
            "Azienda Ospedaliero Universitaria di Parma - U.O. Oncologia Medica, Parma, Italy",
            "Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy",
            "SC Farmacia-Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy",
            "Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",
            "Pusan National University Hospital, Busan, Korea, Republic of",
            "Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of",
            "Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Radboud UMC, Nijmegen, THE Netherlands, Netherlands",
            "Radboud UMC - Apotheek, Clinical Trials Unit, Nijmegen, Netherlands",
            "Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza, Brzozow, Poland",
            "Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Kielce, Poland",
            "Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland",
            "Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain",
            "Clinica Universidad de Navarra Departamento de Oncologia, Pamplona, Navarra, Spain",
            "Hospital General Vall d'Hebron, Barcelona, Spain",
            "Hospital Clinic de Barcelona, Barcelona, Spain",
            "MD Anderson Cancer Center, Madrid, Spain",
            "Hospital Virgen de la Victoria, Malaga, Spain",
            "Instituto Valenciano de Oncologia (IVO-FINCIVO), Valencia, Spain",
            "Hospital Universitari i Politecnic La Fe, Valencia, Spain",
            "Mount Vernon Hospital, Northwood, Middlesex, United Kingdom",
            "The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",
            "Addenbrookes Hospital, Cambridge, United Kingdom",
            "Central Pharmacy, Level 1, Cambridge, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03148795"
      },
      {
        "-rank": "189",
        "nct_id": "NCT01310894",
        "title": "Efficacy and Safety Study of TOOKADÂ® Soluble for Localised Prostate Cancer Compared to Active Surveillance.",
        "acronym": "PCM301",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "TOOKADÂ® Soluble"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Co-primary endpoint 'A': Rate of absence of definite cancer using patients on active surveillance as a comparison.",
            "Co-primary endpoint 'B': Difference in rate of treatment failure associated with observed progression of disease from low risk prostate cancer to moderate or higher risk prostate cancer.",
            "The rate of additional prostate cancer radical therapy",
            "Total number of cores positive for cancer",
            "The rate of incontinence, erectile dysfunction, urinary symptoms",
            "The rate of adverse events",
            "The rate of severe prostate cancer related events: cancer extension to T3, metastasis and prostate cancer related death",
            "The overall quality of life will be recorded for potential utility and descriptive studies."
          ]
        },
        "sponsors": { "lead_sponsor": "Steba Biotech S.A." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "413",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CLIN1001 PCM301" },
        "start_date": "February 2011",
        "primary_completion_date": "June 2015",
        "completion_date": "August 2015",
        "study_first_posted": "March 9, 2011",
        "last_update_posted": "July 11, 2019",
        "locations": {
          "location": [
            "Dept. of Urology-University Hospitals Leuven, Leuven, Belgium",
            "Department of Urology-Tampere University Hospital-, Tampere, Finland",
            "Service d'Urologie - Centre Hospitalier Universitaire d'Angers, Angers, France",
            "CHRU Hopital Jean Minjoz, BesanÃ§on, France",
            "Site MÃ©dipole, Cabestany, France",
            "Polyclinique SÃ©vignÃ©, Cesson SÃ©vignÃ©, France",
            "Clinique d'Urologie et de Transplantation RÃ©nale CHU Grenoble, Grenoble, France",
            "HÃ´pital Claude Huriez, Lille, France",
            "HÃ´pital La Conception, Marseille, France",
            "Clinique Ambroise ParÃ©, Neuilly sur Seine, France",
            "Institut Mutualiste Montsouris (IMM), Paris Cedex 14, France",
            "HÃ´pital Cochin, Paris Cedex 14, France",
            "HÃ´pital Tenon, Paris, France",
            "Institut Mutualiste Montsouris (IMM), Paris, France",
            "Centre Hospitalier Universitaire Lyon Sud, Pierre-BÃ©nite, France",
            "Polyclinique les Bleuets, Reims, France",
            "CHU Pontchaillou, Rennes, France",
            "Clinique Urologique Nantes, Saint Herblain, France",
            "HÃ´pital Foch, Suresnes, France",
            "Centre Hospitalier Universitaire de Rangueil, Toulouse, France",
            "Marien Krankenahaus GmbH, Bergisch Gladbach, Germany",
            "ATURO-Gemeinschaftspraxis fÃ¼r Urologie und Andrologie, Berlin-Wilmersdorf, Germany",
            "Klinikum Braunschweig, Braunschweig, Germany",
            "UniversitÃ¤tsklinikum \"Carl Gustav Carus\" der Technischen UniversitÃ¤t, Dresden, Germany",
            "Urologische Gemeinschaftspraxis, Emmendingen, Germany",
            "Martini-Klinik am UKE Hamburg-Eppendorf Prostate Cancer Center, Hamburg, Germany",
            "Vinzenz Krankenhaus - Department of Urology, Hannover, Germany",
            "SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany",
            "University Hospital Schleswig-Holstein, Kiel, Germany",
            "Ludwig-Maximilians-UniversitÃ¤t MÃ¼nchen, Munich, Germany",
            "Urologie 24, Nuremberg, Germany",
            "UnitÃ  Operativa Urologia Lucca - c/o Azienda USL 2 - Ospedale Campo di Marte, Lucca, Italy",
            "UnitÃ  di Chirurgia Urologica Mininvasiva, Roma, Italy",
            "UnitÃ  Operativa Urologica di Savona, Ospedale San Paolo di Savona, Savona, Italy",
            "Osp. S. Giov. Battista Molinette-Dipartimento di Discipline Medico-Chirurgiche Urologia, Torino, Italy",
            "Netherlands Cancer Institute, Amsterdam, Netherlands",
            "Polikliniek Urologie-Catharina Ziekenhuis, Eindhoven, Netherlands",
            "Hospital Universitari de Bellbitge-Servico de Urologia, L'Hospitalet de Llobregat, Barcelona, Spain",
            "Hospital Universitario de A CoruÃ±a, A CoruÃ±a, Spain",
            "Fundacio Puigvert-Department of Urology, Barcelona, Spain",
            "Hospital Vall d'Hebron, Barcelona, Spain",
            "Department of Urology-Hospital Clinic, University of Barcelona, Barcelona, Spain",
            "Hospital 12 de Octubre - Departmento de Urologia, Madrid, Spain",
            "Complejo Hospitalario Regional Virgen Del Rocio-Department Urology, Sevilla, Spain",
            "Instituto Valenciano de Oncologia, Valencia, Spain",
            "Dept of Urology-University Hospital-, MalmÃ¶, Sweden",
            "Anna-Seiler-Haus Inselspital, Bern, Switzerland",
            "Kings College Hospital (KCH), London, United Kingdom",
            "University College of London Hospital, London, United Kingdom",
            "Oxford John Radcliffe Hospital Trust, Oxford, United Kingdom",
            "Royal Hallamshire Hospital, Sheffield, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01310894"
      },
      {
        "-rank": "190",
        "nct_id": "NCT02288247",
        "title": "A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone",
        "acronym": "PRESIDE",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration Resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Prednisolone"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Progression free survival (PFS)",
            "Time to prostate-specific antigen (PSA) progression",
            "PSA response",
            "Objective response rate",
            "Time to pain progression",
            "Time to opiate use for cancer-related pain",
            "Time to first skeletal-related event (SRE)",
            "Quality of life"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Europe Ltd.",
          "collaborator": [
            "Medivation, Inc.",
            "Astellas Pharma Inc"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "690",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "9785-MA-1001",
            "2013-004711-50"
          ]
        },
        "start_date": "December 1, 2014",
        "primary_completion_date": "August 2019",
        "completion_date": "June 2020",
        "study_first_posted": "November 11, 2014",
        "last_update_posted": "June 5, 2019",
        "locations": {
          "location": [
            "Site AT43004, Linz, Austria",
            "Site AT43001, Vienna, Austria",
            "Site BE32003, Bonheiden, Belgium",
            "Site BE32002, Liege, Belgium",
            "Site BE32004, Ottignies, Belgium",
            "Site CZ42004, Brno, Czechia",
            "Site CZ42003, Olomouc, Czechia",
            "Site CZ42002, PlzeÅˆ -LochotÃ­n, Czechia",
            "Site CZ42001, Praha 2, Czechia",
            "Site FR33012, Albi, France",
            "Site FR33003, Montpellier, France",
            "Site FR33002, NÃ®mes, France",
            "Site FR33008, Paris, France",
            "Site FR33014, Paris, France",
            "Site FR33004, Plerin, France",
            "Site FR33013, Quimper, France",
            "Site FR33011, Reims, France",
            "Site FR33005, Suresnes, France",
            "Site DE49018, NÃ¼rtingen, Baden-WÃ¼rttemberg, Germany",
            "Site DE49008, Aachen, Germany",
            "Site DE49010, Bergisch Gladbach, Germany",
            "Site DE49001, Hannover, Germany",
            "Site DE49006, Heidelberg, Germany",
            "Site DE49003, Mannheim, Germany",
            "Site DE49002, Munster, Germany",
            "Site DE49015, TÃ¼bingen, Germany",
            "Site DE49017, Ulm, Germany",
            "Site DE49004, Wuppertal, Germany",
            "Site GR30001, Heraklion, Crete, Greece",
            "Site GR30004, Heraklion, Crete, Greece",
            "Site GR30003, Athens, Greece",
            "Site GR30006, Athens, Greece",
            "Site GR30005, Thessaloniki, Greece",
            "Site IT39001, Arezzo, Italy",
            "Site IT39012, Brescia, Italy",
            "Site IT39003, Milano, Italy",
            "Site IT39008, Naples, Italy",
            "Site IT39010, Pavia, Italy",
            "Site IT39005, Roma, Italy",
            "Site IT39004, Rome, Italy",
            "Site IT39002, Terni, Italy",
            "Site NL31002, Amsterdam, Netherlands",
            "Site NL31007, Blaricum, Netherlands",
            "Site NL31004, Hoofddorp, Netherlands",
            "Site NL31010, Nieuwegein, Netherlands",
            "Site NL31003, Rotterdam, Netherlands",
            "Site NO47005, Drammen, Norway",
            "Site NO47001, Kristiansand, Norway",
            "Site NO47004, Stavanger, Norway",
            "Site PL48004, GdaÅ„sk, Poland",
            "Site PL48003, Krakow, Poland",
            "Site PL48002, Lodz, Poland",
            "Site PL48006, Warszawa, Poland",
            "Site PL48005, Warszawa, Poland",
            "Site RU70004, Obninsk, Kaluga, Russian Federation",
            "Site RU70002, Moscow, Russian Federation",
            "Site RU70001, Moscow, Russian Federation",
            "Site RU70003, Moscow, Russian Federation",
            "Site RU70005, St. Petersburg, Russian Federation",
            "Site RU70006, St. Petersburg, Russian Federation",
            "Site ES34005, Lugo, Spain",
            "Site ES34003, Madrid, Spain",
            "Site ES34001, Madrid, Spain",
            "Site ES34002, Madrid, Spain",
            "Site ES34010, Madrid, Spain",
            "Site ES34007, Malaga, Spain",
            "Site ES34009, Murcia, Spain",
            "Site ES34008, Santander, Spain",
            "Site ES34004, Sevilla, Spain",
            "Site ES34006, Valencia, Spain",
            "Site SE46002, GÃ¶teborg, Sweden",
            "Site SE46005, Kalmar, Sweden",
            "Site SE46003, Solna, Sweden",
            "Site SE46004, Uppsala, Sweden",
            "Site CH41005, Locarno, Tessin, Switzerland",
            "Site CH41009, Zurich, Switzerland",
            "Site TR90001, Ankara, Turkey",
            "Site TR90003, Istanbul, Turkey",
            "Site TR90002, Izmir, Turkey",
            "Site GB44010, Aberdeen, United Kingdom",
            "Site GB44004, Cambridge, United Kingdom",
            "Site GB44018, Cardiff, United Kingdom",
            "Site GB44014, Exeter, United Kingdom",
            "Site GB44003, London, United Kingdom",
            "Site GB44020, Northwood, United Kingdom",
            "Site GB44015, Norwich, United Kingdom",
            "Site GB44002, Nottingham, United Kingdom",
            "Site GB44017, Swansea, United Kingdom",
            "Site GB44007, Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02288247"
      },
      {
        "-rank": "191",
        "nct_id": "NCT02111577",
        "title": "Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer",
        "acronym": "VIABLE",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castrate Resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "Dendritic Cells DCVAC"
            },
            {
              "-type": "Biological",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Taxotere"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall survival (all cause mortality)",
            "Radiographic Progression Free Survival",
            "Duration to Prostate Specific Antigen (PSA) Progression",
            "Duration to Skeletal Related Events"
          ]
        },
        "sponsors": { "lead_sponsor": "Sotio a.s." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1170",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "SP005",
            "2012-002814-38"
          ]
        },
        "start_date": "April 2014",
        "primary_completion_date": "December 16, 2019",
        "completion_date": "June 2020",
        "study_first_posted": "April 11, 2014",
        "last_update_posted": "February 4, 2019",
        "locations": {
          "location": [
            "University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States",
            "Ironwood Cancer & Research Centers, Chandler, Arizona, United States",
            "Mayo Clinic, Scottsdale, Arizona, United States",
            "Compassionate Care Research Group, Inc., Corona, California, United States",
            "California Cancer Associates for Research and Excellence, Encinitas, California, United States",
            "Compassionate Care Research Group, Inc., Fountain Valley, California, United States",
            "St. Joseph Heritage Healthcare, Fullerton, California, United States",
            "Hao Wei Zhang, MD, LLC, Los Angeles, California, United States",
            "Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States",
            "Compassionate Care Research Group, Inc., Riverside, California, United States",
            "Sharp Clinical Oncology Research, San Diego, California, United States",
            "Oncology Institute of Hope and Innovation, Whittier, California, United States",
            "Rocky Mountain Cancer Centers, Aurora, Colorado, United States",
            "University of Colorado, Aurora, Colorado, United States",
            "Yale Cancer Center, New Haven, Connecticut, United States",
            "Eastern CT Hematology and Oncololgy Associates, Norwich, Connecticut, United States",
            "Medstar Georgetown University Hospital, Washington, District of Columbia, United States",
            "Univ. of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States",
            "Winship Cancer Institute of Emory University, Atlanta, Georgia, United States",
            "Saint Luke's Cancer Institute, Kansas City, Kansas, United States",
            "University of Kansas Cancer Center & Medical Pavilion, Westwood, Kansas, United States",
            "Tulane University, New Orleans, Louisiana, United States",
            "University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States",
            "Associates In Oncology/Hematology,P.C, Rockville, Maryland, United States",
            "Dana-Farber Cancer Institute, Boston, Massachusetts, United States",
            "Umass Memorial Medical Center, Worcester, Massachusetts, United States",
            "Henry Ford Health System, Detroit, Michigan, United States",
            "Karmanos Cancer Center, Detroit, Michigan, United States",
            "Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States",
            "GU Research Network, Omaha, Nebraska, United States",
            "Nebraska Cancer Specialists, Omaha, Nebraska, United States",
            "Comprehensive Cancer Research Centers of Nevada, Henderson, Nevada, United States",
            "New Jersey Hematology Oncology Associates, Brick, New Jersey, United States",
            "Premier Urology Associates, LLC / AdvanceMed Research, Lawrenceville, New Jersey, United States",
            "Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",
            "Montefiore Medical Center, Bronx, New York, United States",
            "Mount Sinai Medical Center, New York, New York, United States",
            "SUNY Upstate Medical University, Syracuse, New York, United States",
            "UC Health University of Cincinnati, Cincinnati, Ohio, United States",
            "Oregon Health & Science University, Portland, Oregon, United States",
            "Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States",
            "Urologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd, Pennsylvania, United States",
            "Cancer Care Associates St. Luke's University and Health Network, Easton, Pennsylvania, United States",
            "Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",
            "UPMC Cancer Center, Pittsburgh, Pennsylvania, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Associates in Oncology & Hematology, Chattanooga, Tennessee, United States",
            "Arlington Cancer Center, Arlington, Texas, United States",
            "UT Health, Internal Medicine, Division of Oncology, Houston, Texas, United States",
            "Texas Health Physicians Group, Plano, Texas, United States",
            "Cancer Care Network of South Texas, San Antonio, Texas, United States",
            "Tyler Hematology Oncology, Tyler, Texas, United States",
            "Utah Cancer Specialists, Salt Lake City, Utah, United States",
            "Fort Belvoir Community Hospital, Fort Belvoir, Virginia, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "Virginia Mason Medical Center, Seattle, Washington, United States",
            "Northwest Medical Specialties, PLLC, Tacoma, Washington, United States",
            "West Virginia University Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States",
            "Universitatsklinikum fur Urologie und Andrologie, Salzburg, Austria",
            "Krankenhaus Barmherzige Bruder, Wien, Austria",
            "AKH Universitatskrankenhaus Wien, Wien, Austria",
            "N.N. Alexandrov national Research Center, Lesnoy, Belarus",
            "Minsk City Oncological Dispensary, Minsk, Belarus",
            "Clinique d'Oncologie Medicale Institut Jules Bordet, Brussels, Belgium",
            "Erasme Hospital- Urologie, Brussels, Belgium",
            "Cliniques Universitaires Saint Luc- Urologie, Brussels, Belgium",
            "Urologie UZ Gent, Gent, Belgium",
            "Urology Department St. Elizabeth Ziekenhuis, Turnhout, Belgium",
            "Specialized Hospital for Active treatment in Oncology, Haskovo, Bulgaria",
            "Central Oncology Hospital, Plovdiv, Bulgaria",
            "Complex Oncology Center, Plovdiv, Bulgaria",
            "Multifunctional Hospital for Active Treatment Serdika, Sofia, Bulgaria",
            "Specialized Hospital for Active Treatment of Oncology Diseases, Sofia, Bulgaria",
            "General Hospital Varazdin, VaraÅ¾din, Croatia",
            "Clinical Hospital Center Zagreb, Zagreb, Croatia",
            "Clinical Hospital Centre Sestre milosrdnice, Zagreb, Croatia",
            "Onkologicke Centrum Nemocnice Chomutov, Chomutov, Czechia",
            "Klinika oncologie a radioterapie fakultni nemocnice, Hradec Kralove, Czechia",
            "Nemocnice Jihlava, Urologike oddeleni, Jihlava, Czechia",
            "Urologicke Oddeleni Krajska Nemocnice, Liberec, Czechia",
            "Onkologicka Klinika Fakultni Nemocnice, Olomouc, Czechia",
            "Klinika Onkologicka Fakultni nemocnice, Ostrava-Poruba, Czechia",
            "Fakultni nemocnice Kralovske Vinohrady, Prague, Czechia",
            "Vseobecna Fakultni nemocnice v Praze, Prague, Czechia",
            "Thomayerova benicbuce, Prague, Czechia",
            "Fakultni nemocnice v Motole, Prague, Czechia",
            "Krajska zdravotni Urologicka oddeleni, Usti nad Labem, Czechia",
            "Rigshospitalet, Copenhagen, Denmark",
            "HEGP medical oncology, Paris Cedex 15, France",
            "St-Louis IDF Medical Oncology, Paris, France",
            "Hopital St. Joseph, Paris, France",
            "Hospital Cochin, Service de Urologie, Paris, France",
            "HIA Begin, Saint MandÃ©, France",
            "Hospital Civil de Strasbourg, Strasbourg, France",
            "Charite Universitatsklinikum Berlin, Berlin, Germany",
            "Stadtisches Klinikum Braunschweig, Braunschweig, Germany",
            "Universtatsklinikum Carl Gustav Carus, Dresden, Germany",
            "Waldkrankenhaus St. Marien, Erlangen, Germany",
            "Krankenhaus Nordwest, Frankfurt, Germany",
            "Universitatsklinikum Halle (Saale), Halle, Germany",
            "Asklepios-Klinik Hamburg-Altona, Hamburg, Germany",
            "Vinzenkrankenhaus Hannover, Hannover, Germany",
            "Medizinische hochschule Hannover, Hannover, Germany",
            "Universitatskinikum Jena, Jena, Germany",
            "Klinik und Poliklinik Urologie, KÃ¶ln, Germany",
            "Universitatsmedizin Mannheim, Mannheim, Germany",
            "Universtatsklinikum Munster, MÃ¼nster, Germany",
            "Studienpraxis Urologie, NÃ¼rtingen, Germany",
            "Klinikum Oldenburg AOR, Oldenburg, Germany",
            "Universitastsklinikum Tubingen, TÃ¼bingen, Germany",
            "Universitatsklinikum Ulm, Ulm, Germany",
            "Ammerland Klinik fur Urologie, Westerstede, Germany",
            "Praxigemeinschaft fur Onkologie und Urologie, Wilhelmshaven, Germany",
            "Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary",
            "Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointeszet, Budapest, Hungary",
            "Bajcsy-Zsilinsky Korhaz, Budapest, Hungary",
            "Jasz-Nagykun-Szolnok Megyei, Szolnok, Hungary",
            "CRO Aviano, Aviano, Italy",
            "A.O.U. Policlinico Vittorio Emanuele, Catania, Italy",
            "A.O. Istituti Ospitalieri di Cremona, Cremona, Italy",
            "A.O. Santa Croce e Carle Oespedale, Cuneo, Italy",
            "Universita di Roma Sapienza, Rome, Italy",
            "Azienda Ospedialiera Universitaria Senese, Sienna, Italy",
            "Oncologia medica Ospedale S. Vincenzo, Toarmina, Italy",
            "Paula Stradina Kliniska Universitates slimnica, Riga, Latvia",
            "Lithuanian University of Health Science Oncology Institute, Kaunas, Lithuania",
            "Klaipeda University Hospital, Klaipeda, Lithuania",
            "Vilnius UniversityHospital, Vilnius, Lithuania",
            "National Cancer Institute, Vilnius, Lithuania",
            "VU medical Center, Amsterdam, Netherlands",
            "Wilhemina Ziekenhuis, Assen, Netherlands",
            "Tergooi Ziekenhuizen, Hilversum, Netherlands",
            "Spaame Gasthuis, Hoofddorp, Netherlands",
            "Oncology Medisch Centrum, Leeuwarden, Netherlands",
            "UMC St.Radboud, Nijmegen, Netherlands",
            "Oncology Maasstad Ziekenhuis, Rotterdam, Netherlands",
            "Przychodnia Lekarska (KOMED), Konin, Poland",
            "Szpital im M.Kopernika, Lodz, Poland",
            "INSTYTUT im. Marii Sklodowskiej-Curie, Warszawa, Poland",
            "Akademicki Szpital Kliniczny im. Jana Mikulicza-Radeckiego, Wroclaw, Poland",
            "Hospital da Luz, Lisboa, Portugal",
            "Centro Hospitalar de Lisboa Norte, E.P.E - Hospital de Santa Maria, Lisboa, Portugal",
            "Instituto PortuguÃªs de Oncologia do Porto Francisco Gentil, E.P.E, Porto, Portugal",
            "CHC Zemun, Belgrade, Serbia",
            "Clinical Center of Serbia, Belgrade, Serbia",
            "Institute of Oncology and Radiology of Serbia, Belgrade, Serbia",
            "KBC Bezanijska Kosa, Belgrade, Serbia",
            "J.Breza MEDICAL s.r.o., Bratislava, Slovakia",
            "Urologicka ambulancia CUIMED s.r.o., Bratislava, Slovakia",
            "Univerzitna nemocnica Martin, Martin, Slovakia",
            "Urologicka ambulancia Uroexam, spol. s r.o., Nitra, Slovakia",
            "UROX s.r.o., Piestany, Slovakia",
            "Urocentrum MILAB s.r.o., Presov, Slovakia",
            "Privatna urologicka ambulancia, Trencin, Slovakia",
            "Fakultna nemocnica s poliklinikou Zilina, Zilina, Slovakia",
            "Hospital Universitario PrÃ­ncipe de Asturias, AlcalÃ¡ de Henares, Spain",
            "Hospital Clinic I Provincial de Barcelona, Barcelona, Spain",
            "Hospital General Universitario Gregorio MaranÃ³n, Madrid, Spain",
            "Hosp. Clinico Univ. San Carlos, Madrid, Spain",
            "Instituto de Investigaciones Sanitarias (IIS), FundacÃ­on Jimenez DÃ­az (FJD), Madrid, Spain",
            "Hosp. 12 de Octubre, Madrid, Spain",
            "Centro Integral OncolÃ³gico Clara Campal (CIOCC), Madrid, Spain",
            "Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain",
            "Hospital Carlos Haya, Malaga, Spain",
            "Hospital Universitario Quiron Madrid, Pozuelo de AlarcÃ³n, Spain",
            "University Hospital UmeÃ¥, Dept Oncology, UmeÃ¥, Sweden",
            "Ã–rebro University Hospital, Ã–rebrÃ¶, Sweden",
            "The Clatterbridge Cancer Centre, Bebington, United Kingdom",
            "University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom",
            "Bristol Haematology and Oncology Centre, Bristol, United Kingdom",
            "Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",
            "Cambridge University Hospitals NHS Foundation Trust, Guildford, United Kingdom",
            "Royal Free Hospital, London, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, London, United Kingdom",
            "The Christie NHS Foundation Trust, Manchester, United Kingdom",
            "Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02111577"
      },
      {
        "-rank": "192",
        "nct_id": "NCT01383863",
        "title": "A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer",
        "acronym": "TRIPTOCARE LT",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Advanced Prostate Cancer" },
        "outcome_measures": {
          "outcome_measure": [
            "Castration-resistant prostate cancer (CRPC)",
            "Disease progression (DP) rate post-androgen deprivation therapy induction",
            "Overall survival",
            "Serum prostate specific antigen",
            "Serum testosterone"
          ]
        },
        "sponsors": { "lead_sponsor": "Ipsen" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "180",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "8-79-52014-187" },
        "start_date": "October 2011",
        "primary_completion_date": "May 2014",
        "completion_date": "May 2014",
        "study_first_posted": "June 28, 2011",
        "last_update_posted": "January 14, 2019",
        "locations": {
          "location": [
            "Fredericia Sygehus, Fredericia, Denmark",
            "Frederiksbergs Hospital, Frederiksberg, Denmark",
            "Herlev University Hospital, Herlev, Denmark",
            "Odense Universitets Hospital, Odense, Denmark",
            "Clinique RhÃ´ne Durance, Avignon, France",
            "HÃ´pital Pellegrin, Bordeaux, France",
            "CHU Henri Mondor, CrÃ©teil, France",
            "Chru Lille, Lille, France",
            "HÃ´pital Nord, Marseille, France",
            "Clinique Beau Soleil, Montpellier, France",
            "Private practice, Nancy, France",
            "CHU Nantes, Nantes, France",
            "CHU Pasteur, Nice, France",
            "HÃ´pital Val de GrÃ¢ce, Paris, France",
            "Institut Mutualiste Monsouris, Paris, France",
            "HÃ´pital Henry Gabrielle, Saint Genis Laval, France",
            "HÃ´pital Foch, Suresnes, France",
            "P.Stradins Clinical University Hospital, Riga, Latvia",
            "Center of Oncology, Riga, Latvia",
            "Medical University Clinics, Kaunas, Lithuania",
            "University Hospital, Klaipeda, Lithuania",
            "University Oncological Institute, Vilnius, Lithuania",
            "Academisch Medisch Centrum, Amsterdam, Netherlands",
            "Diaconessenhuis, Leiden, Netherlands",
            "Medical Center, Arad, Romania",
            "Sc E-Uro Srl, Cluj Napoca, Romania",
            "Oncomed, Timisoara, Romania",
            "Ulster hospital, Belfast, United Kingdom",
            "Bristol Royal Infirmary, Bristol, United Kingdom",
            "Addenbrookes Hospital, Cambridge, United Kingdom",
            "University Hospital Wales, Cardiff, United Kingdom",
            "University Hospital Coventry, Coventry, United Kingdom",
            "Leicester General Hospital, Leicester, United Kingdom",
            "Nottingham City Hospital, Nottingham, United Kingdom",
            "Lister Hospital, Stevenage, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01383863"
      },
      {
        "-rank": "193",
        "nct_id": "NCT01254279",
        "title": "Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer Metastatic" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "CABAZITAXEL"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "To provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen",
            "To document safety of cabazitaxel in these patients"
          ]
        },
        "sponsors": { "lead_sponsor": "Sanofi" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "984",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CABAZ_C_05331",
            "2010-021128-92",
            "U1111-1115-2476"
          ]
        },
        "start_date": "December 2010",
        "primary_completion_date": "December 2014",
        "completion_date": "December 2014",
        "study_first_posted": "December 6, 2010",
        "last_update_posted": "January 21, 2015",
        "locations": {
          "location": [
            "Investigational Site Number 036004, Box Hill, Australia",
            "Investigational Site Number 036020, Campbelltown, Australia",
            "Investigational Site Number 036001, Camperdown, Australia",
            "Investigational Site Number 036002, Camperdown, Australia",
            "Investigational Site Number 036011, Douglas, Australia",
            "Investigational Site Number 036019, Nambour, Australia",
            "Investigational Site Number 036023, North Adelaide, Australia",
            "Investigational Site Number 036008, Parkville, Australia",
            "Investigational Site Number 036005, Perth, Australia",
            "Investigational Site Number 036003, Port Macquarie, Australia",
            "Investigational Site Number 036025, Randwick, Australia",
            "Investigational Site Number 036009, South Brisbane, Australia",
            "Investigational Site Number 036022, South Brisbane, Australia",
            "Investigational Site Number 036017, Southport, Australia",
            "Investigational Site Number 036012, St Leonards, Australia",
            "Investigational Site Number 036010, Sydney, Australia",
            "Investigational Site Number 036013, Sydney, Australia",
            "Investigational Site Number 036014, Sydney, Australia",
            "Investigational Site Number 036016, Tweed Heads, Australia",
            "Investigational Site Number 036024, Wendouree, Australia",
            "Investigational Site Number 036007, Westmead, Australia",
            "Investigational Site Number 036015, Wodonga, Australia",
            "Investigational Site Number 040-004, Linz, Austria",
            "Investigational Site Number 040-005, Salzburg, Austria",
            "Investigational Site Number 040-003, Vienna, Austria",
            "Investigational Site Number 040-002, Wien, Austria",
            "Investigational Site Number 056002, Brugge, Belgium",
            "Investigational Site Number 056007, Bruxelles, Belgium",
            "Investigational Site Number 056003, Haine St Paul, Belgium",
            "Investigational Site Number 056005, LiÃ¨ge, Belgium",
            "Investigational Site Number 056004, Ottignies, Belgium",
            "Investigational Site Number 056001, Roeselare, Belgium",
            "Investigational Site Number 056006, Tournai, Belgium",
            "Investigational Site Number 070003, Banja Luka, Bosnia and Herzegovina",
            "Investigational Site Number 070001, Sarajevo, Bosnia and Herzegovina",
            "Investigational Site Number 070002, Zenica, Bosnia and Herzegovina",
            "Investigational Site Number 100004, Plovdiv, Bulgaria",
            "Investigational Site Number 100001, Sofia, Bulgaria",
            "Investigational Site Number 100003, Sofia, Bulgaria",
            "Investigational Site Number 100002, Sofia, Bulgaria",
            "Investigational Site Number 124012, Kitchener, Canada",
            "Investigational Site Number 124009, Laval, Canada",
            "Investigational Site Number 124004, London, Canada",
            "Investigational Site Number 124007, Moncton, Canada",
            "Investigational Site Number 124001, Montreal, Canada",
            "Investigational Site Number 124011, Montreal, Canada",
            "Investigational Site Number 124010, Quebec, Canada",
            "Investigational Site Number 124003, Toronto, Canada",
            "Investigational Site Number 124002, Toronto, Canada",
            "Investigational Site Number 124006, Winnipeg, Canada",
            "Investigational Site Number 191-001, Zagreb, Croatia",
            "Investigational Site Number 203001, Brno, Czech Republic",
            "Investigational Site Number 208-001, Cph Ã˜, Denmark",
            "Investigational Site Number 208-002, Herlev, Denmark",
            "Investigational Site Number 208-003, Odense, Denmark",
            "Investigational Site Number 246002, Helsinki, Finland",
            "Investigational Site Number 246001, SeinÃ¤joki, Finland",
            "Investigational Site Number 348001, Budapest, Hungary",
            "Investigational Site Number 348002, Szolnok, Hungary",
            "Investigational Site Number 348003, Szombathely, Hungary",
            "Investigational Site Number 348004, VeszprÃ©m, Hungary",
            "Investigational Site Number 356004, Chennai, India",
            "Investigational Site Number 356006, Gurgaon, India",
            "Investigational Site Number 356001, New Delhi, India",
            "Investigational Site Number 356002, New Delhi, India",
            "Investigational Site Number 356005, Trivandrum, India",
            "Investigational Site Number 372004, Cork, Ireland",
            "Investigational Site Number 372003, Dublin 24, Ireland",
            "Investigational Site Number 372001, Dublin 7, Ireland",
            "Investigational Site Number 372002, Dublin 7, Ireland",
            "Investigational Site Number 380-001, Arezzo, Italy",
            "Investigational Site Number 380-011, Aviano, Italy",
            "Investigational Site Number 380-025, Bari, Italy",
            "Investigational Site Number 380-007, Bergamo, Italy",
            "Investigational Site Number 380-015, Bologna, Italy",
            "Investigational Site Number 380-021, Fano, Italy",
            "Investigational Site Number 380-012, Firenze, Italy",
            "Investigational Site Number 380-003, Genova, Italy",
            "Investigational Site Number 380-005, Genova, Italy",
            "Investigational Site Number 380-014, Lecce, Italy",
            "Investigational Site Number 380-023, Messina, Italy",
            "Investigational Site Number 380-018, Milano, Italy",
            "Investigational Site Number 380-022, Milano, Italy",
            "Investigational Site Number 380-006, Napoli, Italy",
            "Investigational Site Number 380-010, Napoli, Italy",
            "Investigational Site Number 380-027, Napoli, Italy",
            "Investigational Site Number 380-004, Orbassano, Italy",
            "Investigational Site Number 380-017, Padova, Italy",
            "Investigational Site Number 380-002, Parma, Italy",
            "Investigational Site Number 380-009, Roma, Italy",
            "Investigational Site Number 380-008, Roma, Italy",
            "Investigational Site Number 380-024, Rozzano, Italy",
            "Investigational Site Number 380-020, San Giovanni Rotondo, Italy",
            "Investigational Site Number 380-013, Sassari, Italy",
            "Investigational Site Number 380-016, Taormina, Italy",
            "Investigational Site Number 398001, Almaty, Kazakhstan",
            "Investigational Site Number 398003, Shymkent, Kazakhstan",
            "Investigational Site Number 442001, Niederkorn, Luxembourg",
            "Investigational Site Number 458002, Georgetown, Malaysia",
            "Investigational Site Number 458001, Kuala Lumpur, Malaysia",
            "Investigational Site Number 458003, Kuching, Malaysia",
            "Investigational Site Number 484002, Durango, Mexico",
            "Investigational Site Number 484006, Irapuato, Mexico",
            "Investigational Site Number 484005, Toluca, Mexico",
            "Investigational Site Number 484001, Zapopan, Mexico",
            "Investigational Site Number 608001, Manila, Philippines",
            "Investigational Site Number 616-001, Gdansk, Poland",
            "Investigational Site Number 620002, Coimbra, Portugal",
            "Investigational Site Number 620003, Lisboa, Portugal",
            "Investigational Site Number 620004, Lisboa, Portugal",
            "Investigational Site Number 620001, Porto, Portugal",
            "Investigational Site Number 620005, SetÃºbal, Portugal",
            "Investigational Site Number 642001, Bucharest, Romania",
            "Investigational Site Number 642002, Cluj-Napoca, Romania",
            "Investigational Site Number 642003, Timisoara, Romania",
            "Investigational Site Number 688001, Belgrade, Serbia",
            "Investigational Site Number 688002, Belgrade, Serbia",
            "Investigational Site Number 702002, Singapore, Singapore",
            "Investigational Site Number 702001, Singapore, Singapore",
            "Investigational Site Number 703001, Bratislava, Slovakia",
            "Investigational Site Number 703002, Kosice, Slovakia",
            "Investigational Site Number 724018, Barcelona, Spain",
            "Investigational Site Number 724019, Barcelona, Spain",
            "Investigational Site Number 724023, CastellÃ³n de la Plana, Spain",
            "Investigational Site Number 724020, CÃ³rdoba, Spain",
            "Investigational Site Number 724025, Elche, Spain",
            "Investigational Site Number 724017, Granada, Spain",
            "Investigational Site Number 724006, Guadalajara, Spain",
            "Investigational Site Number 724011, L'Hospitalet de Llobregat, Spain",
            "Investigational Site Number 724002, La CoruÃ±a, Spain",
            "Investigational Site Number 724010, LeÃ³n, Spain",
            "Investigational Site Number 724003, Madrid, Spain",
            "Investigational Site Number 724012, Madrid, Spain",
            "Investigational Site Number 724007, Madrid, Spain",
            "Investigational Site Number 724008, Manresa, Spain",
            "Investigational Site Number 724021, MÃ¡laga, Spain",
            "Investigational Site Number 724009, Oviedo, Spain",
            "Investigational Site Number 724022, Pamplona, Spain",
            "Investigational Site Number 724005, San CristÃ³bal de La Laguna - Sta. Cruz de Tenerife, Spain",
            "Investigational Site Number 724016, Santander, Spain",
            "Investigational Site Number 724015, Santiago de Compostela, Spain",
            "Investigational Site Number 724024, Sevilla, Spain",
            "Investigational Site Number 724004, Terrassa, Spain",
            "Investigational Site Number 724013, Valencia, Spain",
            "Investigational Site Number 724014, Valencia, Spain",
            "Investigational Site Number 724001, Zaragoza, Spain",
            "Investigational Site Number 752-002, UmeÃ¥, Sweden",
            "Investigational Site Number 752-001, Uppsala, Sweden",
            "Investigational Site Number 005, Kaohsiung Hsien,, Taiwan",
            "Investigational Site Number 004, Taichung, Taiwan",
            "Investigational Site Number 002, Taipei, Taiwan",
            "Investigational Site Number 003, Taipei, Taiwan",
            "Investigational Site Number 001, Tao Yuan Hsien, Taiwan",
            "Investigational Site Number 826011, Birmingham, United Kingdom",
            "Investigational Site Number 826002, Bristol, United Kingdom",
            "Investigational Site Number 826003, Glasgow, United Kingdom",
            "Investigational Site Number 826013, Leeds, United Kingdom",
            "Investigational Site Number 826009, London, United Kingdom",
            "Investigational Site Number 826012, Manchester, United Kingdom",
            "Investigational Site Number 826005, Nottingham, United Kingdom",
            "Investigational Site Number 826008, Preston, United Kingdom",
            "Investigational Site Number 826001, Sutton, United Kingdom",
            "Investigational Site Number 826007, Torquay, United Kingdom",
            "Investigational Site Number 826006, Whitechurch, United Kingdom",
            "Investigational Site Number 826004, Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01254279"
      },
      {
        "-rank": "194",
        "nct_id": "NCT01817738",
        "title": "Trial of RNActiveÂ®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "CV9104"
            },
            {
              "-type": "Biological",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Phase I (Safety Lead-In): Occurrence of dose-limiting toxicity (DLT) during the first 4 weeks of treatment (after administration of 3 vaccinations and after a 1 week observation period",
            "Phase II (Randomised Portion): Overall Survival from time of randomisation- up to 3.5-4 years.",
            "Progression free survival from date of randomisation",
            "Progression free survival from start of first subsequent systemic therapy",
            "Percent change to maximal and to minimal PSA from baseline and before start of first subsequent systemic cancer therapy and from start of first systemic therapy to end of first subsequent systemic therapy",
            "Cellular and humoral immune response rate against the 6 antigens encoded by CV9104",
            "Time to symptom progression based on FACT P score and subscores",
            "Absolute change and area under the curve from baseline EQ-5D score and pain sub-score",
            "Progression free survival from randomisation until second progression on first subsequent therapy"
          ]
        },
        "sponsors": { "lead_sponsor": "CureVac AG" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "197",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CV-9104-004" },
        "start_date": "August 2012",
        "primary_completion_date": "August 2016",
        "completion_date": "January 2017",
        "study_first_posted": "March 25, 2013",
        "last_update_posted": "February 17, 2017",
        "locations": {
          "location": [
            "KrajskÃ¡ zdravotnÃ­, a.s. - Nemocnice Chomutov, o.z.OnkologickÃ© oddÄ›lenÃ­, Chomutov, Czech Republic",
            "FakultnÃ­ nemocnice Olomouc, UrologickÃ¡ klinika, Olomouc, Czech Republic",
            "Multiscan, a.s, OddÄ›lenÃ­ klinickÃ© a radiaÄnÃ­ onkologie, Pardubice, Czech Republic",
            "Thomayerova nemocnice, UrologickÃ© oddÄ›lenÃ­, Praha, Czech Republic",
            "KrajskÃ¡ zdravotnÃ­, a.s. - Masarykova nemocnice ÃšstÃ­ nad Labem, Usti nad Labem, Czech Republic",
            "Institut Gustave Roussy, Villejuif cedex, France",
            "UniversitÃ¤tsklinikum Aachen Klinik fÃ¼r Urologie, Aachen, Germany",
            "Vivantes Klinikum Am Urban Klinik fÃ¼r Urologie, Berlin, Germany",
            "Medizinisches Zentrum Friedensplatz, Bonn, Germany",
            "UniversitÃ¤tsklinikum Dresden Klinik und Poliklinik fÃ¼r Urologie, Dresden, Germany",
            "Chirurgische UniversitÃ¤tsklinik Freiburg Klinik fÃ¼r Urologie, Freiburg, Germany",
            "Urologikum Hamburg, Hamburg, Germany",
            "Nationales Zentrum fÃ¼r Tumorerkrankungen Medizinische Onkologie, Heidelberg, Germany",
            "Urologie am Nordplatz, Leipzig, Germany",
            "UMM UniversitÃ¤tsmedizin Mannheim, Mannheim, Germany",
            "Praxis Dr.schulze, Marklleeberg, Germany",
            "Urologische Klinik und Poliklinik der Technischen UniversitÃ¤t MÃ¼nchen Klinikum Rechts der Isar, Munich, Germany",
            "UniversitÃ¤tsklinikum MÃ¼nster Klinik und Poliklinik fÃ¼r Urologie, MÃ¼nster, Germany",
            "Studienpraxis fÃ¼r Urologie, NÃ¼rtingen, Germany",
            "Ortenau Klinikum Urologie und Kinderurologie, Offenburg, Germany",
            "Urologische Klinik Dr. Castingius MÃ¼nchen, Planegg, Germany",
            "UniversitÃ¤tsklinik fÃ¼r Urologie, TÃ¼bingen, Germany",
            "Medica Pro Familia Krakow, Krakow, Poland",
            "Centrum Urologiczne Sp. z o.o., MysÅ‚owice, Poland",
            "Centralny Szpital Kliniczny MSWiA, Klinika Onkologii I Hematologii, Warsaw, Poland",
            "Szpital Sw. ElÅ¼biety - Mokotowskie Centrum Medyczne, Warsaw, Poland",
            "Instytut M. Curie-SkÅ‚odowskiej Centrum Onkologii, Warsaw, Poland",
            "NZOZ Magodent, Centrum Medyczne Ostrobramska, Oncologii Klinicznej i ChemÃ­oterapii, Warsaw, Poland",
            "Profesorskie Centrum Medyczne OPTIMUM WrocÅ‚aw, Wroclaw, Poland",
            "Szpital Uniwersytecki, Katedra i Klinika Urologii i Onkologii Urologicznej, Wroclaw, Poland",
            "Hospital de Madrid Norte Sanchinarro Centro Integral OncolÃ³gico Clara Campal (CIOCC), Madrid, Spain",
            "Hospital ClÃ­nico Virgen de la Victoria Campus Universitario de Teatinos s/n, Malaga, Spain",
            "ClÃ­nica Universitaria de Navarra Departamento de OncologÃ­a, Pamplona, Spain",
            "Complejo Hospitalario Universitario Santiago Departamento de OncologÃ­a, Santiago de Compostela, Spain",
            "Instituto Valenciano de OncologÃ­a Unidad de InvestigaciÃ³n ClÃ­nica, Valencia, Spain",
            "\"Sahlgrenska Universitetssjukhuset Urologmottagningen, Gothenburg, Sweden",
            "SkÃ¥nes Universitetssjukhus MalmÃ¶ Urologmottagningen, MalmÃ¶, Sweden",
            "Karolinska Universitetssjukhuset Solna Urologiska kliniken, Stockholm, Sweden",
            "Akademiska sjukhuset Urologmottagningen, Uppsala, Sweden",
            "Universitetssjukhuset Ã–rebro Urologmottagningen, Ã–rebro, Sweden",
            "UniversitÃ¤tsspital Basel Medizinische Onkologie, Basel, Switzerland",
            "Kantonsspital GraubÃ¼nden Department Innere Medizin HÃ¤matologie und Onkologie, Chur, Switzerland",
            "CHUV Centre Pluridisciplinaire d'Oncologie, Lausanne, Switzerland",
            "Kantonsspital St. Gallen Department Innere Medizin HÃ¤matologie Medizinische Onkologie, St. Gallen, Switzerland",
            "Royal Free Hospital, London, United Kingdom",
            "Nottingham City Hospital Department of Oncology, Nottingham, United Kingdom",
            "Clatterbridge Cancer Centre, Wirral, Merseyside, United Kingdom",
            "York Hospital, York, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01817738"
      },
      {
        "-rank": "195",
        "nct_id": "NCT02446444",
        "title": "Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer",
        "acronym": "ENZARAD",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Conventional NSAA"
            },
            {
              "-type": "Drug",
              "#text": "LHRHA"
            },
            {
              "-type": "Radiation",
              "#text": "External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall survival time",
            "Cause-specific survival time",
            "Prostate Specific Antigen (PSA) progression free survival time",
            "Clinical progression free survival time",
            "Time to subsequent hormonal therapy (restarting ADT)",
            "Time to castration-resistant disease (PCWG2 criteria)",
            "Metastasis-free survival (MFS)",
            "Adverse events (CTCAE v4.03)",
            "Health-related quality of life (EORTC Core Quality of Life Questionnaire (QLQC-30), Quality of Life Questionnaire for Prostate Cancer (PR-25), Euroqol 5 item preference-based measure of health (EQ-5 D-5L))",
            "Health outcomes relative to costs (incremental cost effectiveness ratio)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University of Sydney",
          "collaborator": [
            "Australian and New Zealand Urogenital and Prostate Cancer Trials Group",
            "National Health and Medical Research Council, Australia",
            "Cancer Trials Ireland",
            "TROG- Trans Tasman Radiation Oncology Group"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "802",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "ANZUP1303",
            "ACTRN12614000126617"
          ]
        },
        "start_date": "March 2014",
        "primary_completion_date": "September 2021",
        "completion_date": "December 2021",
        "study_first_posted": "May 18, 2015",
        "last_update_posted": "July 6, 2018",
        "locations": {
          "location": [
            "Dana Farber Cancer Institute, Boston, Massachusetts, United States",
            "Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States",
            "Blacktown Hospital, Blacktown, New South Wales, Australia",
            "Campbelltown Hospital, Campbelltown, New South Wales, Australia",
            "Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia",
            "Genesis Cancer Care Newcastle, Gateshead, New South Wales, Australia",
            "Gosford Hospital, Gosford, New South Wales, Australia",
            "St George Hospital, Kogarah, New South Wales, Australia",
            "Liverpool Hospital, Liverpool, New South Wales, Australia",
            "Central West Cancer Services, Orange, New South Wales, Australia",
            "Prince of Wales Hospital, Randwick, New South Wales, Australia",
            "Royal North Shore Hospital, St Leonards, New South Wales, Australia",
            "St Vincent's Hospital, Sydney, New South Wales, Australia",
            "Tamworth Rural Referral Hospital, Tamworth, New South Wales, Australia",
            "Sydney Adventist Hospital, Wahroonga, New South Wales, Australia",
            "Calvary Mater Newcastle, Waratah, New South Wales, Australia",
            "Westmead Hospital, Westmead, New South Wales, Australia",
            "Wollongong Hospital, Wollongong, New South Wales, Australia",
            "Genesis Cancer Care Queensland - Wesley and Chermside, Auchenflower, Queensland, Australia",
            "Townsville Hospital, Douglas, Queensland, Australia",
            "Royal Brisbane & Womens Hospital, Herston, Queensland, Australia",
            "Nambour General Hospital, Nambour, Queensland, Australia",
            "Radiation Oncology Mater Centre, South Brisbane, Queensland, Australia",
            "Radiation Oncology Centre- Gold Coast, Southport, Queensland, Australia",
            "Oncology Research Australia, Toowoomba, Queensland, Australia",
            "Genesis Cancer Care Queensland - Tugun and Southport, Tugun, Queensland, Australia",
            "Princess Alexandra Hospital Brisbane, Woolloongabba, Queensland, Australia",
            "Royal Adelaide Hospital, Adelaide, South Australia, Australia",
            "Flinders Medical Centre, Bedford Park, South Australia, Australia",
            "Ashford Cancer Care Research (Adelaide Cancer Centre), Kurralta Park, South Australia, Australia",
            "Royal Hobart Hospital, Hobart, Tasmania, Australia",
            "Peter MacCallum Cancer Centre, Bendigo, Victoria, Australia",
            "Peter MacCallum Cancer Centre (Moorabbin Campus), Bentleigh East, Victoria, Australia",
            "Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia",
            "Epping Radiation Oncology Centre, Epping, Victoria, Australia",
            "Western Radiation Oncology Centre, Footscray, Victoria, Australia",
            "Frankston Radiation Oncology Centre, Frankston, Victoria, Australia",
            "Austin Health, Heidelberg, Victoria, Australia",
            "Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",
            "Epworth HealthCare - Richmond, Richmond, Victoria, Australia",
            "Ringwood Radiation Oncology Centre, Ringwood East, Victoria, Australia",
            "Sunshine Hospital, St Albans, Victoria, Australia",
            "Fiona Stanley Hospital, Murdoch, Western Australia, Australia",
            "Salzburger Landeskliniken - UniversitÃ¤tsklinikum Salzburg, Salzburg, Austria",
            "AZ Groeninge Kortrijk- Campus Kennedylaan, Kortrijk, Belgium",
            "Cork University Hospital, Cork, Co Cork, Ireland",
            "Galway University Hospital, Galway, Co Galway, Ireland",
            "Mater Misericordiae University Hospital, Dublin, Dublin 7, Ireland",
            "Beacon Private Hospital, Dublin, Ireland",
            "Mater Private Hospital, Dublin, Ireland",
            "Auckland City Hospital, Auckland, New Zealand",
            "Christchurch Hospital, Christchurch, New Zealand",
            "Palmerston North Hospital, Palmerston North, New Zealand",
            "The Institute Of Oncology, Ljubljana, Slovenia",
            "Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia), Badalona, Barcelona, Spain",
            "Hospital Donostia, Donostia, Gipuzkoa, Spain",
            "Hospital Universitario de Salamanca, Salamanca, Spain",
            "Velindre Hospital, Whitchurch, Cardiff, United Kingdom",
            "University Hospital Southhampton, Southampton, Hampshire, United Kingdom",
            "St Luke's Hospital, Dublin, Ireland, United Kingdom",
            "Kent and Canterbury Hospital, Canterbury, Kent, United Kingdom",
            "Royal Marsden Hospital, Chelsea, London, United Kingdom",
            "Western General Hospital, Edinburgh, Scotland, United Kingdom",
            "Royal United Hospital Bath, Bath, United Kingdom",
            "Addenbrookes Hospital, Cambridge, United Kingdom",
            "University of London Hospital, London, United Kingdom",
            "Guys and St Thomas Hospital, London, United Kingdom",
            "Charring Cross Hospital: Imperial College Healthcare NHS Trust, London, United Kingdom",
            "Nottingham City Hospital- City Campus, Nottingham, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02446444"
      },
      {
        "-rank": "196",
        "nct_id": "NCT01429064",
        "title": "Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "ODM-201"
          }
        },
        "outcome_measures": { "outcome_measure": "Number of Participants With Adverse Events" },
        "sponsors": { "lead_sponsor": "Orion Corporation, Orion Pharma" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "76",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "3104002" },
        "start_date": "June 2011",
        "primary_completion_date": "November 2015",
        "completion_date": "November 2015",
        "study_first_posted": "September 5, 2011",
        "results_first_posted": "December 22, 2016",
        "last_update_posted": "February 20, 2017",
        "locations": {
          "location": [
            "The Urology Center of Colorado, Wheat Ridge, Colorado, United States",
            "Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States",
            "Cleveland Clinic, Cleveland, Ohio, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Klinika onkologie a radioterapie LFUK a FN, Hradec KrÃ¡lovÃ©, Czech Republic",
            "East-Tallinn Central Hospital, Tallinn, Estonia",
            "Helsinki University Central Hospital, Helsinki, Finland",
            "Kuopio University Hospital, Kuopio, Finland",
            "Oulu University Hospital, Oulu, Finland",
            "Tampere University Hospital, Tampere, Finland",
            "Turku University Hospital, Turku, Finland",
            "Saint Louis Hospital, Paris, France",
            "Institut Gustave Roussy, Villejuif, France",
            "Queen Elizabeth Hospital, Birmingham, United Kingdom",
            "Velindre Cancer Centre, Cardiff, United Kingdom",
            "Christie Hospital, Manchester, United Kingdom",
            "Churchill Hospital, Oxford, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01429064"
      },
      {
        "-rank": "197",
        "nct_id": "NCT02799602",
        "title": "ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer",
        "acronym": "ARASENS",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "BAY1841788 / darolutamide (ODM-201)"
            },
            {
              "-type": "Drug",
              "#text": "Standard ADT (androgen deprivation therapy)"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall survival",
            "Time to castration resistant prostate cancer",
            "Time to initiation of subsequent antineoplastic therapy",
            "Symptomatic skeletal event free survival (SSE-FS)",
            "Time to first symptomatic skeletal event (SSE)",
            "Time to initiation of opioid use",
            "Time to pain progression",
            "Time to worsening of physical symptoms of disease",
            "Number of participants with adverse events as a measure of safety and tolerability"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Bayer",
          "collaborator": "Orion Corporation, Orion Pharma"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1303",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "17777",
            "2015-002590-38"
          ]
        },
        "start_date": "November 30, 2016",
        "primary_completion_date": "August 1, 2022",
        "completion_date": "August 1, 2022",
        "study_first_posted": "June 15, 2016",
        "last_update_posted": "September 2, 2019",
        "locations": {
          "location": [
            "Chandler, Arizona, United States",
            "Tucson, Arizona, United States",
            "Beverly Hills, California, United States",
            "Duarte, California, United States",
            "Los Angeles, California, United States",
            "Stanford, California, United States",
            "Washington, District of Columbia, United States",
            "Boca Raton, Florida, United States",
            "Gainesville, Florida, United States",
            "Tampa, Florida, United States",
            "Atlanta, Georgia, United States",
            "Chicago, Illinois, United States",
            "Peoria, Illinois, United States",
            "Louisville, Kentucky, United States",
            "New Orleans, Louisiana, United States",
            "Baltimore, Maryland, United States",
            "Towson, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Boston, Massachusetts, United States",
            "Boston, Massachusetts, United States",
            "Detroit, Michigan, United States",
            "Billings, Montana, United States",
            "Omaha, Nebraska, United States",
            "Lebanon, New Hampshire, United States",
            "Englewood, New Jersey, United States",
            "Hackensack, New Jersey, United States",
            "Voorhees, New Jersey, United States",
            "Albuquerque, New Mexico, United States",
            "Bronx, New York, United States",
            "Buffalo, New York, United States",
            "New York, New York, United States",
            "Poughkeepsie, New York, United States",
            "Rochester, New York, United States",
            "Winston-Salem, North Carolina, United States",
            "Cleveland, Ohio, United States",
            "Columbus, Ohio, United States",
            "Columbus, Ohio, United States",
            "Kettering, Ohio, United States",
            "Oklahoma City, Oklahoma, United States",
            "Bala-Cynwyd, Pennsylvania, United States",
            "Camp Hill, Pennsylvania, United States",
            "Pittsburgh, Pennsylvania, United States",
            "Charleston, South Carolina, United States",
            "Charleston, South Carolina, United States",
            "Greenville, South Carolina, United States",
            "Myrtle Beach, South Carolina, United States",
            "North Charleston, South Carolina, United States",
            "Dallas, Texas, United States",
            "Temple, Texas, United States",
            "Salt Lake City, Utah, United States",
            "Charlottesville, Virginia, United States",
            "Fairfax, Virginia, United States",
            "Richmond, Virginia, United States",
            "Everett, Washington, United States",
            "Milwaukee, Wisconsin, United States",
            "Randwick, New South Wales, Australia",
            "Sydney, New South Wales, Australia",
            "Adelaide, South Australia, Australia",
            "Melbourne, Victoria, Australia",
            "Kurralta Park, Australia",
            "Wilrijk, Antwerpen, Belgium",
            "Bruxelles - Brussel, Belgium",
            "Bruxelles - Brussel, Belgium",
            "Bruxelles - Brussel, Belgium",
            "Charleroi, Belgium",
            "Gent, Belgium",
            "Namur, Belgium",
            "Salvador, Bahia, Brazil",
            "Cachoeiro de Itapemirim, EspÃ­rito Santo, Brazil",
            "Curitiba, Parana, Brazil",
            "Natal, Rio Grande Do Norte, Brazil",
            "Porto Alegre, Rio Grande Do Sul, Brazil",
            "Santo AndrÃ©, Sao Paulo, Brazil",
            "SÃ£o Paulo, Sao Paulo, Brazil",
            "Rio de Janeiro, Brazil",
            "Rio de Janeiro, Brazil",
            "Gabrovo, Bulgaria",
            "Pleven, Bulgaria",
            "Sofia, Bulgaria",
            "Sofia, Bulgaria",
            "Sofia, Bulgaria",
            "Varna, Bulgaria",
            "Vratsa, Bulgaria",
            "Calgary, Alberta, Canada",
            "Edmonton, Alberta, Canada",
            "Toronto, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Montreal, Quebec, Canada",
            "Hefei, Anhui, China",
            "Xiamen, Fujian, China",
            "Guangzhou, Guangdong, China",
            "Shijiazhuang, Hebei, China",
            "Zhengzhou, Henan, China",
            "Wuhan, Hubei, China",
            "Wuhan, Hubei, China",
            "Changsha, Hunan, China",
            "Nanjing, Jiangsu, China",
            "Nanjing, Jiangsu, China",
            "Nanchang, Jiangxi, China",
            "Changchun, Jilin, China",
            "Shengyang, Liaoning, China",
            "Shenyang, Liaoning, China",
            "Xi'an, Shaanxi, China",
            "Jinan, Shandong, China",
            "Jinan, Shandong, China",
            "Yantai, Shandong, China",
            "Hangzhou, Zhejiang, China",
            "Hangzhou, Zhejiang, China",
            "Wenzhou, Zhejiang, China",
            "Beijing, China",
            "Beijing, China",
            "Beijing, China",
            "Beijing, China",
            "Beijing, China",
            "Chongqing, China",
            "Shanghai, China",
            "Shanghai, China",
            "Shanghai, China",
            "Shanghai, China",
            "Shanghai, China",
            "Tianjin, China",
            "Tianjin, China",
            "Brno, Czechia",
            "Brno, Czechia",
            "Praha 10, Czechia",
            "Praha 2, Czechia",
            "Praha 2, Czechia",
            "Praha 5, Czechia",
            "Praha 8, Czechia",
            "Helsinki, Finland",
            "JyvÃ¤skylÃ¤, Finland",
            "Kuopio, Finland",
            "Mikkeli, Finland",
            "Oulu, Finland",
            "Tampere, Finland",
            "Turku, Finland",
            "Angers Cedex, France",
            "Besancon, France",
            "Bordeaux Cedex, France",
            "Brest, France",
            "Clermont-ferrand, France",
            "Creteil, France",
            "Marseille, France",
            "Montpellier Cedex, France",
            "Nancy, France",
            "Pierre Benite, France",
            "Poitiers, France",
            "Pontoise, France",
            "REIMS cedex, France",
            "Saint Herblain Cedex, France",
            "Saint-gregoire, France",
            "Strasbourg, France",
            "Villejuif Cedex, France",
            "Freiburg, Baden-WÃ¼rttemberg, Germany",
            "Reutlingen, Baden-WÃ¼rttemberg, Germany",
            "TÃ¼bingen, Baden-WÃ¼rttemberg, Germany",
            "Ulm, Baden-WÃ¼rttemberg, Germany",
            "Erlangen, Bayern, Germany",
            "Rostock, Mecklenburg-Vorpommern, Germany",
            "Braunschweig, Niedersachsen, Germany",
            "MÃ¼nster, Nordrhein-Westfalen, Germany",
            "Jena, ThÃ¼ringen, Germany",
            "Berlin, Germany",
            "Magdeburg, Germany",
            "Beer Sheva, Israel",
            "Haifa, Israel",
            "Holon, Israel",
            "Jerusalem, Israel",
            "Petah Tikva, Israel",
            "Tel Aviv, Israel",
            "Zefat, Israel",
            "Zerifin, Israel",
            "Bologna, Emilia-Romagna, Italy",
            "Parma, Emilia-Romagna, Italy",
            "Roma, Lazio, Italy",
            "Milano, Lombardia, Italy",
            "Novara, Piemonte, Italy",
            "Torino, Piemonte, Italy",
            "Trento, Trentino-Alto Adige, Italy",
            "Padova, Veneto, Italy",
            "Verona, Veneto, Italy",
            "Nagoya, Aichi, Japan",
            "Hirosaki, Aomori, Japan",
            "Asahi, Chiba, Japan",
            "Kashiwa, Chiba, Japan",
            "Sakura, Chiba, Japan",
            "Matsuyama, Ehime, Japan",
            "Sapporo, Hokkaido, Japan",
            "Kobe, Hyogo, Japan",
            "Kanazawa, Ishikawa, Japan",
            "Kanazawa, Ishikawa, Japan",
            "Kita, Kagawa, Japan",
            "Yokohama, Kanagawa, Japan",
            "Yokohama, Kanagawa, Japan",
            "Tsu, Mie, Japan",
            "Sendai, Miyagi, Japan",
            "Kashihara, Nara, Japan",
            "Osakasayama, Osaka, Japan",
            "Suita, Osaka, Japan",
            "Hamamatsu, Shizuoka, Japan",
            "Shimotsuke, Tochigi, Japan",
            "Utsunomiya, Tochigi, Japan",
            "Bunkyo-ku, Tokyo, Japan",
            "Bunkyo-ku, Tokyo, Japan",
            "Bunkyo-ku, Tokyo, Japan",
            "Koto-ku, Tokyo, Japan",
            "Meguro-ku, Tokyo, Japan",
            "Minato-ku, Tokyo, Japan",
            "Mitaka, Tokyo, Japan",
            "Nakano-ku, Tokyo, Japan",
            "Shinjuku-ku, Tokyo, Japan",
            "Shinjuku-ku, Tokyo, Japan",
            "Yonago, Tottori, Japan",
            "Ube, Yamaguchi, Japan",
            "Chiba, Japan",
            "Chiba, Japan",
            "Fukuoka, Japan",
            "Gifu, Japan",
            "Kumamoto, Japan",
            "Miyazaki, Japan",
            "Nagasaki, Japan",
            "Okayama, Japan",
            "Osaka, Japan",
            "Osaka, Japan",
            "Tokushima, Japan",
            "Wakayama, Japan",
            "Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of",
            "Seongnam-si, Gyeonggido, Korea, Republic of",
            "Seoul, Seoul Teugbyeolsi, Korea, Republic of",
            "Busan, Korea, Republic of",
            "Daegu, Korea, Republic of",
            "Gyeonggi-do, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Ciudad de Mexico, Distrito Federal, Mexico",
            "Mexico, Distrito Federal, Mexico",
            "Cuernavaca, Morelos, Mexico",
            "Monterrey, Nuevo Leon, Mexico",
            "MazatlÃ¡n, Sinaloa, Mexico",
            "QuerÃ©taro, Mexico",
            "Amsterdam, Netherlands",
            "Amsterdam, Netherlands",
            "Den Haag, Netherlands",
            "Dordrecht, Netherlands",
            "Heerlen, Netherlands",
            "Hilversum, Netherlands",
            "Hoofddorp, Netherlands",
            "Tilburg, Netherlands",
            "Lodz, Poland",
            "Lublin, Poland",
            "Rybnik, Poland",
            "Siedlce, Poland",
            "Waliszew, Poland",
            "Warszawa, Poland",
            "Barnaul, Russian Federation",
            "Chelyabinsk, Russian Federation",
            "Chelyabinsk, Russian Federation",
            "Moscow, Russian Federation",
            "Moscow, Russian Federation",
            "Novosibirsk, Russian Federation",
            "Omsk, Russian Federation",
            "St. Petersburg, Russian Federation",
            "St. Petersburg, Russian Federation",
            "St. Petersburg, Russian Federation",
            "Sabadell, Barcelona, Spain",
            "Palma de Mallorca, Illes Baleares, Spain",
            "Barcelona, Spain",
            "Barcelona, Spain",
            "Barcelona, Spain",
            "Barcelona, Spain",
            "CÃ¡ceres, Spain",
            "CÃ³rdoba, Spain",
            "Lugo, Spain",
            "Madrid, Spain",
            "Madrid, Spain",
            "MÃ¡laga, Spain",
            "Valencia, Spain",
            "GÃ¶teborg, Sweden",
            "Lund, Sweden",
            "Stockholm, Sweden",
            "UmeÃ¥, Sweden",
            "Uppsala, Sweden",
            "Kaohsiung, Taiwan",
            "Taichung, Taiwan",
            "Taipei, Taiwan",
            "Taipei, Taiwan",
            "Taoyuan, Taiwan",
            "Colchester, Essex, United Kingdom",
            "Romford, Essex, United Kingdom",
            "Middlesborough, North Yorkshire, United Kingdom",
            "Belfast, United Kingdom",
            "Glasgow, United Kingdom",
            "London, United Kingdom",
            "London, United Kingdom",
            "London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02799602"
      },
      {
        "-rank": "198",
        "nct_id": "NCT02446405",
        "title": "Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer",
        "acronym": "ENZAMET",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "NSAA"
            },
            {
              "-type": "Drug",
              "#text": "LHRHA or Surgical Castration"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival Time",
            "Prostate specific antigen progression free survival time",
            "Clinical progression free survival time",
            "Adverse events",
            "Health-related quality of life (EORTC Core Quality of Life Questionnaire (QLQ C-30), Quality of Life Questionnaire for Prostate Cancer (PR-25), Euroqol 5 item preference-based measure of health (EQ-5 D-5L))",
            "Healthcare resource cost-effectiveness (incremental cost effectiveness ratio)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University of Sydney",
          "collaborator": [
            "Australian and New Zealand Urogenital and Prostate Cancer Trials Group",
            "National Health and Medical Research Council, Australia",
            "Cancer Trials Ireland",
            "NCIC Clinical Trials Group"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1125",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "ANZUP 1304",
            "ACTRN12614000110684"
          ]
        },
        "start_date": "March 2014",
        "primary_completion_date": "September 2020",
        "completion_date": "December 2020",
        "study_first_posted": "May 18, 2015",
        "last_update_posted": "May 3, 2018",
        "locations": {
          "location": [
            "Dana Farber Cancer Institute, Boston, Massachusetts, United States",
            "Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia",
            "Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia",
            "Concord Cancer Centre - Concord Repatriation General Hospital, Concord, New South Wales, Australia",
            "St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia",
            "Nepean Cancer Care Centre, Kingswood, New South Wales, Australia",
            "St. George Hospital, Kogarah, New South Wales, Australia",
            "Central West Cancer Services, Orange, New South Wales, Australia",
            "Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia",
            "Prince of Wales Hospital, Randwick, New South Wales, Australia",
            "Northern Cancer Institute, St Leonards, New South Wales, Australia",
            "Tamworth Rural Referral Hospital, Tamworth, New South Wales, Australia",
            "The Tweed Hospital, Tweed Heads, New South Wales, Australia",
            "Riverina Cancer Care Centre, Wagga Wagga, New South Wales, Australia",
            "Sydney Adventist Hospital, Wahroonga, New South Wales, Australia",
            "Wollongong Hospital, Wollongong, New South Wales, Australia",
            "Royal Darwin Hospital, Tiwi, Northern Territory, Australia",
            "Townsville Hospital, Douglas, Queensland, Australia",
            "Royal Brisbane and Women's Hospital, Herston, Queensland, Australia",
            "Nambour General Hospital, Nambour, Queensland, Australia",
            "Gold Coast University Hospital, Southport, Queensland, Australia",
            "Princess Alexandra Hospital, Woolloongabba, Queensland, Australia",
            "Royal Adelaide Hospital, Adelaide, South Australia, Australia",
            "Flinders Medical Centre, Bedford Park, South Australia, Australia",
            "Adelaide Cancer Centre - Ashford Cancer Care Centre, Kurralta Park, South Australia, Australia",
            "Royal Hobart Hospital, Hobart, Tasmania, Australia",
            "Bendigo Hospital, Bendigo, Victoria, Australia",
            "Monash Cancer Centre Moorabbin, Bentleigh East, Victoria, Australia",
            "Peter MacCallum Cancer Centre - East Melbourne, East Melbourne, Victoria, Australia",
            "St. Vincents Hospital Melbourne, Fitzroy, Victoria, Australia",
            "Peninsula South Eastern Haematology & Oncology Group- Peninsula Oncology Centre, Frankston, Victoria, Australia",
            "University Hospital Geelong, Geelong, Victoria, Australia",
            "Austin Hospital, Heidelberg, Victoria, Australia",
            "Australian Urology Associates, Malvern, Victoria, Australia",
            "Eastern Health Box Hill Hospital, Melbourne, Victoria, Australia",
            "Goulburn Valley Health, Shepparton, Victoria, Australia",
            "Border Medical Oncology, Wodonga, Victoria, Australia",
            "Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia",
            "Fiona Stanley Hospital (formerly Royal Perth Hospital), Perth, Western Australia, Australia",
            "Prostate Cancer Institute - Southern Alberta Institute of Urology, Calgary, Alberta, Canada",
            "Cross Cancer Institute, Edmonton, Alberta, Canada",
            "BCCA - Fraser Valley Cancer Center, Surrey, British Columbia, Canada",
            "BCCA Vancouver Centre, Vancouver, British Columbia, Canada",
            "CancerCare Manitoba, Winnipeg, Manitoba, Canada",
            "Horizon Health Network - Dr Everett Chalmers Hospital, Fredericton, New Brunswick, Canada",
            "Saint John Regional Hospital, Saint John, New Brunswick, Canada",
            "QEII Health Sciences Centre, Capital District Health Authority, Halifax, Nova Scotia, Canada",
            "Cambridge Memorial Hospital, Cambridge, Ontario, Canada",
            "Juravinski Cancer Centre, Hamilton, Ontario, Canada",
            "Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada",
            "London Regional Cancer Program, London, Ontario, Canada",
            "Lakeridge Health Oshawa, Oshawa, Ontario, Canada",
            "Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada",
            "Algoma District Cancer Program Sault Area Hospital, Sault Ste. Marie, Ontario, Canada",
            "Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada",
            "University Health Network - Princess Margaret Hospital, Toronto, Ontario, Canada",
            "HÃ´pital Notre-Dame, Montreal, Quebec, Canada",
            "CHUQ-Pavillon Hotel-Dieu de Quebec, QuÃ©bec City, Quebec, Canada",
            "Allan Blair Cancer Centre, Regina, Saskatchewan, Canada",
            "Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada",
            "Beaumont Hospital, Beaumont, Dublin, Ireland",
            "Beacon Private Hospital, Dublin, Ireland",
            "St Vincent's University Hospital, Dublin, Ireland",
            "Mater Misercordiae University Hospital, Dublin, Ireland",
            "Mater Private Hospital, Dublin, Ireland",
            "St James Hospital, Dublin, Ireland",
            "Galway University Hospital, Galway, Ireland",
            "Adelaide and Meath Hospital - National Children's Hospital, Tallaght, Ireland",
            "University Hospital Waterford, Waterford, Ireland",
            "Auckland City Hospital, Auckland, New Zealand",
            "Christchurch Hospital, Christchurch, New Zealand",
            "Waikato Hospital, Hamilton, New Zealand",
            "Royal Cornwall Hospital, Truro, Cornwall, United Kingdom",
            "Royal Sussex Hospital, Brighton, East Sussex, United Kingdom",
            "Kent and Canterbury Hospital, Canterbury, Kent, United Kingdom",
            "Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom",
            "Velindre Cancer Centre, Cardiff, Wales, United Kingdom",
            "University College Hospital London, London, United Kingdom",
            "Guys and St Thomas Hospital, London, United Kingdom",
            "Royal Marsden Hospital, London, United Kingdom",
            "University Hospital Southampton, Southampton, United Kingdom",
            "Great Western Hospital, Swindon, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02446405"
      },
      {
        "-rank": "199",
        "nct_id": "NCT01317641",
        "title": "Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "ODM-201"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)",
            "Phase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose",
            "Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Chemotherapy-naÃ¯ve and CYP17i-naÃ¯ve Group",
            "Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-chemotherapy and CYP17i-naÃ¯ve Group",
            "Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-CYP17i Group",
            "Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Chemotherapy-naÃ¯ve and CYP17i-naÃ¯ve Group",
            "Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Post-chemotherapy and CYP17i-naive Group",
            "Phase 1 and 2: Participants With RECIST Responses in Soft Tissue in Post-CYP17i Group",
            "Phase 1 and 2: Participants With Stable Bone Disease in Chemotherapy-naÃ¯ve and CYP17i-naÃ¯ve Group",
            "Phase 1 and 2: Participants With Stable Bone Disease in Post-chemotherapy and CYP17i-naÃ¯ve Group",
            "Phase 1 and 2: Participants With Stable Bone Disease in Post-CYP17i Group",
            "Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of ODM-201 at Steady-state",
            "Phase 1: Maximum Plasma Concentration (Cmax) of ODM-201 at Steady-state",
            "Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of ODM-201 at Day 1",
            "Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of Major Metabolite ORM-15341 at Steady-state",
            "Phase 1: Maximum Plasma Concentration (Cmax) of Major Metabolite ORM-15341 at Steady-state",
            "Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of Major Metabolite ORM-15341 at Day 1"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Orion Corporation, Orion Pharma",
          "collaborator": "Endo Pharmaceuticals"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "136",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "3104001" },
        "start_date": "March 2011",
        "primary_completion_date": "July 2013",
        "completion_date": "July 2013",
        "study_first_posted": "March 17, 2011",
        "results_first_posted": "March 29, 2017",
        "last_update_posted": "March 29, 2017",
        "locations": {
          "location": [
            "The Urology Center of Colorado, Wheat Ridge, Colorado, United States",
            "Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States",
            "Urology Health Team PLLC, Ocala, Florida, United States",
            "Chesapeake Urology Research Associates, Baltimore, Maryland, United States",
            "Delaware Valley urology, LLC, Voorhees, New Jersey, United States",
            "Brooklyn Urology Research Group, Brooklyn, New York, United States",
            "Cleveland Clinic, Cleveland, Ohio, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Klinika onkologie a radioterapie LFUK a FN, Hradec KrÃ¡lovÃ©, Czech Republic",
            "Fakultni Nemonicnice Olomouc, Olomouc, Czech Republic",
            "Oddeleni Radiacni a Klinicke Onkologie Nemocnice Znojmo, Znojmo, Czech Republic",
            "East-Tallinn Central Hospital, Talinn, Estonia",
            "Helsinki University Central Hospital, Helsinki, Finland",
            "Kuopio University Hospital, Kuopio, Finland",
            "Oulu University Hospital, Oulu, Finland",
            "Tampere University Hospital, Tampere, Finland",
            "Turku University Hospital, Turku, Finland",
            "Saint Louis Hospital, Paris, France",
            "Institut Gustave Roussy, Villejuif, France",
            "Queen Elizabeth Hospital, Birmingham, United Kingdom",
            "Velindre Cancer Centre, Cardiff, United Kingdom",
            "Christie Hospital, Manchester, United Kingdom",
            "Churchill Hospital, Oxford, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01317641"
      },
      {
        "-rank": "200",
        "nct_id": "NCT00946920",
        "title": "A Trial of Degarelix in Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Goserelin acetate"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Cumulative Probability of Testosterone at Castrate Level (â‰¤0.5 ng/mL) With Degarelix",
            "Difference in Cumulative Probability of Testosterone at Castrate Level (â‰¤0.5 ng/mL) Between Degarelix and Goserelin",
            "Serum Levels of Testosterone Over Time",
            "Percent Change in Serum Levels of Prostate-specific Antigen (PSA) Over Time",
            "Change in Health-related Quality of Life (HRQoL), as Measured by Short Form-36 (SF-36) Score at Month 10 and Month 13 Compared to Baseline",
            "Change in International Prostate Symptom Score (IPSS) Score at Months 1, 4, 7, and 13 Compared to Baseline"
          ]
        },
        "sponsors": { "lead_sponsor": "Ferring Pharmaceuticals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "859",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "FE200486 CS35",
            "2008-005276-27"
          ]
        },
        "start_date": "June 2009",
        "primary_completion_date": "March 2011",
        "completion_date": "March 2011",
        "study_first_posted": "July 27, 2009",
        "results_first_posted": "June 2, 2014",
        "last_update_posted": "June 2, 2014",
        "locations": {
          "location": [
            "Urology Centers Of Alabama, Homewood, Alabama, United States",
            "Arkansas Urology, Little Rock, Arkansas, United States",
            "Urology Associates of Central CA, Fresno, California, United States",
            "Medresearch, La Mesa, California, United States",
            "South Orange County Medical Research Center, Laguna Hills, California, United States",
            "Atlantic Urology Medical Group, Long Beach, California, United States",
            "Anschutz Cancer Pavillion, Aurora, Colorado, United States",
            "The Urology Center of Colorado, Denver, Colorado, United States",
            "Urological Associates of Bridgeport, P.C., Trumbull, Connecticut, United States",
            "Urology Associates of Dover, PA, Dover, Delaware, United States",
            "Walter Reed Army Medical Center, Washington, District of Columbia, United States",
            "South Florida Medical Research, Aventura, Florida, United States",
            "Florida Foundation for Healthcare Research, Ocala, Florida, United States",
            "Georgis Patsias, MD, PA, Wellington, Florida, United States",
            "Palm Beach Urology Associates, PA, Wellington, Florida, United States",
            "Indiana University Department of Urology, Indianapolis, Indiana, United States",
            "Kansas City Urology Care, PA, Overland Park, Kansas, United States",
            "Urological Associates of Englewood, Englewood, New Jersey, United States",
            "Hamilton Urology PA, Hamilton, New Jersey, United States",
            "Lawrenceville Urology, Lawrenceville, New Jersey, United States",
            "Urology Group of New Mexico, PC, Albuquerque, New Mexico, United States",
            "Capital Region Urological Surgeons and Research Associates, Albany, New York, United States",
            "Hudson Valley Urology P.C., Poughkeepsie, New York, United States",
            "Metrolina Urology Clinic, Charlotte, North Carolina, United States",
            "Northeast Urology Research, Concord, North Carolina, United States",
            "Duke University Medical Center, Durham, North Carolina, United States",
            "Alliance Urology Specialists, Greensboro, North Carolina, United States",
            "Urologic Consultants of SEPA, Bala Cynwyd, Pennsylvania, United States",
            "State College Urologic Association, State College, Pennsylvania, United States",
            "Grand Strand Urology, Myrtle Beach, South Carolina, United States",
            "Urology Clinics of North Texas, PA, Dallas, Texas, United States",
            "Urology San Antonio Research, San Antonio, Texas, United States",
            "Urology of Virginia, Norfolk, Virginia, United States",
            "Virginia Urology Center, Richmond, Virginia, United States",
            "Urology of Virginia, Virginia Beach, Virginia, United States",
            "Seattle Urology Research Center, Burien, Washington, United States",
            "Cliniques Universitaires Saint-Luc, Bruxelles, Belgium",
            "UZ Antwerpen, Edegem, Belgium",
            "UZ Gent, Gent, Belgium",
            "AZ Groeninge - Campus Sint-Maarten, Kortrijk, Belgium",
            "Southern Interior Medical Research Inc., Kelowna, British Columbia, Canada",
            "Dr. Cal Andreou Research, Surrey, British Columbia, Canada",
            "Can-Med Clinical Research Inc., Victoria, British Columbia, Canada",
            "Dr Gary Steinhoff Clinical Research, Victoria, British Columbia, Canada",
            "Bramalea Medical Centre, Brampton, Ontario, Canada",
            "Urology Associates / Urologic Medical Research, Kitchener, Ontario, Canada",
            "Mor Urology, Inc., Newmarket, Ontario, Canada",
            "Ivestigational site, Scarborough, Ontario, Canada",
            "Anthony Skehan Medicine Professionals Corporation, Thunder Bay, Ontario, Canada",
            "Bloor West Professional Center, Toronto, Ontario, Canada",
            "The Health Institute for Men, Toronto, Ontario, Canada",
            "Uro Laval, Laval, Quebec, Canada",
            "Notre Dame Hopital, Montreal, Canada",
            "Urocentrum Brno, Brno, Czech Republic",
            "Nemocnice Jindrichuv Hradec, a.s., Jindrichuv Hradec, Czech Republic",
            "Kromerizska nemocnice a.s., Kromeriz, Czech Republic",
            "Slezska nemocnice, Opava, Czech Republic",
            "Fakultni nemocnice v Motole, Praha 5, Prague, Czech Republic",
            "Fakultni Thomayerova nemocnice s poliklinikou, Praha 4, Prague, Czech Republic",
            "Vseobecna fakultni nemocnice v Praze, Praha 2, Prague, Czech Republic",
            "Krajska nemocnice T. Bati a.s., Zlin, Czech Republic",
            "Pohjois-Karjalan keskussairaala, Joensuu, Finland",
            "ODL Terveys Oy, Oulu, Finland",
            "Pietarsaaren sairaala/ Malmin terveydenhuoltoalue, Pietarsaari, Finland",
            "Tampereen yliopistollinen sairaala, Tampere, Finland",
            "Investigational site, Aachen, Germany",
            "Investigational site, Kirchheim, Germany",
            "Klinikum Mannheim UniversitÃ¤tsklinikum GmbH, Mannheim, Germany",
            "Urologische Studienpraxis, NÃ¼rtingen, Germany",
            "FÃ¶vÃ¡rosi Ã–nkormÃ¡nyzat Bajcsy-Zsilinszky KÃ³rhÃ¡z, Budapest, Hungary",
            "FÃ¶vÃ¡rosi Ã–nkormÃ¡nyzat uzsoki utcai KÃ³rhÃ¡z, Budapest, Hungary",
            "Semmelweis Egyetem, Budapest, Hungary",
            "DombÃ³vÃ¡ri Szent LukÃ¡cs EgÃ©szsÃ©gÃ¼gyi Kht., Dombovar, Hungary",
            "Borsod-AbaÃºj-ZemplÃ©n Megyei KÃ³rhÃ¡z Ã©s Egyetemi OktatÃ³ KÃ³rhÃ¡z, Miskolc, Hungary",
            "Miskolci Semmelweis IgnÃ¡c EgÃ©szsÃ©gÃ¼gyi KÃ¶zpont Ã©s Egyetemi OktatÃ³ KÃ³rhÃ¡z Nonprofit Kft, Miskolc, Hungary",
            "PÃ©csi TudomÃ¡nyegyetem, PÃ©cs, Hungary",
            "Szegedi TudomÃ¡nyegyetem Szent-GyÃ¶rgyi Albert Klinikai KÃ¶zpont, Szeged, Hungary",
            "JÃ¡vorszky Ã–dÃ¶n KÃ³rhÃ¡z, VÃ¡c, Hungary",
            "Hospital Aranda de la Parra , S.A. de C.V., Leon, GTO, Mexico",
            "Hospital Angeles Culiacan, Culiacan, Sinaloa, Mexico",
            "Hospital Christus Muguerza del Parque, Chihuahua, Mexico",
            "Consultorio de Especialidad en Urologia Privado, Durango, Durango, Mexico",
            "Centro Medico Dalinde, Mexico City, Mexico",
            "Hospital Angeles Lindavista, Mexico City, Mexico",
            "Operadora MSB, S.A. de C.V. (Medica Sur CIF-BIOTEC), Mexico City, Mexico",
            "Consultorio Medico, Zapopan, Jalisco, Mexico",
            "AMC, Amsterdam, Netherlands",
            "MC Haaglanden, Den Haag, Netherlands",
            "Catharina-ziekenhuis, Eindhoven, Netherlands",
            "Atrium MC, Heerlen, Netherlands",
            "SPZOZ Wojewodzki Szpital Zespolony im. J.Sniadeckiego, Bialystok, Poland",
            "Centrum Medyczne Medur Sp. z o.o., Bielsko-Biala, Poland",
            "Gabinet Lekarski, Krakow, Poland",
            "Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku, Slupsk, Poland",
            "LexMedica, Wroclaw, Poland",
            "Private Medical Center, Arad, Romania",
            "Brasov Emergency Clinical County Hospital, Brasov, Romania",
            "\"Fundeni\" Clinical Institute, Bucharest, Romania",
            "\"Sfantul Ioan\" Emergency Clinical Hospital, Bucharest, Romania",
            "Dinu Uromedica, Bucharest, Romania",
            "Prof. Dr. Th. Burghele Clinical Urology Hospital, Bucharest, Romania",
            "PROVITA 2000 Medical Center, Constanta, Romania",
            "\"Dr. C.I. Parhon\" Clinical Hospital, Lasi, Romania",
            "Vita Care Flav Medical Center, Pitesti, Romania",
            "Emergency County Clinical Hospital Sibiu, Sibiu, Romania",
            "City Clinical Hospital #60, Moscow, Russian Federation",
            "Moscow State University of Medicine and Dentistry, Moscow, Russian Federation",
            "\"Clinic Andros\" LLC, St. Petersburg, Russian Federation",
            "\"Orkli\" LLC, St. Petersburg, Russian Federation",
            "City Hospital # 26, St. Petersburg, Russian Federation",
            "City Hospital #15, St. Petersburg, Russian Federation",
            "St. Petersburg State Medical University n.a. I.P. Pavlov, St. Petersburg, Russian Federation",
            "St.Petersburg Multi-Field City Hospital #2, St. Petersburg, Russian Federation",
            "Regional Clinical Oncology Center, Vladimir, Russian Federation",
            "Municipal Institution \"Cherkasy Regional Oncology Dispensary\", Cherkassy, Ukraine",
            "Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine",
            "Donetsk Regional Clinical Territorial Medical Association, Donetsk, Ukraine",
            "Ivano-Frankivsk Regional Oncology Dispensary, Ivano-Frankivsk, Ukraine",
            "Regional Clinical Center of Urology and Nephrology n.a. V.I.Shapoval, Kharkiv, Ukraine",
            "Kyiv City Clinical Hospital #3, Kyiv, Ukraine",
            "Odesa Regional Clinical Hospital, Odesa, Ukraine",
            "Municipal Institution \"Zaporizhzhia Regional Clinical Hospital\", Zaporizhzhya, Ukraine",
            "Castle Hill Hospital, Cottingham, United Kingdom",
            "Ipswich Hospital, Ipswich, United Kingdom",
            "Royal Liverpool University Hospital, Liverpool, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00946920"
      },
      {
        "-rank": "201",
        "nct_id": "NCT02066961",
        "title": "A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer",
        "acronym": "ASPIRE-PCa",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Castration-resistant Prostate Cancer",
            "Metastatic Prostate Cancer"
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Patterns of disease management",
            "Clinical outcomes",
            "Factors influencing physician treatment decisions",
            "Documentation of healthcare resource utilization used to manage treatment-related complications"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Global Development, Inc.",
          "collaborator": "Astellas Pharma Inc"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "1533",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "ONC-MA-1001" },
        "start_date": "December 31, 2013",
        "primary_completion_date": "November 2019",
        "completion_date": "November 2019",
        "study_first_posted": "February 20, 2014",
        "last_update_posted": "August 21, 2019",
        "locations": {
          "location": [
            "Site, Algiers, Algeria",
            "Site, Algiers, Algeria",
            "Site, Blida, Algeria",
            "Site, Buenos Aires, Argentina",
            "Site, Cabal, Argentina",
            "Site, La Pampa, Argentina",
            "Site, Port Macquarie, New South Wales, Australia",
            "Site, Tweed Heads, New South Wales, Australia",
            "Site, Kurralta Park, South Australia, Australia",
            "Site, Parkville, Victoria, Australia",
            "Site, Richmond, Victoria, Australia",
            "Site, Wien, Austria",
            "Site, Belo Horizonte, MG, Brazil",
            "Site, IjuÃ­, RS, Brazil",
            "Site, Passo Fundo, RS, Brazil",
            "Site, Porto Alegre, RS, Brazil",
            "Site, SÃ£o Paulo, SP, Brazil",
            "Site, Caxias do Sul, Brazil",
            "Site, Santo AndrÃ©, Brazil",
            "Site, Granby, Quebec, Canada",
            "Site, Quebec, Canada",
            "Site, Bogota, DC, Colombia",
            "Site, BogotÃ¡, DC, Colombia",
            "Site, Cali, Colombia",
            "Site, Cairo, Egypt",
            "Site, Cairo, Egypt",
            "Site, Cairo, Egypt",
            "Site, BesanÃ§on, France",
            "Site, Lille, France",
            "Site, Nimes, France",
            "Site, Pierre Benite, France",
            "Site, Poitiers, France",
            "Site, Saint Mande, France",
            "Site, Suresnes, France",
            "Site, Berlin, Germany",
            "Site, Freiburg, Germany",
            "Site, Hamburg, Germany",
            "Site, Jena, Germany",
            "Site, NÃ¼rtingen, Germany",
            "Site, Rostock, Germany",
            "Site, Ulm, Germany",
            "Site, Jakarta, Indonesia",
            "Site, Beer Ya'akov, Zerifin, Israel",
            "Site, Haifa, Israel",
            "Site, Brescia, Italy",
            "Site, Cremona, Italy",
            "Site, Milano, Italy",
            "Site, Orbassano, Italy",
            "Site, Anyang, Korea, Republic of",
            "Site, Busan, Korea, Republic of",
            "Site, Busan, Korea, Republic of",
            "Site, Incheon, Korea, Republic of",
            "Site, Seoul, Korea, Republic of",
            "Site, Seoul, Korea, Republic of",
            "Site, Seoul, Korea, Republic of",
            "Site, Suwon, Korea, Republic of",
            "Site, Beirut, BA, Lebanon",
            "Site, Beirut, BA, Lebanon",
            "Site, Durango, Mexico",
            "Site, Amsterdam, Netherlands",
            "Site, Nijmegen, Netherlands",
            "Site, Hamilton, Waikato, New Zealand",
            "Site, Christchurch, New Zealand",
            "Site, Tauranga, New Zealand",
            "Site, Tauranga, New Zealand",
            "Site, Muscat, Oman",
            "Site, Miraflores, Lima, Peru",
            "Site, Lima, Peru",
            "Site, Lima, Peru",
            "Site, Makati, Philippines",
            "Site, Pasig, Philippines",
            "Site, San Juan, Philippines",
            "Site, Riyadh, Saudi Arabia",
            "Site, Singapore, Singapore",
            "Site, Singapore, Singapore",
            "Site, Singapore, Singapore",
            "Site, Singapore, Singapore",
            "Site, Vall d'Hebron 119-129, Barcelona, Spain",
            "Site, Madrid, Spain",
            "Site, Sabadell, Spain",
            "Site, Guishan Township, Taoyuan County, Taiwan",
            "Site, Kaohsiung, Taiwan",
            "Site, Kaohsiung, Taiwan",
            "Site, Taichung, Taiwan",
            "Site, Taipei, Taiwan",
            "Site, Taipei, Taiwan",
            "Site, Bangkok, Thailand",
            "Site, Phayathai, Thailand",
            "Site, Songkla, Thailand",
            "Site, Hull, United Kingdom",
            "Site, London, United Kingdom",
            "Site, Newcastle upon Tyne, United Kingdom",
            "Site, Sunderland, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02066961"
      },
      {
        "-rank": "202",
        "nct_id": "NCT02952534",
        "title": "A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency",
        "acronym": "TRITON2",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration Resistant Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Rucaparib"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Objective Response Rate (ORR)",
            "Prostate Specific Antigen (PSA) Response",
            "Duration of Response (DOR)",
            "Radiologic Progression-free Survival (rPFS)",
            "Overall Survival (OS)",
            "Clinical Benefit Rate (CBR), defined as the percentage of patients with a complete response (CR), partial response (PR) or stable disease (SD) according to modified RECIST 1.1 with no progression in bone per PCWG3 criteria",
            "Time to PSA Progression",
            "Trough plasma PK (Cmin) of rucaparib based on sparse sampling",
            "Safety and tolerability of rucaparib assessed by AEs reported; clinical laboratory investigations; Vital signs; 12-lead ECGs; Physical examinations; and ECOG performance status"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Clovis Oncology, Inc.",
          "collaborator": "Foundation Medicine"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "360",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CO-338-052" },
        "start_date": "February 15, 2017",
        "primary_completion_date": "October 2019",
        "completion_date": "April 2020",
        "study_first_posted": "November 2, 2016",
        "last_update_posted": "July 1, 2019",
        "locations": {
          "location": [
            "University of Alabama at Birmingham, Birmingham, Alabama, United States",
            "Mayo Clinc, Phoenix, Arizona, United States",
            "Alliance Research Centers, Laguna Hills, California, United States",
            "VA Greater Los Angeles Healthcare System, Los Angeles, California, United States",
            "University of Southern California, Los Angeles, California, United States",
            "Stanford University, Palo Alto, California, United States",
            "Sharp Memorial Hospital, San Diego, California, United States",
            "Pacific Hematology Oncology Associates, San Francisco, California, United States",
            "San Francisco VA Health Care System, San Francisco, California, United States",
            "UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States",
            "Redwood Regional Medical Group, Santa Rosa, California, United States",
            "Kaiser Permanente Medical Center (Vallejo), Vallejo, California, United States",
            "Rocky Mountain Cancer Centers, Aurora, Colorado, United States",
            "Yale School of Medicine, New Haven, Connecticut, United States",
            "4701 Ogletown Stanton Rd., Newark, Delaware, United States",
            "Georgetown University Medical Center, Washington, District of Columbia, United States",
            "Boca Raton Community Hospital, Inc., Boca Raton, Florida, United States",
            "Florida Cancer Specialists, Fort Myers, Florida, United States",
            "University of Florida Health Cancer Center, Orlando, Florida, United States",
            "Moffitt Cancer Center, Tampa, Florida, United States",
            "Atlanta Urological Group, Atlanta, Georgia, United States",
            "University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",
            "Ochsner Medical Center, New Orleans, Louisiana, United States",
            "University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States",
            "Henry Ford Hospital, Bethesda, Maryland, United States",
            "Massachusetts General Hospital, Boston, Massachusetts, United States",
            "VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States",
            "Henry Ford Hospital, Detroit, Michigan, United States",
            "Fairview Hospital, Edina, Minnesota, United States",
            "Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States",
            "Minnesota Veterans Research Institute, Minneapolis, Minnesota, United States",
            "HCA Midwest Division - Kansas City, Kansas City, Missouri, United States",
            "Alegent Health Bergan Mercy Hospital , GU Research Network, Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "Premier Urology Associates dba/AdvanceMed Research, Lawrenceville, New Jersey, United States",
            "Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",
            "Roswell Park, Buffalo, New York, United States",
            "NYU Perlmutter Cancer Center, New York, New York, United States",
            "Memorial Sloan Kettering CC, New York, New York, United States",
            "Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, United States",
            "University of Rochester, Rochester, New York, United States",
            "SUNY Upstate Medical University, Syracuse, New York, United States",
            "Carolina Urology Partners, Concord, North Carolina, United States",
            "The Urology Group, Cincinnati, Ohio, United States",
            "Clinical Research Solutions, Middleburg Heights, Ohio, United States",
            "VA Portland Health Care System, Portland, Oregon, United States",
            "SCRI - Tennessee Oncology, Nashville, Tennessee, United States",
            "UT Southwestern Medical Center, Dallas, Texas, United States",
            "UT Health Science Center, Houston, Texas, United States",
            "Texas Oncology - Tyler, Tyler, Texas, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "VA Puget Sound, Seattle, Washington, United States",
            "Northern Cancer Insitute, St. Leonards, Saint Leonards, New South Wales, Australia",
            "Royal Hobart Hospital, Hobart, Tasmania, Australia",
            "Peninsula & Southeast Oncology, Frankston, Victoria, Australia",
            "Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia",
            "Cabrini Hospital, Malvern, Victoria, Australia",
            "Southside Cancer Care Centre, Miranda, Australia",
            "Orange Health Services, Orange, Australia",
            "St John of God Hospital, Subiaco, Subiaco, Australia",
            "Riverina Cancer Care Centre, Wagga Wagga, Australia",
            "ZNA Middelheim, Antwerp, Belgium",
            "Universitair Ziekenhuis Gent, Gent, Belgium",
            "AZ Groeninge, Kortrijk, Belgium",
            "CHU Sart-Tilman, LiÃ¨ge, Belgium",
            "Equipe de Recherche Clinique, DÃ©partement d'Oncologie/HÃ©matologie, LiÃ¨ge, Belgium",
            "AZ DELTA, Roeselare, Belgium",
            "Juravinski Cancer Centre Hamilton Health Services, Hamilton, Ontario, Canada",
            "London Health Science Center - Victoria Hospital, London, Ontario, Canada",
            "The Ottawa Hospital, Ottawa, Ontario, Canada",
            "Princess Margaret Hospital, Toronto, Canada",
            "Copenhagen University Hospital, Copenhagen, Denmark",
            "Herlev Hospital, Herlev, Denmark",
            "Vejle Sygehus, Vejle, Denmark",
            "Centre FranÃ§ois Baclesse, Caen, France",
            "Centre Georges FranÃ§ois Leclerc, Dijon, France",
            "Clinique Victor Hugo Centre Jean Bernard, Le Mans, France",
            "HÃ´pital PrivÃ© La LouviÃ¨re, Lille, France",
            "Polyclinique de Gentilly (Centre D'Oncologie De Gentilly), Nancy, France",
            "Institut Curie, Paris, France",
            "HÃ´pital PrivÃ© des CÃ´tes d'Armor, PlÃ©rin, France",
            "CRLCC Eugene Marquis, Rennes, France",
            "Gemeinschaftspraxis fur Hamatologie & Onkologie, Augsburg, Germany",
            "Charite Universitatsmedizin Berlin, Berlin, Germany",
            "Universitatsklinikum Carl Gustav Carus, Dresden, Germany",
            "Universitatsklinikum Dusseldorf, Dusseldorf, Germany",
            "Urologische Gemeinschaftspraxis, Emmendingen, Germany",
            "Universitaetsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany",
            "Universitaetsklinikum Heidelberg, Heidelberg, Germany",
            "Universitatsklinikum Jena, Jena, Germany",
            "UniversitÃ¤tsklinik KÃ¶ln, KÃ¶ln, Germany",
            "UniversitÃ¤tsklinikum Schleswig-Holstein, LÃ¼beck, Germany",
            "Medizinischen FakultÃ¤t Mannheim der UniversitÃ¤t Heidelberg, Mannheim, Germany",
            "Studienpraxis Urologie, NÃ¼rtingen, Germany",
            "University of Tuebingen, Tuebingen, Germany",
            "Die Gesundhehitsunion DGU, Wuppertal, Germany",
            "Cork University Hospital, Cork, Ireland",
            "St. Vincent's University Hospital, Dublin, Ireland",
            "St James's Hospital, Dublin, Ireland",
            "Adelaide & Meath Hospital, Incorporating the National Children's Hospital, Dublin, Ireland",
            "Mater Misericordiae University Hospital, Dublin, Ireland",
            "Rambam Health Care Campus (RHCC), Rambam Medical Center, Haifa, Israel",
            "Hadassah University Hospital, Jerusalem, Israel",
            "Meir Medical Center, Kfar Saba, Israel",
            "Rabin Medical Center-Beilinson Campus, Petach Tikva, Israel",
            "Chaim Sheba Medical Center, Ramat Gan, Israel",
            "The Tel Aviv Sourasky Medical Center (Ichilov Hospital), Tel Aviv, Israel",
            "Ospedale San Donato, Azienda USLSUDEST, Arezzo, Italy",
            "Ospedale Santa Maria delle Croci, Faenza, Italy",
            "IRCCS Istituto Nazionale dei Tumori (INT), Milano, Italy",
            "IEO Instituto Europeo di Oncologia, Milano, Italy",
            "University of Modena and Reggio Emilia Medical Oncology, Modena, Italy",
            "Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy",
            "Azienda Opsedaliera S. Maria di Terni, Terni, Italy",
            "Santa Chiara Hospital, Dept Medical Oncology, Trento, Italy",
            "Hospital Universitari Germans Trias i Pujol, Badalona, Spain",
            "Hospital del Mar, Servicio de OncologÃ­a, Barcelona, Spain",
            "Hospital ClÃ­nic i Provincial de Barcelona-Oncology, Barcelona, Spain",
            "Instituto Catalan de Oncologia, Barcelona, Spain",
            "Hospital Universitari Germans Trias i Pujol, Barcelona, Spain",
            "Hospital General Universitario de Guadalajara, Guadalajara, Spain",
            "Hospital Universitario Lucus Augusti., Lugo, Spain",
            "MD Anderson Cancer Center - Madrid, Madrid, Spain",
            "Hospital Universitario RamÃ³n y Cajal, Madrid, Spain",
            "Hospital 12 de Octubre, Madrid, Spain",
            "Hospital Universitario La Paz, Madrid, Spain",
            "Hospital Puerta de Hierro-Majadahonda, Madrid, Spain",
            "Hospital Universitario Central de Asturias, Oviedo, Spain",
            "Corporacio Sanitaria Parc Tauli, Sabadell, Spain",
            "Marques de Valdecilla University Hospital (HUMV), Santander, Spain",
            "Hospital Universitario Virgen del RocÃ­o, Sevilla, Spain",
            "Instituto Valenciano de Oncologia IVO, Valencia, Spain",
            "Wexham Park Hospital, Slough, Berkshire, United Kingdom",
            "Mount Vernon Cancer Centre, Northwood, England, United Kingdom",
            "Royal Marsden Hospital, Sutton, Surrey, United Kingdom",
            "Oxford University Hospitals, Headington, United Kingdom",
            "Royal Liverpool Hospital, Liverpool, United Kingdom",
            "London Health Science Center - Victoria Hospital, London, United Kingdom",
            "Guy's Hospital, London, United Kingdom",
            "Sarah Cannon Research Institutute - UK, London, United Kingdom",
            "Southampton General Hospital, Southampton, United Kingdom",
            "Musgrove Park Hospital, Taunton, United Kingdom",
            "The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02952534"
      },
      {
        "-rank": "203",
        "nct_id": "NCT02975934",
        "title": "A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency",
        "acronym": "TRITON3",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration Resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Rucaparib"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate or Enzalutamide or Docetaxel"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Progression-free Survival (rPFS)",
            "Objective Response Rate (ORR)",
            "Duration of Response (DOR)",
            "Time to Prostate Specific Antigen (PSA) Progression",
            "PSA Response",
            "Change in Patient-reported Outcome (PRO)",
            "Clinical Benefit Rate (CBR), defined as the percentage of patients with a complete response (CR), partial response (PR), and stable disease (SD) according to modified RECIST Version 1.1 with no progression in bone per PCWG3 criteria",
            "Overall Survival",
            "Trough plasma PK (Cmin) of rucaparib based on sparse sampling",
            "Number of participants with Adverse Events (AEs) as a measure of safety and tolerability"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Clovis Oncology, Inc.",
          "collaborator": "Foundation Medicine"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "400",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CO-338-063" },
        "start_date": "June 13, 2017",
        "primary_completion_date": "February 2022",
        "completion_date": "April 2022",
        "study_first_posted": "November 29, 2016",
        "last_update_posted": "September 9, 2019",
        "locations": {
          "location": [
            "University of Alabama at Birmingham, Birmingham, Alabama, United States",
            "Mayo Clinic - Arizona, Phoenix, Arizona, United States",
            "Arizona Oncology Associates - USOR, Tucson, Arizona, United States",
            "University of Southern California, Beverly Hills, California, United States",
            "Alliance Research Centers, Laguna Hills, California, United States",
            "VA Greater Los Angeles Healthcare System, Los Angeles, California, United States",
            "San Bernardino Urological Associates, San Bernardino, California, United States",
            "Sharp Memorial Hospital, San Diego, California, United States",
            "Pacific Hematology Oncology Associates, San Francisco, California, United States",
            "San Francisco VA Health Care System, San Francisco, California, United States",
            "UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States",
            "St. Joseph Heritage Healthcare, Santa Rosa, California, United States",
            "Kaiser Permanente, Northern CA, Vallejo, California, United States",
            "Rocky Mountain Cancer Centers, Aurora, Colorado, United States",
            "Yale University School of Medicine, New Haven, Connecticut, United States",
            "Medical Oncology Hematology Consultants - USOR, Newark, Delaware, United States",
            "Boca Raton Community Hospital, Inc., Boca Raton, Florida, United States",
            "University of Florida Health Cancer Center, Orlando, Florida, United States",
            "Atlanta Urological Group, Atlanta, Georgia, United States",
            "Kaiser Permanente Medical Group, Honolulu, Hawaii, United States",
            "Ochsner Medical Center, New Orleans, Louisiana, United States",
            "University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States",
            "Walter Reed National Military Medical Center, Bethesda, Maryland, United States",
            "Maryland Oncology Hematology P.A., Columbia, Maryland, United States",
            "Massachusetts General Hospital, Boston, Massachusetts, United States",
            "VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States",
            "Henry Ford Hospital, Detroit, Michigan, United States",
            "Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States",
            "Minnesota Veterans Research Institute, Minneapolis, Minnesota, United States",
            "University of Minnesota, Minneapolis, Minnesota, United States",
            "Alegent Health Bergan Mercy Hospital , GU Research Network, Omaha, Nebraska, United States",
            "Nebraska Cancer Specialists, Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "Premier Urology Associates, Lawrenceville, New Jersey, United States",
            "Roswell Park, Buffalo, New York, United States",
            "NYU Perlmutter Cancer Center, New York, New York, United States",
            "Memorial Sloan Kettering CC, New York, New York, United States",
            "Weill Cornell Medical College, New York, New York, United States",
            "Premier MEdical Group of the Hudson Valley PC, Poughkeepsie, New York, United States",
            "University of Rochester, Rochester, New York, United States",
            "SUNY Upstate Medical University, Syracuse, New York, United States",
            "University of North Carolina Lineberger Cancer Center, Chapel Hill, North Carolina, United States",
            "Carolina Urology Partners, Concord, North Carolina, United States",
            "Durham VA Medical Center, Durham, North Carolina, United States",
            "The Urology Group, Cincinnati, Ohio, United States",
            "Clinical Research Solutions, Middleburg Heights, Ohio, United States",
            "VA Portland Health Care System, Portland, Oregon, United States",
            "Northwest Cancer Specialist DBA Compass Oncology, Portland, Oregon, United States",
            "Knight Cancer Institute, Portland, Oregon, United States",
            "Urology Associates Clinical Research, Nashville, Tennessee, United States",
            "Urology Clinics of North Texas, Dallas, Texas, United States",
            "UT Southwestern Medical Center, Dallas, Texas, United States",
            "UT Health Science Center, Houston, Texas, United States",
            "Texas Oncology Cancer Center-Round Rock, Round Rock, Texas, United States",
            "Urology of Virginia, Virginia Beach, Virginia, United States",
            "MultiCare Regional Cancer Center - Gig Harbor, Gig Harbor, Washington, United States",
            "VA Puget Sound HCS, Seattle, Washington, United States",
            "University of Washington Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",
            "Orange Health Service, Orange, New South Wales, Australia",
            "Northern Cancer Insitute, St. Leonards, Saint Leonards, New South Wales, Australia",
            "St John of God Hospital, Subiaco, Subiaco, Western Australia, Australia",
            "Peninsula & Southeast Oncology, Frankston, Australia",
            "Barwon Health, University Hospital Geelong, Geelong, Australia",
            "Royal Hobart Hospital, Hobart, Australia",
            "Riverina Cancer Care Centre, Wagga Wagga, Australia",
            "ZNA Middelheim, Antwerp, Belgium",
            "AZ Groeninge, Kortrijk, Belgium",
            "CHU Sart-Tilman, LiÃ¨ge, Belgium",
            "Clinique et MaternitÃ© Sainte-Elisabeth, Namur, Belgium",
            "Tom Baker Cancer Centre, Calgary, Alberta, Canada",
            "Cancer Care Manitoba, Winnipeg, Manitoba, Canada",
            "Centre Hospitalier Universitaire Dr-Georges-L.-Dumont, Moncton, New Brunswick, Canada",
            "London Health Sciences Centre, London, Ontario, Canada",
            "The Ottawa Hospital, Ottawa, Ontario, Canada",
            "Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Lakeridge Health Medical Specialty Medical Oncology, Oshawa, Canada",
            "Sunnybrook Odette Cancer Centre, Toronto, Canada",
            "Copenhagen University Hospital, Copenhagen, Denmark",
            "Herlev Hospital, Herlev, Denmark",
            "Vejle Sygehus, Vejle, Denmark",
            "Centre Georges FranÃ§ois Leclerc, Dijon, France",
            "Clinique Victor Hugo Centre Jean Bernard, Le Mans, France",
            "HÃ´pital PrivÃ© La LouviÃ¨re, Lille, France",
            "Centre LÃ©on BÃ©rard, Lyon, France",
            "Polyclinique de Gentilly (Centre D'Oncologie De Gentilly), Nancy, France",
            "Institut Curie, Paris, France",
            "Centre Armoricain de Radiotherapie, Imagerie medicale et Oncologie, CARIO, PlÃ©rin, France",
            "CRLCC Eugene Marquis, Rennes, France",
            "Institut Gustave-Roussy, Villejuif, France",
            "Gemeinschaftspraxis fÃ¼r HÃ¤matologie&Onkologie, Augsburg, Germany",
            "Charite - Universitaetsmedizin Berlin, Berlin, Germany",
            "University Hospital Carl Gustav Carus, Dresden, Germany",
            "Universitatsklinikum Dusseldorf, Dusseldorf, Germany",
            "Urologische Gemeinschaftspraxis, Emmendingen, Germany",
            "Universitaetsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany",
            "Universitatsklinikum Jena, Jena, Germany",
            "UniversitÃ¤tsklinikum KÃ¶ln, KÃ¶ln, Germany",
            "UniversitÃ¤tsklinikum Schleswig-Holstein, Lubeck, Germany",
            "Medizinischen FakultÃ¤t Mannheim der UniversitÃ¤t Heidelberg, Mannheim, Germany",
            "Studienpraxis Urologie, Nurtingen, Germany",
            "University of Tuebingen, Tuebingen, Germany",
            "Die GesundheitsUnion (DGU), Wuppertal, Germany",
            "Cork University Hospital, Cork, Ireland",
            "Adelaide & Meath Hospital, Incorporating the National Children's Hospital, Dublin, Ireland",
            "Mater Misericordiae University Hospital, Dublin, Ireland",
            "Mater Private Hospital (MPH), Dublin, Ireland",
            "St James's Hospital, Dublin, Ireland",
            "St. Vincent's University Hospital, Dublin, Ireland",
            "Rambam Health Care Campus (RHCC), Rambam Medical Center, Haifa, Israel",
            "Hadassah University Hospital, Jerusalem, Israel",
            "Meir Medical Center, Kfar Saba, Israel",
            "Rabin Medical Center-Beilinson Campus, Petach Tikva, Israel",
            "The Tel Aviv Sourasky Medical Center (Ichilov Hospital), Tel Aviv, Israel",
            "Chaim Sheba Medical Center, Tel Hashomer, Israel",
            "Ospedale San Donato, Azienda USLSUDEST, Arezzo, Italy",
            "Ospedale Santa Maria delle Croci, Faenza, Italy",
            "Romagnolo per lo Studio e la Cura dei Tumori IRST-IRCCS - Oncologia medica, Meldola, Italy",
            "IEO Instituto Europeo di Oncologia, Milano, Italy",
            "University of Modena and Reggio Emilia, Modena, Italy",
            "Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy",
            "Azienda Opsedaliera S. Maria di Terni, Terni, Italy",
            "Presidio Ospedaliero Santa Chiara di Trento, Trento, Italy",
            "Hospital Universitari Germans Trias i Pujol, Barcelona, Spain",
            "Hospital Universitario Lucus Augusti., Lugo, Spain",
            "MD Anderson Cancer Center - Madrid, Madrid, Spain",
            "Hospital Universitario RamÃ³n y Cajal, Madrid, Spain",
            "Hospital 12 de Octubre, Madrid, Spain",
            "Hospital Universitario La Paz, Madrid, Spain",
            "Hospital Clinico Universitario Virgen de la Victoria, MÃ¡laga, Spain",
            "Hospital Universitario Central de Asturias, Oviedo, Spain",
            "Corporacio Sanitaria Parc Tauli, Sabadell, Spain",
            "Marques de Valdecilla University Hospital (HUMV), Santander, Spain",
            "Hospital Universitario Virgen del RocÃ­o, Sevilla, Spain",
            "Instituto Valenciano de OncologÃ­a, Valencia, Spain",
            "Guy's and St Thomas' NHS Foundation Trust, London, England, United Kingdom",
            "Royal Marsden Hospital, London, England, United Kingdom",
            "Oxford Cancer Centre, Medical Oncology Unit, Oxford, England, United Kingdom",
            "Royal Preston Hospital, Preston, England, United Kingdom",
            "Wexham Park Hospital, Slough, England, United Kingdom",
            "Velindre Hospital, Cardiff, United Kingdom",
            "Royal Marsden Hospital, London, United Kingdom",
            "Musgrove Park Hospital, Taunton, United Kingdom",
            "The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02975934"
      },
      {
        "-rank": "204",
        "nct_id": "NCT00036556",
        "title": "Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Atrasentan"
          }
        },
        "outcome_measures": { "outcome_measure": "Time-to-disease progression will be determined by the time to onset of the earliest of one of the following events: New skeletal lesions, new metastatic extra-skeletal lesions, or an event due to metastatic prostate cancer." },
        "sponsors": { "lead_sponsor": "Abbott" },
        "gender": "Male",
        "min_age": "19 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "941",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "M00-244" },
        "start_date": "June 2001",
        "study_first_posted": "May 13, 2002",
        "last_update_posted": "August 15, 2007",
        "locations": {
          "location": [
            "Urology Centers Of Alabama, Homewood,, Alabama, United States",
            "Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States",
            "Advanced Clinical Trials, Tucson, Arizona, United States",
            "Arkansas Urologial Associates, PA, Little Rock, Arkansas, United States",
            "Robin V. Smith, MD, Chula Vista, California, United States",
            "Urology Associate Of Central California, Fresno,, California, United States",
            "South Valley Medical Plaza, Gilroy, California, United States",
            "San Diego Urology Center, La Mesa, California, United States",
            "South Orange County Medical Research Center, Laguna Hills, California, United States",
            "UCLA School of Medicine, Los Angeles, California, United States",
            "VA Palo Alto, Palo Alto, California, United States",
            "Hillcrest Urological Medical Group, Inc., San Diego, California, United States",
            "Urology Associates Of San Luis Obispo, San Luis Obispo,, California, United States",
            "Pacific Clinical Research, Santa Monica, California, United States",
            "Western Clinical Research, Inc., Torrance,, California, United States",
            "Urology Associate, Pc, Denver,, Colorado, United States",
            "South Fl Medical Research, Aventura, Florida, United States",
            "Clinical Physiology Associates, Fort Myers, Florida, United States",
            "Advanced Research Institute, New Port Richey, Florida, United States",
            "Dattoli Cancer Center, Sarasota,, Florida, United States",
            "Urology Treatment Center, Sarasota,, Florida, United States",
            "Southeastern Urological Center, P.A., Tallahassee, Florida, United States",
            "Peachtree Hematology/Oncology Consultants, Atlanta, Georgia, United States",
            "Emory Clinic, Atlanta, Georgia, United States",
            "Sandy Springs Urology, Atlanta, Georgia, United States",
            "Atlanta Va Medical Center, Decatur, Georgia, United States",
            "Dreyer Medical Clinic, Aurora, Illinois, United States",
            "Weiss Memorial Hospital, Chicago,, Illinois, United States",
            "Northwestern University Medical School, Chicago, Illinois, United States",
            "Progressive Care, S.C., Chicago, Illinois, United States",
            "Christopher Ryan, MD, Chicago, Illinois, United States",
            "Evanston Hospital Kellogg Cancer Center, Evanston, Illinois, United States",
            "Welborn Clinic, Evansville, Indiana, United States",
            "Welborn Clinic -East, Evansville, Indiana, United States",
            "Urologic Associates, Pc, Davenport, Iowa, United States",
            "Iowa Urology, Des Moines, Iowa, United States",
            "Kansas University Medical Center, Kansas City,, Kansas, United States",
            "Regional Urology, Shreveport, Louisiana, United States",
            "LSUHSC, Shreveport, Louisiana, United States",
            "Johns Hopkins Oncology Center, Baltimore, Maryland, United States",
            "Drs. Werner, Murdock, & Francis, Pa Urology Assoc., Greenbelt, Maryland, United States",
            "Mid Atlantic Clinical Research, Rockville, Maryland, United States",
            "Massachusetts General Hospital, Boston, Massachusetts, United States",
            "Michigan Medical Urology, Grand Rapids, Michigan, United States",
            "Michigan Institute Of Urology, Pc, St. Clair Shores, Michigan, United States",
            "Lakeside Urology, PC, St. Joseph, Michigan, United States",
            "Mayo Clinic, Rochester, Minnesota, United States",
            "The Medical Oncology Group, Gulfport,, Mississippi, United States",
            "Mississippi Center For Clinical Research, LLC, Jackson, Mississippi, United States",
            "St. Joseph Oncology, St. Joseph, Missouri, United States",
            "Washington University, St. Louis, Missouri, United States",
            "Billings Oncology Associates, Billings,, Montana, United States",
            "University of Nebraska Medical Center, Omaha,, Nebraska, United States",
            "Nevada Urology Associate, Reno, Nevada, United States",
            "UNM Medical Center, Albuquerque, New Mexico, United States",
            "Albany Medical Center South Clinical Campus, Albany, New York, United States",
            "HemOnCare, PC, Brooklyn, New York, United States",
            "Beth Israel Medical Center, New York, New York, United States",
            "NYU Medical Center, New York, New York, United States",
            "Nyack Hospital, Nyack, New York, United States",
            "The University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States",
            "Mckay Urology, Charlotte,, North Carolina, United States",
            "Urology Specialists Of The Carolinas, Charlotte,, North Carolina, United States",
            "Blumenthal Cancer Center, Charlotte, North Carolina, United States",
            "The Urology Center, Greensboro,, North Carolina, United States",
            "University Of Cincinnati Medical Center, Cincinnati,, Ohio, United States",
            "Urologic Specialists Of Oklahoma, Inc., Tulsa,, Oklahoma, United States",
            "Oregon Urology Specialists, Eugene, Oregon, United States",
            "Urologic Associates of Allentown, Allentown, Pennsylvania, United States",
            "Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",
            "Urological Associates Of Lancaster, Lancaster, Pennsylvania, United States",
            "Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States",
            "University Of Pittsburgh, Pittsburgh, Pennsylvania, United States",
            "Center for Urologic Care, West Reading,, Pennsylvania, United States",
            "Multimed Research, Providence,, Rhode Island, United States",
            "University of TN - Memphis, Memphis, Tennessee, United States",
            "Vanderbilt University Medical Center, Nashville,, Tennessee, United States",
            "Urology Associates, Nashville, Tennessee, United States",
            "Dept of Veteran's Affairs North Texas Healthcare System, Dallas, Texas, United States",
            "Ntouch Research Corporation, Dallas, Texas, United States",
            "The University Of TX SW Medical Center At Dallas, Dallas, Texas, United States",
            "Uthscsa, San Antonio, Texas, United States",
            "Scott & White Memorial Hospital, Temple,, Texas, United States",
            "Anthony Middleton, M.D., Salt Lake City,, Utah, United States",
            "Western Urological Clinic, Salt Lake City, Utah, United States",
            "University Of Vermont, Burlington,, Vermont, United States",
            "Virginia Urology Center, Richmond,, Virginia, United States",
            "Jeffrey Frankel, M.D., Seattle,, Washington, United States",
            "Seattle Urological Associates, Seattle, Washington, United States",
            "University Of Washington School Of Medicine, Seattle, Washington, United States",
            "Madigan Army Medical Center, Tacoma,, Washington, United States",
            "Midwest Research Specialists, LLC, Milwaukee, Wisconsin, United States",
            "Medical College of Wisconsin, Milwaukee, Wisconsin, United States",
            "Wyoming Research Foundation, Cheyenne, Wyoming, United States",
            "Prince Of Wales Hospital, Randwick, New South Wales, Australia",
            "Westmead Public Hospital, Westmead, New South Wales, Australia",
            "Royal Brisbane Hospital, Herston, Queensland, Australia",
            "Repatriation General Hospital, Daws Park, South Australia, Australia",
            "Peter Maccallum Cancer Institute, East Melbourne, Victoria, Australia",
            "Bayside Urology, Mentone, Victoria, Australia",
            "Royal Melbourne Hospital, Parkville, Victoria, Australia",
            "Princess Alexandra Hospital, Woolloongabba, Australia",
            "A. Ã–. Krankenhaus Mistelbach, Mistelbach, Austria",
            "Klinik fur Urologie der Universitat Wien, Wien, Austria",
            "A.Z. Middelheim, Antwerpen, Belgium",
            "A Z St Jan, Brugge, Belgium",
            "University Hospital Erasme, Bruxelles, Belgium",
            "Uz Gent, Gent, Belgium",
            "Private Practice Dr.Vekemans, Hasselt, Belgium",
            "C.H.U. Liege, Liege, Belgium",
            "St-Elisabeth Ziekenhuis, Turnhout, Belgium",
            "Tom Baker Cancer Center, Calgary,, Alberta, Canada",
            "Cross Cancer Institute, Edmonton,, Alberta, Canada",
            "Wilson Urology, Kelowna, British Columbia, Canada",
            "Dr. Cal Andreou, Surrey, British Columbia, Canada",
            "Vancouver Hospital & Health Sciences Centre, Vancouver, British Columbia, Canada",
            "Dr. P. J. Pommerville, Inc., Victoria, British Columbia, Canada",
            "Dr. Gary Steinhoff, Clinical Research, Victoria, British Columbia, Canada",
            "Abbott Clinic, Winnipeg, Manitoba, Canada",
            "Professional Corporation, Fredericton, New Brunswick, Canada",
            "Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada",
            "Valley Professional Centre, Kentville, Nova Scotia, Canada",
            "The Male Health Centres, Barrie, Ontario, Canada",
            "The Urology Resource Centre, Burlington, Ontario, Canada",
            "Hamilton & District Urology Association, Hamilton,, Ontario, Canada",
            "Kingston General Hospital, Kingston, Ontario, Canada",
            "Probidity Medical Research, Kitchener, Ontario, Canada",
            "London Health Sciences Centre, London, Ontario, Canada",
            "Quest Clinical Trials, Markham, Ontario, Canada",
            "Walk-In Clinic, North Bay, Ontario, Canada",
            "Jack Barkin, M.D., North York, Ontario, Canada",
            "The Male Health Centres, Oakville, Ontario, Canada",
            "Ottawa Hospital Civic Campus, Ottawa, Ontario, Canada",
            "Advanced Male Fertility Clinic, Scarborough,, Ontario, Canada",
            "Northeastern Ontario Regional Cancer Centre, Sudbury,, Ontario, Canada",
            "Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",
            "Princess Margaret Hospital, Toronto, Ontario, Canada",
            "Service Radio-Oncologie, Chus, Fleurimont,, Quebec, Canada",
            "Hopital Notre-Dame, Montreal, Quebec, Canada",
            "Royal Victoria Hospital, Montreal, Quebec, Canada",
            "Ultramed, Pointe Claire, Quebec, Canada",
            "Peter Lau, MD, Saskatoon,, Saskatchewan, Canada",
            "Chuq Pavillon Hotel-Dieu, Quebec, Canada",
            "HÃ´pital Cochin, Paris, Cedex 14, France",
            "Hopital Intercommunal, Creteil, Cedex, France",
            "HÃ´pital Salvator, Marseille, Cedex, France",
            "HÃ´pital Pasteur, Nice, Cedex, France",
            "HÃ´pital Saint Louis, Paris, Cedex, France",
            "Centre Hospitalier Rene Dubos, Pontoise, Cedex, France",
            "Hopital De Pontchaillou, Rennes, Cedex, France",
            "Hopital De Rangueil, Toulouse, Cedex, France",
            "HÃ´pital DÂ´Auxerre, Auxerre, France",
            "HÃ´pital Henri Mondor, Creteil, France",
            "Hopital Bichat Claude Bernard, Paris, France",
            "Allgemeines Krankenhaus Urologie, Celle, Germany",
            "UniversitÃ¤tsklinikum Urologie, Essen, Germany",
            "UniversitÃ¤tsklinkum, Freiburg, Germany",
            "UniversitÃ¤tsklinikum Hamburg-Eppendorf, Hamburg, Germany",
            "Allgemeines Krankenhaus Barmbek, Hamburg, Germany",
            "Klinik Und Poliklinik fÃ¼r Urologie und Kinder, Homburg / Saar, Germany",
            "UniversitÃ¤tsklinikum LÃ¼beck Urologie, LÃ¼beck, Germany",
            "UniversitÃ¤tsklinikum Mannheim, Mannheim, Germany",
            "Urologische Klinik Und Poliklinik Grosshadern, Munchen, Germany",
            "Klinikum Rechts Der Isar, Munchen, Germany",
            "Universitat Ulm, ULM, Germany",
            "Klinikum Wuppertal GmbH, Wuppertal, Germany",
            "'Alexandra' Hospital, Athens, Greece",
            "Pe.Pa.G.N.I Hospital, Heraklion, Greece",
            "G. Genimatas Hospital, Thessaloniki, Greece",
            "Tallaght Hospital, Dublin, Ireland",
            "St Vincent'S Hospital, Dublin, Ireland",
            "Mater Misericordiae Hospital, Dublin, Ireland",
            "Clinica Urologica I - UniversitÃ  di Bari, Bari, Italy",
            "Istituto Nazionale per la Ricerca sul Cancro -IST, Genoa, Italy",
            "Istituto Europeo di Oncologia, Milan, Italy",
            "Clinica Urologica - UniversitÃ  Di Milano, Milan, Italy",
            "Istituto di Urologia, Padova, Italy",
            "Policlinico G. B. Rossi, Verona, Italy",
            "Amc, Amsterdam, Netherlands",
            "Rijnstate Hospital, Arnhem, Netherlands",
            "Medisch Spectrun Twente, Enschede, Netherlands",
            "Atrium Heerlen, Heerlen, Netherlands",
            "University Hospital Rotterdam, Rotterdam, Netherlands",
            "St Franciscus Gasthuis, Rotterdam, Netherlands",
            "Canterbury Urology Research Trust, Christchurch, New Zealand",
            "Promed Urology Ltd., Tauranga, New Zealand",
            "Samodzielny Publiczny ZOZ, Bydgoszcz, Poland",
            "Katedra i Klinika Urologii - Akademia Medyczna w Gdansku, Gdansk, Poland",
            "Specjalistyczny Szpital Urologiczny, Katowice, Poland",
            "Szpital Kliniczny Dzieciatka Jezus, Warszawa, Poland",
            "Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland",
            "Akademia Medyczna we Wroclawiu, Wroclaw, Poland",
            "Mediclinic Hospital, Petermaritzburg, 3201, South Africa",
            "University Of Stellenbosch, Cape Town, South Africa",
            "University Of Natal - Nelson R Mandela School of Medicine, Durban, South Africa",
            "Kenridge St Joseph Wingl, Parktown, South Africa",
            "Medi-Clinic Hospital, Pietermaritzburg, South Africa",
            "Medical Centre, Pietermaritzburg, South Africa",
            "Pretoria Urology Hospital, Pretoria, South Africa",
            "Hospital de la Ribera, Alcira (Valencia), Spain",
            "Hospital Vall D'Hebron, Barcelona, Spain",
            "Hospital de Galdakao, Galdakao-Vizcaya, Spain",
            "Hospital Juan Canalejo, La Coruna, Spain",
            "Clinica Puerta De Hierro, Madrid, Spain",
            "Hospital 12 De Octubre, Madrid, Spain",
            "Hospital Carlos Haya, Malaga, Spain",
            "Hospital Marques De Valdecilla, Santander, Spain",
            "Instituto Valenciano De Oncologia, Valencia, Spain",
            "Sahlgrenska University Hospital, Gothenburg, Sweden",
            "Linkoping University Hospital, Linkoping, Sweden",
            "Lund University Hospital, Lund, Sweden",
            "Malmo University Hospital MAS, Malmo, Sweden",
            "Karolinska Hospital, Stockholm, Sweden",
            "Uppsala University Hospital, Uppsala, Sweden",
            "Royal Devon And Exeter Hospital, Exeter,, Devon, United Kingdom",
            "Lister Hospital, Stevenage, Hertfordshire, United Kingdom",
            "Northwick Park Hospital, Harrow, Middlesex, United Kingdom",
            "Western General Hospital, Edinburgh,, Scotland, United Kingdom",
            "Taunton And Somerset Hospital, Taunton, Somerset, United Kingdom",
            "The Institute Of Cancer Research - Royal Marsden Hospital, Sutton, Surrey, United Kingdom",
            "St Lukes Hospital, Bradford, West Yorkshire, United Kingdom",
            "Clatterbridge Centre For Oncology, Bebington, Wirral, United Kingdom",
            "Southmead Hospital, Bristol, United Kingdom",
            "Addenbrookes Hospital, Cambridge, United Kingdom",
            "St Richard'S Hospital, Chichester, United Kingdom",
            "Leighton Hospital, Crewe, United Kingdom",
            "Gartnavel General Hospital, Glasgow, United Kingdom",
            "Glasgow Royal Infirmary, Glasgow, United Kingdom",
            "St Batholomew'S Hospital, London, United Kingdom",
            "Royal Free Hospital, London, United Kingdom",
            "Clinical Research Centre - St Georges Hospital, London, United Kingdom",
            "Hope Hospital, Salford, United Kingdom",
            "Royal Hallamshire Hospital, Sheffield, United Kingdom",
            "Southampton General, Southampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00036556"
      },
      {
        "-rank": "205",
        "nct_id": "NCT01685268",
        "title": "A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "AT13387"
            },
            {
              "-type": "Drug",
              "#text": "abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Part A: Safety and tolerability of the combination of AT13387 and abiraterone and to select the most promising treatment regimen in CRPC patients who are no longer responding to treatment with abiraterone alone.",
            "Part B: Compare the antitumor activity (response rate per the Prostate Cancer Working Group 2 [PCWG2]) between single-agent AT13387 and combination of AT13387 plus abiraterone in patients who are no longer responding to treatment with abiraterone alone.",
            "Pharmacokinetics of combination treatment of AT13387 and abiraterone.",
            "Pharmacodynamics of combination treatment of AT13387 and abiraterone.",
            "Progression free survival",
            "Overall survival"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Astex Pharmaceuticals",
          "collaborator": "Astex Pharmaceuticals, Inc."
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "49",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "AT13387-04" },
        "start_date": "September 2012",
        "primary_completion_date": "July 2014",
        "completion_date": "December 2014",
        "study_first_posted": "September 14, 2012",
        "last_update_posted": "September 8, 2016",
        "locations": {
          "location": [
            "University of California, Los Angeles Institute of Urologic Oncology, Los Angeles, California, United States",
            "Stanford Cancer Center, Stanford, California, United States",
            "Holy Cross Hospital, Fort Lauderdale, Florida, United States",
            "Florida Cancer Specialists-Fort Myers, Fort Myers, Florida, United States",
            "Lakeland Regional Cancer Center, Lakeland, Florida, United States",
            "Southern Illinois University School of Medicine, Springfield, Illinois, United States",
            "University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States",
            "Center for Cancer & Blood Disorders, Bethesda, Maryland, United States",
            "Washington University School of Medicine, St. Louis, Missouri, United States",
            "University of Nebraska Medical Center, Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "Roswell Park Cancer Institute, Buffalo, New York, United States",
            "Clinical Research Alliance, Inc., Lake Success, New York, United States",
            "Columbia University Medical Center, New York, New York, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "SUNY Upstate Medical University, Syracuse, New York, United States",
            "Cleveland Clinic, Cleveland, Ohio, United States",
            "University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",
            "The West Clinic, Memphis, Tennessee, United States",
            "Northwest Medical Specialists, PLLC, Tacoma, Washington, United States",
            "Centre hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada",
            "Centro Integral Oncologico Clara Campal, Madrid, Spain",
            "Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom",
            "Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",
            "Velindre Cancer Center, Cardiff, United Kingdom",
            "University of Surrey, Guildford, United Kingdom",
            "Charing Cross Hospital, London, United Kingdom",
            "Royal Marsden Foundation Trust Instute of Cancer Researrch, London, United Kingdom",
            "The Christie Hospital NHS Trust, Manchester, United Kingdom",
            "Nottingham University Hospitals, Nottingham, United Kingdom",
            "University Hospital Southampton, Southampton, United Kingdom",
            "Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01685268"
      },
      {
        "-rank": "206",
        "nct_id": "NCT00090363",
        "title": "ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "ZD4054 15 mg"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "ZD4054 10 mg"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Time to Progression (TTP)",
            "Time to Death",
            "Change in Total Prostate Specific Antigen (PSA) Over Time",
            "Objective Response Rate (ORR)",
            "Change in Number of Bone Metastases Over Time"
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "447",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "D4320C00006",
            "Trial 6",
            "ZD4054"
          ]
        },
        "start_date": "July 2004",
        "primary_completion_date": "December 2008",
        "completion_date": "August 2011",
        "study_first_posted": "August 30, 2004",
        "results_first_posted": "September 3, 2012",
        "last_update_posted": "January 8, 2013",
        "locations": {
          "location": [
            "Research Site, Tucson, Arizona, United States",
            "Research Site, Los Angeles, California, United States",
            "Research Site, Gainsville, Florida, United States",
            "Research Site, Chicago, Illinois, United States",
            "Research Site, Baltimore, Maryland, United States",
            "Research Site, Cleveland, Ohio, United States",
            "Research Site, Simpsonville, South Carolina, United States",
            "Research Site, Wolloongabba, Queensland, Australia",
            "Research Site, Ashford, South Australia, Australia",
            "Research Site, Wodonga, Victoria, Australia",
            "Research Site, Nedlands, Australia",
            "Research Site, Brussels, Belgium",
            "Research Site, Gent, Belgium",
            "Research Site, Leuven, Belgium",
            "Research site, Vancouver, British Columbia, Canada",
            "Research site, London, Ontario, Canada",
            "Research site, Toronto, Ontario, Canada",
            "Research site, Montreal, Quebec, Canada",
            "Research site, Quebec, Canada",
            "Research Site, Arhus, Denmark",
            "Research Site, Herlev, Denmark",
            "Research Site, Helsinki, Finland",
            "Research Site, Joensuu, Finland",
            "Research Site, OYS, Finland",
            "Research Site, SeinÃ¤joki, Finland",
            "Research Site, Tampere, Finland",
            "Research Site, Lille, France",
            "Research Site, Montpellier, France",
            "Research Site, Paris, France",
            "Research site, Pontoise, France",
            "Research Site, Toulouse, France",
            "Research Site, Jakarta, Indonesia",
            "Research Site, Eindhoven, Netherlands",
            "Research Site, Groningen, Netherlands",
            "Research Site, Heerlen, Netherlands",
            "Research Site, Leiden, Netherlands",
            "Research Site, Rotterdam, Netherlands",
            "Research Site, Utrecht, Netherlands",
            "Research Site, Bergen, Norway",
            "Research Site, Fredrikstad, Norway",
            "Research Site, Moelv, Norway",
            "Research Site, Oslo, Norway",
            "Research Site, Tonsberg, Norway",
            "Research Site, Tromso, Norway",
            "Research Site, Trondheim, Norway",
            "Research Site, Bydgoszcz, Poland",
            "Research Site, Katowice, Poland",
            "Research Site, Warszawa, Poland",
            "Research Site, Goteborg, Sweden",
            "Research Site, Malmo, Sweden",
            "Research Site, Stockholm, Sweden",
            "Research Site, Geneve, Switzerland",
            "Research Site, Locarno, Switzerland",
            "Research Site, Birmingham, United Kingdom",
            "Research Site, Leeds, United Kingdom",
            "Research Site, London, United Kingdom",
            "Research Site, Maidstone, United Kingdom",
            "Research Site, Manchester, United Kingdom",
            "Research Site, Newcastle, United Kingdom",
            "Research Site, York, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00090363"
      },
      {
        "-rank": "207",
        "nct_id": "NCT01824342",
        "title": "Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Castrate-resistant Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Biological",
            "#text": "Denosumab"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With Treatment-emergent Adverse Events (AEs) and Deaths",
            "Percent Change From Baseline in Laboratory Values",
            "Number of Participants With Anti-denosumab Neutralizing Antibody Formation",
            "Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)"
          ]
        },
        "sponsors": { "lead_sponsor": "Amgen" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "18",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "20080585",
            "2010-021846-23"
          ]
        },
        "start_date": "January 2011",
        "primary_completion_date": "February 2014",
        "completion_date": "February 2014",
        "study_first_posted": "April 4, 2013",
        "results_first_posted": "March 5, 2015",
        "last_update_posted": "March 5, 2015",
        "locations": {
          "location": [
            "Research Site, Hradec Kralove, Czech Republic",
            "Research Site, Pelhrimov, Czech Republic",
            "Research Site, Praha 2, Czech Republic",
            "Research Site, Praha 6, Czech Republic",
            "Research Site, Tabor, Czech Republic",
            "Research Site, Newcastle, United Kingdom",
            "Research Site, Northwood, United Kingdom",
            "Research Site, Sheffield, United Kingdom",
            "Research Site, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01824342"
      },
      {
        "-rank": "208",
        "nct_id": "NCT00975429",
        "title": "Study Using WST11 in Patients With Localized Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "WST11"
            },
            {
              "-type": "Drug",
              "#text": "WST11"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Negative biopsy in the treated lobes",
            "Serum PSA levels and PSA changes after treatment compared to baseline.",
            "Volume of hypoperfusion area shown by dynamic gadolinium MRI.",
            "Adverse events, ECG (12-lead),vital signs,clinical laboratory evaluations, physical examination.",
            "Quality of life IPSS; IIEF",
            "Optimisation of the procedure"
          ]
        },
        "sponsors": { "lead_sponsor": "Steba Biotech S.A." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "86",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CLIN902 PCM203" },
        "start_date": "September 2009",
        "primary_completion_date": "December 2011",
        "completion_date": "August 2012",
        "study_first_posted": "September 11, 2009",
        "last_update_posted": "April 28, 2015",
        "locations": {
          "location": [
            "Centre Hospitalier Universitaire (CHU), Angers, France",
            "HÃ´pital Claude Huriez, Lille, France",
            "Institut Mutualiste Montsouris(IMM), Paris, France",
            "Catharina Ziekenhuis, Eindhoven, Netherlands",
            "Frimley Park Hospital NHS Trust, Frimley, United Kingdom",
            "Kings College Hospital (KCH), London, United Kingdom",
            "University College London Hospital (UCLH), London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00975429"
      },
      {
        "-rank": "209",
        "nct_id": "NCT02480010",
        "title": "A Study of Pertuzumab in Participants With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Pertuzumab"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of Participants With Confirmed, Objective Response, Non-Response or Progressive Disease by PSA Levels Within the First 24 Weeks of Treatment With Pertuzumab",
            "Time to Disease Progression",
            "Percentage of Participants With Objective Response (Complete Response [CR] or Partial Response [PR]) by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria",
            "Time to Response",
            "Duration of Response According to PSA Levels",
            "Duration of Response According to RECIST Criteria",
            "Percentage of Participants Without Progression",
            "Time to Prostate Cancer Pain Progression",
            "Overall Survival",
            "Time to Treatment Failure",
            "Change From Baseline in Bone Alkaline Phosphatase",
            "Change From Baseline in N-Telopeptide",
            "Area Under the Concentration Curve Extrapolated to Infinity (AUC0-Inf) of Pertuzumab",
            "AUC to Last Measurable Concentration (AUC0-last) of Pertuzumab",
            "Maximum Plasma Concentration of Pertuzumab",
            "Time to Maximum Plasma Concentration (Tmax) of Pertuzumab",
            "Terminal Elimination Half-Life (t1/2) of Pertuzumab",
            "Serum Clearance of Pertuzumab",
            "Volume of Distribution at Steady State of Pertuzumab",
            "Mean Residence Time (MRT) of Pertuzumab"
          ]
        },
        "sponsors": { "lead_sponsor": "Hoffmann-La Roche" },
        "gender": "Male",
        "min_age": "19 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "68",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "BO17004" },
        "start_date": "September 2003",
        "primary_completion_date": "September 2005",
        "completion_date": "September 2005",
        "study_first_posted": "June 24, 2015",
        "results_first_posted": "September 18, 2015",
        "last_update_posted": "September 18, 2015",
        "locations": {
          "location": [
            "Lyon, France",
            "Montpellier, France",
            "Berlin, Germany",
            "Parma, Italy",
            "Roma, Italy",
            "Rotterdam, Netherlands",
            "Barcelona, Spain",
            "Valencia, Spain",
            "Cardiff, United Kingdom",
            "Sutton, United Kingdom",
            "Weston Super Mare, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02480010"
      },
      {
        "-rank": "210",
        "nct_id": "NCT01076751",
        "title": "Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients",
        "acronym": "PORTREAT",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "outcome_measures": {
          "outcome_measure": [
            "Overall survival",
            "Sequence of treatment in second-line, third-line",
            "Characteristics and outcomes of patients who receive second-line taxane-based treatment compared to others",
            "Indicators of health care resource utilization",
            "Quality of life"
          ]
        },
        "sponsors": { "lead_sponsor": "Sanofi" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "82",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "DIREG_C_05073" },
        "start_date": "February 2010",
        "primary_completion_date": "October 2010",
        "completion_date": "October 2010",
        "study_first_posted": "February 26, 2010",
        "last_update_posted": "February 14, 2011",
        "locations": {
          "location": [
            "Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",
            "Sanofi-Aventis Administrative Office, Paris, France",
            "Sanofi-Aventis Administrative Office, Frankfurt, Germany",
            "Sanofi-Aventis Administrative Office, Barcelona, Spain",
            "Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01076751"
      },
      {
        "-rank": "211",
        "nct_id": "NCT01732549",
        "title": "A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Metastatic Castrate Resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Tasquinimod"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Time to Radiological Progression Free Survival [PFS]",
            "Overall Survival Based on Number of Subjects Who Died",
            "Time to Progression Free Survival [PFS] on Next-line Therapy (PFS 2)",
            "Symptomatic PFS Based on Number of Subjects Who Had Symptomatic Progression or Death",
            "Time to Further Anticancer Treatment for Prostate Cancer",
            "Time to Deterioration in Functional Assessment of Cancer Therapy - Prostate (FACT-P)",
            "Change From Baseline of EuroQol-5 Dimension QoL Instrument (EQ-5D) VAS Score",
            "Safety Profile of Tasquinimod"
          ]
        },
        "sponsors": { "lead_sponsor": "Ipsen" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "144",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "8-55-58102-002" },
        "start_date": "January 2013",
        "primary_completion_date": "February 2015",
        "completion_date": "May 2015",
        "study_first_posted": "November 26, 2012",
        "results_first_posted": "October 3, 2016",
        "last_update_posted": "January 15, 2019",
        "locations": {
          "location": [
            "AZ Maria Middelares, Gent, Belgium",
            "UZ Gent, Gent, Belgium",
            "Leuven, Belgium",
            "Roeselare, Belgium",
            "Praha, HradÄany, Czechia",
            "Praha, LibeÅˆ, Czechia",
            "Brno, Czechia",
            "Olomouc, Czechia",
            "Prague 2, Czechia",
            "Aalborg, Denmark",
            "Aarhus, Denmark",
            "Herlev, Denmark",
            "KÃ¸benhavn, Denmark",
            "Angers, France",
            "Bordeaux, France",
            "Clermont Ferrand, France",
            "Dijon, France",
            "Lille, France",
            "Besancon, Lyon, France",
            "Centre Leon Berard, Lyon, France",
            "Hopital Edouard Herriot, Lyon, France",
            "Paris, France",
            "St Herblain, France",
            "Toulouse, France",
            "Villejuif, France",
            "Aachen, Germany",
            "Essen, Germany",
            "MÃ¼nchen, Germany",
            "NÃ¼rtingen, Germany",
            "TÃ¼bingen, Germany",
            "Bajcsy-Zsilinszky KÃ³rhÃ¡z, Budapest, Hungary",
            "OrszÃ¡gos OnkolÃ³gia IntÃ©zet, Budapest, Hungary",
            "Uzsoki utcai KÃ³rhÃ¡z, Budapest, Hungary",
            "Genova, Italy",
            "Milano, Italy",
            "Modena, Italy",
            "Pavia, Italy",
            "Roma, Italy",
            "Rozzano, Italy",
            "Torino, Italy",
            "Kaunas, Lithuania",
            "Vilnius, Lithuania",
            "Gdansk, Poland",
            "Gdynia, Poland",
            "Olsztyn, Poland",
            "Urology and Urological Oncology Department and Clinic, Wroclaw, Poland",
            "WojewÃ³dzki Szpital Specjalistyczny we WrocÅ‚awiu, Wroclaw, Poland",
            "Hospital Clinic Vllarroel, Barcelona, Spain",
            "Hospital del Mar, Barcelona, Spain",
            "Hospital Valle de HebrÃ³n, Barcelona, Spain",
            "Elche, Spain",
            "Sabadell, Spain",
            "Valencia, Spain",
            "Leeds, United Kingdom",
            "Guy's & St Thomas NHS Foundation, London, United Kingdom",
            "The Royal Marsden NHS Trust, London, United Kingdom",
            "University College Hospitals London, London, United Kingdom",
            "Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01732549"
      },
      {
        "-rank": "212",
        "nct_id": "NCT02578940",
        "title": "Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer",
        "acronym": "FALCON",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Cancer of the Prostate" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "18F-Fluciclovine PET CT"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Impact on patient treatment /management",
            "Response rate to radical salvage therapy",
            "Diagnostic performance of the fluciclovine (18F) PET/CT scan",
            "Effect of PSA levels on detection of recurrent cancer by the fluciclovine (18F) PET/CT scan",
            "Assessment of safety and tolerability",
            "Comparison of detection rates for fluciclovine (18F) PET/CT and choline PET/CT (in the patient subset who receive choline as standard care)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Blue Earth Diagnostics",
          "collaborator": [
            "Innovate UK",
            "Syne Qua Non Limited",
            "IND 2 Results LLC"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "104",
        "funded_bys": {
          "funded_by": [
            "Industry",
            "Other"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "BED-004" },
        "start_date": "November 2015",
        "primary_completion_date": "May 17, 2017",
        "completion_date": "June 22, 2018",
        "study_first_posted": "October 19, 2015",
        "last_update_posted": "January 16, 2019",
        "locations": {
          "location": [
            "Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom",
            "Churchill Hospital, Oxford, Oxfordshire, United Kingdom",
            "Royal Marsden Hospital, Sutton, Surrey, United Kingdom",
            "St James Institute of Oncology, Leeds, Yorkshire, United Kingdom",
            "Greater Glasgow & Clyde NHS Trust, Glasgow, United Kingdom",
            "University College London Hospital, London, United Kingdom",
            "St Thomas' Hospital, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02578940"
      },
      {
        "-rank": "213",
        "nct_id": "NCT02044172",
        "title": "Prostate Testing for Cancer and Treatment",
        "acronym": "ProtecT",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Procedure",
              "#text": "Radical prostatectomy"
            },
            {
              "-type": "Radiation",
              "#text": "Conformal radiation therapy"
            },
            {
              "-type": "Other",
              "#text": "Active monitoring"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Disease specific mortality",
            "Overall survival",
            "Disease progression",
            "Treatment complications",
            "General health status",
            "Psychological state",
            "Symptoms",
            "Sexual function",
            "Resource use"
          ]
        },
        "sponsors": {
          "lead_sponsor": "University of Oxford",
          "collaborator": "University of Bristol"
        },
        "gender": "Male",
        "min_age": "50 Years",
        "max_age": "69 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "100000",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "HTA96/20/99",
            "20141297"
          ]
        },
        "start_date": "June 1, 2001",
        "primary_completion_date": "June 30, 2021",
        "completion_date": "June 30, 2021",
        "study_first_posted": "January 23, 2014",
        "last_update_posted": "January 25, 2018",
        "locations": {
          "location": [
            "Queen Elizabeth Hospital, Birmingham, United Kingdom",
            "Southmead Hospital, Bristol, United Kingdom",
            "Addenbrokes' Hospital, Cambridge, United Kingdom",
            "University Hospital of Wales, Cardiff, United Kingdom",
            "Western General Hospital, Edinburgh, United Kingdom",
            "Leicester General Hospital, Leicester, United Kingdom",
            "Freeman Hospital, Newcastle, United Kingdom",
            "Royal Hallamshire Hospital, Sheffield, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02044172"
      },
      {
        "-rank": "214",
        "nct_id": "NCT01946204",
        "title": "A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer",
        "acronym": "SPARTAN",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Apalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)",
            "Time to Metastasis (TTM)",
            "Progression-free Survival (PFS)",
            "Time to Symptomatic Progression",
            "Overall Survival",
            "Time to Initiation of Cytotoxic Chemotherapy"
          ]
        },
        "sponsors": { "lead_sponsor": "Aragon Pharmaceuticals, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1207",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR102931",
            "ARN-509-003",
            "2012-004322-24"
          ]
        },
        "start_date": "October 14, 2013",
        "primary_completion_date": "May 19, 2017",
        "completion_date": "November 29, 2022",
        "study_first_posted": "September 19, 2013",
        "results_first_posted": "June 19, 2018",
        "last_update_posted": "May 7, 2019",
        "locations": {
          "location": [
            "Birmingham, Alabama, United States",
            "Anchorage, Alaska, United States",
            "Chandler, Arizona, United States",
            "Tucson, Arizona, United States",
            "Duarte, California, United States",
            "Fullerton, California, United States",
            "Laguna Woods, California, United States",
            "Los Angeles, California, United States",
            "Orange, California, United States",
            "Roseville, California, United States",
            "Sacramento, California, United States",
            "San Bernardino, California, United States",
            "San Diego, California, United States",
            "San Francisco, California, United States",
            "Santa Monica, California, United States",
            "Sherman Oaks, California, United States",
            "Stanford, California, United States",
            "Tarzana, California, United States",
            "Torrance, California, United States",
            "Denver, Colorado, United States",
            "Englewood, Colorado, United States",
            "Glenwood Springs, Colorado, United States",
            "Grand Junction, Colorado, United States",
            "Washington, District of Columbia, United States",
            "Aventura, Florida, United States",
            "Boca Raton, Florida, United States",
            "Bradenton, Florida, United States",
            "Daytona Beach, Florida, United States",
            "Fort Myers, Florida, United States",
            "Hialeah, Florida, United States",
            "Jacksonville, Florida, United States",
            "Miami, Florida, United States",
            "New Port Richey, Florida, United States",
            "Orlando, Florida, United States",
            "Saint Petersburg, Florida, United States",
            "Sarasota, Florida, United States",
            "Wellington, Florida, United States",
            "Meridian, Idaho, United States",
            "Chicago, Illinois, United States",
            "Decatur, Illinois, United States",
            "Maywood, Illinois, United States",
            "Melrose Park, Illinois, United States",
            "Carmel, Indiana, United States",
            "Jeffersonville, Indiana, United States",
            "Muncie, Indiana, United States",
            "West Des Moines, Iowa, United States",
            "Westwood, Kansas, United States",
            "Wichita, Kansas, United States",
            "Metairie, Louisiana, United States",
            "New Orleans, Louisiana, United States",
            "Annapolis, Maryland, United States",
            "Baltimore, Maryland, United States",
            "Rockville, Maryland, United States",
            "Towson, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Detroit, Michigan, United States",
            "Lansing, Michigan, United States",
            "Minneapolis, Michigan, United States",
            "Royal Oak, Michigan, United States",
            "Duluth, Minnesota, United States",
            "Bay Saint Louis, Mississippi, United States",
            "Southaven, Mississippi, United States",
            "Kansas City, Missouri, United States",
            "Missoula, Montana, United States",
            "Omaha, Nebraska, United States",
            "Las Vegas, Nevada, United States",
            "Hooksett, New Hampshire, United States",
            "Hackensack, New Jersey, United States",
            "Lawrenceville, New Jersey, United States",
            "Morristown, New Jersey, United States",
            "Mount Laurel, New Jersey, United States",
            "New Brunswick, New Jersey, United States",
            "Voorhees, New Jersey, United States",
            "Albuquerque, New Mexico, United States",
            "Albany, New York, United States",
            "Bronx, New York, United States",
            "Mineola, New York, United States",
            "New York, New York, United States",
            "Oneida, New York, United States",
            "Poughkeepsie, New York, United States",
            "Syracuse, New York, United States",
            "Concord, North Carolina, United States",
            "Greensboro, North Carolina, United States",
            "Greenville, North Carolina, United States",
            "Salisbury, North Carolina, United States",
            "Winston-Salem, North Carolina, United States",
            "Cincinnati, Ohio, United States",
            "Cleveland, Ohio, United States",
            "Middleburg Heights, Ohio, United States",
            "Middletown, Ohio, United States",
            "Bend, Oregon, United States",
            "Portland, Oregon, United States",
            "Tualatin, Oregon, United States",
            "Bala-Cynwyd, Pennsylvania, United States",
            "Bryn Mawr, Pennsylvania, United States",
            "Lancaster, Pennsylvania, United States",
            "Philadelphia, Pennsylvania, United States",
            "Pittsburgh, Pennsylvania, United States",
            "Warwick, Rhode Island, United States",
            "Charleston, South Carolina, United States",
            "Greenville, South Carolina, United States",
            "Myrtle Beach, South Carolina, United States",
            "West Columbia, South Carolina, United States",
            "Memphis, Tennessee, United States",
            "Nashville, Tennessee, United States",
            "Abilene, Texas, United States",
            "Amarillo, Texas, United States",
            "Dallas, Texas, United States",
            "Fort Sam Houston, Texas, United States",
            "Houston, Texas, United States",
            "McAllen, Texas, United States",
            "San Antonio, Texas, United States",
            "Norfolk, Virginia, United States",
            "Richmond, Virginia, United States",
            "Virginia Beach, Virginia, United States",
            "Burien, Washington, United States",
            "Edmonds, Washington, United States",
            "Seattle, Washington, United States",
            "Tacoma, Washington, United States",
            "Green Bay, Wisconsin, United States",
            "Madison, Wisconsin, United States",
            "Milwaukee, Wisconsin, United States",
            "Adelaide, Australia",
            "Box Hill, Australia",
            "Camperdown, Australia",
            "Darlinghurst, Australia",
            "Geelong, Australia",
            "Gosford, Australia",
            "Hobart, Australia",
            "Kogarah, Australia",
            "Liverpool, Australia",
            "Melbourne, Australia",
            "Nedlands, Australia",
            "Parkville, Australia",
            "South Woodville, Australia",
            "Southport, Australia",
            "Sydney, Australia",
            "Tweed Heads, Australia",
            "Wollongong, Australia",
            "Graz, Austria",
            "Innsbruck, Austria",
            "Linz, Austria",
            "Wien, Austria",
            "Brussels, Belgium",
            "Brussel, Belgium",
            "Gent, Belgium",
            "Kortrijk, Belgium",
            "Leuven, Belgium",
            "Liege, Belgium",
            "Ottignies, Belgium",
            "Calgary, Alberta, Canada",
            "Edmonton, Alberta, Canada",
            "Abbotsford, British Columbia, Canada",
            "Vancouver, British Columbia, Canada",
            "Victoria, British Columbia, Canada",
            "Moncton, New Brunswick, Canada",
            "Saint John, New Brunswick, Canada",
            "Halifax, Nova Scotia, Canada",
            "Barrie, Ontario, Canada",
            "Brampton, Ontario, Canada",
            "Brantford, Ontario, Canada",
            "Hamilton, Ontario, Canada",
            "London, Ontario, Canada",
            "North York, Ontario, Canada",
            "Oakville, Ontario, Canada",
            "Ottawa, Ontario, Canada",
            "Owen Sound, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Gatineau, Quebec, Canada",
            "Granby, Quebec, Canada",
            "Greenfield Park, Quebec, Canada",
            "Laval, Quebec, Canada",
            "Montreal, Quebec, Canada",
            "Pointe-Claire, Quebec, Canada",
            "Sherbrooke, Quebec, Canada",
            "Kelowna, Canada",
            "Montrel, Canada",
            "Quebec, Canada",
            "Toronto, Canada",
            "Liberec, Czechia",
            "Olomouc, Czechia",
            "Opava, Czechia",
            "Plzen, Czechia",
            "Praha 2, Czechia",
            "Praha 4, Czechia",
            "Praha 5, Czechia",
            "Praha, Czechia",
            "Aalborg C, Denmark",
            "Copenhagen, Denmark",
            "Odense N/a, Denmark",
            "Roskilde, Denmark",
            "Helsinki, Finland",
            "Oulu, Finland",
            "SeinÃ¤joki, Finland",
            "Tampere, Finland",
            "Turku, Finland",
            "Angers Cedex 9, France",
            "Angers, France",
            "Besancon, France",
            "Bordeaux, France",
            "Caen CÃ©dex 05, France",
            "Clermont Ferrand, France",
            "Hyers, France",
            "La Roche sur Yon Cedex 9, France",
            "Le Mans, France",
            "Lille Cedex N/a, France",
            "Lyon, France",
            "Marseille cedex 5, France",
            "Marseille Cedex 9, France",
            "Nice Cedex 2, France",
            "NÃ®mes Cedex 9, France",
            "Paris 75, France",
            "Paris Cedex 15, France",
            "Paris, France",
            "Reims Cedex, France",
            "Rennes Cedex, France",
            "Rouen, France",
            "Saint Gregoire, France",
            "Saint Herblain, France",
            "Strasbourg, France",
            "Suresnes, France",
            "Tours, Cedex 9, France",
            "Vandoeuvre Les Nancy Cedex, France",
            "Aachen, Germany",
            "Bergisch Gladbach, Germany",
            "Berlin, Germany",
            "Braunschweig, Germany",
            "Duisburg, Germany",
            "Emmendingen, Germany",
            "Frankfurt / Main, Germany",
            "Greifswald, Germany",
            "GÃ¶ttingen, Germany",
            "Hamburg, Germany",
            "Hannover, Germany",
            "Heidelberg, Germany",
            "Heinsberg, Germany",
            "Homburg/Saar, Germany",
            "Jena, Germany",
            "Kiel, Germany",
            "Kirchheim unter Teck, Germany",
            "KÃ¶ln, Germany",
            "Magdeburg, Germany",
            "Mainz, Germany",
            "Mannheim, Germany",
            "Marburg, Germany",
            "Mettmann, Germany",
            "MÃ¼llheim, Germany",
            "MÃ¼nster, Germany",
            "Nuertingen, Germany",
            "Regensburg, Germany",
            "Rostock, Germany",
            "TÃ¼bingen, Germany",
            "Weiden, Germany",
            "Wilhelmshaven, Germany",
            "Wuppertan, Germany",
            "Zirndorf, Germany",
            "Budapest, Hungary",
            "Miskolc, Hungary",
            "NyÃ­regyhÃ¡, Hungary",
            "Sopron, Hungary",
            "Szentes, Hungary",
            "Haifa, Israel",
            "Jeruselem, Israel",
            "Kfar-Saba, Israel",
            "Petah-Tikva, Israel",
            "Ramat Gan, Israel",
            "Tel Aviv, Israel",
            "Zerifin, Israel",
            "Akita, Japan",
            "Fukuoka-shi, Japan",
            "Gifu, Japan",
            "Hakodate, Japan",
            "Hiroshima, Japan",
            "Hokkaido, Japan",
            "Kanazawa, Japan",
            "Kashiwa, Japan",
            "Kita-Gun, Japan",
            "Kobe, Japan",
            "Koshigaya, Japan",
            "Kumamoto, Japan",
            "Kurume, Japan",
            "Matsuyama, Japan",
            "Nagano, Japan",
            "Nagasaki, Japan",
            "Nagoya, Japan",
            "Niigata, Japan",
            "Osaka-Sayama, Japan",
            "Osaka, Japan",
            "Sagamihara, Japan",
            "Sakura, Japan",
            "Sapporo, Japan",
            "Shinjuku-Ku, Japan",
            "Tokushima, Japan",
            "Tokyo, Japan",
            "Ube, Japan",
            "Wakayama, Japan",
            "Yokohama, Japan",
            "Daegu, Korea, Republic of",
            "Gwangju-si, Korea, Republic of",
            "Pusan, Korea, Republic of",
            "Seongnam, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Alkmaar, Netherlands",
            "Eindhoven, Netherlands",
            "Hoofddorp, Netherlands",
            "Leidschendam, Netherlands",
            "Nijmegen, Netherlands",
            "Rotterdam, Netherlands",
            "Auckland, New Zealand",
            "Christchurch, New Zealand",
            "Hamilton, New Zealand",
            "Nelson City, New Zealand",
            "Tauranga, New Zealand",
            "Whangarei, New Zealand",
            "Nordbyhagen, Norway",
            "Bialystok, Poland",
            "Bydgoszcz, Poland",
            "Gdansk, Poland",
            "Kutno, Poland",
            "Lodz, Poland",
            "Poznan, Poland",
            "Szczecin, Poland",
            "Torun, Poland",
            "Warszawa, Poland",
            "Wroclaw, Poland",
            "Baia Mare, Romania",
            "Brasov, Romania",
            "Bucharest, Romania",
            "Cluj- Napoca, Romania",
            "Targu Mures, Romania",
            "Barnaul, Russian Federation",
            "Ekaterinburg, Russian Federation",
            "Ivanovo, Russian Federation",
            "Moscow, Russian Federation",
            "Obninsk, Kaluga Region, Russian Federation",
            "Omsk, Russian Federation",
            "Ryazan, Russian Federation",
            "Saint Petersburg, Russian Federation",
            "St. Petersburg, Russian Federation",
            "Ufa, Russian Federation",
            "Yaroslavl, Russian Federation",
            "Banska Bystrica, Slovakia",
            "Bratislava, Slovakia",
            "Martin, Slovakia",
            "Nitra, Slovakia",
            "TrenÄÃ­n, Slovakia",
            "Badalona, Spain",
            "Barcelona, Spain",
            "Castellon, Spain",
            "CoruÃ±a, Spain",
            "Girona, Spain",
            "Guadalajara, Spain",
            "Jerez de la Frontera, Spain",
            "Las Palmas De Gran Canaria, Spain",
            "Madrid, Spain",
            "Murcia, Spain",
            "MÃ¡laga, Spain",
            "Palma de Mallorca, Spain",
            "Pamplona, Spain",
            "Sabadell, Spain",
            "Salamanca, Spain",
            "San Sebastian de los Reyes, Spain",
            "Santander, Spain",
            "Sevilla N/a, Spain",
            "Sevilla, Spain",
            "Valencia, Spain",
            "Goteborg, Sweden",
            "Stockholm, Sweden",
            "Umea, Sweden",
            "Uppsala, Sweden",
            "Ã–rebro, Sweden",
            "Kaohsiung, Taiwan",
            "Taichung, Taiwan",
            "Taipei, Taiwan",
            "Taoyuan County, Taiwan",
            "Blackburn, United Kingdom",
            "Cambridge, United Kingdom",
            "Cardiff, United Kingdom",
            "Dundee, United Kingdom",
            "Glasgow, United Kingdom",
            "Guildford, United Kingdom",
            "Leeds, United Kingdom",
            "London, United Kingdom",
            "Maidstone, United Kingdom",
            "Nottingham, United Kingdom",
            "Plymouth, United Kingdom",
            "Southampton, United Kingdom",
            "Surrey, United Kingdom",
            "Swansea, United Kingdom",
            "Wirral, United Kingdom",
            "Wolverhampton, United Kingdom"
          ]
        },
        "study_documents": {
          "study_document": [
            {
              "label": "Study Protocol",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/04/NCT01946204/Prot_000.pdf"
            },
            {
              "label": "Statistical Analysis Plan",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/04/NCT01946204/SAP_001.pdf"
            }
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01946204"
      },
      {
        "-rank": "215",
        "nct_id": "NCT00707356",
        "title": "Study of WST11 in Patients With Localized Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "WST11"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Negative biopsy in the treated lobe",
            "Volume of the hypoperfusion area shown by dynamic gadolinium MRI . Serum PSA levels and PSA changes . Adverse Events, ECG (12-lead), vital signs, clinical laboratory evaluations, physical examination Quality of Life:â€¢IPSS â€¢IIEF"
          ]
        },
        "sponsors": { "lead_sponsor": "Steba Biotech S.A." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "42",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CLIN801 PCM201" },
        "start_date": "September 2008",
        "primary_completion_date": "January 2011",
        "completion_date": "July 2012",
        "study_first_posted": "June 30, 2008",
        "last_update_posted": "April 19, 2016",
        "locations": {
          "location": [
            "University Health Network-Princess Margaret Hospital, Toronto, Canada",
            "Centre Hospitalier Universitaire, Angers, France",
            "HÃ´pital Bocage-CHU, Dijon, France",
            "HÃ´pital Claude Huriez, Lille, France",
            "Institut Mutualiste Montsouris(IMM), Paris, France",
            "Frimley Park Hospital NHS Trust, Frimley, United Kingdom",
            "Kings College Hospital(KCH), London, United Kingdom",
            "Urology Directorate, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00707356"
      },
      {
        "-rank": "216",
        "nct_id": "NCT02279862",
        "title": "Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Ipilimumab"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Progression-free Survival (rPFS)",
            "Number of Participants Who Experienced Immune-related Adverse Events (irAEs)",
            "Overall Survival (OS)",
            "Prostate Specific Antigen Progression-free Survival (PSA PFS)",
            "Time to Pain Progression",
            "Prostate Specific Antigen Response Rate"
          ]
        },
        "sponsors": { "lead_sponsor": "Bristol-Myers Squibb" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "82",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CA184-437",
            "2014-002987-34"
          ]
        },
        "start_date": "December 2, 2014",
        "primary_completion_date": "December 15, 2016",
        "completion_date": "December 15, 2016",
        "study_first_posted": "October 31, 2014",
        "results_first_posted": "July 19, 2018",
        "last_update_posted": "August 27, 2019",
        "locations": {
          "location": [
            "San Francisco Oncology Associates, San Francisco, California, United States",
            "George Washington University Medical Center, Washington, District of Columbia, United States",
            "Baptist Cancer Institute, Jacksonville, Florida, United States",
            "Cancer Center Of Kansas, Wichita, Kansas, United States",
            "North Mississippi Med Center, Tupelo, Mississippi, United States",
            "Nebraska Cancer Specialists, Omaha, Nebraska, United States",
            "Providence Portland Medical Center, Portland, Oregon, United States",
            "Northwest Cancer Specialists, Pc, Tualatin, Oregon, United States",
            "University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania, United States",
            "Texas Oncology, Houston, Texas, United States",
            "Virginia Cancer Institute, Richmond, Virginia, United States",
            "Local Institution, St Leonards, New South Wales, Australia",
            "Local Institution, Wahroonga, New South Wales, Australia",
            "Local Institution, Parkville, Victoria, Australia",
            "Local Institution, Santiago, Metropolitana, Chile",
            "Local Institution, Recoleta, Santiago DE Chile, Chile",
            "Local Institution, Vina Del Mar, Valparaiso, Chile",
            "Local Institution, Clermont Ferrand cedex 01, France",
            "Local Institution, Marseille Cedex 9, France",
            "Local Institution, Poitiers, France",
            "Local Institution, Rennes Cedex, France",
            "Local Institution, Saint Herblain, France",
            "Local Institution, Villejuif, France",
            "Universitaetsklinikum Aachen, Aachen, Germany",
            "Uniklinik Heidelberg, Heidelberg, Germany",
            "Universitaetsklinikum Jena, Jena, Germany",
            "Universitaetsklinikum Magdeburg, Magdeburg, Germany",
            "Universitaetsklinikum Mannheim, Mannheim, Germany",
            "Local Institution, Marktredwitz, Germany",
            "Klinikum rechts der Isar der TU, Muenchen, Germany",
            "Urologische Praxis, Rostock, Germany",
            "Urologische Gemeinschaftspraxis Dres Stammel U. Garcia, Wesel, Germany",
            "Dgu Urologie, Wuppertal, Germany",
            "Local Institution, Milano, Italy",
            "Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy",
            "Local Institution, Amsterdam, Netherlands",
            "Local Institution, Barcelona, Spain",
            "Local Institution, Hospitalet de Llobregat - Barcelona, Spain",
            "Local Institution, Sevilla, Spain",
            "Local Institution, Valencia, Spain",
            "Local Institution, Glasgow, Lanarkshire, United Kingdom",
            "Local Institution, Nottingham, Nottinghamshire, United Kingdom",
            "Local Institution, Guildford, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02279862"
      },
      {
        "-rank": "217",
        "nct_id": "NCT00706628",
        "title": "A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "BIBF 1120"
            },
            {
              "-type": "Drug",
              "#text": "BIBW 2992"
            },
            {
              "-type": "Drug",
              "#text": "Sequential BIBF 1120 + BIBW 2992"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Progression Free Rate (PFR) at 12 Weeks",
            "Progression Free Rate at 24 and 48 Weeks",
            "Number of Patients Showing Prostate Serum Antigen (PSA) Response",
            "Duration of PSA Response",
            "Time to PSA Progression",
            "RECIST Tumour Progression Rate at 12, 24, 36, and 48 Weeks",
            "Overall Objective Response by RECIST Criteria (Version 1.0) (Complete Response [CR] or Partial Response [PR]) for Patients With Measurable Disease at 12, 24, 36 and 48 Weeks",
            "Duration of RECIST Response",
            "Time to Progression",
            "Overall Survival (Time to Death)",
            "Incidence and Worst Intensity of Adverse Events With Grading According CTCAE",
            "Changes in Safety Laboratory Parameters",
            "Trough Plasma Concentrations for BIBF 1120 and BIBW 2992 for the Monotherapy",
            "Trough Plasma Concentrations for BIBF 1120 and BIBW 2992 for the Combination Therapy"
          ]
        },
        "sponsors": { "lead_sponsor": "Boehringer Ingelheim" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "87",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Parallel Assignment",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "1239.3" },
        "start_date": "March 2006",
        "primary_completion_date": "December 2008",
        "study_first_posted": "June 27, 2008",
        "results_first_posted": "January 15, 2015",
        "last_update_posted": "January 15, 2015",
        "locations": {
          "location": [
            "1239.3.4402 Boehringer Ingelheim Investigational Site, Belfast, United Kingdom",
            "1239.3.4406 Boehringer Ingelheim Investigational Site, Bournemouth, United Kingdom",
            "1239.3.4408 Boehringer Ingelheim Investigational Site, Brighton, United Kingdom",
            "1239.3.4409 Boehringer Ingelheim Investigational Site, Cheltenham, United Kingdom",
            "1239.3.4405 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom",
            "1239.3.4403 Boehringer Ingelheim Investigational Site, Newcastle Upon Tyne, United Kingdom",
            "1239.3.4411 Boehringer Ingelheim Investigational Site, Southampton, United Kingdom",
            "1239.3.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom",
            "1239.3.4410 Boehringer Ingelheim Investigational Site, Truro, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00706628"
      },
      {
        "-rank": "218",
        "nct_id": "NCT00041301",
        "title": "Assessing Quality of Life of Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "QoL assessment"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "psychometric validity of the PR25 module",
            "debriefing questionnaire information"
          ]
        },
        "sponsors": { "lead_sponsor": "European Organisation for Research and Treatment of Cancer - EORTC" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "625",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Only",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": {
          "other_id": [
            "EORTC-15011-30011",
            "EORTC-15011",
            "EORTC-30011"
          ]
        },
        "start_date": "March 2002",
        "primary_completion_date": "December 2004",
        "completion_date": "November 2005",
        "study_first_posted": "January 27, 2003",
        "last_update_posted": "August 27, 2012",
        "locations": {
          "location": [
            "Sir Charles Gairdner Hospital - Perth, Perth, Western Australia, Australia",
            "Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels, Belgium",
            "Cliniques Universitaires Saint-Luc, Brussels, Belgium",
            "Universitair Ziekenhuis Gent, Ghent, Belgium",
            "Virga Jesse Hospital, Hasselt, Belgium",
            "Cazk Groeninghe - Campus Maria's Voorzienigheid, Kortrijk, Belgium",
            "U.Z. Gasthuisberg, Leuven, Belgium",
            "Rigshospitalet, Copenhagen, Denmark",
            "Hopital Jean Bernard, Poitiers, France",
            "Universitaetsklinikum Bonn, Bonn, Germany",
            "Universitaets-Krankenhaus Eppendorf, Hamburg, Germany",
            "Spedali Civili, Brescia, Italy",
            "Istituto Scientifico H. San Raffaele, Milano, Italy",
            "Azienda Ospedaliera Maggiore Della Carita, Novara, Italy",
            "Universita di Palermo, Palermo, Italy",
            "Azienda Sanitaria Ospedale San Giovanni Battista Molinette di Torino, Torino, Italy",
            "Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands",
            "Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands",
            "Academisch Medisch Centrum, Amsterdam, Netherlands",
            "Rijnstate Hospital, Arnhem, Netherlands",
            "Academisch Ziekenhuis Groningen, Groningen, Netherlands",
            "University Medical Center Nijmegen, Nijmegen, Netherlands",
            "University Medical Center Rotterdam at Erasmus Medical Center, Rotterdam, Netherlands",
            "Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam, Netherlands",
            "St. Elisabeth Ziekenhuis, Tilburg, Netherlands",
            "Norwegian Radium Hospital, Oslo, Norway",
            "Inselspital, Bern, Bucarest, Romania",
            "Institute of Oncology - Bucarest, Bucarest, Romania",
            "Marmara University Hospital, Istanbul, Turkey",
            "Dokuz Eylul University School of Medicine, Izmir, Turkey",
            "Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom",
            "Velindre Cancer Center at Velinde Hospital, Cardiff, Wales, United Kingdom",
            "University of Wales College of Medicine, Cardiff, Wales, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00041301"
      },
      {
        "-rank": "219",
        "nct_id": "NCT02531516",
        "title": "An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Apalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Bicalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Bicalutamide Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Apalutamide Placebo"
            },
            {
              "-type": "Drug",
              "#text": "GnRH (agonist)"
            },
            {
              "-type": "Radiation",
              "#text": "74-80 Grays (units of radiation)"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Metastasis-free survival",
            "Time to Local-regional Recurrence",
            "Time to Castration-resistant Prostate Cancer (CRPC)",
            "Time to Distant Metastasis",
            "Overall Survival (OS)"
          ]
        },
        "sponsors": { "lead_sponsor": "Aragon Pharmaceuticals, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1503",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR106935",
            "56021927PCR3003",
            "2015-003007-38"
          ]
        },
        "start_date": "November 19, 2015",
        "primary_completion_date": "December 30, 2022",
        "completion_date": "October 6, 2026",
        "study_first_posted": "August 24, 2015",
        "last_update_posted": "August 26, 2019",
        "locations": {
          "location": [
            "Homewood, Alabama, United States",
            "Chandler, Arizona, United States",
            "Scottsdale, Arizona, United States",
            "Tucson, Arizona, United States",
            "Bakersfield, California, United States",
            "Los Angeles, California, United States",
            "Orange, California, United States",
            "San Bernardino, California, United States",
            "San Diego, California, United States",
            "San Francisco, California, United States",
            "Aurora, Colorado, United States",
            "Denver, Colorado, United States",
            "Middlebury, Connecticut, United States",
            "Bradenton, Florida, United States",
            "Daytona Beach, Florida, United States",
            "Fort Myers, Florida, United States",
            "Hialeah, Florida, United States",
            "Lakewood Ranch, Florida, United States",
            "Naples, Florida, United States",
            "Plantation, Florida, United States",
            "Meridian, Idaho, United States",
            "Evergreen Park, Illinois, United States",
            "Harvey, Illinois, United States",
            "Jeffersonville, Indiana, United States",
            "Wichita, Kansas, United States",
            "Ashland, Kentucky, United States",
            "New Orleans, Louisiana, United States",
            "Shreveport, Louisiana, United States",
            "Scarborough, Maine, United States",
            "Baltimore, Maryland, United States",
            "Owings Mills, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Saint Louis, Missouri, United States",
            "Morristown, New Jersey, United States",
            "Albany, New York, United States",
            "Bronx, New York, United States",
            "Brooklyn, New York, United States",
            "New York, New York, United States",
            "Poughkeepsie, New York, United States",
            "Rochester, New York, United States",
            "Syracuse, New York, United States",
            "Cary, North Carolina, United States",
            "Raleigh, North Carolina, United States",
            "Portland, Oregon, United States",
            "Springfield, Oregon, United States",
            "Bala-Cynwyd, Pennsylvania, United States",
            "Bryn Mawr, Pennsylvania, United States",
            "Lancaster, Pennsylvania, United States",
            "Philadelphia, Pennsylvania, United States",
            "Warwick, Rhode Island, United States",
            "Charleston, South Carolina, United States",
            "Myrtle Beach, South Carolina, United States",
            "Nashville, Tennessee, United States",
            "Dallas, Texas, United States",
            "Houston, Texas, United States",
            "San Antonio, Texas, United States",
            "Fairfax, Virginia, United States",
            "Virginia Beach, Virginia, United States",
            "Burien, Washington, United States",
            "Spokane, Washington, United States",
            "Morgantown, West Virginia, United States",
            "C.a.b.a., Argentina",
            "Caba, Argentina",
            "Capital Federal, Argentina",
            "Ciudad Autonoma de Buenos Aires, Argentina",
            "Pergamino, Argentina",
            "Rosario, Argentina",
            "San Salvador de Jujuy, Argentina",
            "Aalst, Belgium",
            "Bonheiden, Belgium",
            "Brussel, Belgium",
            "Haine-St-Paul, Belgium",
            "Leuven, Belgium",
            "LiÃ¨ge, Belgium",
            "Namur, Belgium",
            "Roeselare, Belgium",
            "Sint-Niklaas, Belgium",
            "Turnhout, Belgium",
            "Wilrijk, Belgium",
            "Barretos, Brazil",
            "Belo Horizonte, Brazil",
            "Campinas, Brazil",
            "Curitiba, Brazil",
            "FlorianÃ³polis, Brazil",
            "GoiÃ¢nia, Brazil",
            "Ijui, Brazil",
            "Natal, Brazil",
            "Porto Alegre, Brazil",
            "Ribeirao Preto, Brazil",
            "Rio de Janeiro, Brazil",
            "Salvador, Brazil",
            "Santo AndrÃ©, Brazil",
            "Sao Jose do Rio Preto, Brazil",
            "Sao Paulo, Brazil",
            "Sorocaba, Brazil",
            "SÃ£o Paulo, Brazil",
            "Calgary, Alberta, Canada",
            "Surrey, British Columbia, Canada",
            "Vancouver, British Columbia, Canada",
            "Victoria, British Columbia, Canada",
            "London, Ontario, Canada",
            "Ottawa, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Gatineau, Quebec, Canada",
            "Laval, Quebec, Canada",
            "Montreal, Quebec, Canada",
            "MontrÃ©al, Quebec, Canada",
            "Sherbrooke, Quebec, Canada",
            "Quebec, Canada",
            "Beijing, China",
            "ChengDu, China",
            "ChongQing, China",
            "GuangZhou, China",
            "Hangzhou, China",
            "Nanchang, China",
            "NanJing, China",
            "Ningbo, China",
            "ShangHai, China",
            "Wuhan, China",
            "Xi'An, China",
            "Hradec KrÃ¡love, Czechia",
            "Liberec, Czechia",
            "NovÃ½ Jicin, Czechia",
            "Olomouc, Czechia",
            "Opava, Czechia",
            "Pardubice, Czechia",
            "Praha 10, Czechia",
            "Praha 2, Czechia",
            "Praha 4, Czechia",
            "Praha 5, Czechia",
            "Praha 8, Czechia",
            "Zlin, Czechia",
            "Amiens, France",
            "Angers Cedex 02, France",
            "Avignon Cedex 9, France",
            "Bayonne, France",
            "Besancon, France",
            "Bordeaux, France",
            "Brest, France",
            "Dijon, France",
            "HyÃ¨res, France",
            "La Tronche, France",
            "Le Mans, France",
            "Lille, France",
            "Marseille cedex 05, France",
            "Marseilli, France",
            "Montpellier, France",
            "Neuilly-sur-Seine, France",
            "Paris, France",
            "Ris Orangis, France",
            "Saint Herblain, France",
            "Saint-Brieuc, France",
            "Saint-MandÃ©, France",
            "Saint-Priest-en-Jarez, France",
            "Strasbourg, France",
            "Toulouse, France",
            "Tours, France",
            "Vandoeuvre-les-Nancy, France",
            "Villejuif Cedex, France",
            "Braunschweig, Germany",
            "Chemnitz, Germany",
            "Dessau, Germany",
            "Frankfurt, Germany",
            "Gronau, Germany",
            "Jena, Germany",
            "MÃ¼nster, Germany",
            "NÃ¼rtingen, Germany",
            "Ulm, Germany",
            "Weiden, Germany",
            "Beer Yaakov, Israel",
            "Beer-Sheva, Israel",
            "Haifa, Israel",
            "Jerusalem, Israel",
            "Kfar Saba, Israel",
            "Petach-Tikva, Israel",
            "Ramat-Gan, Israel",
            "Tel-Aviv, Israel",
            "Daegu, Korea, Republic of",
            "Hwasun-gun, Korea, Republic of",
            "Seongnam-si, Gyeonggi-do, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Suwon-si, Korea, Republic of",
            "Georgetown, Malaysia",
            "Kuala Lumpur, Malaysia",
            "Kuching, Malaysia",
            "Putrajaya, Malaysia",
            "Culiacan, Mexico",
            "Guadalajara, Mexico",
            "Leon, Mexico",
            "Mexico, Mexico",
            "Morelia, Mexico",
            "Zapopan, Mexico",
            "Alkmaar, Netherlands",
            "Amsterdam, Netherlands",
            "Den Haag, Netherlands",
            "Nijmegen, Netherlands",
            "Rotterdam, Netherlands",
            "Bialystok, Poland",
            "Bydgoszcz, Poland",
            "Gdynia, Poland",
            "Gliwice, Poland",
            "Kielce, Poland",
            "Lodz, Poland",
            "Olsztyn, Poland",
            "Poznan, Poland",
            "Walbrzych, Poland",
            "Bucuresti, Romania",
            "Cluj-Napoca, Romania",
            "Floresti, Romania",
            "Iasi, Romania",
            "Otopeni, Romania",
            "Ploiesti, Romania",
            "Sibiu, Romania",
            "Targu Mures, Romania",
            "Timisoara, Romania",
            "Barnaul, Russian Federation",
            "Ivanovo, Russian Federation",
            "Moscow, Russian Federation",
            "Nizhny Novgorod, Russian Federation",
            "Obninsk, Russian Federation",
            "Omsk, Russian Federation",
            "Pyatigorsk, Russian Federation",
            "Rostov-on-Don, Russian Federation",
            "Ryazan, Russian Federation",
            "Saint-Petersburg, Russian Federation",
            "Saransk, Russian Federation",
            "St Petersburg, Russian Federation",
            "Tambov, Russian Federation",
            "Tyumen, Russian Federation",
            "Ufa, Russian Federation",
            "Vologda, Russian Federation",
            "Barakaldo, Spain",
            "Barcelona, Spain",
            "Castellon, Spain",
            "Hospitalet de Llobregat, Spain",
            "Las Palmas de Gran Canaria, Spain",
            "Madrid, Spain",
            "MÃ¡laga, Spain",
            "Reus, Spain",
            "Santiago de Compostela, Spain",
            "Sevilla, Spain",
            "Stockholm, Sweden",
            "UmeÃ¥, Sweden",
            "Ã–rebro, Sweden",
            "Kaohsiung, Taiwan",
            "Taichung, Taiwan",
            "Tainan, Taiwan",
            "Taipei City, Taiwan",
            "Taipei, Taiwan",
            "Taoyuan, Taiwan",
            "Adana, Turkey",
            "Ankara, Turkey",
            "Edirne, Turkey",
            "Istanbul, Turkey",
            "Ä°zmir, Turkey",
            "Kayseri, Turkey",
            "Kocaeli, Turkey",
            "Dnipro, Ukraine",
            "Khakhiv, Ukraine",
            "Kyiv, Ukraine",
            "Lviv, Ukraine",
            "Aberdeen, United Kingdom",
            "Birmingham, United Kingdom",
            "Bristol, United Kingdom",
            "Derby, United Kingdom",
            "Glasgow, United Kingdom",
            "Oxford, United Kingdom",
            "Plymouth, United Kingdom",
            "Preston, United Kingdom",
            "Sheffield, United Kingdom",
            "Sutton, United Kingdom",
            "Wolverhampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02531516"
      },
      {
        "-rank": "220",
        "nct_id": "NCT02319837",
        "title": "Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Hormone Sensitive Prostate Cancer",
            "Prostate Cancer",
            "Cancer of the Prostate"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Leuprolide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Metastasis-free survival (MFS)",
            "Overall survival",
            "Time to castration resistance",
            "Composite of safety",
            "Time to prostate specific antigen (PSA) progression;",
            "Time to first use of new antineoplastic therapy",
            "Time to distant metastasis",
            "Proportion of patients per group who remain treatment free 2 years after suspension of study drug treatment at week 37 due to undetectable PSA",
            "Proportion of patients per group with undetectable PSA 2 years after suspension of study drug treatment at week 37 due to undetectable PSA",
            "Proportion of patients per group with undetectable PSA at 36 weeks on study drug",
            "Time to resumption of any hormonal therapy following suspension at week 37 due to undetectable PSA",
            "Time to symptomatic progression",
            "Time to first symptomatic skeletal event",
            "Time to clinically relevant pain",
            "Quality of life via the Functional Assessment of Cancer Therapy Prostate (FACT P) questionnaire,",
            "Quality of life via the European Quality of Life 5 Dimensions 5 Levels Health Questionnaire (EQ 5D 5L),",
            "Quality of life via the Quality of Life Questionnaire Prostate 25 (QLQ PR25) module"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Pfizer",
          "collaborator": [
            "Astellas Pharma Inc",
            "Medivation LLC, a wholly owned subsidiary of Pfizer Inc."
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1068",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "MDV3100-13",
            "C3431004",
            "2014-001634-28"
          ]
        },
        "start_date": "December 17, 2014",
        "primary_completion_date": "July 7, 2020",
        "completion_date": "July 31, 2023",
        "study_first_posted": "December 18, 2014",
        "last_update_posted": "July 31, 2019",
        "locations": {
          "location": [
            "University of Alabama at Birmingham, Birmingham, Alabama, United States",
            "University of Alabama at Birmingham, IDS Pharmacy, Birmingham, Alabama, United States",
            "University of Alabama at Birmingham, Birmingham, Alabama, United States",
            "Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States",
            "Urological Associates of Southern Arizona, PC, Tucson, Arizona, United States",
            "Tower Hematology Oncology Medical Group, Beverly Hills, California, United States",
            "Cedars-Senai OCC Pharmacy, Los Angeles, California, United States",
            "Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States",
            "University of California, Irvine Medical Center, Orange, California, United States",
            "Sutter Medical Group, Roseville, California, United States",
            "UC Davis Comprehensive Cancer Center, Sacramento, California, United States",
            "University of California Davis Medical Center, Sacramento, California, United States",
            "University of California, Davis, School of Medicine, Sacramento, California, United States",
            "The Urology Center of Colorado, Denver, Colorado, United States",
            "Foothills Urology, P.C., Golden, Colorado, United States",
            "Eastern Connecticut Hematology Oncology Associates, Norwich, Connecticut, United States",
            "Johns Hopkins Kimmel Cancer Center/ Sibley Infusion, Washington, District of Columbia, United States",
            "Sibley Memorial Hospital, Washington, District of Columbia, United States",
            "Lakeland Regional Health Hollis Cancer Center, Lakeland, Florida, United States",
            "Emory University Hospital, Atlanta, Georgia, United States",
            "Investigational Drug Service, Atlanta, Georgia, United States",
            "The Emory Clinic, Atlanta, Georgia, United States",
            "Winship Cancer Institute, Emory University, Atlanta, Georgia, United States",
            "Northwestern Medical Group, Chicago, Illinois, United States",
            "Northwestern Memorial Hospital, Chicago, Illinois, United States",
            "First Urology, PSC, Jeffersonville, Indiana, United States",
            "The University of Kansas Hospital, Kansas City, Kansas, United States",
            "Kansas City Urology Care, PA, Overland Park, Kansas, United States",
            "The University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States",
            "The University of Kansas Cancer Center, Investigational Drug Services, Westwood, Kansas, United States",
            "GU Research Network/Wichita Urology Group, Wichita, Kansas, United States",
            "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",
            "The Sidney Kimmel Cancer Center at Johns Hopkins Hospital- Oncology Investigational Drug Services, Baltimore, Maryland, United States",
            "John Hopkins University Hospital, Baltimore, Maryland, United States",
            "Chesapeake Urology Research Associates, Towson, Maryland, United States",
            "Comprehensive Urology - Macomb Office, Macomb, Michigan, United States",
            "Comprehensive Urology - Royal Oak (Stephenson) office, Royal Oak, Michigan, United States",
            "GU Research Network, LLC / Urology Cancer Center, Omaha, Nebraska, United States",
            "VA Lahontan Valley Outpatient Clinic, Fallon, Nevada, United States",
            "Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States",
            "Memorial Sloan Kettering Cancer Center Commack, Commack, New York, United States",
            "Memorial Sloan Kettering Cancer Center Westchester, Harrison, New York, United States",
            "Memorial Hospital, New York, New York, United States",
            "Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York, United States",
            "Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, United States",
            "Memorial Sloan Kettering Cancer Center Rockville Centre, Rockville Centre, New York, United States",
            "Associated Medical Professionals of New York, PLLC, Syracuse, New York, United States",
            "Memorial Sloan Kettering Cancer Center Nassau, Uniondale, New York, United States",
            "Duke Investigational Chemotherapy Services, Durham, North Carolina, United States",
            "Duke Nuclear Medicine, Durham, North Carolina, United States",
            "Duke University Medical Center, Durham, North Carolina, United States",
            "Alliance Urology Specialists, PA, Greensboro, North Carolina, United States",
            "TriState Urologic Services PSC Inc., dba The Urology Group, Cincinnati, Ohio, United States",
            "Mercy Health Jewish Hospital, Cincinnati, Ohio, United States",
            "Clinical Research Solutions, Middleburg Heights, Ohio, United States",
            "Southwest Urology, Middleburg Heights, Ohio, United States",
            "OU Medical Center Presbyterian Tower, Oklahoma City, Oklahoma, United States",
            "Stephenson Cancer Center, Oklahoma City, Oklahoma, United States",
            "Stephenson Cancer Center, Oklahoma City, Oklahoma, United States",
            "Oregon Urology Institute, Springfield, Oregon, United States",
            "Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States",
            "Lancaster Urology, Lancaster, Pennsylvania, United States",
            "Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia, Pennsylvania, United States",
            "Jefferson Medical Oncology, Philadelphia, Pennsylvania, United States",
            "Jefferson Urology Associates, Philadelphia, Pennsylvania, United States",
            "Thomas Jefferson University Hospital, Bodine Buiding, Philadelphia, Pennsylvania, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Vanderbilt Unversity Medical Center, Dept. of Urologic Surgery, Nashville, Tennessee, United States",
            "Vanderbilt Unversity Medical Center, The Urology Clinic, Nashville, Tennessee, United States",
            "Urology Clinics of North Texas, PLLC, Dallas, Texas, United States",
            "Houston Metro Urology, Houston, Texas, United States",
            "Urology San Antonio Research, San Antonio, Texas, United States",
            "Henrico Doctor's Hospital, Henrico, Virginia, United States",
            "Virginia Urology, Richmond, Virginia, United States",
            "Virginia Urology, Richmond, Virginia, United States",
            "Urology of Virginia, PLLC., Virginia Beach, Virginia, United States",
            "Genesis Cancer Care NSW, Gateshead, New South Wales, Australia",
            "Lismore Base hospital, Lismore, New South Wales, Australia",
            "Liverpool Hospital, Liverpool, New South Wales, Australia",
            "Macquarie University, North Ryde, New South Wales, Australia",
            "Genesis Cancer Care, North Sydney, New South Wales, Australia",
            "Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia",
            "Northern Cancer Institute, St Leonards, New South Wales, Australia",
            "The Tweed Hospital, Tweed Heads, New South Wales, Australia",
            "Australian Clinical Trials Pty Ltd, Wahroonga, New South Wales, Australia",
            "Sydney Adventist Hospital, Wahroonga, New South Wales, Australia",
            "Calvary Mater Newcastle, Waratah, New South Wales, Australia",
            "Westmead Hospital, Westmead, New South Wales, Australia",
            "Illawarra Cancer Care Centre, Wollongong, New South Wales, Australia",
            "Crown Princess Mary Cancer Centre, Westmead, NEW, Australia",
            "Icon Cancer Care Wesley, Auchenflower, Queensland, Australia",
            "Icon Cancer Care Chermside, Chermside, Queensland, Australia",
            "Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia",
            "Icon Cancer Foundation, South Brisbane, Queensland, Australia",
            "Icon Cancer Centre Southport, Southport, Queensland, Australia",
            "Royal Adelaide Hospital, Adelaide, South Australia, Australia",
            "Box Hill Hospital, Box Hill, Victoria, Australia",
            "Monash Medical Centre, Clayton, Victoria, Australia",
            "Austin Health, Heidelberg, Victoria, Australia",
            "Australian Urology Associates, Malvern, Victoria, Australia",
            "Sunshine Hospital, St Albans, Victoria, Australia",
            "Fiona Stanley Hospital, Murdoch, Western Australia, Australia",
            "Hospital Barmherzige Schwestern Linz, Linz, Upper Austria, Austria",
            "Hospital Barmherzige Schwestern Linz, Department of Urology, Linz, Austria",
            "Ordensklinikum Linz GmbH, Linz, Austria",
            "Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Austria, Salzburg, Austria",
            "Department of Radiology, University Hospital Salzburg, Austria, Salzburg, Austria",
            "Department of Urology,Paracelsus Medical University Salzburg, Salzburg, Austria",
            "AKH - Medizinische UniversitÃ¤t Wien, Vienna, Austria",
            "Department of Internal Medicine I, Medical university Vienna, Vienna, Austria",
            "Monte Tabor Centro Italo Brasileiro de Promocao Sanitaria - Hospital Sao Rafael, Salvador, BA, Brazil",
            "Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner, Curitiba, PR, Brazil",
            "Associacao Hospital de Caridade Ijui, Ijui, RS, Brazil",
            "CITO - Centro Integrado de Terapia Onco-Hematologica - Hospital da Cidade de Passo Fundo, Passo Fundo, RS, Brazil",
            "Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil",
            "CLINIONCO - Clinica de Oncologia de Porto Alegre Ltda., Porto Alegre, RS, Brazil",
            "Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil",
            "Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, SP, Brazil",
            "Hospital das Clinicas da Faculdade de Ciencias Medicas da UNICAMP, Campinas, SP, Brazil",
            "Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC, Santo Andre, SP, Brazil",
            "Prostate Cancer Centre, Calgary, Alberta, Canada",
            "Cross Cancer Institute, Edmonton, Alberta, Canada",
            "Vancouver Prostate Centre, Vancouver, British Columbia, Canada",
            "Manitoba Prostate Centre CancerCare Manitoba, Winnipeg, Manitoba, Canada",
            "Nova Scotia Heath Authority, Central, Halifax, Nova Scotia, Canada",
            "The Male/Female Health and Research Centre, Royal Court Medical Centre, Barrie, Ontario, Canada",
            "Kingston General Hospital, Kingston, Ontario, Canada",
            "Centre for Applied Urological Research, Kingston, Ontario, Canada",
            "Hotel Dieu Hospital, Kingston, Ontario, Canada",
            "Urology Associates/ Urologic Medical Research, Kitchener, Ontario, Canada",
            "London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada",
            "Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",
            "University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Urology South Shore Research, Greenfield Park, Quebec, Canada",
            "Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada",
            "McGill University Health Centre, Montreal, Quebec, Canada",
            "Ultra-Med Inc., Pointe-Claire, Quebec, Canada",
            "CHU de Quebec - L'Hotel-Dieu de Quebec, Quebec, Canada",
            "CHU de Quebec - L'Hotel-Dieu de Quebec - CRCEO, Quebec, Canada",
            "Aarhus University Hospital, Arhus N, Denmark",
            "Rigshospitalet - Copenhagen University Hospital, Copenhagen N, Denmark",
            "Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark",
            "Rigshospitalet, Dept of Radiology, Copenhagen, Denmark",
            "Odense University Hospital, Odense C, Denmark",
            "Vejle Sygehus, Vejle, Denmark",
            "Helsingin yliopistollinen keskussairaala, Helsinki, Finland",
            "Oulun yliopistollinen sairaala, Oulu, Finland",
            "Satakunnan Keskussairaala, Pori, Finland",
            "Seinaejoen Keskussairaala, Seinaejoki, Finland",
            "Tampereen yliopistollinen sairaala, Tampere, Finland",
            "ICO- site Paul Papin, Angers cedex 09, France",
            "Clinique Pasteur - Lanroze Service Pharmacie, Brest, France",
            "Clinique Pasteur - Lanroze, Brest, France",
            "CHD Vendee, La Roche-sur-Yon, France",
            "CHRU de Lille - Hopital Claude Huriez, Lille cedex, France",
            "ICM Val d'Aurelle, Montpellier cedex, France",
            "CHU de Nantes - Hotel Dieu, Nantes, France",
            "Hopital Saint-Louis, Paris cedex 10, France",
            "Institut Mutualiste Montsouris, Paris Cedex 14, France",
            "CHP Saint-Gregoire, Saint-Gregoire, France",
            "ICO - site Rene Gauducheau, Saint-Herblain cedex, France",
            "Hia Begin, Saint-Mande, France",
            "Hopital Foch, Suresnes, France",
            "Institut Gustave Roussy, Villejuif cedex, France",
            "Institut Gustave Roussy, Villejuif, France",
            "Farmacia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy",
            "Struttura Complessa di Oncologia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy",
            "UO di Radiologia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy",
            "UO di Oncologia,Ospedale Civile degli Infermi, Faenza RA, Italy",
            "UO di Radiologia, Ospedale Civile degli Infermi, Faenza RA, Italy",
            "UO di Oncologia, Ospedale Civile Umberto I, Lugo RA, Italy",
            "Uo di Radiologia, Ospedale Civile Umberto I, Lugo RA, Italy",
            "Laboratorio Farmaci Antiblastici, IRCCS Istituto, Meldola (FC), Italy",
            "U.O. Oncologia Medica, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy",
            "UO Radiologia,IRCCS Istituto Scientifico Romagnolo Per lO Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy",
            "Istituto Nazionale Tumori Fondazione G. Pascale/Oncologia Medica A, Napoli, Italy",
            "Farmacia Ospedaliera, Padiglione specialita, A.O.U. San Luigi Gonzaga, Orbassano (TO), Italy",
            "S.C.D.U. Oncologia Medica, A.O.U. San Luigi Gonzaga, Orbassano (TO), Italy",
            "S.C.D.U. Radiodiagnostica, A.O.U. San Luigi Gonzaga, Orbassano (TO), Italy",
            "Servizio di Farmacia, Ospedale Santa Maria delle Croci, Ravenna, Italy",
            "Servizio di Radiologia, Ospedale Santa Maria Delle Croci, Ravenna, Italy",
            "UO di Oncologia Medica, Ospedale Santa Maria delle Croci, Ravenna, Italy",
            "Farmacia Interna, Ospedale degli Infermi, Rimini, Italy",
            "UO Oncologia, Ospedale degli Infermi, Rimini, Italy",
            "U.O.C. Farmacia, Ospedale Forlanini, Roma, Italy",
            "Azienda Ospedaliera S, Camillo Forlanini, UOC per il governo clinico in Oncologia Medica,pad,Flajani, Roma, Italy",
            "Ospedale San Camillo Forlanini, Roma, Italy",
            "U.O. di Oncologia Medica, Ospedale Santa Chiara, Trento, Italy",
            "U.O. Farmacia, Ospedale Santa Chiara, Trento, Italy",
            "U.O. Medicina Nucleare, Ospedale Santa Chiara, Trento, Italy",
            "U.O. Radiologia, Ospedale Santa Chiara, Trento, Italy",
            "Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",
            "Pusan National University Yangsan Hospital, Yangsan-si, Gyeongsangnam-do, Korea, Republic of",
            "Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of",
            "Gachon University Gil Medical Center, Incheon, Korea, Republic of",
            "Severance Hospital. Yonsei University Health System, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",
            "Samsung Medical Center, Seoul, Korea, Republic of",
            "VU Medical Centrum, Department of Urology, Amsterdam, Netherlands",
            "Academisch Medisch Centrum, Amsterdam, Netherlands",
            "Gelderse Vallei Ziekenhuis, Ede, Netherlands",
            "Catharina Ziekenhuis Eindhoven, Eindhoven, Netherlands",
            "University Medical Centrum Groningen, Department Urologie, Groningen, Netherlands",
            "Medisch Centrum Leeuwarden, Leeuwarden, Netherlands",
            "Maastricht University Medical Center, Department of Urology, Maastricht, Netherlands",
            "Antonius Ziekenhuis, Sneek, Netherlands",
            "Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii, Gdansk, Poland",
            "Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o. o., Slupsk, Poland",
            "Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o., Oddzial Urologiczny, Slupsk, Poland",
            "Kujawsko-Pomorskie Centrum Urologicznw Sp z o.o, Torun, Poland",
            "Centrum Medyczne Melita Medical, Wroclaw, Poland",
            "EMC Instytut Medyczny Spolka Akcyjna, Wroclaw, Poland",
            "Fakultna nemocnica s poliklinikou F.D.Roosevelta, Banska Bystrica, Slovakia",
            "CUIMED, s.r.o., Urologicka ambulancia, Bratislava, Slovakia",
            "Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovakia",
            "Univerzitna nemocnica Martin, Martin, Slovakia",
            "UROEXAM, spol. s r.o., Nitra, Slovakia",
            "MILAB, Presov, Slovakia",
            "Fakultna nemocnica s poliklinikou Zilina, Zilina, Slovakia",
            "Dr. Maria Aranzazu Gonzalez del Alba, Plama De Mallorca, Baleares, Spain",
            "Dr. Montserrat Domenech Santasusana ALTHAIA, Xarxa assist. Univ. de Manresa - H. San Joan de Deu, Manresa, Barcelona, Spain",
            "Dr. Jesus Munoz, Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain",
            "Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, LA Coruna, Spain",
            "Hospital del Mar, Barcelona, Spain",
            "Dr. Antonio Alcaraz Asensio, Hospital Clinic i Provincial de Barcelona, Barcelona, Spain",
            "Hospital Universitario Puerta del Mar, Cadiz, Spain",
            "ICO Girona; Hospital Universitari de Girona Dr. Josep Trueta. Servicio de Oncologia, Girona, Spain",
            "Dr. Almudena Zapatero Laborda, Madrid, Spain",
            "Hospital General Universitario Gregorio Maranon. Servicio de Oncologia., Madrid, Spain",
            "Centro Oncologico MD Anderson International Espana, Madrid, Spain",
            "Dr. Francisco Javier Burgos Revilla, Madrid, Spain",
            "Hospital Universitario 12 de Octubre, Madrid, Spain",
            "Complejo Hospitalario Universitario de Orense, Orense, Spain",
            "Hospital Clinico Universitario de Salamanca, Salamanca, Spain",
            "Instituto Valenciano de Oncologia IVO, Valencia, Spain",
            "Sahlgrenska Universitetssjukhuset, Sahlgrenska, Goteborg, Sweden",
            "Skanes Universitetssjukhus, Malmo, Sweden",
            "Universitetssjukhuset Orebro, Orebro, Sweden",
            "Sodersjukhuset AB, Stockholm, Sweden",
            "Karolinska Universitetssjukhuset Solna, Stockholm, Sweden",
            "Norrlands Universitetssjukhus, Umea, Sweden",
            "Norrlands Universitetssjukhus, Umea, Sweden",
            "Akademiska Sjukhuset, Uppsala, Sweden",
            "Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan",
            "China Medical University Hospital, Taichung, Taiwan",
            "Taichung Veterans General Hospital, Taichung, Taiwan",
            "National Taiwan University Hospital, Taipei, Taiwan",
            "Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan",
            "Ross Hall Hospital, Glasgow, CITY OF Glasgow, United Kingdom",
            "Royal Devon & Exeter Hospital, Wonford, Exeter, Devon, United Kingdom",
            "Royal Free Hospital, London, Greater London, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",
            "Cancer Centre, Queen Elizabeth Hospital, Birmingham, WEST Midlands, United Kingdom",
            "University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom",
            "Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02319837"
      },
      {
        "-rank": "221",
        "nct_id": "NCT01057810",
        "title": "Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Ipilimumab"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival (OS) Time",
            "Progression-Free Survival (PFS) Time",
            "Time to Subsequent Non-hormonal Cytotoxic Therapy",
            "Time to Pain Progression",
            "Number of Participants Who Died or Had Adverse Events (AEs), Serious Adverse Events (SAEs), Immune-related AEs (irAEs), or Immune-mediated Adverse Reactions (imARs)",
            "Number of Treated Participants With Grade 3 or 4 Clinical Laboratory Abnormalities"
          ]
        },
        "sponsors": { "lead_sponsor": "Bristol-Myers Squibb" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "837",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CA184-095",
            "2009-016217-23"
          ]
        },
        "start_date": "July 2010",
        "primary_completion_date": "April 2015",
        "completion_date": "July 2015",
        "study_first_posted": "January 27, 2010",
        "results_first_posted": "August 18, 2016",
        "last_update_posted": "August 18, 2016",
        "locations": {
          "location": [
            "Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States",
            "Pinnacle Oncology Hematology, Scottsdale, Arizona, United States",
            "Arizona Cancer Center, Tucson, Arizona, United States",
            "Desert Hematology Oncology, Rancho Mirage, California, United States",
            "Southern California Permanente Medical Group, San Diego, California, United States",
            "Pacific Hematology Oncology Associates, San Francisco, California, United States",
            "George Washington University, Washington, District of Columbia, United States",
            "Lynn Cancer Institute Center For Hematology-Oncology, Boca Raton, Florida, United States",
            "Baptist Cancer Institute, Jacksonville, Florida, United States",
            "Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States",
            "Md Anderson Cancer Center Orlando, Orlando, Florida, United States",
            "Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States",
            "Northside Hospital, Atlanta, Georgia, United States",
            "Georgia Regents University, Augusta, Georgia, United States",
            "Gwinnett Hospital System Inc., Lawrenceville, Georgia, United States",
            "Straub Clinic And Hospital, Honolulu, Hawaii, United States",
            "University Of Chicago, Chicago, Illinois, United States",
            "Cancer Care Specialists Of Central Illinois, Decatur, Illinois, United States",
            "Goshen Center For Cancer Care, Goshen, Indiana, United States",
            "Hutchinson Clinic, Pa, Hutchinson, Kansas, United States",
            "Cancer Center Of Kansas, Wichita, Kansas, United States",
            "University Of Maryland, Baltimore, Maryland, United States",
            "Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States",
            "Mayo Clinic, Rochester, Minnesota, United States",
            "Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States",
            "Nevada Cancer Institute, Las Vegas, Nevada, United States",
            "Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States",
            "Montefiore Medical Center, Bronx, New York, United States",
            "North Shore Hematology/Oncology Associates, P.C., East Setauket, New York, United States",
            "Goshen Medical Associates, Goshen, New York, United States",
            "Stony Brook University Medical Center, Stony Brook, New York, United States",
            "Suny Upstate Medical University, Syracuse, New York, United States",
            "Novant Health Oncology Specialists, Winston Salem, North Carolina, United States",
            "Tulsa Cancer Institute, Tulsa, Oklahoma, United States",
            "Kaiser Permanente Oncology/Hematology, Portland, Oregon, United States",
            "Oregon Health & Science University, Portland, Oregon, United States",
            "St. Luke'S Hospital & Health Network Laboratory, Bethlehem, Pennsylvania, United States",
            "Cancer Center Of The Carolinas, Greenville, South Carolina, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Scott & White Memorial Hospital And Clinic, Temple, Texas, United States",
            "Utah Cancer Specialists, Salt Lake City, Utah, United States",
            "Providence Regional Medical Center Everett, Everett, Washington, United States",
            "Local Institution, Rosario, Santa Fe, Argentina",
            "Local Institution, Rosario, Santa Fe, Argentina",
            "Local Institution, Buenos Aires, Argentina",
            "Local Institution, Buenos Aires, Argentina",
            "Local Institution, Buenos Aires, Argentina",
            "Local Institution, Cordoba, Argentina",
            "Local Institution, La Rioja, Argentina",
            "Local Institution, Kogarah, New South Wales, Australia",
            "Local Institution, Ashford, South Australia, Australia",
            "Local Institution, Box Hill, Victoria, Australia",
            "Local Institution, East Bentleigh, Victoria, Australia",
            "Local Institution, Frankston, Victoria, Australia",
            "Local Institution, Heidelberg, Victoria, Australia",
            "Local Institution, Subiaco, Western Australia, Australia",
            "Local Institution, Brasilia, Distrito Federal, Brazil",
            "Local Institution, Belo Horizonte - Mg, Minas Gerais, Brazil",
            "Local Institution, Belo Horizonte, Minas Gerais, Brazil",
            "Local Institution, Ijui, Rio Grande Do Sul, Brazil",
            "Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil",
            "Local Institution, Kingston, Ontario, Canada",
            "Local Institution, Montreal, Quebec, Canada",
            "Local Institution, Quebec, Canada",
            "Local Institution, Temuco, Araucania, Chile",
            "Local Institution, Vina Del Mar, Valparaiso, Chile",
            "Local Institution, Santiago, Chile",
            "Local Institution, Monteria, Cordoba, Colombia",
            "Local Institution, Bogota, Colombia",
            "Local Institution, Bucaramanga, Colombia",
            "Local Institution, Medellin, Colombia",
            "Local Institution, Hradec Kralove, Czech Republic",
            "Local Institution, Liberec, Czech Republic",
            "Local Institution, Praha 5, Czech Republic",
            "Local Institution, Praha 8, Czech Republic",
            "Local Institution, Herlev, Denmark",
            "Local Institution, Kobenhavn O, Denmark",
            "Local Institution, Bordeaux, France",
            "Local Institution, Clermont-ferrand, France",
            "Local Institution, Marseille Cedex 9, France",
            "Local Institution, Pointe A Pitre, France",
            "Local Institution, Poitiers, France",
            "Local Institution, Villejuif Cedex, France",
            "Local Institution, Aachen, Germany",
            "Local Institution, Heidelberg, Germany",
            "Local Institution, Marktredwitz, Germany",
            "Local Institution, Munich, Germany",
            "Local Institution, Wesel, Germany",
            "Local Institution, Athens, Greece",
            "Local Institution, Budapest, Hungary",
            "Local Institution, Budapest, Hungary",
            "Local Institution, Gyula, Hungary",
            "Local Institution, Szekesfehervar, Hungary",
            "Local Institution, Meldola (FC), Italy",
            "Local Institution, Milano, Italy",
            "Local Institution, Siena, Italy",
            "Local Institution, Terni, Italy",
            "Local Institution, Mexico City, Distrito Federal, Mexico",
            "Local Institution, Mexico, Distrito Federal, Mexico",
            "Local Institution, Tlalpan, Distrito Federal, Mexico",
            "Local Institution, Guadalajara, Jalisco, Mexico",
            "Local Institution, Zapopan, Jalisco, Mexico",
            "Local Institution, Mexico, Queretaro, Mexico",
            "Local Institution, San Luis Potosi, Mexico",
            "Local Institution, Amsterdam, Netherlands",
            "Local Institution, Sittard-geleen, Netherlands",
            "Local Institution, Kristiansand, Norway",
            "Local Institution, Gdansk, Poland",
            "Local Institution, Koscierzyna, Poland",
            "Local Institution, Krakow, Poland",
            "Local Institution, Kutno, Poland",
            "Local Institution, Lublin, Poland",
            "Local Institution, Poznan, Poland",
            "Local Institution, Slupsk, Poland",
            "Va Caribbean Healthcare System, San Juan, Puerto Rico",
            "Local Institution, Bucuresti, Romania",
            "Local Institution, Cluj-napoca, Cluj County, Romania",
            "Local Institution, Timisoara,timis County, Romania",
            "Local Institution, Barcelona, Spain",
            "Local Institution, Barcelona, Spain",
            "Local Institution, Madrid, Spain",
            "Local Institution, Sevilla, Spain",
            "Local Institution, Valencia, Spain",
            "Local Institution, Stockholm, Sweden",
            "Local Institution, Uppsala, Sweden",
            "Local Institution, Vaxjo, Sweden",
            "Local Institution, Adana, Turkey",
            "Local Institution, Bornova, Izmir, Turkey",
            "Local Institution, Gaziantep, Turkey",
            "Local Institution, Kocaeli, Turkey",
            "Local Institution, Kocaeli, Turkey",
            "Local Institution, Glasgow, Lanarkshire, United Kingdom",
            "Local Institution, Guildford, Surrey, United Kingdom",
            "Local Institution, Birmingham, West Midlands, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01057810"
      },
      {
        "-rank": "222",
        "nct_id": "NCT03767244",
        "title": "A Study of Apalutamide in Participants With Highâ€‘Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",
        "acronym": "PROTEUS",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Apalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Androgen Deprivation Therapy (ADT)"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of Participants with Pathologic complete response (pCR)",
            "Metastasis-Free Survival (MFS)",
            "Prostate Specific Antigen (PSA)-Free Survival",
            "Progression-Free Survival (PFS)",
            "Number of Participants with Adverse Events",
            "Number of Participants with Laboratory Abnormalities as a Measure of Safety and Tolerability",
            "Number of Participants with Treatment Compliance Rate"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Research & Development, LLC" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1500",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR108535",
            "56021927PCR3011",
            "2018â€001746â€34",
            "2018-001746-34"
          ]
        },
        "start_date": "June 11, 2019",
        "primary_completion_date": "April 22, 2024",
        "completion_date": "December 28, 2027",
        "study_first_posted": "December 6, 2018",
        "last_update_posted": "August 22, 2019",
        "locations": {
          "location": [
            "UC San Diego Moores Cancer Center, La Jolla, California, United States",
            "University of Southern California, Los Angeles, California, United States",
            "Cedars-Sinai Medical Center, Los Angeles, California, United States",
            "University of California Los Angeles, Los Angeles, California, United States",
            "University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange, California, United States",
            "UC Davis Medical Center, Sacramento, California, United States",
            "The Urology Center of Colorado, Denver, Colorado, United States",
            "Foothills Urology - Golden Off, Golden, Colorado, United States",
            "Yale Cancer Center, New Haven, Connecticut, United States",
            "Stamford Hospital, Stamford, Connecticut, United States",
            "Urology Specialists LLC, Hialeah, Florida, United States",
            "University of Florida, Jacksonville, Florida, United States",
            "Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States",
            "Miami Cancer Institute at Baptist Health / Baptist Health Medical Group, Miami, Florida, United States",
            "Florida Hospital, Orlando, Florida, United States",
            "Emory University - Winship Cancer Institute, Atlanta, Georgia, United States",
            "University of Chicago, Chicago, Illinois, United States",
            "DuPage Medical Group, Lisle, Illinois, United States",
            "Wichita Urology Group, Wichita, Kansas, United States",
            "Tulane University School of Medicine, New Orleans, Louisiana, United States",
            "Regional Urology, Shreveport, Louisiana, United States",
            "Dana-Farber Cancer Institute, Boston, Massachusetts, United States",
            "Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States",
            "Michigan Institute of Urology, PC, Troy, Michigan, United States",
            "Saint Louis University, Saint Louis, Missouri, United States",
            "Washington University, Saint Louis, Missouri, United States",
            "Washington University, Saint Louis, Missouri, United States",
            "Urology Cancer Center, PC, Omaha, Nebraska, United States",
            "New Hampshire Oncology Hematology, PA, Hooksett, New Hampshire, United States",
            "Garden State Urology, Morristown, New Jersey, United States",
            "Albany Medical College, Albany, New York, United States",
            "Icahn School of Medicine at Mount Sinai, New York, New York, United States",
            "Memorial Sloan-Kettering Cancer Center, New York, New York, United States",
            "Weill Cornell Medical College, New York, New York, United States",
            "Great Lakes Physician PC d/b/a Western New York Urology Associates, Sanborn, New York, United States",
            "SUNY Upstate Med Univ, Syracuse, New York, United States",
            "University of North Carolina, Chapel Hill, North Carolina, United States",
            "Duke University School of Medicine, Durham, North Carolina, United States",
            "Alliance Urology Specialists, Greensboro, North Carolina, United States",
            "Carolina Urology Partners, PLLC, Huntersville, North Carolina, United States",
            "Cleveland VA Medical Center, Cleveland, Ohio, United States",
            "University of Toledo, Toledo, Ohio, United States",
            "Oklahoma City VAMC, Oklahoma City, Oklahoma, United States",
            "Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States",
            "Urologic Consultants of Southeastern PA, Bala-Cynwyd, Pennsylvania, United States",
            "Penn State Health, Hershey, Pennsylvania, United States",
            "Omega Medical Research, Warwick, Rhode Island, United States",
            "Medical University of South Carolina, Charleston, South Carolina, United States",
            "Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina, United States",
            "Greenville Health, Greenville, South Carolina, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Vanderbilt University Medical Center, Nashville, Tennessee, United States",
            "VA North Texas Health Care System, Dallas, Texas, United States",
            "MD Anderson Cancer Center, Houston, Texas, United States",
            "Virginia Urology, Richmond, Virginia, United States",
            "Urology of Virginia, PLCC, Virginia Beach, Virginia, United States",
            "University of Washington School of Medicine, Seattle, Washington, United States",
            "CAMC Memorial Hospital, Charleston Area Medical Center Physicians, Charleston, West Virginia, United States",
            "Hospital Aleman, Caba, Argentina",
            "Hospital Italiano de Buenos Aires, Ciudad Autonoma de, Argentina",
            "Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Cordoba, Argentina",
            "Centro Urologico Profesor Bengio, Cordoba, Argentina",
            "Uroclinica, Mendoza, Argentina",
            "Hospital Italiano de Rosario, Rosario, Argentina",
            "Clinica Mayo de UMCB, San Miguel de Tucuman, Argentina",
            "Epworth Eastern Hospital, Box Hill, Australia",
            "St. Vincent's Hospital Sydney, Darlinghurst, Australia",
            "Austin Health, Heidelberg, Australia",
            "Australian Urology Associates Pty Ltd, Malvern, Australia",
            "Royal Melbourne Hospital, Parkville, Australia",
            "Northern Cancer Institute, St Leonards, Australia",
            "Australian Clinical Trials - SAN Clinic, Wahroonga, Australia",
            "Westmead Hospital, Westmead, Australia",
            "Princess Alexandra Hospital, Woolloongabba, Australia",
            "Hospital Haroldo JuaÃ§aba - Instituto do CÃ¢ncer do CearÃ¡, Fortaleza, Brazil",
            "Hospital AraÃºjo Jorge da AssociaÃ§Ã£o de Combate ao CÃ¢ncer em GoiÃ¡s, GoiÃ¢nia, Brazil",
            "Hospital de Caridade de Ijui - CACON, Ijui, Brazil",
            "Liga Norte Riograndense Contra O Cancer, Natal, Brazil",
            "Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil",
            "Hospital UniversitÃ¡rio Pedro Ernesto, Rio de Janeiro, Brazil",
            "ICESP - INSTITUTO DO CANCER DO ESTADO DE SAO PAULO OCTAVIO FRIAS de OLIVEIRA, Sao Paulo, Brazil",
            "Hospital Samaritano de SÃ£o Paulo, SÃ£o Paulo, Brazil",
            "Instituto Do Cancer Brasil, TrÃªs Lagoas, Brazil",
            "Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada",
            "Cross Cancer Institute, Edmonton, Alberta, Canada",
            "Exdeo Clinical Research Inc, Abbotsford, British Columbia, Canada",
            "Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",
            "McMaster Institute of Urology, Hamilton, Ontario, Canada",
            "London Health Sciences Center, London, Ontario, Canada",
            "Sunnybrook Health Sciences Center, Toronto, Ontario, Canada",
            "University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "CHUM - Centre hospitalier universitaire de Montreal, Montreal, Quebec, Canada",
            "CHUQ - CHU de Quebec, Quebec, Canada",
            "Vancouver Prostate Centre - Diamond Health Care Centre, Vancouver, Canada",
            "Hunan Cancer hospital, ChangSha, China",
            "West China School of Medicine/West China Hospital, Sichuan University, Chengdu, China",
            "Sichuan Provincial People's Hospital, Chengdu, China",
            "Chongqing Cancer hospital, Chongqing, China",
            "Southwest Hospital, ChongQing, China",
            "Daping Hospital Army Characteristic Medical Center, Chongqing, China",
            "Fujian Medical University Union Hospital, Fuzhou, China",
            "Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China",
            "Guangzhou First Municipal People's Hospital, Guangzhou, China",
            "Zhejiang Provincial People's Hospital, Hangzhou, China",
            "The 1st affiliated hospital of Anhui Medical University, Hefei, China",
            "Yunnan Cancer Hospital, Kunming, China",
            "The First Affliated Hospital Of Nanchang University, Nanchang, China",
            "Jiangsu Cancer Hospital, NanJing, China",
            "Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, China",
            "Fudan University Shanghai Cancer Center, Shanghai, China",
            "Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China",
            "Shanghai General Hospital, Shanghai, China",
            "Shengjing Hospital of China Medical University, Shengyang, China",
            "Liaoning Cancer Hospital & Institute, Shenyang, China",
            "Second Affiliated Hospital of Soochow University, Suzhou, China",
            "Tianjin Medical University Cancer Institute and Hospital, Tianjin, China",
            "The first affiliated hospital of Xinjiang medical university, Urumchi, China",
            "The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China",
            "First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China",
            "Fakultni nemocnice Hradec Kralove, Hradec KrÃ¡love, Czechia",
            "KrajskÃ¡ nemocnice Liberec, Liberec, Czechia",
            "Uromedical Center s.r.o., Olomouc, Czechia",
            "Fakultni nemocnice Plzen, Urologicka klinika, Plzen, Czechia",
            "Thomayerova nemocnice, Praha 4, Czechia",
            "Vseobecna fakultni nemocnice v Praze, Praha, Czechia",
            "CHU d'Angers, Angers, France",
            "CHRU BesanÃ§on -HÃ´pital Jean Minjoz, BesanÃ§on Cedex, France",
            "HÃ´pital Pellegrin CHU Bordeaux, Bordeaux N/a, France",
            "APHP - Hopital Henri Mondor, CrÃ©teil, France",
            "Hopital Edouard Herriot - CHU Lyon, Lyon cedex 03, France",
            "CHU de Nantes hÃ´tel-Dieu, Nantes, France",
            "Clinique de la Croix du Sud, Quint-Fonsegrives, France",
            "Chu Rennes - Hopital Pontchaillou, Rennes Cedex, France",
            "CHU de Toulouse - HÃ´pital Rangueil, Toulouse Cedex 9, France",
            "CHRU Tours HÃ´pital Bretonneau, Tours, France",
            "Universitaetsklinikum der RWTH Aachen, Aachen, Germany",
            "StÃ¤dtisches Klinikum Braunschweig gGmbH - Standort Salzdahlumer, Braunschweig, Germany",
            "Universitatsklinikum Essen, Essen, Germany",
            "Martini-Klinik am UniversitÃ¤tsklinikum Hamburg-Eppendorf Urologie, Hamburg, Germany",
            "Urologikum Hamburg, Hamburg, Germany",
            "UniversitÃ¤tsklinikum des Saarlandes, Homburg/Saar, Germany",
            "Universitaetsklinikum Koeln, Koeln, Germany",
            "UniversitÃ¤tsklinikum Schleswig Holstein Campus LÃ¼beck, Lubeck, Germany",
            "Praxis Dr. med. Ralf Eckert, Lutherstadt Eisleben, Germany",
            "Klinikum St. Elisabeth Straubing GmbH, Straubing, Germany",
            "Kliniken Nordoberpfalz, Klinik fÃ¼r Urologie, Weiden/Opf, Germany",
            "Praxisgemeinschaft f. Onkologie u. Urologie - Germany, Wilhelmshaven, Germany",
            "Asaf Harofe Medical Center, Beer Yaakov, Israel",
            "Rambam Health Care Campus, Haifa, Israel",
            "Tel Aviv University Sackler School of Medicine - Meir Medical Center (MMC), Kfar Saba, Israel",
            "Rabin Medical Center, Petach Tikva, Israel",
            "The Chaim Sheba Medical Center, Ramat Gan, Israel",
            "Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",
            "Policlinico Abano Terme, Abano Terme, Italy",
            "Generale Regionale F. Miulli, Acquaviva delle Fonti, Italy",
            "Ospedale di Bassano del Grappa, Bassano del Grappa, Italy",
            "ASST Spedali Civili Brescia, Brescia, Italy",
            "ASL2 Lanciano - Vasto - Chieti - Ospedale 'SS Annunziata' di Chieti, Chieti, Italy",
            "Azienda Ospedaliero Universitaria Careggi, Firenze, Italy",
            "San Raffaele Turro - Istituto di Ricovero e Cura a Carattere Scientifico, MIlano, Italy",
            "Ospedale San Raffaele, Milano, Italy",
            "Istituto Europeo di Oncologia, Milano, Italy",
            "Clinica di Urologia Policlinico di Modena - UniversitÃ  di Modena e reggio Emilia, Modena, Italy",
            "UniversitÃ  del Piemonte Orientale - Ospedale Maggiore della CaritÃ  di Novara, Novara, Italy",
            "Universita degli Studi di Torino - Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, Italy",
            "UniversitÃ  Campus Bio-Medico di Roma, Roma, Italy",
            "Istituto Nazionale Tumori Regina Elena, Roma, Italy",
            "Azienda Ospedaliera Sant Andrea, Roma, Italy",
            "Ospedale Molinette, AO CittÃ  della Salute e della Scienza di, Torino, Italy",
            "Akita University Hospital, Akita, Japan",
            "Chiba University Hospital, Chiba, Japan",
            "Chiba Cancer Center, Chuo-ku, Chiba-City,, Japan",
            "Hakodate Goryokaku Hospital, Hakodate, Japan",
            "Hirosaki University Hospital, Hirosaki, Japan",
            "Kanazawa University Hospital, Kanazawa, Japan",
            "Kobe City Medical Center General Hospital, Kobe, Japan",
            "Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan",
            "Kurume University Hospital, Kurume, Japan",
            "Kyoto University Hospital, Kyoto, Japan",
            "National Shikoku Cancer Center, Matsuyama, Japan",
            "Kitasato University Hospital, Minami-ku, Sagamihara-shi, Japan",
            "University of Miyazaki Hospital, Miyazaki, Japan",
            "Nagano Municipal Hospital, Nagano, Japan",
            "Kindai University Hospital, Osaka-Sayama, Japan",
            "Osaka International Cancer Institute, Osaka-shi, Japan",
            "Toho University Sakura Medical Center, Sakura, Japan",
            "Hokkaido University Hospital, Sapporo, Japan",
            "Juntendo University School of Medicine, Tokyo, Japan",
            "Yamaguchi University Hospital, Ube, Japan",
            "Yokohama City University Medical Center, Yokohama, Japan",
            "Chonnam National University Hospital, Gwangju, Korea, Republic of",
            "Seoul National University Bundang Hospital, Seongnam, Korea, Republic of",
            "Severance Hospital, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Seoul St. Mary's Hospital, Seoul, Korea, Republic of",
            "NKI-AVL, Amsterdam, Amsterdam, Netherlands",
            "Catharinaziekenhuis, Eindhoven, Netherlands",
            "St. Antonius Ziekenhuis (St. Antonius Hospital), Nieuwegein, Netherlands",
            "Canisius-Wilhelmina Ziekenhuis, Nijmegen, Netherlands",
            "Samodzielny Publiczny Wielospecjalistyczny ZakÅ‚ad Opieki Zdrowotnej MSWiA w Bydgoszczy, Bydgoszcz, Poland",
            "Szpital Uniwersytecki NR 1 IM. Dr. Antoniego Jurasza, Bydgoszcz, Poland",
            "Szpital WojewÃ³dzki im. MikoÅ‚aja Kopernika w Koszalinie, Koszalin, Poland",
            "Pratia MCM Krakow, Krakow, Poland",
            "Szpital Mazovia, Warszawa, Poland",
            "Dolnoslaskie Centrum Onkologii, Oddzial Chirurgii Onkoilogicznej II - Urologia, WrocÅ‚aw, Poland",
            "Altai Regional Oncology Dispensary, Barnaul, Russian Federation",
            "Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine, Chelyabinsk, Russian Federation",
            "Moscow City Clinical Hospital # 62, Moscow, Russian Federation",
            "Botkin City Clinical Hospital, Moscow, Russian Federation",
            "Hertzen Oncology Research Institute, Moscow, Russian Federation",
            "Clinical Oncology Dispensary, Omsk, Russian Federation",
            "Medical-sanitary unit 'Neftyanik', Tyumen, Russian Federation",
            "Hosp. Univ. A CoruÃ±a, A CoruÃ±a, Spain",
            "Hosp. Univ. Vall D Hebron, Barcelona, Spain",
            "Hosp. Puerta Del Mar, Cadiz, Spain",
            "Hosp. Gral. Univ. de Castellon, CastellÃ³n, Spain",
            "Hosp. de Jerez de La Frontera, Jerez de la Frontera, Spain",
            "Hosp. Univ. Ramon Y Cajal, Madrid, Spain",
            "Hosp. Univ. 12 de Octubre, Madrid, Spain",
            "Hosp. Univ. La Paz, Madrid, Spain",
            "Fund. Hosp. de Manacor, Manacor, Spain",
            "Hosp. Virgen de La Victoria, MÃ¡laga, Spain",
            "Hosp. Univ. Marques de Valdecilla, Santander, Spain",
            "Hosp. Virgen Del Rocio, Sevilla, Spain",
            "Inst. Valenciano de Oncologia, Valencia, Spain",
            "Hosp. Clinico Univ. de Valencia, Valencia, Spain",
            "Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan",
            "China Medical University Hospital, Taichung, Taiwan",
            "Taichung Veterans General Hospital, Taichung, Taiwan",
            "Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan",
            "Chi Mei Medical Center - Yong Kang, Tainan, Taiwan",
            "National Taiwan University Hospital., Taipei, Taiwan",
            "Southmead Hospital, Bristol, United Kingdom",
            "University Hospital of Wales, Cardiff, United Kingdom",
            "Ninewells Hospital, Dundee, United Kingdom",
            "The Royal Marsden NHS Trust, London, United Kingdom",
            "University College London, London, United Kingdom",
            "Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital, Preston, United Kingdom",
            "Southampton General Hospital, Southampton, United Kingdom",
            "Royal Marsden Hospital, Sutton, United Kingdom",
            "MidYorkshire NHS Trust, Wakefield, United Kingdom",
            "New Cross Hospital, Wolverhampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03767244"
      },
      {
        "-rank": "223",
        "nct_id": "NCT00638690",
        "title": "Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone/prednisolone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Time to Prostate-Specific Antigen Progression According to Prostate Specific Antigen Working Group Criteria",
            "Number of Patients Achieving a Prostate-Specific Antigen Decline >=50%",
            "Radiographic Progression-free Survival"
          ]
        },
        "sponsors": { "lead_sponsor": "Cougar Biotechnology, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1195",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR016924",
            "COU-AA-301"
          ]
        },
        "start_date": "May 2008",
        "primary_completion_date": "August 2010",
        "completion_date": "October 2012",
        "study_first_posted": "March 19, 2008",
        "results_first_posted": "May 16, 2013",
        "last_update_posted": "April 30, 2014",
        "locations": {
          "location": [
            "Birmingham, Alabama, United States",
            "Tucson, Arizona, United States",
            "Beverly Hills, California, United States",
            "Duarte, California, United States",
            "Los Angeles, California, United States",
            "Marina Del Rey, California, United States",
            "Sacramento, California, United States",
            "San Diego, California, United States",
            "San Francisco, California, United States",
            "Aurora, Colorado, United States",
            "Bristol, Connecticut, United States",
            "New Haven, Connecticut, United States",
            "Stamford, Connecticut, United States",
            "Boca Raton, Florida, United States",
            "Fort Lauderdale, Florida, United States",
            "Fort Myers, Florida, United States",
            "West Palm Beach, Florida, United States",
            "Atlanta, Georgia, United States",
            "Honolulu, Hawaii, United States",
            "Chicago, Illinois, United States",
            "Galesburg, Illinois, United States",
            "Indianapolis, Indiana, United States",
            "Westwood, Kansas, United States",
            "Wichita, Kansas, United States",
            "Marrero, Louisiana, United States",
            "New Orleans, Louisiana, United States",
            "Baltimore, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Detroit, Michigan, United States",
            "Robbinsdale, Minnesota, United States",
            "St. Louis, Missouri, United States",
            "Billings, Montana, United States",
            "Omaha, Nebraska, United States",
            "Las Vegas, Nevada, United States",
            "Box 302, New York, United States",
            "East Setauket, New York, United States",
            "New Hyde Park, New York, United States",
            "New York, New York, United States",
            "Stony Brook, New York, United States",
            "Durham, North Carolina, United States",
            "Raleigh, North Carolina, United States",
            "Canton, Ohio, United States",
            "Cincinnati, Ohio, United States",
            "Portland, Oregon, United States",
            "Philadelphia, Pennsylvania, United States",
            "Pittsburgh, Pennsylvania, United States",
            "Myrtle Beach, South Carolina, United States",
            "Chattanooga, Tennessee, United States",
            "Nashville, Tennessee, United States",
            "Dallas, Texas, United States",
            "Houston, Texas, United States",
            "San Antonio, Texas, United States",
            "Virgiania Beach, Virginia, United States",
            "Seattle, Washington, United States",
            "Adelaide, Australia",
            "Camperdown, Australia",
            "Footscray, Australia",
            "Geelong, Australia",
            "Heidelberg, Australia",
            "Herston, Australia",
            "Hobart, Australia",
            "Hornsby, Australia",
            "Kogarah, Australia",
            "Kurralta Park, Australia",
            "Liverpool, Australia",
            "Milton, Australia",
            "Parkville, Australia",
            "Perth, Australia",
            "Subiaco, Australia",
            "Wodonga, Australia",
            "Wollongong, Australia",
            "Linz, Austria",
            "Salzburg, Austria",
            "Wien, Austria",
            "Antwerpen, Belgium",
            "Bonheiden, Belgium",
            "Bruxelles, Belgium",
            "Gent, Belgium",
            "Hasselt, Belgium",
            "Kortrijk, Belgium",
            "Leuven, Belgium",
            "Liege, Belgium",
            "Roeselare, Belgium",
            "Edmonton, Alberta, Canada",
            "Kelowna, British Columbia, Canada",
            "Vancouver, British Columbia, Canada",
            "Victoria, British Columbia, Canada",
            "Halifax, Nova Scotia, Canada",
            "Hamilton, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Montreal, Quebec, Canada",
            "Regina, Saskatchewan, Canada",
            "Calgary Ab, Canada",
            "London, Canada",
            "Angers Cedex 01, France",
            "Caen, France",
            "Cannes, France",
            "Dijon, France",
            "Lyon, France",
            "Paris, France",
            "Saint Herblain, France",
            "Vandoeuvre Les Nancy Cedex, France",
            "Villejuif N/A, France",
            "Aachen, Germany",
            "Berlin, Germany",
            "Dresden, Germany",
            "Hamburg, Germany",
            "Homburg/Saar, Germany",
            "Pecs, Hungary",
            "Szombathely, Hungary",
            "Cork, Ireland",
            "Dublin 7, Ireland",
            "Dublin, Ireland",
            "Nijmegen, Netherlands",
            "Badalona, Spain",
            "Barcelona, Spain",
            "Madrid, Spain",
            "Belfast, United Kingdom",
            "Birmingham, United Kingdom",
            "Cambridge, United Kingdom",
            "Glasgow, United Kingdom",
            "London, United Kingdom",
            "Manchester, United Kingdom",
            "Newcastle Upon Tyne, United Kingdom",
            "Northwood, United Kingdom",
            "Oxford, United Kingdom",
            "Sutton, United Kingdom",
            "Whitchurch, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00638690"
      },
      {
        "-rank": "224",
        "nct_id": "NCT01715285",
        "title": "A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Other",
              "#text": "Androgen deprivation therapy (ADT)"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Progression-Free Survival (PFS)",
            "Overall Survival (OS)",
            "Time to Initiation of Chemotherapy",
            "Time to Subsequent Therapy for Prostate Cancer",
            "Time to Pain Progression",
            "Time to Skeletal-Related Event",
            "Time to Prostate-Specific Antigen (PSA) Progression"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Research & Development, LLC" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1209",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR100900",
            "212082PCR3011",
            "2012-002940-26",
            "U1111-1135-7146"
          ]
        },
        "start_date": "February 12, 2013",
        "primary_completion_date": "October 31, 2016",
        "completion_date": "December 31, 2022",
        "study_first_posted": "October 26, 2012",
        "results_first_posted": "October 15, 2018",
        "last_update_posted": "September 5, 2019",
        "locations": {
          "location": [
            "Buenos Aires, Argentina",
            "Cordoba, Argentina",
            "La Rioja, Argentina",
            "Rosario, Argentina",
            "Adelaide, Australia",
            "Footscray, Australia",
            "Liverpool, Australia",
            "Malvern, Australia",
            "Randwick, Australia",
            "Wahroonga, Australia",
            "Antwerpen, Belgium",
            "Bonheiden, Belgium",
            "Brasschaat, Belgium",
            "Bruxelles, Belgium",
            "Charleroi, Belgium",
            "LiÃ¨ge, Belgium",
            "Namur, Belgium",
            "Ottignies, Belgium",
            "Sint-Niklaas, Belgium",
            "Yvoir, Belgium",
            "Barretos, Brazil",
            "Belo Horizonte, Brazil",
            "Caxias Do Sul, Brazil",
            "Curitiba, Brazil",
            "IjuÃ­, Brazil",
            "Jau, Brazil",
            "Natal, Brazil",
            "Novo Hamburgo, Brazil",
            "Porto Alegre, Brazil",
            "RibeirÃ£o Preto, Brazil",
            "Rio De Janeiro, Brazil",
            "Salvador, Brazil",
            "Sao Jose Do Rio Preto, Brazil",
            "Sao Paulo, Brazil",
            "Gabrovo, Bulgaria",
            "Sofia, Bulgaria",
            "Edmonton, Alberta, Canada",
            "Winnipeg, Manitoba, Canada",
            "Kingston, Ontario, Canada",
            "Oshawa, Ontario, Canada",
            "Ottawa, Ontario, Canada",
            "Montreal, Quebec, Canada",
            "Hamilton, Canada",
            "Quebec, Canada",
            "Toronto, Canada",
            "Vancouver, Canada",
            "Santiago, Chile",
            "Beijing, China",
            "Chengdu, China",
            "Chongqing, China",
            "Guangzhou, China",
            "Hangzhou, China",
            "Nanjing, China",
            "Shanghai, China",
            "Su Zhou, China",
            "Tianjin, China",
            "Wuhan, China",
            "Bogota, Colombia",
            "Floridablanca, Colombia",
            "Medellin, Colombia",
            "Hradec Kralove, Czechia",
            "Olomouc, Czechia",
            "Plzen, Czechia",
            "Praha 10, Czechia",
            "Praha 2, Czechia",
            "Praha 4, Czechia",
            "Aarhus N., Denmark",
            "Holsterbro, Denmark",
            "Odense N/a, Denmark",
            "Roskilde, Denmark",
            "Vejle, Denmark",
            "Oulu, Finland",
            "Tampere, Finland",
            "La Chaussee St Victor, France",
            "Lille, France",
            "Montpellier, France",
            "Paris Cedex 14, France",
            "Suresnes, France",
            "Toulouse, France",
            "Villejuif Cedex, France",
            "DÃ¼sseldorf, Germany",
            "Hamburg, Germany",
            "NÃ¼rtingen, Germany",
            "Budapest N/a, Hungary",
            "Budapest, Hungary",
            "GyÅ‘r, Hungary",
            "Miskolc, Hungary",
            "Pecs, Hungary",
            "Szentes, Hungary",
            "Beer Yaakov, Israel",
            "Beer-Sheva, Israel",
            "Haifa, Israel",
            "Jerusalem, Israel",
            "Kfar Saba, Israel",
            "Petah-Tikva, Israel",
            "Ramat Gan, Israel",
            "Chiba, Japan",
            "Gifu, Japan",
            "Kashiwa, Japan",
            "Matsuyama, Japan",
            "Nankoku, Japan",
            "Osaka-Sayama, Japan",
            "Sakura, Japan",
            "Tokushima, Japan",
            "Tokyo, Japan",
            "Ube, Japan",
            "Yokohama, Japan",
            "Yufu, Japan",
            "Bucheon-si, Korea, Republic of",
            "Busan, Korea, Republic of",
            "Daegu, Korea, Republic of",
            "Daejeon, Korea, Republic of",
            "Gyeonggi-do, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Kuala Lumpur N/a, Malaysia",
            "Kuala Lumpur, Malaysia",
            "Kuching, Malaysia",
            "Chihuahua, Mexico",
            "Cuernavaca, Mexico",
            "Durango, Mexico",
            "Guadalajara, Mexico",
            "Monterrey, Mexico",
            "Oaxaca, Mexico",
            "Pachuca de Soto, Mexico",
            "Zapopan, Mexico",
            "Alkmaar, Netherlands",
            "Amsterdam Zuidoost, Netherlands",
            "Amsterdam, Netherlands",
            "Hilversum, Netherlands",
            "Hoofddorp, Netherlands",
            "Nieuwegein, Netherlands",
            "Rotterdam, Netherlands",
            "Auckland, New Zealand",
            "Christchurch, New Zealand",
            "Hamilton, New Zealand",
            "Tauranga, New Zealand",
            "Bydgoszcz, Poland",
            "Gdansk, Poland",
            "Lodz, Poland",
            "Lublin, Poland",
            "Warszawa, Poland",
            "Braga, Portugal",
            "Coimbra, Portugal",
            "Lisboa, Portugal",
            "Porto, Portugal",
            "Brasov, Romania",
            "Bucharest, Romania",
            "Bucuresti, Romania",
            "Cluj Napoca, Romania",
            "Iasi, Romania",
            "Chelyabinsk, Russian Federation",
            "Ekaterinburg, Russian Federation",
            "Ivanovo, Russian Federation",
            "Izhevsk, Russian Federation",
            "Moscow, Russian Federation",
            "Nizhny Novgorod, Russian Federation",
            "Obninsk, Kaluga Region, Russian Federation",
            "Omsk, Russian Federation",
            "Orenburg, Russian Federation",
            "Pyatigorsk, Russian Federation",
            "Rostov-on-Don, Russian Federation",
            "Ryazan, Russian Federation",
            "Saint-Petersburg, Russian Federation",
            "Saransk, Russian Federation",
            "Saratov, Russian Federation",
            "Sochi, Russian Federation",
            "St.-Petersburg, Russian Federation",
            "Stavropol, Russian Federation",
            "Tumen, Russian Federation",
            "Ufa, Russian Federation",
            "Volgograd, Russian Federation",
            "Yoshkar-Ola, Russian Federation",
            "KoÅ¡ice-Å aca, Slovakia",
            "Martin, Slovakia",
            "Piestany, Slovakia",
            "PreÅ¡ov, Slovakia",
            "Rimavska Sobota, Slovakia",
            "Trnava, Slovakia",
            "George, South Africa",
            "Port Elizabeth, South Africa",
            "Pretoria, South Africa",
            "Vosloorus, South Africa",
            "Barcelona, Spain",
            "Cordoba, Spain",
            "CoruÃ±a, Spain",
            "Madrid N/a, Spain",
            "Madrid, Spain",
            "Murcia N/a, Spain",
            "GÃ¶teborg, Sweden",
            "MalmÃ¶, Sweden",
            "Stockholm, Sweden",
            "UmeÃ¥, Sweden",
            "Uppsala, Sweden",
            "Adana, Turkey",
            "Ankara, Turkey",
            "Istanbul, Turkey",
            "Izmir, Turkey",
            "Zonguldak, Turkey",
            "Cherkassy, Ukraine",
            "Dnepropetrovsk, Ukraine",
            "Dnipro, Ukraine",
            "Khakhiv, Ukraine",
            "Kharkiv, Ukraine",
            "Kyiv, Ukraine",
            "Lviv, Ukraine",
            "Makiivka, Ukraine",
            "Odessa, Ukraine",
            "Uzhgorod, Ukraine",
            "Zaporizhzhia, Ukraine",
            "Cambridge, United Kingdom",
            "Glasgow, United Kingdom",
            "Manchester, United Kingdom",
            "Nottingham, United Kingdom",
            "Oxford, United Kingdom",
            "Plymouth, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01715285"
      },
      {
        "-rank": "225",
        "nct_id": "NCT02854436",
        "title": "An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies",
        "acronym": "Galahad",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Niraparib"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Objective Response Rate (ORR)",
            "Circulating Tumor Cells (CTC) Response",
            "Overall Survival (OS)",
            "Radiographic Progression-Free Survival (rPFS)",
            "Time to Prostate Specific Antigen (PSA) Progression",
            "Time to Symptomatic Skeletal Event (SSE)",
            "Number of Participants With Adverse Events as a Measure of Safety and Tolerability",
            "Duration of Objective Response"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Research & Development, LLC" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "301",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR108208",
            "64091742PCR2001",
            "2016-002057-38"
          ]
        },
        "start_date": "August 31, 2016",
        "primary_completion_date": "February 21, 2020",
        "completion_date": "June 21, 2020",
        "study_first_posted": "August 3, 2016",
        "last_update_posted": "August 9, 2019",
        "locations": {
          "location": [
            "Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States",
            "University of Southern California, Los Angeles, California, United States",
            "Kaiser Permanente, Riverside, California, United States",
            "UC Davis Comprehensive Cancer Center, Sacramento, California, United States",
            "University Of California, San Francisco, California, United States",
            "Stanford University School of Medicine, Stanford, California, United States",
            "Cedars-Sinai Medical Center, West Hollywood, California, United States",
            "University of Colorado Health Sciences Center, Aurora, Colorado, United States",
            "The Urology Center of Colorado, Denver, Colorado, United States",
            "Northshore Universite Healthsystem, Evanston, Illinois, United States",
            "Commonwealth Cancer Center, Danville, Kentucky, United States",
            "Norton Healthcare, Louisville, Kentucky, United States",
            "Oncology & Hematology Specialists, Metairie, Louisiana, United States",
            "Tulane University School of Medicine, New Orleans, Louisiana, United States",
            "Chesapeake Urology Research Associates, Baltimore, Maryland, United States",
            "Massachusetts General, Boston, Massachusetts, United States",
            "Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "Duke Cancer Institute, Durham, North Carolina, United States",
            "Oregon Health & Science University, Portland, Oregon, United States",
            "Lancaster Urology, Lancaster, Pennsylvania, United States",
            "Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States",
            "Atlantic Urology Clinics, Myrtle Beach, South Carolina, United States",
            "MD Anderson Cancer Center, Houston, Texas, United States",
            "Millennium Oncology, Houston, Texas, United States",
            "Intermountain Healthcare, Saint George, Utah, United States",
            "University of Virginia, Charlottesville, Virginia, United States",
            "INOVA, Fairfax, Virginia, United States",
            "University of Washington School of Medicine, Seattle, Washington, United States",
            "University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",
            "Chris O'Brien Lifehouse, Camperdown, Australia",
            "St. Vincent's Hospital Sydney, Darlinghurst, Australia",
            "Border Medical Oncology, East Albury, Australia",
            "Ashford Cancer Centre, Kurralta Park, Australia",
            "Peter MacCallum Cancer Centre, Melbourne, Australia",
            "Fiona Stanley Hospital, Murdoch, Australia",
            "Macquarie University Hospital, North Ryde, Australia",
            "Port Macquarie Base Hospital, Port Macquarie, Australia",
            "Prince Of Wales Hospital, Randwick, Australia",
            "Sydney Adventist Hospital, Wahroonga, Australia",
            "OLV Ziekenhuis Aalst, Aalst, Belgium",
            "Institut Jules Bordet, Brussel, Belgium",
            "Grand HÃ´pital de Charleroi, site Notre Dame, Charleroi, Belgium",
            "AZ Maria Middelares, Gent, Belgium",
            "Universitair Ziekenhuis Gent, Gent, Belgium",
            "Jolimont, Haine-Saint-Paul, La Louviere, Belgium",
            "Virga Jessa Ziekenhuis, Hasselt, Belgium",
            "Az Groeninge, Kortrijk, Belgium",
            "Sart Tilman, LiÃ¨ge, Belgium",
            "Clinique et MaternitÃ© Sainte Elisabeth, Namur, Belgium",
            "Clinique St Pierre, Ottignies, Belgium",
            "GZA Ziekenhuizen- Campus St Augustinus, Wilrijk, Belgium",
            "Hospital Do Cancer De Barretos - Fundacao Pio Xii, Barretos, Brazil",
            "PERSONAL - Oncologia de PrecisÃ£o e Personalizada, Belo Horizonte, Brazil",
            "Hospital Erasto Gaertner, Curitiba, Brazil",
            "Pronutrir, Fortaleza, Brazil",
            "Hospital de Caridade de Ijui, IjuÃ­, Brazil",
            "ClÃ­nica de Neoplasias Litoral Ltda., Itajai, Brazil",
            "Instituto Joinvilense De Hematologia e Oncologia, Joinville, Brazil",
            "Liga Norte Riograndense Contra O Cancer, Natal, Brazil",
            "Hospital Sao Rafael, Salvador, Brazil",
            "Instituto de Ensino E Pesquisa Sao Lucas, Sao Paulo, Brazil",
            "Hospital Israelita Albert Einstein, SÃ£o Paulo, Brazil",
            "Prostate Cancer Centre, Calgary, Alberta, Canada",
            "British Columbia Cancer Agency(BCCA)-Sindi Ahluwalia Hawkins Centre for the Southern Interior(CSI), Kelowna, British Columbia, Canada",
            "British Columbia Cancer Agency (BCCA) - Vancouver Centre, Vancouver, British Columbia, Canada",
            "Lakeridge Health Oshawa, Oshawa, Ontario, Canada",
            "Sunnybrook Health Sciences Center, Toronto, Ontario, Canada",
            "University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Centre de Recherche du CHUM, Montreal, Quebec, Canada",
            "Centre hospitalier universitaire de QuÃ©bec (CHUQ), L'Hotel-Dieu de QuebÃ©c, Quebec, Canada",
            "Aarhus University Hospital, Aarhus N., Denmark",
            "Rigshospitalet, Copenhagen, Denmark",
            "Herlev Hospital, Herlev, Denmark",
            "Odense Universitetshospital, Odense C, Denmark",
            "Institut Sainte Catherine, Avignon Cedex 9, France",
            "CHRU De Besancon, Besancon, France",
            "Centre Francois Baclesse, Caen, France",
            "Centre Leon BÃ©rard, Lyon, France",
            "Centre Antoine Lacassagne, Nice Cedex 2, France",
            "HÃ´pital Saint Louis, Paris, France",
            "Hopital Europeen Georges-Pompidou, Paris, France",
            "Institut Jean Godinot, Reims, France",
            "HÃ´pitaux Universitaire de Strasbourg -CHU, Strasbourg, France",
            "Gustave Roussy, Villejuif Cedex, France",
            "Soroka Hospital, Beer-Sheva, Israel",
            "Rambam Hospital, Haifa, Israel",
            "Hadassah Medical Organization Ein Kerem, Jerusalem, Israel",
            "Meir Hospital, Kfar Saba, Israel",
            "Sheba Medical Center, Ramat Gan, Israel",
            "Asaf Harofe Medical Center, Zrifin, Israel",
            "Severance Hospital, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Gangnam Severance Hospital, Seoul, Korea, Republic of",
            "Samsung Medical Center, Seoul, Korea, Republic of",
            "The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of",
            "Mc Alkmaar, Alkmaar, Netherlands",
            "VUMC Amsterdam, Amsterdam, Netherlands",
            "Universitair Medisch Centrum Groningen, Groningen, Netherlands",
            "AZ Maastricht, Maastricht, Netherlands",
            "Radboudumc, Nijmegen, Netherlands",
            "Erasmus MC, Rotterdam, Netherlands",
            "Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation",
            "Moscow City Clinical Hospital # 62, Moscow, Russian Federation",
            "Hertzen Oncology Research Institute, Moscow, Russian Federation",
            "Clinical Oncology Dispansary, Omsk, Russian Federation",
            "Tomsk Cancer Research Institute, Tomsk, Russian Federation",
            "Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain",
            "Hosp. Univ. Vall D Hebron, Barcelona, Spain",
            "Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain",
            "Hosp. Reina Sofia, CÃ³rdoba, Spain",
            "Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain",
            "Hosp. Clinico San Carlos, Madrid, Spain",
            "Hosp. Univ. Hm Sanchinarro, Madrid, Spain",
            "Hosp. Virgen de La Victoria, MÃ¡laga, Spain",
            "Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcon, Spain",
            "Hosp. Univ. Marques de Valdecilla, Santander, Spain",
            "Hosp. Clinico Univ. de Santiago, Santiago de Compostela, Spain",
            "Hosp. Virgen Del Rocio, Sevilla, Spain",
            "Hosp. Univ. I Politecni La Fe, Valencia, Spain",
            "Salgrenska University hospital, GÃ¶teborg, Sweden",
            "Lund University Hospital/SkÃ¥ne, Lund, Sweden",
            "Karolinska Universitetssjukhuset Solna, Stockholm, Sweden",
            "Norrlands Universitetssjukhus, UmeÃ¥, Sweden",
            "Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",
            "China Medical University Hospital, Taichung, Taiwan",
            "Taichung Veterans General Hospital, Taichung, Taiwan",
            "National Cheng Kung University Hospital, Tainan, Taiwan",
            "National Taiwan University Hospital, Taipei, Taiwan",
            "Tri-Service General Hospital, Taipei, Taiwan",
            "Chang Gung Memorial Hospital Linkou Branch, Taoyuan County, Taiwan",
            "The Queen Elizabeth Hospital, Birmingham, United Kingdom",
            "Royal Blackburn Hospital, Blackburn, United Kingdom",
            "The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United Kingdom",
            "Bristol Haematology and Oncology Centre, Bristol, United Kingdom",
            "Velindre Hospital, Cardiff, United Kingdom",
            "Royal Devon & Exeter Hospital, Exeter, United Kingdom",
            "Royal Marsden Hospital, London, United Kingdom",
            "University College London Hospitals, London, United Kingdom",
            "Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital, Preston, United Kingdom",
            "Taunton and Somerset NHS Foundation Trust, Taunton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02854436"
      },
      {
        "-rank": "226",
        "nct_id": "NCT02257736",
        "title": "An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Apalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Progression-free Survival (rPFS).",
            "Overall Survival (OS)",
            "Time to Chronic Opioid Use",
            "Time to Initiation of Cytotoxic Chemotherapy",
            "Time to Pain Progression"
          ]
        },
        "sponsors": { "lead_sponsor": "Aragon Pharmaceuticals, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "983",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR105505",
            "56021927PCR3001",
            "2014-001718-25"
          ]
        },
        "start_date": "November 26, 2014",
        "primary_completion_date": "March 19, 2018",
        "completion_date": "August 24, 2021",
        "study_first_posted": "October 6, 2014",
        "last_update_posted": "March 26, 2019",
        "locations": {
          "location": [
            "Phoenix, Arizona, United States",
            "La Mesa, California, United States",
            "Los Angeles, California, United States",
            "Modesto, California, United States",
            "San Diego, California, United States",
            "San Francisco, California, United States",
            "Santa Barbara, California, United States",
            "Aurora, Colorado, United States",
            "Denver, Colorado, United States",
            "New Haven, Connecticut, United States",
            "Jensen Beach, Florida, United States",
            "Lakeland, Florida, United States",
            "New Port Richey, Florida, United States",
            "Ocala, Florida, United States",
            "Atlanta, Georgia, United States",
            "Melrose, Illinois, United States",
            "Niles, Illinois, United States",
            "Marrero, Louisiana, United States",
            "New Orleans, Louisiana, United States",
            "Shreveport, Louisiana, United States",
            "Auburn, Maine, United States",
            "Baltimore, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Saint Louis, Missouri, United States",
            "Omaha, Nebraska, United States",
            "Las Vegas, Nevada, United States",
            "Albany, New York, United States",
            "Bronx, New York, United States",
            "Johnson City, New York, United States",
            "New York, New York, United States",
            "Poughkeepsie, New York, United States",
            "Syracuse, New York, United States",
            "Columbus, Ohio, United States",
            "Tualatin, Oregon, United States",
            "Lancaster, Pennsylvania, United States",
            "Pittsburgh, Pennsylvania, United States",
            "Charleston, South Carolina, United States",
            "Myrtle Beach, South Carolina, United States",
            "Nashville, Tennessee, United States",
            "Austin, Texas, United States",
            "Houston, Texas, United States",
            "Norfolk, Virginia, United States",
            "Richmond, Virginia, United States",
            "Auburn, Washington, United States",
            "Seattle, Washington, United States",
            "Spokane, Washington, United States",
            "Wenatchee, Washington, United States",
            "Madison, Wisconsin, United States",
            "Ciudad Automoma Buenos Aires, Argentina",
            "Ciudad De Buenos Aires, Argentina",
            "Cordoba, Argentina",
            "La Rioja, Argentina",
            "Mendoza, Argentina",
            "Rosario, Argentina",
            "Adelaide, Australia",
            "Ashford, Australia",
            "Camperdown, Australia",
            "Herston, Australia",
            "Liverpool, Australia",
            "Malvern, Australia",
            "Melbourne, Australia",
            "Southport, Australia",
            "Wahroonga, Australia",
            "West Heidelberg, Australia",
            "Woolloongabba, Australia",
            "Antwerpen, Belgium",
            "Bruxelles, Belgium",
            "Gent, Belgium",
            "Gosselies, Belgium",
            "Leuven, Belgium",
            "Liege, Belgium",
            "Namur, Belgium",
            "Ottignies, Belgium",
            "Roeselare, Belgium",
            "Sint-Niklaas, Belgium",
            "Barretos, Brazil",
            "IjuÃ­, Brazil",
            "Natal, Brazil",
            "Porto Alegre, Brazil",
            "Sao Jose Do Rio Preto, Brazil",
            "Sao Paulo, Brazil",
            "Abbotsford, British Columbia, Canada",
            "Kelowna, British Columbia, Canada",
            "Vancouver, British Columbia, Canada",
            "Halifax, Nova Scotia, Canada",
            "Barrie, Ontario, Canada",
            "London, Ontario, Canada",
            "Oakville, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Weston, Ontario, Canada",
            "Montreal, Quebec, Canada",
            "Sherbrooke, Quebec, Canada",
            "Quebec, Canada",
            "Toronto, Canada",
            "Angers Cedex 9, France",
            "Caen Cedex 05, France",
            "Dijon Cedex, France",
            "Le Mans Cedex 2, France",
            "Lyon Cedex 03, France",
            "Lyon, France",
            "Montpellier, France",
            "Paris Cedex 15, France",
            "Saint Herblain, France",
            "Toulouse Cedex 9, France",
            "Berlin, Germany",
            "Braunschweig, Germany",
            "Dresden, Germany",
            "Frankfurt, Germany",
            "Freiburg, Germany",
            "Hamburg, Germany",
            "Heidelberg, Germany",
            "Muenchen, Germany",
            "Muenster, Germany",
            "Nuertingen, Germany",
            "TÃ¼bingen, Germany",
            "Wuppertal, Germany",
            "Fukuoka-Shi, Japan",
            "Kanazawa, Japan",
            "Kashiwa, Japan",
            "Kita-Gun, Japan",
            "Kumamoto, Japan",
            "Kurume, Japan",
            "Matsuyama-Shi, Japan",
            "Miyazaki, Japan",
            "Nagasaki, Japan",
            "Osaka-Sayama, Japan",
            "Osaka, Japan",
            "Sakura, Japan",
            "Sapporo, Japan",
            "Ube, Japan",
            "Yokohama, Japan",
            "Goyang-Si, Korea, Republic of",
            "Seongnam, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Chihuahua, Mexico",
            "Cuernavaca, Mexico",
            "Culiacan, Mexico",
            "Mexico, Mexico",
            "Oaxaca, Mexico",
            "Zapopan, Mexico",
            "Amsterdam Zuidoost, Netherlands",
            "Amsterdam, Netherlands",
            "Blaricum, Netherlands",
            "Den Haag, Netherlands",
            "Dordrecht, Netherlands",
            "Groningen, Netherlands",
            "Heerlen, Netherlands",
            "Nieuwegein, Netherlands",
            "Nijmegen, Netherlands",
            "Rotterdam, Netherlands",
            "Kursk, Russian Federation",
            "Moscow, Russian Federation",
            "Omsk, Russian Federation",
            "Pyatigorsk, Russian Federation",
            "Rostov-On-Don, Russian Federation",
            "Saint Petersburg, Russian Federation",
            "Saint-Petersburg, Russian Federation",
            "Ufa, Russian Federation",
            "Bloemfontein, South Africa",
            "Cape Town, South Africa",
            "Johannesburg, South Africa",
            "Pretoria, South Africa",
            "Alcorcon, Spain",
            "Barcelona, Spain",
            "Cadiz, Spain",
            "Cordoba, Spain",
            "Madrid, Spain",
            "San SebastiÃ¡n De Los Reyes, Spain",
            "Valencia, Spain",
            "Ayr, United Kingdom",
            "Belfast, United Kingdom",
            "Birmingham, United Kingdom",
            "Bristol, United Kingdom",
            "Edinburgh, United Kingdom",
            "Glasgow, United Kingdom",
            "London, United Kingdom",
            "Manchester, United Kingdom",
            "Plymouth, United Kingdom",
            "Preston, United Kingdom",
            "Stevenage, United Kingdom",
            "Sutton, United Kingdom",
            "Westcliff On Sea, United Kingdom",
            "Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02257736"
      },
      {
        "-rank": "227",
        "nct_id": "NCT02003924",
        "title": "Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer",
        "acronym": "PROSPER",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Nonmetastatic Castration-Resistant Prostate Cancer",
            "Prostate Cancer",
            "Cancer of the Prostate"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Metastasis Free Survival (MFS)",
            "Time to Prostate-Specific Antigen (PSA) Progression",
            "Time to First Use of New Antineoplastic Therapy",
            "Overall Survival",
            "Time to Pain Progression",
            "Time to First Use of Cytotoxic Chemotherapy",
            "Chemotherapy-Free Disease Specific Survival",
            "Chemotherapy-Free Survival",
            "Percentage of Participants With Prostate Specific Antigen (PSA) Response",
            "Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score",
            "Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Mobility Domain Score",
            "Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Self-Care Domain Score",
            "Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Usual Activities Domain Score",
            "Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Pain/Discomfort Domain Score",
            "Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Anxiety/ Depression Domain Score",
            "European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Overall Health Status Visual Analog Score (VAS)",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 31",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 32",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 33",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 34",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 35",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 36",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 37",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 38",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 39",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 40",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 41",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 42",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 43",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 44",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 45",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 46",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 47",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 48",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 49",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 50",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 51",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 52",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 53",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 54",
            "Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 55",
            "Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)",
            "Number of Participants With Treatment-Emergent Adverse Events Greater Than or Equal to Grade 3, Based on National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE), Version 4.0",
            "Number of Participants With Discontinuations From Study Treatment Due to Adverse Events (AEs)",
            "Number of Participants With Increase of 2 or More National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) (Version 4.0) Toxicity Grades Above Baseline - Hematology",
            "Number of Participants With Increase of 2 or More National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) (Version 4.0) Toxicity Grades Above Baseline - Chemistry",
            "Number of Participants With Clinically Significant Vital Signs"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Pfizer",
          "collaborator": [
            "Astellas Pharma Inc",
            "Medivation LLC, a wholly owned subsidiary of Pfizer Inc."
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1401",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "MDV3100-14",
            "C3431005",
            "2012-005665-12"
          ]
        },
        "start_date": "October 31, 2013",
        "primary_completion_date": "June 28, 2017",
        "completion_date": "April 28, 2021",
        "study_first_posted": "December 6, 2013",
        "results_first_posted": "July 12, 2018",
        "last_update_posted": "July 1, 2019",
        "locations": {
          "location": [
            "Urological Associates of Southern Arizona, PC, Tucson, Arizona, United States",
            "Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",
            "UCLA Clark Urology Center, Los Angeles, California, United States",
            "University of California, Irvine Medical Center, Orange, California, United States",
            "Urology Associates of San Luis Obispo, a Medical Group, Inc, San Luis Obispo, California, United States",
            "Urology Associates, P.C., Englewood, Colorado, United States",
            "c/o Lynn Buchwalder, New Haven, Connecticut, United States",
            "C/O Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States",
            "Smilow Cancer Center at Yale New Haven-Hospital, New Haven, Connecticut, United States",
            "Yale New Haven Hospital, New Haven, Connecticut, United States",
            "Yale University School of Medicine, New Haven, Connecticut, United States",
            "Lakeland Regional Cancer Center, Lakeland, Florida, United States",
            "Urology of Indiana, LLC, Carmel, Indiana, United States",
            "First Urology, PSC, Jeffersonville, Indiana, United States",
            "IU Health Arnett Cancer Care, Lafayette, Indiana, United States",
            "Kansas City Urology Care, PA, Overland Park, Kansas, United States",
            "GU Research Network/ Wichita Urology Group, Wichita, Kansas, United States",
            "Chesapeake Urology Research Associates, Baltimore, Maryland, United States",
            "University of Michigan Health System, Ann Arbor, Michigan, United States",
            "Michigan Institute of Urology, Troy, Michigan, United States",
            "GU Research Network, Omaha, Nebraska, United States",
            "Brooklyn Urology Research Group, Brooklyn, New York, United States",
            "Premier Medical Group of the Hudson Valley, Newburgh, New York, United States",
            "Duke University Medical Center, Cary, North Carolina, United States",
            "Carolina Urology Partners, PPLC, Charlotte, North Carolina, United States",
            "Carolina Urology Partners, PLLC, Gastonia, North Carolina, United States",
            "Gaston Medical Associates, Gastonia, North Carolina, United States",
            "Duke Women's Cancer Care Raleigh, Raleigh, North Carolina, United States",
            "Clinical Research Solutions, Middleburg Heights, Ohio, United States",
            "Oregon Urology Institute, Springfield, Oregon, United States",
            "Lancaster Urology, Lancaster, Pennsylvania, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville, Tennessee, United States",
            "Vanderbilt University Medical Center, The Urologic Clinic, Nashville, Tennessee, United States",
            "Urology San Antonio (CT scans), San Antonio, Texas, United States",
            "Urology San Antonio Research, San Antonio, Texas, United States",
            "Urology of Virginia, PLLC., Virginia Beach, Virginia, United States",
            "COIBA(Centro de Oncologia e Investigacion Buenos Aires), Berazategui, Buenos Aires, Argentina",
            "Centro Medico Austral(OMI), Caba, Buenos Aires, Argentina",
            "Centro de Urologia, Caba, Buenos Aires, Argentina",
            "Hospital Italiano de Buenos Aires, Caba, Buenos Aires, Argentina",
            "Sanatorio Parque, Rosario, Santa FE, Argentina",
            "Instituto De Oncologia De Rosario, Rosario, Santa FE, Argentina",
            "Clinica Universidad Reina Fabiola, Cordoba, Argentina",
            "Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina",
            "Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina",
            "The Canberra Hospital, Garran, Australian Capital Territory, Australia",
            "Border Medical Oncology Research Unit, Albury, New South Wales, Australia",
            "The Border Cancer Hospital Dispensary, Albury, New South Wales, Australia",
            "The Border Cancer Hospital, Albury, New South Wales, Australia",
            "Sydney cancer centre, Concord, New South Wales, Australia",
            "Epic pharmacy, Lismore, New South Wales, Australia",
            "North Coast Cancer Institute, Lismore, New South Wales, Australia",
            "Macquarie University Hospital, North Ryde, New South Wales, Australia",
            "Macquarie University, North Ryde, New South Wales, Australia",
            "Epic Pharmacy Port Macquarie base hospital, Port Macquarie, New South Wales, Australia",
            "Mid North Coast Cancer Institute, Port Macquarie, New South Wales, Australia",
            "Royal North Shore Hospital, St Leonards, New South Wales, Australia",
            "The Tweed Hospital, Tweed Heads, New South Wales, Australia",
            "Australian Clinical Trials, Wahroonga, New South Wales, Australia",
            "Sydney Adventist Hospital, Wahroonga, New South Wales, Australia",
            "Calvary Mater Newcastle, Waratah, New South Wales, Australia",
            "Westmead Hospital, Westmead, New South Wales, Australia",
            "Icon Cancer Care Wesley, Auchenflower, Queensland, Australia",
            "River City Pharmacy - APHS, Auchenflower, Queensland, Australia",
            "Icon Cancer Care Chermside, Chermside, Queensland, Australia",
            "Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia",
            "Icon Cancer Care, South Brisbane, Queensland, Australia",
            "Icon Cancer Foundation, South Brisbane, Queensland, Australia",
            "Integrated Clinical Oncology Network (ICON), South Brisbane, Queensland, Australia",
            "Icon Cancer Care Southport, Southport, Queensland, Australia",
            "Tasman Health Care Pharmacy, Southport, Queensland, Australia",
            "Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia",
            "Princess Alexandra Hospital, Woolloongabba, Queensland, Australia",
            "Adelaide Cancer Centre, Kurralta Park, South Australia, Australia",
            "Ashford Cancer Centre Research, Kurralta park, South Australia, Australia",
            "Cancer Care SA Pty Ltd, Kurralta Park, South Australia, Australia",
            "Cancer Care SA trading as Icon Pharmacy Adelaide, Kurralta Park, South Australia, Australia",
            "Southern Urology, Bentleigh East, Victoria, Australia",
            "Box Hill Hospital (Eastern health), Box Hill, Victoria, Australia",
            "Eastern Clinical Research Unit (Eastern Health), Box Hill, Victoria, Australia",
            "Cabrini Hospital Brighton, Brighton, Victoria, Australia",
            "Monash Medical Centre, Clayton, Victoria, Australia",
            "Monash Cancer Centre, East Bentleigh, Victoria, Australia",
            "Austin Health, Austin Hospital, Heidelberg, Victoria, Australia",
            "Cabrini Hospital Malvern, Malvern, Victoria, Australia",
            "Cabrini Hospital- Education and Research Precinct, Malvern, Victoria, Australia",
            "Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",
            "Sunshine Hospital, St Albans, Victoria, Australia",
            "Krankenhaus Barmherzige Schwestern Linz, Abteilung Radiologie, Linz, Upper Austria, Austria",
            "Krankenhaus Barmherzige Schwestern Linz, Abteilung Urologie, Linz, Upper Austria, Austria",
            "St. Vincent's Hospital, PET - CT Center, Linz, Upper Austria, Austria",
            "Isotopix, Ambulatorium fuer Nuklearmedizin, Vienna, Austria",
            "Medizinische Universitaet Wien, Universitaetsklinik fuer Innere Medizin I, Vienna, Austria",
            "Diagnosezentrum Meidling GesmbH, Vienna, Austria",
            "Algemeen Ziekenhuis Groeninge, Kortrijk, West-vlaanderen, Belgium",
            "Clinique Universitaire de Bruxelles Hopital Erasme, Bruxelles, Belgium",
            "Cliniques universitaires saint-Luc, Bruxelles, Belgium",
            "Vzw Algemeen Ziekenhuis Maria Middelares, Gent, Belgium",
            "Universitaire Ziekenhuizen Leuven, Leuven, Belgium",
            "Centre Hospitalier Universitaire de Liege, Site du Sart-Tilman, Liege, Belgium",
            "Hospital Sao Rafael, Salvador, Bahia, Brazil",
            "Liga Paranaense de Combate ao cancer / Hospital Erasto Gaertner, Curitiba, Parana, Brazil",
            "Associacao Hospital de Caridade de Ijui, Ijui, RIO Grande DO SUL, Brazil",
            "Hospital da Cidade de Passo Fundo, Passo Fundo, RIO Grande DO SUL, Brazil",
            "Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil",
            "CLINIONCO - Clinica de Oncologia de Porto Alegre Ltda., Porto Alegre, RIO Grande DO SUL, Brazil",
            "Hospital Sao Lucas da PUCRS, Porto Alegre, RIO Grande DO SUL, Brazil",
            "Instituto D'or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil",
            "Hospital Amaral Carvalho - Fundacao Dr. Amaral Carvalho, Jau, SAO Paulo, Brazil",
            "Fundacao Dr. Amaral Carvalho, Jau, SAO Paulo, Brazil",
            "Fundacao Dr.Amaral Carvalho, Jau, SAO Paulo, Brazil",
            "Hospital Israelita Albert Einstein, Sao Paulp, SAO Paulo, Brazil",
            "Hospital das Clinicas da Faculdade de Ciencias Medicas da UNICAMP, Campinas, SP, Brazil",
            "Centro de Estudos e Pesquisas em Hematologia e Oncologia (CEPHO), Santo Andre, SP, Brazil",
            "IAMSPE-Inst. de Assist. ao Servidor Publico Estadual, Sao Paulo, SP, Brazil",
            "Hospital Universitario Pedro Ernesto - UERJ, Rio de Janeiro, Brazil",
            "Oncologia Rede D'Or, Rio de Janeiro, Brazil",
            "Tom Baker Cancer Centre, Calgary, Alberta, Canada",
            "Cross Cancer Institute, Edmonton, Alberta, Canada",
            "Vancouver Prostate Centre, Vancouver, British Columbia, Canada",
            "Manitoba Prostate Centre CancerCare Manitoba, Winnipeg, Manitoba, Canada",
            "NS Health Authority, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada",
            "The Male/Female Health and Research Centre, Barrie, Ontario, Canada",
            "McMaster Institute of Urology @ St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",
            "Urology Associates / Urologic Medical Research, Kitchener, Ontario, Canada",
            "London Regional Cancer Program - Victoria Hospital, London Health Sciences Centre(LHSC), London, Ontario, Canada",
            "Urology Reasearch - Victoria Hospital, London Health Sciences Centre(LHSC), London, Ontario, Canada",
            "Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",
            "University Health Network- Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Urology South Shore Research, Greenfield Park, Quebec, Canada",
            "Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada",
            "McGill University Health Centre, Montreal, Quebec, Canada",
            "CHU de Quebec, Quebec, Canada",
            "Fundacion Arturo Lopez Perez, Santiago, Chile",
            "Centro de Investigaciones Clinicas Vina del Mar, Santiago, Chile",
            "Instituto Clinico Oncologico del Sur (ICOS), Temuco, Chile",
            "Instituto Oncologico Ltda., Vina del Mar, Chile",
            "Centro de Investigaciones Clinicas, Vina del Mar, Chile",
            "Peking University First Hospital, Beijing, Beijing, China",
            "Beijing Cancer Hospital, Beijing, Beijing, China",
            "Peking University Third Hospital, Beijing, Beijing, China",
            "Beijing Hospital, Beijing, Beijing, China",
            "Peking Union Medical College Hospital, Beijing, Beijing, China",
            "Chongqing Cancer Hospital, Chongqing, Chongqing, China",
            "The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",
            "Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",
            "Office of Hongqian Guo, Nanjing, Jiangsu, China",
            "Jiangsu Cancer Hospital, Nanjing, Jiangsu, China",
            "Jiangsu Province Hospital, Nanjing, Jiangsu, China",
            "The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China",
            "Wuxi People's Hospital, Wuxi, Jiangsu, China",
            "Qingdao Municipal Hospital (East Hospital), Qingdao, Shandong, China",
            "Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",
            "Huashan Hospital Fudan University, Shanghai, Shanghai, China",
            "Shanghai First People's Hospital, Shanghai, Shanghai, China",
            "Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",
            "Shanghai Changhai Hospital, Shanghai, Shanghai, China",
            "The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China",
            "The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",
            "The First Affiliated Hospital of Wenzhou University, Wenzhou, Zhejiang, China",
            "UNIMED Medical Institute Limited, Hong Kong, China",
            "The Second Hospital of Tianjin Medical University, Tianjin, China",
            "Rigshospitalet 7521, Copenhagen, Norrebro, Denmark",
            "Copenhagen Prostate Cancer Center, Copenhagen, N, Denmark",
            "Aarhus University Hospital, Arhus N, Denmark",
            "Rigshospitalet, Copenhagen, Denmark",
            "Frederiksberg Hospital, Frederiksberg, Denmark",
            "Herlev Hospital, Herlev, Denmark",
            "Odense University Hospital, Odense C, Denmark",
            "Vejle Sygehus, Vejle, Denmark",
            "Docrates Syopasairaala, Helsinki, Finland",
            "Helsingin yliopistollinen keskussairaala, Meilahden sairaala, Helsinki, Finland",
            "Oulun yliopistollinen sairaala, Oulu, Finland",
            "Satakunnan keskussairaala, Pori, Finland",
            "Tampereen yliopistollinen Sairaala, Tampere, Finland",
            "Hopitaux Universitaires de Strasbourg - Hopital Civil, STRASBOURG Cedex, Alsace, France",
            "Centre Paul Strauss, Strasbourg, Bas-rhin, France",
            "Clinique Sainte Anne, Strasbourg, Bas-rhin, France",
            "Societe MIM, Clinique Sainte Anne, Strasbourg, Bas-rhin, France",
            "Institut Curie, Paris Cedex, Paris, France",
            "Centre Hospitalier Lyon Sud, Pierre Benite Cedex, Rhone, France",
            "Institut Gustave Roussy, Villejuif Cedex, VAL DE Marne, France",
            "Institut de Cancerologie de l'Ouest - Paul Papin, Angers Cedex 2, France",
            "Institut Sainte Catherine, Avignon, Cedex 9, France",
            "Institut Bergonie, Bordeaux Cedex, France",
            "Urologic Oncology Department- Institut Bergonie - Centre regional de Lutte contre le Cancer, Bordeaux Cedex, France",
            "Cabinet de Radiologie, Brest, France",
            "CHU Brest Hopital Morvan, Brest, France",
            "Clinique pasteur Lancroze, Brest, France",
            "Clinique Pasteur-Lanroze, Brest, France",
            "CHRU de Brest, Brest, France",
            "Hopital Pasteur, Colmar Cedex, France",
            "Hopitaux Civils de Colmar, Colmar, France",
            "Centre Regional de lutte Contre le Cancer Georges Francois Leclerc, Dijon, France",
            "Clinique Victor Hugo, Le Mans,Cedex, France",
            "Hopital Calude Huriez - CHU Lille, Lille, France",
            "Hopital Edouard Herriot - CHU Lyon, Lyon Cedex 03, France",
            "Centre Leon Berard, Lyon Cedex, France",
            "Centre de Medecine Nucleaire LUMEN, Lyon, France",
            "Hopital Nord, Marseille, France",
            "ICM Val D'Aurelle, Montpellier Cedex, France",
            "Hopital Europeen Georges Pompidou, Paris, Cedex 15, France",
            "Centre Hospitalier Lyon Sud, Pierre Benite, France",
            "CHU Poitiers - Hopital la Miletrie, Poitiers, Cedex, France",
            "Institut de Cancerologie de I'Ouest - Rene Gauducheau, Saint-Herblain Cedex, France",
            "Clinique Pasteur - CIMOF, Toulouse Cedex 3, France",
            "Clinique Pasteur- Service Imagerie et Radiologie, Toulouse Cedex 3, France",
            "Clinique Pasteur, Toulouse Cedex 3, France",
            "IUCT-Oncopole, Toulouse Cedex 9, France",
            "Institut Claudius Regaud, Toulouse, France",
            "Studienpraxis Urologie, Nuertingen, Baden-wuerttemberg, Germany",
            "Universitatsmedizin Mannheim, Medizinische Fakultat Mannheim der Universitat Heidelberg, Mannheim, Baden-wurttemberg, Germany",
            "MVZ Zentrum fuer Diagnostische Radiologie und Nuklearmedizin Braunschweig GmbH, Braunschweig, Niedersachsen, Germany",
            "Staedtisches Klinikum Braunschweig, Braunschweig, Niedersachsen, Germany",
            "Hannover Medical School, Hannover, Niedersachsen, Germany",
            "Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany",
            "RWTH University Aachen, Aachen, Nordrhein-westfalen, Germany",
            "Uniklinik der RWTH Aachen, Aachen, Nordrhein-westfalen, Germany",
            "Clinic of Radiology, Aachen, Nordrhein-westfalen, Germany",
            "Universitaetsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Saxony, Germany",
            "Charite, Campus Benjamin Franklin, Berlin, Germany",
            "Charite, Universitaetsmedizin Berlin, Berlin, Germany",
            "Martini-Klinik am UKE GmbH, Hamburg, Germany",
            "Diagnostikzentrum Esslingen, Kirchheim, Germany",
            "University General Hospital of Heraklion, Urology Clinic, Heraklion, Crete, Greece",
            "General Hospital of Athens\"Korgialeneio-Benakeio EES\".Urology Clinic, Athens, Greece",
            "General Hospital of Athens \"Alexandra\", Therapeutic Clinic, Athens, Greece",
            "University General Hospital of Larissa, Urology Department, Larissa, Greece",
            "University General Hospital of Patras, Oncology Department, Internal Medicine Clinic, Patra, Greece",
            "General Hospital\" Papageorgiou\",B' Univ.Urology Clinic, Thessaloniki, Greece",
            "Queen Mary Hospital, Hong Kong, Hong Kong",
            "Tuen Mun Hospital, Hong Kong, Hong Kong",
            "Prince of Wales Hospital, Shatin, Hong Kong",
            "Laboratorio Medicina Nucleare-Ospedale G.B. Morgagni-Pierantoni, Forli, FC, Italy",
            "Farmacia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy",
            "Medicina Nucleare, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy",
            "Servizio di Radiologia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy",
            "Struttura Complessa di Oncologia, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy",
            "U.O. di Oncologia, Ospedale Civile Degli Infermi, Faenza (RA), Italy",
            "U.O. di Radiologia, Ospedale Civile degli Infermi, Faenza (RA), Italy",
            "U.O. di Oncologia, Ospedale Civile Umberto I, Lugo (RA), Italy",
            "U.O. di Radiologia, Ospedale Civile Umberto I, Lugo (RA), Italy",
            "Laboratorio Farmaci Antiblastici, Meldola (FC), Italy",
            "U.O. Oncologia Medica, Meldola (FC), Italy",
            "UO Radiologia, Meldola (FC), Italy",
            "Dipartimento di Radiologia, Ospedale San Raffaele, Milano, Italy",
            "Servizio di Farmacia, Ospedale San Raffaele, Milano, Italy",
            "U.O. di Medicina Nucleare e Centro PET, Ospedale San Raffaele, Milano, Italy",
            "U.O. di Urologia, Ospedale San Raffaele, Milano, Italy",
            "Farmacia Studi Clinici e Sperimentali, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",
            "S.C. di Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",
            "S.C. Diagnostica Radiologica 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy",
            "Divisione di Radiologia, Istituto Europeo di Oncologia, Milano, Italy",
            "Reparto Oncologia Medica Urogenitale e Cervico Facciale, Istituto Europeo di Oncologia, Milano, Italy",
            "Servizio Farmacia, Istituto Europeo di Oncologia, Milano, Italy",
            "A. O. U. Policlinico di Modena, U. O. Oncologia, Modena, Italy",
            "Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy",
            "Farmacia Interna, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy",
            "Medicina Nucleare, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy",
            "Radiologia I, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy",
            "U.O.S.C. di Oncologia Medica, A.O.R.N. \"A. Cardarelli\", Napoli, Italy",
            "Farmacia Ospedaliera, AOU San Luigi Gonzaga, Orbassano (TO), Italy",
            "SCDU Oncologia Medica II Pad, AOU San Luigi Gonzaga, Orbassano (TO), Italy",
            "SCDU Radiodiagnostica, AOU San Luigi Gonzaga, Orbassano (TO), Italy",
            "SS Medicina Nucleare, AOU San Luigi Gonzaga, Orbassano (TO), Italy",
            "Farmacia, Istituto Oncologico Veneto (IOV), Padova, Italy",
            "IRCCS - Istituto Oncologico Veneto (IOV), UOC Oncologia Medica 1, Padova, Italy",
            "Medicina Nucleare, Istituto Oncologico Veneto (IOV), Padova, Italy",
            "UOC Radiodiagnostica Oncologica, Istituto Oncologico Veneto (IOV), Padova, Italy",
            "Ospedale Santa Maria delle Croci, Ravenna, Italy",
            "Servizio di Farmacia, AUSL di Ravenna, Ravenna, Italy",
            "Servizio di Radiologia, AUSL di Ravenna, Ravenna, Italy",
            "Azienda Ospedaliera S. Camillo Forlanini, UOC per il governo clinico in Oncologia Medica, Roma, Italy",
            "U.O. di Oncologia Medica, Ospedale Santa Chiara, Trento, Italy",
            "U.O. Farmacia, Ospedale Santa Chiara, Trento, Italy",
            "U.O. Radiologia, Ospedale Santa Chiara, Trento, Italy",
            "National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of",
            "Chonnam National University Hwasun Hospital, Hwasun-gun, Jeonnam, Korea, Republic of",
            "Gachon University Gil Medical Center, Incheon, Korea, Republic of",
            "Seoul National University Hospital, Seoul, Korea, Republic of",
            "Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",
            "Samsung Medical Center, Seoul, Korea, Republic of",
            "Universiti Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur, Malaysia",
            "Sarawak General Hospital, Kuching, Sarawak, Malaysia",
            "Subang Jaya Medical Centre Sdn. Bhd., Subang Jaya, Selangor Darul Ehsan, Malaysia",
            "Hospital Kuala Lumpur, Kuala Lumpur, Malaysia",
            "University Malaya Medical Centre, Kuala Lumpur, Malaysia",
            "Catharina Ziekenhuis, Eindhoven, Noord-brabant, Netherlands",
            "Netherlands Cancer Institute, Amsterdam, Netherlands",
            "Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands",
            "University Medical Center Groningen, Groningen, Netherlands",
            "University Hospital Maastricht (MUMC), Maastricht, Netherlands",
            "Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",
            "Canterbury Regional Cancer & Blood Service, Christchurch, Canterbury, New Zealand",
            "Palmerston North Hospital, Palmerston North, Manawatu, New Zealand",
            "Waikato Urology Research LTD, Hamilton, Waikato, New Zealand",
            "Regional Blood and Cancer Services, Auckland, New Zealand",
            "Greenlane Clinical Centre, Auckland, New Zealand",
            "Uniwersyteckie Centrum Kliniczne, Gdansk, Poland",
            "UROMEDYK, Poradnia Urologiczna, Kielce, Poland",
            "Malopolskie Centrum Medyczne s.c., Krakow, Poland",
            "Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ, Lublin, Poland",
            "Wojewodzki Szpital Specjalistyczny im. Janusza. Korczaka, Slupsk, Poland",
            "Profesorskie Centrum Medyczne Optimum, Wroclaw, Poland",
            "Centrum Medyczne Melita Medical, Wroclaw, Poland",
            "Wro Medica, Wroclaw, Poland",
            "Lexmedica, Wroclaw, Poland",
            "Federal State Budgetary Institution \"N.N. Blokhin Russian Cancer Research Center\", Moscow, Russian Federation",
            "P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research, Moscow, Russian Federation",
            "State Budgetary Healthcare Institution City Multifield Hospital No.2, Saint-Petersburg, Russian Federation",
            "SBEI HPE \"First Pavlov State Medical University of St. Petersburg\" of, Saint-Petersburg, Russian Federation",
            "SBEI HPE \"First Pavlov State Medical University of St. Petersburg\" of, Saint-Petersburg, Russian Federation",
            "Saint-Petersburg State Budgetary Healthcare Institution \"Hospital for Veterans of War\", Saint-Petersburg, Russian Federation",
            "SBHI \"Saint-Petersburg clinical scientific, Saint-Petersburg, Russian Federation",
            "SBEI of HPE \"Bashkir State Medical University\" of MoH of the RF, Ufa, Russian Federation",
            "Clinical Center Of Serbia, Clinic of Urology, Belgrade, Serbia",
            "Clinical Center \"Dr Dragisa Misovic -Dedinje\", Clinic of Urology, Belgrade, Serbia",
            "Clinical Center \"Bezanijska Kosa\", Department of Urology, Belgrade, Serbia",
            "Clinical Center Zemun, Belgrade, Serbia",
            "National University Hospital, Singapore, Singapore",
            "National Cancer Centre Singapore, Singapore, Singapore",
            "Fakultna nemocnica s poliklinikou F.D. Roosevelta, Banska Bystrica, Slovakia",
            "Institut nuklearnej a molekularnej mediciny, Banska Bystrica, Slovakia",
            "Bratislavske radiodiagnosticke centrum, a.s., Bratislava, Slovakia",
            "CUIMED, s.r.o., Urologicka ambulancia, Bratislava, Slovakia",
            "Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovakia",
            "Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovakia",
            "Institut nuklearnej a molekularnej mediciny, Kosice, Slovakia",
            "Univerzitna nemocnica Martin, Martin, Slovakia",
            "IZOTOPCENTRUM, s.r.o., Nitra, Slovakia",
            "Jessenius-diagnosticke centrum, a.s., Nitra, Slovakia",
            "UROEXAM spol. s r.o. urologicka ambulancia, Nitra, Slovakia",
            "Alfamedis, s.r.o., Presov, Slovakia",
            "MILAB s.r.o., UROCENTRUM, Presov, Slovakia",
            "Vivamed, s.r.o, Presov, Slovakia",
            "UVN SNP - FN Ruzomberok, Pracovisko Nuklearnej mediciny CCSR, Ruzomberok, Slovakia",
            "Fakultna nemocnica s Poliklinikou Skalica a.s, Skalica, Slovakia",
            "GAMMALAB, spol. s.r.o., Oddelenie nuklearnej mediciny, Trnava, Slovakia",
            "GAMMALAB, spol.s.r.o., Oddelenie nuklearnej mediciny, Trnava, Slovakia",
            "KK MED s.r.o., Zilina, Slovakia",
            "Fakultna nemocnica s poliklinikou Zilina, Urologicke oddelenie, Zilina, Slovakia",
            "Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruna, Spain",
            "Hospital Universitari Son Espases,, Palma de Mallorca, Baleares, Spain",
            "Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain",
            "ALTAHIA. Xarxa Assistencial Universitaria de Manresa, Manresa, Barcelona, Spain",
            "Hospital Universitario Parc Tauli, Sabadell, Barcelona, Spain",
            "ICO Girona-Hospital Universitari de Girona Dr. Josep Trueta, Gerona, Cataluna, Spain",
            "Hospital de Navarra, Pamplona, Navarra, Spain",
            "Complejo Hospitalario Universitario A Coruna, A Coruna, Spain",
            "Hospital Del Mar, Barcelona, Spain",
            "Cetir Centre Medic, S.L., Barcelona, Spain",
            "Hospital Clinic de Barcelona, Barcelona, Spain",
            "Hospital Universitario de la Princesa, Madrid, Spain",
            "MD Anderson Cancer Center, Madrid, Spain",
            "Hospital Universitario 12 de octubre, Madrid, Spain",
            "Urologmottagningen, Goteborg, Sweden",
            "Diagnostiskt centrum for bild- och funktionsmedicin, Malmo, Sweden",
            "Urologiska Kliniken, Malmo, Sweden",
            "Apoteket AB Kliniska Provningar Molnlycke, Molnlycke, Sweden",
            "Karolinska Universitetssjukhuset, Solna, Sweden",
            "Urologmottagningen, Stockholm, Sweden",
            "Urologkliniken, Umea, Sweden",
            "Urologiska Kliniken, Ã–rebro, Sweden",
            "Chang Gung Medical Fundation, Chiayi Branch(Chiayi Chang Gung Memorial Hospital), Chiayi County, Taiwan",
            "Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan",
            "Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan",
            "Chang Gung Medical Fundation,Kaohsiung (Kaohsiung Chang Gung Memorial Hospital), Kaohsiung, Taiwan",
            "Chang Gung Memorial Hospital, Keelung Branch (Keelung Chang Gung Memorial Hospital), Keelung City, Taiwan",
            "China Medical University Hospital, Taichung, Taiwan",
            "Taichung Veterans General Hospital, Taichung, Taiwan",
            "Chi Mei Medical Centre, Tainan City, Taiwan",
            "National Taiwan University Hospital, Taipei, Taiwan",
            "Taipei Veterans General Hospital, Taipei, Taiwan",
            "Chang-Gung Memorial Hospital at Linkuo, Taoyuan County, Taiwan",
            "Maharaj Nakorn Chiang Mai Hospital, Muang, Chiang MAI, Thailand",
            "Songklanagarind Hospital, Hat Yai, Songkla, Thailand",
            "King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand",
            "Rajavithi Hospital, Bangkok, Thailand",
            "Cukurova Universitesi Tip Fakultesi, Adana, Turkey",
            "Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey",
            "Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey",
            "Izmir Bozyaka Egitim Arastirma Hastanesi, Izmir, Turkey",
            "Celal Bayar Universitesi Tip Fakultesi, Manisa, Turkey",
            "RCI Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine",
            "CI Dnipropetrovsk I.I. Mechnykov RCH, Department of Urology #2, Dnipropetrovsk, Ukraine",
            "CHI V.I.Shapoval RCC of Urology and Nephrology, Dep. Of Urology#4, Kharkiv, Ukraine",
            "Kyiv City Clinical Hospital #3, Department of Urology, Kyiv, Ukraine",
            "Central City Clinical Hospital, City Oncological Center, Uzhgorod, Ukraine",
            "CI Zaporizhzhia Regional Clinical Hospital, Dep. Of Urology,, Zaporizhzhia, Ukraine",
            "East and North Hertfordshire NHS Trust, Northwood, Middlesex, United Kingdom",
            "Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom",
            "Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",
            "The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne and Wear, United Kingdom",
            "University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom",
            "University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom",
            "University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom",
            "University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom",
            "Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",
            "University College Hospitals NHS Trust, London, United Kingdom",
            "Imperial College Healthcare NHS Trust, London, United Kingdom",
            "University College London Hospitals NHS Foundation Trust, London, United Kingdom",
            "The Christie NHS Foundation Trust, Manchester, United Kingdom",
            "Oxford University Hospitals NHS Trust, Oxford, United Kingdom"
          ]
        },
        "study_documents": {
          "study_document": [
            {
              "label": "Study Protocol",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/24/NCT02003924/Prot_000.pdf"
            },
            {
              "label": "Statistical Analysis Plan",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/24/NCT02003924/SAP_001.pdf"
            }
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02003924"
      },
      {
        "-rank": "228",
        "nct_id": "NCT02200614",
        "title": "Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer",
        "acronym": "ARAMIS",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer Non-Metastatic",
            "Castration-Resistant"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Darolutamide (BAY1841788)"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Metastasis-Free Survival",
            "Overall Survival",
            "Time to first symptomatic skeletal event (SSE)",
            "Time to initiation of first cytotoxic chemotherapy for prostate cancer",
            "Time to pain progression",
            "Safety and tolerability of ODM-201"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Bayer",
          "collaborator": "Orion Corporation, Orion Pharma"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1509",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "17712",
            "2013-003820-36"
          ]
        },
        "start_date": "September 12, 2014",
        "primary_completion_date": "September 3, 2018",
        "completion_date": "June 30, 2020",
        "study_first_posted": "July 25, 2014",
        "last_update_posted": "June 21, 2019",
        "locations": {
          "location": [
            "Homewood, Alabama, United States",
            "Anchorage, Alaska, United States",
            "Tucson, Arizona, United States",
            "Fountain Valley, California, United States",
            "La Jolla, California, United States",
            "Laguna Hills, California, United States",
            "Los Angeles, California, United States",
            "Los Angeles, California, United States",
            "San Diego, California, United States",
            "Whittier, California, United States",
            "Denver, Colorado, United States",
            "Denver, Colorado, United States",
            "Parker, Colorado, United States",
            "Boca Raton, Florida, United States",
            "Orlando, Florida, United States",
            "Port Saint Lucie, Florida, United States",
            "Coeur d'Alene, Idaho, United States",
            "Chicago, Illinois, United States",
            "Evanston, Illinois, United States",
            "Springfield, Illinois, United States",
            "Greenwood, Indiana, United States",
            "Indianapolis, Indiana, United States",
            "Jeffersonville, Indiana, United States",
            "West Des Moines, Iowa, United States",
            "Wichita, Kansas, United States",
            "New Orleans, Louisiana, United States",
            "Annapolis, Maryland, United States",
            "Baltimore, Maryland, United States",
            "Salisbury, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Grand Rapids, Michigan, United States",
            "Royal Oak, Michigan, United States",
            "Omaha, Nebraska, United States",
            "Omaha, Nebraska, United States",
            "Lebanon, New Hampshire, United States",
            "Voorhees, New Jersey, United States",
            "Bronx, New York, United States",
            "Bronx, New York, United States",
            "Syracuse, New York, United States",
            "Asheboro, North Carolina, United States",
            "Charlotte, North Carolina, United States",
            "Canton, Ohio, United States",
            "Cincinnati, Ohio, United States",
            "Cleveland, Ohio, United States",
            "Gahanna, Ohio, United States",
            "Middleburg Heights, Ohio, United States",
            "Oklahoma City, Oklahoma, United States",
            "Bala-Cynwyd, Pennsylvania, United States",
            "Bryn Mawr, Pennsylvania, United States",
            "Myrtle Beach, South Carolina, United States",
            "Nashville, Tennessee, United States",
            "Dallas, Texas, United States",
            "Fairfax, Virginia, United States",
            "Richmond, Virginia, United States",
            "Virginia Beach, Virginia, United States",
            "Wheeling, West Virginia, United States",
            "Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina",
            "Santa FÃ©, Santa Fe, Argentina",
            "San Miguel de TucumÃ¡n, Tucuman, Argentina",
            "CÃ³rdoba, Argentina",
            "CÃ³rdoba, Argentina",
            "CÃ³rdoba, Argentina",
            "La Rioja, Argentina",
            "Randwick, New South Wales, Australia",
            "St Leonards, New South Wales, Australia",
            "Douglas, Queensland, Australia",
            "South Brisbane, Queensland, Australia",
            "Fitzroy, Victoria, Australia",
            "Kurralta Park, Australia",
            "Wien, Austria",
            "Wien, Austria",
            "Lesnoy, Belarus",
            "Minsk, Belarus",
            "Bonheiden, Belgium",
            "Kortrijk, Belgium",
            "Libramont, Belgium",
            "Liege, Belgium",
            "Sint-truiden, Belgium",
            "Salvador-Bahia, Bahia, Brazil",
            "Fortaleza, CearÃ¡, Brazil",
            "GoiÃ¢nia, GoiÃ¡s, Brazil",
            "Belo Horizonte, Minas Gerais, Brazil",
            "Juiz de Fora, Minas Gerais, Brazil",
            "Uberlandia, Minas Gerais, Brazil",
            "Curitiba, Parana, Brazil",
            "Recife, Pernambuco, Brazil",
            "Passo Fundo, Rio Grande Do Sul, Brazil",
            "Porto Alegre, Rio Grande Do Sul, Brazil",
            "Porto Alegre, Rio Grande Do Sul, Brazil",
            "ItajaÃ­, Santa Catarina, Brazil",
            "Barretos, Sao Paulo, Brazil",
            "Jau, Sao Paulo, Brazil",
            "Ribeirao Preto - SP, Sao Paulo, Brazil",
            "Sorocaba, Sao Paulo, Brazil",
            "SÃ£o Paulo, Sao Paulo, Brazil",
            "SÃ£o Paulo, Sao Paulo, Brazil",
            "SÃ£o Paulo, Sao Paulo, Brazil",
            "SÃ£o Paulo, Sao Paulo, Brazil",
            "SÃ£o Paulo, Sao Paulo, Brazil",
            "Sofia, Bulgaria",
            "Varna, Bulgaria",
            "Calgary, Alberta, Canada",
            "Halifax, Nova Scotia, Canada",
            "Burlington, Ontario, Canada",
            "Hamilton, Ontario, Canada",
            "Kingston, Ontario, Canada",
            "London, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Granby, Quebec, Canada",
            "Pointe-Claire, Quebec, Canada",
            "MedellÃ­n, Antioquia, Colombia",
            "MonterÃ­a, CÃ³rdoba, Colombia",
            "Floridablanca, Santander, Colombia",
            "Jablonec nad Nisou, Czechia",
            "Kolin, Czechia",
            "Olomouc, Czechia",
            "Opava, Czechia",
            "Praha 2, Czechia",
            "Praha 2, Czechia",
            "Praha 6, Czechia",
            "Praha 8, Czechia",
            "Tallinn, Estonia",
            "Helsinki, Finland",
            "Kuopio, Finland",
            "SeinÃ¤joki, Finland",
            "Tampere, Finland",
            "Turku, Finland",
            "Angers, France",
            "Bayonne, France",
            "Besancon, France",
            "Bordeaux Cedex, France",
            "CAEN cedex 05, France",
            "Cergy Pontoise, France",
            "Clermont Ferrand Cedex 1, France",
            "Creteil, France",
            "Dijon, France",
            "LA ROCHE SUR YON cedex, France",
            "Limoges Cedex, France",
            "Montpellier Cedex, France",
            "Montpellier Cedex, France",
            "Nancy, France",
            "Nantes Cedex, France",
            "Paris, France",
            "Paris, France",
            "Pierre Benite, France",
            "POITIERS cedex, France",
            "REIMS cedex, France",
            "Rennes Cedex, France",
            "Rouen Cedex, France",
            "Saint Mande, France",
            "Strasbourg, France",
            "Suresnes, France",
            "Tours, France",
            "Villejuif Cedex, France",
            "Emmendingen, Baden-WÃ¼rttemberg, Germany",
            "Kirchheim unter Teck, Baden-WÃ¼rttemberg, Germany",
            "MÃ¼hlacker, Baden-WÃ¼rttemberg, Germany",
            "NÃ¼rtingen, Baden-WÃ¼rttemberg, Germany",
            "Reutlingen, Baden-WÃ¼rttemberg, Germany",
            "TÃ¼bingen, Baden-WÃ¼rttemberg, Germany",
            "Zirndorf, Bayern, Germany",
            "Frankfurt, Hessen, Germany",
            "Marburg, Hessen, Germany",
            "Hagenow, Mecklenburg-Vorpommern, Germany",
            "Herzberg Am Harz, Niedersachsen, Germany",
            "Holzminden, Niedersachsen, Germany",
            "DÃ¼sseldorf, Nordrhein-Westfalen, Germany",
            "KÃ¶ln, Nordrhein-Westfalen, Germany",
            "MÃ¼lheim, Nordrhein-Westfalen, Germany",
            "MÃ¼nster, Nordrhein-Westfalen, Germany",
            "Wuppertal, Nordrhein-Westfalen, Germany",
            "Mainz, Rheinland-Pfalz, Germany",
            "Magdeburg, Sachsen-Anhalt, Germany",
            "Dresden, Sachsen, Germany",
            "Berlin, Germany",
            "Hamburg, Germany",
            "Hamburg, Germany",
            "Budapest, Hungary",
            "Budapest, Hungary",
            "Budapest, Hungary",
            "Debrecen, Hungary",
            "Gyor, Hungary",
            "Nyiregyhaza, Hungary",
            "Szeged, Hungary",
            "Szekszard, Hungary",
            "Szolnok, Hungary",
            "Zalaegerszeg, Hungary",
            "Haifa, Israel",
            "Chieti, Abruzzo, Italy",
            "Catanzaro, Calabria, Italy",
            "Napoli, Campania, Italy",
            "ForlÃ¬-Cesena, Emilia-Romagna, Italy",
            "Modena, Emilia-Romagna, Italy",
            "Parma, Emilia-Romagna, Italy",
            "Roma, Lazio, Italy",
            "Roma, Lazio, Italy",
            "Torino, Piemonte, Italy",
            "Torino, Piemonte, Italy",
            "Lecce, Puglia, Italy",
            "Messina, Sicilia, Italy",
            "Palermo, Sicilia, Italy",
            "Arezzo, Toscana, Italy",
            "Nagoya, Aichi, Japan",
            "Kashiwa, Chiba, Japan",
            "Kurume, Fukuoka, Japan",
            "Koriyama, Fukushima, Japan",
            "Maebashi, Gunma, Japan",
            "Otake, Hiroshima, Japan",
            "Sapporo, Hokkaido, Japan",
            "Kobe, Hyogo, Japan",
            "Higashiibaraki, Ibaraki, Japan",
            "Kanazawa, Ishikawa, Japan",
            "Sagamihara, Kanagawa, Japan",
            "Yokohama, Kanagawa, Japan",
            "Yokosuka, Kanagawa, Japan",
            "Sendai, Miyagi, Japan",
            "Ueda, Nagano, Japan",
            "Kashihara, Nara, Japan",
            "Yufu, Oita, Japan",
            "Osakasayama, Osaka, Japan",
            "Wako, Saitama, Japan",
            "Hamamatsu, Shizuoka, Japan",
            "Utsunomiya, Tochigi, Japan",
            "Bunkyo-ku, Tokyo, Japan",
            "Bunkyo-ku, Tokyo, Japan",
            "Itabashi-ku, Tokyo, Japan",
            "Minato-ku, Tokyo, Japan",
            "Mitaka, Tokyo, Japan",
            "Nakano-ku, Tokyo, Japan",
            "Shinjuku-ku, Tokyo, Japan",
            "Sumida-ku, Tokyo, Japan",
            "Ube, Yamaguchi, Japan",
            "Chiba, Japan",
            "Fukui, Japan",
            "Hiroshima, Japan",
            "Kyoto, Japan",
            "Nagasaki, Japan",
            "Nagasaki, Japan",
            "Okayama, Japan",
            "Osaka, Japan",
            "Osaka, Japan",
            "Osaka, Japan",
            "Toyama, Japan",
            "Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of",
            "Seoul, Seoul Teugbyeolsi, Korea, Republic of",
            "Chungchungbuk-do, Korea, Republic of",
            "Daegu, Korea, Republic of",
            "Daegu, Korea, Republic of",
            "Incheon, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Daugavpils, Latvia",
            "Jelgava, Latvia",
            "Leipaja, Latvia",
            "Riga, Latvia",
            "Riga, Latvia",
            "Riga, Latvia",
            "Kaunas, Lithuania",
            "Kaunas, Lithuania",
            "Klaipeda, Lithuania",
            "Vilnius, Lithuania",
            "Vilnius, Lithuania",
            "La Victoria, Arequipa, Peru",
            "Lima, Peru",
            "Lima, Peru",
            "San Isidro, Peru",
            "Elblag, Poland",
            "Gdansk, Poland",
            "Lodz, Poland",
            "Lublin, Poland",
            "Otwock, Poland",
            "Rzeszow, Poland",
            "Siedlce, Poland",
            "Warszawa, Poland",
            "Warszawa, Poland",
            "Warszawa, Poland",
            "Wroclaw, Poland",
            "Guimaraes, Braga, Portugal",
            "Almada, Lisboa, Portugal",
            "Matosinhos, Porto, Portugal",
            "Braga, Portugal",
            "Lisboa, Portugal",
            "Lisboa, Portugal",
            "Lisboa, Portugal",
            "Lisboa, Portugal",
            "Porto, Portugal",
            "Porto, Portugal",
            "Bucuresti, Romania",
            "Bucuresti, Romania",
            "Bucuresti, Romania",
            "Bucuresti, Romania",
            "Cluj-Napoca, Romania",
            "Craiova, Romania",
            "Craiova, Romania",
            "Oradea, Romania",
            "Ploiesti, Romania",
            "Targu-Mures, Romania",
            "Chelyabinsk, Russian Federation",
            "Ivanovo, Russian Federation",
            "Kazan, Russian Federation",
            "Krasnoyarsk, Russian Federation",
            "Moscow, Russian Federation",
            "Moscow, Russian Federation",
            "Moscow, Russian Federation",
            "Moscow, Russian Federation",
            "Nizhny Novgorod, Russian Federation",
            "Novosibirsk, Russian Federation",
            "Obninsk, Russian Federation",
            "Omsk, Russian Federation",
            "Orenburg, Russian Federation",
            "Pyatigorsk, Russian Federation",
            "Rostov-on-Don, Russian Federation",
            "Saratov, Russian Federation",
            "St. Petersburg, Russian Federation",
            "St. Petersburg, Russian Federation",
            "St. Petersburg, Russian Federation",
            "St. Petersburg, Russian Federation",
            "Tyumen, Russian Federation",
            "Ufa, Russian Federation",
            "Vladimir, Russian Federation",
            "Belgrade, Serbia",
            "Belgrade, Serbia",
            "Nis, Serbia",
            "Bratislava, Slovakia",
            "Bratislava, Slovakia",
            "Martin, Slovakia",
            "Trencin, Slovakia",
            "George, Eastern Cape, South Africa",
            "Port Elizabeth, Eastern Cape, South Africa",
            "Pretoria, Gauteng, South Africa",
            "Pretoria, Gauteng, South Africa",
            "Paarl, Western Cape, South Africa",
            "Rondebosch, Western Cape, South Africa",
            "Cape Town, South Africa",
            "Cape Town, South Africa",
            "Elche, Alicante, Spain",
            "CÃ¡diz, AndalucÃ­a, Spain",
            "L'Hospitalet de Llobregat, Barcelona, Spain",
            "Sabadell, Barcelona, Spain",
            "Terrassa, Barcelona, Spain",
            "Jerez de la Frontera, CÃ¡diz, Spain",
            "Manacor, Illes Baleares, Spain",
            "Palma de Mallorca, Illes Baleares, Spain",
            "AlcorcÃ³n, Madrid, Spain",
            "Barcelona, Spain",
            "Barcelona, Spain",
            "Bilbao, Spain",
            "CÃ³rdoba, Spain",
            "Granada, Spain",
            "Lugo, Spain",
            "Madrid, Spain",
            "Madrid, Spain",
            "Madrid, Spain",
            "Madrid, Spain",
            "MÃ¡laga, Spain",
            "Salamanca, Spain",
            "Sevilla, Spain",
            "Sevilla, Spain",
            "Valencia, Spain",
            "Valencia, Spain",
            "Valencia, Spain",
            "GÃ¶teborg, Sweden",
            "Stockholm, Sweden",
            "Uppsala, Sweden",
            "Ã–rebro, Sweden",
            "Kaohsiung City ,, Taiwan",
            "Kaoshiung, Taiwan",
            "Taichung, Taiwan",
            "Taipei, Taiwan",
            "Taoyuan, Taiwan",
            "Ankara, Turkey",
            "Istanbul, Turkey",
            "Izmir, Turkey",
            "Izmir, Turkey",
            "Manisa, Turkey",
            "Sivas, Turkey",
            "Chernivtsi, Ukraine",
            "Dnipro, Ukraine",
            "Kharkiv, Ukraine",
            "Kryvyi Rih, Ukraine",
            "Kyiv, Ukraine",
            "Kyiv, Ukraine",
            "Uzhgorod, Ukraine",
            "Zaporozhye, Ukraine",
            "Reading, Berkshire, United Kingdom",
            "Llanelli, Carmarthenshire, United Kingdom",
            "Romford, Essex, United Kingdom",
            "Stevenage, Hertfordshire, United Kingdom",
            "Dartford, Kent, United Kingdom",
            "Maidstone, Kent, United Kingdom",
            "Preston, Lancashire, United Kingdom",
            "Bebington, Merseyside, United Kingdom",
            "Scunthorpe, North East Lincolnshire, United Kingdom",
            "Bath, Somerset, United Kingdom",
            "Stoke-on-Trent, Staffordshire, United Kingdom",
            "Dudley, West Midlands, United Kingdom",
            "Huddersfield, West Yorkshire, United Kingdom",
            "Wakefield, West Yorkshire, United Kingdom",
            "Cardiff, United Kingdom",
            "Glasgow, United Kingdom",
            "London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02200614"
      },
      {
        "-rank": "229",
        "nct_id": "NCT01618370",
        "title": "Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Radium-223 dichloride (BAY88-8223)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Acute safety, variables will be summarized using descriptive statistics based on adverse events collection",
            "Long-term safety, variables will be summarized using descriptive statistics based on adverse events collection",
            "Brief Pain Inventory, as assessed by BPI-SF questionnaire (Brief Pain Inventory-Short Form)"
          ]
        },
        "sponsors": { "lead_sponsor": "Bayer" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "705",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "16216",
            "2012-000075-16"
          ]
        },
        "start_date": "July 22, 2012",
        "primary_completion_date": "August 13, 2014",
        "completion_date": "February 28, 2016",
        "study_first_posted": "June 13, 2012",
        "last_update_posted": "March 31, 2017",
        "locations": {
          "location": [
            "Brugge, Belgium",
            "Bruxelles - Brussel, Belgium",
            "Bruxelles - Brussel, Belgium",
            "Bruxelles - Brussel, Belgium",
            "Edegem, Belgium",
            "Gent, Belgium",
            "Kortrijk, Belgium",
            "Leuven, Belgium",
            "Ottignies, Belgium",
            "Edmonton, Alberta, Canada",
            "Vancouver, British Columbia, Canada",
            "Ottawa, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Montreal, Quebec, Canada",
            "Brno, Czech Republic",
            "Ostrava, Czech Republic",
            "Plzen - Bory, Czech Republic",
            "Praha 4, Czech Republic",
            "Praha 5, Czech Republic",
            "Herlev, Denmark",
            "KÃ¸benhavn, Denmark",
            "Odense, Denmark",
            "Helsinki, Finland",
            "HUS, Finland",
            "Kuopio, Finland",
            "SeinÃ¤joki, Finland",
            "Tampere, Finland",
            "Angers Cedex 01, France",
            "Avignon, France",
            "Caen Cedex 5, France",
            "Clermont Ferrand Cedex 1, France",
            "Grenoble, France",
            "La Roche Sur Yon Cedex, France",
            "Lille Cedex, France",
            "Lille, France",
            "Montpellier Cedex, France",
            "Montpellier, France",
            "Paris Cedex 15, France",
            "Paris, France",
            "Paris, France",
            "Poitiers Cedex, France",
            "Saint Herblain, France",
            "Suresnes, France",
            "TOULOUSE cedex, France",
            "Vandoeuvre les Nancy, France",
            "Villejuif Cedex, France",
            "Freiburg im Breisgrau, Baden-WÃ¼rttemberg, Germany",
            "Heidelberg, Baden-WÃ¼rttemberg, Germany",
            "TÃ¼bingen, Baden-WÃ¼rttemberg, Germany",
            "Ulm, Baden-WÃ¼rttemberg, Germany",
            "Erlangen, Bayern, Germany",
            "MÃ¼nchen, Bayern, Germany",
            "MÃ¼nchen, Bayern, Germany",
            "Frankfurt, Hessen, Germany",
            "Marburg, Hessen, Germany",
            "Greifswald, Mecklenburg-Vorpommern, Germany",
            "Rostock, Mecklenburg-Vorpommern, Germany",
            "Rostock, Mecklenburg-Vorpommern, Germany",
            "Braunschweig, Niedersachsen, Germany",
            "GÃ¶ttingen, Niedersachsen, Germany",
            "Hannover, Niedersachsen, Germany",
            "Hannover, Niedersachsen, Germany",
            "Aachen, Nordrhein-Westfalen, Germany",
            "Bonn, Nordrhein-Westfalen, Germany",
            "DÃ¼sseldorf, Nordrhein-Westfalen, Germany",
            "MÃ¼nster, Nordrhein-Westfalen, Germany",
            "Recklinghausen, Nordrhein-Westfalen, Germany",
            "Mainz, Rheinland-Pfalz, Germany",
            "Homburg, Saarland, Germany",
            "Chemnitz, Sachsen, Germany",
            "Dresden, Sachsen, Germany",
            "Jena, ThÃ¼ringen, Germany",
            "Berlin, Germany",
            "Berlin, Germany",
            "Berlin, Germany",
            "Berlin, Germany",
            "Bremen, Germany",
            "Hamburg, Germany",
            "Magdeburg, Germany",
            "Cork, Ireland",
            "Dublin 6, Ireland",
            "Galway, Ireland",
            "Beer Sheva, Israel",
            "Haifa, Israel",
            "Jerusalem, Israel",
            "Kfar Saba, Israel",
            "Petah Tikva, Israel",
            "Ramat Gan, Israel",
            "Rehovot, Israel",
            "Tel Aviv, Israel",
            "Zerifin, Israel",
            "Napoli, Campania, Italy",
            "ForlÃ¬, Emilia-Romagna, Italy",
            "Modena, Emilia-Romagna, Italy",
            "Reggio Emilia, Emilia-Romagna, Italy",
            "Pordenone, Friuli-Venezia Giulia, Italy",
            "Roma, Lazio, Italy",
            "Roma, Lazio, Italy",
            "Roma, Lazio, Italy",
            "Roma, Lazio, Italy",
            "Roma, Lazio, Italy",
            "Genova, Liguria, Italy",
            "Genova, Liguria, Italy",
            "Bergamo, Lombardia, Italy",
            "Brescia, Lombardia, Italy",
            "Milano, Lombardia, Italy",
            "Milano, Lombardia, Italy",
            "Milano, Lombardia, Italy",
            "Milano, Lombardia, Italy",
            "Torino, Piemonte, Italy",
            "Torino, Piemonte, Italy",
            "Bari, Puglia, Italy",
            "Brindisi, Puglia, Italy",
            "Foggia, Puglia, Italy",
            "Cagliari, Sardegna, Italy",
            "Messina, Sicilia, Italy",
            "Arezzo, Toscana, Italy",
            "Firenze, Toscana, Italy",
            "Pisa, Toscana, Italy",
            "Trento, Trentino-Alto Adige, Italy",
            "Padova, Veneto, Italy",
            "Treviso, Veneto, Italy",
            "Verona, Veneto, Italy",
            "Mexico, D.F., Distrito Federal, Mexico",
            "MÃ©xico, Distrito Federal, Mexico",
            "Alkmaar, Netherlands",
            "Amsterdam, Netherlands",
            "Leiden, Netherlands",
            "Nijmegen, Netherlands",
            "Zwolle, Netherlands",
            "Bergen, Norway",
            "BodÃ¸, Norway",
            "LÃ¸renskog, Norway",
            "Oslo, Norway",
            "Oslo, Norway",
            "Ã…lesund, Norway",
            "Bialystok, Poland",
            "Warszawa, Poland",
            "Moscow, Russian Federation",
            "Obninsk, Russian Federation",
            "Santiago de Compostela, A CoruÃ±a, Spain",
            "CÃ³rdoba, AndalucÃ­a, Spain",
            "Hospitalet de Llobregat, Barcelona, Spain",
            "Cruces/Barakaldo, Bilbao, Spain",
            "Santa Cruz de Tenerife, Canarias, Spain",
            "Palma de Mallorca, Illes Baleares, Spain",
            "Las Palmas de Gran Canaria, Las Palmas, Spain",
            "A CoruÃ±a, Spain",
            "Barcelona, Spain",
            "Barcelona, Spain",
            "Barcelona, Spain",
            "LeÃ³n, Spain",
            "Lugo, Spain",
            "Madrid, Spain",
            "Madrid, Spain",
            "Madrid, Spain",
            "Madrid, Spain",
            "Malaga, Spain",
            "MÃ¡laga, Spain",
            "Oviedo, Spain",
            "Pamplona, Spain",
            "Salamanca, Spain",
            "Santander, Spain",
            "Sevilla, Spain",
            "Sevilla, Spain",
            "Valencia, Spain",
            "Valencia, Spain",
            "Valencia, Spain",
            "Zaragoza, Spain",
            "Eskilstuna, Sweden",
            "Kalmar, Sweden",
            "Karlstad, Sweden",
            "LinkÃ¶ping, Sweden",
            "Lund, Sweden",
            "Stockholm, Sweden",
            "Sundsvall, Sweden",
            "UmeÃ¥, Sweden",
            "Uppsala, Sweden",
            "Ã–rebro, Sweden",
            "Aarau, Aargau, Switzerland",
            "Basel, Basel-Stadt, Switzerland",
            "Chur, GraubÃ¼nden, Switzerland",
            "St. Gallen, Sankt Gallen, Switzerland",
            "Bellinzona, Ticino, Switzerland",
            "Lausanne, Vaud, Switzerland",
            "Bern, Switzerland",
            "ZÃ¼rich, Switzerland",
            "Cambridge, Cambridgeshire, United Kingdom",
            "Romford, Essex, United Kingdom",
            "Leicester, Leicestershire, United Kingdom",
            "Edinburgh, Lothian, United Kingdom",
            "Bebington, Merseyside, United Kingdom",
            "Northwood, Middlesex, United Kingdom",
            "Nottingham, Nottinghamshire, United Kingdom",
            "Taunton, Somerset, United Kingdom",
            "Sheffield, South Yorkshire, United Kingdom",
            "Guildford, Surrey, United Kingdom",
            "Sutton, Surrey, United Kingdom",
            "Coventry, Warwickshire, United Kingdom",
            "Birmingham, West Midlands, United Kingdom",
            "Wolverhampton, West Midlands, United Kingdom",
            "Aberdeen, United Kingdom",
            "Belfast, United Kingdom",
            "Bristol, United Kingdom",
            "Cardiff, United Kingdom",
            "Derby, United Kingdom",
            "Glasgow, United Kingdom",
            "Hull, United Kingdom",
            "Leeds, United Kingdom",
            "London, United Kingdom",
            "Manchester, United Kingdom",
            "Newcastle Upon Tyne, United Kingdom",
            "Plymouth, United Kingdom",
            "Southampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01618370"
      },
      {
        "-rank": "230",
        "nct_id": "NCT02813408",
        "title": "A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants",
        "acronym": "AQUARiUS",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "outcome_measures": {
          "outcome_measure": [
            "Health Related Quality of Life (HRQoL)",
            "Fatigue (BFI-SF)",
            "Pain (BPI-SF)",
            "Cognitive Function (FACT-Cog)",
            "Medical Resource Use (MRU)"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Pharmaceutica N.V., Belgium" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "226",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR108141",
            "212082PCR4039"
          ]
        },
        "start_date": "May 3, 2016",
        "primary_completion_date": "March 21, 2018",
        "completion_date": "March 21, 2018",
        "study_first_posted": "June 27, 2016",
        "last_update_posted": "May 24, 2019",
        "locations": {
          "location": [
            "Holstebro N/a, Denmark",
            "Naestved, Denmark",
            "Odense, Denmark",
            "Besancon Cedex, France",
            "Beuvry, France",
            "Bordeaux, France",
            "Challes-les-Eaux, France",
            "Chalon sur SaÃ´ne, France",
            "Dijon, France",
            "Lyon, France",
            "Marseille, France",
            "Paris, France",
            "Quimper, France",
            "Saint Mande, France",
            "Strasbourg, France",
            "Toulouse, France",
            "Berkshire, United Kingdom",
            "Birmingham, United Kingdom",
            "Bolton, United Kingdom",
            "Derby, United Kingdom",
            "Glasgow, United Kingdom",
            "Lancaster, United Kingdom",
            "Middlesbrough, United Kingdom",
            "Oldham, United Kingdom",
            "Sutton, United Kingdom",
            "Wolverhampton., United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02813408"
      },
      {
        "-rank": "231",
        "nct_id": "NCT01288911",
        "title": "A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "bicalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Progression Free Survival (PFS) Based on Independent Central Review (ICR) Assessment",
            "PFS Based on Investigator Assessment",
            "Prostate-specific Antigen (PSA) Response by Week 13",
            "Best PSA Response",
            "Time to PSA Progression",
            "Time to PSA â‰¤ 4 ng/mL",
            "Time to â‰¥ 30% PSA Decline From Baseline",
            "Time to â‰¥ 50% PSA Decline From Baseline",
            "Time to â‰¥ 90% PSA Decline From Baseline",
            "Radiographic PFS Based on ICR Assessment",
            "Percentage of Participants With an Objective Response",
            "Percentage of Participants With Adverse Events"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Inc",
          "collaborator": "Medivation LLC, a wholly owned subsidiary of Pfizer Inc."
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "375",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "9785-CL-0222",
            "2010-021868-15"
          ]
        },
        "start_date": "March 22, 2011",
        "primary_completion_date": "October 19, 2014",
        "completion_date": "November 8, 2017",
        "study_first_posted": "February 3, 2011",
        "results_first_posted": "December 3, 2015",
        "last_update_posted": "August 14, 2019",
        "locations": {
          "location": [
            "Site US1934, Homewood, Alabama, United States",
            "Site US1527, Anchorage, Alaska, United States",
            "Site US3026, Tucson, Arizona, United States",
            "Site US2977, Highland, California, United States",
            "Site US3630, San Diego, California, United States",
            "Site US2935, Denver, Colorado, United States",
            "Site US2945, Middlebury, Connecticut, United States",
            "Site US2014, Melrose Park, Illinois, United States",
            "Site US2067, Springfield, Illinois, United States",
            "Site US2027, Jeffersonville, Indiana, United States",
            "Site US1838, West Des Moines, Iowa, United States",
            "Site US62, Kansas City, Kansas, United States",
            "Site US2976, Baltimore, Maryland, United States",
            "Site US3182, Bethesda, Maryland, United States",
            "Site US2975, Ann Arbor, Michigan, United States",
            "Site US892, Grand Rapids, Michigan, United States",
            "Site US20, Minneapolis, Minnesota, United States",
            "Site US3078, Billings, Montana, United States",
            "Site US2968, Lawrenceville, New Jersey, United States",
            "Site US3025, Poughkeepsie, New York, United States",
            "Site US1675, Rochester, New York, United States",
            "Site US2934, Staten Island, New York, United States",
            "Site US81, Chapel Hill, North Carolina, United States",
            "Site US2104, Greensboro, North Carolina, United States",
            "Site US44, Cincinnati, Ohio, United States",
            "Site US2185, Columbus, Ohio, United States",
            "Site US1598, Bala-Cynwyd, Pennsylvania, United States",
            "Site US1680, Lancaster, Pennsylvania, United States",
            "Site US2926, Myrtle Beach, South Carolina, United States",
            "Site US1657, Nashville, Tennessee, United States",
            "Site US464, Houston, Texas, United States",
            "Site US2978, San Antonio, Texas, United States",
            "Site US1653, Virginia Beach, Virginia, United States",
            "Site US1580, Burien, Washington, United States",
            "Site US1709, Wenatchee, Washington, United States",
            "Site US51, Milwaukee, Wisconsin, United States",
            "Site BE3015, Brussels, Belgium",
            "Site BE1322, Gent, Belgium",
            "Site BE3018, Kortrijk, Belgium",
            "Site BE3288, Leuven, Belgium",
            "Site BE3289, Liege, Belgium",
            "Site BE3013, Turnhout, Belgium",
            "Site CA3104, Calgary, Alberta, Canada",
            "Site CA3242, Abbotsford, British Columbia, Canada",
            "Site CA2646, Kingston, Ontario, Canada",
            "Site CA166, Toronto, Ontario, Canada",
            "Site CA3084, Toronto, Ontario, Canada",
            "Site CA2984, Granby, Quebec, Canada",
            "Site CA170, Montreal, Quebec, Canada",
            "Site DK3354, Aalborg, Denmark",
            "Site DK3356, Aarhus, Denmark",
            "Site DK1857, Copenhagen, Denmark",
            "Site DK1263, Herlev, Denmark",
            "Site FR1091, Creteil, France",
            "Site FR3009, Lille, France",
            "Site FR442, Lyon Cedex 3, France",
            "Site FR3002, Paris Cedex 10, France",
            "Site FR3003, Poitiers Cedex, France",
            "Site FR3000, Rennes Cedex, France",
            "Site FR3007, Rouen, France",
            "Site FR3005, Suresnes Cedex, France",
            "Site DE4000, Nuertingen, Baden-Wuerttemberg, Germany",
            "Site DE2989, Aachen, Germany",
            "Site DE3287, Bergisch Gladbach, Germany",
            "Site DE2993, Bonn, Germany",
            "Site DE2995, Bonn, Germany",
            "Site DE2994, Bonn, Germany",
            "Site DE2990, Hamburg, Germany",
            "Site DE3270, Hannover, Germany",
            "Site DE2992, Reutlingen, Germany",
            "Site DE3286, Waldshut-Tiengen, Germany",
            "Site DE2988, Wuppertal, Germany",
            "Site RO3042, Bucharest, RO, Romania",
            "Site RO3039, Bucharest, RO, Romania",
            "Site RO3035, Bucharest, Romania",
            "Site GB3029, Bristol, UK, United Kingdom",
            "Site GB3027, London, UK, United Kingdom",
            "Site GB3030, London, UK, United Kingdom",
            "Site GB3028, Cardiff, Wales, United Kingdom",
            "Site GB3244, Belfast, United Kingdom",
            "Site GB2702, Cambridge, United Kingdom",
            "Site GB3166, Glasgow, United Kingdom",
            "Site GB1862, Leicher, United Kingdom",
            "Site GB3163, London, United Kingdom",
            "Site GB2624, Manchester, United Kingdom",
            "Site GB3355, Merseyside, United Kingdom",
            "Site GB3245, Northwood, Middlesex, United Kingdom",
            "Site GB3290, Preston, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01288911"
      },
      {
        "-rank": "232",
        "nct_id": "NCT01673984",
        "title": "GP Extended Action Triptorelin",
        "acronym": "GREAT",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "DecapeptylÂ® SR 22.5mg"
            },
            {
              "-type": "Drug",
              "#text": "DecapeptylÂ® SR 11.25mg; ProstapÂ® 3 DCS 11.25mg; ZoladexÂ® LA 10.8mg"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of Participants Maintaining Biochemical Castration",
            "Percentage of Participants Maintaining Biochemical Castration After 12 Months of Treatment.",
            "Percentage of Participants Demonstrating Stable Prostate-specific Antigen (PSA) Levels",
            "Change From Baseline in Quality of Life Using EuroQol 5 Dimensions 5 Levels [EQ-5D-5L] Questionnaire.",
            "Change From Baseline in Patient Satisfaction With Medication Using Treatment Satisfaction Questionnaire for Medication (TSQM Version II)",
            "Patient Satisfaction With Treatment.",
            "Percentage of Participants Who Changed Injection Frequency After Completion of the Study"
          ]
        },
        "sponsors": { "lead_sponsor": "Ipsen" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 4" },
        "enrollment": "27",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "A-97-52014-181",
            "2011-004213-16"
          ]
        },
        "start_date": "August 2012",
        "primary_completion_date": "February 2014",
        "completion_date": "February 2014",
        "study_first_posted": "August 28, 2012",
        "results_first_posted": "September 29, 2015",
        "last_update_posted": "January 29, 2019",
        "locations": {
          "location": [
            "The Crouch Oak Family Practice, Addlestone, United Kingdom",
            "Dr Carter & Partners, Ashford, United Kingdom",
            "Westongrove Research Centre, Aston Clinton Surgery, Aylesbury, United Kingdom",
            "Clinical Research Unit, Oldfield Surgery, Bath, United Kingdom",
            "Clinical Research Unit, The Pulteney Practice, Bath, United Kingdom",
            "St James' Surgery, Bath, United Kingdom",
            "Waterloo Medical Centre, Blackpool, United Kingdom",
            "Woolpit Health Centre, Bury St. Edmunds, United Kingdom",
            "Cossington House Surgery, Canterbury, United Kingdom",
            "Research Office, Avondale Surgery, Chesterfield, United Kingdom",
            "Clinical Research Dept., Rowden Surgery, Chippenham, United Kingdom",
            "Clinical Research Unit, Hathaway Medical Centre, Chippenham, United Kingdom",
            "The Porch Surgery, Corsham, United Kingdom",
            "Pound Hill Surgery, Crawley, United Kingdom",
            "The Medical Centre, East Horsley, United Kingdom",
            "Burbage Surgery, Hinckley, United Kingdom",
            "The Portmill Surgery, Hitchin, United Kingdom",
            "Townhead Surgery, Irvine, United Kingdom",
            "Sherbourne Medical Centre, Leamington Spa, United Kingdom",
            "Mortimer Surgery, Mortimer, United Kingdom",
            "Kiltearn Medical Centre, Nantwich, United Kingdom",
            "Danes Camp Surgery, Northampton, United Kingdom",
            "Kingsthorpe Medical Centre, Northampton, United Kingdom",
            "Cape Cornwall Surgery, Penzance, United Kingdom",
            "The Alverton Practice, Penzance, United Kingdom",
            "Wansford & Kings Cliffe Practice, Wansford Surgery, Peterborough, United Kingdom",
            "Knowle House Surgery, Plymouth, United Kingdom",
            "The Rame Group Practice, Plymouth, United Kingdom",
            "Ashfields Primary Care Centre, Sandbach, United Kingdom",
            "Brannel Surgery, St Austell, United Kingdom",
            "Sunbury Health Centre Group Practice, Sunbury-on-Thames, United Kingdom",
            "Adcroft Surgery, Trowbridge, United Kingdom",
            "Sheepcot Medical Centre, Watford, United Kingdom",
            "Albany House Medical Centre, Wellingborough, United Kingdom",
            "Woosehill Medical Centre, Wokingham, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01673984"
      },
      {
        "-rank": "233",
        "nct_id": "NCT01522443",
        "title": "Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",
        "acronym": "COMET-2",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Castration Resistant Prostate Cancer",
            "Pain",
            "Prostatic Neoplasms"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "cabozantinib"
            },
            {
              "-type": "Drug",
              "#text": "mitoxantrone"
            },
            {
              "-type": "Drug",
              "#text": "prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Pain Response at Week 6 Confirmed at Week 12, Week 12 Reported",
            "Bone Scan Response (BSR)",
            "Overall Survival (OS)"
          ]
        },
        "sponsors": { "lead_sponsor": "Exelixis" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "119",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "XL184-306" },
        "start_date": "March 2012",
        "primary_completion_date": "October 2014",
        "completion_date": "January 13, 2015",
        "study_first_posted": "January 31, 2012",
        "results_first_posted": "May 23, 2018",
        "last_update_posted": "May 23, 2018",
        "locations": {
          "location": [
            "Scottsdale, Arizona, United States",
            "La Jolla, California, United States",
            "Los Angeles, California, United States",
            "Los Angeles, California, United States",
            "Marina Del Rey, California, United States",
            "San Diego, California, United States",
            "San Francisco, California, United States",
            "Santa Barbara, California, United States",
            "Stanford, California, United States",
            "Aurora, Colorado, United States",
            "Littleton, Colorado, United States",
            "Washington, District of Columbia, United States",
            "Boca Raton, Florida, United States",
            "Athens, Georgia, United States",
            "Chicago, Illinois, United States",
            "Indianapolis, Indiana, United States",
            "Iowa City, Iowa, United States",
            "Westwood, Kansas, United States",
            "Louisville, Kentucky, United States",
            "New Orleans, Louisiana, United States",
            "Baltimore, Maryland, United States",
            "Detroit, Michigan, United States",
            "Detroit, Michigan, United States",
            "Minneapolis, Minnesota, United States",
            "Tupelo, Mississippi, United States",
            "Saint Louis, Missouri, United States",
            "Omaha, Nebraska, United States",
            "Las Vegas, Nevada, United States",
            "New Brunswick, New Jersey, United States",
            "Buffalo, New York, United States",
            "New York, New York, United States",
            "New York, New York, United States",
            "New York, New York, United States",
            "Chapel Hill, North Carolina, United States",
            "Durham, North Carolina, United States",
            "Raleigh, North Carolina, United States",
            "Cleveland, Ohio, United States",
            "Oklahoma City, Oklahoma, United States",
            "Pittsburgh, Pennsylvania, United States",
            "Watertown, South Dakota, United States",
            "Memphis, Tennessee, United States",
            "Nashville, Tennessee, United States",
            "Dallas, Texas, United States",
            "Round Rock, Texas, United States",
            "Salt Lake City, Utah, United States",
            "Norfolk, Virginia, United States",
            "Seattle, Washington, United States",
            "Madison, Wisconsin, United States",
            "Milwaukee, Wisconsin, United States",
            "Concord, New South Wales, Australia",
            "Darlinghurst, New South Wales, Australia",
            "Kogarah, New South Wales, Australia",
            "Port Macquarie, New South Wales, Australia",
            "Randwick, New South Wales, Australia",
            "Wahroonga, New South Wales, Australia",
            "Milton, Queensland, Australia",
            "South Brisbane, Queensland, Australia",
            "Woolloongabba, Queensland, Australia",
            "Box Hill, Victoria, Australia",
            "Wodonga, Victoria, Australia",
            "Subiaco, Western Australia, Australia",
            "Kelowna, British Columbia, Canada",
            "Vancouver, British Columbia, Canada",
            "London, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Dublin, Ireland",
            "Dublin, Ireland",
            "Bath, England, United Kingdom",
            "Cambridge, England, United Kingdom",
            "Leeds, England, United Kingdom",
            "London, England, United Kingdom",
            "London, England, United Kingdom",
            "London, England, United Kingdom",
            "Manchester, England, United Kingdom",
            "Sutton, England, United Kingdom",
            "Wirral, England, United Kingdom",
            "Aberdeen, Scotland, United Kingdom",
            "Edinburgh, Scotland, United Kingdom",
            "Glasgow, Scotland, United Kingdom",
            "Inverness, Scotland, United Kingdom",
            "Belfast, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01522443"
      },
      {
        "-rank": "234",
        "nct_id": "NCT03431350",
        "title": "A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
        "acronym": "QUEST",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms, Castration-Resistant" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Niraparib 200 mg"
            },
            {
              "-type": "Drug",
              "#text": "JNJ-63723283 240 mg"
            },
            {
              "-type": "Drug",
              "#text": "JNJ-63723283 480 mg"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone Acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Part 1: Combination 1: Incidence of Specified Toxicities",
            "Part 2: Combination 1: Objective Response Rate (ORR)",
            "Part 2: Combination 2: Composite Response Rate (RR)",
            "Part 2: Combinations 1 and 2: Incidence of Adverse Events (AEs)",
            "Part 2: Combinations 1 and 2: Severity of Adverse Events",
            "Part 1 and Part 2 (Combination 1): Plasma Concentrations of Niraparib and JNJ-63723283",
            "Part 1 and Part 2 (Combination 1): Number of participants with Anti-Drug Antibodies",
            "Part 2: Combinations 1 and 2: Number of Participants with Circulating Tumor Cell (CTC) Response",
            "Part 2: Combination 1: Composite Response Rate (RR)",
            "Part 2: Combination 2: Objective Response Rate (ORR)",
            "Part 2: Combinations 1 and 2: Duration of Objective Response",
            "Part 2: Combinations 1 and 2: Overall Survival (OS)"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Research & Development, LLC" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "150",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Sequential Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR108406",
            "64091742PCR2002",
            "2017-003552-23"
          ]
        },
        "start_date": "March 2, 2018",
        "primary_completion_date": "July 1, 2021",
        "completion_date": "December 31, 2021",
        "study_first_posted": "February 13, 2018",
        "last_update_posted": "August 15, 2019",
        "locations": {
          "location": [
            "Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States",
            "The Urology Center of Colorado, Denver, Colorado, United States",
            "University of Florida, Jacksonville, Florida, United States",
            "Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States",
            "Florida Hospital, Orlando, Florida, United States",
            "First Urology, PSC, Jeffersonville, Indiana, United States",
            "Chesapeake Urology Research Associates, Towson, Maryland, United States",
            "Massachusetts General, Boston, Massachusetts, United States",
            "Michigan Institute of Urology, Troy, Michigan, United States",
            "Memorial Sloan Kettering Cancer Center, Harrison, New York, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "Thomas Jefferson University, Philadelphia, Pennsylvania, United States",
            "University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States",
            "MUSC-Hollings Cancer Center, Charleston, South Carolina, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Houston Metro Urology, Houston, Texas, United States",
            "The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",
            "Intermountain Healthcare, Saint George, Utah, United States",
            "University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States",
            "Utah Cancer Specialists, Salt Lake City, Utah, United States",
            "Urology of Virginia, PLCC, Virginia Beach, Virginia, United States",
            "University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",
            "OLV Ziekenhuis Aalst, Aalst, Belgium",
            "ZNA Middelheim, Antwerpen, Belgium",
            "ULB HÃ´pital Erasme, Brussels, Belgium",
            "Universitair Ziekenhuis Gent, Gent, Belgium",
            "Az Groeninge, Kortrijk, Belgium",
            "Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium",
            "Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada",
            "University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Centre de Recherche du CHUM, Montreal, Quebec, Canada",
            "British Columbia Cancer Agency, Vancouver, Canada",
            "Asaf Harofe Medical Center, Beer Yaakov, Israel",
            "Soroka Hospital, Beer-Sheva, Israel",
            "Rambam Medical Center, Haifa, Israel",
            "Rabin Medical Center, Petach Tikva, Israel",
            "Sheba Medical Center Tel Hashomer, Ramat Gan, Israel",
            "Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy",
            "Policlinico Sant'Orsola Malpighi, Bologna, Italy",
            "Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy",
            "Oncologia Azienda Ospedaliera \"Istituti Ospitalieri\" di Cremona, Cremona, Italy",
            "Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy",
            "Azienda Ospedaliera \"Vito Fazzi\", Lecce, Italy",
            "UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy",
            "ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy",
            "IRCCS-Fondazione Pascale, Napoli, Italy",
            "Policlinico Universitario Agostino Gemelli, Roma, Italy",
            "Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain",
            "Hospital Vall D'Hebron, Barcelona, Spain",
            "Hosp. Univ. de La Princesa, Madrid, Spain",
            "Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain",
            "Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain",
            "Hosp. Univ. Hm Sanchinarro, Madrid, Spain",
            "Hosp. Virgen de La Victoria, Malaga, Spain",
            "Royal United Hospital, Bath, United Kingdom",
            "Guy's Hospital, London, United Kingdom",
            "University College London Hospitals, London, United Kingdom",
            "Southampton General Hospital, Southampton, United Kingdom",
            "The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom",
            "Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03431350"
      },
      {
        "-rank": "235",
        "nct_id": "NCT01605227",
        "title": "Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100",
        "acronym": "COMET-1",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Castration Resistant Prostate Cancer",
            "Pain",
            "Prostatic Neoplasms"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "cabozantinib"
            },
            {
              "-type": "Drug",
              "#text": "prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival (OS)",
            "Bone Scan Response (BSR)"
          ]
        },
        "sponsors": { "lead_sponsor": "Exelixis" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1028",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "XL184-307",
            "2012-001834-33"
          ]
        },
        "start_date": "July 2012",
        "primary_completion_date": "September 2014",
        "completion_date": "March 2015",
        "study_first_posted": "May 24, 2012",
        "results_first_posted": "March 14, 2018",
        "last_update_posted": "March 14, 2018",
        "locations": {
          "location": [
            "Birmingham, Alabama, United States",
            "Anchorage, Alaska, United States",
            "Phoenix, Arizona, United States",
            "Scottsdale, Arizona, United States",
            "Tucson, Arizona, United States",
            "Jonesboro, Arkansas, United States",
            "Duarte, California, United States",
            "Highland, California, United States",
            "La Jolla, California, United States",
            "Los Angeles, California, United States",
            "Montebello, California, United States",
            "Orange, California, United States",
            "Palo Alto, California, United States",
            "Rancho Mirage, California, United States",
            "Saint Helena, California, United States",
            "San Marcos, California, United States",
            "Vallejo, California, United States",
            "Aurora, Colorado, United States",
            "New Haven, Connecticut, United States",
            "Southington, Connecticut, United States",
            "Miami Beach, Florida, United States",
            "Ocala, Florida, United States",
            "Orlando, Florida, United States",
            "Tampa, Florida, United States",
            "Titusville, Florida, United States",
            "Wellington, Florida, United States",
            "West Palm Beach, Florida, United States",
            "Athens, Georgia, United States",
            "Atlanta, Georgia, United States",
            "Marietta, Georgia, United States",
            "Galesburg, Illinois, United States",
            "Niles, Illinois, United States",
            "Ames, Iowa, United States",
            "Sioux City, Iowa, United States",
            "Wichita, Kansas, United States",
            "Hazard, Kentucky, United States",
            "Louisville, Kentucky, United States",
            "Brewer, Maine, United States",
            "Baltimore, Maryland, United States",
            "Bethesda, Maryland, United States",
            "Towson, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Boston, Massachusetts, United States",
            "Methuen, Massachusetts, United States",
            "Detroit, Michigan, United States",
            "Wyoming, Michigan, United States",
            "Minneapolis, Minnesota, United States",
            "Jefferson City, Missouri, United States",
            "Springfield, Missouri, United States",
            "Lincoln, Nebraska, United States",
            "Omaha, Nebraska, United States",
            "Hackensack, New Jersey, United States",
            "Lawrenceville, New Jersey, United States",
            "Albany, New York, United States",
            "Garden City, New York, United States",
            "New York, New York, United States",
            "Pinehurst, North Carolina, United States",
            "Bismarck, North Dakota, United States",
            "Cincinnati, Ohio, United States",
            "Columbus, Ohio, United States",
            "Portland, Oregon, United States",
            "Bryn Mawr, Pennsylvania, United States",
            "Hershey, Pennsylvania, United States",
            "Lancaster, Pennsylvania, United States",
            "Greenville, South Carolina, United States",
            "Chattanooga, Tennessee, United States",
            "Amarillo, Texas, United States",
            "Bedford, Texas, United States",
            "Houston, Texas, United States",
            "Laredo, Texas, United States",
            "San Antonio, Texas, United States",
            "Salt Lake City, Utah, United States",
            "Burlington, Vermont, United States",
            "Fairfax, Virginia, United States",
            "Newport News, Virginia, United States",
            "Spokane, Washington, United States",
            "Green Bay, Wisconsin, United States",
            "Albury, New South Wales, Australia",
            "Concord, New South Wales, Australia",
            "Darlinghurst, New South Wales, Australia",
            "Kogarah, New South Wales, Australia",
            "Port Macquarie, New South Wales, Australia",
            "Randwick, New South Wales, Australia",
            "Wahroonga, New South Wales, Australia",
            "Westmead, New South Wales, Australia",
            "South Brisbane, Queensland, Australia",
            "Southport, Queensland, Australia",
            "Woolloongabba, Queensland, Australia",
            "Adelaide, South Australia, Australia",
            "Kurralta Park, South Australia, Australia",
            "Hobart, Tasmania, Australia",
            "Bentleigh East, Victoria, Australia",
            "Box Hill, Victoria, Australia",
            "Wodonga, Victoria, Australia",
            "Perth, Western Australia, Australia",
            "Linz, Austria",
            "Salzburg, Austria",
            "Wein, Austria",
            "Wien, Austria",
            "Aalst, Belgium",
            "Bonheiden, Belgium",
            "Brussels, Belgium",
            "Brussels, Belgium",
            "Brussels, Belgium",
            "Gent, Belgium",
            "Hasselt, Belgium",
            "Leuven, Belgium",
            "LiÃ¨ge, Belgium",
            "Roeselare, Belgium",
            "Calgary, Alberta, Canada",
            "Vancouver, British Columbia, Canada",
            "Miramichi, New Brunswick, Canada",
            "Halifax, Nova Scotia, Canada",
            "London, Ontario, Canada",
            "Owen Sound, Ontario, Canada",
            "Montreal, Quebec, Canada",
            "Quebec, Canada",
            "Angers, France",
            "BesanÃ§on, France",
            "Bordeaux, France",
            "Caen, France",
            "Clermont Ferrand, France",
            "Dijon, France",
            "La Roche sur Yon, France",
            "Le Mans, France",
            "Lille, France",
            "Lyon Cedex 08, France",
            "Marseille, France",
            "Nancy, France",
            "Paris, France",
            "Paris, France",
            "Paris, France",
            "Paris, France",
            "Paris, France",
            "Pierre Benite, France",
            "Rennes, France",
            "Saint Herblain, France",
            "Strasbourg, France",
            "Suresnes, France",
            "Villejuif Cedex, France",
            "Aachen, Germany",
            "Aachen, Germany",
            "Berlin, Germany",
            "Berlin, Germany",
            "Braunschweig, Germany",
            "Dresden, Germany",
            "Dusseldorf, Germany",
            "Frankfurt am Main, Germany",
            "Freiburg, Germany",
            "Furth, Germany",
            "GÃ¼tersloh, Germany",
            "Hamburg, Germany",
            "Hamburg, Germany",
            "Hamburg, Germany",
            "Hannover, Germany",
            "Heidelberg, Germany",
            "Homburg, Germany",
            "Kassel, Germany",
            "Kempen, Germany",
            "Kirchheim, Germany",
            "Koln, Germany",
            "Mannheim, Germany",
            "Munchen, Germany",
            "Munster, Germany",
            "Nurtingen, Germany",
            "Offenburg, Germany",
            "Traunstein, Germany",
            "Tubingen, Germany",
            "Weiden, Germany",
            "Wuppertal, Germany",
            "Cork, Ireland",
            "Dublin, Ireland",
            "Dublin, Ireland",
            "Galway, Ireland",
            "Ancona, Italy",
            "Arezzo, Italy",
            "Aviano, Italy",
            "Brindisi, Italy",
            "Cremona, Italy",
            "Genova, Italy",
            "Livorno, Italy",
            "Meldola, Italy",
            "Milano, Italy",
            "Milano, Italy",
            "Milano, Italy",
            "Modena, Italy",
            "Napoli, Italy",
            "Novara, Italy",
            "Orbassano, Italy",
            "Padova, Italy",
            "Pavia, Italy",
            "Pisa, Italy",
            "Pordenone, Italy",
            "Ravenna, Italy",
            "Rimini, Italy",
            "Roma, Italy",
            "Roma, Italy",
            "Rozzano, Italy",
            "Terni, Italy",
            "Torino, Italy",
            "Verona, Italy",
            "Amsterdam, Netherlands",
            "Groningen, Netherlands",
            "Groningen, Netherlands",
            "Hoofddorp, Netherlands",
            "Nieuwegein, Netherlands",
            "Nijmegen, Netherlands",
            "Rotterdam, Netherlands",
            "Rotterdam, Netherlands",
            "Tilburg, Netherlands",
            "Zwolle, Netherlands",
            "Ponce, Puerto Rico",
            "MÃ¡laga, AndalucÃ­a, Spain",
            "Sevilla, AndalucÃ­a, Spain",
            "Oviedo, Asturias, Spain",
            "Palma de Mallorca, Baleares, Spain",
            "La Laguna, Canarias, Spain",
            "Badalona, CataluÃ±a, Spain",
            "Barcelona, CataluÃ±a, Spain",
            "Barcelona, CataluÃ±a, Spain",
            "Barcelona, CataluÃ±a, Spain",
            "Barcelona, CataluÃ±a, Spain",
            "Barcelona, CataluÃ±a, Spain",
            "L'Hospitalet de Llobregat, CataluÃ±a, Spain",
            "Manresa, CataluÃ±a, Spain",
            "Elche, Comunidad Valenciana, Spain",
            "Valencia, Comunidad Valenciana, Spain",
            "A CoruÃ±a, Galicia, Spain",
            "Santiago de Compostela, Galicia, Spain",
            "Madrid, Madrid, Communidad De, Spain",
            "Madrid, Madrid, Communidad De, Spain",
            "Madrid, Madrid, Communidad De, Spain",
            "Madrid, Madrid, Communidad De, Spain",
            "Madrid, Madrid, Communidad De, Spain",
            "Majadahonda, Madrid, Communidad De, Spain",
            "Pamplona, Navarra, Spain",
            "Gotenborg, Sweden",
            "Malmo, Sweden",
            "Orebro, Sweden",
            "Stockholm, Sweden",
            "Umea, Sweden",
            "Uppsala, Sweden",
            "Vaxjo, Sweden",
            "Aberdeen, United Kingdom",
            "Bath, United Kingdom",
            "Birmingham, United Kingdom",
            "Brighton, United Kingdom",
            "Bristol, United Kingdom",
            "Cambridge, United Kingdom",
            "Cardiff, United Kingdom",
            "Cottingham, United Kingdom",
            "Edinburgh, United Kingdom",
            "Inverness, United Kingdom",
            "Lancaster, United Kingdom",
            "Leeds, United Kingdom",
            "London, United Kingdom",
            "London, United Kingdom",
            "Maidstone, United Kingdom",
            "Northwood, United Kingdom",
            "Plymouth, United Kingdom",
            "Sheffield, United Kingdom",
            "Southampton, United Kingdom",
            "Sutton, United Kingdom",
            "Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01605227"
      },
      {
        "-rank": "236",
        "nct_id": "NCT02578797",
        "title": "A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Castration-Resistant Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Apalutamide"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "QTc Fridericia (QTcF) parameter",
            "Electrocardiographic parameters (HR, RR, PR, and QRS)",
            "Electrocardiographic parameters (QT)",
            "Electrocardiographic parameters T- and U-wave morphology",
            "Plasma concentrations apalutamide (and its active metabolite JNJ-56142060)",
            "Number of participants with Adverse Events",
            "Pharmacokinetic parameter area under the plasma drug concentration-time curve (AUC) from time 0 to 24 hours",
            "Pharmacokinetic parameter maximum concentration observed (Cmax)",
            "Pharmacokinetic parameter time to reach Cmax (tmax)",
            "Pharmacokinetic parameter minimum observed plasma concentration (Cmin)"
          ]
        },
        "sponsors": { "lead_sponsor": "Aragon Pharmaceuticals, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "45",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR108049",
            "2015-004044-19",
            "56021927PCR1019"
          ]
        },
        "start_date": "December 2015",
        "primary_completion_date": "September 2016",
        "completion_date": "March 2020",
        "study_first_posted": "October 19, 2015",
        "last_update_posted": "August 16, 2019",
        "locations": {
          "location": [
            "Greenville, South Carolina, United States",
            "Montreal, Quebec, Canada",
            "Chisinau, Moldova, Republic of",
            "Rotterdam, Netherlands",
            "Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02578797"
      },
      {
        "-rank": "237",
        "nct_id": "NCT00558363",
        "title": "ARTS - AVODART After Radical Therapy For Prostate Cancer Study",
        "acronym": "ARTS",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Neoplasms, Prostate",
            "Prostate Cancer After a Radical Treatment"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Avodart"
            },
            {
              "-type": "Other",
              "#text": "placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Time to Prostate-specific Antigen (PSA) Doubling From Baseline (in Days)",
            "Number of Participants With PSA Doubling From Baseline",
            "Time to PSA Doubling From Baseline (in Days) Within Year 1",
            "Number of Participants With PSA Doubling From Baseline During Year 1",
            "Time to Disease Progression From Baseline (in Days)",
            "Number of Participants With Disease Progression",
            "Number of Participants Classified as Treatment Responders at Months 3, 6, 9, 12, 15, 18, 21, and 24",
            "Time to PSA Rise From Baseline (in Days)",
            "Number of Participants With a PSA Rise From Baseline",
            "Time to PSA Progression (in Days)",
            "Number of Participants With PSA Progression",
            "Change in Total PSA From Baseline at Months 12 and 24",
            "Percent Change in Total PSA From Baseline at Months 12 and 24",
            "Change in PSA From Nadir PSA at Months 12 and 24",
            "Percent Change in PSA From Nadir PSA at Months 12 and 24",
            "Number of Participants With the Indicated Change in PSA Doubling Time (PSADT) From Baseline at Month 12, Month 24, and End-of-treatment (up to 28 Months)",
            "Changes From Baseline in Disease-related Anxiety Measured by the Memorial Anxiety Scale for Prostate Cancer (MAX-PC)",
            "Number of Participants With a Shift From Normal at Baseline to at Least One Abnormal Laboratory Value for Any Parameter Any Time During the Study",
            "Number of Participants With a Threshold Laboratory Value for Any Parameter at Baseline (BL) and Any Time Post-baseline",
            "Number of Participants With Palpable Breast Tissue (PBT) at Baseline (BL) and Any Time Post-baseline",
            "Number of Participants With Nipple Tenderness (NT) at Baseline (BL) and Any Time Post-baseline",
            "Number of Participants With a Digital Rectal Examination (DRE) Evaluation Changing From Normal/Diffusely Enlarged at Baseline to Focal Abnormality at Any Time Post-baseline",
            "Number of Participants With Threshold Vital Signs at Baseline and Any Time Post-baseline"
          ]
        },
        "sponsors": { "lead_sponsor": "GlaxoSmithKline" },
        "gender": "All",
        "min_age": "18 Years",
        "max_age": "85 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "294",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "ARI109924" },
        "start_date": "November 2007",
        "primary_completion_date": "December 2010",
        "completion_date": "March 2011",
        "study_first_posted": "November 14, 2007",
        "results_first_posted": "December 13, 2011",
        "last_update_posted": "March 21, 2012",
        "locations": {
          "location": [
            "GSK Investigational Site, Tallinn, Estonia",
            "GSK Investigational Site, Tallinn, Estonia",
            "GSK Investigational Site, Kouvola, Finland",
            "GSK Investigational Site, Oulu, Finland",
            "GSK Investigational Site, Tampere, Finland",
            "GSK Investigational Site, Angers Cedex 9, France",
            "GSK Investigational Site, Chambery, France",
            "GSK Investigational Site, CrÃ©teil, France",
            "GSK Investigational Site, Lyon Cedex 03, France",
            "GSK Investigational Site, Orleans, France",
            "GSK Investigational Site, Aichach, Bayern, Germany",
            "GSK Investigational Site, Hagenow, Brandenburg, Germany",
            "GSK Investigational Site, Oranienburg, Brandenburg, Germany",
            "GSK Investigational Site, Schwedt, Brandenburg, Germany",
            "GSK Investigational Site, Marburg, Hessen, Germany",
            "GSK Investigational Site, Seligenstadt, Hessen, Germany",
            "GSK Investigational Site, Wismar, Mecklenburg-vorpommern, Germany",
            "GSK Investigational Site, Leer, Niedersachsen, Germany",
            "GSK Investigational Site, Dessau, Sachsen-anhalt, Germany",
            "GSK Investigational Site, Eisleben, Sachsen-anhalt, Germany",
            "GSK Investigational Site, Hettstedt, Sachsen-anhalt, Germany",
            "GSK Investigational Site, Leipzig, Sachsen, Germany",
            "GSK Investigational Site, Kiel, Schleswig-holstein, Germany",
            "GSK Investigational Site, Ilmenau, Thueringen, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Amsterdam, Netherlands",
            "GSK Investigational Site, Hengelo, Netherlands",
            "GSK Investigational Site, Maastricht, Netherlands",
            "GSK Investigational Site, Nijmegen, Netherlands",
            "GSK Investigational Site, Rotterdam, Netherlands",
            "GSK Investigational Site, Tilburg, Netherlands",
            "GSK Investigational Site, Winterswijk, Netherlands",
            "GSK Investigational Site, Moscow, Russian Federation",
            "GSK Investigational Site, Moscow, Russian Federation",
            "GSK Investigational Site, Moscow, Russian Federation",
            "GSK Investigational Site, Moscow, Russian Federation",
            "GSK Investigational Site, Alava, Spain",
            "GSK Investigational Site, Alcala de Henares (madrid), Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Bormujo (sevilla), Spain",
            "GSK Investigational Site, Getafe, Spain",
            "GSK Investigational Site, Granada, Spain",
            "GSK Investigational Site, Guadalajara, Spain",
            "GSK Investigational Site, Madrid, Spain",
            "GSK Investigational Site, Marbella, Spain",
            "GSK Investigational Site, Mendaro, Guipuzcoa, Spain",
            "GSK Investigational Site, Murcia, Spain",
            "GSK Investigational Site, Pamplona, Spain",
            "GSK Investigational Site, Sevilla, Spain",
            "GSK Investigational Site, Valencia, Spain",
            "GSK Investigational Site, Valladolid, Spain",
            "GSK Investigational Site, GÃ¶teborg, Sweden",
            "GSK Investigational Site, GÃ¶teborg, Sweden",
            "GSK Investigational Site, MalmÃ¶, Sweden",
            "GSK Investigational Site, UmeÃ¥, Sweden",
            "GSK Investigational Site, Uppsala, Sweden",
            "GSK Investigational Site, Ã–rebro, Sweden",
            "GSK Investigational Site, Exeter, Devon, United Kingdom",
            "GSK Investigational Site, Stevenage, Hertfordshire, United Kingdom",
            "GSK Investigational Site, Nottingham, Nottinghamshire, United Kingdom",
            "GSK Investigational Site, Bath, Somerset, United Kingdom",
            "GSK Investigational Site, Bristol, United Kingdom",
            "GSK Investigational Site, High Heaton, Newcastle Upon Tyne, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00558363"
      },
      {
        "-rank": "238",
        "nct_id": "NCT03551782",
        "title": "A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Castration-Resistant Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Cetrelimab 480 mg"
            },
            {
              "-type": "Drug",
              "#text": "Apalutamide 240 mg"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With Adverse Events (AEs)",
            "Number of Participants with AEs by Severity",
            "Percentage of Participants with Prostate-Specific Antigen (PSA) Response at Week 12",
            "Maximal PSA Decline",
            "Percentage of Participants with Circulating Tumor Cell (CTC) Response"
          ]
        },
        "sponsors": { "lead_sponsor": "Janssen Research & Development, LLC" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "98",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR108476",
            "2018-000182-37",
            "56021927PCR2032"
          ]
        },
        "start_date": "June 28, 2018",
        "primary_completion_date": "May 21, 2020",
        "completion_date": "June 8, 2022",
        "study_first_posted": "June 11, 2018",
        "last_update_posted": "August 15, 2019",
        "locations": {
          "location": [
            "University of California, Los Angeles UCLA, Los Angeles, California, United States",
            "VA San Diego Health Care System, San Diego, California, United States",
            "University of California San Francisco (UCSF) - Prostate Cancer Center, San Francisco, California, United States",
            "Regional Urology LLC, Shreveport, Louisiana, United States",
            "University of Michigan Health System, Ann Arbor, Michigan, United States",
            "Washington University, Bay Saint Louis, Mississippi, United States",
            "New York University Langone Medical Center, New York, New York, United States",
            "Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg, New York, New York, United States",
            "Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, United States",
            "Urologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd, Pennsylvania, United States",
            "Thomas Jefferson University, Philadelphia, Pennsylvania, United States",
            "University of Texas, MD Anderson Cancer Center, Houston, Texas, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "ZNA Middelheim, Antwerpen, Belgium",
            "Grand HÃ´pital de Charleroi, site Notre Dame, Charleroi, Belgium",
            "AZ Maria Middelares, Gent, Belgium",
            "Cross Cancer Institute, Edmonton, Alberta, Canada",
            "Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Centre de Recherche du CHUM, Montreal, Quebec, Canada",
            "Centro di Riferimento Oncologico di Aviano, Aviano, Italy",
            "Istituto di Candiolo, IRCCS, Candiolo, Italy",
            "Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano N/a, Italy",
            "Istituto Europeo di Oncologia Servizio Radioterapia, Milano, Italy",
            "Ospedale S. Maria Delle Croci, Ravenna, Italy",
            "Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy",
            "Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte, Siena, Italy",
            "NKI-AVL, Amsterdam, Amsterdam, Netherlands",
            "AZ Maastricht, Maastricht, Netherlands",
            "UMC Radboud, Nijmegen, Netherlands",
            "Sint Franciscus Gasthuis, Rotterdam, Netherlands",
            "Moscow City Clinical Hospital # 62, Moscow, Russian Federation",
            "Hertzen Oncology Research Institute, Moscow, Russian Federation",
            "Clinical Oncology Dispensary, Omsk, Russian Federation",
            "Non-State Healthcare Institution 'Road Clinical Hospital of Russian Railways', Saint Petersburg, Russian Federation",
            "Russian Scientific Center of Radiology and Surgical Technologies, Saint-Petersburg, Russian Federation",
            "Bashkiria State Medical University, Ufa, Russian Federation",
            "Hosp. Univ. Vall D Hebron, Barcelona, Spain",
            "Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain",
            "Hosp. Univ. Ramon Y Cajal, Madrid, Spain",
            "Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain",
            "Hosp. Univ. Hm Sanchinarro, Madrid, Spain",
            "Hosp. Virgen de La Victoria, MÃ¡laga, Spain",
            "Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcon, Spain",
            "Hosp. Univ. Marques de Valdecilla, Santander, Spain",
            "Instituto Valenciano de Oncologia, Valencia, Spain",
            "Belfast City Hospital, Belfast, United Kingdom",
            "Sussex Oncology Centre, Brighton Sussex, United Kingdom",
            "Velindre Cancer Centre, Cardiff, United Kingdom",
            "Charing Cross Hospital, London, United Kingdom",
            "Royal Preston Hospital, Preston, United Kingdom",
            "Royal Marsden Hospital, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03551782"
      },
      {
        "-rank": "239",
        "nct_id": "NCT02489318",
        "title": "A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC",
        "acronym": "TITAN",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Apalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Androgen Deprivation Therapy (ADT)"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Progression-Free Survival (rPFS)",
            "Overall Survival (OS)",
            "Time to Pain Progression",
            "Time to Skeletal-Related Event (SRE)",
            "Time to Chronic Opioid Use",
            "Time to Initiation of Cytotoxic Chemotherapy"
          ]
        },
        "sponsors": { "lead_sponsor": "Aragon Pharmaceuticals, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1052",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR107614",
            "2015-000735-32",
            "56021927PCR3002"
          ]
        },
        "start_date": "November 27, 2015",
        "primary_completion_date": "November 4, 2020",
        "completion_date": "July 13, 2022",
        "study_first_posted": "July 3, 2015",
        "last_update_posted": "June 27, 2019",
        "locations": {
          "location": [
            "Homewood, Alabama, United States",
            "Tucson, Arizona, United States",
            "San Bernardino, California, United States",
            "San Diego, California, United States",
            "Denver, Colorado, United States",
            "Norwalk, Connecticut, United States",
            "Fort Myers, Florida, United States",
            "Chicago, Illinois, United States",
            "Fort Wayne, Indiana, United States",
            "Jeffersonville, Indiana, United States",
            "New Orleans, Louisiana, United States",
            "Baltimore, Maryland, United States",
            "Rockville, Maryland, United States",
            "Lansing, Michigan, United States",
            "Troy, Michigan, United States",
            "Omaha, Nebraska, United States",
            "Las Vegas, Nevada, United States",
            "Bronx, New York, United States",
            "Brooklyn, New York, United States",
            "Poughkeepsie, New York, United States",
            "Syracuse, New York, United States",
            "Raleigh, North Carolina, United States",
            "Salisbury, North Carolina, United States",
            "Cleveland, Ohio, United States",
            "Middleburg Heights, Ohio, United States",
            "Springfield, Oregon, United States",
            "Bala-Cynwyd, Pennsylvania, United States",
            "Bryn Mawr, Pennsylvania, United States",
            "Lancaster, Pennsylvania, United States",
            "Charleston, South Carolina, United States",
            "Nashville, Tennessee, United States",
            "Dallas, Texas, United States",
            "Houston, Texas, United States",
            "San Antonio, Texas, United States",
            "Salt Lake City, Utah, United States",
            "Richmond, Virginia, United States",
            "Virginia Beach, Virginia, United States",
            "Burien, Washington, United States",
            "Spokane, Washington, United States",
            "Milwaukee, Wisconsin, United States",
            "Berazategui, Argentina",
            "C.a.b.a., Argentina",
            "Capital Federal, Argentina",
            "Ciudad Automoma Buenos Aires, Argentina",
            "Ciudad Autonoma Buenos Aires, Argentina",
            "Ciudad Autonoma de Buenos Aires, Argentina",
            "Ciudad De Buenos Aires, Argentina",
            "Cordoba, Argentina",
            "La Plata, Argentina",
            "Pergamino, Argentina",
            "Rosario, Argentina",
            "San Miguel de Tucuman, Argentina",
            "San Salvador de Jujuy, Argentina",
            "Albury, Australia",
            "Elizabeth Vale, Australia",
            "Kogarah, Australia",
            "Port Macquarie, Australia",
            "South Brisbane, Australia",
            "St Leonards, Australia",
            "Barretos, Brazil",
            "FlorianÃ³polis, Brazil",
            "GoiÃ¢nia, Brazil",
            "Ijui, Brazil",
            "Natal, Brazil",
            "Ribeirao Preto, Brazil",
            "Rio de Janeiro, Brazil",
            "Salvador, Brazil",
            "Santo AndrÃ©, Brazil",
            "Sao Paulo, Brazil",
            "Sorocaba, Brazil",
            "SÃ£o Paulo, Brazil",
            "Calgary, Alberta, Canada",
            "Vancouver, British Columbia, Canada",
            "Hamilton, Ontario, Canada",
            "Kingston, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Quebec, Canada",
            "Beijing, China",
            "ChengDu, China",
            "ChongQing, China",
            "Fuzhou, China",
            "Guangzhou, China",
            "Hangzhou, China",
            "NanJing, China",
            "ShangHai, China",
            "Suzhou, China",
            "WuHan, China",
            "Wuxi, China",
            "Xi'An, China",
            "Hradec KrÃ¡love, Czechia",
            "Liberec, Czechia",
            "NovÃ½ Jicin, Czechia",
            "Olomouc, Czechia",
            "Opava, Czechia",
            "Pardubice, Czechia",
            "Praha 10, Czechia",
            "Praha 2, Czechia",
            "Praha 4, Czechia",
            "Praha 5, Czechia",
            "Praha 8, Czechia",
            "Zlin, Czechia",
            "Clermont Ferrand, France",
            "Montpellier, France",
            "Nancy, France",
            "Paris, France",
            "Pierre BÃ©nite, France",
            "Strasbourg, France",
            "Suresnes, France",
            "Bonn, Germany",
            "Braunschweig, Germany",
            "Hamburg, Germany",
            "Hannover, Germany",
            "Leipzig, Germany",
            "Lubeck, Germany",
            "Lutherstadt Eisleben, Germany",
            "NÃ¼rtingen, Germany",
            "Sindelfingen, Germany",
            "Straubing, Germany",
            "Budapest, Hungary",
            "GyÅ‘r, Hungary",
            "PÃ©cs, Hungary",
            "Sopron, Hungary",
            "Beer Sheva, Israel",
            "Haifa, Israel",
            "Holon, Israel",
            "Kfar Saba, Israel",
            "Petach Tikva, Israel",
            "Ramat Gan, Israel",
            "Zrifin, Israel",
            "Chuo-ku, Chiba-City,, Japan",
            "Hakata-ku, Japan",
            "Koshigaya, Japan",
            "Matsuyama, Japan",
            "Minami-ku, Sagamihara-shi, Japan",
            "Miyazaki, Japan",
            "Nagano, Japan",
            "Nagasaki, Japan",
            "Osaka-Sayama, Japan",
            "Osaka-shi, Japan",
            "Sakura, Japan",
            "Sapporo, Japan",
            "Yokohama, Japan",
            "Yufu, Japan",
            "Daegu, Korea, Republic of",
            "Daejeon, Korea, Republic of",
            "Goyangsi, Korea, Republic of",
            "Hwasun-gun, Korea, Republic of",
            "Seongnam-si, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Ciudad de MÃ©xico, Mexico",
            "Durango, Mexico",
            "Guadalajara, Mexico",
            "Leon, Mexico",
            "Mexico City, Mexico",
            "Mexico, Mexico",
            "Morelia, Mexico",
            "Zapopan, Mexico",
            "Bialystok, Poland",
            "Bydgoszcz, Poland",
            "Krakow, Poland",
            "Kutno, Poland",
            "Lodz, Poland",
            "Lublin, Poland",
            "Siedlce, Poland",
            "Sochaczew, Poland",
            "Warszawa, Poland",
            "Wroclaw, Poland",
            "Bucharest, Romania",
            "Cluj Napoca, Romania",
            "Craiova, Romania",
            "Targu Mures, Romania",
            "Barnaul, Russian Federation",
            "Ivanovo, Russian Federation",
            "Moscow, Russian Federation",
            "Nizhny Novgorod, Russian Federation",
            "Obninsk, Russian Federation",
            "Omsk, Russian Federation",
            "Pyatigorsk, Russian Federation",
            "Rostov-on-Don, Russian Federation",
            "Ryazan, Russian Federation",
            "Saint-Petersburg, Russian Federation",
            "Saransk, Russian Federation",
            "Sochi, Russian Federation",
            "St Petersburg, Russian Federation",
            "Tambov, Russian Federation",
            "Tomsk, Russian Federation",
            "Tyumen, Russian Federation",
            "Ufa, Russian Federation",
            "Vologda, Russian Federation",
            "Barcelona, Spain",
            "Cordoba, Spain",
            "Jerez de la Frontera, Spain",
            "Madrid, Spain",
            "Pamplona, Spain",
            "GÃ¶teborg, Sweden",
            "MalmÃ¶, Sweden",
            "Stockholm, Sweden",
            "UmeÃ¥, Sweden",
            "Uppsala, Sweden",
            "VÃ¤xjÃ¶, Sweden",
            "Ã–rebro, Sweden",
            "Ankara, Turkey",
            "Edirne, Turkey",
            "Istanbul, Turkey",
            "Ä°zmir, Turkey",
            "Mersin, Turkey",
            "Cherkasy, Ukraine",
            "Dnipo, Ukraine",
            "Dnipro, Ukraine",
            "Ivano-Frankivsk, Ukraine",
            "Khakhiv, Ukraine",
            "Kharkiv, Ukraine",
            "Khmelnytsky, Ukraine",
            "Kyiv, Ukraine",
            "Lviv, Ukraine",
            "Odesa, Ukraine",
            "Poltava, Ukraine",
            "Uzhgorod, Ukraine",
            "Vinnitsa, Ukraine",
            "Zaporizhzhya, Ukraine",
            "Carlisle, United Kingdom",
            "Dundee, United Kingdom",
            "Glasgow, United Kingdom",
            "London, United Kingdom",
            "Newcastle Upon Tyne, United Kingdom",
            "Oxford, United Kingdom",
            "Plymouth, United Kingdom",
            "Scunthorpe, United Kingdom",
            "Stockton on Tees, United Kingdom",
            "Wolverhampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02489318"
      },
      {
        "-rank": "240",
        "nct_id": "NCT04017325",
        "title": "European Randomised Study of TOOKADÂ® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Cancer of the Prostate" },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "no intervention (post study follow up)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Disease progression",
            "Other prostate cancer therapy",
            "Prostate cancer-related death.",
            "Absence of cancer",
            "Radical therapy",
            "Cancer burden",
            "Urinary incontinence",
            "Erectile dysfunction",
            "Urethral stenosis",
            "Prostate cancer complication",
            "Patients Questionnaires Quality of life"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Steba Biotech S.A.",
          "collaborator": [
            "International Drug Development Institute",
            "ICON plc"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "374",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "CLIN1001 PCM301-FU5" },
        "start_date": "March 17, 2016",
        "primary_completion_date": "June 2020",
        "completion_date": "June 2020",
        "study_first_posted": "July 12, 2019",
        "last_update_posted": "July 12, 2019",
        "locations": {
          "location": [
            "Department of Urology-Tampere University Hospital-, Tampere, Finland",
            "Centre Hospitalier Universitaire (CHU), Angers, France",
            "CHRU Hopital Jean Minjoz, BesanÃ§on, France",
            "Site MÃ©dipole, Cabestany, France",
            "Polyclinique SÃ©vignÃ©, Cesson SÃ©vignÃ©, France",
            "HÃ´pital Claude Huriez, Lille, France",
            "HÃ´pital La Conception, Marseille, France",
            "Institut Mutualiste Montsouris (IMM), Paris Cedex 14, France",
            "HÃ´pital Cochin, Paris Cedex 14, France",
            "HÃ´pital Tenon, Paris, France",
            "Centre Hospitalier Universitaire Lyon Sud, Pierre-BÃ©nite, France",
            "CHU Pontchaillou, Rennes, France",
            "Clinique Urologique Nantes, Saint Herblain, France",
            "Marien Krankenahaus GmbH, Bergisch Gladbach, Germany",
            "ATURO-Gemeinschaftspraxis fÃ¼r Urologie und Andrologie, Berlin-Wilmersdorf, Germany",
            "Klinikum Braunschweig, Braunschweig, Germany",
            "UniversitÃ¤tsklinikum \"Carl Gustav Carus\" der Technischen UniversitÃ¤t, Dresden, Germany",
            "Urologische Gemeinschaftspraxis, Emmendingen, Germany",
            "Martini-Klinik am UKE Hamburg-Eppendorf Prostate Cancer Center, Hamburg, Germany",
            "Vinzenz Krankenhaus - Department of Urology, Hannover, Germany",
            "SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany",
            "University Hospital Schleswig-Holstein, Kiel, Germany",
            "Ludwig-Maximilians-UniversitÃ¤t MÃ¼nchen, Munich, Germany",
            "Urologie 24, Nuremberg, Germany",
            "Osp. S. Giov. Battista Molinette-Dipartimento di Discipline Medico-Chirurgiche Urologia, Torino, Italy",
            "Netherlands Cancer Institute, Amsterdam, Netherlands",
            "Catharina Ziekenhuis, Eindhoven, Netherlands",
            "Hospital Universitario de A CoruÃ±a, A CoruÃ±a, Spain",
            "Department of Urology-Hospital Clinic, University of Barcelona, Barcelona, Spain",
            "Complejo Hospitalario Regional Virgen Del Rocio-Department Urology, Sevilla, Spain",
            "Instituto Valenciano de Oncologia, Valencia, Spain",
            "Dept of Urology-University Hospital-, MalmÃ¶, Sweden",
            "Kings College Hospital (KCH), London, United Kingdom",
            "University College London Hospital (UCLH), London, United Kingdom",
            "Oxford John Radcliffe Hospital Trust, Oxford, United Kingdom",
            "Royal Hallamshire Hospital, Sheffield, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT04017325"
      },
      {
        "-rank": "241",
        "nct_id": "NCT00676650",
        "title": "Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy",
        "acronym": "SUN 1120",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Drug",
              "#text": "sunitinib"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival (OS)",
            "Progression-Free Survival (PFS)",
            "Percent of Participants With Objective Response (OR)",
            "Duration of Response (DR)",
            "Change From Baseline in Pain Severity",
            "Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P)",
            "Change From Baseline in Euro Quality of Life (EQ-5D)- Health State Profile Utility Score"
          ]
        },
        "sponsors": { "lead_sponsor": "Pfizer" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "873",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "A6181120" },
        "start_date": "July 2008",
        "primary_completion_date": "December 2011",
        "completion_date": "December 2011",
        "study_first_posted": "May 13, 2008",
        "results_first_posted": "March 8, 2013",
        "last_update_posted": "March 8, 2013",
        "locations": {
          "location": [
            "Pfizer Investigational Site, Decatur, Alabama, United States",
            "Pfizer Investigational Site, Huntsville, Alabama, United States",
            "Pfizer Investigational Site, Huntsville, Alabama, United States",
            "Pfizer Investigational Site, Anaheim, California, United States",
            "Pfizer Investigational Site, Encinitas, California, United States",
            "Pfizer Investigational Site, Glendale, California, United States",
            "Pfizer Investigational Site, La Jolla, California, United States",
            "Pfizer Investigational Site, Los Angeles, California, United States",
            "Pfizer Investigational Site, Modesto, California, United States",
            "Pfizer Investigational Site, Thousand Oaks, California, United States",
            "Pfizer Investigational Site, Thousands Oaks, California, United States",
            "Pfizer Investigational Site, Vista, California, United States",
            "Pfizer Investigational Site, Westlake Village, California, United States",
            "Pfizer Investigational Site, Denver, Colorado, United States",
            "Pfizer Investigational Site, Lafayette, Colorado, United States",
            "Pfizer Investigational Site, Gainesville, Florida, United States",
            "Pfizer Investigational Site, Orlando, Florida, United States",
            "Pfizer Investigational Site, Winter Park, Florida, United States",
            "Pfizer Investigational Site, Arlington Heights, Illinois, United States",
            "Pfizer Investigational Site, Niles, Illinois, United States",
            "Pfizer Investigational Site, Winfield, Illinois, United States",
            "Pfizer Investigational Site, Zion, Illinois, United States",
            "Pfizer Investigational Site, Carmel, Indiana, United States",
            "Pfizer Investigational Site, Fishers, Indiana, United States",
            "Pfizer Investigational Site, Greenfield, Indiana, United States",
            "Pfizer Investigational Site, Indianapolis, Indiana, United States",
            "Pfizer Investigational Site, Indianapolis, Indiana, United States",
            "Pfizer Investigational Site, Lafayette, Indiana, United States",
            "Pfizer Investigational Site, Louisville, Kentucky, United States",
            "Pfizer Investigational Site, Baltimore, Maryland, United States",
            "Pfizer Investigational Site, Boston, Massachusetts, United States",
            "Pfizer Investigational Site, Danvers, Massachusetts, United States",
            "Pfizer Investigational Site, Minneapolis, Minnesota, United States",
            "Pfizer Investigational Site, St. Cloud, Minnesota, United States",
            "Pfizer Investigational Site, Corinth, Mississippi, United States",
            "Pfizer Investigational Site, Southaven, Mississippi, United States",
            "Pfizer Investigational Site, Lincoln, Nebraska, United States",
            "Pfizer Investigational Site, Omaha, Nebraska, United States",
            "Pfizer Investigational Site, Henderson, Nevada, United States",
            "Pfizer Investigational Site, Henderson, Nevada, United States",
            "Pfizer Investigational Site, Las Vegas, Nevada, United States",
            "Pfizer Investigational Site, Las Vegas, Nevada, United States",
            "Pfizer Investigational Site, Las Vegas, Nevada, United States",
            "Pfizer Investigational Site, Sewell, New Jersey, United States",
            "Pfizer Investigational Site, Bronx, New York, United States",
            "Pfizer Investigational Site, Bronx, New York, United States",
            "Pfizer Investigational Site, New York, New York, United States",
            "Pfizer Investigational Site, Cary, North Carolina, United States",
            "Pfizer Investigational Site, Durham, North Carolina, United States",
            "Pfizer Investigational Site, Kernersville, North Carolina, United States",
            "Pfizer Investigational Site, Lexington, North Carolina, United States",
            "Pfizer Investigational Site, Mount Airy, North Carolina, United States",
            "Pfizer Investigational Site, North Wilkesboro, North Carolina, United States",
            "Pfizer Investigational Site, Raleigh, North Carolina, United States",
            "Pfizer Investigational Site, Raleigh, North Carolina, United States",
            "Pfizer Investigational Site, Winston-Salem, North Carolina, United States",
            "Pfizer Investigational Site, Bismarck, North Dakota, United States",
            "Pfizer Investigational Site, Cleveland, Ohio, United States",
            "Pfizer Investigational Site, Mayfield Heights, Ohio, United States",
            "Pfizer Investigational Site, Mentor, Ohio, United States",
            "Pfizer Investigational Site, Orange Village, Ohio, United States",
            "Pfizer Investigational Site, Westlake, Ohio, United States",
            "Pfizer Investigational Site, Eugene, Oregon, United States",
            "Pfizer Investigational Site, Springfield, Oregon, United States",
            "Pfizer Investigational Site, Clairton, Pennsylvania, United States",
            "Pfizer Investigational Site, Greensburg, Pennsylvania, United States",
            "Pfizer Investigational Site, Johnstown, Pennsylvania, United States",
            "Pfizer Investigational Site, Kingston, Pennsylvania, United States",
            "Pfizer Investigational Site, Lancaster, Pennsylvania, United States",
            "Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States",
            "Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States",
            "Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States",
            "Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States",
            "Pfizer Investigational Site, Uniontown, Pennsylvania, United States",
            "Pfizer Investigational Site, Wexford, Pennsylvania, United States",
            "Pfizer Investigational Site, Brighton, Tennessee, United States",
            "Pfizer Investigational Site, Memphis, Tennessee, United States",
            "Pfizer Investigational Site, Memphis, Tennessee, United States",
            "Pfizer Investigational Site, Arlington, Texas, United States",
            "Pfizer Investigational Site, Dallas, Texas, United States",
            "Pfizer Investigational Site, Fort Worth, Texas, United States",
            "Pfizer Investigational Site, Houston, Texas, United States",
            "Pfizer Investigational Site, Webster, Texas, United States",
            "Pfizer Investigational Site, Everett, Washington, United States",
            "Pfizer Investigational Site, Monroe, Washington, United States",
            "Pfizer Investigational Site, Seattle, Washington, United States",
            "Pfizer Investigational Site, Milwaukee, Wisconsin, United States",
            "Pfizer Investigational Site, Port Macquarie, New South Wales, Australia",
            "Pfizer Investigational Site, Wahroong, New South Wales, Australia",
            "Pfizer Investigational Site, Westmead, New South Wales, Australia",
            "Pfizer Investigational Site, Wodonga, Victoria, Australia",
            "Pfizer Investigational Site, Bruxelles, Belgium",
            "Pfizer Investigational Site, Liege, Belgium",
            "Pfizer Investigational Site, Mons, Belgium",
            "Pfizer Investigational Site, Namur, Belgium",
            "Pfizer Investigational Site, Wilrijk, Belgium",
            "Pfizer Investigational Site, Salvador, BA, Brazil",
            "Pfizer Investigational Site, Belo Horizonte, MG, Brazil",
            "Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil",
            "Pfizer Investigational Site, Caxias do Sul, RS, Brazil",
            "Pfizer Investigational Site, Porto Alegre, RS, Brazil",
            "Pfizer Investigational Site, Santo AndrÃ©, SP, Brazil",
            "Pfizer Investigational Site, Kelowna, British Columbia, Canada",
            "Pfizer Investigational Site, Barrie, Ontario, Canada",
            "Pfizer Investigational Site, Oshawa, Ontario, Canada",
            "Pfizer Investigational Site, Montreal, Quebec, Canada",
            "Pfizer Investigational Site, Montreal, Quebec, Canada",
            "Pfizer Investigational Site, Sherbrooke, Quebec, Canada",
            "Pfizer Investigational Site, WuHan, Hubei, China",
            "Pfizer Investigational Site, Beijing, China",
            "Pfizer Investigational Site, Chongqing, China",
            "Pfizer Investigational Site, Shanghai, China",
            "Pfizer Investigational Site, Shanghai, China",
            "Pfizer Investigational Site, Brno, Czech Republic",
            "Pfizer Investigational Site, Olomouc, Czech Republic",
            "Pfizer Investigational Site, Usti nad Labem, Czech Republic",
            "Pfizer Investigational Site, Herlev, Denmark",
            "Pfizer Investigational Site, Koebenhavn Oe, Denmark",
            "Pfizer Investigational Site, Odense C, Denmark",
            "Pfizer Investigational Site, Vejle, Denmark",
            "Pfizer Investigational Site, Helsinki, Finland",
            "Pfizer Investigational Site, Tampere, Finland",
            "Pfizer Investigational Site, Besancon, France",
            "Pfizer Investigational Site, Bordeaux Cedex, France",
            "Pfizer Investigational Site, Clermont-Ferrand Cedex 1, France",
            "Pfizer Investigational Site, Lille, France",
            "Pfizer Investigational Site, Lyon, France",
            "Pfizer Investigational Site, Paris Cedex 15, France",
            "Pfizer Investigational Site, Poitiers cedex, France",
            "Pfizer Investigational Site, Rennes, France",
            "Pfizer Investigational Site, ROUEN Cedex, France",
            "Pfizer Investigational Site, Saint Gregoire, France",
            "Pfizer Investigational Site, Tours, France",
            "Pfizer Investigational Site, Berlin, Germany",
            "Pfizer Investigational Site, Homburg/Saar, Germany",
            "Pfizer Investigational Site, Kempen, Germany",
            "Pfizer Investigational Site, Leipzig, Germany",
            "Pfizer Investigational Site, Muenchen, Germany",
            "Pfizer Investigational Site, Muenster, Germany",
            "Pfizer Investigational Site, Tuebingen, Germany",
            "Pfizer Investigational Site, Ulm, Germany",
            "Pfizer Investigational Site, Kfar Saba, Israel",
            "Pfizer Investigational Site, Petach Tikva, Israel",
            "Pfizer Investigational Site, Tel Hashomer, Israel",
            "Pfizer Investigational Site, Zerifin, Israel",
            "Pfizer Investigational Site, Meldola, FC, Italy",
            "Pfizer Investigational Site, Lido di Camaiore (LU), Italy",
            "Pfizer Investigational Site, Napoli, Italy",
            "Pfizer Investigational Site, Padova, Italy",
            "Pfizer Investigational Site, Pavia, Italy",
            "Pfizer Investigational Site, Pisa, Italy",
            "Pfizer Investigational Site, Potenza, Italy",
            "Pfizer Investigational Site, Roma, Italy",
            "Pfizer Investigational Site, Roma, Italy",
            "Pfizer Investigational Site, Goyang-si, Gyeonggi-do, Korea, Republic of",
            "Pfizer Investigational Site, Seongnam, Gyunggido, Korea, Republic of",
            "Pfizer Investigational Site, Seoul, Korea, Republic of",
            "Pfizer Investigational Site, Seoul, Korea, Republic of",
            "Pfizer Investigational Site, Seoul, Korea, Republic of",
            "Pfizer Investigational Site, Bellavista, Callao, Peru",
            "Pfizer Investigational Site, Arequipa, Peru",
            "Pfizer Investigational Site, Lima, Peru",
            "Pfizer Investigational Site, Gdansk, Poland",
            "Pfizer Investigational Site, Kielce, Poland",
            "Pfizer Investigational Site, Warszawa, Poland",
            "Pfizer Investigational Site, Warszawa, Poland",
            "Pfizer Investigational Site, Porto, Portugal",
            "Pfizer Investigational Site, Porto, Portugal",
            "Pfizer Investigational Site, SetÃºbal, Portugal",
            "Pfizer Investigational Site, Bratislava, Slovakia",
            "Pfizer Investigational Site, Bratislava, Slovakia",
            "Pfizer Investigational Site, Martin, Slovakia",
            "Pfizer Investigational Site, PreÅ¡ov, Slovakia",
            "Pfizer Investigational Site, Zilina, Slovakia",
            "Pfizer Investigational Site, Elche, Alicante, Spain",
            "Pfizer Investigational Site, L'hospitalet de Llobregat, Barcelona, Spain",
            "Pfizer Investigational Site, Pamplona, Navarra, Spain",
            "Pfizer Investigational Site, A CoruÃ±a, Spain",
            "Pfizer Investigational Site, Barcelona, Spain",
            "Pfizer Investigational Site, Gerona, Spain",
            "Pfizer Investigational Site, Guadalajara, Spain",
            "Pfizer Investigational Site, Madrid, Spain",
            "Pfizer Investigational Site, Madrid, Spain",
            "Pfizer Investigational Site, Madrid, Spain",
            "Pfizer Investigational Site, Sevilla, Spain",
            "Pfizer Investigational Site, Valencia, Spain",
            "Pfizer Investigational Site, Lund, Sweden",
            "Pfizer Investigational Site, Malmo, Sweden",
            "Pfizer Investigational Site, Stockholm, Sweden",
            "Pfizer Investigational Site, Vaxjo, Sweden",
            "Pfizer Investigational Site, Taichung, Taiwan",
            "Pfizer Investigational Site, Taipei, Taiwan",
            "Pfizer Investigational Site, Taipei, Taiwan",
            "Pfizer Investigational Site, Taoyuan, Taiwan",
            "Pfizer Investigational Site, Bournemouth, Dorset, United Kingdom",
            "Pfizer Investigational Site, Preston, Lancashire, United Kingdom",
            "Pfizer Investigational Site, Northwood,, Middlesex, United Kingdom",
            "Pfizer Investigational Site, Bristol, United Kingdom",
            "Pfizer Investigational Site, Cardiff, United Kingdom",
            "Pfizer Investigational Site, Glasgow, United Kingdom",
            "Pfizer Investigational Site, Glasgow, United Kingdom",
            "Pfizer Investigational Site, Guildford, United Kingdom",
            "Pfizer Investigational Site, London, United Kingdom",
            "Pfizer Investigational Site, Sheffield, United Kingdom",
            "Pfizer Investigational Site, Swansea, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00676650"
      },
      {
        "-rank": "242",
        "nct_id": "NCT00699751",
        "title": "A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases",
        "acronym": "ALSYMPCA",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Hormone Refractory Prostate Cancer",
            "Bone Metastases"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Radium-223 dichloride (Xofigo, BAY88-8223)"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Best standard of care (BSoC)"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Time to Total Alkaline Phosphatase (ALP) Progression",
            "Percentage of Participants With Total ALP Response at Week 12",
            "Percentage of Participants With Total ALP Response at End of Treatment (EOT; Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)",
            "Percentage of Participants With Total ALP Normalization at Week 12",
            "Percentage Change From Baseline in Total ALP at Week 12",
            "Maximum Percentage Decrease From Baseline in Total ALP up to Week 12",
            "Percentage Change From Baseline in Total ALP at EOT (Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)",
            "Maximum Percentage Decrease From Baseline in Total ALP During the 24 Week Treatment",
            "Time to Prostate Specific Antigen (PSA) Progression",
            "Percentage of Participants With PSA Response at Week 12",
            "Percentage of Participants With PSA Response at EOT (Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)",
            "Percentage Change From Baseline in PSA at Week 12",
            "Maximum Percentage Decrease From Baseline in PSA up to Week 12",
            "Percentage Change From Baseline in PSA at EOT (Week 24 or at the Time the Patient Dies or Discontinues Treatment Phase)",
            "Maximum Percentage Decrease From Baseline in PSA Response During the 24 Week Treatment Period",
            "Time to First Skeletal Related Event (SRE)",
            "Time to Occurrence of First Use of External Beam Radiation Therapy (EBRT) to Relieve Skeletal Symptoms",
            "Time to Occurrence of First Use of Radioisotopes to Relieve Skeletal Symptoms",
            "Time to Occurrence of First New Symptomatic Pathological Bone Fractures, Vertebral and Non-vertebral",
            "Time to Occurrence of First Tumor Related Orthopedic Surgical Intervention",
            "Time to Occurrence of First Spinal Cord Compression",
            "Time to Occurrence of First Start of Any Other Anti-cancer Treatment",
            "Time to Occurrence of First Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) by at Least 2 Points From Baseline"
          ]
        },
        "sponsors": { "lead_sponsor": "Bayer" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "921",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "15245",
            "BC1-06",
            "2007-006195-11"
          ]
        },
        "start_date": "June 2008",
        "primary_completion_date": "July 2011",
        "completion_date": "February 2014",
        "study_first_posted": "June 18, 2008",
        "results_first_posted": "May 7, 2014",
        "last_update_posted": "May 27, 2016",
        "locations": {
          "location": [
            "Los Angeles, California, United States",
            "Roseville, California, United States",
            "Tampa, Florida, United States",
            "New Orleans, Louisiana, United States",
            "St. Louis, Missouri, United States",
            "Las Vegas, Nevada, United States",
            "Philadelphia, Pennsylvania, United States",
            "Liverpool, New South Wales, Australia",
            "Randwick, New South Wales, Australia",
            "St Leonards, New South Wales, Australia",
            "Sydney, New South Wales, Australia",
            "Wahroonga, New South Wales, Australia",
            "Wollongong, New South Wales, Australia",
            "Brisbane, Queensland, Australia",
            "Toowoomba, Queensland, Australia",
            "Adelaide, South Australia, Australia",
            "Adelaide, South Australia, Australia",
            "Hobart, Tasmania, Australia",
            "Fitzroy, Victoria, Australia",
            "Nedlands, Western Australia, Australia",
            "Kortrijk, Belgium",
            "Ottignies, Belgium",
            "Salvador, Bahia, Brazil",
            "Belo Horizonte, Minas Gerais, Brazil",
            "Porto Alegre, Rio Grande do Sul, Brazil",
            "Barretos, Sao Paulo, Brazil",
            "Piracicaba, Sao Paulo, Brazil",
            "Belo Horizonte, Brazil",
            "Rio de Janeiro, Brazil",
            "Sao Paulo, Brazil",
            "Edmonton, Alberta, Canada",
            "London, Ontario, Canada",
            "Ottawa, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Brno, Czech Republic",
            "Chomutov, Czech Republic",
            "Olomouc, Czech Republic",
            "Ostrava, Czech Republic",
            "Plzen - Bory, Czech Republic",
            "Praha 4, Czech Republic",
            "Usti nad Labem, Czech Republic",
            "La Roche Sur Yon, France",
            "Montbeliard, France",
            "Saint Cloud, France",
            "Ulm, Baden-WÃ¼rttemberg, Germany",
            "Frankfurt, Hessen, Germany",
            "Marburg, Hessen, Germany",
            "GÃ¶ttingen, Niedersachsen, Germany",
            "Hannover, Niedersachsen, Germany",
            "Dortmund, Nordrhein-Westfalen, Germany",
            "Mainz, Rheinland-Pfalz, Germany",
            "Berlin, Germany",
            "Berlin, Germany",
            "Hamburg, Germany",
            "Chai Wan, Hong Kong",
            "Hong Kong, Hong Kong",
            "Hongkong, Hong Kong",
            "Kowloon, Hong Kong",
            "Beer Sheva, Israel",
            "Kfar Saba, Israel",
            "Tel Aviv, Israel",
            "Zrifin, Israel",
            "Meldola, ForlÃ¬, Italy",
            "Candiolo, Torino, Italy",
            "Bergamo, Italy",
            "Milano, Italy",
            "Reggio Emilia, Italy",
            "Alkmaar, Netherlands",
            "Nijmegen, Netherlands",
            "Rotterdam, Netherlands",
            "Bergen, Norway",
            "BodÃ¸, Norway",
            "Kristiansand, Norway",
            "Oslo, Norway",
            "Oslo, Norway",
            "TromsÃ¸, Norway",
            "Trondheim, Norway",
            "Ã…lesund, Norway",
            "Bydgoszcz, Poland",
            "Gliwice, Poland",
            "Kielce, Poland",
            "Krakow, Poland",
            "Luiblin, Poland",
            "Warszawa, Poland",
            "Wroclaw, Poland",
            "Wroclaw, Poland",
            "Singapore, Singapore",
            "Singapore, Singapore",
            "Banska Bystrica, Slovakia",
            "Bratislava, Slovakia",
            "Bratislava, Slovakia",
            "Martin, Slovakia",
            "Presov, Slovakia",
            "Trnava, Slovakia",
            "Santiago de Compostela, A CoruÃ±a, Spain",
            "AlcorcÃ³n, Madrid, Spain",
            "Barakaldo, Vizcaya, Spain",
            "Barcelona, Spain",
            "Barcelona, Spain",
            "Barcelona, Spain",
            "CÃ³rdoba, Spain",
            "Pamplona, Spain",
            "Valencia, Spain",
            "Zaragoza, Spain",
            "GÃ¶teborg, Sweden",
            "JÃ¶nkÃ¶ping, Sweden",
            "Kalmar, Sweden",
            "MalmÃ¶, Sweden",
            "Sandviken, Sweden",
            "Stockholm, Sweden",
            "Sundsvall, Sweden",
            "UmeÃ¥, Sweden",
            "Romford, Essex, United Kingdom",
            "Leicester, Leicestershire, United Kingdom",
            "Bebington, Merseyside, United Kingdom",
            "Nottingham, Nottinghamshire, United Kingdom",
            "Taunton, Somerset, United Kingdom",
            "Ipswich, Suffolk, United Kingdom",
            "Guildford, Surrey, United Kingdom",
            "Sutton, Surrey, United Kingdom",
            "Coventry, Warwickshire, United Kingdom",
            "Birmingham, West Midlands, United Kingdom",
            "Belfast, United Kingdom",
            "Brighton, United Kingdom",
            "Bristol, United Kingdom",
            "Cardiff, United Kingdom",
            "Derby, United Kingdom",
            "Hull, United Kingdom",
            "Leeds, United Kingdom",
            "Manchester, United Kingdom",
            "Northwood, United Kingdom",
            "Plymouth, United Kingdom",
            "Sheffield, United Kingdom",
            "Southampton, United Kingdom",
            "Wolverhampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00699751"
      },
      {
        "-rank": "243",
        "nct_id": "NCT00127465",
        "title": "Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Breast Neoplasms",
            "Prostatic Neoplasms",
            "Laryngeal Neoplasms",
            "Cervix Neoplasms"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Procedure",
            "#text": "Issue of information booklet"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "patients' views three months after intervention",
            "use of booklet with others between intervention and three month follow up",
            "change in reported social support between recruitment and three month follow up",
            "change in anxiety and depression between recruitment and three month follow up",
            "confidants' views three months after intervention",
            "change in confidants' anxiety and depression between recruitment and three month follow up"
          ]
        },
        "sponsors": { "lead_sponsor": "University of Plymouth" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "400",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Factorial Assignment",
            "Masking: None (Open Label)"
          ]
        },
        "other_ids": { "other_id": "ESRC-L328253025" },
        "start_date": "November 2001",
        "completion_date": "July 2003",
        "study_first_posted": "August 5, 2005",
        "last_update_posted": "December 11, 2008",
        "locations": { "location": "Beatson Oncology Centre, Glasgow, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00127465"
      },
      {
        "-rank": "244",
        "nct_id": "NCT00744497",
        "title": "Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer",
        "acronym": "READY",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Dasatinib"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival: Time From Randomization to Date of Death",
            "Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST)",
            "Time to First Skeletal-related Event (SRE)",
            "Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline",
            "Progression-free Survival (PFS)",
            "Time to Prostate Specific Antigen (PSA) Progression",
            "Percentage of Participants With a Reduction in Pain Intensity From Baseline"
          ]
        },
        "sponsors": { "lead_sponsor": "Bristol-Myers Squibb" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1930",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CA180-227",
            "2008-000701-11"
          ]
        },
        "start_date": "October 2008",
        "primary_completion_date": "August 2012",
        "completion_date": "July 2015",
        "study_first_posted": "September 1, 2008",
        "results_first_posted": "February 6, 2014",
        "last_update_posted": "October 17, 2016",
        "locations": {
          "location": [
            "University Of South Alabama / Mitchell Cancer Institute, Mobile, Alabama, United States",
            "Southern Cancer Center, Mobile, Alabama, United States",
            "Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States",
            "Highlands Oncology Group, Fayetteville, Arkansas, United States",
            "Compassionate Cancer Care Medical Group, Inc., Corona, California, United States",
            "Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States",
            "Compassionate Cancer Care Medical Group Inc, Riverside, California, United States",
            "Sharp Clinical Oncology Research, San Diego, California, United States",
            "Va San Diego Healthcare System, San Diego, California, United States",
            "Edward Alexson, Md, Inc., Santa Ana, California, United States",
            "Connecticut Oncology Group, Middletown, Connecticut, United States",
            "Va Connecticut Healthcare System, West Haven, Connecticut, United States",
            "Gwinnett Hospital System Inc., Lawrenceville, Georgia, United States",
            "University Of Chicago, Chicago, Illinois, United States",
            "Midwestern Regional Medical Center, Zion, Illinois, United States",
            "Fort Wayne Medical Oncology And Hematology Inc, Fort Wayne, Indiana, United States",
            "Cancer Center Of Kansas, Wichita, Kansas, United States",
            "Maine Center For Cancer Medicine, Scarborough, Maine, United States",
            "Tufts Medical Center, Boston, Massachusetts, United States",
            "Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States",
            "North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States",
            "New York Oncology Hematology, Pc, Albany, New York, United States",
            "New York Oncology Hematology, Pc, Albany, New York, United States",
            "Samuel S. Stratton Vamc, Albany, New York, United States",
            "Roswell Park Cancer Institute, Buffalo, New York, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "Duke University Medical Center, Durham, North Carolina, United States",
            "Piedmont Hematology Oncology Associates, Pllc, Winston-salem, North Carolina, United States",
            "Summa Health System, Akron, Ohio, United States",
            "Mid Ohio Oncology/Hematology, Inc,Dba, Columbus, Ohio, United States",
            "Providence Portland Med Ctr, Portland, Oregon, United States",
            "Regional Hemetology Oncology, Pc, Langhorne, Pennsylvania, United States",
            "Upmc Cancer Pavilion, Pittsburgh, Pennsylvania, United States",
            "Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States",
            "Associates In Hematology & Oncology, P.C., Upland, Pennsylvania, United States",
            "The Miriam Hospital, Providence, Rhode Island, United States",
            "Cancer Centers Of The Carolinas, Greenville, South Carolina, United States",
            "Boston Baskin Cancer Foundation, Memphis, Tennessee, United States",
            "Cancer Specialists Of South Texas, Pa, Corpus Christi, Texas, United States",
            "The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States",
            "Providence Regional Cancer System, Lacey, Washington, United States",
            "University Of Washington, Seattle, Washington, United States",
            "Dean Hematology And Oncology Clinic, Madison, Wisconsin, United States",
            "Local Institution, Caba, Buenos Aires, Argentina",
            "Local Institution, Capital Federal, Buenos Aires, Argentina",
            "Local Institution, Capital Federal, Buenos Aires, Argentina",
            "Local Institution, Capital Federal, Buenos Aires, Argentina",
            "Local Institution, La Plata, Buenos Aires, Argentina",
            "Local Institution, Ramos Mejia, Buenos Aires, Argentina",
            "Local Institution, Cipolletti, Rio Negro, Argentina",
            "Local Institution, Rosario, Santa Fe, Argentina",
            "Local Institution, Rosario, Santa Fe, Argentina",
            "Local Institution, San Miguel De Tucuman, Tucuman, Argentina",
            "Local Institution, Buenos Aires, Argentina",
            "Local Institution, Buenos Aires, Argentina",
            "Local Institution, Buenos Aires, Argentina",
            "Local Institution, Cordaba, Argentina",
            "Local Institution, Coffs Harbour, New South Wales, Australia",
            "Local Institution, Lismore, New South Wales, Australia",
            "Local Institution, Port Macquarie, New South Wales, Australia",
            "Local Institution, Sydney, New South Wales, Australia",
            "Local Institution, Douglas, Queensland, Australia",
            "Local Institution, Milton, Queensland, Australia",
            "Local Institution, Kurralta Park, South Australia, Australia",
            "Local Institution, Hobart, Tasmania, Australia",
            "Local Institution, Frankston, Victoria, Australia",
            "Local Institution, Ringwood, Victoria, Australia",
            "Local Institution, Fremantle, Western Australia, Australia",
            "Local Institution, Salvador, Bahia, Brazil",
            "Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil",
            "Local Institution, Barretos, Sao Paulo, Brazil",
            "Local Institution, Campinas, Sao Paulo, Brazil",
            "Local Institution, Jau, Sao Paulo, Brazil",
            "Local Institution, Santo Andre, Sao Paulo, Brazil",
            "Local Institution, Rio De Janeiro, Brazil",
            "Local Institution, Rio De Janeiro, Brazil",
            "Local Institution, Edmonton, Alberta, Canada",
            "Local Institution, Abbottsford, British Columbia, Canada",
            "Local Institution, Moncton, New Brunswick, Canada",
            "Local Institution, Ottawa, Ontario, Canada",
            "Local Institution, Owen Sound, Ontario, Canada",
            "Local Institution, Sudbury, Ontario, Canada",
            "Local Institution, Thunder Bay, Ontario, Canada",
            "Local Institution, Greenfield Park, Quebec, Canada",
            "Local Institution, Montreal, Quebec, Canada",
            "Local Institution, Montreal, Quebec, Canada",
            "Local Institution, Rimouski, Quebec, Canada",
            "Local Institution, Sherbrooke, Quebec, Canada",
            "Local Institution, Regina, Saskatchewan, Canada",
            "Local Institution, Saskatoon, Saskatchewan, Canada",
            "Local Institution, Brno, Czech Republic",
            "Local Institution, Hradec Kralove, Czech Republic",
            "Local Institution, Praha 2, Czech Republic",
            "Local Institution, Praha 8, Czech Republic",
            "Local Institution, Turku, Finland",
            "Local Institution, Vaasa, Finland",
            "Local Institution, Avignon, France",
            "Local Institution, Besancon Cedex, France",
            "Local Institution, Caen, France",
            "Local Institution, Creteil, France",
            "Local Institution, Paris, France",
            "Local Institution, St Genis Laval, France",
            "Local Institution, Strasbourg, France",
            "Local Institution, Aachen, Germany",
            "Local Institution, Berlin, Germany",
            "Local Institution, Erlangen, Germany",
            "Local Institution, Essen, Germany",
            "Local Institution, Kirchheim, Germany",
            "Local Institution, Markkleeberg, Germany",
            "Local Institution, Athens, Greece",
            "Local Institution, Budapest, Hungary",
            "Local Institution, Kecskemet, Hungary",
            "Local Institution, Zalaegerszeg, Hungary",
            "Local Institution, Trivandrum, Kerala, India",
            "Local Institution, Mumbai, Maharashtra, India",
            "Local Institution, Pune, Maharashtra, India",
            "Local Institution, Pune, Maharashtra, India",
            "Local Institution, Ahmedabad, India",
            "Local Institution, Jaipur, India",
            "Local Institution, Kolkata, India",
            "Local Institution, Kolkatta, India",
            "Local Institution, Dublin 7, Dublin, Ireland",
            "Local Institution, Tallaght, Dublin, Ireland",
            "Local Institution, Cork, Ireland",
            "Local Institution, Dublin, Ireland",
            "Local Institution, Arezzo, Italy",
            "Local Institution, Genova, Italy",
            "Local Institution, Lecce, Italy",
            "Local Institution, Milan, Italy",
            "Local Institution, Napoli, Italy",
            "Local Institution, Perugia, Italy",
            "Local Institution, Roma, Italy",
            "Local Institution, Seoul, Korea, Republic of",
            "Local Institution, Seoul, Korea, Republic of",
            "Local Institution, Seoul, Korea, Republic of",
            "Local Institution, Seoul, Korea, Republic of",
            "Local Institution, Tijuana, Baja California, Mexico",
            "Local Institution, Df, Distrito Federal, Mexico",
            "Local Institution, Mexico D.f., Distrito Federal, Mexico",
            "Local Institution, Tlalpan, Distrito Federal, Mexico",
            "Local Institution, Tlalpan, Distrito Federal, Mexico",
            "Local Institution, Huixquilucan, Estado De Mexico, Mexico",
            "Local Institution, Toluca, Estado De Mexico, Mexico",
            "Local Institution, Guadalajara, Jalisco, Mexico",
            "Local Institution, Zapopan, Jalisco, Mexico",
            "Local Institution, Monterrey, Nuevo Leon, Mexico",
            "Local Institution, Mexico, Queretaro, Mexico",
            "Local Institution, Stavanger, Norway",
            "Local Institution, Callao, Peru",
            "Local Institution, Lima, Peru",
            "Local Institution, Lima, Peru",
            "Local Institution, Lima, Peru",
            "Local Institution, Lima, Peru",
            "Local Institution, Lima, Peru",
            "Local Institution, Bialystok, Poland",
            "Local Institution, Lodz, Poland",
            "Local Institution, Warszawa, Poland",
            "Local Institution, Baia Mare, Romania",
            "Local Institution, Cluj Napoca, Romania",
            "Local Institution, Timisoara, Timis, Romania",
            "Local Institution, Moscow, Russian Federation",
            "Local Institution, Moscow, Russian Federation",
            "Local Institution, St Petersburg, Russian Federation",
            "Local Institution, St Petersburg, Russian Federation",
            "Local Institution, Bloemfontein, Free State, South Africa",
            "Local Institution, Pretoria, Gauteng, South Africa",
            "Local Institution, Saxonwold, Gauteng, South Africa",
            "Local Institution, Barcelona, Spain",
            "Local Institution, Barcelona, Spain",
            "Local Institution, Barcelona, Spain",
            "Local Institution, Gijon, Spain",
            "Local Institution, Madrid, Spain",
            "Local Institution, Madrid, Spain",
            "Local Institution, Madrid, Spain",
            "Local Institution, Santander, Spain",
            "Local Institution, Sevilla, Spain",
            "Local Institution, Valencia, Spain",
            "Local Institution, Kungalv, Sweden",
            "Local Institution, Sundsvall, Sweden",
            "Local Institution, Uppsala, Sweden",
            "Local Institution, Vaxjo, Sweden",
            "Local Institution, Cardiff, Glamorgan, United Kingdom",
            "Local Institution, London, Middlesex, United Kingdom",
            "Local Institution, Sutton, Surrey, United Kingdom",
            "Local Institution, Leeds, West Yorkshire, United Kingdom",
            "Local Institution, Essex, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00744497"
      },
      {
        "-rank": "245",
        "nct_id": "NCT00537381",
        "title": "An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Biological",
              "#text": "Intetumumab"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Progression-Free Survival (PFS)",
            "Number of Participants With Best Overall Response (OR)",
            "Number of Participants With Prostate Specific Antigen (PSA) Response",
            "Overall Survival",
            "Percent Change From Baseline in 'C-telopeptide of Type I Collagen (CTx)' Marker Concentration",
            "Percent Change From Baseline in 'N-telopeptide of Type I Collagen (NTx)' Marker Concentration",
            "Percent Change From Baseline in 'Vascular Endothelial Growth Factor (VEGF)' Marker Concentration"
          ]
        },
        "sponsors": { "lead_sponsor": "Centocor, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "131",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR013249",
            "C1034T08",
            "2006-005766-39"
          ]
        },
        "start_date": "May 2007",
        "primary_completion_date": "November 2009",
        "completion_date": "November 2009",
        "study_first_posted": "October 1, 2007",
        "results_first_posted": "May 20, 2013",
        "last_update_posted": "June 20, 2013",
        "locations": {
          "location": [
            "Birmingham, Alabama, United States",
            "Los Angeles, California, United States",
            "San Bernardino, California, United States",
            "Wichita, Kansas, United States",
            "Shreveport, Louisiana, United States",
            "Charleston, South Carolina, United States",
            "N Charleston, South Carolina, United States",
            "Graz, Austria",
            "Wels N/A, Austria",
            "Wien, Austria",
            "Antwerpen, Belgium",
            "Brasschaat, Belgium",
            "Brussel, Belgium",
            "Doornik, Belgium",
            "Haine-Saint-Paul, La Louviere, Belgium",
            "Leuven, Belgium",
            "LiÃ¿ge, Belgium",
            "Ottignies, Belgium",
            "Roeselare, Belgium",
            "Wilrijk, Belgium",
            "Aschaffenburg, Germany",
            "Berlin, Germany",
            "Freiburg, Germany",
            "Kirchheim, Germany",
            "KÃ¶ln, Germany",
            "Marburg, Germany",
            "MÃ¼nchen, Germany",
            "TÃ¼bingen, Germany",
            "Ahmedabad, India",
            "Bangalore, India",
            "Chennai, India",
            "Mumbai, India",
            "New Delhi, India",
            "Pune, India",
            "Apeldoorn, Netherlands",
            "Den Haag, Netherlands",
            "Leiden, Netherlands",
            "Maastricht, Netherlands",
            "Nijmegen, Netherlands",
            "Bydgoszcz, Poland",
            "Gdansk, Poland",
            "Inowroclaw, Poland",
            "Koscierzyna, Poland",
            "Lodz, Poland",
            "Lublin, Poland",
            "Ekaterinburg, Russian Federation",
            "Moscow N/A, Russian Federation",
            "Moscow Region, Russian Federation",
            "Moscow, Russian Federation",
            "St Petersburg, Russian Federation",
            "St-Petersburg Leningrad, Russian Federation",
            "Voronezh, Russian Federation",
            "Yaroslavl, Russian Federation",
            "Johannesburg Gauteng, South Africa",
            "Pretoria Gauteng, South Africa",
            "Pretoria, South Africa",
            "Cambridge, United Kingdom",
            "Leicester, United Kingdom",
            "Lincoln, United Kingdom",
            "London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00537381"
      },
      {
        "-rank": "246",
        "nct_id": "NCT02204072",
        "title": "BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms, Castration-Resistant" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "BI 836845"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of patients with dose limiting toxicities (phase Ib escalation)",
            "Maximum tolerated dose (phase Ib escalation)",
            "Prostate Surface Antigen (PSA) response - defined as a decline in PSA value >50% (which is confirmed by a second value 3 to 4 weeks apart) (phase Ib expansion)",
            "Radiological Progression free survival - time from randomisation to disease progression based on investigator assessment in bone, or soft tissue, or death (phase II)",
            "Overall survival - defined as the time from randomisation to death from any cause (phase II)",
            "Time to prostate serum antigen (PSA) progression - defined as the date that a 25% or greater increase in PSA, and an absolute increase of 2 ng/mL or more from the nadir, is documented, which is confirmed by a second value 3 or more weeks later (phase II)",
            "Maximum decline in PSA - compared to baseline that occurs at any point after treatment start (phase II)",
            "Percentage change in PSA - from baseline to week 12 of treatment (phase II)",
            "CTC response-CTC reduction compared to baseline for at least one time point after treatment start assessed by maximum change in CTC counts compared to baseline that occurs at any point after treatment start (phase II)",
            "Radiological progression free survival - defined as time from start of treatment to disease progression based on investigator assessment in bone based on PCWG2 or soft tissue based on modified RECIST 1.1 where applicable, or death (phase Ib expansion)",
            "Changes in CTC response - CTC reduction compared to baseline for at least one time point after treatment start assessed by CTC decline from, equal to, or more than, 5 to <5 cells per 7.5ml blood (phase II)",
            "Changes in circulating tumour cells (CTC) response - CTC reduction compared to baseline for at least one time point after treatment defined as CTC decline from, equal to, or more than, 5 to <5 cells per 7.5ml blood (phase Ib expansion)",
            "PSA response - defined as a decline in PSA value >50%, which is confirmed by a second value 3 to 4 weeks apart (phase II)",
            "Radiological progression free survival - defined as time from randomisation to disease progression based on central review in bone based on PCWG2 or soft tissue based on modified RECIST 1.1 where applicable, or death (phase II)"
          ]
        },
        "sponsors": { "lead_sponsor": "Boehringer Ingelheim" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "117",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "1280.8",
            "2013-004011-41"
          ]
        },
        "start_date": "November 11, 2014",
        "primary_completion_date": "August 30, 2019",
        "completion_date": "December 27, 2019",
        "study_first_posted": "July 30, 2014",
        "last_update_posted": "September 10, 2019",
        "locations": {
          "location": [
            "Kamanos Cancer Institute, Detroit, Michigan, United States",
            "NewYork-Presbyterian/Weill Cornell Medical Center, New York, New York, United States",
            "Oregon Health and Sciences University, Portland, Oregon, United States",
            "Prince of Wales Hospital, Hong Kong, Hong Kong",
            "Queen Mary Hospital, Hong Kong, Hong Kong",
            "Samsung Medical Center, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Erasmus MC - Daniel den Hoed, Rotterdam, Netherlands",
            "Tweesteden Ziekenhuis, locatie Tilburg, Tilburg, Netherlands",
            "National Cancer Centre, Singapore, Singapore",
            "OncoCare Cancer Centre, Singapore, Singapore",
            "Johns Hopkins Singapore International Medical Center, Singapore, Singapore",
            "Hospital Vall d'Hebron, Barcelona, Spain",
            "Hospital ClÃ­nic de Barcelona, Barcelona, Spain",
            "Hospital Santa Creu i Sant Pau, Barcelona, Spain",
            "Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain",
            "Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, Spain",
            "Hospital RamÃ³n y Cajal, Madrid, Spain",
            "Instituto Valenciano de OncologÃ­a, Valencia, Spain",
            "Taichung Veterans General Hospital, Taichung, Taiwan",
            "National Taiwan University Hospital, Taipei, Taiwan",
            "Taipe Veterans General Hospital, Taipei, Taiwan",
            "Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom",
            "Velindre Cancer Centre, Cardiff, United Kingdom",
            "The Christie Hospital, Manchester, United Kingdom",
            "Churchill Hospital, Oxford, United Kingdom",
            "The Royal Marsden Hospital, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02204072"
      },
      {
        "-rank": "247",
        "nct_id": "NCT00048659",
        "title": "YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Hormone-Refractory Prostate Cancer",
            "Prostatic Neoplasms"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "YM598"
          }
        },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Inc",
          "collaborator": "Astellas Pharma US, Inc."
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "598-CL-008" },
        "completion_date": "June 2004",
        "study_first_posted": "November 6, 2002",
        "last_update_posted": "June 7, 2012",
        "locations": {
          "location": [
            "Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States",
            "San Bernardino Urological Associates, San Bernardino, California, United States",
            "Western Clinical Research, Inc., Torrance, California, United States",
            "Shands Hospital, Gainesville, Florida, United States",
            "Sylvester Comprehensive Cancer Center, Miami, Florida, United States",
            "Georgia Urology,PA Research Institute, Atlanta, Georgia, United States",
            "University of Chicago, Section of Hematology/Oncology, Chicago, Illinois, United States",
            "University of Illinois, Department of Urology, Chicago, Illinois, United States",
            "Michiana Hematology/Oncology, South Bend, Indiana, United States",
            "The Urologic Institute of New Orleans, Gretna, Louisiana, United States",
            "Henry Ford Hospital, Detroit, Michigan, United States",
            "Washington University School of Medicine, St. Louis, Missouri, United States",
            "Memphis Cancer Center, Memphis, Tennessee, United States",
            "Virginia Mason Medical Center, Seattle, Washington, United States",
            "Department of Medical Oncology, The Canberra Hospital, Canberra, Australia",
            "Department of Medical Oncology, Concord Hospital Medical Centre, Concord, Australia",
            "Division of Oncology Ward, Royal Brisbane Hospital, Herston, Australia",
            "Department of Clinical Oncology, Royal North Shore Hospital, St Leonards, Australia",
            "Cancer Care Centre, St. George Hospital, Sydney, Australia",
            "Department of Medical Oncology, Newcastle Mater Hospital, Waratah, Australia",
            "Southern Medical Day Care Centre, Wollongong, Australia",
            "Queen Elizabeth Hospital, Clinical Hematology & Oncology, Woodville, Australia",
            "Cliniques Universitaires St-Luc, Service d'Urologie, Bruxelles, Belgium",
            "Centre Hospitalier Notre Dame et Reine Fabiola, Service d'oncologie, Charleroi, Belgium",
            "Centre Paul Papin, Angers, France",
            "Service d'Urologie, HÃ´pital Henri Mondor, Creteil, France",
            "Pavillon V, Service d'Urologie et de transplatation, HÃ´pital Edouard Herriot, Lyon, France",
            "Service d' Urologie CHU, Hopital Bichat, Paris, France",
            "Krankenhause am Urban, Urologie Dieffenfachstr, Berlin, Germany",
            "Dept Urology University of Essen, Essen, Germany",
            "Urologische Klinik der MHH, Hannover, Germany",
            "Klinikum Mannheim Urology, Mannheim, Germany",
            "Mater Misericordiae Hospital, Dublin, Ireland",
            "Universitair Medisch Centrum Utrecht, Dienst Medische Oncologie, Utrecht, Netherlands",
            "Kilinika Chemioterapii, Centrum Onkologii Instytut im M sklodowskiej Curie, Krakow, Poland",
            "Oddzial Chemioterapii, Krakow, Poland",
            "Klinika Chemioterapii AM, Lodz, Poland",
            "Samodzielny Publiczny Zaklad Opieki zdrowotnej, Wojewodzki Osrodek Onkologii, Opole, Poland",
            "Szpital Wojewodzki im Sw Lukasza SP ZOZ Tarnow, Tarnow, Poland",
            "Szpital CSK WAMl, Klinika Okologii, Warsaw, Poland",
            "Klinika Nowotworow Ukladu, Warszawa, Poland",
            "Hospital Clinic i Provincial, Servicio de Oncologia, Barcelona, Spain",
            "Hospital General Vall d'Hebron, Servicio de OncologÃ­a, Barcelona, Spain",
            "Hospital Universitario de Getafe, Servicio de Urologia, Crta, Getafe (Madrid), Spain",
            "Hospital Universitario PrÃ­ncipe de Asturias, Servicio de UrologÃ­a, Madrid, Spain",
            "Instituto Valenciano de Oncologia, Servicio de Oncologia, Valencia, Spain",
            "Department of Urological Research, Derriford Hospital, Devon, United Kingdom",
            "Clinical Research Centre, St George's Hospital, Urology Division, London, United Kingdom",
            "Department of Urology, St Bartholomew's Hospital, London, United Kingdom",
            "Imperial College School of Medicine, Dept Cancer Medicine, London, United Kingdom",
            "Department of Urology, East Surrey Hospital, Surrey, United Kingdom",
            "Royal Surrey County Hospital, Surrey, United Kingdom",
            "St Richard's Hospital, West Sussex, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00048659"
      },
      {
        "-rank": "248",
        "nct_id": "NCT02043678",
        "title": "Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",
        "acronym": "ERA 223",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Radium-223 dichloride (Xofigo, BAY88-8223)"
            },
            {
              "-type": "Drug",
              "#text": "Matching placebo (normal saline)"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone/Prednisolone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Symptomatic Skeletal Event Free Survival (SSE-FS)",
            "Overall Survival (OS)",
            "Radiological Progression Free Survival (rPFS)",
            "Time to Pain Progression",
            "Time to Cytotoxic Chemotherapy",
            "Time to Opiate Use for Cancer Pain"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Bayer",
          "collaborator": "Janssen Research & Development, LLC"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "806",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "15396",
            "2013-003438-33"
          ]
        },
        "start_date": "March 30, 2014",
        "primary_completion_date": "February 15, 2018",
        "completion_date": "March 31, 2020",
        "study_first_posted": "January 23, 2014",
        "results_first_posted": "March 5, 2019",
        "last_update_posted": "August 5, 2019",
        "locations": {
          "location": [
            "Anchorage, Alaska, United States",
            "Tucson, Arizona, United States",
            "Tucson, Arizona, United States",
            "Oceanside, California, United States",
            "Denver, Colorado, United States",
            "Washington, District of Columbia, United States",
            "Fort Myers, Florida, United States",
            "Atlanta, Georgia, United States",
            "Jeffersonville, Indiana, United States",
            "New Orleans, Louisiana, United States",
            "Baltimore, Maryland, United States",
            "Rockville, Maryland, United States",
            "Towson, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Burlington, Massachusetts, United States",
            "Detroit, Michigan, United States",
            "Traverse City, Michigan, United States",
            "Saint Louis, Missouri, United States",
            "Omaha, Nebraska, United States",
            "Las Vegas, Nevada, United States",
            "Hackensack, New Jersey, United States",
            "Poughkeepsie, New York, United States",
            "Syracuse, New York, United States",
            "Bala-Cynwyd, Pennsylvania, United States",
            "Pittsburgh, Pennsylvania, United States",
            "Pittsburgh, Pennsylvania, United States",
            "Norfolk, Virginia, United States",
            "Seattle, Washington, United States",
            "Spokane, Washington, United States",
            "Wheeling, West Virginia, United States",
            "St Leonards, New South Wales, Australia",
            "Adelaide, South Australia, Australia",
            "East Bentleigh, Victoria, Australia",
            "Heidelberg, Victoria, Australia",
            "Melbourne, Victoria, Australia",
            "Darlinghurst, Australia",
            "East Melbourne, Australia",
            "Randwick, Australia",
            "Bruxelles - Brussel, Belgium",
            "Bruxelles - Brussel, Belgium",
            "Edegem, Belgium",
            "Gent, Belgium",
            "Belo Horizonte, Minas Gerais, Brazil",
            "Porto Alegre, Rio Grande Do Sul, Brazil",
            "Barretos, Sao Paulo, Brazil",
            "SÃ£o Paulo, Sao Paulo, Brazil",
            "Sao Paulo, Brazil",
            "Calgary, Alberta, Canada",
            "Vancouver, British Columbia, Canada",
            "Winnipeg, Manitoba, Canada",
            "Hamilton, Ontario, Canada",
            "Ottawa, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Montreal, Quebec, Canada",
            "Quebec, Canada",
            "HUS, Finland",
            "Kuopio, Finland",
            "SeinÃ¤joki, Finland",
            "Tampere, Finland",
            "Besancon, France",
            "Bordeaux Cedex, France",
            "Paris Cedex 10, France",
            "Paris, France",
            "POITIERS cedex, France",
            "Saint Herblain, France",
            "Toulouse Cedex 9, France",
            "Ulm, Baden-WÃ¼rttemberg, Germany",
            "MÃ¼nchen, Bayern, Germany",
            "Marburg, Hessen, Germany",
            "MÃ¼nster, Nordrhein-Westfalen, Germany",
            "Dresden, Sachsen, Germany",
            "Jena, ThÃ¼ringen, Germany",
            "Berlin, Germany",
            "Afula, Israel",
            "Beer Sheva, Israel",
            "Haifa, Israel",
            "Jerusalem, Israel",
            "Kfar Saba, Israel",
            "Petah Tikva, Israel",
            "Ramat Gan, Israel",
            "Tel Aviv, Israel",
            "Zerifin, Israel",
            "Modena, Emilia-Romagna, Italy",
            "Roma, Lazio, Italy",
            "Roma, Lazio, Italy",
            "Genova, Liguria, Italy",
            "Milano, Lombardia, Italy",
            "Milano, Lombardia, Italy",
            "Cagliari, Sardegna, Italy",
            "Arezzo, Toscana, Italy",
            "Trento, Trentino-Alto Adige, Italy",
            "Nagoya, Aichi, Japan",
            "Hirosaki, Aomori, Japan",
            "Kashiwa, Chiba, Japan",
            "Matsuyama, Ehime, Japan",
            "Sapporo, Hokkaido, Japan",
            "Kobe, Hyogo, Japan",
            "Tsukuba, Ibaraki, Japan",
            "Kanazawa, Ishikawa, Japan",
            "Kita, Kagawa, Japan",
            "Yokohama, Kanagawa, Japan",
            "Yokohama, Kanagawa, Japan",
            "Sendai, Miyagi, Japan",
            "Matsumoto, Nagano, Japan",
            "Kurashiki, Okayama, Japan",
            "Osakasayama, Osaka, Japan",
            "Hamamatsu, Shizuoka, Japan",
            "Bunkyo-ku, Tokyo, Japan",
            "Bunkyo-ku, Tokyo, Japan",
            "Koto-ku, Tokyo, Japan",
            "Shinjuku-ku, Tokyo, Japan",
            "Ube, Yamaguchi, Japan",
            "Chiba, Japan",
            "Chiba, Japan",
            "Fukuoka, Japan",
            "Fukuoka, Japan",
            "Kumamoto, Japan",
            "Miyazaki, Japan",
            "Nagasaki, Japan",
            "Okayama, Japan",
            "Amsterdam, Netherlands",
            "Nijmegen, Netherlands",
            "Zwolle, Netherlands",
            "BodÃ¸, Norway",
            "LÃ¸renskog, Norway",
            "Oslo, Norway",
            "Gdansk, Poland",
            "Gdynia, Poland",
            "Gliwice, Poland",
            "Poznan, Poland",
            "Moscow, Russian Federation",
            "Obninsk, Russian Federation",
            "Singapore, Singapore",
            "Singapore, Singapore",
            "Singapore, Singapore",
            "Singapore, Singapore",
            "Badalona, Barcelona, Spain",
            "Hospitalet de Llobregat, Barcelona, Spain",
            "Barcelona, Spain",
            "Barcelona, Spain",
            "Madrid, Spain",
            "Madrid, Spain",
            "Madrid, Spain",
            "Madrid, Spain",
            "MÃ¡laga, Spain",
            "Oviedo, Spain",
            "Pamplona, Spain",
            "Sevilla, Spain",
            "LinkÃ¶ping, Sweden",
            "Stockholm, Sweden",
            "Sundsvalls, Sweden",
            "UmeÃ¥, Sweden",
            "VÃ¤xjÃ¶, Sweden",
            "Edinburgh, Lothian, United Kingdom",
            "Bebington, Merseyside, United Kingdom",
            "Northwood, Middlesex, United Kingdom",
            "Guildford, Surrey, United Kingdom",
            "Sutton, Surrey, United Kingdom",
            "Newcastle Upon Tyne, Tyne And Wear, United Kingdom",
            "Coventry, Warwickshire, United Kingdom",
            "Belfast, United Kingdom",
            "Leeds, United Kingdom",
            "London, United Kingdom",
            "Romford, United Kingdom"
          ]
        },
        "study_documents": {
          "study_document": [
            {
              "label": "Study Protocol",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/78/NCT02043678/Prot_000.pdf"
            },
            {
              "label": "Statistical Analysis Plan",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/78/NCT02043678/SAP_001.pdf"
            }
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02043678"
      },
      {
        "-rank": "249",
        "nct_id": "NCT03644303",
        "title": "Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.",
        "acronym": "TRAP",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Metastasis",
            "Toxicity Due to Radiotherapy",
            "Circulating Tumour DNA"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Radiation",
            "#text": "SBRT + ADT"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Median Progression-Free Survival (PFS)",
            "Local control rate following SBRT",
            "Incidence and severity of treatment induced symptoms",
            "Health Related Quality of Life",
            "Time to administration of next line of therapy",
            "Association between selected WB DW MRI characteristics at baseline and prognosis after SBRT"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborator": [
            "Prostate Cancer UK",
            "University College, London",
            "The Christie NHS Foundation Trust",
            "The Leeds Teaching Hospitals NHS Trust",
            "Velindre NHS Trust",
            "University Hospital Birmingham NHS Foundation Trust",
            "Newcastle-upon-Tyne Hospitals NHS Trust",
            "Belfast Health and Social Care Trust"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "84",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CCR 4781" },
        "start_date": "August 13, 2018",
        "primary_completion_date": "October 1, 2020",
        "completion_date": "October 1, 2021",
        "study_first_posted": "August 23, 2018",
        "last_update_posted": "December 18, 2018",
        "locations": {
          "location": [
            "The Christie NHS Foundation Trust, Manchester, Manchester Greater, United Kingdom",
            "Belfast Health & Social care Trust, Belfast, Northern Ireland, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",
            "The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Tyne And Wear, United Kingdom",
            "Velindre Cancer Centre, Cardiff, Wales, United Kingdom",
            "University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom",
            "Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03644303"
      },
      {
        "-rank": "250",
        "nct_id": "NCT00313781",
        "title": "Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "CP-751,871"
            },
            {
              "-type": "Drug",
              "#text": "docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "prednisone"
            },
            {
              "-type": "Drug",
              "#text": "docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of Participants With Prostate Specific Antigen (PSA) Best Response",
            "Progression Free Survival (PFS)",
            "Human Anti-human Antibody (HAHA) at Baseline (Day 1 of Cycle 1)",
            "Human Anti-human Antibody (HAHA) at the Last Follow-up Visit",
            "Population PK Parameters of CP-751,871",
            "Total Number of Circulation Tumor Cells (CTCs)",
            "Total Number of the Insulin Like Growth Factor Receptor Type 1 (IGF-1R) Positive CTCs",
            "Quality of Life Measured by the Functional Assessment of Cancer Treatmentâ€‘Prostate (FACTâ€‘P)",
            "Pain Measured by the Modified Brief Pain Inventoryâ€‘Short Form (mBPIâ€‘sf Modified Pfizer)",
            "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for CP-751,871",
            "Maximum Observed Plasma Concentration (Cmax) for CP-751,871",
            "Minimum Observed Plasma Trough Concentration (Cmin) for CP-751,871",
            "Area Under the Curve From Time Zero to End of Dosing Interval (AUC0-tau) for CP-751,871"
          ]
        },
        "sponsors": { "lead_sponsor": "Pfizer" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "204",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "A4021011" },
        "start_date": "May 2006",
        "primary_completion_date": "April 2011",
        "completion_date": "December 2011",
        "study_first_posted": "April 12, 2006",
        "results_first_posted": "April 11, 2013",
        "last_update_posted": "April 11, 2013",
        "locations": {
          "location": [
            "Pfizer Investigational Site, Los Angeles, California, United States",
            "Pfizer Investigational Site, New York, New York, United States",
            "Pfizer Investigational Site, Cleveland, Ohio, United States",
            "Pfizer Investigational Site, Cleveland, Ohio, United States",
            "Pfizer Investigational Site, Orange Village, Ohio, United States",
            "Pfizer Investigational Site, Philadelphia, Pennsylvania, United States",
            "Pfizer Investigational Site, Montreal, Quebec, Canada",
            "Pfizer Investigational Site, Montreal, Quebec, Canada",
            "Pfizer Investigational Site, Berlin, Germany",
            "Pfizer Investigational Site, Muenchen, Germany",
            "Pfizer Investigational Site, Hospitalet de Llobregat, Barcelona, Spain",
            "Pfizer Investigational Site, A CoruÃ±a, Spain",
            "Pfizer Investigational Site, Barcelona, Spain",
            "Pfizer Investigational Site, St. Gallen, Switzerland",
            "Pfizer Investigational Site, Sutton, Surrey, United Kingdom",
            "Pfizer Investigational Site, Glasgow, United Kingdom",
            "Pfizer Investigational Site, Glasgow, United Kingdom",
            "Pfizer Investigational Site, Guildford, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00313781"
      },
      {
        "-rank": "251",
        "nct_id": "NCT02438007",
        "title": "A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC",
        "acronym": "ARMOR3-SV",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Galeterone"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic Progression-free survival",
            "Overall Survival",
            "Time to Initiation of Cytotoxic Chemotherapy"
          ]
        },
        "sponsors": { "lead_sponsor": "Novus Therapeutics, Inc" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "953",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "ARMOR3-SV" },
        "start_date": "June 2015",
        "primary_completion_date": "July 2016",
        "completion_date": "November 2016",
        "study_first_posted": "May 8, 2015",
        "last_update_posted": "September 28, 2017",
        "locations": {
          "location": [
            "Pinnacle Oncology Hematology, Scottsdale, Arizona, United States",
            "University Of Arizona Cancer Center, Tucson, Arizona, United States",
            "City of Hope, Duarte, California, United States",
            "USC Norris Comprehensive Cancer Center, Los Angeles, California, United States",
            "UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",
            "Prostate Oncology Specialists, Inc., Marina del Rey, California, United States",
            "UC Davis Cancer Center, Sacramento, California, United States",
            "San Bernardino Urological Associates, San Bernardino, California, United States",
            "Urology Speciality Group, Torrance, California, United States",
            "University of Colorado Cancer Center Anschultz Cancer Pavilion, Aurora, Colorado, United States",
            "The Urology Center of Colorado, Denver, Colorado, United States",
            "Yale University School of Medicine, New Haven, Connecticut, United States",
            "Georgetown University Medical Center, Washington, D.C., District of Columbia, United States",
            "Sibley Memorial Hospital, Washington, D.C., District of Columbia, United States",
            "Boca Raton Community Hospital, Inc., Boca Raton, Florida, United States",
            "University of Florida Health Cancer Center, Orlando, Florida, United States",
            "Moffitt Cancer Center, Tampa, Florida, United States",
            "First Urology, Jeffersonville, Indiana, United States",
            "Tulane Medical Center, New Orleans, Louisiana, United States",
            "Regional Urology, LLC, Shreveport, Louisiana, United States",
            "University of Maryland Greenenbaum Cancer Center, Baltimore, Maryland, United States",
            "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",
            "Walter Reed National Military Medical Center, Bethesda, Maryland, United States",
            "Massachusetts General Hospital, Boston, Massachusetts, United States",
            "Dana-Farber Cancer Institute, Boston, Massachusetts, United States",
            "Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",
            "University of Michigan Health System, Ann Arbor, Michigan, United States",
            "Karmanos Cancer Center, Detroit, Michigan, United States",
            "Urology Cancer Center and GU Research Network, Omaha, Nebraska, United States",
            "Coastal Urology Associates, Bricktown, New Jersey, United States",
            "Brooklyn Urology Research Group, Brooklyn, New York, United States",
            "Advanced Urology Centers of New York, Plainview, New York, United States",
            "Premier Medical Group of the Hudson Valley, Poughkeepsie, New York, United States",
            "Associated Medical Professionals of NY, Syracuse, New York, United States",
            "University of North Carolina Lineberger Cancer Center, Chapel Hill, North Carolina, United States",
            "Carolina Urology Partners, PLLC, Charlotte, North Carolina, United States",
            "Carolina Urology Partners, Concord, North Carolina, United States",
            "The Urology Group, Cincinnati, Ohio, United States",
            "Clinical Research Solutions, Middleburg Heights, Ohio, United States",
            "Oregon Urology Institute, Springfield, Oregon, United States",
            "Lancaster Urology, Lancaster, Pennsylvania, United States",
            "Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",
            "UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Urology Associates Clinical Research, Nashville, Tennessee, United States",
            "Urology Clinics of North Texas, Dallas, Texas, United States",
            "Texas Oncology/Baylor University Medical Center, Dallas, Texas, United States",
            "Urology San Antonio, San Antonio, Texas, United States",
            "Virginia Urology, Richmond, Virginia, United States",
            "Urology of Virginia, Virginia Beach, Virginia, United States",
            "The University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States",
            "St. George Private Hospital, Oncology Day Care Centre, Kogarah, New South Wales, Australia",
            "Ashford Cancer Centre/Adelaide Cancer Centre Research, Kurralta Park, New South Wales, Australia",
            "North Coast Cancer Institute, Port Macquarie, New South Wales, Australia",
            "Prince of Wales Hospital, Randwick, New South Wales, Australia",
            "Macquarie University, Sydney, New South Wales, Australia",
            "Peninsula Specialist Centre, Kippa-Ring, Queensland, Australia",
            "ICON Cancer Care, Southport, Queensland, Australia",
            "Princess Alexandra Hospital, Woolloongabba, Queensland, Australia",
            "Ashford Cancer Centre/Adelaide Cancer Centre Research, Kurralta Park, South Australia, Australia",
            "Box Hill Hospital, Box Hill, Victoria, Australia",
            "Monash Medical Centre, East Bentleigh, Victoria, Australia",
            "Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia",
            "Cabrini Hospital, Malvern, Victoria, Australia",
            "Jules Bordet Institute Clinique d'Oncologie Medicale, Brussels, Belgium",
            "Universitair Ziekenhuis Gent, Gent, Belgium",
            "Jessa Ziekenhuis, Hasselt, Belgium",
            "CHU Sart Tilman, LiÃ¨ge, Belgium",
            "British Columbia Cancer, Kelowna, British Columbia, Canada",
            "British Columbia Cancer, Vancouver, British Columbia, Canada",
            "London Health Sciences Centre, London, Ontario, Canada",
            "Sunnybrook Research Institute, Toronto, Ontario, Canada",
            "Princess Margaret Hospital, Toronto, Ontario, Canada",
            "Centre Hospitalier De I'Universite de Montreal, Montreal, Quebec, Canada",
            "Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada",
            "Centre Paul Papin, Angers Cedex 9, France",
            "Institut Sainte Catherine, Avignon, France",
            "Institut BergoniÃ©, Bordeaux, France",
            "Centre FranÃ§ois Baclesse, Caen Cedex, France",
            "Service de MÃ©decine Interne Onco-HÃ©matologie, La Roche Sur Yon Cedex 9, France",
            "Clinique Victor Hugo Centre Jean Bernard, Le Mans, France",
            "Centre LÃ©on BÃ©rard, Lyon, France",
            "HÃ´pital Edouard Herriot, Lyon, France",
            "Centre Antoine Lacassagne, Nice Cedex 2, France",
            "Institut de CancÃ©rologie de l'Ouest, Saint Herblain, France",
            "Institut de Cancerlogie de la Loire, Saint Priest en Jarez, France",
            "Centre RenÃ© Gauducheau, Saint-Herblain, France",
            "Institut Gustave-Roussy, Villejuif, France",
            "Centro Oncologico c/o Presidio Ospedaliero San Donato - Arezzo, Arezzo, Italy",
            "UnitÃ  Operativa di Oncologia Ospedale Civile degli Infe, Faenza (RA), Italy",
            "Romagnolo per lo Studio e la Cura dei Tumori IRST-IRCCS - Oncologia medica, Meldola (FC), Italy",
            "AOU \"S. Luigi\", SCDU Oncologia Medica, Orbassano (Torino), Italy",
            "Az. Ospedaliera San Camillo-Forlanini, Roma, Italy",
            "University of Turin, Torino, Italy",
            "Santa Chiara Hospital, Trento, Italy",
            "Hospital ClÃ­nic i Provincial de Barcelona-Oncology, Barcelona, Spain",
            "Instituto Catalan de Oncologia (Hospital Durans i Reynals), Barcelona, Spain",
            "Hospital General Universitario de Elche, Elche, Spain",
            "Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, Spain",
            "Spanish National Cancer Research Centre, Madrid, Spain",
            "Unidad Cnio Ibima de Investigacion en Prostata, Malaga, Spain",
            "FundaciÃ³n Althaia Manresa, Manresa, Spain",
            "Hospital Son Espases - OncologÃ­a, Palma de Mallorca, Spain",
            "Hospital Clinico Universitario de Navarra, Pamplona, Spain",
            "Consorci Hospitalari de Parc TaulÃ­, Sabadell, Spain",
            "Hospital Universitario Virgen del Rocio, Sevilla, Spain",
            "IVO-OncologÃ­a MÃ©dica, Valencia, Spain",
            "CR-UK Institute for Cancer Studies, Birmingham, England, United Kingdom",
            "Sussex Cancer Centre, Brighton, England, United Kingdom",
            "University College of London Hospitals, London, England, United Kingdom",
            "Guy's and St. Thomas' NHS Foundation Trust, London, England, United Kingdom",
            "Southampton General Hospital, Southampton, England, United Kingdom",
            "University of Surrey Post Graduate Medical Hospital, Surrey, England, United Kingdom",
            "Royal Marsden Hospital, Surrey, England, United Kingdom",
            "The Royal Cornwall Hospital, Truro, England, United Kingdom",
            "The Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom",
            "Velindre Hospital, Cardiff, Wales, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02438007"
      },
      {
        "-rank": "252",
        "nct_id": "NCT00314782",
        "title": "Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "ZD4054 (Zibotentan)"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": { "outcome_measure": "Part A: Maximum Tolerated Dose (MTD)" },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "44",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "D4320C00020",
            "4054IL/0020"
          ]
        },
        "start_date": "March 2006",
        "primary_completion_date": "March 2008",
        "completion_date": "March 2009",
        "study_first_posted": "April 17, 2006",
        "last_update_posted": "March 12, 2013",
        "locations": {
          "location": [
            "Research Site, Buffalo, New York, United States",
            "Research Site, Greenville, South Carolina, United States",
            "Research Site, Nashville, Tennessee, United States",
            "Research Site, Berlin, Germany",
            "Research Site, Dresden, Germany",
            "Research Site, Rostock, Germany",
            "Research Site, London, United Kingdom",
            "Research Site, Plymouth, United Kingdom",
            "Research Site, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00314782"
      },
      {
        "-rank": "253",
        "nct_id": "NCT01950871",
        "title": "Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning",
        "acronym": "PHSTT-01",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "Prostate HistoScanning"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Diagnostic performance of prostate HistoScanning (HS) to identify clinically significant PCa using histology outcomes from systematic prostate biopsy (Bx) as reference",
            "Diagnostic performance of prostate HS to identify PCa using histology outcomes from systematic Bx as reference",
            "Diagnostic performance of prostate HS to identify clinically significant PCa using a combination of outcomes of both systematic Bx and HS-guided biopsy histology as reference",
            "Difference in detection rates of clinically significant PCa between systematic and HS-guided biopsy."
          ]
        },
        "sponsors": { "lead_sponsor": "Advanced Medical Diagnostics s.a." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 4" },
        "enrollment": "80",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR2P01127",
            "DRKS00005263"
          ]
        },
        "start_date": "October 2013",
        "primary_completion_date": "July 2014",
        "completion_date": "July 2014",
        "study_first_posted": "September 26, 2013",
        "last_update_posted": "January 5, 2015",
        "locations": {
          "location": [
            "Krankenhaus der Barmherzigen BrÃ¼der, Vienna, Austria",
            "Medical Center Hanuschkrankenhaus, Vienna, Austria",
            "Medical Center Med.Landeskrankenhaus VÃ¶cklabruck, VÃ¶cklabruck, Austria",
            "Medical Center Onze Lieve Vrouw Ziekenhuis OLVZ, Aalst, Belgium",
            "University Medical Center UZ VUB, Brussels, Belgium",
            "â€¢ University Medical Center Cliniques Universitaires Saint Luc, Brussels, Belgium",
            "University Medical Center St. Marina University Hospital, Varna, Bulgaria",
            "Medical Center UrologickÃ¡ klinika - FakultnÃ­ nemocnice, Olomouc, Czech Republic",
            "University Medical Center VÅ¡eobecnÃ¡ fakultnÃ­ nemocnice v Praze (VFN) a 1. -General University Hospital and First Faculty of Medicine Charles University, Praha, Czech Republic",
            "â€¢ University Medical Center Urinary Tract Surgery - Urology Dpt - Odense Universitetshospital Svendborg Sygehus, Odense C, Denmark",
            "Medical Center North-Estonian Medical Center Foundation, Tallinn, Estonia",
            "Medical Center Institut Mutualiste Montouris, Paris, France",
            "University Medical Center CHU Saint Etienne, Saint Etienne, France",
            "Medical Center Cancer Center - Prostatazentrum, Braunschweig, Germany",
            "Medical Center Paracelsus Klinik, DÃ¼sseldorf, Germany",
            "Medical Center Martini Klinik - Prostate Cancer Center, Hamburg, Germany",
            "Medical Center Klinikum Herford, Herford, Germany",
            "Medical Center PAN Klinik, KÃ¶ln, Germany",
            "Medical Center St. Elisabeth Krankenhaus, Leipzig, Germany",
            "Medical Center Klinikum Leverkusen, Leverkusen, Germany",
            "Medical Center Klinikum Wolfsburg Urologie, Wolfsburg, Germany",
            "Medical Center Uro-Clin Ltd, PÃ©cs, Hungary",
            "University Medical Center University Vita-Salute, Scientific Institute H. San Raffaele, Milano, Italy",
            "Medical Center URO, Riga, Latvia",
            "University Medical Center Vilniaus Universiteto Onkologijos Institutas - SantariÅ¡kiu Clinics, Vilnius, Lithuania",
            "Medical Center Antoni Van Leeuwenhoek Ziekenhuis - Nederlands Kanker Instituut, Amsterdam, Netherlands",
            "University Medical Center Moscow State University of Medicine and Dentistry named after A.I.Evdokimov, Moscow, Russian Federation",
            "University Medical Center Vall d'Hebron University Hospital - Autonoma Universitat Barcelona, Barcelona, Spain",
            "Carouge medical centre, Carouge, Switzerland",
            "Medical Center URO-TIP Urological Diagnosis Center, Istanbul, Turkey",
            "Medical Center AcÄ±badem KozyataÄŸÄ± Hospital, Istanbul, Turkey",
            "Medical Center Blackpool Victoria Hospital, Blackpool, United Kingdom",
            "University Medical Center Nuffield Health - University Hospitals Bristol (UHB) - Bristol Royal Infirmary and Southmead Hospitals, Bristol, United Kingdom",
            "Medical Center Spire Washington Hospital, Tyne and Wear, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01950871"
      },
      {
        "-rank": "254",
        "nct_id": "NCT02131649",
        "title": "PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy",
        "acronym": "PROPS",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Device",
            "#text": "18F-FCH PET/MRI Scan"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Proportion of men with negative or equivocal conventional restaging imaging (bone scan + CT scan of abdomen and pelvis) with uptake identified outside of the prostate bed on 18F-FCH PET",
            "Biochemical disease free survival at 3 years post-treatment"
          ]
        },
        "sponsors": { "lead_sponsor": "Lawson Health Research Institute" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "99",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "GAP02-01.1" },
        "start_date": "February 2015",
        "primary_completion_date": "January 2017",
        "completion_date": "January 2020",
        "study_first_posted": "May 6, 2014",
        "last_update_posted": "March 13, 2018",
        "locations": {
          "location": [
            "St. Vincent's Hospital, Sydney, New South Wales, Australia",
            "Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",
            "Austin Hospital, Melbourne, Victoria, Australia",
            "Eastern Health, Melbourne, Victoria, Australia",
            "Lawson Health Research Institute, London Health Sciences Centre, London, Ontario, Canada",
            "University of Toronto, Toronto, Ontario, Canada",
            "Universite Laval Quebec, Laval, Quebec, Canada",
            "Velindre Cancer Centre, Cardiff, South Glamorgan, United Kingdom",
            "University College London Hospital, London, United Kingdom",
            "Royal Marsden Hospital, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02131649"
      },
      {
        "-rank": "255",
        "nct_id": "NCT02023697",
        "title": "Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Radium-223 dichloride (Xofigo, BAY88-8223)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With an Event Defining SSE Free Survival - High Dose vs. Standard Dose",
            "Symptomatic Skeletal Event-Free Survival - High Dose vs. Standard Dose",
            "Number of Participants With an Event Defining SSE Free Survival - Extended Dose vs. Standard Dose",
            "Symptomatic Skeletal Event-Free Survival - Extended Dose vs. Standard Dose",
            "Number of Participants With an Event Defining SSE Free Survival - Three Dose Groups As Randomized",
            "Symptomatic Skeletal Event Free Survival - Three Dose Groups As Randomized",
            "Number of Participants With an Overall Survival Event - High Dose vs. Standard Dose",
            "Overall Survival - High Dose vs. Standard Dose",
            "Number of Participants With an Overall Survival Event - Extended Dose vs. Standard Dose",
            "Overall Survival - Extended Dose vs. Standard Dose",
            "Number of Participants With an Overall Survival - Three Dose Groups As Randomized",
            "Overall Survival Event - Three Dose Groups as Randomized",
            "Number of Participants With First Symptomatic Skeletal Event - High Dose vs. Standard Dose",
            "Time to First Symptomatic Skeletal Event - High Dose vs. Standard Dose",
            "Number of Participants With First Symptomatic Skeletal Event - Extended Dose vs. Standard Dose",
            "Time to First Symptomatic Skeletal Event - Extended Dose vs. Standard Dose",
            "Number of Participants With First Symptomatic Skeletal Event - Three Dose Groups as Randomized",
            "Time to First Symptomatic Skeletal Event - Three Dose Groups as Randomized",
            "Number of Participants With a Radiological Progression Event-Free - High Dose vs. Standard Dose",
            "Radiological Progression Free Survival - High Dose vs. Standard Dose",
            "Number of Participants With a Radiological Progression Event-Free - Extended Dose vs. Standard Dose",
            "Radiological Progression Free Survival - Extended Dose vs. Standard Dose",
            "Number of Participants With a Radiological Progression Event-Free - Three Dose Groups as Randomized",
            "Radiological Progression Free Survival - Three Dose Groups as Randomized",
            "Number of Participants With a Radiological Progression Event - High Dose vs. Standard Dose",
            "Time to Radiological Progression - High Dose vs. Standard Dose",
            "Number of Participants With a Radiological Progression Event - Extended Dose vs. Standard Dose",
            "Time to Radiological Progression - Extended Dose vs. Standard Dose",
            "Number of Participants With a Radiological Progression Event - Three Dose Groups as Randomized",
            "Time to Radiological Progression - Three Dose Groups as Randomized",
            "Timepoint Pain Improvement Rate - Three Dose Groups as Randomized",
            "Timepoint Pain Improvement Rate - Extended Dose vs. Standard Dose",
            "Number of Participants With a Pain Progression Event - High Dose vs. Standard Dose",
            "Time to Pain Progression - High Dose vs. Standard Dose",
            "Number of Participants With a Pain Progression Event - Extended Dose vs. Standard Dose",
            "Time to Pain Progression - Extended Dose vs. Standard Dose",
            "Number of Participants With a Pain Progression Event - Three Dose Groups as Randomized",
            "Time to Pain Progression - Three Dose Groups as Randomized",
            "Number of Participants With Treatment-Emergent Adverse Events"
          ]
        },
        "sponsors": { "lead_sponsor": "Bayer" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "391",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "16507",
            "2013-003118-42"
          ]
        },
        "start_date": "March 10, 2014",
        "primary_completion_date": "March 1, 2017",
        "completion_date": "August 9, 2018",
        "study_first_posted": "December 30, 2013",
        "results_first_posted": "July 12, 2018",
        "last_update_posted": "July 12, 2019",
        "locations": {
          "location": [
            "Scottsdale, Arizona, United States",
            "New Haven, Connecticut, United States",
            "Fort Myers, Florida, United States",
            "Bethesda, Maryland, United States",
            "Rockville, Maryland, United States",
            "Ann Arbor, Michigan, United States",
            "Detroit, Michigan, United States",
            "Saint Louis, Missouri, United States",
            "Omaha, Nebraska, United States",
            "East Setauket, New York, United States",
            "Portland, Oregon, United States",
            "Pittsburgh, Pennsylvania, United States",
            "Adelaide, South Australia, Australia",
            "Melbourne, Victoria, Australia",
            "Box Hill, Australia",
            "Darlinghurst, Australia",
            "Westmead, Australia",
            "Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",
            "Hospital de ClÃ­nicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",
            "Instituto do CÃ¢ncer do Estado de SÃ£o Paulo, SÃ£o Paulo, Sao Paulo, Brazil",
            "IBCC - Instituto Brasileiro de Controle do Cancer, SÃ£o Paulo, Sao Paulo, Brazil",
            "Hospital Israelita Albert Einstein, SÃ£o Paulo, Sao Paulo, Brazil",
            "London, Ontario, Canada",
            "Ottawa, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Toronto, Ontario, Canada",
            "Montreal, Quebec, Canada",
            "Santiago, Chile",
            "Chomutov, Czechia",
            "Praha 5, Czechia",
            "Nantes, France",
            "Vandoeuvre les Nancy, France",
            "Villejuif Cedex, France",
            "TÃ¼bingen, Baden-WÃ¼rttemberg, Germany",
            "MÃ¼nchen, Bayern, Germany",
            "Dresden, Sachsen, Germany",
            "Beer Sheva, Israel",
            "Haifa, Israel",
            "Jerusalem, Israel",
            "Kfar Saba, Israel",
            "Petah Tikva, Israel",
            "Ramat Gan, Israel",
            "Meldola, Emilia-Romagna, Italy",
            "Roma, Lazio, Italy",
            "Torino, Piemonte, Italy",
            "Arezzo, Toscana, Italy",
            "Busan, Busan Gwang''yeogsi, Korea, Republic of",
            "Seoul, Seoul Teugbyeolsi, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Seoul, Korea, Republic of",
            "Hospitalet de Llobregat, Barcelona, Spain",
            "Palma de Mallorca, Illes Baleares, Spain",
            "Barcelona, Spain",
            "Madrid, Spain",
            "Pamplona, Spain",
            "GÃ¶teborg, Sweden",
            "Karlstad, Sweden",
            "Sundsvalls, Sweden",
            "UmeÃ¥, Sweden",
            "Taipei City, Taipei, Taiwan",
            "Guishan Township, Taoyuan, Taiwan",
            "Kaohsiung, Taiwan",
            "Taichung, Taiwan",
            "Taipei, Taiwan",
            "Bebington, Merseyside, United Kingdom",
            "Taunton, Somerset, United Kingdom",
            "Northwood, United Kingdom"
          ]
        },
        "study_documents": {
          "study_document": [
            {
              "label": "Study Protocol",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/97/NCT02023697/Prot_002.pdf"
            },
            {
              "label": "Statistical Analysis Plan",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/97/NCT02023697/SAP_003.pdf"
            }
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02023697"
      },
      {
        "-rank": "256",
        "nct_id": "NCT00050297",
        "title": "YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "YM598"
          }
        },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Inc",
          "collaborator": "Astellas Pharma US, Inc."
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "598-CL-004" },
        "completion_date": "February 2004",
        "study_first_posted": "December 4, 2002",
        "last_update_posted": "June 7, 2012",
        "locations": {
          "location": [
            "University Clinic AZ, Brussels, Belgium",
            "University Clinic UCL St. Luc, Brussels, Belgium",
            "Private Urology Out-patient Ward, Jablonec nad Nisou, Czech Republic",
            "Clinic of Urology, University Hospital, KrÃ¡lovÃ©, Czech Republic",
            "Clinic of Urology, University Hospital, Olomouc, Czech Republic",
            "Clinic of Urology, University Hospital, Prague, Czech Republic",
            "HÃ´pital Bichat, service de Urology, Paris, France",
            "Haingasse 22, Bad Homburg, Germany",
            "Klinik und Poliklinik fÃ¼r Urologie, UniversitÃ¤tsklinikum Carl-Gustav-Carus, Dresden, Germany",
            "Klinik u. Poliklinik fÃ¼r Urologie, Philipps UniversitÃ¤t, BaldingerstraÃŸe, Marburg, Germany",
            "Krummbogen 15, Marburg, Germany",
            "Regional Hospital, Department of Urology, Bydgoszcz, Poland",
            "MedSource Poland, Gdansk, Poland",
            "Bielanski Hospital, Department of Urology, Warszawa, Poland",
            "Oncology Center, Department of Urinary Tract Cancer, Warszawa, Poland",
            "Medical University, Clinic of Urology, Wroclaw, Poland",
            "Complejo Hospitaliaro Juan Canalejo, Servicio de UrologÃ­a, Corunna, Spain",
            "Fundacion Hospital AlcorcÃ³n, Servicio UrologÃ­a, Madrid, Spain",
            "Hospital Universitario Principe de Asturias, Servicio de UrologÃ­a, Ctra., Madrid, Spain",
            "Department of Urology, Bristol Royal Infirmary, Bristol, United Kingdom",
            "Department of Urology, Gartnavel Hospital, Glasgow, United Kingdom",
            "Department of Urology, Norfolk & Norwich Hospital, Norwich, United Kingdom",
            "Department of Urology, Taunton & Somerset Hospital, Taunton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00050297"
      },
      {
        "-rank": "257",
        "nct_id": "NCT01242748",
        "title": "A Degarelix Trial in Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Goserelin acetate"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Hazard Ratio of Prostate-specific Antigen (PSA) Progression-free Survival (PFS) Failure Rates During 3 Years' Treatment Between Degarelix and Goserelin",
            "Hazard Ratio of PFS Failure Rates During 3 Years Treatment Between Degarelix and Goserelin",
            "Hazard Ratio of PSA Failure Rates During 3 Years Treatment Between Degarelix and Goserelin",
            "Hazard Ratio of Testosterone Escape Rates During 3 Years' Treatment Between Degarelix and Goserelin",
            "Hazard Ratio of the Rates of Introduction of Additional Therapy Related to Prostate Cancer During 3 Years' Treatment Between Degarelix and Goserelin",
            "Hazard Ratio of Mortality Rates During 3 Years' Treatment Between Degarelix and Goserelin",
            "Serum Levels of Testosterone During 3 Years' Treatment With Degarelix or Goserelin",
            "Serum Levels of Prostate-specific Antigen (PSA) During 3 Years' Treatment With Degarelix or Goserelin"
          ]
        },
        "sponsors": { "lead_sponsor": "Ferring Pharmaceuticals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "288",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "FE200486 CS35A",
            "2010-021434-55"
          ]
        },
        "start_date": "October 2010",
        "primary_completion_date": "December 2011",
        "completion_date": "January 2012",
        "study_first_posted": "November 17, 2010",
        "results_first_posted": "June 3, 2015",
        "last_update_posted": "June 3, 2015",
        "locations": {
          "location": [
            "University of Colorado School of Medicine, Aurora, Colorado, United States",
            "The Urology Center of Colorado, Denver, Colorado, United States",
            "Urology Associates of Dover, PA, Dover, Delaware, United States",
            "South Florida Medical Research, Aventura, Florida, United States",
            "Urology Group of New Mexico, PC, Albuquerque, New Mexico, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Urology San Antonio Research, Pa, San Antonio, Texas, United States",
            "Seattle Urology Research Center, Burien, Washington, United States",
            "AZ Groeninge - Campus Sint-Maarten, Kortrijk, Belgium",
            "Jonathan Giddens Medicine Professional Corporation, Brampton, Ontario, Canada",
            "Southern Interior Medical Research Inc., Kelowna, Canada",
            "Mor Urology, Inc., Newmarket, Canada",
            "Investigational site, Scarborough, Canada",
            "Investigational site, Toronto, Canada",
            "Urocentrum Brno, Brno, Czech Republic",
            "Nemocnice Jindrichuv Hradec, a.s., Jindrichuv Hradec, Czech Republic",
            "Kromerizska nemocnice a.s., Kromeriz, Czech Republic",
            "Fakultni nemocnice v Motole, Praha 5, Praha, Czech Republic",
            "Vseobecna fakultni nemocnice v Praze, Praha 2, Praha, Czech Republic",
            "Krajska nemocnice T. Bati a.s., Zlin, Czech Republic",
            "ODL Terveys Oy, Oulu, Finland",
            "Pohjois-Karjalan keskussairaala, Tampere, Finland",
            "Tampereen yliopistollinen sairaala, Tampere, Finland",
            "Gemeinschaftspraxis Rudolph & WÃ¶rner, Kirchheim, Germany",
            "Urologische Studienpraxis, NÃ¼rtingen, Germany",
            "FÃ¶vÃ¡rosi Ã–nkormÃ¡nyzat Bajcsy-Zsilinszky KÃ³rhÃ¡z, Budapest, Hungary",
            "FÃ¶vÃ¡rosi Ã–nkormÃ¡nyzat uzsoki utcai KÃ³rhÃ¡z, Budapest, Hungary",
            "Semmelweis Egyetem, Budapest, Hungary",
            "DombÃ³vÃ¡ri Szent LukÃ¡cs EgÃ©szsÃ©gÃ¼gyi Nonprofit Kft., DombÃ³vÃ¡r, Hungary",
            "Borsod-AbaÃºj-ZemplÃ©n Megyei KÃ³rhÃ¡z Ã©s Egyetemi OktatÃ³ KÃ³rhÃ¡z, Miskolc, Hungary",
            "Miskolci Semmelweis IgnÃ¡c EgÃ©szsÃ©gÃ¼gyi KÃ¶zpont Ã©s Egyetemi OktatÃ³ KÃ³rhÃ¡z Nonprofit Kft, Miskolc, Hungary",
            "PÃ©csi TudomÃ¡nyegyetem, PÃ©cs, Hungary",
            "Szegedi TudomÃ¡nyegyetem Szent-GyÃ¶rgyi Albert Klinikai KÃ¶zpont, Szeged, Hungary",
            "JÃ¡vorszky Ã–dÃ¶n KÃ³rhÃ¡z, VÃ¡c, Hungary",
            "Hospital Christus Muguerza del Parque, Chihuahua, Chih., Mexico",
            "Hospital Angeles Culiacan, Culiacan, Sinaloa, Mexico",
            "Consultorio de Especialidad en Urologia Privado, Durango, Mexico",
            "Hospital Angeles Lindavista, Mexico City, DF, Mexico",
            "MÃ©dica Sur, S.A.B. de C.V., Mexico City, Mexico",
            "Consultorio Medico, Zapopan, Jalisco, Mexico",
            "MC Haaglanden, Den Haag, Netherlands",
            "Catharina-ziekenhuis, Eindhoven, Netherlands",
            "SPZOZ Wojewodzki Szpital Zespolony im. J.Sniadeckiego, Bialystok, Poland",
            "Centrum Medyczne Medur Sp. z o.o., Bielsko-Biala, Poland",
            "Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku, Slupsk, Poland",
            "Private Medical Center SRL, Arad, Romania",
            "Brasov Emergency Clinical County Hospital, Brasov, Romania",
            "\"Prof. Dr. Th. Burghele\" Clinical Hospital, Bucharest, Romania",
            "\"Sfantul Ioan\" Emergency Clinical Hospital, Bucharest, Romania",
            "Dinu Uromedica, Bucharest, Romania",
            "Fundeni Clinical Institute of Uronephrology and Renal Transplantation, Bucharest, Romania",
            "PROVITA 2000 Medical Center, Constanta, Romania",
            "\"Dr. C.I. Parhon\" Clinical Hospital, Iasi, Romania",
            "Vita Care Flav Medical Center, Pitesti, Romania",
            "Sibiu Emergency Clinical County Hospital, Sibiu, Romania",
            "Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine",
            "Donetsk Regional Clinical Territorial Medical Association, Donetsk, Ukraine",
            "Regional Clinical Center of Urology and Nephrology n.a. V.I.Shapoval, Kharkiv, Ukraine",
            "Kyiv City Clinical Hospital #3, Kyiv, Ukraine",
            "Odesa Regional Clinical Hospital, Odesa, Ukraine",
            "Municipal Institution \"Zaporizhzhia Regional Clinical Hospital\", Zaporizhzhya, Ukraine",
            "Ipswich Hospital, Ipswich, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01242748"
      },
      {
        "-rank": "258",
        "nct_id": "NCT01477749",
        "title": "Sipuleucel-T Manufacturing Demonstration Study",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Cancer of Prostate",
            "Cancer of the Prostate",
            "Neoplasms, Prostate",
            "Neoplasms, Prostatic",
            "Prostate Cancer",
            "Prostate Neoplasms",
            "Prostatic Cancer"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Biological",
            "#text": "sipuleucel-T"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Cumulative CD54+ Cell Count",
            "Cumulative CD54 Upregulation",
            "Cumulative Total Nucleated Cell (TNC) Count",
            "Product Viability (Percentage)"
          ]
        },
        "sponsors": { "lead_sponsor": "Dendreon" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "47",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)"
          ]
        },
        "other_ids": {
          "other_id": [
            "P11-1",
            "2011-001192-39"
          ]
        },
        "start_date": "June 2012",
        "primary_completion_date": "June 2014",
        "completion_date": "June 2014",
        "study_first_posted": "November 23, 2011",
        "results_first_posted": "December 9, 2015",
        "last_update_posted": "December 9, 2015",
        "locations": {
          "location": [
            "Ludwig Boltzmann-Institute for Applied Cancer Research, Wien, Austria",
            "Department of Cancer Medicine and Genitourinary Oncology Group Institut Gustave Roussy (IGR) DÃ©partement de mÃ©dicine, Vaillant, Villejuif Cedex, France",
            "Radboud University Nijmegen; UMC St Radboud Hospital; Faculteit der Medische Wetenschappen, Urologie, Nijmegen, Gelderland, Netherlands",
            "Barts Cancer Institute - a Cancer Research UK Centre of Excellence, Queen Mary University of London, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01477749"
      },
      {
        "-rank": "259",
        "nct_id": "NCT01191931",
        "title": "Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)",
        "acronym": "PHS-02",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "sponsors": { "lead_sponsor": "Advanced Medical Diagnostics s.a." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "52",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "CR2P00113" },
        "start_date": "February 2008",
        "completion_date": "June 2012",
        "study_first_posted": "August 31, 2010",
        "last_update_posted": "October 29, 2012",
        "locations": {
          "location": [
            "Bordet Institute, Brussels, Belgium",
            "UZ-Brussel, Brussels, Belgium",
            "Olomouc Hospital, Olomouc, Czech Republic",
            "UniversitÃ¤tsklinikum TÃ¼bingen, TÃ¼bingen, Germany",
            "Semmelweis University, Budapest, Hungary",
            "Imperial College Healthcare NHS Trust, Charing Cross Hospital, Hammersmith, London, United Kingdom",
            "University College London Hospital (UCLH), London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01191931"
      },
      {
        "-rank": "260",
        "nct_id": "NCT00485303",
        "title": "An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Prostatic Neoplasms",
            "Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of Participants With Prostate Specific Antigen (PSA) Response",
            "Prostate-Specific Antigen Based Progression-free Survival (PSA-PFS)",
            "Radiographic Progression Free Survival (PFS)",
            "Overall Survival (OS)",
            "Percentage of Participants With Objective Radiographic Response",
            "Time to PSA Progression",
            "Time to Radiographic Progression",
            "Shift From Baseline in Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score",
            "Percentage of Participants With Clinical Benefit"
          ]
        },
        "sponsors": { "lead_sponsor": "Cougar Biotechnology, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "58",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR016921",
            "COU-AA-004",
            "2007-002725-74"
          ]
        },
        "start_date": "June 2007",
        "primary_completion_date": "October 2011",
        "completion_date": "October 2011",
        "study_first_posted": "June 12, 2007",
        "results_first_posted": "June 17, 2013",
        "last_update_posted": "July 2, 2013",
        "locations": {
          "location": [
            "UCLA, Los Angeles, California, United States",
            "Los Angeles, California, United States",
            "UCSF Comprehensive Cancer Center, San Francisco, California, United States",
            "San Francisco, California, United States",
            "John Hopkins, Baltimore, Maryland, United States",
            "Baltimore, Maryland, United States",
            "Masachussetts General Hospital Cancer Center, Boston, Massachusetts, United States",
            "Dana-Farber Cancer Institute, Boston, Massachusetts, United States",
            "Beth Israel Hospital, Boston, Massachusetts, United States",
            "Boston, Massachusetts, United States",
            "Memorial Sloan-Kettering Cancer Center, New York, New York, United States",
            "New York, New York, United States",
            "Royal Marsden Hospital, Sutton, United Kingdom",
            "Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00485303"
      },
      {
        "-rank": "261",
        "nct_id": "NCT01083615",
        "title": "A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Castrate-Resistant Prostate Cancer",
            "Hormone Refractory Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "custirsen sodium"
            },
            {
              "-type": "Drug",
              "#text": "isotonic, 0.9% sodium chloride"
            },
            {
              "-type": "Drug",
              "#text": "docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "cabazitaxel"
            },
            {
              "-type": "Drug",
              "#text": "prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "To ascertain whether the investigational arm has a greater proportion of patients with durable pain palliation as compared to the control arm.",
            "To ascertain whether patients randomized to the investigational arm have a longer time to pain progression as compared to patients randomized to the control arm.",
            "Safety"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Achieve Life Sciences",
          "collaborator": "Teva Pharmaceuticals USA"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "99 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "14",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "OGX-011-10" },
        "start_date": "March 2010",
        "primary_completion_date": "March 2013",
        "completion_date": "March 2013",
        "study_first_posted": "March 10, 2010",
        "last_update_posted": "October 12, 2016",
        "locations": {
          "location": [
            "La Verne, California, United States",
            "Ft. Lauderdale, Florida, United States",
            "Tampa, Florida, United States",
            "Honolulu, Hawaii, United States",
            "Urbana, Illinois, United States",
            "Metairie, Louisiana, United States",
            "Baltimore, Maryland, United States",
            "Burlington, Massachusetts, United States",
            "Detroit, Michigan, United States",
            "Kansas City, Missouri, United States",
            "Omaha, Nebraska, United States",
            "Las Vegas, Nevada, United States",
            "Syracuse, New York, United States",
            "Raleigh, North Carolina, United States",
            "Canton, Ohio, United States",
            "Oklahoma City, Oklahoma, United States",
            "Portland, Oregon, United States",
            "Columbia, South Carolina, United States",
            "Memphis, Tennessee, United States",
            "Tyler, Texas, United States",
            "Winnipeg, Manitoba, Canada",
            "Hamilton, Ontario, Canada",
            "Lyon, France",
            "Paris, France",
            "Saint Herblain, France",
            "Villejuif, France",
            "Barcelona, Spain",
            "Madrid, Spain",
            "Pamplona, Spain",
            "Sabadell, Spain",
            "Valencia, Spain",
            "Cambridge, United Kingdom",
            "Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01083615"
      },
      {
        "-rank": "262",
        "nct_id": "NCT03437941",
        "title": "Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration-Resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "CORT125281"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide (Xtandi)"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Maximum Tolerated Dose",
            "Number of participants with treatment-related adverse events as assessed by CTCAE v4.0",
            "AUC 0-last Pharmacokinetic (PK) parameter",
            "AUC 0-24hr PK parameter",
            "AUC 0-infinity PK parameter",
            "Cmax PK parameter",
            "Cmin,ss PK parameter",
            "CL/F PK parameter",
            "Tmax PK parameter",
            "Î»z PK parameter",
            "Effect of food on the Cmax PK of CORT125281",
            "Effect of food on the AUC0-t PK of CORT125281",
            "Effect of food on the AUCinf PK of CORT125281",
            "Objective Response Rate (ORR)",
            "Reduction in prostate-specific antigen (PSA)",
            "Time to symptomatic skeletal event (SSE)",
            "Radiographic progression-free survival (rPFS)",
            "Time to prostate-specific antigen (PSA) progression",
            "Time to clinical progression",
            "Duration of Response (DOR)",
            "Overall Survival (OS)"
          ]
        },
        "sponsors": { "lead_sponsor": "Corcept Therapeutics" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "80",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CORT125281-601" },
        "start_date": "December 15, 2017",
        "primary_completion_date": "March 31, 2021",
        "completion_date": "July 31, 2021",
        "study_first_posted": "February 19, 2018",
        "last_update_posted": "April 3, 2019",
        "locations": {
          "location": [
            "Honor Health, Scottsdale, Arizona, United States",
            "Karmanos Cancer Institute, Detroit, Michigan, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "Oregon Health and Science University, Portland, Oregon, United States",
            "University of Wisconsin, Madison, Wisconsin, United States",
            "University College Hospital London, London, England, United Kingdom",
            "University of Southampton, Southampton, England, United Kingdom",
            "Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03437941"
      },
      {
        "-rank": "263",
        "nct_id": "NCT02012920",
        "title": "A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Castration-resistant Prostate Cancer",
            "CRPC"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Seviteronel: given orally once daily in 28 day cycles"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Proportion of subjects who have â‰¥50% PSA decline at any time on study from the start of treatment with seviteronel.",
            "Median time to radiographic disease progression evaluated by computerized tomography (CT scan) or magnetic resonance imaging (MRI) and radionuclide bone scans by RECIST 1.1",
            "Radiographic response rate by RECIST 1.1 & PCWG3. Safety of seviteronel with or without concurrent glucocorticoid administration"
          ]
        },
        "sponsors": { "lead_sponsor": "Innocrin Pharmaceutical" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "200",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "INO-VT-464-CL-001",
            "VMT-VT-464-CL-001"
          ]
        },
        "start_date": "December 2011",
        "primary_completion_date": "December 2018",
        "completion_date": "January 2019",
        "study_first_posted": "December 17, 2013",
        "last_update_posted": "February 1, 2019",
        "locations": {
          "location": [
            "Urology Centers of Alabama, Homewood, Alabama, United States",
            "H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, United States",
            "First Urology, PSC, Jeffersonville, Indiana, United States",
            "Wichita Urology, Wichita, Kansas, United States",
            "Urology Cancer Center, Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "NY Cancer and Blood Specialists, Bronx, New York, United States",
            "North Shore Hematology Oncology Associates, East Setauket, New York, United States",
            "Associated Medical Professionals of NY, Syracuse, New York, United States",
            "Duke Cancer Institute at Cary: Medical Oncology, Cary, North Carolina, United States",
            "Duke University Medical Center, Durham, North Carolina, United States",
            "Gabrail Cancer Center Research, Canton, Ohio, United States",
            "Urologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd, Pennsylvania, United States",
            "Charleston Hematology Oncology Associates, Charleston, South Carolina, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Urology Clinics of North Texas, Dallas, Texas, United States",
            "University of Texas MD Anderson Cancer Center, Houston, Texas, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",
            "Alexandria Hospital, Department of Oncology, Athens, Greece",
            "Kantonsspital St Gallen, Onkologie/ Hamatologie, St Gallen, Saint Gallen, Switzerland",
            "The Royal Marsden Hospital - Institute of Cancer Research, Sutton, Surrey, United Kingdom",
            "Guys and St. Thomas' NHS Foundation Trust, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02012920"
      },
      {
        "-rank": "264",
        "nct_id": "NCT02194842",
        "title": "Phase III Radium 223 mCRPC-PEACE III",
        "acronym": "PEACE III",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Ra223"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "radiological progression-free survival",
            "Overall survival",
            "prostate cancer specific survival",
            "First symptomatic skeletal event",
            "Time and incidence of first skeletal progression-free",
            "Time from entry to initiation of next systemic therapy",
            "Treatments elected after first disease progression",
            "Second progression-free survival in sequential regimen",
            "Pain",
            "Time to pain progression",
            "Occurence of adverse events",
            "Time to use of opioid analgesics",
            "Quality of Life"
          ]
        },
        "sponsors": {
          "lead_sponsor": "European Organisation for Research and Treatment of Cancer - EORTC",
          "collaborator": [
            "Bayer",
            "Astellas Pharma Europe Ltd.",
            "Academic and Community Cancer Research United",
            "Cancer Trials Ireland",
            "UNICANCER",
            "Canadian Urologic Oncology Group"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "560",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "EORTC-1333-GUCG",
            "2014-001787-36"
          ]
        },
        "start_date": "October 2015",
        "primary_completion_date": "November 2019",
        "completion_date": "April 2021",
        "study_first_posted": "July 18, 2014",
        "last_update_posted": "April 25, 2018",
        "locations": {
          "location": [
            "Hopital Universitaire Brugmann, Brussels, Belgium",
            "Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels, Belgium",
            "Cliniques Universitaires Saint-Luc, Brussels, Belgium",
            "Universitair Ziekenhuis Antwerpen, Edegem, Belgium",
            "AZ Groeninge Kortrijk, Kortrijk, Belgium",
            "CHU UCL Namur - Site Sainte-Elisabeth, Namur, Belgium",
            "AZ Turnhout, Turnhout, Belgium",
            "CHU Dinant Godinne - UCL Namur, Yvoir, Belgium",
            "Rigshospitalet, Copenhagen, Denmark",
            "Institut J. Paoli & I. Calmettes, Marseille, France",
            "Institut rÃ©gional du Cancer Montpellier, Montpellier, France",
            "Gustave Roussy, Villejuif, France",
            "The Adelaide and Meath Hospital, Dublin, Ireland",
            "Ospedale B.Ramazzini, Carpi, Italy",
            "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy",
            "Istituto Europeo di Oncologia, Milano, Italy",
            "Medical University Of Gdansk, GdaÅ„sk, Poland",
            "Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland",
            "Hospital Del Mar, Barcelona, Spain",
            "Hospital De La Santa Creu I Sant Pau, Barcelona, Spain",
            "Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain",
            "Corporacio Sanitaria Parc Tauli, Sabadell, Spain",
            "Hospital Universitario de Salamanca, Salamanca, Spain",
            "Inselspital, Bern, Switzerland",
            "Kantonsspital St Gallen, St Gallen, Switzerland",
            "UniversitaetsSpital Zurich, Zurich, Switzerland",
            "The Christie NHS Foundation Trust, Manchester, United Kingdom",
            "Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02194842"
      },
      {
        "-rank": "265",
        "nct_id": "NCT00085228",
        "title": "Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "oblimersen sodium"
            },
            {
              "-type": "Drug",
              "#text": "docetaxel"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Prostate-specific antigen response as measured by Bubley criteria every course until progression or after 12 courses",
            "Severe toxic events as measured by CTCAE v3.0 every course until progression or after 12 courses",
            "Time to progression as measured by RECIST and Bubley criteria every 3 courses, and then every 8 weeks until progression, and every 16 weeks from progression until death",
            "Toxicity as measured by CTCAE v3.0 every 3 courses, and then every 8 weeks until progression, and every 16 weeks from progression until death",
            "Objective response as measured by RECIST every 3 courses, and then every 8 weeks until progression, and every 16 weeks from progression until death",
            "Overall survival as measured by Logrank every 3 courses, and then every 8 weeks until progression, and every 16 weeks from progression until death"
          ]
        },
        "sponsors": { "lead_sponsor": "European Organisation for Research and Treatment of Cancer - EORTC" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "116",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "EORTC-30021",
            "AVENTIS-AVE3139E/2501"
          ]
        },
        "start_date": "April 2004",
        "primary_completion_date": "January 2006",
        "study_first_posted": "June 11, 2004",
        "last_update_posted": "September 24, 2012",
        "locations": {
          "location": [
            "Kaiser Franz Josef Hospital, Vienna, Austria",
            "Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, Belgium",
            "Institut Jules Bordet, Brussels, Belgium",
            "Cliniques Universitaires Saint-Luc, Brussels, Belgium",
            "Universitair Ziekenhuis Gent, Ghent, Belgium",
            "U.Z. Gasthuisberg, Leuven, Belgium",
            "Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark",
            "CHU de Grenoble - Hopital de la Tronche, Grenoble, France",
            "Assaf Harofeh Medical Center, Zerifin, Israel",
            "Ospedale S. Camillo-Forlanini, Rome, Italy",
            "Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands",
            "Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland",
            "Hospital Desterro, Lisboa, Portugal",
            "Hospital General Universitari Vall d'Hebron, Barcelona, Spain",
            "Saint Bartholomew's Hospital, London, England, United Kingdom",
            "Western Infirmary, Glasgow, Scotland, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00085228"
      },
      {
        "-rank": "266",
        "nct_id": "NCT03016312",
        "title": "A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",
        "acronym": "IMbassador250",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms, Castration-Resistant" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Atezolizumab"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall surivival (OS)",
            "Percentage of Participants who Survived at Month 12 and 24",
            "Time to Cancer-Related Pain Progression, as Assessed Using Modified Brief Pain Inventory (BPI)",
            "Time to First Symptomatic Skeletal Event (SSE)",
            "Radiographic Progression-Free Survival (rPFS), as Assessed by the Investigator and Adapted From the PCWG3 Criteria",
            "Percentage of Participants Who are Radiographic Progression-Free, as Assessed by the Investigator and Adapted From the PCWG3 Criteria",
            "Immune-Modified rPFS, as Assessed by the Investigator as per PCWG3 Criteria and Immune-Modified Response Evaluation Criteria in Solid Tumors (RECIST)",
            "Percentage of Participants With Greater Than (>) 50 Percent (%) Decrease in Prostate-Specific Antigen (PSA) From Baseline",
            "Time to PSA Progression, Assessed as per PCWG3 Criteria",
            "Percentage of Participant With Objective Response, as Determined by the Investigator Through use of PCWG3 Criteria",
            "Percentage of Participant With Objective Response, as Determined by the Investigator Through use of Immune-Modified RECIST",
            "Percentage of Participants With Adverse Events",
            "Minimum Observed Serum Concentration (Cmin) of Atezolizumab",
            "Maximum Observed Serum Concentration (Cmax) of Atezolizumab",
            "Plasma Concentration of Enzalutamide",
            "Plasma Concentration of N-Desmethyl Enzalutamide",
            "Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab",
            "Time to Initiation or Increased Opiate Analgesic Use"
          ]
        },
        "sponsors": { "lead_sponsor": "Hoffmann-La Roche" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "730",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CO39385",
            "2016-003092-22"
          ]
        },
        "start_date": "January 10, 2017",
        "primary_completion_date": "November 11, 2020",
        "completion_date": "July 9, 2022",
        "study_first_posted": "January 10, 2017",
        "last_update_posted": "July 2, 2019",
        "locations": {
          "location": [
            "City of Hope Medical Grp Inc., Duarte, California, United States",
            "University of California San Diego, La Jolla, California, United States",
            "Kaiser Permanente San Diego - Los Angeles, Los Angeles, California, United States",
            "USC Norris Cancer Center, Los Angeles, California, United States",
            "USC/Westside Cancer Ctr, Los Angeles, California, United States",
            "Prostate Oncology Specialists, Marina Del Rey, California, United States",
            "UC Irvine Medical Center, Orange, California, United States",
            "Pacific Hematology Oncology Assocociates, San Francisco, California, United States",
            "University of Colorado; Division of Medical Oncology, Aurora, Colorado, United States",
            "Hartford Hospital, Hartford, Connecticut, United States",
            "Yale School of Medicine, New Haven, Connecticut, United States",
            "Stamford Hospital; BCC, MOHR, Stamford, Connecticut, United States",
            "Lynn Cancer Institute/Boca Raton Regional Hospital, Boca Raton, Florida, United States",
            "SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States",
            "Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States",
            "Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States",
            "SCRI Florida Cancer Specialists East, Tallahassee, Florida, United States",
            "Investigative Clin Rsch of IN, Indianapolis, Indiana, United States",
            "Associates in Oncology/Hematology P.C., Rockville, Maryland, United States",
            "Massachusetts General Hospital, Boston, Massachusetts, United States",
            "Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",
            "Dana-Farber Cancer Institute, Boston, Massachusetts, United States",
            "Karmanos Cancer Institute.., Detroit, Michigan, United States",
            "HCA Midwest Division, Kansas City, Missouri, United States",
            "St. Vincent Frontier Cancer Center, Billings, Montana, United States",
            "Nebraska Cancer Specialists; Oncology Hematology West, PC, Omaha, Nebraska, United States",
            "Urology Cancer Center & GU Research Network, Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "MSKCC at Basking Ridge, Basking Ridge, New Jersey, United States",
            "Hunterdon Medical Center, Flemington, New Jersey, United States",
            "New York Oncology Hematology, P.C., Albany, New York, United States",
            "MSKCC @ Commack, Commack, New York, United States",
            "MSKCC @ West Harrison, Harrison, New York, United States",
            "Columbia University Medical Center, New York, New York, United States",
            "Memorial Sloan-Kettering Cancer Center, New York, New York, United States",
            "MSKC @ Rockville, Rockville Centre, New York, United States",
            "Oncology Hematology Care, Inc., Cincinnati, Ohio, United States",
            "James Cancer Hospital;Solove Research Institute, Columbus, Ohio, United States",
            "Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States",
            "Lehigh Valley Health Network, Allentown, Pennsylvania, United States",
            "Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",
            "Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States",
            "University of Pittsburgh Cancer Institute; Division of Medical Oncology, Pittsburgh, Pennsylvania, United States",
            "Miriam Hospital, Providence, Rhode Island, United States",
            "Charleston Hematology Oncology, Charleston, South Carolina, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States",
            "Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States",
            "Texas Oncology Cancer Center, Austin, Texas, United States",
            "Texas Oncology - Methodist Dallas Cancer Center, Dallas, Texas, United States",
            "Texas Oncology, P.A. - Fort Worth, Fort Worth, Texas, United States",
            "Texas Oncology - Memorial City, Houston, Texas, United States",
            "Texas Oncology-Tyler, Irving, Texas, United States",
            "Virginia Cancer Specialists - Alexandria, Alexandria, Virginia, United States",
            "Virginia Oncology Associates, Norfolk, Virginia, United States",
            "Eastern Health; Cancer Services, Box Hill, New South Wales, Australia",
            "Concord Repatriation General Hospital; Concord Cancer Centre, Concord, New South Wales, Australia",
            "Macquarie University Hospital, Sydney, New South Wales, Australia",
            "Royal Brisbane & Women's Hosp; Cancer Care Serv, Herston, Queensland, Australia",
            "Adelaide Cancer Centre, Kurralta Park, South Australia, Australia",
            "Monash Medical Centre; Oncology, Clayton, Victoria, Australia",
            "St Vincents Hospital, Melbourne, Victoria, Australia",
            "LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung fÃ¼r Onkologie, Graz, Austria",
            "Ordensklinikum Linz Elisabethinen; Abteilung fÃ¼r Urologie und Andrologie, Linz, Austria",
            "Medizinische UniversitÃ¤t Wien; UniversitÃ¤tsklinik fÃ¼r Urologie, Wien, Austria",
            "Onze Lieve Vrouwziekenhuis Aalst, Aalst, Belgium",
            "UZ Gent, Gent, Belgium",
            "CHU Sart-Tilman, LiÃ¨ge, Belgium",
            "Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada",
            "Kingston General Hospital, Kingston, Ontario, Canada",
            "Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada",
            "Sunnybrook Research Institute, Toronto, Ontario, Canada",
            "Princess Margaret Cancer Center, Toronto, Ontario, Canada",
            "Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie, Greenfield Park, Quebec, Canada",
            "McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada",
            "CHU de QuÃ©bec - UniversitÃ© Laval - HÃ´tel-Dieu de QuÃ©bec, QuÃ©bec, Quebec, Canada",
            "CHUS (Centre Hospitalier Universitaire de Sherbrooke), Sherbrooke, Quebec, Canada",
            "Friendship Hospital, Capital Medical University, Beijing, China",
            "Jiangsu Cancer Hospital, Nanjing, China",
            "Fudan University Shanghai Cancer Center, Shanghai, China",
            "Zhongshan Hospital Fudan University, Shanghai, China",
            "Masarykuv onkologicky ustav, Brno, Czechia",
            "Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia",
            "Thomayerova nemocnice, Praha 4 - Krc, Czechia",
            "Aalborg Universitetshospital, Klinik Kirurgi-KrÃ¦ft, Onkologisk afd., Aalborg, Denmark",
            "Herlev Hospital; Onkologisk afdeling, Herlev, Denmark",
            "Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark",
            "Institut de Cancerologie de l Ouest, Angers, France",
            "Institut Sainte-Catherine; Oncologie, Avignon, France",
            "CHU de Bordeaux - Groupe Hospitalier Saint-AndrÃ© - Hopital Saint-Andre, Bordeaux, France",
            "Centre Francois Baclesse; Oncologie, Caen, France",
            "Hopital Louis Pasteur; Medecine B, Colmar, France",
            "Centre Oscar Lambret; Chir Cancerologie General, Lille, France",
            "Clinique Chenieux; Oncology, Limoges, France",
            "Centre Leon Berard; Departement Oncologie Medicale, Lyon, France",
            "Hopital Saint Louis, Service D Oncologie Medicale, Paris, France",
            "Hopital d'Instruction des Armees de Begin, Saint-Mande, France",
            "Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France",
            "Institut Gustave Roussy, Villejuif, France",
            "StÃ¤dtisches Klinikum Braunschweig gGmbH, Klinik fÃ¼r Urologie und Uroonkologie, Braunschweig, Germany",
            "UniversitÃ¤tsklinikum \"Carl Gustav Carus\"; Klinik und Poliklinik fÃ¼r Urologie, Dresden, Germany",
            "UniversitÃ¤tsklinikum Freiburg; Chirurgische Klinik; Abteilung Urologie, Freiburg, Germany",
            "Medizinische Hochschule Hannover; Klinik fÃ¼r Urologie und Onkologische Urologie, Hannover, Germany",
            "Uniklinik KÃ¶ln, Klinik fÃ¼r Urologie, Uro-Onkologie und spezielle urologische Chirurgie, KÃ¶ln, Germany",
            "UniversitÃ¤tsklinikum MÃ¼nster, Klinik fÃ¼r Urologie und Kinderurologie, MÃ¼nster, Germany",
            "Klinikum NÃ¼rnberg 5. Medizinische Klinik HÃ¤matologie/Onkologie UniversitÃ¤tsklinik der Paracelsus, NÃ¼rnberg, Germany",
            "UniversitÃ¤tsklinikum TÃ¼bingen; Klinik fÃ¼r Urologie, TÃ¼bingen, Germany",
            "Urologisches Zentrum Euregio; Urologische Praxis am Wasserturm, WÃ¼rselen, Germany",
            "Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece",
            "Alexandras Hospital; Dept. of Clin. Therapeutics, Athens Uni School of Medicine, Athens, Greece",
            "Athens Medical Center; Dept. of Oncology, Athens, Greece",
            "IASO General Hospital of Athens, Athens, Greece",
            "Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept., Kifisia, Greece",
            "University Hospital of Patras Medical Oncology, Patras, Greece",
            "Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece",
            "Semmelwies University of Medicine; Urology Dept., Budapest, Hungary",
            "Orszagos Onkologiai Intezet; \"C\" BelgyÃ³gyÃ¡szati-OnkolÃ³giai Ã©s Klinikai FarmakolÃ³giai OsztÃ¡ly, Budapest, Hungary",
            "Uzsoki Utcai Korhaz, Budapest, Hungary",
            "Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen, Hungary",
            "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico, Napoli, Campania, Italy",
            "I.R.S.T Srl IRCCS; Oncologia Medica, Meldola, Emilia-Romagna, Italy",
            "A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, Italy",
            "Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica, Roma, Lazio, Italy",
            "IRCCS AOU San Martino - IST; Oncologia Medica 1, Genova, Liguria, Italy",
            "A.O. Istituti Ospitalieri - Cremona; S.C. Oncologia, Cremona, Lombardia, Italy",
            "Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy",
            "Irccs Istituto Europeo Di Oncologia (IEO); Cure Mediche, Milano, Lombardia, Italy",
            "Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica, Bari, Puglia, Italy",
            "IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia, San Giovanni Rotondo, Puglia, Italy",
            "Ospedale Area Aretina Nord; U.O.C. Oncologia, Arezzo, Toscana, Italy",
            "Ospedale di Trento-Presidio Ospedaliero Santa Chiara; Oncologia Medica, Trento, Trentino-Alto Adige, Italy",
            "IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima, Padova, Veneto, Italy",
            "Nagoya City University Hospital, Aichi, Japan",
            "National Cancer Center East, Chiba, Japan",
            "Toho University Sakura Medical Center, Chiba, Japan",
            "Kyushu University Hospital, Fukuoka, Japan",
            "National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan",
            "Yokohama City University Medical Center, Kanagawa, Japan",
            "Kitasato University Hospital, Kanagawa, Japan",
            "University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan",
            "Nara Medical University Hospital, Nara, Japan",
            "Niigata University Medical & Dental Hospital, Niigata, Japan",
            "Kansai Medical University Hospital, Osaka, Japan",
            "Toranomon Hospital, Tokyo, Japan",
            "The Jikei University Hospital, Tokyo, Japan",
            "Nippon Medical School Hospital, Tokyo, Japan",
            "National Cancer Center, Gyeonggi-do, Korea, Republic of",
            "Seoul National University Hospital, Seoul, Korea, Republic of",
            "Asan Medical Center - Oncology, Seoul, Korea, Republic of",
            "Samsung Medical Center, Seoul, Korea, Republic of",
            "Medical University of Bialystok; Oncology clinic, Bialystok, Poland",
            "Przychodnia Lekarska KOMED, Konin, Poland",
            "Szpital Uniwersytecki w Krakowie, OddziaÅ‚ Kliniczny Kliniki Onkologii, Krakow, Poland",
            "SPZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarawskiego, Opole, Poland",
            "Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland",
            "Szpital Sw. Elzbiety - Mokotowskie Centrum Medyczne Sp. z o.o., Warszawa, Poland",
            "Wojewodzki Szpital; Specjalistyczny ul., Wroclaw, Poland",
            "Woj. Wielospec. Centrum Onkologii i Traumatologii, ÅÃ³dÅº, Poland",
            "SBEI HPE \"The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova\"of MoH of RF, Sankt-peterburg, Leningrad, Russian Federation",
            "Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation",
            "P.A. Herzen Oncological Inst. ; Oncology, Moscow, Russian Federation",
            "Institut Catala dÂ´Oncologia Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain",
            "Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain",
            "Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain",
            "Hospital Universitario Reina Sofia; Servicio de Oncologia, CÃ³rdoba, Cordoba, Spain",
            "Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain",
            "Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain",
            "Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain",
            "Hospital ClÃ­nic i Provincial; Servicio de OncologÃ­a, Barcelona, Spain",
            "Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, Spain",
            "Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain",
            "Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain",
            "Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain",
            "Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain",
            "Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain",
            "Inselspital Bern; UniversitÃ¤tsklinik fÃ¼r medizinische Onkologie, Bern, Switzerland",
            "Kantonsspital St. Gallen; Onkologie/HÃ¤matologie, St. Gallen, Switzerland",
            "Taichung Veterans General Hospital; Division of Urology, Taichung, Taiwan",
            "National Taiwan University Hospital, Department of Urology, Taipei, Taiwan",
            "TAIPEI VETERANS GENERAL HOSPITAL, Urology, Taipei, Taiwan",
            "Chang Gung Memorial Hospital-LinKou; Urology, Taoyuan, Taiwan",
            "Queen Elizabeth Hospital, Birmingham, United Kingdom",
            "Royal Blackburn Hospital, Blackburn, United Kingdom",
            "BRISTOL ONCOLOGY CENTRE; CLINICAL TRIALS UNIT; R & D department, Bristol, United Kingdom",
            "Leicester Royal Infirmary, Leicester, United Kingdom",
            "Barts and the London NHS Trust., London, United Kingdom",
            "Sarah Cannon Research Institute, London, United Kingdom",
            "The Christie NHS Foundation Trust, Manchester, United Kingdom",
            "Royal Marsden Hospital; Institute of Cancer Research, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03016312"
      },
      {
        "-rank": "267",
        "nct_id": "NCT01692262",
        "title": "Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.",
        "acronym": "PYRUS",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Metastatic Castrate-Resistant Prostate Cancer (mCRPC),",
            "Efficacy,",
            "Safety and Tolerability,",
            "Pharmacokinetics,",
            "Pharmacodynamics,",
            "Tumour Response."
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Intermittent dosing of AZD5363"
            },
            {
              "-type": "Drug",
              "#text": "Intermittent dosing of AZD5363"
            },
            {
              "-type": "Drug",
              "#text": "Intermittent dosing of AZD5363"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Parts A and B: Anti-tumour activity by measurement of changes in circulating prostate-specific antigen (PSA)",
            "Parts A and B: Anti-tumour activity by measurement of changes in circulating tumour cells (CTC)",
            "Parts A and B: Anti-tumour activity by measurement of malignant soft tissue response rate",
            "Parts A and B: Anti-tumour activity by measurement of metastatic bone disease status",
            "Parts A and B: Safety and tolerability of AZD5363 in terms of adverse events, serious adverse events (including death) and safety measures: ECG, ECHO/MUGA, physical examination, pulse, blood pressure, weight and laboratory variables",
            "Parts A and B: AZD5363 PK: time to maximum plasma concentration, terminal rate constant,terminal half life, area under plasma concentration time curve, plasma clearance & volume of distribution",
            "Parts A and B: Plasma concentrations of pharmacodynamic (PD) biomarker",
            "Parts A and B: Progression-free survival (PFS)",
            "Parts A and B: Quality of life (QoL)"
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "59",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Screening"
          ]
        },
        "other_ids": {
          "other_id": [
            "D3610C00003",
            "GU86"
          ]
        },
        "start_date": "November 2012",
        "primary_completion_date": "June 2014",
        "completion_date": "June 2014",
        "study_first_posted": "September 25, 2012",
        "last_update_posted": "June 19, 2014",
        "locations": {
          "location": [
            "Research Site, Sarasota, Florida, United States",
            "Research Site, Boston, Massachusetts, United States",
            "Research Site, Ann Arbor, Michigan, United States",
            "Research Site, Hackensack, New Jersey, United States",
            "Research Site, Nashville, Tennessee, United States",
            "Research Site, Cardiff, Wales, United Kingdom",
            "Research Site, London, United Kingdom",
            "Research Site, Southampton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01692262"
      },
      {
        "-rank": "268",
        "nct_id": "NCT00962494",
        "title": "Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Blood Cancer",
            "Breast Cancer",
            "Prostatic Neoplasms",
            "Colorectal Neoplasms",
            "Neoplasms"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Behavioral",
            "#text": "Cancer: Thriving and Surviving Online Workshop"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Document patterns of health care utilization",
            "Quality of Life",
            "Outcome Measure: Better Interactions with Oncologists",
            "Health Behaviors",
            "Satisfaction with intervention"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Stanford University",
          "collaborator": "University of Hawaii Cancer Research Center"
        },
        "gender": "All",
        "min_age": "19 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "585",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Supportive Care"
          ]
        },
        "other_ids": {
          "other_id": [
            "VAR0044",
            "SU-07292009-3460"
          ]
        },
        "start_date": "July 2009",
        "primary_completion_date": "August 2011",
        "completion_date": "December 2011",
        "study_first_posted": "August 20, 2009",
        "last_update_posted": "February 7, 2013",
        "locations": {
          "location": [
            "Stanford University School of Medicine, Stanford, California, United States",
            "Macmillan Cancer Support, London, UK, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00962494"
      },
      {
        "-rank": "269",
        "nct_id": "NCT01087268",
        "title": "Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Bladder Cancer",
            "Cervical Cancer",
            "Colorectal Cancer",
            "Endometrial Cancer",
            "Gastrointestinal Complications",
            "Long-term Effects Secondary to Cancer Therapy in Adults",
            "Ovarian Cancer",
            "Prostate Cancer",
            "Radiation Toxicity",
            "Sarcoma",
            "Testicular Germ Cell Tumor",
            "Vaginal Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            },
            {
              "-type": "Procedure",
              "#text": "gastrointestinal complications management/prevention"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Gastrointestinal symptoms score using the IBDQ quality-of-life questionnaire",
            "Physician assessment of adverse effects using LENT SOMA scales of radiation injury",
            "Patient self-assessments using EORTC QLQ-C30 and Defecation Problem Subscale of QLQ-CR38",
            "Photographic images of rectal mucosa",
            "Physician assessment of rectal dysfunction based on the modified CTCAE grading system",
            "Health economics data"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "75",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Masking: Double",
            "Primary Purpose: Supportive Care"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000667367",
            "RMH-CCR3086",
            "EUDRACT-2008-002152-26",
            "EU-21010",
            "MREC-08/H0903/40"
          ]
        },
        "start_date": "January 2009",
        "primary_completion_date": "December 2011",
        "study_first_posted": "March 16, 2010",
        "last_update_posted": "July 15, 2011",
        "locations": { "location": "Royal Marsden - Surrey, Sutton, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01087268"
      },
      {
        "-rank": "270",
        "nct_id": "NCT01414517",
        "title": "Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet.",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Radiation Enteritis",
            "Radiation Proctitis"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Dietary Supplement",
              "#text": "FructoOligoSaccharide"
            },
            {
              "-type": "Dietary Supplement",
              "#text": "Maltodextrin"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Gastrointestinal Status",
            "Short Term Toxicity",
            "See Effects of FOS",
            "Effect of FOS on Chronic Radiation Bowel Disease",
            "Effect on Gut Microbiota"
          ]
        },
        "sponsors": { "lead_sponsor": "University College London Hospitals" },
        "gender": "All",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "220",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Prevention"
          ]
        },
        "other_ids": { "other_id": "09/H0715/61" },
        "start_date": "August 2010",
        "primary_completion_date": "June 2012",
        "completion_date": "August 2012",
        "study_first_posted": "August 11, 2011",
        "last_update_posted": "August 11, 2011",
        "locations": { "location": "University College London Hospital, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT01414517"
      },
      {
        "-rank": "271",
        "nct_id": "NCT02453139",
        "title": "Exercise, Prostate Cancer and Circulating Tumour Cells",
        "acronym": "ExPeCT",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Obesity"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Behavioral",
            "#text": "Exercise"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Change in Platelet cloaking of Circulating Tumour Cells",
            "Change in systemic inflammation",
            "Change in Quality of Life Questionnaire"
          ]
        },
        "sponsors": { "lead_sponsor": "University of Dublin, Trinity College" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "67",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Single (Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "202370" },
        "start_date": "October 2014",
        "primary_completion_date": "June 2017",
        "completion_date": "June 2017",
        "study_first_posted": "May 25, 2015",
        "last_update_posted": "May 2, 2018",
        "locations": {
          "location": [
            "Adelaide and Meath Incorporating the National Children's Hospital, Tallaght, Dublin, Ireland",
            "St James's Hospital, Dublin, Ireland",
            "Beaumont Hospital, Dublin, Ireland",
            "Mater Misericordiae University Hospital, Dublin, Ireland",
            "St Luke's Hospital, Dublin, Ireland",
            "Guy's St Thomas, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02453139"
      },
      {
        "-rank": "272",
        "nct_id": "NCT00056407",
        "title": "\"REDUCE\" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk",
        "acronym": "REDUCE",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Neoplasms, Prostate" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Dutasteride"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Crude Rate Approach)",
            "Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Modified Crude Rate Approach)",
            "Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Restricted Crude Rate Approach)",
            "Number of Participants With the Indicated Gleason Score at Diagnosis",
            "Number of Participants With HGPIN, ASAP, and Prostate Cancer at Biopsy",
            "Volume of HGPIN at Biopsy",
            "Percentage of Core Involved at Diagnosis",
            "Number of Cancer-positive Cores",
            "Treatment Alteration Score",
            "Number of Participants Undergoing Intervention (Surgical and Non-surgical) for Prostate Cancer Treatment",
            "Adjusted Mean Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 48",
            "Adjusted Mean Percentage Change From Baseline in Prostate Volume at Months 24 and 48",
            "Adjusted Mean Change From Baseline in Maximum Urinary Flow (Qmax) at Months 12, 24, 36, and 48",
            "Number of Participants Starting Alpha Blockers to Control Benign Prostatic Hyperplasia (BPH) Symptoms",
            "Number of Participants With at Least One Event of Acute Urinary Retention (AUR)",
            "Number of Participants With at Least One Urinary Tract Infection (UTI)",
            "Number of Participants With Post-biopsy Macroscopic Hematuria",
            "Number of Participants With Post-biopsy Macroscopic Hematospermia",
            "Overall Survival",
            "Adjusted Mean Change From Baseline in the Benign Prostatic Hypertrophy (BPH) Impact Index (BII) at Month 48",
            "Adjusted Mean Change From Baseline in The Medical Outcomes Study Sleep Problems Index 6-item Standard Version (MOS Sleep-6S) at Month 48",
            "Adjusted Mean Change From Baseline in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH CPSI) at Month 48",
            "Adjusted Mean Change From Baseline in Quality of Life Question 8 (QOL Q8) at Month 48",
            "Adjusted Mean Change From Baseline in the Problem Assessment Scale of the Sexual Function Index (PASSFI) at Month 48",
            "Number of Participants With the Indicated Serum Dihydrotestosterone (DHT) Concentration at Month 48",
            "Mean Change From Baseline in Testosterone at Month 48"
          ]
        },
        "sponsors": { "lead_sponsor": "GlaxoSmithKline" },
        "gender": "Male",
        "min_age": "50 Years",
        "max_age": "75 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "8231",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Prevention"
          ]
        },
        "other_ids": { "other_id": "ARI40006" },
        "start_date": "March 2003",
        "primary_completion_date": "January 2009",
        "completion_date": "April 2009",
        "study_first_posted": "March 13, 2003",
        "results_first_posted": "March 5, 2010",
        "last_update_posted": "September 23, 2016",
        "locations": {
          "location": [
            "GSK Investigational Site, Birmingham, Alabama, United States",
            "GSK Investigational Site, Homewood, Alabama, United States",
            "GSK Investigational Site, Huntsville, Alabama, United States",
            "GSK Investigational Site, Mobile, Alabama, United States",
            "GSK Investigational Site, Anchorage, Alaska, United States",
            "GSK Investigational Site, Phoenix, Arizona, United States",
            "GSK Investigational Site, Phoenix, Arizona, United States",
            "GSK Investigational Site, Phoenix, Arizona, United States",
            "GSK Investigational Site, Scottsdale, Arizona, United States",
            "GSK Investigational Site, Sun City, Arizona, United States",
            "GSK Investigational Site, Tucson, Arizona, United States",
            "GSK Investigational Site, Tucson, Arizona, United States",
            "GSK Investigational Site, Little Rock, Arkansas, United States",
            "GSK Investigational Site, Little Rock, Arkansas, United States",
            "GSK Investigational Site, Anaheim, California, United States",
            "GSK Investigational Site, Atherton, California, United States",
            "GSK Investigational Site, Culver City, California, United States",
            "GSK Investigational Site, Encino, California, United States",
            "GSK Investigational Site, Fountain Valley, California, United States",
            "GSK Investigational Site, Fresno, California, United States",
            "GSK Investigational Site, Irvine, California, United States",
            "GSK Investigational Site, La Mesa, California, United States",
            "GSK Investigational Site, Laguna Hills, California, United States",
            "GSK Investigational Site, Long Beach, California, United States",
            "GSK Investigational Site, Los Angeles, California, United States",
            "GSK Investigational Site, Los Angeles, California, United States",
            "GSK Investigational Site, Los Angeles, California, United States",
            "GSK Investigational Site, Los Angeles, California, United States",
            "GSK Investigational Site, Los Angeles, California, United States",
            "GSK Investigational Site, Mather, California, United States",
            "GSK Investigational Site, Newport Beach, California, United States",
            "GSK Investigational Site, Orange, California, United States",
            "GSK Investigational Site, Pico Rivera, California, United States",
            "GSK Investigational Site, Poway, California, United States",
            "GSK Investigational Site, Sacramento, California, United States",
            "GSK Investigational Site, Salinas, California, United States",
            "GSK Investigational Site, San Bernardino, California, United States",
            "GSK Investigational Site, San Diego, California, United States",
            "GSK Investigational Site, San Diego, California, United States",
            "GSK Investigational Site, San Diego, California, United States",
            "GSK Investigational Site, San Diego, California, United States",
            "GSK Investigational Site, San Francisco, California, United States",
            "GSK Investigational Site, San Francisco, California, United States",
            "GSK Investigational Site, San Ramon, California, United States",
            "GSK Investigational Site, Santa Monica, California, United States",
            "GSK Investigational Site, Stanford, California, United States",
            "GSK Investigational Site, Temecula, California, United States",
            "GSK Investigational Site, Torrance, California, United States",
            "GSK Investigational Site, Upland, California, United States",
            "GSK Investigational Site, Van Nuys, California, United States",
            "GSK Investigational Site, Walnut Creek, California, United States",
            "GSK Investigational Site, Westchester, California, United States",
            "GSK Investigational Site, Aurora, Colorado, United States",
            "GSK Investigational Site, Aurora, Colorado, United States",
            "GSK Investigational Site, Denver, Colorado, United States",
            "GSK Investigational Site, Denver, Colorado, United States",
            "GSK Investigational Site, Englewood, Colorado, United States",
            "GSK Investigational Site, Longmont, Colorado, United States",
            "GSK Investigational Site, Hartford, Connecticut, United States",
            "GSK Investigational Site, Middlebury, Connecticut, United States",
            "GSK Investigational Site, New Britain, Connecticut, United States",
            "GSK Investigational Site, Trumbull, Connecticut, United States",
            "GSK Investigational Site, Washington, District of Columbia, United States",
            "GSK Investigational Site, Aventura, Florida, United States",
            "GSK Investigational Site, Clearwater, Florida, United States",
            "GSK Investigational Site, Clearwater, Florida, United States",
            "GSK Investigational Site, Delray Beach, Florida, United States",
            "GSK Investigational Site, Fort Myers, Florida, United States",
            "GSK Investigational Site, Jacksonville, Florida, United States",
            "GSK Investigational Site, Jacksonville, Florida, United States",
            "GSK Investigational Site, Jacksonville, Florida, United States",
            "GSK Investigational Site, Lake Worth, Florida, United States",
            "GSK Investigational Site, Largo, Florida, United States",
            "GSK Investigational Site, Longwood, Florida, United States",
            "GSK Investigational Site, Margate, Florida, United States",
            "GSK Investigational Site, Melbourne, Florida, United States",
            "GSK Investigational Site, Miami, Florida, United States",
            "GSK Investigational Site, New Port Richey, Florida, United States",
            "GSK Investigational Site, Ocala, Florida, United States",
            "GSK Investigational Site, Ocala, Florida, United States",
            "GSK Investigational Site, Okeechobee, Florida, United States",
            "GSK Investigational Site, Orange Park, Florida, United States",
            "GSK Investigational Site, Orlando, Florida, United States",
            "GSK Investigational Site, Panama City, Florida, United States",
            "GSK Investigational Site, Plantation, Florida, United States",
            "GSK Investigational Site, Sarasota, Florida, United States",
            "GSK Investigational Site, South Daytona, Florida, United States",
            "GSK Investigational Site, St. Petersburg, Florida, United States",
            "GSK Investigational Site, Stuart, Florida, United States",
            "GSK Investigational Site, Tallahassee, Florida, United States",
            "GSK Investigational Site, Tamarac, Florida, United States",
            "GSK Investigational Site, West Palm Beach, Florida, United States",
            "GSK Investigational Site, Atlanta, Georgia, United States",
            "GSK Investigational Site, Atlanta, Georgia, United States",
            "GSK Investigational Site, Atlanta, Georgia, United States",
            "GSK Investigational Site, Augusta, Georgia, United States",
            "GSK Investigational Site, Fayetteville, Georgia, United States",
            "GSK Investigational Site, Marietta, Georgia, United States",
            "GSK Investigational Site, Roswell, Georgia, United States",
            "GSK Investigational Site, Woodstock, Georgia, United States",
            "GSK Investigational Site, Honolulu, Hawaii, United States",
            "GSK Investigational Site, Coeur d'Alene, Idaho, United States",
            "GSK Investigational Site, Chicago, Illinois, United States",
            "GSK Investigational Site, Chicago, Illinois, United States",
            "GSK Investigational Site, Chicago, Illinois, United States",
            "GSK Investigational Site, Chicago, Illinois, United States",
            "GSK Investigational Site, Galesburg, Illinois, United States",
            "GSK Investigational Site, Kankakee, Illinois, United States",
            "GSK Investigational Site, Maywood, Illinois, United States",
            "GSK Investigational Site, Melrose Park, Illinois, United States",
            "GSK Investigational Site, Niles, Illinois, United States",
            "GSK Investigational Site, Springfield, Illinois, United States",
            "GSK Investigational Site, Evansville, Indiana, United States",
            "GSK Investigational Site, Fort Wayne, Indiana, United States",
            "GSK Investigational Site, Indianapolis, Indiana, United States",
            "GSK Investigational Site, Jeffersonville, Indiana, United States",
            "GSK Investigational Site, Kansas City, Kansas, United States",
            "GSK Investigational Site, Overland Park, Kansas, United States",
            "GSK Investigational Site, Wichita, Kansas, United States",
            "GSK Investigational Site, Lexington, Kentucky, United States",
            "GSK Investigational Site, Covington, Louisiana, United States",
            "GSK Investigational Site, Gretna, Louisiana, United States",
            "GSK Investigational Site, Houma, Louisiana, United States",
            "GSK Investigational Site, Lafayette, Louisiana, United States",
            "GSK Investigational Site, Metairie, Louisiana, United States",
            "GSK Investigational Site, New Orleans, Louisiana, United States",
            "GSK Investigational Site, New Orleans, Louisiana, United States",
            "GSK Investigational Site, New Orleans, Louisiana, United States",
            "GSK Investigational Site, Ruston, Louisiana, United States",
            "GSK Investigational Site, Shreveport, Louisiana, United States",
            "GSK Investigational Site, Annapolis, Maryland, United States",
            "GSK Investigational Site, Baltimore, Maryland, United States",
            "GSK Investigational Site, Greenbelt, Maryland, United States",
            "GSK Investigational Site, Owings Mills, Maryland, United States",
            "GSK Investigational Site, Rockville, Maryland, United States",
            "GSK Investigational Site, Towson, Maryland, United States",
            "GSK Investigational Site, Boston, Massachusetts, United States",
            "GSK Investigational Site, Braintree, Massachusetts, United States",
            "GSK Investigational Site, Haverhill, Massachusetts, United States",
            "GSK Investigational Site, Milford, Massachusetts, United States",
            "GSK Investigational Site, Newton, Massachusetts, United States",
            "GSK Investigational Site, Springfield, Massachusetts, United States",
            "GSK Investigational Site, Waltham, Massachusetts, United States",
            "GSK Investigational Site, Watertown, Massachusetts, United States",
            "GSK Investigational Site, West Yarmouth, Massachusetts, United States",
            "GSK Investigational Site, Wocester, Massachusetts, United States",
            "GSK Investigational Site, Ann Arbor, Michigan, United States",
            "GSK Investigational Site, Detroit, Michigan, United States",
            "GSK Investigational Site, Royal Oak, Michigan, United States",
            "GSK Investigational Site, St. Joseph, Michigan, United States",
            "GSK Investigational Site, Chaska, Minnesota, United States",
            "GSK Investigational Site, Edina, Minnesota, United States",
            "GSK Investigational Site, Minneapolis, Minnesota, United States",
            "GSK Investigational Site, Rochester, Minnesota, United States",
            "GSK Investigational Site, St. Cloud, Minnesota, United States",
            "GSK Investigational Site, Hattiesburg, Mississippi, United States",
            "GSK Investigational Site, Jackson, Mississippi, United States",
            "GSK Investigational Site, Kansas City, Missouri, United States",
            "GSK Investigational Site, Springfield, Missouri, United States",
            "GSK Investigational Site, St. Louis, Missouri, United States",
            "GSK Investigational Site, St. Louis, Missouri, United States",
            "GSK Investigational Site, St. Louis, Missouri, United States",
            "GSK Investigational Site, Billings, Montana, United States",
            "GSK Investigational Site, Omaha, Nebraska, United States",
            "GSK Investigational Site, Omaha, Nebraska, United States",
            "GSK Investigational Site, Henderson, Nevada, United States",
            "GSK Investigational Site, Las Vegas, Nevada, United States",
            "GSK Investigational Site, Las Vegas, Nevada, United States",
            "GSK Investigational Site, Reno, Nevada, United States",
            "GSK Investigational Site, Reno, Nevada, United States",
            "GSK Investigational Site, Lebanon, New Hampshire, United States",
            "GSK Investigational Site, Edison, New Jersey, United States",
            "GSK Investigational Site, Hackensack, New Jersey, United States",
            "GSK Investigational Site, Lawrencevill, New Jersey, United States",
            "GSK Investigational Site, Marlton, New Jersey, United States",
            "GSK Investigational Site, Perth Amboy, New Jersey, United States",
            "GSK Investigational Site, Voorhees, New Jersey, United States",
            "GSK Investigational Site, West Orange, New Jersey, United States",
            "GSK Investigational Site, Albany, New York, United States",
            "GSK Investigational Site, Binghamton, New York, United States",
            "GSK Investigational Site, Bronx, New York, United States",
            "GSK Investigational Site, Brooklyn, New York, United States",
            "GSK Investigational Site, East Syracuse, New York, United States",
            "GSK Investigational Site, Elmont, New York, United States",
            "GSK Investigational Site, Endwell, New York, United States",
            "GSK Investigational Site, Garden City, New York, United States",
            "GSK Investigational Site, Great Neck, New York, United States",
            "GSK Investigational Site, Mineola, New York, United States",
            "GSK Investigational Site, New York, New York, United States",
            "GSK Investigational Site, New York, New York, United States",
            "GSK Investigational Site, Orchard Park, New York, United States",
            "GSK Investigational Site, Poughkeepsie, New York, United States",
            "GSK Investigational Site, Rochester, New York, United States",
            "GSK Investigational Site, Staten Island, New York, United States",
            "GSK Investigational Site, Syracuse, New York, United States",
            "GSK Investigational Site, Cary, North Carolina, United States",
            "GSK Investigational Site, Cary, North Carolina, United States",
            "GSK Investigational Site, Chapel Hill, North Carolina, United States",
            "GSK Investigational Site, Charlotte, NC 28207, North Carolina, United States",
            "GSK Investigational Site, Charlotte, North Carolina, United States",
            "GSK Investigational Site, Charlotte, North Carolina, United States",
            "GSK Investigational Site, Concord, North Carolina, United States",
            "GSK Investigational Site, Durham, North Carolina, United States",
            "GSK Investigational Site, Greensboro, North Carolina, United States",
            "GSK Investigational Site, Greenville, North Carolina, United States",
            "GSK Investigational Site, Raleigh, North Carolina, United States",
            "GSK Investigational Site, Raleigh, North Carolina, United States",
            "GSK Investigational Site, Winston-Salem, North Carolina, United States",
            "GSK Investigational Site, Bismarck, North Dakota, United States",
            "GSK Investigational Site, Cincinnati, Ohio, United States",
            "GSK Investigational Site, Cincinnati, Ohio, United States",
            "GSK Investigational Site, Columbus, Ohio, United States",
            "GSK Investigational Site, Columbus, Ohio, United States",
            "GSK Investigational Site, Columbus, Ohio, United States",
            "GSK Investigational Site, Elyria, Ohio, United States",
            "GSK Investigational Site, Kettering, Ohio, United States",
            "GSK Investigational Site, Marion, Ohio, United States",
            "GSK Investigational Site, Zanesville, Ohio, United States",
            "GSK Investigational Site, Oklahoma City, Oklahoma, United States",
            "GSK Investigational Site, Poca City, Oklahoma, United States",
            "GSK Investigational Site, Tulsa, Oklahoma, United States",
            "GSK Investigational Site, Oregon City, Oregon, United States",
            "GSK Investigational Site, Portland, Oregon, United States",
            "GSK Investigational Site, Portland, Oregon, United States",
            "GSK Investigational Site, Portland, Oregon, United States",
            "GSK Investigational Site, Springfield, Oregon, United States",
            "GSK Investigational Site, Bala Cynwyd, Pennsylvania, United States",
            "GSK Investigational Site, Bryn Mawr, Pennsylvania, United States",
            "GSK Investigational Site, Camp Hill, Pennsylvania, United States",
            "GSK Investigational Site, Harrisburg, Pennsylvania, United States",
            "GSK Investigational Site, Hershey, Pennsylvania, United States",
            "GSK Investigational Site, Lancaster, Pennsylvania, United States",
            "GSK Investigational Site, Lancaster, Pennsylvania, United States",
            "GSK Investigational Site, Monroeville, Pennsylvania, United States",
            "GSK Investigational Site, Newton, Pennsylvania, United States",
            "GSK Investigational Site, Philadelphia, Pennsylvania, United States",
            "GSK Investigational Site, Philadelphia, Pennsylvania, United States",
            "GSK Investigational Site, Philadelphia, Pennsylvania, United States",
            "GSK Investigational Site, Philadelphia, Pennsylvania, United States",
            "GSK Investigational Site, Pittsburgh, Pennsylvania, United States",
            "GSK Investigational Site, Pittsburgh, Pennsylvania, United States",
            "GSK Investigational Site, Rosemont, Pennsylvania, United States",
            "GSK Investigational Site, Sellersville, Pennsylvania, United States",
            "GSK Investigational Site, State College, Pennsylvania, United States",
            "GSK Investigational Site, Cranston, Rhode Island, United States",
            "GSK Investigational Site, Providence, Rhode Island, United States",
            "GSK Investigational Site, West Warwick, Rhode Island, United States",
            "GSK Investigational Site, Charleston, South Carolina, United States",
            "GSK Investigational Site, Greenville, South Carolina, United States",
            "GSK Investigational Site, Greer, South Carolina, United States",
            "GSK Investigational Site, Myrtle Beach, South Carolina, United States",
            "GSK Investigational Site, Simpsonville, South Carolina, United States",
            "GSK Investigational Site, Fort Pierre, South Dakota, United States",
            "GSK Investigational Site, Germantown, Tennessee, United States",
            "GSK Investigational Site, Knoxville, Tennessee, United States",
            "GSK Investigational Site, Memphis, Tennessee, United States",
            "GSK Investigational Site, Nashville, Tennessee, United States",
            "GSK Investigational Site, Nashville, Tennessee, United States",
            "GSK Investigational Site, Amarillo, Texas, United States",
            "GSK Investigational Site, Arlington, Texas, United States",
            "GSK Investigational Site, Austin, Texas, United States",
            "GSK Investigational Site, Dallas, Texas, United States",
            "GSK Investigational Site, Dallas, Texas, United States",
            "GSK Investigational Site, Dallas, Texas, United States",
            "GSK Investigational Site, Dallas, Texas, United States",
            "GSK Investigational Site, Dallas, Texas, United States",
            "GSK Investigational Site, Fort Worth, Texas, United States",
            "GSK Investigational Site, Fort Worth, Texas, United States",
            "GSK Investigational Site, Houston, Texas, United States",
            "GSK Investigational Site, Houston, Texas, United States",
            "GSK Investigational Site, San Antonio, Texas, United States",
            "GSK Investigational Site, Texarkana, Texas, United States",
            "GSK Investigational Site, Salt Lake City, Utah, United States",
            "GSK Investigational Site, South Burlington, Vermont, United States",
            "GSK Investigational Site, Alexandria, Virginia, United States",
            "GSK Investigational Site, Charlottesville, Virginia, United States",
            "GSK Investigational Site, Fairfax, Virginia, United States",
            "GSK Investigational Site, Harrisonburg, Virginia, United States",
            "GSK Investigational Site, Mechanicsville, Virginia, United States",
            "GSK Investigational Site, Norfolk, Virginia, United States",
            "GSK Investigational Site, Richmond, Virginia, United States",
            "GSK Investigational Site, Salem, Virginia, United States",
            "GSK Investigational Site, Virginia Beach, Virginia, United States",
            "GSK Investigational Site, Graham, Washington, United States",
            "GSK Investigational Site, Seattle, Washington, United States",
            "GSK Investigational Site, Seattle, Washington, United States",
            "GSK Investigational Site, Seattle, Washington, United States",
            "GSK Investigational Site, Seattle, Washington, United States",
            "GSK Investigational Site, Seattle, Washington, United States",
            "GSK Investigational Site, Spokane, Washington, United States",
            "GSK Investigational Site, Tacoma, Washington, United States",
            "GSK Investigational Site, Tacoma, Washington, United States",
            "GSK Investigational Site, Tacoma, Washington, United States",
            "GSK Investigational Site, Madison, Wisconsin, United States",
            "GSK Investigational Site, Milwaukee, Wisconsin, United States",
            "GSK Investigational Site, Milwaukee, Wisconsin, United States",
            "GSK Investigational Site, Cheyenne, Wyoming, United States",
            "GSK Investigational Site, Av CÃ³rdoba 2424, Buenos Aires, Argentina",
            "GSK Investigational Site, Bahia Blanca, Buenos Aires, Argentina",
            "GSK Investigational Site, Capital Federal, Buenos Aires, Argentina",
            "GSK Investigational Site, Capital Federal, Buenos Aires, Argentina",
            "GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina",
            "GSK Investigational Site, CÃ³rdoba, CÃ³rdova, Argentina",
            "GSK Investigational Site, CÃ³rdoba, CÃ³rdova, Argentina",
            "GSK Investigational Site, Rosario, Santa Fe, Argentina",
            "GSK Investigational Site, Buenos Aires, Argentina",
            "GSK Investigational Site, Darlinghurst, New South Wales, Australia",
            "GSK Investigational Site, Kogarah, New South Wales, Australia",
            "GSK Investigational Site, Randwick, New South Wales, Australia",
            "GSK Investigational Site, Westmead, New South Wales, Australia",
            "GSK Investigational Site, Herston, Queensland, Australia",
            "GSK Investigational Site, Kippa Ring, Queensland, Australia",
            "GSK Investigational Site, Woolloongabba, Queensland, Australia",
            "GSK Investigational Site, Adelaide, South Australia, Australia",
            "GSK Investigational Site, Mentone, Victoria, Australia",
            "GSK Investigational Site, Parkville, Victoria, Australia",
            "GSK Investigational Site, Innsbruck, Austria",
            "GSK Investigational Site, Vienna, Austria",
            "GSK Investigational Site, Vienna, Austria",
            "GSK Investigational Site, Minsk, Belarus",
            "GSK Investigational Site, Minsk, Belarus",
            "GSK Investigational Site, Aalst, Belgium",
            "GSK Investigational Site, Antwerpen, Belgium",
            "GSK Investigational Site, Brussels, Belgium",
            "GSK Investigational Site, Bruxelles, Belgium",
            "GSK Investigational Site, Bruxelles, Belgium",
            "GSK Investigational Site, Gent, Belgium",
            "GSK Investigational Site, Hasselt, Belgium",
            "GSK Investigational Site, Kortrijk, Belgium",
            "GSK Investigational Site, Leuven, Belgium",
            "GSK Investigational Site, Mons, Belgium",
            "GSK Investigational Site, Turnhout, Belgium",
            "GSK Investigational Site, Wilrijk, Belgium",
            "GSK Investigational Site, Yvoir, Belgium",
            "GSK Investigational Site, Salvador, BahÃ­a, Brazil",
            "GSK Investigational Site, Belo Horizonte, Minas Gerais, Brazil",
            "GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil",
            "GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil",
            "GSK Investigational Site, RibeirÃ£o Preto, SÃ£o Paulo, Brazil",
            "GSK Investigational Site, Rio de Janeiro, Brazil",
            "GSK Investigational Site, SÃ£o Paulo, Brazil",
            "GSK Investigational Site, Sofia, Bulgaria",
            "GSK Investigational Site, Sofia, Bulgaria",
            "GSK Investigational Site, Sofia, Bulgaria",
            "GSK Investigational Site, Sofia, Bulgaria",
            "GSK Investigational Site, Varna, Bulgaria",
            "GSK Investigational Site, Calgary, Alberta, Canada",
            "GSK Investigational Site, Edmonton, Alberta, Canada",
            "GSK Investigational Site, Kelowna, British Columbia, Canada",
            "GSK Investigational Site, Surrey, British Columbia, Canada",
            "GSK Investigational Site, Vancouver, British Columbia, Canada",
            "GSK Investigational Site, Victoria, British Columbia, Canada",
            "GSK Investigational Site, Victoria, British Columbia, Canada",
            "GSK Investigational Site, Fredericton, New Brunswick, Canada",
            "GSK Investigational Site, Miramichi, New Brunswick, Canada",
            "GSK Investigational Site, Saint John, New Brunswick, Canada",
            "GSK Investigational Site, Halifax, Nova Scotia, Canada",
            "GSK Investigational Site, Barrie, Ontario, Canada",
            "GSK Investigational Site, Burlington, Ontario, Canada",
            "GSK Investigational Site, Burlington, Ontario, Canada",
            "GSK Investigational Site, Kingston, Ontario, Canada",
            "GSK Investigational Site, Kitchener, Ontario, Canada",
            "GSK Investigational Site, Markham, Ontario, Canada",
            "GSK Investigational Site, Newmarket, Ontario, Canada",
            "GSK Investigational Site, Niagara Falls, Ontario, Canada",
            "GSK Investigational Site, North Bay, Ontario, Canada",
            "GSK Investigational Site, North York, Ontario, Canada",
            "GSK Investigational Site, Oakville, Ontario, Canada",
            "GSK Investigational Site, Orillia, Ontario, Canada",
            "GSK Investigational Site, Richmond Hill, Ontario, Canada",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Chicoutimi, Quebec, Canada",
            "GSK Investigational Site, Granby, Quebec, Canada",
            "GSK Investigational Site, Greenfield Park, Quebec, Canada",
            "GSK Investigational Site, Laval, Quebec, Canada",
            "GSK Investigational Site, Montreal, Quebec, Canada",
            "GSK Investigational Site, Montreal, Quebec, Canada",
            "GSK Investigational Site, Montreal, Quebec, Canada",
            "GSK Investigational Site, Montreal, Quebec, Canada",
            "GSK Investigational Site, Montreal, Quebec, Canada",
            "GSK Investigational Site, Montreal, Quebec, Canada",
            "GSK Investigational Site, Pointe-Claire, Quebec, Canada",
            "GSK Investigational Site, Trois Rivieres, Quebec, Canada",
            "GSK Investigational Site, Quebec, Canada",
            "GSK Investigational Site, Santiago, RegiÃ³n Metro De Santiago, Chile",
            "GSK Investigational Site, ViÃ±a del Mar, ValparaÃ­so, Chile",
            "GSK Investigational Site, Zagreb, Croatia",
            "GSK Investigational Site, Herlev, Denmark",
            "GSK Investigational Site, Middelfart, Denmark",
            "GSK Investigational Site, Nakskov, Denmark",
            "GSK Investigational Site, Tallinn, Estonia",
            "GSK Investigational Site, Tallinn, Estonia",
            "GSK Investigational Site, Helsinki, Finland",
            "GSK Investigational Site, Helsinki, Finland",
            "GSK Investigational Site, Kuopio, Finland",
            "GSK Investigational Site, Lahti, Finland",
            "GSK Investigational Site, Lappeenranta, Finland",
            "GSK Investigational Site, Oulu, Finland",
            "GSK Investigational Site, Oulu, Finland",
            "GSK Investigational Site, Rovaniemi, Finland",
            "GSK Investigational Site, Seinajoki, Finland",
            "GSK Investigational Site, Tampere, Finland",
            "GSK Investigational Site, Turku, Finland",
            "GSK Investigational Site, Amiens, France",
            "GSK Investigational Site, Arcachon, France",
            "GSK Investigational Site, Auch, France",
            "GSK Investigational Site, Besancon Cedex, France",
            "GSK Investigational Site, Bois Bernard, France",
            "GSK Investigational Site, Bordeaux Cedex, France",
            "GSK Investigational Site, Boujan sur Libron, France",
            "GSK Investigational Site, Cabestany, France",
            "GSK Investigational Site, Caen cedex, France",
            "GSK Investigational Site, Cannes, France",
            "GSK Investigational Site, Carpentras, France",
            "GSK Investigational Site, Chalon Sur Saone, France",
            "GSK Investigational Site, Cholet, France",
            "GSK Investigational Site, ChÃ¢lons-En-Champagne, France",
            "GSK Investigational Site, CrÃ©teil Cedex, France",
            "GSK Investigational Site, Dijon, France",
            "GSK Investigational Site, Domarin, France",
            "GSK Investigational Site, Dunkerque, France",
            "GSK Investigational Site, Fourmies Cedex, France",
            "GSK Investigational Site, Grande Synthe Cedex, France",
            "GSK Investigational Site, Guilherand Granges, France",
            "GSK Investigational Site, Le Havre, France",
            "GSK Investigational Site, Le Raincy, France",
            "GSK Investigational Site, Lille Cedex, France",
            "GSK Investigational Site, Longjumeau, France",
            "GSK Investigational Site, Lyon Cedex 03, France",
            "GSK Investigational Site, Marseille, France",
            "GSK Investigational Site, Marseille, France",
            "GSK Investigational Site, Montauban, France",
            "GSK Investigational Site, Montpellier, France",
            "GSK Investigational Site, Nimes, France",
            "GSK Investigational Site, Orleans, France",
            "GSK Investigational Site, Orsay, France",
            "GSK Investigational Site, Paris Cedex 10, France",
            "GSK Investigational Site, Paris Cedex 18, France",
            "GSK Investigational Site, Pau, France",
            "GSK Investigational Site, Pierre Benite Cedex, France",
            "GSK Investigational Site, Ploemeur, France",
            "GSK Investigational Site, Poitiers Cedex, France",
            "GSK Investigational Site, Reims, France",
            "GSK Investigational Site, Rouen, France",
            "GSK Investigational Site, Saint Cyr sur Loire, France",
            "GSK Investigational Site, Saint Etienne Cedex 2, France",
            "GSK Investigational Site, Saint Etienne, France",
            "GSK Investigational Site, Saint GrÃ©goire, France",
            "GSK Investigational Site, Saint Martin d'Heres, France",
            "GSK Investigational Site, Saint Nazaire, France",
            "GSK Investigational Site, Saint Quentin Cedex, France",
            "GSK Investigational Site, Suresnes, France",
            "GSK Investigational Site, Toulouse Cedex 4, France",
            "GSK Investigational Site, Tours, France",
            "GSK Investigational Site, Tours, France",
            "GSK Investigational Site, Troyes, France",
            "GSK Investigational Site, Vannes, France",
            "GSK Investigational Site, Backnang, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Bad Schoenborn, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Bruchsal, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Esslingen, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Kleinblittersdorf, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Neckargemuend, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Ostfildern, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Rheinfelden, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Waldkirch, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Aichach, Bayern, Germany",
            "GSK Investigational Site, Augsburg, Bayern, Germany",
            "GSK Investigational Site, Bad Griesbach, Bayern, Germany",
            "GSK Investigational Site, Bamberg, Bayern, Germany",
            "GSK Investigational Site, Dachau, Bayern, Germany",
            "GSK Investigational Site, Ebersberg, Bayern, Germany",
            "GSK Investigational Site, Forchheim, Bayern, Germany",
            "GSK Investigational Site, Fuerth, Bayern, Germany",
            "GSK Investigational Site, Garmisch-Partenkirchen, Bayern, Germany",
            "GSK Investigational Site, GÃ¼nzburg, Bayern, Germany",
            "GSK Investigational Site, Herzogenaurach, Bayern, Germany",
            "GSK Investigational Site, Hoechberg, Bayern, Germany",
            "GSK Investigational Site, Kelheim, Bayern, Germany",
            "GSK Investigational Site, Koenigsbrunn, Bayern, Germany",
            "GSK Investigational Site, Muenchen, Bayern, Germany",
            "GSK Investigational Site, Muenchen, Bayern, Germany",
            "GSK Investigational Site, Muenchen, Bayern, Germany",
            "GSK Investigational Site, Neumarkt, Bayern, Germany",
            "GSK Investigational Site, Nuernberg, Bayern, Germany",
            "GSK Investigational Site, Nuernberg, Bayern, Germany",
            "GSK Investigational Site, Nuernberg, Bayern, Germany",
            "GSK Investigational Site, Nuernberg, Bayern, Germany",
            "GSK Investigational Site, Planegg, Bayern, Germany",
            "GSK Investigational Site, Rosenheim, Bayern, Germany",
            "GSK Investigational Site, Roth, Bayern, Germany",
            "GSK Investigational Site, Starnberg, Bayern, Germany",
            "GSK Investigational Site, Starnberg, Bayern, Germany",
            "GSK Investigational Site, Weiden, Bayern, Germany",
            "GSK Investigational Site, Weissenburg, Bayern, Germany",
            "GSK Investigational Site, Wertheim, Bayern, Germany",
            "GSK Investigational Site, Hagenow, Brandenburg, Germany",
            "GSK Investigational Site, Hennigsdorf, Brandenburg, Germany",
            "GSK Investigational Site, Oranienburg, Brandenburg, Germany",
            "GSK Investigational Site, Schwedt, Brandenburg, Germany",
            "GSK Investigational Site, Senftenberg, Brandenburg, Germany",
            "GSK Investigational Site, Strausberg, Brandenburg, Germany",
            "GSK Investigational Site, Wedel, Hamburg, Germany",
            "GSK Investigational Site, Bad Homburg, Hessen, Germany",
            "GSK Investigational Site, Frankfurt, Hessen, Germany",
            "GSK Investigational Site, Frankfurt, Hessen, Germany",
            "GSK Investigational Site, Frankfurt, Hessen, Germany",
            "GSK Investigational Site, Frankfurt, Hessen, Germany",
            "GSK Investigational Site, Hochheim, Hessen, Germany",
            "GSK Investigational Site, Kelkheim, Hessen, Germany",
            "GSK Investigational Site, Marburg, Hessen, Germany",
            "GSK Investigational Site, Neustadt, Hessen, Germany",
            "GSK Investigational Site, Offenbach, Hessen, Germany",
            "GSK Investigational Site, Seligenstadt, Hessen, Germany",
            "GSK Investigational Site, Vellmar, Hessen, Germany",
            "GSK Investigational Site, Wiesbaden, Hessen, Germany",
            "GSK Investigational Site, Bad Doberan, Mecklenburg-Vorpommern, Germany",
            "GSK Investigational Site, Ludwigslust, Mecklenburg-Vorpommern, Germany",
            "GSK Investigational Site, Ribnitz-Damgarten, Mecklenburg-Vorpommern, Germany",
            "GSK Investigational Site, Rostock, Mecklenburg-Vorpommern, Germany",
            "GSK Investigational Site, Rostock, Mecklenburg-Vorpommern, Germany",
            "GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany",
            "GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany",
            "GSK Investigational Site, Wismar, Mecklenburg-Vorpommern, Germany",
            "GSK Investigational Site, Braunschweig, Niedersachsen, Germany",
            "GSK Investigational Site, Braunschweig, Niedersachsen, Germany",
            "GSK Investigational Site, Bremervoerde, Niedersachsen, Germany",
            "GSK Investigational Site, Buchholz, Niedersachsen, Germany",
            "GSK Investigational Site, Buxtehude, Niedersachsen, Germany",
            "GSK Investigational Site, Ganderkesee, Niedersachsen, Germany",
            "GSK Investigational Site, Goettingen, Niedersachsen, Germany",
            "GSK Investigational Site, Hildesheim, Niedersachsen, Germany",
            "GSK Investigational Site, Holzminden, Niedersachsen, Germany",
            "GSK Investigational Site, Leer, Niedersachsen, Germany",
            "GSK Investigational Site, Salzgitter, Niedersachsen, Germany",
            "GSK Investigational Site, Wolfsburg, Niedersachsen, Germany",
            "GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Arnsberg, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Bocholt, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Bonn, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Borken, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Dortmund, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Duelmen, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Erkrath, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Gelsenkirchen, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Gelsenkirchen, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Kamp-Lintfort, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Kempen, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Koenigswinter, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Krefeld, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Krefeld, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Langenfeld, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Marl, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Moers, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Muelheim, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Oberhausen, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Paderborn, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Pulheim, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Wesseling, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Wuppertal, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Bad Bergzabern, Rheinland-Pfalz, Germany",
            "GSK Investigational Site, Bad Ems, Rheinland-Pfalz, Germany",
            "GSK Investigational Site, Dierdorf, Rheinland-Pfalz, Germany",
            "GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany",
            "GSK Investigational Site, Nieder-Olm, Rheinland-Pfalz, Germany",
            "GSK Investigational Site, Homburg, Saarland, Germany",
            "GSK Investigational Site, Dessau, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Dessau, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Eisleben, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Gardelegen, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Halle, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Hettstedt, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Leuna, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Magdeburg, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Naumburg, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Weissenfels, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Wolmirstedt, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Bautzen, Sachsen, Germany",
            "GSK Investigational Site, Chemnitz, Sachsen, Germany",
            "GSK Investigational Site, Chemnitz, Sachsen, Germany",
            "GSK Investigational Site, Doebeln, Sachsen, Germany",
            "GSK Investigational Site, Dresden, Sachsen, Germany",
            "GSK Investigational Site, Dresden, Sachsen, Germany",
            "GSK Investigational Site, Grimma, Sachsen, Germany",
            "GSK Investigational Site, Leipzig, Sachsen, Germany",
            "GSK Investigational Site, Leipzig, Sachsen, Germany",
            "GSK Investigational Site, Leipzig, Sachsen, Germany",
            "GSK Investigational Site, Leipzig, Sachsen, Germany",
            "GSK Investigational Site, Leipzig, Sachsen, Germany",
            "GSK Investigational Site, Markkleeberg, Sachsen, Germany",
            "GSK Investigational Site, Neustadt, Sachsen, Germany",
            "GSK Investigational Site, Oelsnitz, Sachsen, Germany",
            "GSK Investigational Site, Pirna, Sachsen, Germany",
            "GSK Investigational Site, Plauen, Sachsen, Germany",
            "GSK Investigational Site, Radebeul, Sachsen, Germany",
            "GSK Investigational Site, Schlema, Sachsen, Germany",
            "GSK Investigational Site, Schwarzenberg, Sachsen, Germany",
            "GSK Investigational Site, Wilkau-Hasslau, Sachsen, Germany",
            "GSK Investigational Site, Zwickau, Sachsen, Germany",
            "GSK Investigational Site, Ahrensburg, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Bad Schwartau, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Flensburg, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Hemmoor, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Husum, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Itzehoe, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Kiel, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Lauenburg, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Neumuenster, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Ploen, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Schleswig, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Gera, Thueringen, Germany",
            "GSK Investigational Site, Gotha, Thueringen, Germany",
            "GSK Investigational Site, Ilmenau, Thueringen, Germany",
            "GSK Investigational Site, Meiningen, Thueringen, Germany",
            "GSK Investigational Site, Waltershausen, Thueringen, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Hamburg, Germany",
            "GSK Investigational Site, Hamburg, Germany",
            "GSK Investigational Site, Hamburg, Germany",
            "GSK Investigational Site, Hamburg, Germany",
            "GSK Investigational Site, Hamburg, Germany",
            "GSK Investigational Site, Hamburg, Germany",
            "GSK Investigational Site, Athens, Greece",
            "GSK Investigational Site, Athens, Greece",
            "GSK Investigational Site, Athens, Greece",
            "GSK Investigational Site, Athens, Greece",
            "GSK Investigational Site, Athens, Greece",
            "GSK Investigational Site, Athens, Greece",
            "GSK Investigational Site, Heraklion, Crete, Greece",
            "GSK Investigational Site, Ioannina, Greece",
            "GSK Investigational Site, Larisa, Greece",
            "GSK Investigational Site, Periohi Dragana, Alexandroupolis, Greece",
            "GSK Investigational Site, Rhodes, Greece",
            "GSK Investigational Site, Rio, Patras, Greece",
            "GSK Investigational Site, Thessaloniki, Greece",
            "GSK Investigational Site, Thessaloniki, Greece",
            "GSK Investigational Site, Budapest, Hungary",
            "GSK Investigational Site, Budapest, Hungary",
            "GSK Investigational Site, GyÅ‘r, Hungary",
            "GSK Investigational Site, KecskemÃ©t, Hungary",
            "GSK Investigational Site, Miskolc, Hungary",
            "GSK Investigational Site, Cork, Ireland",
            "GSK Investigational Site, Dublin, Ireland",
            "GSK Investigational Site, Tallaght, Ireland",
            "GSK Investigational Site, Lanciano (CH), Abruzzo, Italy",
            "GSK Investigational Site, Caserta, Campania, Italy",
            "GSK Investigational Site, Napoli, Campania, Italy",
            "GSK Investigational Site, ForlÃ¬, Emilia-Romagna, Italy",
            "GSK Investigational Site, Roma, Lazio, Italy",
            "GSK Investigational Site, Milano, Lombardia, Italy",
            "GSK Investigational Site, Milano, Lombardia, Italy",
            "GSK Investigational Site, Voghera (PV), Lombardia, Italy",
            "GSK Investigational Site, Bari, Puglia, Italy",
            "GSK Investigational Site, Cagliari, Sardegna, Italy",
            "GSK Investigational Site, Sassari, Sardegna, Italy",
            "GSK Investigational Site, Catania, Sicilia, Italy",
            "GSK Investigational Site, Ragusa (CT), Sicilia, Italy",
            "GSK Investigational Site, Pisa, Toscana, Italy",
            "GSK Investigational Site, Isola della Scala (VR), Veneto, Italy",
            "GSK Investigational Site, Napoli, Veneto, Italy",
            "GSK Investigational Site, Chiba, Japan",
            "GSK Investigational Site, Fukuoka, Japan",
            "GSK Investigational Site, Hokkaido, Japan",
            "GSK Investigational Site, Ibaraki, Japan",
            "GSK Investigational Site, Nagasaki, Japan",
            "GSK Investigational Site, Oita, Japan",
            "GSK Investigational Site, Daugavpils, Latvia",
            "GSK Investigational Site, Riga, Latvia",
            "GSK Investigational Site, Riga, Latvia",
            "GSK Investigational Site, Riga, Latvia",
            "GSK Investigational Site, Riga, Latvia",
            "GSK Investigational Site, Kaunas, Lithuania",
            "GSK Investigational Site, Siauliai, Lithuania",
            "GSK Investigational Site, Vilnius, Lithuania",
            "GSK Investigational Site, Vilnius, Lithuania",
            "GSK Investigational Site, Vilnius, Lithuania",
            "GSK Investigational Site, Zapopan, Jalisco, Jalisco, Mexico",
            "GSK Investigational Site, Zapopan, Jalisco, Mexico",
            "GSK Investigational Site, Zapopan, Jalisco, Mexico",
            "GSK Investigational Site, Durango, Mexico",
            "GSK Investigational Site, Durango, Mexico",
            "GSK Investigational Site, Mexico city, Mexico",
            "GSK Investigational Site, Mexico, D.F., Mexico",
            "GSK Investigational Site, Mexico, Mexico",
            "GSK Investigational Site, MÃ©xico, City, Mexico",
            "GSK Investigational Site, Puebla, Mexico",
            "GSK Investigational Site, Amsterdam, Netherlands",
            "GSK Investigational Site, Amsterdam, Netherlands",
            "GSK Investigational Site, Arnhem, Netherlands",
            "GSK Investigational Site, Breda, Netherlands",
            "GSK Investigational Site, Capelle Aan Den Ijssel, Netherlands",
            "GSK Investigational Site, Den Bosch, Netherlands",
            "GSK Investigational Site, Den Haag, Netherlands",
            "GSK Investigational Site, Den Haag, Netherlands",
            "GSK Investigational Site, EDE, Netherlands",
            "GSK Investigational Site, Eindhoven, Netherlands",
            "GSK Investigational Site, Harderwijk, Netherlands",
            "GSK Investigational Site, Hengelo, Netherlands",
            "GSK Investigational Site, Nieuwegein, Netherlands",
            "GSK Investigational Site, Nijmegen, Netherlands",
            "GSK Investigational Site, Nijmegen, Netherlands",
            "GSK Investigational Site, Roermond, Netherlands",
            "GSK Investigational Site, Roosendaal, Netherlands",
            "GSK Investigational Site, Rotterdam, Netherlands",
            "GSK Investigational Site, Rotterdam, Netherlands",
            "GSK Investigational Site, Stadskanaal, Netherlands",
            "GSK Investigational Site, Tilburg, Netherlands",
            "GSK Investigational Site, Auckland, New Zealand",
            "GSK Investigational Site, Christchurch, New Zealand",
            "GSK Investigational Site, Hamilton, New Zealand",
            "GSK Investigational Site, Nelson, New Zealand",
            "GSK Investigational Site, Tauranga, New Zealand",
            "GSK Investigational Site, Whangarei, New Zealand",
            "GSK Investigational Site, Arendal, Norway",
            "GSK Investigational Site, Moelv, Norway",
            "GSK Investigational Site, Oslo, Norway",
            "GSK Investigational Site, Porsgrunn, Norway",
            "GSK Investigational Site, Stavanger, Norway",
            "GSK Investigational Site, Bydgoszcz, Poland",
            "GSK Investigational Site, Bydgoszcz, Poland",
            "GSK Investigational Site, Checiny, Poland",
            "GSK Investigational Site, Elblag, Poland",
            "GSK Investigational Site, Gdansk, Poland",
            "GSK Investigational Site, Inowroclaw, Poland",
            "GSK Investigational Site, Katowice, Poland",
            "GSK Investigational Site, Koscierzyna, Poland",
            "GSK Investigational Site, Krakow, Poland",
            "GSK Investigational Site, Lublin, Poland",
            "GSK Investigational Site, Rzeszow, Poland",
            "GSK Investigational Site, Szczecin, Poland",
            "GSK Investigational Site, Warszawa, Poland",
            "GSK Investigational Site, Warszawa, Poland",
            "GSK Investigational Site, Warszawa, Poland",
            "GSK Investigational Site, Wejherowo, Poland",
            "GSK Investigational Site, Wroclaw, Poland",
            "GSK Investigational Site, Almada, Portugal",
            "GSK Investigational Site, Amadora, Portugal",
            "GSK Investigational Site, Lisboa, Portugal",
            "GSK Investigational Site, Porto, Portugal",
            "GSK Investigational Site, Porto, Portugal",
            "GSK Investigational Site, Ponce, Puerto Rico",
            "GSK Investigational Site, San Juan, Puerto Rico",
            "GSK Investigational Site, San Juan, Puerto Rico",
            "GSK Investigational Site, Bucharest, Romania",
            "GSK Investigational Site, Moscow, Russian Federation",
            "GSK Investigational Site, Moscow, Russian Federation",
            "GSK Investigational Site, Moscow, Russian Federation",
            "GSK Investigational Site, Moscow, Russian Federation",
            "GSK Investigational Site, Moscow, Russian Federation",
            "GSK Investigational Site, Nizhniy Novgorod, Russian Federation",
            "GSK Investigational Site, Saratov, Russian Federation",
            "GSK Investigational Site, St. Petersburg, Russian Federation",
            "GSK Investigational Site, St. Petersburg, Russian Federation",
            "GSK Investigational Site, Bratislava, Slovakia",
            "GSK Investigational Site, Martin, Slovakia",
            "GSK Investigational Site, Celje, Slovenia",
            "GSK Investigational Site, Ljubljana, Slovenia",
            "GSK Investigational Site, Maribor, Slovenia",
            "GSK Investigational Site, Slovenj Gradec, Slovenia",
            "GSK Investigational Site, Rosebank, Gauteng, South Africa",
            "GSK Investigational Site, Cape Town, South Africa",
            "GSK Investigational Site, Cape Town, South Africa",
            "GSK Investigational Site, Capital Park, South Africa",
            "GSK Investigational Site, George, South Africa",
            "GSK Investigational Site, Johannesburg, South Africa",
            "GSK Investigational Site, Parktown, South Africa",
            "GSK Investigational Site, Pretoria, South Africa",
            "GSK Investigational Site, Westville, Durban, South Africa",
            "GSK Investigational Site, Alava, Spain",
            "GSK Investigational Site, Alcala De Henares (Madrid), Spain",
            "GSK Investigational Site, Alcorcon, Spain",
            "GSK Investigational Site, Badalona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Bilbao, Spain",
            "GSK Investigational Site, CastellÃ³n, Spain",
            "GSK Investigational Site, Ciudad Real, Spain",
            "GSK Investigational Site, Don Benito (Badajoz), Spain",
            "GSK Investigational Site, Galdakano, Spain",
            "GSK Investigational Site, Granada, Spain",
            "GSK Investigational Site, Ibiza, Spain",
            "GSK Investigational Site, Jaen, Spain",
            "GSK Investigational Site, La Laguna (Santa Cruz de Tenerife), Spain",
            "GSK Investigational Site, Leganes, Spain",
            "GSK Investigational Site, LogroÃ±o, Spain",
            "GSK Investigational Site, Madrid, Spain",
            "GSK Investigational Site, Madrid, Spain",
            "GSK Investigational Site, Madrid, Spain",
            "GSK Investigational Site, Madrid, Spain",
            "GSK Investigational Site, Madrid, Spain",
            "GSK Investigational Site, Madrid, Spain",
            "GSK Investigational Site, Madrid, Spain",
            "GSK Investigational Site, Malaga, Spain",
            "GSK Investigational Site, Manacor, Spain",
            "GSK Investigational Site, Orihuela, Spain",
            "GSK Investigational Site, Oviedo, Spain",
            "GSK Investigational Site, Pamplona, Spain",
            "GSK Investigational Site, Sagunto, Spain",
            "GSK Investigational Site, San Juan De Alicante, Spain",
            "GSK Investigational Site, San Sebastian, Spain",
            "GSK Investigational Site, Santa Cruz de Tenerife, Spain",
            "GSK Investigational Site, Sevilla, Spain",
            "GSK Investigational Site, Sevilla, Spain",
            "GSK Investigational Site, Sevilla, Spain",
            "GSK Investigational Site, Sevilla, Spain",
            "GSK Investigational Site, Soria, Spain",
            "GSK Investigational Site, Valencia, Spain",
            "GSK Investigational Site, Valencia, Spain",
            "GSK Investigational Site, Valencia, Spain",
            "GSK Investigational Site, Valladolid, Spain",
            "GSK Investigational Site, Via-Real (CastellÃ³n), Spain",
            "GSK Investigational Site, BorÃ¥s, Sweden",
            "GSK Investigational Site, Eskilstuna, Sweden",
            "GSK Investigational Site, GÃ¤vle, Sweden",
            "GSK Investigational Site, GÃ¶teborg, Sweden",
            "GSK Investigational Site, GÃ¶teborg, Sweden",
            "GSK Investigational Site, Karlshamn, Sweden",
            "GSK Investigational Site, Kristianstad, Sweden",
            "GSK Investigational Site, Kristianstad, Sweden",
            "GSK Investigational Site, MalmÃ¶, Sweden",
            "GSK Investigational Site, SkÃ¤rholmen, Sweden",
            "GSK Investigational Site, SkÃ¶vde, Sweden",
            "GSK Investigational Site, Stockholm, Sweden",
            "GSK Investigational Site, UmeÃ¥, Sweden",
            "GSK Investigational Site, VÃ¥lberg, Sweden",
            "GSK Investigational Site, Ã–stersund, Sweden",
            "GSK Investigational Site, Aarau, Switzerland",
            "GSK Investigational Site, Bern, Switzerland",
            "GSK Investigational Site, Biel, Switzerland",
            "GSK Investigational Site, Fribourg, Switzerland",
            "GSK Investigational Site, GenÃ¨ve, Switzerland",
            "GSK Investigational Site, Lausanne, Switzerland",
            "GSK Investigational Site, Olten, Switzerland",
            "GSK Investigational Site, Sarnen, Switzerland",
            "GSK Investigational Site, Zollikon, Switzerland",
            "GSK Investigational Site, Sfax, Tunisia",
            "GSK Investigational Site, Sousse, Tunisia",
            "GSK Investigational Site, Tunis, Tunisia",
            "GSK Investigational Site, Tunis, Tunisia",
            "GSK Investigational Site, Tunis, Tunisia",
            "GSK Investigational Site, Ankara, Turkey",
            "GSK Investigational Site, Capa/Istanbul, Turkey",
            "GSK Investigational Site, Istanbul, Turkey",
            "GSK Investigational Site, Izmir, Turkey",
            "GSK Investigational Site, Dnepropetrovsk, Ukraine",
            "GSK Investigational Site, Kharkiv, Ukraine",
            "GSK Investigational Site, Odesa, Ukraine",
            "GSK Investigational Site, Zaporizhzhya, Ukraine",
            "GSK Investigational Site, Aberdeen, Aberdeenshire, United Kingdom",
            "GSK Investigational Site, Ayr, Ayrshire, United Kingdom",
            "GSK Investigational Site, Reading, Berkshire, United Kingdom",
            "GSK Investigational Site, Stockport, Cheshire, United Kingdom",
            "GSK Investigational Site, Exeter, Devon, United Kingdom",
            "GSK Investigational Site, Plymouth, Devon, United Kingdom",
            "GSK Investigational Site, Cardiff, Glamorgan, United Kingdom",
            "GSK Investigational Site, Bristol, Gloucestershire, United Kingdom",
            "GSK Investigational Site, Portsmouth, Hampshire, United Kingdom",
            "GSK Investigational Site, Southampton, Hampshire, United Kingdom",
            "GSK Investigational Site, Stevenage, Hertfordshire, United Kingdom",
            "GSK Investigational Site, Glasgow, Lanarkshire, United Kingdom",
            "GSK Investigational Site, Buckshaw Village, Chorley, Lancashire, United Kingdom",
            "GSK Investigational Site, Lancs, Lancashire, United Kingdom",
            "GSK Investigational Site, Manchester, Lancashire, United Kingdom",
            "GSK Investigational Site, Manchester, Lancashire, United Kingdom",
            "GSK Investigational Site, Oldham, Lancashire, United Kingdom",
            "GSK Investigational Site, Leicester, Leicestershire, United Kingdom",
            "GSK Investigational Site, Leytonstone, London, United Kingdom",
            "GSK Investigational Site, Liverpool, Merseyside, United Kingdom",
            "GSK Investigational Site, Liverpool, Merseyside, United Kingdom",
            "GSK Investigational Site, Edinburgh, Midlothian, United Kingdom",
            "GSK Investigational Site, Norwich, Norfolk, United Kingdom",
            "GSK Investigational Site, Newcastle Upon Tyne, Northumberland, United Kingdom",
            "GSK Investigational Site, Nottingham, Nottinghamshire, United Kingdom",
            "GSK Investigational Site, Bath, Somerset, United Kingdom",
            "GSK Investigational Site, Tauton, Somerset, United Kingdom",
            "GSK Investigational Site, Stoke-on-Trent, Staffordshire, United Kingdom",
            "GSK Investigational Site, Redhill, Surrey, United Kingdom",
            "GSK Investigational Site, Chichester, Sussex West, United Kingdom",
            "GSK Investigational Site, Birmingham, Warwickshire, United Kingdom",
            "GSK Investigational Site, Coventry, Warwickshire, United Kingdom",
            "GSK Investigational Site, Bradford, United Kingdom",
            "GSK Investigational Site, Bristol, United Kingdom",
            "GSK Investigational Site, Clydebank, Glasgow, United Kingdom",
            "GSK Investigational Site, Crewe, United Kingdom",
            "GSK Investigational Site, Edgbaston, Birmingham, United Kingdom",
            "GSK Investigational Site, Falkirk, United Kingdom",
            "GSK Investigational Site, Leeds, United Kingdom",
            "GSK Investigational Site, London, United Kingdom",
            "GSK Investigational Site, London, United Kingdom",
            "GSK Investigational Site, London, United Kingdom",
            "GSK Investigational Site, London, United Kingdom",
            "GSK Investigational Site, Manchester, United Kingdom",
            "GSK Investigational Site, Sheffield, United Kingdom",
            "GSK Investigational Site, Torquay, United Kingdom",
            "GSK Investigational Site, Wakefield, United Kingdom",
            "GSK Investigational Site, Waterloo, Liverpool, United Kingdom",
            "GSK Investigational Site, Wolverhampton, United Kingdom",
            "GSK Investigational Site"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00056407"
      },
      {
        "-rank": "273",
        "nct_id": "NCT00541047",
        "title": "Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Gastrointestinal Complications",
            "Prostate Cancer",
            "Sexual Dysfunction",
            "Urinary Complications"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "bicalutamide"
            },
            {
              "-type": "Drug",
              "#text": "goserelin acetate"
            },
            {
              "-type": "Drug",
              "#text": "leuprolide acetate"
            },
            {
              "-type": "Procedure",
              "#text": "adjuvant therapy"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            },
            {
              "-type": "Radiation",
              "#text": "radiation therapy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Disease-specific survival (i.e., death due to prostate cancer)",
            "Freedom from treatment failure",
            "Clinical progression-free survival",
            "Overall survival",
            "Non-protocol hormone therapy",
            "Treatment toxicity",
            "Patient reported outcomes"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Medical Research Council",
          "collaborator": "Canadian Cancer Trials Group"
        },
        "gender": "Male",
        "max_age": "120 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "4236",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Factorial Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000571528",
            "MRC-RADICALS-PR10",
            "ISRCTN40814031",
            "EUDRACT-2006-000205-34",
            "EU-20767",
            "PR13"
          ]
        },
        "start_date": "November 2007",
        "primary_completion_date": "September 2020",
        "completion_date": "September 2021",
        "study_first_posted": "October 8, 2007",
        "last_update_posted": "October 13, 2017",
        "locations": {
          "location": [
            "British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada",
            "British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada",
            "London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada",
            "Ottawa Health Research Institute, Ottawa, Ontario, Canada",
            "Princess Margaret Hospital, Toronto, Ontario, Canada",
            "William Harvey Hospital, Ashford-Kent, England, United Kingdom",
            "North Devon District Hospital, Barnstaple, England, United Kingdom",
            "Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom",
            "Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom",
            "Royal Bournemouth Hospital, Bournemouth, England, United Kingdom",
            "Bradford Royal Infirmary, Bradford, England, United Kingdom",
            "Southmead Hospital, Bristol, England, United Kingdom",
            "Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom",
            "Addenbrooke's Hospital, Cambridge, England, United Kingdom",
            "Kent and Canterbury Hospital, Canterbury, England, United Kingdom",
            "Walsgrave Hospital, Coventry, England, United Kingdom",
            "Mid Cheshire Hospitals Trust- Leighton Hopsital, Crewe, England, United Kingdom",
            "Mayday University Hospital, Croydon, England, United Kingdom",
            "Doncaster Royal Infirmary, Doncaster, England, United Kingdom",
            "Dorset County Hospital, Dorchester, England, United Kingdom",
            "Princess Alexandra Hospital, Essex, England, United Kingdom",
            "Royal Devon and Exeter Hospital, Exeter, England, United Kingdom",
            "St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford, England, United Kingdom",
            "Ipswich Hospital, Ipswich, England, United Kingdom",
            "Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom",
            "Lincoln County Hospital, Lincoln, England, United Kingdom",
            "Helen Rollason Cancer Care Centre at North Middlesex Hospital, London, England, United Kingdom",
            "University College Hospital, London, England, United Kingdom",
            "Guy's Hospital, London, England, United Kingdom",
            "Royal Marsden - London, London, England, United Kingdom",
            "Maidstone Hospital, Maidstone, England, United Kingdom",
            "Christie Hospital, Manchester, England, United Kingdom",
            "Clatterbridge Centre for Oncology, Merseyside, England, United Kingdom",
            "James Cook University Hospital, Middlesbrough, England, United Kingdom",
            "Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom",
            "Derriford Hospital, Plymouth, England, United Kingdom",
            "Dorset Cancer Centre, Poole Dorset, England, United Kingdom",
            "Queen's Hospital, Romford, England, United Kingdom",
            "Rotherham General Hospital, Rotherham, England, United Kingdom",
            "Hope Hospital, Salford, England, United Kingdom",
            "Cancer Research Centre at Weston Park Hospital, Sheffield, England, United Kingdom",
            "Southampton General Hospital, Southampton, England, United Kingdom",
            "Stepping Hill Hospital, Stockport, England, United Kingdom",
            "University Hospital of North Staffordshire, Stoke-On-Trent, England, United Kingdom",
            "Royal Marsden - Surrey, Sutton, England, United Kingdom",
            "Torbay Hospital, Torquay, England, United Kingdom",
            "Hillingdon Hospital, Uxbridge, England, United Kingdom",
            "Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, England, United Kingdom",
            "Cancer Care Centre at York Hospital, York, England, United Kingdom",
            "Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom",
            "Ayr Hospital, Ayr, Scotland, United Kingdom",
            "Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom",
            "Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom",
            "Pinderfields General Hospital, Wakefield, Scotland, United Kingdom",
            "Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom",
            "University Hospital of Wales, Cardiff, Wales, United Kingdom",
            "Royal Gwent Hospital, Newport Gwent, Wales, United Kingdom",
            "Glan Clwyd Hospital, Rhyl, Denbighshire, Wales, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00541047"
      },
      {
        "-rank": "274",
        "nct_id": "NCT00295750",
        "title": "The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Degarelix"
            },
            {
              "-type": "Drug",
              "#text": "Leuprolide 7.5 mg"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage of Patients With Testosterone <=0.5ng/mL From Day 28 Through Day 364",
            "Percentage of Patients With Testosterone Surge During the First Two Weeks of Treatment",
            "Percentage of Patients With Testosterone Level <=0.5 ng/mL at Day 3",
            "Frequency and Size of Testosterone Changes at Day 255 and/or Day 259 Compared to the Testosterone Level at Day 252",
            "Percentage Change in Prostate-specific Antigen From Baseline to Day 14 and Day 28",
            "Participants Grouped by Time to Prostate-specific Antigen Failure",
            "Participants With Markedly Abnormal Change in Laboratory Variables (>=20 Percent of Patients)",
            "The Mean Value of QTc Interval as Measured by Electrocardiogram",
            "Participants With Markedly Abnormal Change in Vital Signs and Body Weight"
          ]
        },
        "sponsors": { "lead_sponsor": "Ferring Pharmaceuticals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "620",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "FE200486 CS21" },
        "start_date": "February 2006",
        "primary_completion_date": "October 2007",
        "completion_date": "October 2007",
        "study_first_posted": "February 24, 2006",
        "results_first_posted": "April 16, 2009",
        "last_update_posted": "December 19, 2012",
        "locations": {
          "location": [
            "Urology Centers of Alabama, Homewood, Alabama, United States",
            "Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States",
            "Advanced Urology Medical Center, Anaheim, California, United States",
            "Pacific Clinical Center, Beverly Hills, California, United States",
            "Simi-San Faernando Valley Urology Associates, Granada Hills, California, United States",
            "South Orange County Medical Research Center, Laguna Woods,, California, United States",
            "Western Clinical Research, Torrance, California, United States",
            "Urology Associate PC, Denver, Colorado, United States",
            "University of Colorado, Denver, Colorado, United States",
            "South Florida Medical Research, Aventura, Florida, United States",
            "Florida Foundation for Healthcare Research, Ocala, Florida, United States",
            "Regional Urology, Shreveport, Louisiana, United States",
            "Lawrenceville Urology, Lawrenceville, New Jersey, United States",
            "Jay A. Motola, MD, FACS, Carmel, New York, United States",
            "Northeast Urology Research, Concord, North Carolina, United States",
            "The Urology Center, Greensboro, North Carolina, United States",
            "State College Urologic Association, State College, Pennsylvania, United States",
            "Univeristy Urological Research Institute, Providence, Rhode Island, United States",
            "University Urological Research Institute, Providence, Rhode Island, United States",
            "Grand Strand Urology, Myrtle Beach, South Carolina, United States",
            "Urology San Antonio Research, San Antonio, Texas, United States",
            "Urology of Virginia Research, Norfolk, Virginia, United States",
            "Office of Jeffrey Frankel, Seattle, Washington, United States",
            "Bruce W. Palmer Urology Inc, 125-70 Exhibition Street, Kentville, Nova Scotia, Canada",
            "Nemocnice Jindrichuv Hradec a.s., U Nemocnice 380/III, Jindrichuv Hradec, Czech Republic",
            "Urologische Klinik, Universitatsklinikum Mannheim, Theodor-Kutzer-Ufer 1-3, Mannheim, Germany",
            "Szeged M.J.V.O. Korhaza, Urologiai Osztaly, Kalvaria sugarut 57, Szeged, Hungary",
            "Hospital General \"Dr Santiago Ramon y Cajal\", ISSSTE, Predio Canoas S/N, Durango, DGO, Mexico",
            "Atrium MC, Henri Dunantstraat 5, Heerlen, Netherlands",
            "Cristo Redentor Hospital, La Hacienda, Puerto Rico",
            "San Juan VA Medical Center, San Juan, Puerto Rico",
            "Provita Center, 2 Primaverii Street, Constanta, Romania",
            "Andros Urology Clinic, Ulitsa Lenina 36A, St Petersburg, Russian Federation",
            "Kiev City Clinical Hospital #3, Petr Ivaschenko 26, Petra Zaporogtsa str., Kiev, Ukraine",
            "Derriford Hospital, Derriford Road, Plymouth, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00295750"
      },
      {
        "-rank": "275",
        "nct_id": "NCT00558272",
        "title": "Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Breast Cancer",
            "Prostate Cancer",
            "Bone Neoplasms"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "AZD0530"
            },
            {
              "-type": "Drug",
              "#text": "Zoledronic Acid"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4",
            "Percentage Change From Baseline in Serum Bone-specific Alkaline Phosphatase (bALP) at Week 4",
            "Percentage Change From Baseline in Serum Cross-linked C-terminal Telopeptide of Type I Collagen (ICTP) at Week 4",
            "Percentage Change From Baseline in Serum N-terminal Propeptide of Type I Procollagen (PINP) at Week 4",
            "Percentage Change From Baseline in Serum Tartrate-resistant Acid Phosphatase 5b (TRAP5b) at Week 4",
            "Percentage Change From Baseline in Urine N-terminal Cross-linking Telopeptide of Type I Collagen Normalised to Creatinine (NTx/Cr) at Week 4",
            "Percentage Change From Baseline in Urine Alpha-alpha C-terminal Cross-linking Telopeptide of Type I Collagen Normalised to Creatinine (aaCTx/Cr) at Week 4",
            "Saracatinib: Area Under the Curve at Steady State (AUCss)",
            "Saracatinib: Plasma Clearance at Steady State (CLss/F)",
            "Saracatinib: Maximum Plasma Concentration at Steady State (Css,Max)",
            "Saracatinib: Minimum Plasma Concentration at Steady State (Css,Min)",
            "Saracatinib: Time to Cssmax (Tmax)",
            "N-desmethyl Metabolite of Saracatinib: Area Under the Curve at Steady State (AUCss)",
            "N-desmethyl Metabolite of Saracatinib: Maximum Plasma Concentration at Steady State (Css,Max)",
            "N-desmethyl Metabolite of Saracatinib: Minimum Plasma Concentration at Steady State (Css,Min)",
            "N-desmethyl Metabolite of Saracatinib: AUCss Metabolite to Parent Ratio",
            "N-desmethyl Metabolite of Saracatinib: Time to Cssmax (Tmax)"
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "139",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "D8180C00034" },
        "start_date": "February 2008",
        "primary_completion_date": "January 2010",
        "completion_date": "August 2012",
        "study_first_posted": "November 14, 2007",
        "results_first_posted": "June 27, 2011",
        "last_update_posted": "May 27, 2013",
        "locations": {
          "location": [
            "Research Site, Pleasant Hill, California, United States",
            "Research Site, Sacramento, California, United States",
            "Research Site, Middlebury, Connecticut, United States",
            "Research Site, Aventura, Florida, United States",
            "Research Site, Baltimore, Maryland, United States",
            "Research Site, Ann Arbor, Michigan, United States",
            "Research Site, Poughkeepsie, New York, United States",
            "Research Site, Winston-salem, North Carolina, United States",
            "Research Site, Hershey, Pennsylvania, United States",
            "Research Site, Edmonton, Alberta, Canada",
            "Research Site, Vancouver, British Columbia, Canada",
            "Research Site, Toronto, Ontario, Canada",
            "Research Site, Montreal, Quebec, Canada",
            "Research Site, Quebec, Canada",
            "Research Site, Arhus N, Denmark",
            "Research Site, Frederica, Denmark",
            "Research Site, Herlev, Denmark",
            "Research Site, Holstebro, Denmark",
            "Research Site, Kristiansand, Norway",
            "Research Site, Oslo, Norway",
            "Research Site, Lisboa, Portugal",
            "Research Site, Barcelona, Cataluna, Spain",
            "Research Site, Lerida, Cataluna, Spain",
            "Research Site, Valencia, Comunidad Valenciana, Spain",
            "Research Site, Uppsala, Sweden",
            "Research Site, Cardiff, United Kingdom",
            "Research Site, Glasgow, United Kingdom",
            "Research Site, Manchester, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00558272"
      },
      {
        "-rank": "276",
        "nct_id": "NCT00451958",
        "title": "A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Degarelix 80 mg / Degarelix 80 mg"
            },
            {
              "-type": "Drug",
              "#text": "Degarelix 160 mg / Degarelix 160 mg"
            },
            {
              "-type": "Drug",
              "#text": "Leuprolide 7.5 mg / Degarelix 80 mg"
            },
            {
              "-type": "Drug",
              "#text": "Leuprolide 7.5 mg / Degarelix 160 mg"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight",
            "Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables",
            "Percentage of Participants With no Prostate-specific Antigen (PSA) Progression",
            "Percentage of Participants With Testosterone Level Maintained at <=0.5 ng/mL From Day 28 in CS21 and Onwards",
            "Serum Levels of Testosterone From the Time of Switch From Leuprolide to Degarelix up to Day 56",
            "Serum Levels of PSA From the Time of Switch From Leuprolide to Degarelix to Day 56",
            "Serum Levels of Luteinizing Hormone (LH) From the Time of Switch From Leuprolide to Degarelix to Day 56",
            "Serum Levels of Follicle Stimulating Hormone (FSH) From the Time of Switch From Leuprolide to Degarelix to Day 56"
          ]
        },
        "sponsors": { "lead_sponsor": "Ferring Pharmaceuticals" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "386",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "FE200486 CS21A",
            "2006-006913-34"
          ]
        },
        "start_date": "March 2007",
        "primary_completion_date": "October 2011",
        "completion_date": "December 2011",
        "study_first_posted": "March 26, 2007",
        "results_first_posted": "March 21, 2013",
        "last_update_posted": "March 21, 2013",
        "locations": {
          "location": [
            "Urology Centers Of Alabama, Homewood, Alabama, United States",
            "South Orange County Medical Research Center, Laguna Hills, California, United States",
            "Western Clinical Research, Torrance, California, United States",
            "Urology Associates Research, Englewood, Colorado, United States",
            "South Florida Medical Research, Aventura, Florida, United States",
            "Investigational Site, Ocala, Florida, United States",
            "Regional Urology, Shreveport, Louisiana, United States",
            "Lawrenceville Urology, Lawrenceville, New Jersey, United States",
            "Investigational Site, Carmel, New York, United States",
            "North Urology Research, Concord, North Carolina, United States",
            "Investigational Site, Greensboro, North Carolina, United States",
            "State College Urologic Association, State College, Pennsylvania, United States",
            "Urology San Antonio Research, San Antonio, Texas, United States",
            "Seattle Urology Research Center, Burien, Washington, United States",
            "Investigational Site, Kentville, Nova Scotia, Canada",
            "The Female/Male Health Centres, Barrie, Ontario, Canada",
            "Brantford Urology Research, Brantford, Ontario, Canada",
            "Burlington Professional Centre, Burlington, Ontario, Canada",
            "The Urology Research Centre, Burlington, Ontario, Canada",
            "Investigational Site, Newmarket, Ontario, Canada",
            "The Female/Male Health Centres, Oakville, Ontario, Canada",
            "Urology South Shore Research, Greenfields, Quebec, Canada",
            "Can-Med Clinical Research Inc, Victoria, Canada",
            "Urocentrum Brno, Brno, Czech Republic",
            "UROHELP - Bozetechova, Brno, Czech Republic",
            "Nemocnice Jindrichuv Hradec, a.s., Jindrichuv Hradec, Czech Republic",
            "Fakultni Nemocnice Olomouc, Olomouc, Czech Republic",
            "Slezska nemocnice, Opava, Czech Republic",
            "Fakultni nemocnice v Motole, Prague5, Prague, Czech Republic",
            "Vseobecna fakultni nemocnice v Praze, Prague2, Prague, Czech Republic",
            "Klinikum Mannheim UniversitÃ¤tsklinikum GmbH, Mannheim, Germany",
            "Klinikum der UniversitÃ¤t Regensburg, Regensburg, Germany",
            "FÃ¶vÃ¡rosi Ã–nkormÃ¡nyzat uzsoki utcai KÃ³rhÃ¡z, Budapest, Hungary",
            "DombÃ³vÃ¡ri Szent LukÃ¡cs EgÃ©szsÃ©gÃ¼gyi Kht., DombÃ³vÃ¡r, Hungary",
            "Petz AladÃ¡r Megyei OktatÃ³ KÃ³rhÃ¡z, GyÃ¶r, Hungary",
            "Borsod-AbaÃºj-ZemplÃ©n Megyei KÃ³rhÃ¡z Ã©s Egyetemi OktatÃ³ KÃ³rhÃ¡z, Miskolc, Hungary",
            "Miskolci Semmelweis IgnÃ¡c EgÃ©szsÃ©gÃ¼gyi KÃ¶zpont Ã©s Egyetemi OktatÃ³ KÃ³rhÃ¡z Nonprofit Kft, Miskolc, Hungary",
            "PÃ©csi TudomÃ¡nyegyetem, PÃ©cs, Hungary",
            "Investigational Site, Szeged, Hungary",
            "Investigational Site, Acapulco, Mexico",
            "Hospital Christus Muguerza del Parque, Chihuahua, Chih., Mexico",
            "Investigational Sit, Durango, Mexico",
            "Hospital Aranda de la Parra , S.A. de C.V., Leon, GTO, Mexico",
            "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Mexico, DF Mexico, Mexico, DF, Mexico",
            "Investigational Site, Mexico, DF, Mexico",
            "Consultorio Medico, Zapopan, Jalisco, Mexico",
            "Investigational Site, Zapopan, Jalisco, Mexico",
            "Investigational Site, Ede, Netherlands",
            "Investigational Site, Eindhoven, Netherlands",
            "Atrium MC, Heerlen, Netherlands",
            "Hospital Andres Grillasca, Ponce, Puerto Rico",
            "Investigational Site, Arad, Romania",
            "Fundeni Uronephrology and Renal Transplant Clinical Institute, Bucharest, Romania",
            "Investigational Site, Bucharest, Romania",
            "Sfantul Ioan\" Emergency Clinical Hospital, Bucharest, Romania",
            "PROVITA 2000 Medical Center, Constanta, Romania",
            "Investigational Site, Iasi, Romania",
            "Sibiu Emergency Clinical County Hospital, Sibiu, Romania",
            "City Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation",
            "City Clinical Hospital #60, Moscow, Russian Federation",
            "Moscow State University of Medicine and Dentistry, Moscow, Russian Federation",
            "City Pokrovskaya Hospital, St. Petersburg, Russian Federation",
            "Investigational Site, St. Petersburg, Russian Federation",
            "St.Petersburg State Medical Academy n. a. I.I.Mechnikov, St. Petersburg, Russian Federation",
            "Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine",
            "Regional Clinical Center of Urology and Nephrology n.a. V.I.Shapoval, Kharkiv, Ukraine",
            "Kyiv City Clinical Hospital #3, Kyiv, Ukraine",
            "Odesa State Medical University, Odesa, Ukraine",
            "Clatterbridge Centre For Oncology, Bebington, Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00451958"
      },
      {
        "-rank": "277",
        "nct_id": "NCT01634061",
        "title": "Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Castration-resistant Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "BEZ235"
            },
            {
              "-type": "Drug",
              "#text": "BKM120"
            },
            {
              "-type": "Drug",
              "#text": "BEZ235"
            },
            {
              "-type": "Drug",
              "#text": "BKM120"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Incidence of dose limiting toxicities (DLTs)",
            "Prostate specific antigen (PSA) decline â‰¥ 30%",
            "Number of patients with at least one adverse event",
            "radiological Progression Free Survival as per RECIST 1.1 and PCWG2",
            "radiological Response Rate according to RECIST 1.1",
            "Overall Survival",
            "Number and percentage of patients with laboratory abnormalities",
            "Changes in ECG (electrocardiogram)",
            "Changes in vital signs",
            "Changes in mood scales"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Novartis Pharmaceuticals",
          "collaborator": "Novartis"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "43",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CBEZ235D2101",
            "2012-002250-23"
          ]
        },
        "start_date": "September 2012",
        "primary_completion_date": "July 2015",
        "completion_date": "July 2015",
        "study_first_posted": "July 6, 2012",
        "last_update_posted": "September 14, 2015",
        "locations": {
          "location": [
            "Cedars Sinai Medical Center SC, Los Angeles, California, United States",
            "Hackensack University Medical Center Hackensack Univ, Hackensack, New Jersey, United States",
            "Novartis Investigative Site, Brussels, Belgium",
            "Novartis Investigative Site, Wilrijk, Belgium",
            "Novartis Investigative Site, Vancouver, British Columbia, Canada",
            "Novartis Investigative Site, Marseille, France",
            "Novartis Investigative Site, Villejuif Cedex, France",
            "Novartis Investigative Site, Barcelona, Catalunya, Spain",
            "Novartis Investigative Site, Madrid, Spain",
            "Novartis Investigative Site, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01634061"
      },
      {
        "-rank": "278",
        "nct_id": "NCT01138527",
        "title": "Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach",
        "acronym": "PCa-MAP",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "MRI examination"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Area under the ROC curve to distinguish between cancer and non-cancer tissue in the prostate",
            "Area under the ROC curve to separate low aggressive from intermediate and high aggressive prostate cancer"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Radboud University",
          "collaborator": [
            "Siemens AG",
            "Mount Vernon Hospital",
            "Multi-Imagem and CDPI, Rio de Janeiro, Brasil",
            "Norwegian University of Science and Technology",
            "University of California, Los Angeles",
            "University Hospital, Ghent",
            "Johns Hopkins University",
            "Medical University of Vienna",
            "University Health Network, Toronto",
            "Heidelberg University"
          ]
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "150",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "RU PCa-MAP" },
        "start_date": "June 2010",
        "primary_completion_date": "August 2015",
        "completion_date": "December 2016",
        "study_first_posted": "June 7, 2010",
        "last_update_posted": "November 10, 2015",
        "locations": {
          "location": [
            "David Geffen School of Medicine at UCLA, Los Angeles, California, United States",
            "Johns Hopkins Medical Institutions, Baltimore, Maryland, United States",
            "Medical University Vienna, Vienna, Austria",
            "Ghent University Hospita, Ghent, Belgium",
            "University Health Network, Princess Margaret Hospital, Toronto, Canada",
            "University Medical Center Mannheim, Heidelberg University, Mannheim, Germany",
            "Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",
            "Norwegian University of Science and Technology, Trondheim, Norway",
            "Mount Vernon Hospital, Paul Strickland Scanner Centre, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01138527"
      },
      {
        "-rank": "279",
        "nct_id": "NCT00021450",
        "title": "Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "bicalutamide"
            },
            {
              "-type": "Drug",
              "#text": "goserelin acetate"
            },
            {
              "-type": "Procedure",
              "#text": "adjuvant therapy"
            },
            {
              "-type": "Radiation",
              "#text": "radiation therapy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Biochemical and clinical disease-free survival as measured by Logrank prostate-specific antigen progression every 6 months until year 5, and annually thereafter",
            "Clinical disease-free survival as measured by Logrank every 6 months until year 5, and annually thereafter",
            "Overall survival as measured by Logrank every 6 months until year 5, and annually thereafter",
            "Local control as measured by Gray scale every 6 months until year 5, and annually thereafter",
            "Acute toxicity as measured by NCI-CTC v2.0 up to 1 month post radiotherapy",
            "Late toxicity as measured by EORTC and RTOG every 6 months until year 5, and annually thereafter",
            "Quality of life as measured by EORTC QLQ-C30 and EORTC PR-25 every 6 months until year 5, and annually thereafter"
          ]
        },
        "sponsors": { "lead_sponsor": "European Organisation for Research and Treatment of Cancer - EORTC" },
        "gender": "Male",
        "max_age": "80 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "819",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "EORTC-22991" },
        "start_date": "April 2001",
        "primary_completion_date": "April 2008",
        "completion_date": "January 2016",
        "study_first_posted": "January 27, 2003",
        "last_update_posted": "September 2, 2016",
        "locations": {
          "location": [
            "Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels, Belgium",
            "Cliniques Universitaires Saint-Luc, Brussels, Belgium",
            "U.Z. Gasthuisberg, Leuven, Belgium",
            "Bank Of Cyprus Oncology Centre, Nicosia, Cyprus",
            "Charles University Hospital, Hradec Kralove, Czech Republic",
            "Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France",
            "Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France",
            "CHU de Grenoble - Hopital de la Tronche, Grenoble, France",
            "Centre Paul Strauss, Strasbourg, France",
            "Centre d'Oncologie Saint-Yves, Vannes, France",
            "Saint Luke's Hospital, Dublin, Ireland",
            "Spedali Civili di Brescia, Brescia, Italy",
            "Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",
            "Hopital de la Ville D'Esch-sur-Alzette, Esch-sur-Alzette, Luxembourg",
            "Arnhems Radiotherapeutisch Instituut, Arnhem, Netherlands",
            "University Medical Center Groningen, Groningen, Netherlands",
            "Dr. Bernard Verbeeten Instituut, Tilburg, Netherlands",
            "Medical University of Gdansk, Gdansk, Poland",
            "Institut Catala d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain",
            "Belfast City Hospital Trust Incorporating Belvoir Park Hospital, Belfast, Northern Ireland, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00021450"
      },
      {
        "-rank": "280",
        "nct_id": "NCT00003734",
        "title": "Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "flutamide"
            },
            {
              "-type": "Drug",
              "#text": "triptorelin"
            },
            {
              "-type": "Radiation",
              "#text": "radiation therapy"
            }
          ]
        },
        "sponsors": {
          "lead_sponsor": "St. Luke's Hospital, Ireland",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "120 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "276",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000066849",
            "ICORG-97-01",
            "EU-98060"
          ]
        },
        "start_date": "December 1998",
        "study_first_posted": "December 9, 2003",
        "last_update_posted": "July 21, 2016",
        "locations": {
          "location": [
            "Cork University Hospital, Cork, Ireland",
            "Letterkenny Hospital, Donnegal, Ireland",
            "St. Vincent's Hospital, Dublin, Ireland",
            "Saint Luke's Hospital, Dublin, Ireland",
            "Mater Misericordiae Hospital, Dublin, Ireland",
            "Adelaide and Meath Hospital, Dublin, Ireland",
            "Beaumont Hospital, Dublin, Ireland",
            "Bon Secours Hospital, Galway, Ireland",
            "Galway University Hospital, Galway, Ireland",
            "Regional Hospital - Limerick, Limerick, Ireland",
            "Sligo General, Sligo, Ireland",
            "Belfast City Hospital Trust Incorporating Belvoir Park Hospital, Belfast, Northern Ireland, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00003734"
      },
      {
        "-rank": "281",
        "nct_id": "NCT02215096",
        "title": "Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "GSK2636771"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety and tolerability as assessed by Adverse events (AEs) and serious adverse events (SAEs)",
            "Safety and tolerability as assessed by dose-limiting toxicities (DLTs)",
            "Safety and tolerability as assessed changes in laboratory values",
            "Safety and tolerability as assessed by electrocardiograms (ECGs)",
            "Safety and tolerability as assessed by vital signs",
            "Non-progressive disease (PD) rate for 12 weeks according to PCWG2 criteria",
            "Plasma concentrations of enzalutamide and N desmethyl enzalutamide",
            "Blood GSK2636771 concentrations",
            "Prostate specific antigen (PSA) as defined in PCWG2 guidelines and RECIST 1.1 response"
          ]
        },
        "sponsors": { "lead_sponsor": "GlaxoSmithKline" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "35",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "200331",
            "2013-005111-27"
          ]
        },
        "start_date": "November 13, 2014",
        "primary_completion_date": "December 2, 2019",
        "completion_date": "December 2, 2019",
        "study_first_posted": "August 13, 2014",
        "last_update_posted": "August 14, 2019",
        "locations": {
          "location": [
            "GSK Investigational Site, Duarte, California, United States",
            "GSK Investigational Site, Los Angeles, California, United States",
            "GSK Investigational Site, Los Angeles, California, United States",
            "GSK Investigational Site, Washington, District of Columbia, United States",
            "GSK Investigational Site, Detroit, Michigan, United States",
            "GSK Investigational Site, New York, New York, United States",
            "GSK Investigational Site, Houston, Texas, United States",
            "GSK Investigational Site, London, United Kingdom",
            "GSK Investigational Site, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02215096"
      },
      {
        "-rank": "282",
        "nct_id": "NCT00128531",
        "title": "Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "leuprolide acetate"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Efficacy: to determine the proportion of patients achieving castration levels of plasma testosterone (defined as <0.5 ng/mL) 4 weeks after the first administration",
            "to determine the proportion of patients maintaining castration levels of plasma testosterone from week 4 to study end",
            "to determine the proportion of patients showing acute rises in plasma testosterone levels upon repeated dosing from week 4 to study end",
            "Safety: evaluation of the safety of the new formulation based on adverse events (AEs), local tolerability, vital signs, electrocardiograms (ECGs), and clinical parameters",
            "Efficacy: determination of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prostate-specific antigen (PSA) concentrations",
            "World Health Organization/Eastern Cooperative Oncology Group (WHO/ECOG) performance status, bone pain, urinary symptoms and urinary pain after administration"
          ]
        },
        "sponsors": { "lead_sponsor": "GP-Pharm" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "120",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CRO-04-62" },
        "start_date": "September 2005",
        "completion_date": "November 2007",
        "study_first_posted": "August 10, 2005",
        "last_update_posted": "November 14, 2007",
        "locations": {
          "location": [
            "Urology Centers of Alabama, Homewood, Alabama, United States",
            "Desert Oasis Cancer Center, Casa Granda, Arizona, United States",
            "Southwest Florida Urologic Associates, Fort Myers, Florida, United States",
            "Advanced Research Institute, Inc., New Port Richey, Florida, United States",
            "Florida Urology Specialists, Sarasota, Florida, United States",
            "Regional Urology, Shreveport, Louisiana, United States",
            "Lakeside Urology, St. Joseph, Michigan, United States",
            "Hamilton Urology, P.A., Hamilton, New Jersey, United States",
            "Lawrenceville Urology, Lawrenceville, New Jersey, United States",
            "AccuMed Research Associates, Garden City, New York, United States",
            "Urological Surgeons of Long Island, Garden City, New York, United States",
            "Hudson Valley Urology, Kingston, New York, United States",
            "Hudson Valley Urology, Poughkeepsie, New York, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Urology Associates, PC, Nashville, Tennessee, United States",
            "Department of Urology, Vienna University Medical School, Vienna, Austria",
            "Urocentrum Praha, Prague, Czech Republic",
            "Urology Department, Hviezdoslavova, Prague, Czech Republic",
            "Charles University, Clinic of Urology, Praha, Czech Republic",
            "Masaryk Hospital, Urology Dept., Usti nad Labem, Czech Republic",
            "Department of Urology, Technical University of Dresden, Dresden, Germany",
            "Department of Urology, Semmelweis University, Budapest, Hungary",
            "Department of Urology, Medical School, University of PÃ©cs, Pecs, Hungary",
            "Department of Urology, General Hospital of Bolzano, Bolzano, Italy",
            "Sexual Medicine Unit and Urology, UniversitÃ  Vita Salute San Raffaele Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy",
            "Department of Urology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia",
            "Institut CatalÃ  d'Oncologia, Hospital Duran I Reynals, Servicio de Oncologia Medica, Barcelona, Spain",
            "Royal Free Hospital and School of Medicine, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00128531"
      },
      {
        "-rank": "283",
        "nct_id": "NCT00415246",
        "title": "Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Triptorelin (DecapeptylÂ®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Proportion of patients with testosterone serum levels maintained below the castration threshold of 50 ng/dL.",
            "Proportion of patients with testosterone serum levels maintained below the castration threshold of 20 ng/dL.",
            "Time to achieve castration in days post treatment (Tlag)",
            "Time to escape from castration (Texit)",
            "Tlag and Texit confirmed by two consecutive measurements taken 1 week apart.",
            "Duration of castration in days (Tcast) Changes in PSA levels."
          ]
        },
        "sponsors": { "lead_sponsor": "Ipsen" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "100",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "2-55-52014-145" },
        "start_date": "November 2006",
        "completion_date": "October 2007",
        "study_first_posted": "December 22, 2006",
        "last_update_posted": "January 14, 2019",
        "locations": {
          "location": [
            "ULB Erasme, Bruxelles, Belgium",
            "Academisch Ziekenhuis Vrije Universiteit Brussel, Bruxelles, Belgium",
            "UCL St Luc, Bruxelles, Belgium",
            "Universitair Ziekenhuis Antwerpen, Edegem, Belgium",
            "UZ Gasthuisberg, Leuven, Belgium",
            "CHU HÃ´pital Gabriel Montpied, Clermont Ferrand, France",
            "HÃ´pital Claude Huriez, Lille, France",
            "HÃ´pital Edouard Herriot, Lyon, France",
            "CHU HÃ´pital Salvator, Marseille, France",
            "HÃ´tel Dieu, Nantes Cedex 1, France",
            "HÃ´pital du Val de Grace, Paris Cedex 05, France",
            "Centre Hospitalier Saint Louis, Paris Cedex 10, France",
            "HÃ´pital Cochin, Paris cedex 14, France",
            "HÃ´pital Bichat, Paris Cedex 18, France",
            "CHU HÃ´pital de la Miletrie, Poitiers, France",
            "HÃ´pital Pontchaillou, Rennes Cedex 9, France",
            "CHU Rangueil, Toulouse Cedex 9, France",
            "Olega Hublarova arsta prakse urologija, Daugavpils, Latvia",
            "Latvijas Onkologijas centre, Riga, Latvia",
            "Paula Stradina Kliniska Universitates slimnica, Riga, Latvia",
            "Kauno Medicinos Universitteto Klinikos, Kaunas, Lithuania",
            "UAB 'Vilniaus onkourologijos-ginekologijos klinika, Vilnius, Lithuania",
            "Vilniaus universiteto, Vilnius, Lithuania",
            "Swietokrzyskie Centrum Onkologii, Kielce, Poland",
            "NZOZ Specjalista Sp, z.o.o., Kutno, Poland",
            "Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Warszawa, Poland",
            "Akademicki Szpital Kliniczny, Wroclaw, Poland",
            "Hospital Gregorio Maranon, Madrid, Spain",
            "Ivano Frankovsk State Medical University, Ivano-Frankivsk, Ukraine",
            "Scientific Research Institute of Urology, Kiev, Ukraine",
            "Aberdeen Royal Infirmary, Aberdeen, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00415246"
      },
      {
        "-rank": "284",
        "nct_id": "NCT02123758",
        "title": "A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostatic Neoplasms",
            "Metastatic Castration-Resistant Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abiraterone Acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Drug",
              "#text": "JNJ-56021927"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours (AUC [0-24]) of abiraterone",
            "Maximum plasma concentration (Cmax) of abiraterone, prednisone and its metabolite prednisolone",
            "Area Under the Plasma Concentration-time Curve From Time Zero to Time 12 Hours (AUC [0-12]) of prednisone and its metabolite prednisolone",
            "Area Under the Plasma Concentration Curve (AUC [0- 24h]) of JNJ-56021927 and its metabolite JNJ-56142060",
            "Maximum plasma concentration (Cmax) of JNJ-56021927 and its metabolite JNJ-56142060",
            "Change in prostate specific antigen (PSA)",
            "Maximal decline in prostate specific antigen (PSA)"
          ]
        },
        "sponsors": { "lead_sponsor": "Aragon Pharmaceuticals, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "max_age": "99 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "61",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR104358",
            "56021927PCR1010",
            "2014-001426-14"
          ]
        },
        "start_date": "July 9, 2014",
        "primary_completion_date": "June 27, 2016",
        "completion_date": "December 3, 2019",
        "study_first_posted": "April 28, 2014",
        "last_update_posted": "July 19, 2019",
        "locations": {
          "location": [
            "Los Angeles, California, United States",
            "San Francisco, California, United States",
            "Houston, Texas, United States",
            "Vancouver, British Columbia, Canada",
            "Montreal, Quebec, Canada",
            "Rotterdam, Netherlands",
            "Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02123758"
      },
      {
        "-rank": "285",
        "nct_id": "NCT03150056",
        "title": "Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Solid Tumours" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "GSK525762"
            },
            {
              "-type": "Drug",
              "#text": "Abiraterone"
            },
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of subjects with adverse events (AE) and serious adverse events (SAE)",
            "Number of subjects with dose reductions or delays",
            "Number of subjects withdrawn due to toxicity",
            "Number of subjects with abnormality in laboratory parameters",
            "Number of subjects with abnormality in vital signs",
            "Number of subjects with abnormality in electrocardiogram (ECG)",
            "Number of subjects with abnormality in any cardiotoxicity parameters",
            "Number of subjects with abnormality in gastrointestinal parameters",
            "Percentage of subjects with Prostate Specific Antigen 50 (PSA50)",
            "Plasma concentration of GSK525762 and selected metabolites",
            "Plasma concentration of abiraterone or enzalutamide",
            "Overall response rate (ORR) based on Prostate Cancer Working Group (PCWG3)-modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1",
            "Circulating Tumor Cell (CTC) response",
            "Percentage of subjects with PSA response at Week 4",
            "Time to disease progression",
            "Radiographic Progression-free survival (rPFS) based on PCWG3-modified RECIST 1.1",
            "Composite Response Rate defined as any one of the following: a) Response based on PCWG3-modified RECIST1.1, b) PSA decrease of â‰¥50% at Week 12 and thereafter, or c) Circulating Tumor-cell Count Conversion",
            "The performance status as measured by Eastern Cooperative Oncology Group (ECOG) scale",
            "The change in the quality of life as measured by European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire (EORTC QLQ-C30)",
            "Pain as assessed with The Brief Pain Inventory-Short Form (BPI-SF)"
          ]
        },
        "sponsors": { "lead_sponsor": "GlaxoSmithKline" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "130",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "204697",
            "2016-003416-13"
          ]
        },
        "start_date": "July 18, 2017",
        "primary_completion_date": "February 26, 2021",
        "completion_date": "February 28, 2022",
        "study_first_posted": "May 11, 2017",
        "last_update_posted": "July 22, 2019",
        "locations": {
          "location": [
            "GSK Investigational Site, Los Angeles, California, United States",
            "GSK Investigational Site, Baltimore, Maryland, United States",
            "GSK Investigational Site, Towson, Maryland, United States",
            "GSK Investigational Site, Boston, Massachusetts, United States",
            "GSK Investigational Site, Detroit, Michigan, United States",
            "GSK Investigational Site, Saint Louis, Missouri, United States",
            "GSK Investigational Site, New York, New York, United States",
            "GSK Investigational Site, Philadelphia, Pennsylvania, United States",
            "GSK Investigational Site, Madison, Wisconsin, United States",
            "GSK Investigational Site, Sydney, New South Wales, Australia",
            "GSK Investigational Site, Clayton, Victoria, Australia",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Lyon, France",
            "GSK Investigational Site, Lyon, France",
            "GSK Investigational Site, Villejuif cedex, France",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Malaga, Spain",
            "GSK Investigational Site, Sutton, London, United Kingdom",
            "GSK Investigational Site, Glasgow, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03150056"
      },
      {
        "-rank": "286",
        "nct_id": "NCT02677896",
        "title": "A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",
        "acronym": "ARCHES",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Hormone Sensitive Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic progression-free survival (rPFS)",
            "Overall survival (OS)",
            "Time to first symptomatic skeletal event (SSE)",
            "Time to castration resistance",
            "Time to deterioration of quality of life (QoL)",
            "Time to deterioration in urinary symptoms",
            "Time to initiation of a new antineoplastic therapy",
            "Time to PSA progression",
            "PSA undetectable rate",
            "Objective response rate",
            "Time to pain progression"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Global Development, Inc.",
          "collaborator": [
            "Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",
            "Astellas Pharma Inc"
          ]
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1150",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "9785-CL-0335",
            "2015-003869-28"
          ]
        },
        "start_date": "March 7, 2016",
        "primary_completion_date": "October 14, 2018",
        "completion_date": "December 2023",
        "study_first_posted": "February 9, 2016",
        "last_update_posted": "August 12, 2019",
        "locations": {
          "location": [
            "Site US10016, Homewood, Alabama, United States",
            "Site US10007, Anchorage, Alaska, United States",
            "Site US10008, Tucson, Arizona, United States",
            "Site US10034, Fountain Valley, California, United States",
            "Site US10056, La Jolla, California, United States",
            "Site US10026, Santa Rosa, California, United States",
            "Site US10035, Aurora, Colorado, United States",
            "Site US10050, Denver, Colorado, United States",
            "Site US10048, Saint Petersburg, Florida, United States",
            "Site US10054, Thomasville, Georgia, United States",
            "Site US10015, Chicago, Illinois, United States",
            "Site US10043, Springfield, Illinois, United States",
            "Site US10045, Jeffersonville, Indiana, United States",
            "Site US10020, West Des Moines, Iowa, United States",
            "Site US10055, Kansas City, Kansas, United States",
            "Site US10017, Towson, Maryland, United States",
            "Site US10036, Omaha, Nebraska, United States",
            "Site US10018, Lawrenceville, New Jersey, United States",
            "Site US10025, Newburgh, New York, United States",
            "Site US10029, Syracuse, New York, United States",
            "Site US10068, Charlotte, North Carolina, United States",
            "Site US10014, Durham, North Carolina, United States",
            "Site US10060, Greenville, North Carolina, United States",
            "Site US10044, Middleburg Heights, Ohio, United States",
            "Site US10011, Lancaster, Pennsylvania, United States",
            "Site US10012, Myrtle Beach, South Carolina, United States",
            "Site US10059, Nashville, Tennessee, United States",
            "Site US10046, Dallas, Texas, United States",
            "Site US10004, Dallas, Texas, United States",
            "Site US10040, Virginia Beach, Virginia, United States",
            "Site US10002, Burien, Washington, United States",
            "Site US10013, Seattle, Washington, United States",
            "Site US10028, Wenatchee, Washington, United States",
            "Site AR54002, Rosario, Santa Fe, Argentina",
            "Site AR54007, San Miguel de Tucuman, Tucuman, Argentina",
            "Site AR54010, Buenos Aires, Argentina",
            "Site AU61016, Camperdown, New South Wales, Australia",
            "Site AU61007, St Leonards, New South Wales, Australia",
            "Site AU61006, Sydney, New South Wales, Australia",
            "Site AU61009, Tweed Heads, New South Wales, Australia",
            "Site AU61013, Waratah, New South Wales, Australia",
            "Site AU61001, Woodville South, South Australia, Australia",
            "Site AU61004, Ballarat, Victoria, Australia",
            "Site AU61015, Clayton, Victoria, Australia",
            "Site AU61017, Parkville, Victoria, Australia",
            "Site AU61008, St. Albans, Victoria, Australia",
            "Site BE32001, Mons, Hainaut, Belgium",
            "Site BE32012, Gent, Oost-Vlaanderen, Belgium",
            "Site BE32005, Kortrijk, West-Vlaanderen, Belgium",
            "Site BE32008, Liege, Belgium",
            "Site BE32007, Yvoir, Belgium",
            "Site CA15016, Edmonton, Alberta, Canada",
            "Site CA15024, Abbotsford, British Columbia, Canada",
            "Site CA15003, Kelowna, British Columbia, Canada",
            "Site CA15022, Kelowna, British Columbia, Canada",
            "Site CA15010, Brampton, Ontario, Canada",
            "Site CA15021, Kingston, Ontario, Canada",
            "Site CA15013, Oakville, Ontario, Canada",
            "Site CA15020, Toronto, Ontario, Canada",
            "Site CA15023, Granby, Quebec, Canada",
            "Site CA15004, Montreal, Quebec, Canada",
            "Site CL56002, Temuco, IX Region, Chile",
            "Site CL56001, Santiago, RM, Chile",
            "Site CL56007, Providencia, Santiago, Chile",
            "Site CL56005, ViÃ±a Del Mar, Valparaiso, Chile",
            "Site CL56004, ReÃ±aca, ViÃ±a Del Mar, Chile",
            "Site CL56003, Santiago, Chile",
            "Site DK45002, Copenhagen, Hovestaden, Denmark",
            "Site DK45005, Aarhus, Midtjylland, Denmark",
            "Site DK45008, Holstebro, Midtjylland, Denmark",
            "Site DK45004, Aalborg, Nordjylland, Denmark",
            "Site DK45003, Herlev, Denmark",
            "Site DK45001, Odense C, Denmark",
            "Site FI35802, Helsinki, EtelÃ¤-Suomen LÃ¤Ã¤ni, Finland",
            "Site FI35804, Pori, LÃ¤nsi-Suomen LÃ¤Ã¤ni, Finland",
            "Site FI35803, SeinÃ¤joki, LÃ¤nsi-Suomen LÃ¤Ã¤ni, Finland",
            "Site FI35801, Tampere, Oulun Laani, Finland",
            "Site FI35805, Oulu, Finland",
            "Site FI35806, Pietarsaari, Finland",
            "Site FI35807, Turku, Finland",
            "Site FR33010, Angers, Maine-et-Loire, France",
            "Site FR33003, Creteil, Val-de-Marne, France",
            "Site FR33006, Bordeaux, France",
            "Site FR33014, Caen Cedex 05, France",
            "Site FR33005, La Roche sur Yon, France",
            "Site FR33015, Le Mans Cedex 2, France",
            "Site FR33012, Lille Cedex, France",
            "Site FR33007, Lyon Cedex 3, France",
            "Site FR33011, Nimes, France",
            "Site FR33001, Pierre Benite, France",
            "Site FR33009, Quimper, France",
            "Site FR33013, Saint Mande, France",
            "Site DE49002, Freiburg, Baden-WÃ¼rttemberg, Germany",
            "Site DE49004, NÃ¼rtingen, Baden-WÃ¼rttemberg, Germany",
            "Site DE49005, Bonn, Germany",
            "Site DE49014, Hamburg, Germany",
            "Site DE49013, Heidelberg, Germany",
            "Site DE49006, TÃ¼bingen, Germany",
            "Site IL97201, Kfar-Saba, HaMerkaz, Israel",
            "Site IL97211, Zerifin, HaMerkaz, Israel",
            "Site IL97210, Beer-Sheva, Israel",
            "Site IL97202, Haifa, Israel",
            "Site IL97205, Haifa, Israel",
            "Site IL97206, Jerusalem, Israel",
            "Site IT39005, Meldola, Emilia-Romagna, Italy",
            "Site IT39004, Cremona, Lombardia, Italy",
            "Site IT39003, Milano, Lombardia, Italy",
            "Site IT39012, Milano, Lombardia, Italy",
            "Site IT39007, Novara, Piemonte, Italy",
            "Site IT39008, Pisa, Toscana, Italy",
            "Site IT39011, Trento, Trentino-Alto Adige, Italy",
            "Site IT39006, Padova, Veneto, Italy",
            "Site IT39009, Candiolo, Italy",
            "Site JP81003, Sakura, Chiba, Japan",
            "Site JP81001, Maebashi, Gunma, Japan",
            "Site JP81013, Kita-gun, Kagawa, Japan",
            "Site JP81007, Yokohama, Kanagawa, Japan",
            "Site JP81016, Sendai, Miyagi, Japan",
            "Site JP81010, Abeno-ku, Osaka, Japan",
            "Site JP81011, Chuo-ku, Osaka, Japan",
            "Site JP81012, Osakasayama, Osaka, Japan",
            "Site JP81006, Bunkyo-ku, Tokyo, Japan",
            "Site JP81004, Koto-ku, Tokyo, Japan",
            "Site JP81005, Shinjuku-ku, Tokyo, Japan",
            "Site JP81017, Ube, Yamaguchi, Japan",
            "Site JP81002, Chiba, Japan",
            "Site JP81014, Fukuoka, Japan",
            "Site JP81015, Fukuoka, Japan",
            "Site JP81008, Kyoto, Japan",
            "Site JP81018, Nagasaki, Japan",
            "Site JP81020, Niigata, Japan",
            "Site JP81019, Yamagata, Japan",
            "Site KR82008, Seongnam-si, Gyeonggi-do, Korea, Republic of",
            "Site KR82007, Busan, Korea, Republic of",
            "Site KR82004, Incheon, Korea, Republic of",
            "Site KR82001, Seoul, Korea, Republic of",
            "Site KR82002, Seoul, Korea, Republic of",
            "Site KR82003, Seoul, Korea, Republic of",
            "Site NL31002, Sneek, Friesland, Netherlands",
            "Site NL31003, Nijmegen, Gelderland, Netherlands",
            "Site NL31007, Nijmegen, Gelderland, Netherlands",
            "Site NL31005, Eindhoven, Noord-Brabant, Netherlands",
            "Site NL31010, Alkmaar, Noord-Holland, Netherlands",
            "Site NL31008, Amsterdam, Noord-Holland, Netherlands",
            "Site NL31009, Zwolle, Overijssel, Netherlands",
            "Site NL31006, Rotterdam, Zuid-Holland, Netherlands",
            "Site NZ64003, Tauranga, Bay Of Plenty, New Zealand",
            "Site NZ64008, Kensington, Northland, New Zealand",
            "Site NZ64002, Dunedin, South Island, New Zealand",
            "Site NZ64005, Nelson, Tasman District, New Zealand",
            "Site NZ64004, Hamilton, New Zealand",
            "Site PL48003, Wroclaw, Dolnoslaskie, Poland",
            "Site PL48007, Krakow, Malopolskie, Poland",
            "Site PL48011, Warszawa, Mazowieckie, Poland",
            "Site PL48005, GdaÅ„sk, Pomerania, Poland",
            "Site PL48010, Slupsk, Pomorskie, Poland",
            "Site PL48001, Myslowice, Poland",
            "Site RO40008, Cluj-Napoca, Cluj, Romania",
            "Site RO40009, Cluj-Napoca, Cluj, Romania",
            "Site RO40002, Floresti, Cluj, Romania",
            "Site RO40011, Timisoara, Timis, Romania",
            "Site RO40007, Brasov, Romania",
            "Site RO40003, Bucharest, Romania",
            "Site RO40006, Bucharest, Romania",
            "Site RU70013, Ivanovo, Russian Federation",
            "Site RU70001, Moscow, Russian Federation",
            "Site RU70003, Moscow, Russian Federation",
            "Site RU70014, Moscow, Russian Federation",
            "Site RU70006, Omsk, Russian Federation",
            "Site RU70005, Penza, Russian Federation",
            "Site RU70007, St. Petersburg, Russian Federation",
            "Site RU70008, St. Petersburg, Russian Federation",
            "Site RU70009, St. Petersburg, Russian Federation",
            "Site RU70012, St. Petersburg, Russian Federation",
            "Site RU70016, St. Petersburg, Russian Federation",
            "Site SK42110, Bratislava, Slovakia",
            "Site SK42109, Kosice, Slovakia",
            "Site SK42102, Michalovce, Slovakia",
            "Site SK42103, Nitra, Slovakia",
            "Site SK42101, Poprad, Slovakia",
            "Site SK42107, Trencin, Slovakia",
            "Site SK42106, Å½ilina, Slovakia",
            "Site ES34011, Salamanca, A CoruÃ±a, Spain",
            "Site ES34020, Oviedo, Asturias, Spain",
            "Site ES34010, Sabadell, Barcelona, Spain",
            "Site ES34012, Barcelona, CataluÃ±a, Spain",
            "Site ES34014, Barcelona, CataluÃ±a, Spain",
            "Site ES34013, Valencia, Comunidad Valenciana, Spain",
            "Site ES34006, Pamplona, Navarra, Spain",
            "Site ES34001, Avila, Spain",
            "Site ES34007, Barcelona, Spain",
            "Site ES34004, Madrid, Spain",
            "Site ES34019, Madrid, Spain",
            "Site SE46002, Ã–rebro, Orebro LÃ¤n, Sweden",
            "Site SE46001, MalmÃ¶, SkÃ¥ne LÃ¤n, Sweden",
            "Site SE46006, Stockholm, Sodermanlands Lan, Sweden",
            "Site SE46004, Sundsvall, Vasternorrlands Lan, Sweden",
            "Site SE46007, Goteborg, Vastra Gotalands Lan, Sweden",
            "Site TW88601, Kaohsiung, Taiwan",
            "Site TW88606, Taichung, Taiwan",
            "Site TW88605, Taipei, Taiwan",
            "Site TW88607, Taoyuan, Taiwan",
            "Site GB44002, Withington, Manchester, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02677896"
      },
      {
        "-rank": "287",
        "nct_id": "NCT01517802",
        "title": "A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Metastatic Castration-resistant Prostate Cancer",
            "Metastatic Breast Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": { "outcome_measure": "The number of participants affected by a serious adverse event" },
        "sponsors": { "lead_sponsor": "Janssen Research & Development, LLC" },
        "gender": "All",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "32",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR100797",
            "212082PCR3010",
            "2011-005243-28"
          ]
        },
        "start_date": "March 28, 2012",
        "primary_completion_date": "April 9, 2021",
        "completion_date": "April 9, 2021",
        "study_first_posted": "January 25, 2012",
        "last_update_posted": "August 26, 2019",
        "locations": {
          "location": [
            "Aurora, Colorado, United States",
            "Marrero, Louisiana, United States",
            "Boston, Massachusetts, United States",
            "Omaha, Nebraska, United States",
            "East Setauket, New York, United States",
            "New York, New York, United States",
            "Myrtle Beach, South Carolina, United States",
            "Chattanooga, Tennessee, United States",
            "Dallas, Texas, United States",
            "Houston, Texas, United States",
            "Kogarah, Australia",
            "Kurralta Park, Australia",
            "South Brisbane, Australia",
            "Subiaco, Australia",
            "Antwerpen, Belgium",
            "Hamburg, Germany",
            "Barcelona, Spain",
            "Uppsala, Sweden",
            "Newcastle Upon Tyne, United Kingdom",
            "Northwood, United Kingdom",
            "Sutton, United Kingdom",
            "Whitchurch, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01517802"
      },
      {
        "-rank": "288",
        "nct_id": "NCT00385827",
        "title": "A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Cancer, Prostate" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Mitoxantrone"
            },
            {
              "-type": "Drug",
              "#text": "Siltuximab"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",
            "Part 2: Progression Free Survival (PFS)",
            "Time to Clinical Deterioration (TtCD)",
            "Number of Participants With Palliative Response",
            "Number of Participants With Prostate Specific Antigen (PSA) Response",
            "Overall Survival (OS)"
          ]
        },
        "sponsors": { "lead_sponsor": "Centocor, Inc." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "106",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CR012346",
            "C0328T07",
            "2006-001671-38"
          ]
        },
        "start_date": "November 2006",
        "primary_completion_date": "November 2008",
        "completion_date": "November 2008",
        "study_first_posted": "October 11, 2006",
        "results_first_posted": "June 12, 2014",
        "last_update_posted": "August 20, 2014",
        "locations": {
          "location": [
            "Norwalk, Connecticut, United States",
            "Port Saint Lucie, Florida, United States",
            "Atlanta, Georgia, United States",
            "Shreveport, Louisiana, United States",
            "Baltimore, Maryland, United States",
            "Saint Louis, Missouri, United States",
            "New York, New York, United States",
            "Philadelphia, Pennsylvania, United States",
            "Charleston, South Carolina, United States",
            "N Charleston, South Carolina, United States",
            "Milwaukee, Wisconsin, United States",
            "Innsbruck, Austria",
            "St Veit An Der Glan, Austria",
            "Wels N/A, Austria",
            "Wien, Austria",
            "Aalst, Belgium",
            "Antwerpen, Belgium",
            "Brasschaat, Belgium",
            "Brussel, Belgium",
            "Roeselare, Belgium",
            "Sint-Niklaas, Belgium",
            "Wilrijk, Belgium",
            "Caen Cedex 1, France",
            "Le Mans Cedex 2, France",
            "Lyon Cedex 08, France",
            "Villejuif, France",
            "Berlin, Germany",
            "Cologne, Germany",
            "Kassel, Germany",
            "Barcelona N/A, Spain",
            "Barcelona, Spain",
            "Madrid N/A, Spain",
            "Madrid, Spain",
            "MÃ¡laga, Spain",
            "London, United Kingdom",
            "Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00385827"
      },
      {
        "-rank": "289",
        "nct_id": "NCT00082927",
        "title": "Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Metastatic Cancer",
            "Pain",
            "Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "ibandronate sodium"
          }
        },
        "sponsors": {
          "lead_sponsor": "Cancer Research UK",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "580",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Masking: None (Open Label)",
            "Primary Purpose: Supportive Care"
          ]
        },
        "other_ids": {
          "other_id": [
            "CRUK-NCRI-RT-02-01",
            "CDR0000361728",
            "EU-20224",
            "RIB",
            "ISRCTN86185157"
          ]
        },
        "start_date": "April 2003",
        "completion_date": "July 2011",
        "study_first_posted": "May 19, 2004",
        "last_update_posted": "June 26, 2013",
        "locations": {
          "location": [
            "William Harvey Hospital, Ashford-Kent, England, United Kingdom",
            "North Devon District Hospital, Barnstaple, England, United Kingdom",
            "Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom",
            "Royal United Hospital, Bath, England, United Kingdom",
            "Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom",
            "Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom",
            "Queen's Hospital, Burton-upon-Trent, England, United Kingdom",
            "Kent and Canterbury Hospital, Canterbury, England, United Kingdom",
            "Cumberland Infirmary, Carlisle, England, United Kingdom",
            "Essex County Hospital, Colchester, England, United Kingdom",
            "Walsgrave Hospital, Coventry, England, United Kingdom",
            "Mayday University Hospital, Croydon, England, United Kingdom",
            "Russells Hall Hospital, Dudley, England, United Kingdom",
            "Eastbourne District General Hospital, Eastbourne, England, United Kingdom",
            "Royal Devon and Exeter Hospital, Exeter, England, United Kingdom",
            "Diana Princess of Wales Hospital, Grimsby, England, United Kingdom",
            "St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford, England, United Kingdom",
            "Harrogate District Hospital, Harrogate, England, United Kingdom",
            "Kidderminster Hospital, Kidderminster Worcestershire, England, United Kingdom",
            "Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom",
            "Lincoln County Hospital, Lincoln, England, United Kingdom",
            "Cancer Research UK and University College London Cancer Trials Centre, London, England, United Kingdom",
            "Royal Marsden - London, London, England, United Kingdom",
            "St. Mary's Hospital, London, England, United Kingdom",
            "Charing Cross Hospital, London, England, United Kingdom",
            "Clatterbridge Centre for Oncology, Merseyside, England, United Kingdom",
            "Northampton General Hospital NHS Trust, Northampton, England, United Kingdom",
            "Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom",
            "King's Mills Hospital, Nottinghamshire, England, United Kingdom",
            "Nottingham City Hospital NHS Trust, Nottingham, England, United Kingdom",
            "George Eliot Hospital, Nuneaton, England, United Kingdom",
            "Alexandra Healthcare NHS, Redditch, Worcestershire, England, United Kingdom",
            "Oldchurch Hospital, Romford, England, United Kingdom",
            "Conquest Hospital, Saint Leonards-on-Sea, England, United Kingdom",
            "Scarborough General Hospital, Scarborough, England, United Kingdom",
            "Scunthorpe General Hospital, Scunthorpe, England, United Kingdom",
            "Royal Shrewsbury Hospital, Shrewsbury, England, United Kingdom",
            "Southampton General Hospital, Southampton, England, United Kingdom",
            "Royal Marsden - Surrey, Sutton, England, United Kingdom",
            "Musgrove Park Hospital, Taunton, England, United Kingdom",
            "Torbay Hospital, Torquay, England, United Kingdom",
            "Warrington Hospital NHS Trust, Warrington, England, United Kingdom",
            "Warwick Hospital, Warwick, England, United Kingdom",
            "Sandwell General Hospital, West Bromwich, England, United Kingdom",
            "Weston General Hospital, Weston-super-Mare, England, United Kingdom",
            "West Cumberland Hospital, Whitehaven, England, United Kingdom",
            "New Cross Hospital, Wolverhampton, England, United Kingdom",
            "Worthing Hospital, Worthing, England, United Kingdom",
            "Yeovil District Hospital, Yeovil, England, United Kingdom",
            "Cancer Care Centre at York Hospital, York, England, United Kingdom",
            "Ninewells Hospital, Dundee, Scotland, United Kingdom",
            "Glan Clwyd Hospital, Rhyl, Denbighshire, Wales, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00082927"
      },
      {
        "-rank": "290",
        "nct_id": "NCT00106301",
        "title": "Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Carcinoma, Renal Cell",
            "Prostatic Neoplasms"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "FK228 (romidepsin)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of participants with adverse events",
            "To evaluate the effect of depsipeptide therapy on performance status as measured by the Karnofsky score assessment",
            "To evaluate the time to objective disease progression."
          ]
        },
        "sponsors": { "lead_sponsor": "Celgene Corporation" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "2",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "FJ-228-0007" },
        "start_date": "April 2004",
        "primary_completion_date": "September 2006",
        "completion_date": "September 2006",
        "study_first_posted": "March 23, 2005",
        "last_update_posted": "March 31, 2016",
        "locations": {
          "location": [
            "City of Hope National Medical Center, Duarte, California, United States",
            "University of Florida, Gainesville, Florida, United States",
            "University of Chicago, Chicago, Illinois, United States",
            "Seattle Cancer Care Alliance, Seattle, Washington, United States",
            "Royal Marsden Hospital, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00106301"
      },
      {
        "-rank": "291",
        "nct_id": "NCT01977651",
        "title": "A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide",
        "acronym": "UPWARD",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration-resistant Prostate Cancer (mCRPC)" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Enzalutamide"
          }
        },
        "outcome_measures": { "outcome_measure": "The proportion of evaluable subjects with at least one confirmed seizure as adjudicated by the Independent Adjudication Committee (IAC)" },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Global Development, Inc.",
          "collaborator": [
            "Medivation, Inc.",
            "Astellas Pharma Inc"
          ]
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 4" },
        "enrollment": "424",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "9785-CL-0403",
            "2013-003022-92",
            "U1111-1157-0224"
          ]
        },
        "start_date": "September 24, 2013",
        "primary_completion_date": "February 1, 2016",
        "completion_date": "January 11, 2019",
        "study_first_posted": "November 7, 2013",
        "last_update_posted": "February 15, 2019",
        "locations": {
          "location": [
            "Site US10005, Anchorage, Alaska, United States",
            "Site US10024, Detroit, Michigan, United States",
            "Site US10026, Bronx, New York, United States",
            "Site US10001, New York, New York, United States",
            "Site US10014, New York, New York, United States",
            "Site US10039, Syracuse, New York, United States",
            "Site US10016, Durham, North Carolina, United States",
            "Site US10008, Dallas, Texas, United States",
            "Site US10025, Seattle, Washington, United States",
            "Site AR54001, Berazategui, Buenos Aires, Argentina",
            "Site AR54006, Ciudad Autonoma de BuenosAires, Buenos Aires, Argentina",
            "Site AR54002, Buenos Aires, Caba, Argentina",
            "Site AR54003, Cordoba, Argentina",
            "Site AR54004, Santa Fe, Argentina",
            "Site AR54005, Tucuman, Argentina",
            "Site AU61012, Kogarah, New South Wales, Australia",
            "Site AU61005, Randwick, New South Wales, Australia",
            "Site AU61011, Sydney, New South Wales, Australia",
            "Site AU61001, Tweed Heads, New South Wales, Australia",
            "Site AU61002, Nambour, Queensland, Australia",
            "Site AU61007, Adelaide, South Australia, Australia",
            "Site AU61004, Ballarat, Victoria, Australia",
            "Site BE32004, Anderlecht, Belgium",
            "Site BE32001, Kortrijk, Belgium",
            "Site BE32003, Liege, Belgium",
            "Site CA15005, Abbotsford, British Columbia, Canada",
            "Site CA15014, Halifax, Nova Scotia, Canada",
            "Site CA15004, Brampton, Ontario, Canada",
            "Site CA15010, Scarborough, Ontario, Canada",
            "Site CA15001, Quebec City, Quebec, Canada",
            "Site CL56001, Temuco, IX Region, Chile",
            "Site CL56004, Santiago, Chile",
            "Site CL56002, Temuco, Chile",
            "Site CL56003, Vina del Mar, Chile",
            "Site CZ42004, Praha 2, Czechia",
            "Site CZ42002, Praha 6, Czechia",
            "Site FI35803, Helsinki, Finland",
            "Site FI35801, Oulu, Finland",
            "Site FI35802, Tampere, Finland",
            "Site FR33002, Lyon Cedex 03, France",
            "Site FR33004, Rouen Cedex, France",
            "Site FR33005, Suresnes, France",
            "Site DE49009, NÃ¼rtingen, Baden-WÃ¼rttemberg, Germany",
            "Site DE49003, Berlin, Germany",
            "Site DE49001, Munster, Germany",
            "Site HU36002, Sopron, Gyor-Moson Sopron, Hungary",
            "Site IL97202, Kfar Saba, HaMerkaz, Israel",
            "Site IL97201, Be'er Ya'akov, Israel",
            "Site IL97203, Beer-Sheva, Israel",
            "Site IL97205, Haifa, Israel",
            "Site IL97204, Jerusalem, Israel",
            "Site IL97208, Nahariya, Israel",
            "Site IL97206, Petah-Tiqva, Israel",
            "Site IL97207, Ramat Gan, Israel",
            "Site IT39005, Meldola, Emilia-Romagna, Italy",
            "Site IT39001, Cremona, Lombardia, Italy",
            "Site IT39002, Arezzo, Italy",
            "Site IT39003, Roma, Italy",
            "Site KR82006, Seongnam-Si, Gyeonggi-do, Korea, Republic of",
            "Site KR82007, Seoul, Korea, Republic of",
            "Site KR82003, Seoul, Korea, Republic of",
            "Site KR82001, Seoul, Korea, Republic of",
            "Site KR82004, Seoul, Korea, Republic of",
            "Site NZ64001, Hamilton, New Zealand",
            "Site SG65002, Singapore, Singapore",
            "Site ES34007, Hospitalet de Llobregat, Barcelona, Spain",
            "Site ES34005, Sabadell, Barcelona, Spain",
            "Site ES34001, Pamplona, Navarra, Spain",
            "Site ES34003, Barcelona, Spain",
            "Site ES34004, Barcelona, Spain",
            "Site ES34006, Madrid, Spain",
            "Site SE46001, Goteborg, Sweden",
            "Site SE46002, Orebro, Sweden",
            "Site TW88601, Kaohsiung, Taiwan",
            "Site TW88603, Taipei City, Taiwan",
            "Site GB44002, Sutton, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01977651"
      },
      {
        "-rank": "292",
        "nct_id": "NCT00003026",
        "title": "Hormone Therapy in Treating Patients With Advanced Prostate Cancer",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "bicalutamide"
            },
            {
              "-type": "Drug",
              "#text": "flutamide"
            },
            {
              "-type": "Drug",
              "#text": "triptorelin"
            },
            {
              "-type": "Radiation",
              "#text": "radiation therapy"
            }
          ]
        },
        "sponsors": { "lead_sponsor": "European Organisation for Research and Treatment of Cancer - EORTC" },
        "gender": "All",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "966",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "EORTC-22961",
            "EORTC-GU-22961"
          ]
        },
        "start_date": "April 1997",
        "primary_completion_date": "September 2001",
        "study_first_posted": "January 27, 2003",
        "last_update_posted": "July 2, 2012",
        "locations": {
          "location": [
            "Institut Jules Bordet, Brussels (Bruxelles), Belgium",
            "Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels, Belgium",
            "Universitair Ziekenhuis Antwerpen, Edegem, Belgium",
            "Universitair Ziekenhuis Gent, Ghent, Belgium",
            "Virga Jesse Hospital, Hasselt, Belgium",
            "U.Z. Gasthuisberg, Leuven, Belgium",
            "Rambam Medical Center, Haifa, Israel",
            "St. Luke's Hospital and Medical School, Guardamangia, Malta",
            "Groot Ziekengasthuis 's-Hertogenbosch, 's-Hertogenbosch, Netherlands",
            "Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands",
            "Academisch Medisch Centrum, Amsterdam, Netherlands",
            "Academisch Ziekenhuis Groningen, Groningen, Netherlands",
            "Academisch Ziekenhuis Maastricht, Maastricht, Netherlands",
            "St. Elisabeth Ziekenhuis, Tilburg, Netherlands",
            "Medical Radiological Research Center, Obninsk, Russian Federation",
            "Marmara University Hospital, Istanbul, Turkey",
            "City General Hospital, Stoke-On-Trent, England, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00003026"
      },
      {
        "-rank": "293",
        "nct_id": "NCT01884285",
        "title": "AZD8186 First Time In Patient Ascending Dose Study",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Advanced Castrate-resistant Prostate Cancer CRPC",
            "Squamous Non-Small Cell Lung Cancer sqNSCLC",
            "Triple Negative Breast Cancer TNBC"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Part A: AZD8186 monotherapy"
            },
            {
              "-type": "Drug",
              "#text": "Part B: AZD8186 monotherapy"
            },
            {
              "-type": "Drug",
              "#text": "Part C1: Abiraterone acetate combination with AZD8186"
            },
            {
              "-type": "Drug",
              "#text": "Part D1: AZD2014 combination with AZD8186"
            },
            {
              "-type": "Drug",
              "#text": "Part D2 AZD2014 combination with AZD8186"
            },
            {
              "-type": "Drug",
              "#text": "Part C2: Abiraterone acetate combination with AZD8186"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety and tolerability",
            "Part A: The number of evaluable patients with dose limiting toxicities (DLTs).",
            "Part A, B, C + D: Antitumor activity of AZD8186 monotherapy or in combination",
            "Part A, B, C and D: Anti-tumour activity of AZD8186 monotherapy or in combination",
            "Part A + B: Plasma concentrations of AZD8186 and pharmacokinetic parameters (Cmax, tmax, AUC, terminal rate constant, clearance, half life, volume of distribution and mean resistance time)",
            "Part A + B: 4 beta-hydroxy cholesterol concentration in blood samples.",
            "Part B: Obtaining a preliminary assessment of the antitumour activity of AZD8186 as monotherapy",
            "Part B: Obtaining a preliminary assessment of AZD8186 drug effect in the tumour",
            "Part A: Urine concentrations of AZD8186 and pharmacokinetic parameters (Cmax, tmax, AUC, terminal rate constant, clearance, half life, volume of distribution and mean residence time)",
            "Part C: safety and tolerability assessed by dose limiting toxicity of AZD8186 with abiraterone acetate (and prednisone)",
            "Part C: pharmacokinetics of and exposure to AZD8186, its major metabolite M1, and abiraterone",
            "Part C: steady state exposure to abiraterone",
            "Part C: steady state exposure of AZD8186 in combination with abiraterone acetate",
            "Part D: Measure the dose limiting toxicity of AZD8186 in combination with AZD2014.",
            "Part D: Single dose and multiple dose pharmacokinetics of and assess exposure to AZD8186, its major metabolite M1, and AZD2014 when co-administered",
            "Part D: Measure the exposure to AZD2014 following the last weekly dose of AZD2014 in the absence and presence of multiple dose AZD8186.",
            "Part D: Measure the exposure on the 4th administred dose of AZD8186 in the absence and presence of multiple dose AZD2014"
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "All",
        "min_age": "18 Years",
        "max_age": "130 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "150",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "D4620C00001" },
        "start_date": "July 9, 2013",
        "primary_completion_date": "March 29, 2019",
        "completion_date": "September 30, 2019",
        "study_first_posted": "June 24, 2013",
        "last_update_posted": "June 20, 2019",
        "locations": {
          "location": [
            "Research Site, Boston, Massachusetts, United States",
            "Research Site, Detroit, Michigan, United States",
            "Research Site, New York, New York, United States",
            "Research Site, Seattle, Washington, United States",
            "Research Site, Madison, Wisconsin, United States",
            "Research Site, Toronto, Ontario, Canada",
            "Research Site, Barcelona, Spain",
            "Research Site, Barcelona, Spain",
            "Research Site, Pozuelo de Alarcon, Spain",
            "Research Site, Cambridge, United Kingdom",
            "Research Site, London, United Kingdom",
            "Research Site, Manchester, United Kingdom",
            "Research Site, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01884285"
      },
      {
        "-rank": "294",
        "nct_id": "NCT00002503",
        "title": "Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Metastatic Cancer",
            "Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Radiation",
            "#text": "strontium chloride Sr 89"
          }
        },
        "sponsors": { "lead_sponsor": "European Organisation for Research and Treatment of Cancer - EORTC" },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "204",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": { "study_design": "Primary Purpose: Treatment" },
        "other_ids": { "other_id": "EORTC-30921" },
        "start_date": "October 1992",
        "primary_completion_date": "November 2000",
        "study_first_posted": "May 20, 2004",
        "last_update_posted": "September 24, 2012",
        "locations": {
          "location": [
            "Cliniques Universitaires Saint-Luc, Brussels, Belgium",
            "Universitair Ziekenhuis Antwerpen, Edegem, Belgium",
            "Universitair Ziekenhuis Gent, Ghent, Belgium",
            "U.Z. Gasthuisberg, Leuven, Belgium",
            "Aarhus Kommunehospital, Aarhus, Denmark",
            "Rigshospitalet, Copenhagen, Denmark",
            "Ospedale B. Ramazzini, Carpi, Italy",
            "Universita Degli Studi di Firenze - Policlin. di Careggi, Florence, Italy",
            "Instituto Scientifico H.S. Raffaele, Milan, Italy",
            "San Raffaele Hospital, Rome, Italy",
            "Ospedale di Circolo e Fondazione Macchi, Varese, Italy",
            "Groot Ziekengasthuis 's-Hertogenbosch, 's-Hertogenbosch, Netherlands",
            "Antoni van Leeuwenhoekhuis, Amsterdam, Netherlands",
            "Academisch Medisch Centrum, Amsterdam, Netherlands",
            "Academisch Ziekenhuis Groningen, Groningen, Netherlands",
            "University Medical Center Nijmegen, Nijmegen, Netherlands",
            "Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland",
            "Hospital Santa Maria, Lisbon, Portugal",
            "Medical Radiological Research Center, Obninsk, Russian Federation",
            "Inselspital, Bern, Bern, Switzerland",
            "Newcastle General Hospital, Newcastle Upon Tyne, England, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00002503"
      },
      {
        "-rank": "295",
        "nct_id": "NCT03834506",
        "title": "Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naÃ¯ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Biological",
              "#text": "Pembrolizumab"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "Dexamethasone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival (OS)",
            "Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review",
            "Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)",
            "Prostate-specific Antigen (PSA) Response Rate",
            "Objective Response Rate (ORR) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review",
            "Duration of Response (DOR) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review",
            "Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 (\"Worst Pain in 24 Hours\") and Opiate Analgesic Use (Analgesic Quantification Algorithm [AQA] Score)",
            "Time to First Symptomatic Skeletal-related Event (SSRE)",
            "Time to Prostate-specific Antigen (PSA) Progression",
            "Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review",
            "Number of Participants Who Experience an Adverse Event (AE)",
            "Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)"
          ]
        },
        "sponsors": { "lead_sponsor": "Merck Sharp & Dohme Corp." },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1000",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "3475-921",
            "2018-004116-22",
            "MK-3475-921",
            "KEYNOTE-921",
            "JAPAC-CTI"
          ]
        },
        "start_date": "May 2, 2019",
        "primary_completion_date": "September 12, 2021",
        "completion_date": "February 28, 2023",
        "study_first_posted": "February 8, 2019",
        "last_update_posted": "September 6, 2019",
        "locations": {
          "location": [
            "University of South Alabama, Mitchell Cancer Institute ( Site 0065), Mobile, Alabama, United States",
            "St. Joseph Heritage Healthcare ( Site 0069), Fullerton, California, United States",
            "University of Southern California Norris Comprehensive Cancer Center ( Site 0061), Los Angeles, California, United States",
            "University of Colorado Cancer Center ( Site 0022), Aurora, Colorado, United States",
            "Mount Sinai Hospital Medical Center ( Site 0042), Chicago, Illinois, United States",
            "Methodist Hospital- Merriillville ( Site 0008), Merrillville, Indiana, United States",
            "Karmanos Cancer Institute ( Site 0077), Detroit, Michigan, United States",
            "Cancer & Hematology Centers of Western Michigan ( Site 0013), Grand Rapids, Michigan, United States",
            "Washington University School of Medicine ( Site 0057), Saint Louis, Missouri, United States",
            "St. Vincent Frontier Cancer Center ( Site 0016), Billings, Montana, United States",
            "Nebraska Cancer Specialists ( Site 0034), Omaha, Nebraska, United States",
            "Comprehensive Cancer Centers of Nevada ( Site 0092), Las Vegas, Nevada, United States",
            "Hackensack University Medical Center ( Site 0004), Hackensack, New Jersey, United States",
            "Oregon Health Sciences University ( Site 0031), Portland, Oregon, United States",
            "Carolina Urologic Research Center ( Site 0070), Myrtle Beach, South Carolina, United States",
            "Virginia Cancer Institute ( Site 0052), Richmond, Virginia, United States",
            "Instituto de Investigaciones Clinicas ( Site 1000), Mar del Plata, Buenos Aires, Argentina",
            "Centro de Diagnostico Urologico ( Site 1008), Buenos Aires, Caba, Argentina",
            "Sanatorio Parque ( Site 1002), Rosario, Santa Fe, Argentina",
            "Instituto de Investigaciones Metabolicas [Buenos Aires, Argentina] ( Site 1011), Buenos Aires, Argentina",
            "CEMAIC ( Site 1014), Cordoba, Argentina",
            "Macquarie University ( Site 0151), Macquarie University, New South Wales, Australia",
            "Port Macquarie Base Hospital ( Site 0153), Port Macquarie, New South Wales, Australia",
            "Calvary Mater Newcastle ( Site 0148), Waratah, New South Wales, Australia",
            "John Flynn Hospital & Medical Centre ( Site 0164), Tugun, Queensland, Australia",
            "Medizinische Universitat Graz ( Site 0374), Graz, Austria",
            "Ordensklinikum Linz GmbH Elisabethinen ( Site 0373), Linz, Austria",
            "SCRI-CCCIT GesmbH ( Site 0371), Salzburg, Austria",
            "Medizinische Universitaet Wien ( Site 0375), Wien, Austria",
            "Juravinski Cancer Centre ( Site 0116), Hamilton, Ontario, Canada",
            "Lakeridge Health ( Site 0117), Oshawa, Ontario, Canada",
            "CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102), Rimouski, Quebec, Canada",
            "CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105), Sherbrooke, Quebec, Canada",
            "CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0103), Quebec, Canada",
            "Fundacion Arturo Lopez Perez ( Site 1049), Santiago, Chile",
            "Pontificia Universidad Catolica de Chile ( Site 1047), Santiago, Chile",
            "Bradford Hill Centro de Investigaciones Clinicas ( Site 1044), Santiago, Chile",
            "Private practice ( Site 1048), Temuco, Chile",
            "Sociedad de Investigaciones Medicas Limitadas ( Site 1041), Temuco, Chile",
            "Centro de Investigaciones Clinicas Vina del Mar ( Site 1042), Vna Del Mar, Chile",
            "Institut Sainte Catherine ( Site 0447), Avignon, Cedex 9, France",
            "CHU Amiens Picardie Site Sud Amiens ( Site 0438), Amiens, France",
            "CHU Jean Minjoz ( Site 0423), Besancon, France",
            "Institut Bergonie ( Site 0421), Bordeaux, France",
            "CHU de Brest. Hopital Morvan ( Site 0441), Brest, France",
            "Centre Jean Perrin ( Site 0434), Clermont-Ferrand, France",
            "Centre D Oncologie de Gentilly ( Site 0432), Nancy, France",
            "Centre Hospitalier Regional du Orleans ( Site 0430), Orleans, France",
            "Institut Mutualiste Montsouris ( Site 0446), Paris, France",
            "C.H.U. Lyon Sud ( Site 0436), Pierre Benite, France",
            "C.H. de Saint Quentin ( Site 0481), Saint Quentin, France",
            "Hopital Foch ( Site 0428), Suresnes, France",
            "Institut Claudius Regaud IUCT Oncopole ( Site 0418), Toulouse, France",
            "Institut Gustave Roussy ( Site 0416), Villejuif, France",
            "Assaf Harofeh MC ( Site 0547), Beer Yaakov-Zerifin, Israel",
            "Rambam Medical Center ( Site 0543), Haifa, Israel",
            "Hadassah Ein Kerem Medical Center ( Site 0546), Jerusalem, Israel",
            "Rabin Medical Center ( Site 0545), Petach-Tikwa, Israel",
            "Chaim Sheba Medical Center ( Site 0541), Ramat Gan, Israel",
            "Sourasky Medical Center ( Site 0542), Tel Aviv, Israel",
            "Istituto Clinico Humanitas Research Hospital ( Site 0452), Rozzano, Milano, Italy",
            "Azienda Ospedaliera Cannizzaro ( Site 0458), Catania, Italy",
            "A.O. Universitaria di Modena ( Site 0454), Modena, Italy",
            "Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0457), Napoli, Italy",
            "Azienda Ospedaliera San Camillo Forlanini ( Site 0455), Roma, Italy",
            "Azienda Ospedaliera Santa Maria Terni ( Site 0456), Terni, Italy",
            "Presidio Ospedaliero Santa Chiara ( Site 0451), Trento, Italy",
            "Toho University Sakura Medical Center ( Site 0703), Sakura, Chiba, Japan",
            "Kanazawa University Hospital ( Site 0701), Kanazawa, Ishikawa, Japan",
            "Nara Medical University Hospital ( Site 0715), Kashihara, Nara, Japan",
            "Osaka University Hospital ( Site 0713), Suita, Osaka, Japan",
            "Saitama Medical University International Medical Center ( Site 0708), Hidaka, Saitama, Japan",
            "Nagasaki University Hospital ( Site 0719), Nagasaki, Japan",
            "Nippon Medical School Hospital ( Site 0709), Tokyo, Japan",
            "Keio University Hospital ( Site 0710), Tokyo, Japan",
            "National Cancer Center ( Site 0174), Goyang-si, Gyeonggi-do, Korea, Republic of",
            "Seoul National University Bundang Hospital ( Site 0175), Seongnam-si, Gyeonggi-do, Korea, Republic of",
            "Seoul National University Hospital ( Site 0171), Seoul, Korea, Republic of",
            "Asan Medical Center ( Site 0176), Seoul, Korea, Republic of",
            "Samsung Medical Center ( Site 0172), Seoul, Korea, Republic of",
            "Antoni van Leeuwenhoek Ziekenhuis ( Site 0480), Amsterdam, Netherlands",
            "Catharina Ziekenhuis ( Site 0472), Eindhoven, Netherlands",
            "Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565), Chelyabinsk, Russian Federation",
            "Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0585), Krasnoyarsk, Russian Federation",
            "SBIH City clinical hospital named after D.D. Pletniov ( Site 0575), Moscow, Russian Federation",
            "Russian Scientific Center of Roentgenoradiology ( Site 0559), Moscow, Russian Federation",
            "Central Clinical Hospital with Polyclinic ( Site 0562), Moscow, Russian Federation",
            "Omsk Clinical Oncology Dispensary ( Site 0568), Omsk, Russian Federation",
            "Clinical Research Center of specialized types medical care-Oncology ( Site 0570), Saint Petersburg, Russian Federation",
            "Russian Scientific Center of Radiology and Surgical Technologies ( Site 0567), Saint Petersburg, Russian Federation",
            "SBHI Samara Regional Clinical Oncology Dispensary ( Site 0576), Samara, Russian Federation",
            "Tomsk National Research Medical Center of Russian Academy of Sciences ( Site 0579), Tomsk, Russian Federation",
            "Instituto Catalan de Oncologia - ICO ( Site 0330), L Hospitalet De Llobregat, Barcelona, Spain",
            "Hospital del Mar ( Site 0333), Barcelona, Spain",
            "Hospital Clinic ( Site 0323), Barcelona, Spain",
            "Hospital Josep Trueta ( Site 0321), Girona, Spain",
            "Hospital Universitario Ramon y Cajal ( Site 0328), Madrid, Spain",
            "Hospital Clinico San Carlos ( Site 0324), Madrid, Spain",
            "Hospital Universitario HM Sanchinarro ( Site 0322), Madrid, Spain",
            "Hospital Universitario Virgen de la Victoria ( Site 0337), Malaga, Spain",
            "Hospital Consorci Sanitari Parc Tauli ( Site 0335), Sabadell, Spain",
            "Hospital Universitario Marques de Valdecilla ( Site 0336), Santander, Spain",
            "Hospital Virgen del Rocio ( Site 0329), Sevilla, Spain",
            "China Medical University Hospital ( Site 0132), Taichung, Taiwan",
            "Taichung Veterans General Hospital ( Site 0133), Taichung, Taiwan",
            "National Cheng Kung University Hospital ( Site 0134), Tainen, Taiwan",
            "National Taiwan University Hospital ( Site 0131), Taipei, Taiwan",
            "Taipei Veterans General Hospital ( Site 0135), Taipei, Taiwan",
            "University Hospitals Bristol NHS Foundation Trust ( Site 0530), Bristol, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03834506"
      },
      {
        "-rank": "296",
        "nct_id": "NCT00303784",
        "title": "Prostate Adenocarcinoma TransCutaneous Hormones",
        "acronym": "PATCH",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Anemia",
            "Cardiovascular Complications",
            "Hot Flashes",
            "Osteoporosis",
            "Prostate Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Goserelin"
            },
            {
              "-type": "Drug",
              "#text": "Estradiol"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Progression-Free Survival",
            "Overall Survival",
            "Hormone activity by castrate levels of hormones",
            "Other toxicity",
            "Cardiovascular morbidity",
            "Cardiovascular mortality",
            "Quality of Life"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Imperial College London",
          "collaborator": [
            "Medical Research Council",
            "University College, London"
          ]
        },
        "gender": "Male",
        "max_age": "120 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "2200",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000455583",
            "MRC-PATCH",
            "EU-205106",
            "MRC-PR09",
            "ISRCTN70406718",
            "EUDRACT-2005-001030-33"
          ]
        },
        "start_date": "March 2006",
        "primary_completion_date": "August 2021",
        "completion_date": "August 2021",
        "study_first_posted": "March 17, 2006",
        "last_update_posted": "October 27, 2016",
        "locations": {
          "location": [
            "Queen's Hospital, Burton-upon-Trent, England, United Kingdom",
            "Addenbrooke's Hospital, Cambridge, England, United Kingdom",
            "Walsgrave Hospital, Coventry, England, United Kingdom",
            "Mid Cheshire Hospitals Trust- Leighton Hopsital, Crewe, England, United Kingdom",
            "Mayday University Hospital, Croydon, England, United Kingdom",
            "Derbyshire Royal Infirmary, Derby, England, United Kingdom",
            "Castle Hill Hospital, East Yorkshire, England, United Kingdom",
            "Royal Devon and Exeter Hospital, Exeter, England, United Kingdom",
            "Grantham and District Hospital, Grantham, Lincolnshire, England, United Kingdom",
            "Ipswich Hospital, Ipswich, England, United Kingdom",
            "Kidderminster Hospital, Kidderminster Worcestershire, England, United Kingdom",
            "Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom",
            "St. Mary's Hospital, London, England, United Kingdom",
            "Charing Cross Hospital, London, England, United Kingdom",
            "Maidstone Hospital, Maidstone, England, United Kingdom",
            "James Cook University Hospital, Middlesbrough, England, United Kingdom",
            "Kings Mill Hospital, Nottinghamshire, England, United Kingdom",
            "Nottingham City Hospital, Nottingham, England, United Kingdom",
            "George Eliot Hospital, Nuneaton, England, United Kingdom",
            "Alexandra Healthcare NHS, Redditch, Worcestershire, England, United Kingdom",
            "Hope Hospital, Salford, England, United Kingdom",
            "Scarborough General Hospital, Scarborough, England, United Kingdom",
            "Stepping Hill Hospital, Stockport, England, United Kingdom",
            "Hillingdon Hospital, Uxbridge, England, United Kingdom",
            "Walsall Manor Hospital, Walsall, England, United Kingdom",
            "Warwick Hospital, Warwick, England, United Kingdom",
            "Worthing Hospital, Worthing, England, United Kingdom",
            "Yeovil District Hospital, Yeovil, England, United Kingdom",
            "Ayr Hospital, Ayr, Scotland, United Kingdom",
            "Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom",
            "Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom",
            "University Hospital of Wales, Cardiff, Wales, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00303784"
      },
      {
        "-rank": "297",
        "nct_id": "NCT00283062",
        "title": "Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": { "condition": "Prostatic Neoplasms" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Docetaxel (TAXOTEREÂ®) Chemotherapy"
            },
            {
              "-type": "Drug",
              "#text": "Leuprolide acetate ( ELIGARDÂ®) Hormonal Therapy"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel (TAXOTEREÂ®) Chemotherapy"
            },
            {
              "-type": "Drug",
              "#text": "Leuprolide acetate ( ELIGARDÂ®) Hormonal Therapy"
            },
            {
              "-type": "Drug",
              "#text": "Leuprolide acetate ( ELIGARDÂ®) Hormonal Therapy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression",
            "Median Overall Survival (OS)",
            "Median Cancer-specific Survival (CSS)",
            "Median Metastasis-free Survival (MFS)",
            "To Evaluate Quality of Life (QoL) as Measured Using a Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire",
            "Assessment of Safety and Tolerability - Number of Participants With Adverse Events (AE)"
          ]
        },
        "sponsors": { "lead_sponsor": "Sanofi" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "228",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Factorial Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "XRP6976J_3501",
            "EudraCT # : 2004-002203-32"
          ]
        },
        "start_date": "December 2005",
        "primary_completion_date": "December 2010",
        "completion_date": "December 2010",
        "study_first_posted": "January 27, 2006",
        "results_first_posted": "January 23, 2012",
        "last_update_posted": "January 26, 2012",
        "locations": {
          "location": [
            "Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",
            "Sanofi-Aventis Administrative Office, Macquarie Park, Australia",
            "Sanofi-Aventis Administrative Office, Vienna, Austria",
            "Sanofi-Aventis Administrative Office, Sao Paulo, Brazil",
            "Sanofi-Aventis Administrative Office, QuÃ©bec, Canada",
            "Sanofi-Aventis Administrative Office, Paris, France",
            "Sanofi-Aventis Administrative Office, Frankfurt, Germany",
            "Sanofi-Aventis Administrative Office, Mumbai, India",
            "Sanofi-Aventis Administrative Office, Natanya, Israel",
            "Sanofi-Aventis Administrative Office, Milan, Italy",
            "Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico",
            "Sanofi-Aventis Administrative Office, PE Gouda, Netherlands",
            "Sanofi-Aventis Administrative Office, Warsaw, Poland",
            "Sanofi-Aventis Administrative Office, Moscow, Russian Federation",
            "Sanofi-Aventis Administrative Office, Gauteng, South Africa",
            "Sanofi-Aventis Administrative Office, Istanbul, Turkey",
            "Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00283062"
      },
      {
        "-rank": "298",
        "nct_id": "NCT00174863",
        "title": "Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer",
        "acronym": "ODYSSEY",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostatic Neoplasm" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "SR31747A"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Time To Clinical Progression assessed by every 4 weeks clinical examination and every 12 weeks radiological examinations (Thoraco-abdominopelvic CT scan ; Bone scan Â± centered Bone X-rays, MRI)",
            "Every 4 weeks: Clinical examination (safety, Tumor related symptoms deterioration), PSA level determination (PSA endpoints), EuroQoL instrument (Quality of Life), Laboratory tests (Hematology, Biochemistry), one PK sample",
            "Every 12 weeks: radiological examinations (tumor response),"
          ]
        },
        "sponsors": { "lead_sponsor": "Sanofi" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "232",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "EFC5378" },
        "start_date": "October 2003",
        "primary_completion_date": "August 2006",
        "completion_date": "August 2006",
        "study_first_posted": "September 15, 2005",
        "last_update_posted": "December 23, 2008",
        "locations": {
          "location": [
            "sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia",
            "Sanofi-Aventis Administrative Office, Diegem, Belgium",
            "Sanofi-Aventis Administrative Office, Laval, Canada",
            "Sanofi-Aventis Administrative Office, Santiago, Chile",
            "Sanofi-Aventis Administrative Office, Praha, Czech Republic",
            "Sanofi-Aventis Administrative Office, Paris, France",
            "Sanofi-Aventis Administrative Office, Milano, Italy",
            "Sanofi-Aventis Administrative Office, Mexico, Mexico",
            "Sanofi-Aventis Administrative Office, Gouda, Netherlands",
            "Sanofi-Aventis Administrative Office, Warszawa, Poland",
            "Sanofi-Aventis Administrative Office, Porto Salvo, Portugal",
            "Sanofi-Aventis Administrative Office, Barcelona, Spain",
            "Sanofi-Aventis Administrative Office, Guilford Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00174863"
      },
      {
        "-rank": "299",
        "nct_id": "NCT00911027",
        "title": "SonoVue Guided Prostate Biopsy",
        "status": {
          "-open": "N",
          "#text": "Terminated"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Contrast-enhanced ultrasound guided biopsy"
            },
            {
              "-type": "Procedure",
              "#text": "ultrasound guided systematic biopsy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Determination of potentiality of SonoVue to guide prostate biopsy increasing detection rate of malignant lesions of 6% points (absolute terms) compared to detection rate of conventional systematic biopsy on patients candidates to a bioptic procedure.",
            "Evaluation of the rate of patients negative to the systematic biopsy among the population that will not receive the targeted biopsy",
            "Assessment of potentiality of SonoVue guided biopsy to increase % of positive bioptic cores compared to % of positive cores obtained with systematic biopsy, intra-patient in the population of the patients that received both bioptic procedures.",
            "Evaluation of the Gleason Score of bioptic samples and its relationship with the contrast enhanced signal assessment scores."
          ]
        },
        "sponsors": {
          "lead_sponsor": "Bracco Diagnostics, Inc",
          "collaborator": "Bracco Imaging S.p.A."
        },
        "gender": "Male",
        "min_age": "40 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "282",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Crossover Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Diagnostic"
          ]
        },
        "other_ids": { "other_id": "BR1-127" },
        "start_date": "February 2009",
        "primary_completion_date": "March 2011",
        "completion_date": "March 2011",
        "study_first_posted": "June 1, 2009",
        "last_update_posted": "April 25, 2012",
        "locations": {
          "location": [
            "Medical University Innsbruck, Innsbruck, Austria",
            "University Hospital K.U. Leuven, Leuven, Belgium",
            "HÃ´pital Edouard Herriot, Lyon, France",
            "HÃ´pital Necker-Enfants Malades, Paris, France",
            "CHRU Tours - HÃ´pital Bretonneau, Tours, France",
            "Institut fÃ¼r Radiologie der CharitÃ©, Berlin, Germany",
            "Martini-Klinik, Prostate Cancer Center, Hamburg, Germany",
            "Urologische Klinik und Poliklinik, Munich, Germany",
            "Orsola-Malpighi Hospital, Urology and Radiology Unit \"Malpighi\", Bologna, Italy",
            "Ospedale Valduce, Como, Italy",
            "European Institute of Oncology, Milan, Italy",
            "I.R.C.C.S. San Raffaele, Milan, Italy",
            "University of Palermo, Palermo, Italy",
            "University of Trieste, Trieste, Italy",
            "AMC University Amsterdam, Amsterdam, Netherlands",
            "Erasmus MC, Rotterdam, Netherlands",
            "Imperial College NHS Trust - Charing Cross, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00911027"
      },
      {
        "-rank": "300",
        "nct_id": "NCT02485691",
        "title": "Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent",
        "acronym": "CARD",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Prostate Cancer Metastatic" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "cabazitaxel XRP6258"
            },
            {
              "-type": "Drug",
              "#text": "enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "abiraterone acetate"
            },
            {
              "-type": "Drug",
              "#text": "prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Radiographic progression-free survival defined as the time from randomization to the occurrence of radiological tumor progressions using RECIST 1.1 and progression of bone lesions using Prostate Cancer Working Group 2 (PCWG2) criteria",
            "Radiographic progression-free survival defined as the time from randomization to the occurrence of death due to any cause",
            "Number of patients achieving PSA decline >=50%",
            "Progression-free survival-Time",
            "Overall survival defined as the time interval from the date of randomization to the date of death due to any cause",
            "Time to Prostate Specific Antigen (PSA) progression defined as the time interval between the date of randomization and the date of PSA progression using PCWG2 definition",
            "Number of patients achieving tumor response",
            "Duration of tumor response",
            "Pain response using Brief Pain Inventory-Short Form (BPI-SF) for pain intensity score",
            "Time to pain progression",
            "Symptomatic skeletal event (SSE) rate",
            "Assessment of Health-related Quality of Life (HRQOL) using the Functional Assessment of Cancer Therapy - Prostate (FACT-P) scale",
            "Assessment of health status using the 5-Level EuroQol Group's 5-Dimension (EQ-5D-5L) questionnaire",
            "Number of treatment-emergent adverse events (TEAEs)"
          ]
        },
        "sponsors": { "lead_sponsor": "Sanofi" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 4" },
        "enrollment": "234",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "LPS14201",
            "2014-004676-29",
            "U1111-1166-5329"
          ]
        },
        "start_date": "November 9, 2015",
        "primary_completion_date": "August 2019",
        "completion_date": "August 2019",
        "study_first_posted": "June 30, 2015",
        "last_update_posted": "April 29, 2019",
        "locations": {
          "location": [
            "Investigational Site Number 040002, Linz, Austria",
            "Investigational Site Number 040003, Wien, Austria",
            "Investigational Site Number 040004, Wien, Austria",
            "Investigational Site Number 056013, Brugge, Belgium",
            "Investigational Site Number 056011, Brugge, Belgium",
            "Investigational Site Number 056007, Brussels, Belgium",
            "Investigational Site Number 056003, Bruxelles, Belgium",
            "Investigational Site Number 056002, Bruxelles, Belgium",
            "Investigational Site Number 056006, Charleroi, Belgium",
            "Investigational Site Number 056001, Gent, Belgium",
            "Investigational Site Number 056005, Leuven, Belgium",
            "Investigational Site Number 056010, Roeselare, Belgium",
            "Investigational Site Number 056008, Turnhout, Belgium",
            "Investigational Site Number 203005, Brno, Czechia",
            "Investigational Site Number 203001, Olomouc, Czechia",
            "Investigational Site Number 203002, Plzen, Czechia",
            "Investigational Site Number 203003, Praha 4, Czechia",
            "Investigational Site Number 250012, Besancon, France",
            "Investigational Site Number 250010, Clermont Ferrand, France",
            "Investigational Site Number 250006, LYON Cedex 8, France",
            "Investigational Site Number 250019, Lyon, France",
            "Investigational Site Number 250004, Marseille, France",
            "Investigational Site Number 250011, Montpellier, France",
            "Investigational Site Number 250002, PARIS Cedex 15, France",
            "Investigational Site Number 250013, Paris, France",
            "Investigational Site Number 250007, Paris, France",
            "Investigational Site Number 250014, Plerin, France",
            "Investigational Site Number 250016, Reims, France",
            "Investigational Site Number 250018, Saint-MandÃ©, France",
            "Investigational Site Number 250009, Strasbourg, France",
            "Investigational Site Number 250005, Suresnes, France",
            "Investigational Site Number 250008, Tours, France",
            "Investigational Site Number 250001, Villejuif, France",
            "Investigational Site Number 276028, Aschaffenburg, Germany",
            "Investigational Site Number 276027, Berlin, Germany",
            "Investigational Site Number 276008, Berlin, Germany",
            "Investigational Site Number 276022, Duisburg, Germany",
            "Investigational Site Number 276013, DÃ¼sseldorf, Germany",
            "Investigational Site Number 276016, Erlangen, Germany",
            "Investigational Site Number 276023, Essen, Germany",
            "Investigational Site Number 276002, Frankfurt am Main, Germany",
            "Investigational Site Number 276007, GÃ¶ttingen, Germany",
            "Investigational Site Number 276009, Hamburg, Germany",
            "Investigational Site Number 276001, Hamburg, Germany",
            "Investigational Site Number 276017, Homburg/Saar, Germany",
            "Investigational Site Number 276026, Jena, Germany",
            "Investigational Site Number 276012, KÃ¶ln, Germany",
            "Investigational Site Number 276025, LÃ¼beck, Germany",
            "Investigational Site Number 276004, Magdeburg, Germany",
            "Investigational Site Number 276019, Mainz, Germany",
            "Investigational Site Number 276018, Mannheim, Germany",
            "Investigational Site Number 276006, MÃ¼nster, Germany",
            "Investigational Site Number 276003, NÃ¼rtingen, Germany",
            "Investigational Site Number 276010, Rostock, Germany",
            "Investigational Site Number 276024, Stuttgart, Germany",
            "Investigational Site Number 276011, TÃ¼bingen, Germany",
            "Investigational Site Number 276020, Wuppertal, Germany",
            "Investigational Site Number 300001, Athens, Greece",
            "Investigational Site Number 300002, Athens, Greece",
            "Investigational Site Number 300005, Marousi, Athens, Greece",
            "Investigational Site Number 300004, Thessaloniki, Greece",
            "Investigational Site Number 352001, Reykjavik, Iceland",
            "Investigational Site Number 372001, Dublin 24, Ireland",
            "Investigational Site Number 372003, Dublin 7, Ireland",
            "Investigational Site Number 372004, Dublin, Ireland",
            "Investigational Site Number 380003, Arezzo, Italy",
            "Investigational Site Number 380004, Brescia, Italy",
            "Investigational Site Number 380005, Candiolo, Italy",
            "Investigational Site Number 380009, Meldola, Italy",
            "Investigational Site Number 380007, Napoli, Italy",
            "Investigational Site Number 380006, Napoli, Italy",
            "Investigational Site Number 380011, Parma, Italy",
            "Investigational Site Number 380002, Pisa, Italy",
            "Investigational Site Number 380001, Roma, Italy",
            "Investigational Site Number 380008, Verona, Italy",
            "Investigational Site Number 528002, Breda, Netherlands",
            "Investigational Site Number 528007, Enschede, Netherlands",
            "Investigational Site Number 528003, Nijmegen, Netherlands",
            "Investigational Site Number 528005, Rotterdam, Netherlands",
            "Investigational Site Number 528004, Sittard-Geleen, Netherlands",
            "Investigational Site Number 578001, GrÃ¥lum, Norway",
            "Investigational Site Number 578002, Trondheim, Norway",
            "Investigational Site Number 724001, Barcelona, Spain",
            "Investigational Site Number 724004, Madrid, Spain",
            "Investigational Site Number 724002, Madrid, Spain",
            "Investigational Site Number 724003, Sevilla, Spain",
            "Investigational Site Number 826001, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02485691"
      },
      {
        "-rank": "301",
        "nct_id": "NCT02141438",
        "title": "Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer",
        "acronym": "REASSURE",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Metastatic Castration-resistant Prostate Cancer" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Radium-223 dichloride (Xofigo, BAY88-8223)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Incidence of developing second primary malignancies",
            "Incidence of treatment-emergent SAEs",
            "Incidence of drug-related treatment-emergent adverse events",
            "Incidence of drug-related SAEs",
            "Bone marrow suppression",
            "Overall survival",
            "The worst pain score and pain interference score over time as determined by patient responses on the \"Brief pain inventory short form\" (BPI-SF) questionnaire",
            "Incidence of bone fractures",
            "The number of bone associated events"
          ]
        },
        "sponsors": { "lead_sponsor": "Bayer" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "1474",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Cohort",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "16913" },
        "start_date": "August 20, 2014",
        "primary_completion_date": "December 31, 2024",
        "completion_date": "February 28, 2025",
        "study_first_posted": "May 19, 2014",
        "last_update_posted": "August 29, 2019",
        "locations": {
          "location": [
            "Homewood, Alabama, United States",
            "Anchorage, Alaska, United States",
            "Scottsdale, Arizona, United States",
            "Daly City, California, United States",
            "Long Beach, California, United States",
            "Sacramento, California, United States",
            "San Diego, California, United States",
            "Colorado Springs, Colorado, United States",
            "Boca Raton, Florida, United States",
            "Fort Myers, Florida, United States",
            "Jacksonville, Florida, United States",
            "Lakewood Ranch, Florida, United States",
            "Plantation, Florida, United States",
            "Atlanta, Georgia, United States",
            "Decatur, Georgia, United States",
            "Honolulu, Hawaii, United States",
            "Evanston, Illinois, United States",
            "Maywood, Illinois, United States",
            "Urbana, Illinois, United States",
            "Warrenville, Illinois, United States",
            "Wichita, Kansas, United States",
            "Ashland, Kentucky, United States",
            "New Orleans, Louisiana, United States",
            "Baltimore, Maryland, United States",
            "Rockville, Maryland, United States",
            "Towson, Maryland, United States",
            "Boston, Massachusetts, United States",
            "Troy, Michigan, United States",
            "Saint Louis, Missouri, United States",
            "Billings, Montana, United States",
            "Omaha, Nebraska, United States",
            "Lebanon, New Hampshire, United States",
            "Neptune, New Jersey, United States",
            "Township, New Jersey, United States",
            "Buffalo, New York, United States",
            "East Setauket, New York, United States",
            "Lake Success, New York, United States",
            "Syracuse, New York, United States",
            "Winston-Salem, North Carolina, United States",
            "Middleburg Heights, Ohio, United States",
            "Oklahoma City, Oklahoma, United States",
            "Springfield, Oregon, United States",
            "Abington, Pennsylvania, United States",
            "Charleston, South Carolina, United States",
            "Myrtle Beach, South Carolina, United States",
            "Nashville, Tennessee, United States",
            "Houston, Texas, United States",
            "Lubbock, Texas, United States",
            "San Antonio, Texas, United States",
            "Temple, Texas, United States",
            "Charlottesville, Virginia, United States",
            "Virginia Beach, Virginia, United States",
            "Seattle, Washington, United States",
            "Multiple Locations, Argentina",
            "Multiple Locations, Austria",
            "Multiple Locations, Belgium",
            "Multiple Locations, Canada",
            "Multiple Locations, Colombia",
            "Multiple Locations, Czechia",
            "Multiple Locations, Denmark",
            "Multiple Locations, France",
            "Multiple Locations, Germany",
            "Multiple Locations, Greece",
            "Multiple Locations, Israel",
            "Multiple Locations, Italy",
            "Multiple Locations, Luxembourg",
            "Multiple Locations, Mexico",
            "Multiple Locations, Netherlands",
            "Multiple Locations, Portugal",
            "Multiple Locations, Spain",
            "Multiple Locations, Sweden",
            "Multiple Locations, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02141438"
      },
      {
        "-rank": "302",
        "nct_id": "NCT00417079",
        "title": "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer",
        "acronym": "TROPIC",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Neoplasms",
            "Prostatic Neoplasms"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "cabazitaxel (XRP6258) (RPR116258)"
            },
            {
              "-type": "Drug",
              "#text": "mitoxantrone"
            },
            {
              "-type": "Drug",
              "#text": "prednisone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Time to Progression Free Survival (PFS)",
            "Overall Tumor Response",
            "Time to Tumor Progression",
            "Time to Prostatic Specific Antigen (PSA) Progression",
            "PSA (Prostate-Specific Antigen) Response",
            "Time to Pain Progression",
            "Pain Response"
          ]
        },
        "sponsors": { "lead_sponsor": "Sanofi" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "755",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "EFC6193" },
        "start_date": "January 2007",
        "primary_completion_date": "September 2009",
        "completion_date": "September 2009",
        "study_first_posted": "December 29, 2006",
        "results_first_posted": "December 23, 2010",
        "last_update_posted": "March 10, 2011",
        "locations": {
          "location": [
            "sanofi-aventis US, Bridgewater, New Jersey, United States",
            "sanofi-aventis Argentina, Buenos Aires, Argentina",
            "sanofi-aventis Belgium, Diegem, Belgium",
            "sanofi-aventis Brazil, Sao Paulo, Brazil",
            "sanofi-aventis Canada, Laval, Quebec, Canada",
            "sanofi-aventis Chile, Santiago, Chile",
            "sanofi-aventis Czech Republic, Praha, Czech Republic",
            "sanofi-aventis Denmark, Horsholm, Denmark",
            "sanofi-aventis Finland, Helsinki, Finland",
            "sanofi-aventis France, Paris, France",
            "sanofi-aventis Germany, Berlin, Germany",
            "Sanofi-Aventis Hungaria, Budapest, Hungary",
            "sanofi-aventis India, Mumbai, India",
            "sanofi-aventis Italy, Milano, Italy",
            "sanofi-aventis South Korea, Seoul, Korea, Republic of",
            "sanofi-aventis Mexico, Mexico, Mexico",
            "sanofi-aventis Netherlands, Gouda, Netherlands",
            "sanofi-aventis Russia, Moscow, Russian Federation",
            "sanofi-aventis Singapore, Singapore, Singapore",
            "sanofi-aventis Slovakia, Bratislava, Slovakia",
            "sanofi-aventis South Africa, Midrand, South Africa",
            "sanofi-aventis Spain, Barcelona, Spain",
            "sanofi-aventis Sweden, Bromma, Sweden",
            "sanofi-aventis Taiwan, Taipei, Taiwan",
            "sanofi-aventis Turkey, Istanbul, Turkey",
            "sanofi-aventis UK, Guildford, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00417079"
      },
      {
        "-rank": "303",
        "nct_id": "NCT00519285",
        "title": "Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer",
        "acronym": "VENICE",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Prostatic Neoplasms",
            "Neoplasm Metastasis"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Aflibercept"
            },
            {
              "-type": "Drug",
              "#text": "Placebo (for aflibercept)"
            },
            {
              "-type": "Drug",
              "#text": "Docetaxel"
            },
            {
              "-type": "Drug",
              "#text": "Prednisone or Prednisolone"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival Time",
            "Prostate Specific Antigen Response Rate",
            "Time to Skeletal Related Events",
            "Progression Free Survival Time",
            "Tumor Response Rate in Participants With Measurable Disease",
            "Prostate Specific Antigen Progression-free Survival Time",
            "Pain Progression-free Survival Time",
            "Pain Response Rate",
            "Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life",
            "Number of Participants With Adverse Events as a Measure of Safety",
            "Number of Participants With Positive Anti-aflibercept Antibody Levels as a Measure of Immunogenicity of Aflibercept"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Sanofi",
          "collaborator": "Regeneron Pharmaceuticals"
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1224",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "EFC6546",
            "2006-004756-20"
          ]
        },
        "start_date": "August 2007",
        "primary_completion_date": "April 2012",
        "completion_date": "April 2012",
        "study_first_posted": "August 22, 2007",
        "results_first_posted": "October 10, 2013",
        "last_update_posted": "July 22, 2016",
        "locations": {
          "location": [
            "Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",
            "Sanofi-Aventis Administrative Office, Buenos Aires, Argentina",
            "Sanofi-Aventis Administrative Office, Macquarie Park, Australia",
            "Sanofi-Aventis Administrative Office, Diegem, Belgium",
            "Sanofi-Aventis Administrative Office, Sao Paulo, Brazil",
            "Sanofi-Aventis Administrative Office, Laval, Canada",
            "Sanofi-Aventis Administrative Office, Providencia Santiago, Chile",
            "Sanofi-Aventis Administrative Office, City of Zagreb, Croatia",
            "Sanofi-Aventis Administrative Office, Praha, Czech Republic",
            "Sanofi-Aventis Administrative Office, Horsholm, Denmark",
            "Sanofi-Aventis Administrative Office, Tallinn, Estonia",
            "Sanofi-Aventis Administrative Office, Paris, France",
            "Sanofi-Aventis Administrative Office, Frankfurt, Germany",
            "Sanofi-Aventis Administrative Office, Hong Kong, Hong Kong",
            "Sanofi-Aventis Administrative Office, Budapest, Hungary",
            "Sanofi-Aventis Administrative Office, Natanya, Israel",
            "Sanofi-Aventis Administrative Office, Milan, Italy",
            "Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of",
            "Sanofi-Aventis Administrative Office, Gouda, Netherlands",
            "Sanofi-Aventis Administrative Office, Warsaw, Poland",
            "Sanofi-Aventis Administrative Office, Porto Salvo, Portugal",
            "Sanofi-Aventis Administrative Office, Moscow, Russian Federation",
            "Sanofi-Aventis Administrative Office, Singapore, Singapore",
            "Sanofi-Aventis Administrative Office, Gauteng, South Africa",
            "Sanofi-Aventis Administrative Office, Barcelona, Spain",
            "Sanofi-Aventis Administrative Office, Bromma, Sweden",
            "Sanofi-Aventis Administrative Office, Geneva, Switzerland",
            "Sanofi-Aventis Administrative Office, Taipei, Taiwan",
            "Sanofi-Aventis Administrative Office, Istanbul, Turkey",
            "Sanofi-Aventis Administrative Office, Kiev, Ukraine",
            "Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00519285"
      },
      {
        "-rank": "304",
        "nct_id": "NCT03756597",
        "title": "PAN-study: Pan-Cancer Early Detection Study (PAN)",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Gastric Cancer",
            "Esophageal Cancer",
            "Renal Cancer",
            "Prostate Cancer",
            "Bladder Cancer",
            "Pancreatic Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Device",
              "#text": "ReCIVA"
            },
            {
              "-type": "Device",
              "#text": "CASPER"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Ability of the breath-test to discriminate between patients with and without any cancer or a specific tumour type using GC-FAIMS and GC-TOF-MS",
            "Patient feedback on usability and acceptability of Breath Biopsy as assessed using a a structured interview"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Owlstone Ltd",
          "collaborator": [
            "Cambridge University Hospitals NHS Foundation Trust",
            "Cancer Research UK"
          ]
        },
        "gender": "All",
        "min_age": "45 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "1134",
        "funded_bys": {
          "funded_by": [
            "Industry",
            "Other"
          ]
        },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Control",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "PAN" },
        "start_date": "September 26, 2018",
        "primary_completion_date": "December 2021",
        "completion_date": "December 2021",
        "study_first_posted": "November 28, 2018",
        "last_update_posted": "November 28, 2018",
        "locations": { "location": "Cambridge University Hospital NHS, Cambridge, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03756597"
      },
      {
        "-rank": "305",
        "nct_id": "NCT00601406",
        "title": "Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer",
        "status": {
          "-open": "N",
          "#text": "Unknown status"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Breast Cancer",
            "Cervical Cancer",
            "Endometrial Cancer",
            "Fallopian Tube Cancer",
            "Ovarian Cancer",
            "Primary Peritoneal Cavity Cancer",
            "Prostate Cancer",
            "Sarcoma",
            "Vaginal Cancer",
            "Vulvar Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Genetic",
              "#text": "gene expression analysis"
            },
            {
              "-type": "Genetic",
              "#text": "gene rearrangement analysis"
            },
            {
              "-type": "Genetic",
              "#text": "polymorphism analysis"
            },
            {
              "-type": "Other",
              "#text": "laboratory biomarker analysis"
            },
            {
              "-type": "Radiation",
              "#text": "radiation therapy"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Correlation of association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, with individual patient variability in normal tissue radiation response and toxicity",
            "Comparison of different clinical scoring systems for late normal tissue effects",
            "Comparison of clinical scoring systems with analytical measures of normal tissue outcome using volume change in the breast measured by laser camera",
            "Correlation of family history information with SNP analysis to produce a polymorphism risk score (PRS)",
            "Comparison of detailed 3D dose-volume analysis with late effects and SNP results",
            "Correlation of actuarial analysis of late effects changes over time with PRS",
            "PRS analyses against tumor control probability (TCP), using survival as a surrogate for TCP where necessary, and normal tissue complications vs tumor control probability"
          ]
        },
        "sponsors": {
          "lead_sponsor": "The Christie NHS Foundation Trust",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "All",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "2200",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000581139",
            "CHNT-RAPPER",
            "EU-20798"
          ]
        },
        "start_date": "March 2006",
        "primary_completion_date": "February 2008",
        "study_first_posted": "January 28, 2008",
        "last_update_posted": "August 26, 2013",
        "locations": {
          "location": [
            "Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom",
            "Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom",
            "Addenbrooke's Hospital, Cambridge, England, United Kingdom",
            "Ipswich Hospital, Ipswich, England, United Kingdom",
            "Christie Hospital, Manchester, England, United Kingdom",
            "Clatterbridge Centre for Oncology, Merseyside, England, United Kingdom",
            "Whiston Hospital, Prescot, England, United Kingdom",
            "Cancer Research Centre at Weston Park Hospital, Sheffield, England, United Kingdom",
            "Southport and Formby District General Hospital, Southport, England, United Kingdom",
            "Royal Marsden - Surrey, Sutton, England, United Kingdom",
            "Warrington Hospital NHS Trust, Warrington, England, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00601406"
      },
      {
        "-rank": "306",
        "nct_id": "NCT00751205",
        "title": "Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Ovarian Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid"
            },
            {
              "-type": "Drug",
              "#text": "Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall incidence of peripheral neuropathy (any grade) during at most 6 cycles of Sagopilone treatment, based on the Adverse Events.",
            "Efficacy of ALC: incidence of neuropathy of grade 3 or 4, time to onset of neuropathy, duration of neuropathy.",
            "Efficacy of ALC: Percentage of discontinuations due to neuropathy.",
            "Safety of Sagopilone in combination with ALC.",
            "Efficacy of Sagopilone: 'best overall response' according to modRECIST criteria",
            "Efficacy of Sagopilone: 'best overall response' according to CA-125 or PSA response",
            "Efficacy of Sagopilone: Time to disease progression, Progression-free survival",
            "Efficacy of Sagopilone: Duration of response",
            "Efficacy of Sagopilone: WHO performance status.",
            "Pharmacokinetic: Sagopilone concentrations (optional)",
            "Pharmacokinetic: ALC concentrations",
            "Pharmacogenomics (optional): in tumor tissue, blood and ascites"
          ]
        },
        "sponsors": { "lead_sponsor": "Bayer" },
        "gender": "All",
        "min_age": "18 Years",
        "max_age": "70 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "150",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "91695",
            "2008-000879-26"
          ]
        },
        "start_date": "August 2008",
        "primary_completion_date": "February 2010",
        "completion_date": "August 2010",
        "study_first_posted": "September 11, 2008",
        "last_update_posted": "October 28, 2014",
        "locations": {
          "location": [
            "Bruxelles - Brussel, Belgium",
            "Caen, France",
            "Montpellier Cedex, France",
            "Nantes, France",
            "Paris, France",
            "Villejuif, France",
            "TÃ¼bingen, Baden-WÃ¼rttemberg, Germany",
            "Rostock, Mecklenburg-Vorpommern, Germany",
            "Bonn, Nordrhein-Westfalen, Germany",
            "Essen, Nordrhein-Westfalen, Germany",
            "Essen, Nordrhein-Westfalen, Germany",
            "Magdeburg, Sachsen-Anhalt, Germany",
            "Meldola, ForlÃ¬, Italy",
            "Bologna, Italy",
            "Rimini, Italy",
            "Roma, Italy",
            "Amsterdam, Netherlands",
            "Amsterdam, Netherlands",
            "Leiden, Netherlands",
            "Maastricht, Netherlands",
            "Leicester, Leicestershire, United Kingdom",
            "Northwood, Middlesex, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00751205"
      },
      {
        "-rank": "307",
        "nct_id": "NCT00257478",
        "title": "A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Cancer of Prostate",
            "Prostatic Cancer",
            "Cancer of the Prostate"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "YM155"
          }
        },
        "sponsors": {
          "lead_sponsor": "Astellas Pharma Inc",
          "collaborator": "Astellas Pharma US, Inc."
        },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "155-CL-007" },
        "completion_date": "March 2007",
        "study_first_posted": "November 23, 2005",
        "last_update_posted": "June 7, 2012",
        "locations": {
          "location": [
            "Tuscon, Arizona, United States",
            "Los Angeles, California, United States",
            "Coeur d'Alene, Idaho, United States",
            "Bronx, New York, United States",
            "New York, New York, United States",
            "Philadelphia, Pennsylvania, United States",
            "San Antonio, Texas, United States",
            "Amsterdam, Netherlands",
            "Sutton, Surry, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00257478"
      },
      {
        "-rank": "308",
        "nct_id": "NCT03064308",
        "title": "The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery",
        "acronym": "POETold",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Impaired Cognition",
            "Quality of Life",
            "Surgery",
            "Delirium",
            "Colorectal Carcinoma",
            "Bladder Carcinoma",
            "Abdominal Hysterectomy (& Wertheim)",
            "Prostatic Neoplasms",
            "Colon Carcinoma",
            "Renal Carcinoma"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Other",
            "#text": "Exercise Programme"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Feasibility of a home based exercise programme following surgery in the older patient.",
            "Step Box Test",
            "Muscle Architecture Ultrasound",
            "Cognitive testing",
            "Frailty",
            "Subjective Outcome measure: Physical Activity.",
            "Subjective Outcome measure: VO2max measure",
            "Subjective Outcome measure: Physical Activity",
            "Subjective Outcome measure: Quality of Life",
            "Hand Strength Test"
          ]
        },
        "sponsors": { "lead_sponsor": "University of Nottingham" },
        "gender": "All",
        "min_age": "70 Years",
        "age_groups": { "age_group": "Older Adult" },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "11",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Other"
          ]
        },
        "other_ids": { "other_id": "16014" },
        "start_date": "June 26, 2017",
        "primary_completion_date": "July 26, 2018",
        "completion_date": "July 27, 2018",
        "study_first_posted": "February 27, 2017",
        "last_update_posted": "April 17, 2019",
        "locations": { "location": "Division of Graduate Entry Medicine and Health, School of Medicine, University of Nottingham. Royal Derby Hospital,, Derby, Derbyshire, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03064308"
      },
      {
        "-rank": "309",
        "nct_id": "NCT00127478",
        "title": "A Long Term Safety Study With Atrasentan",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Adenocarcinoma"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Atrasentan"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Adverse events",
            "Serious adverse events",
            "Oncology-related events (OREs)",
            "Deaths",
            "Study drug exposure",
            "Change from baseline in Karnofsky performance status",
            "Vital signs",
            "Stratification by treatment group from prior study",
            "Safety and laboratory parameters"
          ]
        },
        "sponsors": { "lead_sponsor": "Abbott" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 2",
            "Phase 3"
          ]
        },
        "enrollment": "166",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "M01-304" },
        "start_date": "July 2001",
        "completion_date": "June 2007",
        "study_first_posted": "August 8, 2005",
        "last_update_posted": "November 29, 2007",
        "locations": {
          "location": [
            "Prostate Oncology Specialists, Marina Del Rey, California, United States",
            "Western Clinical Research, Inc., Torrance, California, United States",
            "South Florida Medical Research, Aventura, Florida, United States",
            "Beth Isreal Medical Center, Phillips Ambulatory Care Ceneter, New York, New York, United States",
            "ViaHealth Rochester General Hospital Center for Urology, Rochester, New York, United States",
            "Oregon Urology Specialist, Division of Clinical Research, Springfield, Oregon, United States",
            "University of Pittsburgh Department of Urology, Pittsburgh, Pennsylvania, United States",
            "Cross Cancer Institute, Edmonton, Alberta, Canada",
            "CroMedia Prime/Prime Trials Vancouver Hospital, Vancouver, British Columbia, Canada",
            "Ken Janz MD, Burlington, Ontario, Canada",
            "McMaster Institute of Urology, Hamilton, Ontario, Canada",
            "McGill University Health Center Royal VIctoria Hosptial, Montreal, Quebec, Canada",
            "Hoptial de Ranguell Service d'Urologie, Toulouse, Cedex, France",
            "University Hospital Rotterdam, Department of Urology, Rotterdam, Netherlands",
            "Leighton Hospital Urology Research Dept., Michael Heal Outpatients Dept., Crewe, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00127478"
      },
      {
        "-rank": "310",
        "nct_id": "NCT03367819",
        "title": "Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Non-small Cell Lung Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Isatuximab SAR650984"
            },
            {
              "-type": "Drug",
              "#text": "Cemiplimab REGN2810"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Dose Limiting Toxicities (DLTs)",
            "AEs",
            "Response Rate",
            "Immunogenicity: isatuximab",
            "Pharmacokinetic (PK) parameters: area under the curve (AUC)",
            "Tumor burden change",
            "Duration of response",
            "Progression-free survival",
            "Assessment of PK parameter: Cmax",
            "Immunogenicity: REGN2810",
            "Disease control rate"
          ]
        },
        "sponsors": { "lead_sponsor": "Sanofi" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "134",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "ACT15319",
            "2017-002846-61",
            "U1111-1197-7792"
          ]
        },
        "start_date": "January 4, 2018",
        "primary_completion_date": "June 2021",
        "completion_date": "June 2021",
        "study_first_posted": "December 11, 2017",
        "last_update_posted": "August 13, 2019",
        "locations": {
          "location": [
            "Investigational Site Number 8400003, Birmingham, Alabama, United States",
            "Investigational Site Number 8400009, Santa Monica, California, United States",
            "Investigational Site Number 8400007, Atlanta, Georgia, United States",
            "Investigational Site Number 8400002, Hackensack, New Jersey, United States",
            "Investigational Site Number 8400005, Nashville, Tennessee, United States",
            "Investigational Site Number 8400004, Houston, Texas, United States",
            "Investigational Site Number 2500002, Bordeaux Cedex, France",
            "Investigational Site Number 2500001, Villejuif Cedex, France",
            "Investigational Site Number 3800006, Napoli, Italy",
            "Investigational Site Number 3800001, Orbassano, Italy",
            "Investigational Site Number 3800004, Padova, Italy",
            "Investigational Site Number 3800002, Pavia, Italy",
            "Investigational Site Number 3800003, Rozzano, Italy",
            "Investigational Site Number 3800005, Verona, Italy",
            "Investigational Site Number 1580002, Tainan, Taiwan",
            "Investigational Site Number 1580001, Taipei 100, Taiwan",
            "Investigational Site Number 8260002, Newcastle Upon Tyne, United Kingdom",
            "Investigational Site Number 8260001, Sutton, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03367819"
      },
      {
        "-rank": "311",
        "nct_id": "NCT03934827",
        "title": "MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour",
        "acronym": "MICROBIOME",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Melanoma",
            "Breast Cancer",
            "Uterine Cancer",
            "Ovarian Cancer",
            "Prostate Cancer",
            "Urethral Cancer",
            "Bladder Cancer",
            "Renal Cancer",
            "Lung Cancer",
            "Head and Neck Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "MRx0518 Capsules"
            },
            {
              "-type": "Drug",
              "#text": "MRx0518/placebo Capsules"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety and tolerability of MRx0518 as determined through the collection of the number and severity of adverse vents (AEs) and serious adverse events (SAEs).",
            "Safety and tolerability of MRx0518 determined by clinically significant changes in biochemistry, haematology and urinalysis laboratory results.",
            "Safety and tolerability of MRx0518 determined by clinically significant changes in vital signs.",
            "Safety and tolerability of MRx0518 as determined by clinically significant changes in electrocardiogram (ECG) results.",
            "Safety and tolerability of MRx0518 as determined by clinically significant changes upon physical examination.",
            "Response of MRx0518 determined by the measurement of tumour markers.",
            "Overall survival of patients who receive MRx0518 compared to placebo."
          ]
        },
        "sponsors": {
          "lead_sponsor": "Imperial College London",
          "collaborator": "4D pharma plc"
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "120",
        "funded_bys": {
          "funded_by": [
            "Other",
            "Industry"
          ]
        },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Sequential Assignment",
            "Masking: Double (Participant, Investigator)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "C/35/2017" },
        "start_date": "April 10, 2019",
        "primary_completion_date": "August 2021",
        "completion_date": "February 2022",
        "study_first_posted": "May 2, 2019",
        "last_update_posted": "May 14, 2019",
        "locations": { "location": "Imperial College Healthcare NHS Trust, London, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT03934827"
      },
      {
        "-rank": "312",
        "nct_id": "NCT03395197",
        "title": "Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC",
        "acronym": "TALAPRO-2",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "mCRPC" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Talazoparib with enzalutamide"
            },
            {
              "-type": "Drug",
              "#text": "Placebo with enzalutamide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Confirm the dose of Talazoparib (part 1)",
            "Radiographic PFS (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Overall survival (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Objective response in measurable soft tissue disease (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Duration of soft tissue response (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "PSA response (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Time to PSA progression (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Time to initiation of cytotoxic chemotherapy (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Time to initiation of antineoplastic therapy (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Time to first symptomatic skeletal event (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "PFS on next line of therapy (PFS2) in unselected patients and in patients harboring DDR deficiencies",
            "Opiate use for cancer pain (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Incidence of adverse events (part 1 and 2)",
            "Pharmacokinetic assessment of talazoparib (part 1)",
            "Pharmacokinetic assessment of talazoparib (part 2)",
            "Pharmacokinetic assessment of enzalutamide (part 1)",
            "Pharmacokinetic assessment of enzalutamide (part 2)",
            "Patient-reported outcome:pain symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Patient-reported outcome: pain symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Patient-reported outcome: cancer specific global health status/QoL, functioning, and symptoms (part 2) in unselected patients and in patients harboring DDR deficiencies",
            "Patient-reported outcome: general health status (part2) in unselected patients and patients harboring DDR deficiencies",
            "Patient-reported outcome: general health status (part 2) in unselected patients and patients harboring DDR deficiencies"
          ]
        },
        "sponsors": { "lead_sponsor": "Pfizer" },
        "gender": "Male",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "1037",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "C3441021",
            "2017-003295-31",
            "TALAPRO-2"
          ]
        },
        "start_date": "December 18, 2017",
        "primary_completion_date": "September 14, 2022",
        "completion_date": "November 25, 2024",
        "study_first_posted": "January 10, 2018",
        "last_update_posted": "September 5, 2019",
        "locations": {
          "location": [
            "Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States",
            "Urological Associates of Southern Arizona, PC, Tucson, Arizona, United States",
            "Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States",
            "Glendale Adventist Medical Center, Glendale, California, United States",
            "Marin Cancer Care, Inc., Greenbrae, California, United States",
            "San Diego Clinical Trials, La Mesa, California, United States",
            "Tower Urology, Los Angeles, California, United States",
            "San Diego Clinical Trials, San Diego, California, United States",
            "University of Colorado Denver CTO/CTRC, Aurora, Colorado, United States",
            "University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States",
            "University of Colorado Hospital- Anschutz Inpatient Pavilion, Aurora, Colorado, United States",
            "University of Colorado Hospital- Anschutz Outpatient Pavilion, Aurora, Colorado, United States",
            "The Urology Center of Colorado, Denver, Colorado, United States",
            "Lakeland Regional Health Hollis Cancer Center, Lakeland, Florida, United States",
            "UroPartners LLC, Melrose Park, Illinois, United States",
            "First Urology, PSC, Jeffersonville, Indiana, United States",
            "Advanced Cancer Therapies, Wichita, Kansas, United States",
            "Wichita Urology Group, Wichita, Kansas, United States",
            "First Urology, PSC, Louisville, Kentucky, United States",
            "Regional Urology Oncology & Radiation Center, Shreveport, Louisiana, United States",
            "Regional Urology, LLC, Shreveport, Louisiana, United States",
            "Michigan Institute of Urology, Troy, Michigan, United States",
            "St. Vincent Healthcare, Billings, Montana, United States",
            "St. Vincent Frontier Cancer Center, Billings, Montana, United States",
            "Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States",
            "Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States",
            "GU Research Network/Urology Cancer Center, Omaha, Nebraska, United States",
            "Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States",
            "New Jersey Urology, LLC, Voorhees, New Jersey, United States",
            "Urology Group of New Mexico, Albuquerque, New Mexico, United States",
            "Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, United States",
            "Associated Medical Professionals of New York, PLLC, Syracuse, New York, United States",
            "TriState urologic Services PSC Inc., dba The Urology Group, Cincinnati, Ohio, United States",
            "Clinical Research Solutions, Middleburg Heights, Ohio, United States",
            "Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States",
            "Cascade View Medical Building, Corvallis, Oregon, United States",
            "Good Samaritan Hospital - Corvallis, Corvallis, Oregon, United States",
            "Providence Cancer Institute Newberg Clinic, Newberg, Oregon, United States",
            "Providence Cancer Institute Franz Clinic, Portland, Oregon, United States",
            "Providence Oncology and Hematology Care Clinic - Westside, Portland, Oregon, United States",
            "Lancaster Urology, Lancaster, Pennsylvania, United States",
            "Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States",
            "Urology Associates P.C., Nashville, Tennessee, United States",
            "The Vanderbilt Clinic, Nashville, Tennessee, United States",
            "Vanderbuilt University Medical Center, Department of Urology, Nashville, Tennessee, United States",
            "Houston Metro Urology, Houston, Texas, United States",
            "Farmington Health Center -University of Utah, Farmington, Utah, United States",
            "Huntsman Cancer Hospital, Salt Lake City, Utah, United States",
            "University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States",
            "Redwood Health Center-University of Utah, Salt Lake City, Utah, United States",
            "South Jordan Health Center -University of Utah, South Jordan, Utah, United States",
            "Swedish Cancer Institute, Seattle, Washington, United States",
            "Swedish Medical Center, Seattle, Washington, United States",
            "University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States",
            "University of Wisconsin Hospital & Clinics, Madison, Wisconsin, United States",
            "Instituto de Oncologia de Rosario, Rosario, Santa FE, Argentina",
            "Centro de Urologia-CDU, Caba, Argentina",
            "Hospital BritÃ¡nico de Buenos Aires, Caba, Argentina",
            "St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia",
            "Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia",
            "ICON Cancer Centre Wesley, Auchenflower, Queensland, Australia",
            "River City Pharmacy, Auchenflower, Queensland, Australia",
            "Princess Alexandra Hospital, Brisbane, Queensland, Australia",
            "ICON Cancer Centre Chermside, Chermside, Queensland, Australia",
            "ICON Cancer Centre South Brisbane, South Brisbane, Queensland, Australia",
            "Integrated Clinical Oncology Network Pty Ltd (ICON), South Brisbane, Queensland, Australia",
            "ICON Cancer Centre Southport, Southport, Queensland, Australia",
            "A.Z. Sint-Lucas, Gent, Belgium",
            "CHU UCL Namur site Godinne, Yvoir, Belgium",
            "Socicdad Prosalud Montes y Orlandi Ltda., Santiago, Metropolitana, Chile",
            "Centro de Investigacion Clinica del Sur, Temuco, Region DE LA Araucania, Chile",
            "Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Region DE LA Araucania, Chile",
            "Centro de Investigaciones Clinicas Vina del Mar, Vina del Mar, Valparaiso, Chile",
            "HUS Helsinki University Hospital, Helsinki, Finland",
            "Docrates Cancer Center, Helsinki, Finland",
            "HUS Pharmacy, Clinical Trials, Helsinki, Finland",
            "OYS apteekki, Kempele, Finland",
            "Kuopio University Hospital, Kuopio, Finland",
            "Kuopio University Hospital, Kuopio, Finland",
            "Oulun yliopistollinen sairaala, Oulu, Finland",
            "Pirkanmaan sairaanhoitopiiri/Sairaala-apteekki/Tutkimusfarmaseutti, Tampere, Finland",
            "Tampere University Hospital, Tampere, Finland",
            "Turku University Hospital, Turku, Finland",
            "Diagnostikzentrum, Kirchheim, Germany",
            "Universitaetsklinikum Muenster, Muenster, Germany",
            "Studienpraxis Urologie, Nuertingen, Germany",
            "Orszagos Onkologiai Intezet, Budapest, Hungary",
            "OrszÃ¡gos OnkolÃ³giai IntÃ©zet, Budapest, Hungary",
            "Uzoki Utcai Korhaz, Budapest, Hungary",
            "Uzsoki Utcai KÃ³rhÃ¡z, Budapest, Hungary",
            "Debreceni Egyetem Klinikai Kozpont Klinikai Gyogyszertar, Debrecen, Hungary",
            "Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary",
            "Pecsi Tudomanyegyetem Klinikai Kozpont Gyogyszereszeti Intezet es Klinikai Kozponti Gyogyszertar, Pecs, Hungary",
            "Pecsi Tudomanyegyetem Klinikai Kozpont Onkoterapias Intezet, Pecs, Hungary",
            "Rambam Health Care Campus, Haifa, Israel",
            "Shaare Zedek Medical Center, Jerusalem, Israel",
            "Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel",
            "Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",
            "Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",
            "ASST di Cremona, Cremona, CR, Italy",
            "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, FC, Italy",
            "Azienda Ospedaliera S. Maria, Terni, TN, Italy",
            "Istituto Nazionale Tumori IRCCS Fondazione G. Pascale - Napoli, Napoli, Italy",
            "Nagoya University Hospital, Nagoya, Aichi, Japan",
            "National Cancer Center Hospital East, Kashiwa, Chiba, Japan",
            "National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan",
            "Hokkaido University Hospital, Sapporo, Hokkaido, Japan",
            "Kanazawa University Hospital, Kanazawa, Ishikawa, Japan",
            "Yokohama City University Medical Center, Yokohama, Kanagawa, Japan",
            "Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan",
            "Osaka International Cancer Institute, Osaka-shi, Osaka, Japan",
            "Kindai University Hospital, Osakasayama, Osaka, Japan",
            "Osaka University Hospital, Suita, Osaka, Japan",
            "Hamamatsu University School of Medicine, University Hospital, Hamamatsu, Shizuoka, Japan",
            "National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan",
            "Keio University Hospital, Shinjuku-ku, Tokyo, Japan",
            "Chiba Cancer Center, Chiba, Japan",
            "National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan",
            "Kagoshima University Hospital, Kagoshima, Japan",
            "National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan",
            "Tokushima University Hospital, Tokushima, Japan",
            "Yamagata Prefectural Central Hospital, Yamagata, Japan",
            "Clinical Trial Pharmacy, National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of",
            "National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of",
            "Pusan National University Hospital, Busan, Korea, Republic of",
            "Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of",
            "Clinical Trials Center Pharmacy, Seoul, Korea, Republic of",
            "Department of Urology, Seoul National University Hospital, Seoul, Korea, Republic of",
            "Clinical Trial Center, Serverance Hospital, yonsei University Health System, Seoul, Korea, Republic of",
            "Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Cancer Center Clinical Trial, Asan Medical Center, Seoul, Korea, Republic of",
            "Clinical Trials Center Pharmacy, Seoul, Korea, Republic of",
            "Samsung Medical Center, Seoul, Korea, Republic of",
            "Clinical Trial Pharmacy, The Catholic University of Korea, Seoul, Korea, Republic of",
            "The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of",
            "Tauranga Urology Research Limited, Tauranga, BAY OF Plenty, New Zealand",
            "Waikato Hospital, Hamilton, Waikato, New Zealand",
            "Auckland City Hospital, Auckland, New Zealand",
            "Akershus University Hospital, Lorenskog, Norway",
            "Sykehusapoteket Ahus Lorenskog, Norbyhagen, Norway",
            "Oslo University Hospital -UllevÃ¥l & Radiumhospitalet, Oslo, Norway",
            "Sykehusapoteket Oslo, Oslo, Norway",
            "St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway",
            "Sykehusapoteket i Trondheim, Trondheim, Norway",
            "Centro Medico Monte Carmelo SCRLtda, Arequipa, Peru",
            "Szpital Specjalistczny W Brzozowie Podkarpack I Osrodek Onkologiczny im. Ks. B Markiewicza, Brzozow, Poland",
            "Szpitale Pomorskie Sp. z o.o. Oddzial Onkologii i Radioterapii, Gdynia, Poland",
            "Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Otwock, Poland",
            "NZOZ Szpital Mazovia; Oddzial urologiczny, Warszawa, Poland",
            "Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth, Eastern CAPE, South Africa",
            "CancerCare Rondebosch Oncology, Cape Town, Western CAPE, South Africa",
            "Outeniqua Cancercare Oncology Unit, George, Western CAPE, South Africa",
            "Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruna, Spain",
            "Hospital General Universitario de Elche, Elche, Alicante, Spain",
            "Institut Catala d'Oncologia - ICO L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain",
            "Institut Catala d'Oncologia ICO L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain",
            "Hospital Universitari Vall d'Hebron, Barcelona, Spain",
            "Hospital Clinic de Barcelona, Barcelona, Spain",
            "Hospital General Universitario Gregorio Maranon, Madrid, Spain",
            "Hospital Universitario 12 De Octubre, Madrid, Spain",
            "Cancercentrum Norrlands Universitetssjukhus, UmeÃ¥, Sweden",
            "Sjukhusapoteket UmeÃ¥, UmeÃ¥, Sweden",
            "Akademiska University Hospital, Uppsala, Sweden",
            "Akademiska sjukhuset, Kliniska prÃ¶vingar, Uppsala, Sweden",
            "Royal Cornwall Hospitals NHS Trust, Cornwall, United Kingdom",
            "NHS Greater Glasgow and Clyde (Radiology/Scans Address), Glasgow, United Kingdom",
            "NHS Greater Glasgow and Clyde, The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03395197"
      },
      {
        "-rank": "313",
        "nct_id": "NCT00883909",
        "title": "ARI103094-Follow-Up Study for REDUCE Study Subjects",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Neoplasms, Prostate" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "dutasteride"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "To collect and summarize data for 2 years beyond the prospectively planned 4 year double blind, placebo-controlled REDUCE study.",
            "To collect and summarize data on Adverse Events for 2 years beyond the prospectively planned 4 year double blind, placebo-controlled REDUCE study."
          ]
        },
        "sponsors": { "lead_sponsor": "GlaxoSmithKline" },
        "gender": "Male",
        "min_age": "50 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "2795",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Other",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "103094" },
        "start_date": "April 9, 2009",
        "primary_completion_date": "December 1, 2010",
        "completion_date": "December 29, 2010",
        "study_first_posted": "April 20, 2009",
        "last_update_posted": "July 11, 2017",
        "locations": {
          "location": [
            "GSK Investigational Site, Anchorage, Alaska, United States",
            "GSK Investigational Site, Phoenix, Arizona, United States",
            "GSK Investigational Site, Little Rock, Arkansas, United States",
            "GSK Investigational Site, Anaheim, California, United States",
            "GSK Investigational Site, La Mesa, California, United States",
            "GSK Investigational Site, Laguna Hills, California, United States",
            "GSK Investigational Site, Los Angeles, California, United States",
            "GSK Investigational Site, Los Angeles, California, United States",
            "GSK Investigational Site, Poway, California, United States",
            "GSK Investigational Site, San Bernardino, California, United States",
            "GSK Investigational Site, San Diego, California, United States",
            "GSK Investigational Site, Tarzana, California, United States",
            "GSK Investigational Site, Torrance, California, United States",
            "GSK Investigational Site, Denver, Colorado, United States",
            "GSK Investigational Site, Englewood, Colorado, United States",
            "GSK Investigational Site, Longmont, Colorado, United States",
            "GSK Investigational Site, New Britain, Connecticut, United States",
            "GSK Investigational Site, Washington, D.C., District of Columbia, United States",
            "GSK Investigational Site, Longwood, Florida, United States",
            "GSK Investigational Site, Orlando, Florida, United States",
            "GSK Investigational Site, Pinecrest, Florida, United States",
            "GSK Investigational Site, Pinellas Park, Florida, United States",
            "GSK Investigational Site, Coeur d'Alene, Idaho, United States",
            "GSK Investigational Site, Galesburg, Illinois, United States",
            "GSK Investigational Site, Fort Wayne, Indiana, United States",
            "GSK Investigational Site, Greenwood, Indiana, United States",
            "GSK Investigational Site, Jeffersonville, Indiana, United States",
            "GSK Investigational Site, Overland Park, Kansas, United States",
            "GSK Investigational Site, Wichita, Kansas, United States",
            "GSK Investigational Site, Annapolis, Maryland, United States",
            "GSK Investigational Site, Towson, Maryland, United States",
            "GSK Investigational Site, Boston, Massachusetts, United States",
            "GSK Investigational Site, Watertown, Massachusetts, United States",
            "GSK Investigational Site, Royal Oak, Michigan, United States",
            "GSK Investigational Site, Saint Joseph, Michigan, United States",
            "GSK Investigational Site, Chaska, Minnesota, United States",
            "GSK Investigational Site, Sartell, Minnesota, United States",
            "GSK Investigational Site, Kansas City, Missouri, United States",
            "GSK Investigational Site, Saint Louis, Missouri, United States",
            "GSK Investigational Site, Springfield, Missouri, United States",
            "GSK Investigational Site, Omaha, Nebraska, United States",
            "GSK Investigational Site, West Orange, New Jersey, United States",
            "GSK Investigational Site, Albany, New York, United States",
            "GSK Investigational Site, Garden City, New York, United States",
            "GSK Investigational Site, Great Neck, New York, United States",
            "GSK Investigational Site, New York, New York, United States",
            "GSK Investigational Site, Poughkeepsie, New York, United States",
            "GSK Investigational Site, Staten Island, New York, United States",
            "GSK Investigational Site, Syracuse, New York, United States",
            "GSK Investigational Site, Cary, North Carolina, United States",
            "GSK Investigational Site, Greenville, North Carolina, United States",
            "GSK Investigational Site, Raleigh, North Carolina, United States",
            "GSK Investigational Site, Winston-Salem, North Carolina, United States",
            "GSK Investigational Site, Cincinnati, Ohio, United States",
            "GSK Investigational Site, Columbus, Ohio, United States",
            "GSK Investigational Site, Sheffield, Ohio, United States",
            "GSK Investigational Site, Ponca City, Oklahoma, United States",
            "GSK Investigational Site, Portland, Oregon, United States",
            "GSK Investigational Site, Bala-Cynwyd, Pennsylvania, United States",
            "GSK Investigational Site, Lancaster, Pennsylvania, United States",
            "GSK Investigational Site, Philadelphia, Pennsylvania, United States",
            "GSK Investigational Site, Philadelphia, Pennsylvania, United States",
            "GSK Investigational Site, Pittsburgh, Pennsylvania, United States",
            "GSK Investigational Site, State College, Pennsylvania, United States",
            "GSK Investigational Site, Providence, Rhode Island, United States",
            "GSK Investigational Site, Myrtle Beach, South Carolina, United States",
            "GSK Investigational Site, Simpsonville, South Carolina, United States",
            "GSK Investigational Site, Nashville, Tennessee, United States",
            "GSK Investigational Site, Norfolk, Virginia, United States",
            "GSK Investigational Site, Richmond, Virginia, United States",
            "GSK Investigational Site, Virginia Beach, Virginia, United States",
            "GSK Investigational Site, Seattle, Washington, United States",
            "GSK Investigational Site, Milwaukee, Wisconsin, United States",
            "GSK Investigational Site, Av CÃ³rdoba 2424, Buenos Aires, Argentina",
            "GSK Investigational Site, Capital Federal, Buenos Aires, Argentina",
            "GSK Investigational Site, Capital Federal, Buenos Aires, Argentina",
            "GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina",
            "GSK Investigational Site, Calgary, Alberta, Canada",
            "GSK Investigational Site, Kelowna, British Columbia, Canada",
            "GSK Investigational Site, Surrey, British Columbia, Canada",
            "GSK Investigational Site, Victoria, British Columbia, Canada",
            "GSK Investigational Site, Burlington, Ontario, Canada",
            "GSK Investigational Site, Kingston, Ontario, Canada",
            "GSK Investigational Site, Newmarket, Ontario, Canada",
            "GSK Investigational Site, Oakville, Ontario, Canada",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Toronto, Ontario, Canada",
            "GSK Investigational Site, Waterloo, Ontario, Canada",
            "GSK Investigational Site, Chicoutimi, Quebec, Canada",
            "GSK Investigational Site, Granby, Quebec, Canada",
            "GSK Investigational Site, Greenfield Park, Quebec, Canada",
            "GSK Investigational Site, Laval, Quebec, Canada",
            "GSK Investigational Site, Montreal, Quebec, Canada",
            "GSK Investigational Site, Montreal, Quebec, Canada",
            "GSK Investigational Site, Montreal, Quebec, Canada",
            "GSK Investigational Site, Pointe-Claire, Quebec, Canada",
            "GSK Investigational Site, Santiago, RegiÃ³n Metro De Santiago, Chile",
            "GSK Investigational Site, Helsinki, Finland",
            "GSK Investigational Site, Lappeenranta, Finland",
            "GSK Investigational Site, Oulu, Finland",
            "GSK Investigational Site, Oulu, Finland",
            "GSK Investigational Site, Seinajoki, Finland",
            "GSK Investigational Site, Tampere, Finland",
            "GSK Investigational Site, Auch, France",
            "GSK Investigational Site, Bourgoin-Jallieu, France",
            "GSK Investigational Site, Cannes, France",
            "GSK Investigational Site, Carpentras, France",
            "GSK Investigational Site, CrÃ©teil cedex, France",
            "GSK Investigational Site, Dijon, France",
            "GSK Investigational Site, Le Havre, France",
            "GSK Investigational Site, Lille Cedex, France",
            "GSK Investigational Site, Longjumeau, France",
            "GSK Investigational Site, Lyon Cedex 03, France",
            "GSK Investigational Site, Mantes La Jolie, France",
            "GSK Investigational Site, Montauban, France",
            "GSK Investigational Site, Montpellier, France",
            "GSK Investigational Site, Orleans, France",
            "GSK Investigational Site, Paris Cedex 10, France",
            "GSK Investigational Site, Paris Cedex 18, France",
            "GSK Investigational Site, Ploemeur, France",
            "GSK Investigational Site, Saint Etienne, France",
            "GSK Investigational Site, Saint Martin d'Heres, France",
            "GSK Investigational Site, Suresnes, France",
            "GSK Investigational Site, Toulouse Cedex 4, France",
            "GSK Investigational Site, Tours, France",
            "GSK Investigational Site, Troyes, France",
            "GSK Investigational Site, Backnang, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Bruchsal, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Neckargemuend, Baden-Wuerttemberg, Germany",
            "GSK Investigational Site, Aichach, Bayern, Germany",
            "GSK Investigational Site, Herzogenaurach, Bayern, Germany",
            "GSK Investigational Site, Muenchen, Bayern, Germany",
            "GSK Investigational Site, Nuernberg, Bayern, Germany",
            "GSK Investigational Site, Planegg, Bayern, Germany",
            "GSK Investigational Site, Tirschenreuth, Bayern, Germany",
            "GSK Investigational Site, Hagenow, Brandenburg, Germany",
            "GSK Investigational Site, Hennigsdorf, Brandenburg, Germany",
            "GSK Investigational Site, Oranienburg, Brandenburg, Germany",
            "GSK Investigational Site, Senftenberg, Brandenburg, Germany",
            "GSK Investigational Site, Strausberg, Brandenburg, Germany",
            "GSK Investigational Site, Frankfurt, Hessen, Germany",
            "GSK Investigational Site, Hochheim, Hessen, Germany",
            "GSK Investigational Site, Marburg, Hessen, Germany",
            "GSK Investigational Site, Seligenstadt, Hessen, Germany",
            "GSK Investigational Site, Wismar, Mecklenburg-Vorpommern, Germany",
            "GSK Investigational Site, Buchholz, Niedersachsen, Germany",
            "GSK Investigational Site, Ganderkesee, Niedersachsen, Germany",
            "GSK Investigational Site, Holzminden, Niedersachsen, Germany",
            "GSK Investigational Site, Leer, Niedersachsen, Germany",
            "GSK Investigational Site, Erkrath, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Gelsenkirchen, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Kempen, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Langenfeld, Nordrhein-Westfalen, Germany",
            "GSK Investigational Site, Bad Bergzabern, Rheinland-Pfalz, Germany",
            "GSK Investigational Site, Eisleben, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Gardelegen, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Halle, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Hettstedt, Sachsen-Anhalt, Germany",
            "GSK Investigational Site, Bautzen, Sachsen, Germany",
            "GSK Investigational Site, Chemnitz, Sachsen, Germany",
            "GSK Investigational Site, Doebeln, Sachsen, Germany",
            "GSK Investigational Site, Grimma, Sachsen, Germany",
            "GSK Investigational Site, Leipzig, Sachsen, Germany",
            "GSK Investigational Site, Leipzig, Sachsen, Germany",
            "GSK Investigational Site, Leipzig, Sachsen, Germany",
            "GSK Investigational Site, Leipzig, Sachsen, Germany",
            "GSK Investigational Site, Neustadt, Sachsen, Germany",
            "GSK Investigational Site, Plauen, Sachsen, Germany",
            "GSK Investigational Site, Radebeul, Sachsen, Germany",
            "GSK Investigational Site, Schlema, Sachsen, Germany",
            "GSK Investigational Site, Schwarzenberg, Sachsen, Germany",
            "GSK Investigational Site, Wilkau-Hasslau, Sachsen, Germany",
            "GSK Investigational Site, Zwickau, Sachsen, Germany",
            "GSK Investigational Site, Kiel, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Lauenburg, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Ploen, Schleswig-Holstein, Germany",
            "GSK Investigational Site, Gotha, Thueringen, Germany",
            "GSK Investigational Site, Ilmenau, Thueringen, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Berlin, Germany",
            "GSK Investigational Site, Hamburg, Germany",
            "GSK Investigational Site, Athens, Greece",
            "GSK Investigational Site, Athens, Greece",
            "GSK Investigational Site, Heraklion, Crete, Greece",
            "GSK Investigational Site, Larisa, Greece",
            "GSK Investigational Site, Periohi Dragana, Alexandroupolis, Greece",
            "GSK Investigational Site, Rhodes, Greece",
            "GSK Investigational Site, Thessaloniki, Greece",
            "GSK Investigational Site, Amsterdam, Netherlands",
            "GSK Investigational Site, Arnhem, Netherlands",
            "GSK Investigational Site, Capelle Aan Den Ijssel, Netherlands",
            "GSK Investigational Site, Den Haag, Netherlands",
            "GSK Investigational Site, Den Haag, Netherlands",
            "GSK Investigational Site, EDE, Netherlands",
            "GSK Investigational Site, Eindhoven, Netherlands",
            "GSK Investigational Site, Harderwijk, Netherlands",
            "GSK Investigational Site, Nieuwegein, Netherlands",
            "GSK Investigational Site, Nijmegen, Netherlands",
            "GSK Investigational Site, Nijmegen, Netherlands",
            "GSK Investigational Site, Roermond, Netherlands",
            "GSK Investigational Site, Rotterdam, Netherlands",
            "GSK Investigational Site, Tilburg, Netherlands",
            "GSK Investigational Site, Alava, Spain",
            "GSK Investigational Site, Alcala De Henares (Madrid), Spain",
            "GSK Investigational Site, Badalona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Barcelona, Spain",
            "GSK Investigational Site, Bilbao, Spain",
            "GSK Investigational Site, Ciudad Real, Spain",
            "GSK Investigational Site, Don Benito (Badajoz), Spain",
            "GSK Investigational Site, Galdakano, Spain",
            "GSK Investigational Site, Granada, Spain",
            "GSK Investigational Site, Ibiza, Spain",
            "GSK Investigational Site, La Laguna-Tenerife, Spain",
            "GSK Investigational Site, LogroÃ±o, Spain",
            "GSK Investigational Site, Madrid, Spain",
            "GSK Investigational Site, Madrid, Spain",
            "GSK Investigational Site, Malaga, Spain",
            "GSK Investigational Site, Manacor (Palma de Mallorca), Spain",
            "GSK Investigational Site, Oviedo, Spain",
            "GSK Investigational Site, Pamplona, Spain",
            "GSK Investigational Site, Sagunto, Spain",
            "GSK Investigational Site, San Juan De Alicante, Spain",
            "GSK Investigational Site, San SebastiÃ¡n, Spain",
            "GSK Investigational Site, Sevilla, Spain",
            "GSK Investigational Site, Soria, Spain",
            "GSK Investigational Site, Valencia, Spain",
            "GSK Investigational Site, Valencia, Spain",
            "GSK Investigational Site, Valencia, Spain",
            "GSK Investigational Site, Valladolid, Spain",
            "GSK Investigational Site, BorÃ¥s, Sweden",
            "GSK Investigational Site, Eskilstuna, Sweden",
            "GSK Investigational Site, GÃ¤vle, Sweden",
            "GSK Investigational Site, GÃ¶teborg, Sweden",
            "GSK Investigational Site, GÃ¶teborg, Sweden",
            "GSK Investigational Site, Karlshamn, Sweden",
            "GSK Investigational Site, Kristianstad, Sweden",
            "GSK Investigational Site, MalmÃ¶, Sweden",
            "GSK Investigational Site, Stockholm, Sweden",
            "GSK Investigational Site, Stockholm, Sweden",
            "GSK Investigational Site, UmeÃ¥, Sweden",
            "GSK Investigational Site, VÃ¥lberg, Sweden",
            "GSK Investigational Site, Ã–stersund, Sweden",
            "GSK Investigational Site, Reading, Berkshire, United Kingdom",
            "GSK Investigational Site, Exeter, Devon, United Kingdom",
            "GSK Investigational Site, Plymouth, Devon, United Kingdom",
            "GSK Investigational Site, Buckshaw Village, Chorley, Lancashire, United Kingdom",
            "GSK Investigational Site, Liverpool, Merseyside, United Kingdom",
            "GSK Investigational Site, Nottingham, Nottinghamshire, United Kingdom",
            "GSK Investigational Site, Chichester, Sussex West, United Kingdom",
            "GSK Investigational Site, Bristol, United Kingdom",
            "GSK Investigational Site, Cardiff, United Kingdom",
            "GSK Investigational Site, Clydebank, Glasgow, United Kingdom",
            "GSK Investigational Site, Edgbaston, Birmingham, United Kingdom",
            "GSK Investigational Site, High Heaton, Newcastle upon Tyne, United Kingdom",
            "GSK Investigational Site, Leeds, United Kingdom",
            "GSK Investigational Site, Torquay, United Kingdom",
            "GSK Investigational Site, Waterloo, Liverpool, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00883909"
      },
      {
        "-rank": "314",
        "nct_id": "NCT00950911",
        "title": "Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Bone Metastases in Men With Hormone-Refractory Prostate Cancer",
            "Bone Metastases in Subjects With Advanced Breast Cancer",
            "Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "amg 162"
          }
        },
        "outcome_measures": { "outcome_measure": "Number of Participants Survived" },
        "sponsors": { "lead_sponsor": "Amgen" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "35",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Supportive Care"
          ]
        },
        "other_ids": { "other_id": "20080540" },
        "start_date": "July 2009",
        "primary_completion_date": "February 2012",
        "completion_date": "April 2012",
        "study_first_posted": "August 3, 2009",
        "results_first_posted": "February 11, 2014",
        "last_update_posted": "February 11, 2014",
        "locations": {
          "location": [
            "Research Site, Jindrichuv Hradec, Czech Republic",
            "Research Site, Kromeriz, Czech Republic",
            "Research Site, Olomouc, Czech Republic",
            "Research Site, Praha 1, Czech Republic",
            "Research Site, Praha 4, Czech Republic",
            "Research Site, Praha 4, Czech Republic",
            "Research Site, Praha 5, Czech Republic",
            "Research Site, Praha 6, Czech Republic",
            "Research Site, Zlin, Czech Republic",
            "Research Site, Chichester, United Kingdom",
            "Research Site, Leeds, United Kingdom",
            "Research Site, London, United Kingdom",
            "Research Site, London, United Kingdom",
            "Research Site, Manchester, United Kingdom",
            "Research Site, Northwood, United Kingdom",
            "Research Site, Peterborough, United Kingdom",
            "Research Site, York, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00950911"
      },
      {
        "-rank": "315",
        "nct_id": "NCT00632138",
        "title": "Pelvic Floor Muscle Training and Biofeedback or Standard Therapy in Men Who Have Undergone Radical Prostatectomy or Transurethral Resection of the Prostate",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Nonmalignant Neoplasm",
            "Prostate Cancer",
            "Psychosocial Effects of Cancer and Its Treatment",
            "Sexual Dysfunction",
            "Urinary Incontinence"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Behavioral",
              "#text": "exercise intervention"
            },
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            },
            {
              "-type": "Procedure",
              "#text": "biofeedback"
            },
            {
              "-type": "Procedure",
              "#text": "management of therapy complications"
            },
            {
              "-type": "Procedure",
              "#text": "psychosocial assessment and care"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Subjective report of urinary continence at 12 months",
            "Incremental cost per quality-adjusted year",
            "Subjective report of continence or improvement of urinary incontinence at 3, 6, and 9 months after randomization and improvement at 12 months",
            "Objective report of the number of incontinent episodes in the previous week from the urinary diary",
            "Duration of incontinence based on time of resolution relative to time of operation and randomization",
            "Use of absorbent pads, penile collecting sheath, bladder catheter, or bed/chair pads",
            "Number and type of incontinence products used",
            "Co-existence, cure or development of urgency, or urge incontinence",
            "Urinary frequency",
            "Nocturia",
            "Fecal incontinence (passive or urge)",
            "Other bowel dysfunction (i.e., urgency, constipation, or other bowel diseases)",
            "Sexual function at 12 months including information about erection, ejaculation, retrograde ejaculation, pain, change in sex life, and reason for change",
            "Incontinence-specific quality of life outcome measure using the 10-point scale and ICI questionnaire",
            "General health measures",
            "Need for alternative management for incontinence (e.g., surgery or drugs)",
            "Use of GP, nurse, consultant urologist, or physiotherapist",
            "Visits to GP",
            "Visits to practice nurse",
            "Use of pelvic floor muscle training",
            "Lifestyle changes (i.e., weight, constipation, lifting, coughing, or exercise)",
            "Patient costs (e.g., self care [e.g., pads or laundry], travel to health services, or sick leave)",
            "Cost of conservative trial treatment",
            "Cost of alternative or additional NHS treatments (e.g., pads, catheters, drugs [e.g., adrenergic agonists, anticholinergics, or oral medication for erectile dysfunction], hospital admissions, or further surgery)",
            "Other measures of cost-effectiveness (e.g., incremental cost per additional man continent at 12 months)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Aberdeen Royal Infirmary",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "Male",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "800",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Primary Purpose: Supportive Care"
          ]
        },
        "other_ids": {
          "other_id": [
            "ABROIN-MAPS",
            "CDR0000586420",
            "ISRCTN87696430"
          ]
        },
        "start_date": "January 2005",
        "primary_completion_date": "December 2008",
        "completion_date": "July 2011",
        "study_first_posted": "March 10, 2008",
        "last_update_posted": "August 7, 2013",
        "locations": {
          "location": [
            "Tameside General Hospital, Ashton-Under-Lyne, England, United Kingdom",
            "Southmead Hospital, Bristol, England, United Kingdom",
            "Bristol Royal Infirmary, Bristol, England, United Kingdom",
            "Mid Cheshire Hospitals Trust- Leighton Hopsital, Crewe, England, United Kingdom",
            "Royal Bolton Hospital, Farnworth, England, United Kingdom",
            "King George Hospital, Ilford, Essex, England, United Kingdom",
            "Ipswich Hospital, Ipswich, England, United Kingdom",
            "Airedale General Hospital, Keighley, England, United Kingdom",
            "Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom",
            "St. Mary's Hospital, London, England, United Kingdom",
            "Macclesfield District General Hospital, Macclesfield, England, United Kingdom",
            "James Cook University Hospital, Middlesbrough, England, United Kingdom",
            "Freeman Hospital, Newcastle-Upon-Tyne, England, United Kingdom",
            "Norfolk and Norwich University Hospital, Norwich, England, United Kingdom",
            "Nottingham City Hospital, Nottingham, England, United Kingdom",
            "Berkshire Cancer Centre at Royal Berkshire Hospital, Reading, England, United Kingdom",
            "Queens Hospital, Romford, England, United Kingdom",
            "Hope Hospital, Salford, England, United Kingdom",
            "Royal Hallamshire Hospital, Sheffield, England, United Kingdom",
            "Lister Hospital, Stevenage, England, United Kingdom",
            "Stepping Hill Hospital, Stockport, England, United Kingdom",
            "Taunton and Somerset Hospital, Taunton, England, United Kingdom",
            "Hillingdon Hospital, Uxbridge, England, United Kingdom",
            "New Cross Hospital, Wolverhampton, England, United Kingdom",
            "Yeovil District Hospital, Yeovil, England, United Kingdom",
            "Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom",
            "Ayr Hospital, Ayr, Scotland, United Kingdom",
            "Ninewells Hospital, Dundee, Scotland, United Kingdom",
            "Queen Margaret Hospital - Dunfermline, Dunfermline, Scotland, United Kingdom",
            "Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom",
            "Falkirk and District Royal Infirmary, Falkirk, Scotland, United Kingdom",
            "Southern General Hospital, Glasgow, Scotland, United Kingdom",
            "Inverclyde Royal Hospital, Greenock, Scotland, United Kingdom",
            "Raigmore Hospital, Inverness, Scotland, United Kingdom",
            "Pinderfields General Hospital, Wakefield, Scotland, United Kingdom",
            "Morriston Hospital NHS Trust, West Glamorgen, Scotland, United Kingdom",
            "University Hospital of Wales, Cardiff, Wales, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00632138"
      },
      {
        "-rank": "316",
        "nct_id": "NCT02759783",
        "title": "Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases",
        "acronym": "CORE",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Prostate Cancer",
            "Breast Cancer",
            "Carcinoma, Non-Small-Cell Lung"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Radiation",
              "#text": "SBRT"
            },
            {
              "-type": "Other",
              "#text": "Standard of Care"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Progression Free Survival",
            "Feasibility of recruitment",
            "Feasibility of SBRT delivery",
            "Overall Survival",
            "Local lesion control",
            "Clinical reported acute and late toxicity",
            "Patient reported Quality of Life"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborator": [
            "Institute of Cancer Research, United Kingdom",
            "National Health Service, United Kingdom"
          ]
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 2",
            "Phase 3"
          ]
        },
        "enrollment": "245",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "CCR4323",
            "182152",
            "ISRCTN45961438"
          ]
        },
        "start_date": "November 2016",
        "primary_completion_date": "October 2024",
        "completion_date": "October 2024",
        "study_first_posted": "May 3, 2016",
        "last_update_posted": "August 21, 2019",
        "locations": {
          "location": [
            "Liverpool Hospital, Liverpool, New South Wales, Australia",
            "Calvary Mater Newcastle, Waratah, New South Wales, Australia",
            "Princess Alexandra Hospital, Brisbane, Queensland, Australia",
            "Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia",
            "GenesisCare - Adelaide Radiotherapy Centre, Adelaide, South Australia, Australia",
            "Royal Adelaide Hospital, Adelaide, South Australia, Australia",
            "Austin Health, Melbourne, Victoria, Australia",
            "Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",
            "Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia",
            "Churchill Hospital, Oxford, Oxfordshire, United Kingdom",
            "Mount Vernon Cancer Centre, London, Surrey, United Kingdom",
            "Belfast City Hospital, Belfast, United Kingdom",
            "Queen Elizabeth Hospital, Birmingham, United Kingdom",
            "Bristol Haematology and Oncology Centre, Bristol, United Kingdom",
            "Addenbrooke's Hospital, Cambridge, United Kingdom",
            "The Beatson, Glasgow, United Kingdom",
            "Royal Surrey County Hospital, Guildford, United Kingdom",
            "St James's University Hospital, Leeds, United Kingdom",
            "Leicester Royal Infirmary, Leicester, United Kingdom",
            "Royal Marsden Hospital, London, United Kingdom",
            "Guy's Hospital, London, United Kingdom",
            "St Bartholomew's Hospital, London, United Kingdom",
            "University College Hospital, London, United Kingdom",
            "The Christie Hospital, Manchester, United Kingdom",
            "James Cook University Hospital, Middlesborough, United Kingdom",
            "Freeman Hospital, Newcastle upon Tyne, United Kingdom",
            "Nottingham City Hospital, Nottingham, United Kingdom",
            "Weston Park Hospital, Sheffield, United Kingdom",
            "Royal Marsden Hospital, Sutton, United Kingdom",
            "Clatterbridge Cancer Centre, Wirral, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02759783"
      },
      {
        "-rank": "317",
        "nct_id": "NCT02144051",
        "title": "Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "AZD5312"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Maximum Tolerated Dose of AZD5312 in pts with advanced solid tumours where androgen receptor pathway is a potential factor.",
            "Safety and tolerability of AZD5312 in patients assessed in terms of AEs, labs, vitals, ECGs and conc. med use.",
            "Recommended Phase 2 Dose of AZD5312 in patients with advanced solid tumours where androgen receptor pathway is a potential factor.",
            "Preliminary anti-tumour activity of AZD5312 in patients with advanced solid tumours.",
            "Pharmacokinetics of AZD5312 determined by Cmax",
            "Pharmacokinetics of AZD5312 determined by tmax",
            "Pharmacokinetics of AZD5312 determined by Î»z",
            "Pharmacokinetics of AZD5312 determined by tÂ½Î»z",
            "Pharmacokinetics of AZD5312 determined by (AUC(0-24)",
            "Pharmacokinetics of AZD5312 determined by AUC(0-t)",
            "Pharmacokinetics of AZD5312 determined by AUC",
            "Pharmacokinetics of AZD5312 determined by CL",
            "PK of AZD5312 determined Vz",
            "Pharmacokinetics of AZD5312 determined by MRT",
            "Pharmacokinetics of AZD5312 determined by CLR",
            "Pharmacokinetics of AZD5312 determined by Ae;%dose",
            "Pharmacokinetics of AZD5312 determined by Css max",
            "Pharmacokinetics of AZD5312 determined by tss max",
            "Pharmacokinetics of AZD5312 determined by Css min",
            "Pharmacokinetics of AZD5312 determined byAUCss",
            "Pharmacokinetics of AZD5312 determined by CLss",
            "Pharmacokinetics of AZD5312 determined by RAC"
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "All",
        "min_age": "18 Years",
        "max_age": "130 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "32",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "D5860C00001" },
        "start_date": "May 2014",
        "primary_completion_date": "March 2016",
        "completion_date": "March 2016",
        "study_first_posted": "May 21, 2014",
        "last_update_posted": "July 14, 2016",
        "locations": {
          "location": [
            "Research Site, Sarasota, Florida, United States",
            "Research Site, Nashville, Tennessee, United States",
            "Research Site, Milwaukee, Wisconsin, United States",
            "Research Site, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02144051"
      },
      {
        "-rank": "318",
        "nct_id": "NCT03245736",
        "title": "Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Ovary Cancer",
            "Cervix Cancer",
            "Endometrium Cancer",
            "Bladder Cancer",
            "Prostate Cancer",
            "Esophagus Cancer",
            "Lung Cancer, Nonsmall Cell",
            "Squamous Cell Carcinoma of the Head and Neck"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Tisotumab Vedotin"
          }
        },
        "outcome_measures": { "outcome_measure": "Adverse events" },
        "sponsors": { "lead_sponsor": "Genmab" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "5",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "GCT1015-03" },
        "start_date": "August 23, 2017",
        "primary_completion_date": "January 10, 2019",
        "completion_date": "January 10, 2019",
        "study_first_posted": "August 10, 2017",
        "last_update_posted": "July 25, 2019",
        "locations": {
          "location": [
            "Brian Slomovitz, Miami, Florida, United States",
            "Johann de Bono, Chelsea, United Kingdom",
            "Beatson Cancer Centre, Glasgow, United Kingdom",
            "Fiona Thistlethwaite, Manchester, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03245736"
      },
      {
        "-rank": "319",
        "nct_id": "NCT02804815",
        "title": "Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Cancer",
            "Breast Cancer",
            "Prostate Cancer",
            "Colorectal Cancer",
            "Gastro-oesophageal Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Aspirin 100mg"
            },
            {
              "-type": "Drug",
              "#text": "Aspirin 300mg"
            },
            {
              "-type": "Drug",
              "#text": "Placebo 100mg"
            },
            {
              "-type": "Drug",
              "#text": "Placebo 300mg"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Overall Survival",
            "Invasive disease-free survival (IDFS)",
            "Disease-free survival (DFS)",
            "Overall survival",
            "Biochemical recurrence-free survival (bRFS)",
            "Adherence",
            "Number of participants with serious haemorrhage (grade 3 or above) as measured by CTCAE V4.0. Data will be collected on case report forms.",
            "Number of participants with treatment-related (active drug and placebo) cardiovascular events as assessed by CTCAE v4.0",
            "Number of participants with second malignancies as assessed by case report form",
            "Number of participants that show a decline in cognition and extent of decline as assessed by the Montreal Cognitive Assessment (MoCA)"
          ]
        },
        "sponsors": { "lead_sponsor": "University College, London" },
        "gender": "All",
        "min_age": "16 Years",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 3" },
        "enrollment": "11000",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Triple (Participant, Care Provider, Investigator)",
            "Primary Purpose: Other"
          ]
        },
        "other_ids": {
          "other_id": [
            "14/0814",
            "2013-004398-28",
            "120104"
          ]
        },
        "start_date": "October 2015",
        "primary_completion_date": "October 2026",
        "completion_date": "October 2026",
        "study_first_posted": "June 17, 2016",
        "last_update_posted": "November 22, 2017",
        "locations": {
          "location": [
            "William Harvey Hospital, Ashford, United Kingdom",
            "Stoke Mandeville Hospital, Aylesbury, United Kingdom",
            "Ysbyty Gwynedd, Bangor, United Kingdom",
            "North Devon District Hospital, Barnstaple, United Kingdom",
            "Basildon Hospital, Basildon, United Kingdom",
            "Bedford Hospital, Bedford, United Kingdom",
            "Victoria Hospital, Blackpool, United Kingdom",
            "Pilgrim Hospital, Boston, United Kingdom",
            "Royal Sussex County Hospital, Brighton, United Kingdom",
            "Bristol Haematology & Oncology Centre, Bristol, United Kingdom",
            "West Suffolk Hospital, Bury St Edmunds, United Kingdom",
            "Fairfield Hospital, Bury, United Kingdom",
            "Kent and Canterbury Hospital, Canterbury, United Kingdom",
            "University Hospital of Wales, Cardiff, United Kingdom",
            "Velindre Hospital, Cardiff, United Kingdom",
            "Cumberland Infirmary, Carlisle, United Kingdom",
            "Cheltenham General Hospital, Cheltenham, United Kingdom",
            "University Hospital Coventry and Warwickshire, Coventry, United Kingdom",
            "Darlington Memorial Hospital, Darlington, United Kingdom",
            "Darent Valley Hospital, Dartford, United Kingdom",
            "Glan Clwyd Hospital, Denbighshire, United Kingdom",
            "Western General Hospital, Edinburgh, United Kingdom",
            "North Middlesex Hospital, Edmonton, United Kingdom",
            "Royal Devon and Exeter Hospital, Exeter, United Kingdom",
            "Queen Elizabeth Hospital, Gateshead, United Kingdom",
            "Inverclyde Royal Hospital,, Greenock, United Kingdom",
            "Princess Alexandra Hospital, Harlow, United Kingdom",
            "Northwick Park Hospital, Harrow, United Kingdom",
            "Wycombe Hospital, High Wycombe, United Kingdom",
            "Hinchingbrooke Hospital, Huntingdon, United Kingdom",
            "Raigmore Hospital, Inverness, United Kingdom",
            "Ipswich Hospital, Ipswich, United Kingdom",
            "Airedale General Hospital, Keighley, United Kingdom",
            "Kidderminster General Hospital, Kidderminster, United Kingdom",
            "Kingston Hospital, Kingston, United Kingdom",
            "Royal Lancaster Infirmary, Lancaster, United Kingdom",
            "Lincoln County Hospital, Lincoln, United Kingdom",
            "Royal Marsden Hospital, London And Sutton, United Kingdom",
            "St George's Hospital, London, United Kingdom",
            "Luton & Dunstable Hospital, Luton, United Kingdom",
            "Maidstone Hospital, Maidstone, United Kingdom",
            "Christie Hospital, Manchester, United Kingdom",
            "North Manchester General Hospital, Manchester, United Kingdom",
            "Wythenshawe Hospital,, Manchester, United Kingdom",
            "Queen Elizabeth The Queen Mother Hospital, Margate, United Kingdom",
            "Milton Keynes University Hospital, Milton Keynes, United Kingdom",
            "Northampton General Hospital, Northampton, United Kingdom",
            "George Eliot Hospital, Nuneaton, United Kingdom",
            "Royal Oldham Hospital, Oldham, United Kingdom",
            "Royal Alexandra Hospital, Paisley, United Kingdom",
            "Queen Alexandra Hospital, Portsmouth, United Kingdom",
            "Royal Berkshire Hospital, Reading, United Kingdom",
            "Alexandra Hospital, Redditch, United Kingdom",
            "East Surrey Hospital, Redhill, United Kingdom",
            "Queen's Hospital, Romford, United Kingdom",
            "Salisbury District Hospital, Salisbury, United Kingdom",
            "Weston Park Hospital, Sheffield, United Kingdom",
            "Lister Hospital, Stevenage, United Kingdom",
            "King's Mill Hospital, Sutton-in-Ashfield, United Kingdom",
            "Singleton Hospital, Swansea, United Kingdom",
            "Great Western Hospital, Swindon, United Kingdom",
            "Royal Cornwall Hospital, Truro, United Kingdom",
            "Weston General Hospital, Weston Super Mare, United Kingdom",
            "West Cumberland Hospital, Whitehaven, United Kingdom",
            "Royal Albert Edward Infirmary, Wigan, United Kingdom",
            "Worcestershire Royal Hospital, Worcester, United Kingdom",
            "Wrexham Maelor Hospital, Wrexham, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02804815"
      },
      {
        "-rank": "320",
        "nct_id": "NCT02552121",
        "title": "Tisotumab Vedotin (HuMaxÂ®-TF-ADC) Safety Study in Patients With Solid Tumors",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Ovary Cancer",
            "Cervix Cancer",
            "Endometrium Cancer",
            "Bladder Cancer",
            "Prostate Cancer (CRPC)",
            "Esophagus Cancer",
            "Lung Cancer (NSCLC)"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Tisotumab vedotin (HuMax-TF-ADC)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Part 1: Number of Participants Who Experience at Least One Adverse Event (AE)",
            "Part 2: Number of Participants Who Experience at Least One Adverse Event (AE)",
            "Part 1: Number of Participants Who Experienced at Least One or More Serious Adverse Event (SAE)",
            "Part 2: Number of Participants Reporting One or More Serious Adverse Events (SAE)",
            "Part 1: Number of Participants Reporting One or More Infusion-related Adverse Events",
            "Part 2: Number of Participants Reporting One or More Infusion-related Adverse Events",
            "Part 1: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events",
            "Part 2: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events",
            "Part 1: Number of Participants Reporting One or More Treatment-related Adverse Events",
            "Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events",
            "Part 1: Number of Participants With Markedly Abnormal Laboratory Values",
            "Part 2: Number of Participants With Markedly Abnormal Laboratory Values",
            "Part 1: Number of Participants Who Experienced a Skin Rash",
            "Part 2: Number of Participants Who Experienced a Skin Rash",
            "Part 1: Number of Participants Who Experienced a Bleeding Event",
            "Part 2: Number of Participants Who Experienced a Bleeding Event",
            "Part 1: Number of Participants Who Experienced a Neuropathy Event",
            "Part 2: Number of Participants Who Experienced a Neuropathy Event",
            "Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 1: Cmax: Maximum Observed Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 2: Cmax: Maximum Observed Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 1: Terminal Phase Elimination Half-life (T1/2) for Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 1: Total Clearance (CL) of Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 1: Apparent Volume of Distribution (Vz) for Tisotumab Vedotin (HuMax-TF-ADC)",
            "Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 1: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 2: Cmax: Maximum Observed Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 1: Terminal Phase Elimination Half-life (T1/2) for Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 1 and Part 2: Total Clearance (CL) of Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 1 & Part 2: Apparent Volume of Distribution (Vz) for Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Total HuMax-TF (Conjugated and Non-conjugated)",
            "Part 1: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Free Toxin (MMAE)",
            "Part 2: AUC0-t: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration for Free Toxin (MMAE)",
            "Part 1: Cmax: Maximum Observed Plasma Concentration for Free Toxin (MMAE)",
            "Part 2: Cmax: Maximum Observed Plasma Concentration for Free Toxin (MMAE)",
            "Part 1: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)",
            "Part 2: Tmax: Time to Reach the Maximum Plasma Concentration for Free Toxin (MMAE)",
            "Part 1: Trough Concentration (Ctrough) Steady State Plasma Pharmacokinetic for Free Toxin (MMAE)",
            "Part 1: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result",
            "Part 2: Number of Participants With a Positive Anti-drug Antibody (ADA) Immunogenicity Result",
            "Part 1: Number of Patients Who Experienced Anti-tumor Activity Measured by Tumor Shrinkage",
            "Part 2: Anti-tumor Activity Measured by Percentage of Change in Sum of Lesion Measurements",
            "Part 1: Response Evaluation Based on PSA (Prostate Specific Antigen [Prostate Cancer]): Percentage Change From Baseline to End of Study",
            "Part 1: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study",
            "Part 2: Response Evaluation Based on CA125 (Cancer Antigen 125 [Ovarian and Endometrial Cancer]): Percentage of Change From Baseline to End of Study",
            "Part 1: Best Overall Response (OR)",
            "Part 2: Best Overall Response (OR)",
            "Part 1: Number of Participants Who Experienced Disease Control",
            "Part 2: Number of Participants Who Experienced Disease Control",
            "Part 1: Progression Free Survival (PFS)",
            "Part 2: Progression Free Survival (PFS)",
            "Part 1: Duration of Response",
            "Part 2: Duration of Response"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Genmab",
          "collaborator": "Seattle Genetics, Inc."
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "33",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Sequential Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "GEN702",
            "innovaTV 202"
          ]
        },
        "start_date": "November 30, 2015",
        "primary_completion_date": "December 13, 2017",
        "completion_date": "December 13, 2017",
        "study_first_posted": "September 16, 2015",
        "results_first_posted": "March 12, 2019",
        "last_update_posted": "March 12, 2019",
        "locations": {
          "location": [
            "MD Anderson Cancer Center, Houston, Texas, United States",
            "Institut Jules Bordet, Bruxelles, Brussels, Belgium",
            "Universitaire Ziekenhuizen Leuven, Leuven, Flemish Brabant, Belgium",
            "Grand HÃ´pital de Charleroi, Charleroi, Hainaut, Belgium",
            "CHU de LiÃ¨ge, Liege, LiÃ¨ge, Belgium",
            "CHU UCL Namur - site Godinne, Yvoir, Namur, Belgium",
            "Cliniques Universitaires Saint-Luc, Brussels, Belgium",
            "CHU UCL Namur - Sainte Elisabeth, Namur, Belgium",
            "Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark",
            "Petz AladÃ¡r Megyei OktatÃ³ KÃ³rhÃ¡z, Gyor, Gyor-Moson-Sopron, Hungary",
            "Debreceni Egyetem Klinikai KÃ¶zpont, Debrecen, Hajdu-Bihar, Hungary",
            "Semmelweis Egyetem OnkolÃ³giai KÃ¶zpont, Budapest, Hungary",
            "University College London Hospitals NHS Foundation Trust, London, England, United Kingdom",
            "Sarah Cannon Cancer Center, London, England, United Kingdom",
            "The Christie NHS Foundation Trust, Manchester, England, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom"
          ]
        },
        "study_documents": {
          "study_document": [
            {
              "label": "Study Protocol",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/21/NCT02552121/Prot_000.pdf"
            },
            {
              "label": "Statistical Analysis Plan",
              "url": "https://ClinicalTrials.gov/ProvidedDocs/21/NCT02552121/SAP_001.pdf"
            }
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02552121"
      },
      {
        "-rank": "321",
        "nct_id": "NCT02001623",
        "title": "Tisotumab Vedotin (HuMaxÂ®-TF-ADC) Safety Study in Patients With Solid Tumors",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Ovary Cancer",
            "Cervix Cancer",
            "Endometrium Cancer",
            "Bladder Cancer",
            "Prostate Cancer (CRPC)",
            "Esophagus Cancer",
            "Lung Cancer(NSCLC)",
            "Squamous Cell Carcinoma of the Head and Neck (SCCHN)"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Tisotumab Vedotin (HuMax-TF-ADC)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Adverse events measured throughout the study from first treatment until end of trial.",
            "PK profile of HuMax-TF-ADC after single and multiple infusions",
            "Anti-tumor activity of HuMax-TF-ADC; tumor size (RECIST), PSA and/or CA-125"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Genmab",
          "collaborator": "Seattle Genetics, Inc."
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "195",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "GEN701",
            "innovaTV 201"
          ]
        },
        "start_date": "November 2013",
        "primary_completion_date": "April 24, 2019",
        "completion_date": "April 24, 2019",
        "study_first_posted": "December 5, 2013",
        "last_update_posted": "June 24, 2019",
        "locations": {
          "location": [
            "University of California Irvine Medical Center (UCIMC), Orange, California, United States",
            "Yale Cancer Center, New Haven, Connecticut, United States",
            "University of Miami, Miami, Florida, United States",
            "University Gynecologic Oncology, Atlanta, Georgia, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "Sarah Cannon Research Institute, Nashville, Tennessee, United States",
            "MD Anderson Cancer Center, Houston, Texas, United States",
            "University of Virginia, Charlottesville, Virginia, United States",
            "Universitair Ziekenhuis Antwerpen, Edegem, Antwerpen, Belgium",
            "Universitair Ziekenhuis Leuven, Leuven, Flemish Brabant, Belgium",
            "Grand HÃ´pital de Charleroi, Charleroi, Hainaut, Belgium",
            "Centre Hospitalier Universitaire Ambroise ParÃ©, Mons, Hainaut, Belgium",
            "CHU UCL Namur - site Godinne, Yvoir, Namur, Belgium",
            "Saint-Luc University Hospital, Brussels, Belgium",
            "CHU de LiÃ¨ge, LiÃ¨ge, Belgium",
            "CHU UCL Namur - Sainte Elisabeth, Namur, Belgium",
            "Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark",
            "Herlev and Gentofte Hospital, Herlev, Denmark",
            "Karolinska Universitetssjukhuset, Stockholm, Solna, Sweden",
            "Lungemedicinska Kliniken, LinkÃ¶ping, Sweden",
            "The Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom",
            "University College London Hospitals, London, England, United Kingdom",
            "Sarah Cannon Research Institute - London, London, England, United Kingdom",
            "Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, Newcastle, United Kingdom",
            "The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",
            "Velindre NHS Trust, Cardiff, Wales, United Kingdom",
            "Beatson Cancer Centre, Glasgow, United Kingdom",
            "Guys hospital, London, United Kingdom",
            "The Christie NHS Foundation Trust, Manchester, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02001623"
      },
      {
        "-rank": "322",
        "nct_id": "NCT03330405",
        "title": "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "Avelumab Phase 1b"
            },
            {
              "-type": "Drug",
              "#text": "Talazoparib Phase 1b"
            },
            {
              "-type": "Drug",
              "#text": "Avelumab Phase 2"
            },
            {
              "-type": "Drug",
              "#text": "Talazoparib Phase 2"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Dose Limiting Toxicity (DLT)",
            "Overall Response (OR)",
            "Serum concentrations of avelumab",
            "Anti drug antibody (ADA) levels of avelumab",
            "OR",
            "PSA Tumor Marker",
            "CA-125 Tumor Marker",
            "Biomarker PD-L1",
            "Genomic",
            "Plasma concentrations of talazoparib",
            "Plasma concentration of talazoparib",
            "Neutralizing antibodies (Nab) levels against avelumab.",
            "Time to Tumor Response (TTR)",
            "Duration of response (DR)",
            "Progression-Free Survival (PFS)",
            "Prostate-Specific Antigen (PSA) response",
            "Overall Survival (OS)",
            "Biomarker Tumor Mutational Burden"
          ]
        },
        "sponsors": { "lead_sponsor": "Pfizer" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "242",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Sequential Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "B9991025",
            "2017-001509-33",
            "JAVELIN PARP MEDLEY"
          ]
        },
        "start_date": "October 19, 2017",
        "primary_completion_date": "August 4, 2020",
        "completion_date": "August 4, 2020",
        "study_first_posted": "November 6, 2017",
        "last_update_posted": "September 9, 2019",
        "locations": {
          "location": [
            "Highlands Oncology Group, Fayetteville, Arkansas, United States",
            "Highlands Oncology Group, Rogers, Arkansas, United States",
            "Tower Hematology Oncology Medical Group, Beverly Hills, California, United States",
            "Keck Hospital of USC, Los Angeles, California, United States",
            "LAC+USC Medical Center, Los Angeles, California, United States",
            "USC/Norris Comprehensive Cancer Center/Investigational Drug Services, Los Angeles, California, United States",
            "USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States",
            "Cedars-Sinai Medical Center, Los Angeles, California, United States",
            "Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",
            "Freidenrich Center for Translational Research (CTRU), Palo Alto, California, United States",
            "Stanford Cancer Institute, Stanford, California, United States",
            "Stanford Hospital and Clinics, Stanford, California, United States",
            "Stanford Women's Cancer Center, Stanford, California, United States",
            "Georgetown University Medical Center, Washington, District of Columbia, United States",
            "Massachusetts General Hospital (MGH), Boston, Massachusetts, United States",
            "Massachusetts General Hospital Attn: Svetlana Rashkova, Boston, Massachusetts, United States",
            "Brigham & Women's Hospital, Boston, Massachusetts, United States",
            "Dana Farber Cancer Institute, Attn: Vasilika Koci, PharmD, Boston, Massachusetts, United States",
            "Dana-Farber Cancer Institute, Boston, Massachusetts, United States",
            "Karmanos Cancer Institute, Detroit, Michigan, United States",
            "Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States",
            "University Of Minesota Health: Clinics And Surgery Center, Minneapolis, Minnesota, United States",
            "University of Minesota Medical Center, Fairview IDS Pharmacy, Minneapolis, Minnesota, United States",
            "University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States",
            "Roswell Park Cancer Center Institute, Buffalo, New York, United States",
            "NYU Investigational Pharmacy, New York, New York, United States",
            "NYU Langone Medical Center, New York, New York, United States",
            "NYU Laura and Isaac Perlmutter Cancer Center, New York, New York, United States",
            "Icahn School of Medicine at Mount Sinai, New York, New York, United States",
            "Mount Sinai Hospital- Pharmacy department, New York, New York, United States",
            "Cleveland Clinic Taussig Cancer Center Investigational Pharmacy, Cleveland, Ohio, United States",
            "Cleveland Clinic, Cleveland, Ohio, United States",
            "Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",
            "The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",
            "Concord Repatriation General Hospital, Concord, New South Wales, Australia",
            "Macquarie University, North Ryde, New South Wales, Australia",
            "Northern Cancer Institute, Sydney, New South Wales, Australia",
            "Mater Misericordiae Ltd, Brisbane, Queensland, Australia",
            "Fiona Stanley Hospital, Murdoch, Western Australia, Australia",
            "Institut Jules Bordet, Brussels, Belgium",
            "Cliniques Universitaires Saint-Luc, Bruxelles, Belgium",
            "Grand HÃ´pital de Charleroi - Site Notre-Dame, Charleroi, Belgium",
            "CHU UCL Namur/Site Sainte Elisabeth, Namur, Belgium",
            "Cross Cancer Institute, Edmonton, Alberta, Canada",
            "Princess Margaret Cancer Centre, Toronto, Ontario, Canada",
            "Phase 1 Unit, Department of Oncology, Section 5073., Copenhagen, Denmark",
            "The Experimental Cancer Therapy Unit, Herlev, Denmark",
            "Orszagos Onkologiai Intezet, Budapest, Hungary",
            "CRU Hungary Kft., Miskolc, Hungary",
            "Pecsi Tudomanyegyetem, Pecs, Hungary",
            "Gachon University Gil Medical Center, Incheon, Korea, Republic of",
            "Korea University Anam Hospital, Seoul, Korea, Republic of",
            "Seoul National University Hospital, Seoul, Korea, Republic of",
            "Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",
            "Asan Medical Center, Seoul, Korea, Republic of",
            "Medical Radiological Research Center n.a. A.F. Tsyba -, Obninsk, Kaluga Region, Russian Federation",
            "Medical Radiological Research Center n.a. A.F. Tsyba, Obninsk, Kaluga Region, Russian Federation",
            "GBUZ, Chelyabinsk, Russian Federation",
            "FSBI \"National Medical Research Centre of Oncology n.a., Moscow, Russian Federation",
            "Budget Healthcare Institution of Omsk Region \"Clinical Oncology Dispensary\", Omsk, Russian Federation",
            "State budgetary institution of healthcare of Yaroslavl region \"Clinical oncology hospital\", Yaroslavl, Russian Federation",
            "Nuffield Health Wessex Hospital, Eastleigh, Hampshire, United Kingdom",
            "University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom",
            "University Hospitals of Leicester NHS Trust, Leicester, United Kingdom",
            "UCL Cancer Institute, NIHR UCLH Clinical Research Facility, London, United Kingdom",
            "Freeman Hospital, The Sir Bobby Robson Cancer Trials, Newcastle Upon Tyne, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03330405"
      },
      {
        "-rank": "323",
        "nct_id": "NCT00378482",
        "title": "A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Colorectal Neoplasms",
            "Melanoma",
            "Prostatic Neoplasms",
            "Renal Cell Carcinoma",
            "Neoplasms",
            "Patients Who Have/Have Had Melanoma and Other Tumors"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "CP-675,206 (Tremelimumab)"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety Endpoints: â€¢ Serious adverse events â€¢ Grade 3 or 4 CP-675,206-related adverse events â€¢ Immune-mediated adverse events â€¢ Hypersensitivity reactions to CP-675,206",
            "Efficacy Endpoints: â€¢ Tumor status: alive with disease (AWD) or no evidence of disease (NED) â€¢ Survival"
          ]
        },
        "sponsors": { "lead_sponsor": "AstraZeneca" },
        "gender": "All",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "37",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "D4881C00024",
            "A3671024"
          ]
        },
        "start_date": "March 5, 2007",
        "primary_completion_date": "February 28, 2020",
        "completion_date": "February 28, 2020",
        "study_first_posted": "September 20, 2006",
        "last_update_posted": "June 25, 2019",
        "locations": {
          "location": [
            "Research Site, Little Rock, Arkansas, United States",
            "Research Site, Los Angeles, California, United States",
            "Research Site, Los Angeles, California, United States",
            "Research Site, Aurora, Colorado, United States",
            "Research Site, Aurora, Colorado, United States",
            "Research Site, Tampa, Florida, United States",
            "Research Site, Tampa, Florida, United States",
            "Research Site, Indianapolis, Indiana, United States",
            "Research Site, Ann Arbor, Michigan, United States",
            "Research Site, Ann Arbor, Michigan, United States",
            "Research Site, New York, New York, United States",
            "Research Site, Houston, Texas, United States",
            "Research Site, Madison, Wisconsin, United States",
            "Research Site, Meldola, FC, Italy",
            "Research Site, Newcastle Upon Tyne, United Kingdom",
            "Research Site, Newcastle Upon Tyne, United Kingdom",
            "Research Site, Newecastle Upon Tyne, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00378482"
      },
      {
        "-rank": "324",
        "nct_id": "NCT00737230",
        "title": "Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Cancer" },
        "interventions": {
          "intervention": [
            {
              "-type": "Other",
              "#text": "educational intervention"
            },
            {
              "-type": "Other",
              "#text": "questionnaire administration"
            },
            {
              "-type": "Procedure",
              "#text": "assessment of therapy complications"
            },
            {
              "-type": "Procedure",
              "#text": "gastrointestinal complications management/prevention"
            },
            {
              "-type": "Procedure",
              "#text": "management of therapy complications"
            },
            {
              "-type": "Procedure",
              "#text": "quality-of-life assessment"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Improvement in gastrointestinal symptoms as measured by the modified IBDQ-B score, Rockwood Fecal Incontinence Quality of Life score, St Mark's Incontinence score, and the LENTSOMA score at baseline, 6 months, and 1 year",
            "Quality of life as measured by the modified IBDQ and SF-12 questionnaires at baseline, 6 months, and 1 year",
            "Anxiety and depression scores as measured by the Hospital Anxiety and Depression Scale questionnaire at baseline, 6 months, and 1 year",
            "Other pelvic symptoms (i.e., urinary function as measured by the ICSmaleSF and BFLUTSQ and sexual function as measured by the IIEF-6, ICSsex, and Jensen questionnaires) at baseline, 6 months, and 1 year",
            "Cost-effectiveness of diagnostic tests and treatment compared to \"usual care\" as measured by the ED-5D questionnaire at 6 months and 1 year",
            "Cost-effectiveness of nurse practitioner delivery of algorithm compared to gastroenterologist as measured by the ED-5D questionnaire at 6 months and 1 year",
            "Other unmet healthcare needs as a direct result of pelvic radiotherapy"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Royal Marsden NHS Foundation Trust",
          "collaborator": "National Cancer Institute (NCI)"
        },
        "gender": "All",
        "age_groups": {
          "age_group": [
            "Child",
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "250",
        "funded_bys": { "funded_by": "Other" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Primary Purpose: Health Services Research"
          ]
        },
        "other_ids": {
          "other_id": [
            "CDR0000601214",
            "RMNHS-CCR2918-ORBIT",
            "EU-20868"
          ]
        },
        "start_date": "April 2007",
        "primary_completion_date": "September 2010",
        "completion_date": "July 2012",
        "study_first_posted": "August 18, 2008",
        "last_update_posted": "August 26, 2013",
        "locations": { "location": "Royal Marsden - London, London, England, United Kingdom" },
        "url": "https://ClinicalTrials.gov/show/NCT00737230"
      },
      {
        "-rank": "325",
        "nct_id": "NCT03149549",
        "title": "PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Solid Tumor, Adult",
            "Breast Cancer",
            "Non Small Cell Lung Cancer",
            "Prostate Cancer",
            "Ovarian Cancer",
            "Endometrial Cancer",
            "Head and Neck Cancer",
            "Cholangiocarcinoma"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "CX-2009"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "The number of subjects experiencing a dose limiting toxicity at various dose levels when given CX-2009 as a monotherapy",
            "The percentage of subjects experiencing anti-cancer activity (ORR) at various dose levels when given CX-2009 as a monotherapy"
          ]
        },
        "sponsors": { "lead_sponsor": "CytomX Therapeutics" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "150",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "CTMX-M-2009-001" },
        "start_date": "June 1, 2017",
        "primary_completion_date": "December 2019",
        "completion_date": "December 2021",
        "study_first_posted": "May 11, 2017",
        "last_update_posted": "April 22, 2019",
        "locations": {
          "location": [
            "USC Norris Comprehensive Cancer Center, Los Angeles, California, United States",
            "University of California, Los Angeles (UCLA) - Medical Center, Santa Monica, California, United States",
            "Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States",
            "Rush University Medical Center, Chicago, Illinois, United States",
            "University of Chicago, Chicago, Illinois, United States",
            "Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States",
            "Dana-Farber Cancer Institute, Boston, Massachusetts, United States",
            "Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",
            "Roswell Park Cancer Institute, Buffalo, New York, United States",
            "New York University (NYU) Clinical Cancer Center, New York, New York, United States",
            "Columbia University College of Physicians & Surgeons, Columbia University, New York, New York, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",
            "Providence Portland Medical Center, Portland, Oregon, United States",
            "The Sarah Cannon Research Institute, Nashville, Tennessee, United States",
            "Mary Crowley Medical Research Center, Dallas, Texas, United States",
            "MD Anderson Cancer Center, Houston, Texas, United States",
            "Huntsman Cancer Institute, Salt Lake City, Utah, United States",
            "Viriginia Cancer Specialists, Fairfax, Virginia, United States",
            "Swedish Cancer Institute (SCI), Seattle, Washington, United States",
            "University of Wisconsin-Carbone Cancer Center, Madison, Wisconsin, United States",
            "Amsterdam UMC - Locatie VUmc, Amsterdam, Netherlands",
            "Universitair Medisch Centrum Groningen, Groningen, Netherlands",
            "Clinica Universidad de Navarra, Pamplona, Navarre, Spain",
            "Instituto Catalan de Oncologia - Hospital Duran i Reynals, Barcelona, Spain",
            "Hospital Clinic Barcelona, Barcelona, Spain",
            "Centro Integral Oncologico Clara Campal, Madrid, Spain",
            "Instituto Valenciano de Oncologia, Valencia, Spain",
            "Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom",
            "Sarah Cannon Research Institute UK Limited, London, United Kingdom",
            "Northern Centre for Cancer Care, Newcastle Upon Tyne, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03149549"
      },
      {
        "-rank": "326",
        "nct_id": "NCT01459653",
        "title": "Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor",
        "acronym": "Monitor-GCSF",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Febrile Neutropenia",
            "Cancer",
            "Breast Cancer",
            "Ovarian Cancer",
            "Lung Cancer",
            "Prostate Cancer",
            "Multiple Myeloma",
            "Bladder Cancer",
            "B-cell Lymphoma"
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Chemotherapy Toxicity (%FN Risk)",
            "Cancer Treatment Type - Ever Received During Study",
            "Fever and Infections Ever During the Study",
            "Clinical Events Ever During Study (Frequency Threshold: 5%)",
            "Type of EP2006 Prophylaxis",
            "Type of EP2006 Prophylaxis by Gender",
            "Type of EP 2006 Prophylaxis by Age Group",
            "Type of EP 2006 Prophylaxis by Tumor Type",
            "Concomitant Antibiotic Prophylaxis",
            "EP2006 Dose (All Cycles)",
            "EP2006 Dose (Enrollment Cycle)",
            "EP2006 Dose (Cycle 1)",
            "EP2006 Dose (Cycle 2)",
            "EP2006 Dose (Cycle 3)",
            "EP2006 Dose (Cycle 4)",
            "EP2006 Dose (Cycle 5)",
            "EP2006 Dose (Cycle 6)",
            "EP2006 Dose by Patient Weight: Cycle Level",
            "EP2006 Dose by Tumor Type: Cycle Level",
            "Patient Weight by Tumor Type (Solid Tumor vs. Hematological Tumor)",
            "EP2006 Dose by Chemotherapy Toxicity: Cycle Level",
            "EP2006 Day of Initiation: All Cycles",
            "EP2006 Day of Initiation: Cycle 1",
            "EP2006 Day of Initiation: Cycle 2",
            "EP2006 Day of Initiation: Cycle 3",
            "EP2006 Day of Initiation: Cycle 4",
            "EP2006 Day of Initiation: Cycle 5",
            "EP2006 Day of Initiation: Cycle 6",
            "EP2006 Day of Initiation by Tumor Type (Solid Tumor vs. Hematological Tumor): Cycle Level",
            "EP2006 Day of Initiation by Prophylaxis Type: Cycle Level",
            "EP2006 Day of Initiation by Chemotherapy Toxicity: Cycle Level",
            "EP2006 Treatment Duration in Any Cycle",
            "EP2006 Treatment Duration in Cycle 1",
            "EP2006 Treatment Duration in Cycle 2",
            "EP2006 Treatment Duration in Cycle 3",
            "EP2006 Treatment Duration in Cycle 4",
            "EP2006 Treatment Duration in Cycle 5",
            "EP2006 Treatment Duration in Cycle 6",
            "EP2006 Duration by Tumor Type: Cycle Level",
            "EP2006 Duration by Prophylaxis Type: Cycle Level",
            "EP2006 Duration by Chemotherapy Toxicity: Cycle Level",
            "Percentage of Patients With Each EORTC-identified Risk Factors for FN at Baseline",
            "Percentage of Patients With Each EORTC-identified Risk Factors for FN in Patients With Chemotherapy Risk 10-20% at Baseline",
            "Patient Risk Score (PRS) for All Patients",
            "Patient Risk Score (PRS) for Patients Receiving Chemotherapy With 10-20% FN Risk by Tumor Type",
            "Percentage of Patients With Each Prophylaxis Decision by Chemotherapy-associated FN Risk",
            "Percentage of Patients With Each Chemotherapy Risk Score (CRS) Result by Tumor Type",
            "EP2006 Day of Initiation Relative to Guidelines by Cancer Type",
            "GCSF Initiation Score (GIS)",
            "GCSF Persistence Score (GPS)",
            "GCSF Congruence Score (GCS)",
            "Absolute Neutrophil Count (ANC) at EP2006 Initiation",
            "Absolute Neutrophil Count (ANC) Across All Cycles",
            "Number of Patients With CIN/FN Episodes: Patient Level",
            "CIN/FN Episodes: Cycle Level",
            "Incidence of Outcomes by Chemotherapy Risk: Patient Level",
            "Incidence of CIN/FN-related Chemotherapy Disturbance by EP2006 Prophylaxis Type: Patient Level",
            "Incidence of CIN/FN-related Hospitalization Outcomes by EP2006 Practice Patterns (Relative to Guidelines): Patient Level",
            "Incidence of CIN Grade 4 Episodes by EP2006 Dose: Patient Level",
            "Incidence of Outcomes by Mean GIS: Patient Level",
            "Incidence of Outcomes: Cycles Level",
            "Incidence of Outcomes by Day of Study Drug Initiation: Cycle Level",
            "Incidence of Outcomes by Study Drug Duration: Cycle Level",
            "Number of Patients by Cause of Death",
            "Number of Participants With All-cause Mortality by Any/no Grade 4 CIN and/or FN",
            "Number of Participants With All-cause Mortality by CIN/FN-related Chemotherapy Disturbance",
            "Number of Participants With Cancer-related Mortality by Any/no Grade 4 CIN or FN",
            "Number of Participants With Cancer-related Mortality by Any CIN/FN-related Chemotherapy Disturbance",
            "Number of Participants With Any CIN/FN-related Chemotherapy Disturbance by Prophylaxis Type",
            "Number of Participants With Any CIN/FN-related Chemotherapy Disturbance by Treatment Decision",
            "Predictors of Absolute Neutrophil Count",
            "Patient/Center-level Covariance Parameter Estimates of Absolute Neutrophil Count",
            "EP2006 Day of Initiation: Cycle Distribution",
            "EP2006 Cycles by Treatment Duration",
            "Incidence of Outcomes",
            "Cohort Identification",
            "Characteristics of Clusters: Hemoglobin Study Start",
            "Characteristics of Clusters: ECOG Performance Status",
            "Characteristics of Clusters: Cancer Stage",
            "Characteristics of Clusters: History of Antibiotic Use for CIN",
            "Characteristics of Clusters: Liver, Renal and/or Cardiovascular Disease",
            "Modeling Grade 4 CIN Episode: Cycle Level",
            "Modeling Grade 4 CIN Episode: Patient Level",
            "Modeling FN Episode: Cycle Level",
            "Modeling FN Episode: Patient Level",
            "Modeling CIN/FN-related Hospitalization: Cycle Level",
            "Modeling CIN/FN-related Hospitalization: Patient Level",
            "Modeling CIN/FN-related Chemotherapy Disturbance: Cycle Level",
            "Modeling CIN/FN-related Chemotherapy Disturbance: Patient Level (Patient-level Predictors)",
            "Modeling Composite Outcome (Any of CIN Grade 4, FN, CIN/FN-related Hospitalization, CIN/FN-related Chemotherapy Disturbance): Cycle Level",
            "Modeling Composite Outcome (Any of CIN Grade 4, FN, CIN/FN-related Hospitalization, CIN/FN-related Chemotherapy Disturbance): Patient Level",
            "Patient-level Predictors for All-cause Mortality",
            "Patient-level Predictor for Cancer-related Mortality"
          ]
        },
        "sponsors": { "lead_sponsor": "Sandoz" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "enrollment": "1496",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Observational",
        "study_designs": {
          "study_design": [
            "Observational Model: Case-Only",
            "Time Perspective: Prospective"
          ]
        },
        "other_ids": { "other_id": "EP06-502" },
        "start_date": "March 2010",
        "primary_completion_date": "August 2013",
        "completion_date": "August 2013",
        "study_first_posted": "October 25, 2011",
        "results_first_posted": "July 7, 2015",
        "last_update_posted": "January 11, 2016",
        "locations": {
          "location": [
            "Sandoz Investigational Site, Innsbruck, Austria",
            "Sandoz Investigational Site, Kufstein, Austria",
            "Sandoz Investigational Site, Leoben, Austria",
            "Sandoz Investigational Site, Deurne, Belgium",
            "Sandoz Investigational Site, Tournai, Belgium",
            "Sandoz Investigational Site, Cheb, Czech Republic",
            "Sandoz Investigational Site, Chomutov, Czech Republic",
            "Sandoz Investigational Site, Praha, Czech Republic",
            "Sandoz Investigational Site, Teplice, Czech Republic",
            "Sandoz Investigational Site, VÃ­tkovice, Czech Republic",
            "Sandoz Investigational Site, Agen, France",
            "Sandoz Investigational Site, Arras, France",
            "Sandoz Investigational Site, Avignon, France",
            "Sandoz Investigational Site, Bayonne, France",
            "Sandoz Investigational Site, Beauvais Cedex, France",
            "Sandoz Investigational Site, Blois, France",
            "Sandoz Investigational Site, Bois Guillaume Cedex, France",
            "Sandoz Investigational Site, Bordeaux Cedex, France",
            "Sandoz Investigational Site, Bordeaux, France",
            "Sandoz Investigational Site, Boulogne Sur Mer cedex, France",
            "Sandoz Investigational Site, Brest Cedex 2, France",
            "Sandoz Investigational Site, Colmar CEDEX, France",
            "Sandoz Investigational Site, CompiÃ¨gne, France",
            "Sandoz Investigational Site, Gap Cedex, France",
            "Sandoz Investigational Site, Grenoble, France",
            "Sandoz Investigational Site, Libourne, France",
            "Sandoz Investigational Site, Lille Cedex, France",
            "Sandoz Investigational Site, Lyon 8, France",
            "Sandoz Investigational Site, Lyon Cedex 03, France",
            "Sandoz Investigational Site, Marseille, France",
            "Sandoz Investigational Site, Melun, France",
            "Sandoz Investigational Site, Montauban Cedex, France",
            "Sandoz Investigational Site, Montpellier Cedex 5, France",
            "Sandoz Investigational Site, Nancy, France",
            "Sandoz Investigational Site, NÃ®mes Cedex 9, France",
            "Sandoz Investigational Site, OrlÃ©ans, France",
            "Sandoz Investigational Site, Paris Cedex 12, France",
            "Sandoz Investigational Site, Paris Cedex 15, France",
            "Sandoz Investigational Site, Perpignan, France",
            "Sandoz Investigational Site, Pierre BÃ©nite, France",
            "Sandoz Investigational Site, Poitiers, France",
            "Sandoz Investigational Site, Reims Cedex, France",
            "Sandoz Investigational Site, Sainteâ€Foyâ€lÃ¨sâ€Lyon, France",
            "Sandoz Investigational Site, Strasbourg Cedex, France",
            "Sandoz Investigational Site, Berlin, Germany",
            "Sandoz Investigational Site, Chemnitz, Germany",
            "Sandoz Investigational Site, Coburg, Germany",
            "Sandoz Investigational Site, Dortmund, Germany",
            "Sandoz Investigational Site, Erlangen, Germany",
            "Sandoz Investigational Site, Frankfurt, Germany",
            "Sandoz Investigational Site, Gera, Germany",
            "Sandoz Investigational Site, Hamburg, Germany",
            "Sandoz Investigational Site, Heinsberg, Germany",
            "Sandoz Investigational Site, Herne, Germany",
            "Sandoz Investigational Site, Langen, Germany",
            "Sandoz Investigational Site, Lehrte, Germany",
            "Sandoz Investigational Site, Leipzig, Germany",
            "Sandoz Investigational Site, LÃ¼beck, Germany",
            "Sandoz Investigational Site, Munich, Germany",
            "Sandoz Investigational Site, MÃ¼lheim a. d. Ruhr, Germany",
            "Sandoz Investigational Site, Weiden, Germany",
            "Sandoz Investigational Site, Wismar, Germany",
            "Sandoz Investigational Site, Witten, Germany",
            "Sandoz Investigational Site, Wolfsburg, Germany",
            "Sandoz Investigational Site, WÃ¼rselen, Germany",
            "Sandoz Investigational Site, Budapest, Hungary",
            "Sandoz Investigational Site, Gyor, Hungary",
            "Sandoz Investigational Site, Kecskemet, Hungary",
            "Sandoz Investigational Site, Pecs, Hungary",
            "Sandoz Investigational Site, Szekszard, Hungary",
            "Sandoz Investigational Site, Szombathely, Hungary",
            "Sandoz Investigational Site, Avezzano, Italy",
            "Sandoz Investigational Site, Avola, Italy",
            "Sandoz Investigational Site, Bari, Italy",
            "Sandoz Investigational Site, Campobasso, Italy",
            "Sandoz Investigational Site, Colleferro, Italy",
            "Sandoz Investigational Site, Cosenza, Italy",
            "Sandoz Investigational Site, Cuneo, Italy",
            "Sandoz Investigational Site, Frosinone, Italy",
            "Sandoz Investigational Site, Gaeta, Italy",
            "Sandoz Investigational Site, Genova, Italy",
            "Sandoz Investigational Site, La Spezia, Italy",
            "Sandoz Investigational Site, Matera, Italy",
            "Sandoz Investigational Site, Milano, Italy",
            "Sandoz Investigational Site, Monza, Italy",
            "Sandoz Investigational Site, Rieti, Italy",
            "Sandoz Investigational Site, Roma, Italy",
            "Sandoz Investigational Site, S. Giovanni Rotondo, Italy",
            "Sandoz Investigational Site, Sora, Italy",
            "Sandoz Investigational Site, Torino, Italy",
            "Sandoz Investigational Site, BiaÅ‚ystok, Poland",
            "Sandoz Investigational Site, BrzozÃ³w, Poland",
            "Sandoz Investigational Site, Bydgoszcz, Poland",
            "Sandoz Investigational Site, GdaÅ„sk, Poland",
            "Sandoz Investigational Site, Krakow, Poland",
            "Sandoz Investigational Site, KrakÃ³w, Poland",
            "Sandoz Investigational Site, Lublin, Poland",
            "Sandoz Investigational Site, PrzemyÅ›l, Poland",
            "Sandoz Investigational Site, Warszawa, Poland",
            "Sandoz Investigational Site, Wodzislaw Slaski, Poland",
            "Sandoz Investigational Site, Bucuresti, Romania",
            "Sandoz Investigational Site, Suceava, Romania",
            "Sandoz Investigational Site, Timisoara, Romania",
            "Sandoz Investigational Site, Tirgu Mures, Romania",
            "Sandoz Investigational Site, Alicante, Spain",
            "Sandoz Investigational Site, Barcelona, Spain",
            "Sandoz Investigational Site, Benidorm Alicante, Spain",
            "Sandoz Investigational Site, Bilbao, Spain",
            "Sandoz Investigational Site, Donostiaâ€San SebastiÃ¡n, Spain",
            "Sandoz Investigational Site, La Rioja, Spain",
            "Sandoz Investigational Site, Lorca, Spain",
            "Sandoz Investigational Site, Pamplona, Spain",
            "Sandoz Investigational Site, Valencia, Spain",
            "Sandoz Investigational Site, Vitoriaâ€Gasteiz, Spain",
            "Sandoz Investigational Site, Genolier, Switzerland",
            "Sandoz Investigational Site, Zurich, Switzerland",
            "Sandoz Investigational Site, Cottingham, United Kingdom",
            "Sandoz Investigational Site, Liverpool, United Kingdom",
            "Sandoz Investigational Site, Rotherham, United Kingdom",
            "Sandoz Investigational Site, Scunthorpe, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01459653"
      },
      {
        "-rank": "327",
        "nct_id": "NCT00428220",
        "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Metastatic Breast Cancer",
            "Advanced Breast Cancer",
            "Metastatic Castration Resistant Prostate Cancer",
            "Metastatic Renal Cell Cancer",
            "Non-Small Cell Lung Cancer",
            "Thyroid Cancer",
            "Advanced/Metastatic Non-Small Cell Lung Cancer",
            "Advanced Gastric Cancer",
            "Gastrointestinal Stromal Tumor",
            "Hepatocellular Carcinoma",
            "Pancreatic Islet Cell Carcinoma",
            "Pancreatic Neuroendocrine Tumor"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "sunitinib"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With Treatment-emergent Adverse Events (AEs) (All Causalities)",
            "Number of Participants With Treatment-emergent AEs (Treatment-Related)"
          ]
        },
        "sponsors": { "lead_sponsor": "Pfizer" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Not Applicable" },
        "enrollment": "223",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "A6181114",
            "2006-006538-16"
          ]
        },
        "start_date": "July 2007",
        "primary_completion_date": "August 2014",
        "completion_date": "September 2014",
        "study_first_posted": "January 29, 2007",
        "results_first_posted": "November 6, 2015",
        "last_update_posted": "June 27, 2019",
        "locations": {
          "location": [
            "Emory University, Winship Cancer Institute, Atlanta, Georgia, United States",
            "Investigational Drug Service, Atlanta, Georgia, United States",
            "The Emory Clinic, Atlanta, Georgia, United States",
            "Loyola University Medical Center, Maywood, Illinois, United States",
            "University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",
            "Siteman Cancer Center-West County, Creve Coeur, Missouri, United States",
            "Barnes Jewish Hospital, Saint Louis, Missouri, United States",
            "Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States",
            "Siteman Cancer Center, Saint Peters, Missouri, United States",
            "Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "Northwest Cancer Specialists, P.C., Portland, Oregon, United States",
            "Northwest Cancer Specialists, P.C., Portland, Oregon, United States",
            "US Oncology Research and Clinical Pharmacy (Drug Shipment Only), Fort Worth, Texas, United States",
            "The Strelitz Diabetes Institute of Eastern Virginia Medical School, Norfolk, Virginia, United States",
            "Clinica Viedma, Viedma, Rio Negro, Argentina",
            "Centro OncolÃ³gico Rosario, Rosario, Santa FÃ©, Argentina",
            "Instituto Oncologico de Cordoba, Nueva Cordoba, Argentina",
            "Centro Medico San Roque, San Miguel de Tucuman, Argentina",
            "Royal Brisbane & Women's Hospital, Herston, Queensland, Australia",
            "Royal Adelaide Hospital, Department of Medical Oncology, Adelaide, South Australia, Australia",
            "Austin Health, Heidelberg, Victoria, Australia",
            "Royal Melbourne Hospital, Parkville, Victoria, Australia",
            "Mount Medical Centre, Perth, Western Australia, Australia",
            "Hopital Erasme / Gastroenterologie, Bruxelles, Belgium",
            "Cliniques Universitaires Saint Luc / GastroentÃ©rologie, Bruxelles, Belgium",
            "Cliniques Universitaires Saint-Luc, Oncologie, Bruxelles, Belgium",
            "UZ Gasthuisberg, Department Internal Medicine - Gastroenterology - Gastro-intestinal Oncology, Leuven, Belgium",
            "Centre Hospitalier Universitaire de Liege, Liege, Belgium",
            "Algemeen Ziekenhuis Nikolaas, Sint-Niklaas, Belgium",
            "AZ Sint-Augustinus, Oncologisch Centrum, Wilrijk, Belgium",
            "Hospital SÃ£o Lucas da PUCRS, Porto Alegre, RS, Brazil",
            "Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil",
            "Sociedade Beneficente de Senhoras Hospital Sirio Libanes, Sao Paulo, SP, Brazil",
            "Centro de Oncologia do Instituto de Radiologia, SÃ£o Paulo, SP, Brazil",
            "BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada",
            "QEII Health Sciences Centre - Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada",
            "QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia, Canada",
            "QEII Health Sciences Centre - Halifax Infirmary Site, Halifax, Nova Scotia, Canada",
            "London Regional Cancer Program, London, Ontario, Canada",
            "Princess Margaret Hospital, Toronto, Ontario, Canada",
            "CHUM, Hopital Saint-Luc, Montreal, Quebec, Canada",
            "Royal Victoria Hospital, Montreal, Quebec, Canada",
            "Fundacion Centro de Investigacion Clinica CIC, Medellin, Anquioquia, Colombia",
            "Hospital Universitario San Vicente de Paul, Medellin, Antioquia, Colombia",
            "Clinica Astorga, Medellin, Antioquia, Colombia",
            "Centre Antoine Lacassagne, Nice, Cedex 02, France",
            "Hopital Beaujon, Clichy Cedex, Cedex, France",
            "Groupe Hospitalier Cochin, Cancer Quest AP-HP, Paris, Cedex, France",
            "CHU-HÃ´pital Jean Minjoz, Besancon, France",
            "Hopital Saint-Andre, Bordeaux Cedex, France",
            "Centre Jean Perrin, Clermont Ferrand, France",
            "Polyclinique du Bois, Lille, France",
            "Centre Oscar Lambret, Lille, France",
            "Hopital Edouard Herriot, Lyon Cedex 03, France",
            "Centre Leon Berard, Lyon, France",
            "Chu La Timone, Marseille Cedex 5, France",
            "Clinique Hartmann, Neuilly Sur Seine, France",
            "Hopital Saint-Antoine, Paris, France",
            "Centre Eugene Marquis, Rennes Cedex, France",
            "Klinik fuer Innere Medizin, Gastroenterologie, Onkologie, Endokrinologie, Bad Berka, Germany",
            "Universitaetsklinikum CharitÃ©, Campus Virchow Klinikum, Berlin, Germany",
            "eps - early phase GmbH, Jena, Germany",
            "Frauenaerzte Pruener Gang, Kiel, Germany",
            "Klinik fuer Frauenheilkunde und Geburtshilfe, Universitaetsklinikum Schleswig-Holstein, Luebeck, Germany",
            "Universitaetsklinikum Schleswig-Holstein, Campus Luebeck, Luebeck, Germany",
            "Universitaetsklinikum Giessen und Marburg, Standort Marburg, Marburg, Germany",
            "Rhoen Klinikum Meiningen, Gynaekologie und Geburtshilfe, Meiningen, Germany",
            "Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universitaet Muenchen, Muenchen, Germany",
            "Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong",
            "Queen Mary Hospital, Hong Kong, Hong Kong",
            "Division of Haematology/Oncology, Department of Medicine, Queen Mary Hospital,, Hong Kong, Hong Kong",
            "Queen Elizabeth Hospital, Department of Clinical Oncology, Kowloon, Hong Kong",
            "Tuen Mun Hospital, Department of Clinical Oncology, Tuen Mun, New Territories, Hong Kong",
            "UNIMED Medical Institute, Wan Chai,, Hong Kong",
            "National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of",
            "Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",
            "Seoul National University Hospital / Department of Internal Medecine, Seoul, Republic Of Korea, Korea, Republic of",
            "Asan Medical Center, Division of Oncology, Department of Internal Medicine, Seoul, Republic Of Korea, Korea, Republic of",
            "Yeungnam University Medical Center/Department of Internal medicine, Daegu, Korea, Republic of",
            "Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of",
            "Hospital Universitario Dr. Jose Eleuterio Gonzalez Centro Universitario contra el cancer, Monterrey, Nuevo Leon, Mexico",
            "Hospital Christus Muguerza del Parque, Chihuahua, Mexico",
            "Cancer Care Clinic, Quezon City, Metro Manila, Philippines",
            "National University Hospital/Department of Heamatology-Oncology, Singapore, Singapore",
            "National Cancer Center/Department of Medical Oncology, Singapore, Singapore",
            "Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain",
            "Fundacion Hospital Alcorcon, Alcorcon, Madrid, Spain",
            "Servicio de Oncologia, Barcelona, Spain",
            "Complexo Hospitalario Universitario A CoruÃ±a, La CoruÃ±a, Spain",
            "Centro Oncologico Md Anderson International EspaÃ±a, Madrid, Spain",
            "Hospital Clinico San Carlos, Madrid, Spain",
            "Hospital 12 de Octubre, Madrid, Spain",
            "Hospital Universitario La Paz, Madrid, Spain",
            "Chang Gung Medical Foundation, Linkou Branch, Kuei-Shan, Taoyuan, Taiwan",
            "Changhua Christian Hospital, Changhua, Taiwan",
            "Chung-Ho Memorial Hospital, Kaohsiung Medical University/Department of Surgery, Kaohsiung, Taiwan",
            "Chi Mei Medical Center, Liouying, Liouying Township, Tainan,, Taiwan",
            "Taichung Veterans General Hospital, Department of Surgery, Taichung, Taiwan",
            "National Taiwan University Hospital/Department of Oncology, Taipei, Taiwan",
            "Koo Foundation Sun Yat-Sen Cancer Center, Div. of Hematology/Oncology, Taipei, Taiwan",
            "Taipei Veterans General Hospital, Taipei, Taiwan",
            "Chi-Mei Medical Center, YungKang City, Tainan, Taiwan",
            "Division of Surgery and Oncology, Liverpool, Merseyside, United Kingdom",
            "Deparment of Cardiology, Glasgow, United Kingdom",
            "The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom",
            "Dainton Building, Leeds, United Kingdom",
            "St James' Institute of Oncology, Leeds, United Kingdom",
            "Management Offices, 4th Floor, Thomas Guy House, London, United Kingdom",
            "Royal Marsden Hospital, London, United Kingdom",
            "Department of Medical Oncology, Manchester, United Kingdom",
            "Cardiology Department, Wythenshawe Hospital, Manchester, United Kingdom",
            "Nottingham City Hospital, Nottingham, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00428220"
      },
      {
        "-rank": "328",
        "nct_id": "NCT00739453",
        "title": "A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (TarcevaÂ®)",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Advanced Solid Tumors" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "OSI-906"
            },
            {
              "-type": "Drug",
              "#text": "erlotinib"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Determine the maximum tolerated dose (MTD) and recommended phase 2 dose of OSI-906 and erlotinib",
            "Safety profile, Pharmacokinetic profile, pharmacodynamic activity, Preliminary antitumor activity"
          ]
        },
        "sponsors": { "lead_sponsor": "Astellas Pharma Inc" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "95",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "OSI-906-103",
            "2008-001743-20"
          ]
        },
        "start_date": "October 2008",
        "primary_completion_date": "August 2011",
        "completion_date": "December 2011",
        "study_first_posted": "August 21, 2008",
        "last_update_posted": "December 22, 2011",
        "locations": {
          "location": [
            "University of Colorado Health Science Center, Aurora, Colorado, United States",
            "Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States",
            "Hudson-Webber Cancer Research Center, Karmanos Cancer Institute, Detroit, Michigan, United States",
            "University of Oxford Department of Medical Oncology, Oxford, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00739453"
      },
      {
        "-rank": "329",
        "nct_id": "NCT01286987",
        "title": "Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "Has Results",
        "conditions": {
          "condition": [
            "Advanced or Recurrent Solid Tumors",
            "Breast Neoplasms",
            "Ovarian Cancer, Epithelial",
            "Ewing Sarcoma",
            "Small Cell Lung Carcinoma",
            "Prostate Cancer",
            "Pancreas Cancer"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Talazoparib"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of Participants With Objective Response",
            "Number of Participants With Best Overall Response",
            "Progression-Free Survival (PFS)",
            "Duration of Response",
            "Number of Participants With Stable Disease",
            "Part 1: Maximum Tolerated Dose (MTD)",
            "Part 1: Recommended Part 2 Dose of Talazoparib"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Pfizer",
          "collaborator": "Medivation, Inc."
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "113",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "PRP-001",
            "2010-023062-40",
            "C3441007"
          ]
        },
        "start_date": "January 3, 2011",
        "primary_completion_date": "March 31, 2015",
        "completion_date": "January 30, 2017",
        "study_first_posted": "February 1, 2011",
        "results_first_posted": "January 10, 2019",
        "last_update_posted": "January 10, 2019",
        "locations": {
          "location": [
            "Scottsdale Healthcare, Scottsdale, Arizona, United States",
            "Virginia G. Piper Cancer Center Research Pharmacy, Scottsdale, Arizona, United States",
            "(IRB# 12-000131) Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States",
            "Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",
            "UCLA Hematology/Oncology, Los Angeles, California, United States",
            "Westwood Bowyer Clinic, Peter Morton Medical Building, Los Angeles, California, United States",
            "Santa Monica - UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States",
            "UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States",
            "IU Health Bloomington Hospital, Bloomington, Indiana, United States",
            "Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States",
            "Investigational Drug Services, Indianapolis, Indiana, United States",
            "IU Health University Hospital, Indianapolis, Indiana, United States",
            "University of Michigan Health System, Ann Arbor, Michigan, United States",
            "The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",
            "Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01286987"
      },
      {
        "-rank": "330",
        "nct_id": "NCT03170960",
        "title": "Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Urothelial Carcinoma",
            "Renal Cell Carcinoma",
            "Non-Small Cell Lung Cancer",
            "Castration-resistant Prostate Cancer",
            "Triple Negative Breast Cancer",
            "Ovarian Cancer",
            "Endometrial Cancer",
            "Hepatocellular Carcinoma",
            "Gastric Cancer",
            "Gastroesophageal Junction Adenocarcinoma",
            "Colorectal Cancer",
            "Head and Neck Cancer",
            "Differentiated Thyroid Cancer",
            "Lower Esophageal Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "cabozantinib"
            },
            {
              "-type": "Drug",
              "#text": "atezolizumab"
            },
            {
              "-type": "Drug",
              "#text": "cabozantinib"
            },
            {
              "-type": "Drug",
              "#text": "cabozantinib"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Dose Escalation: MTD/Recommended Dose",
            "Dose Expansion: ORR",
            "Incidence and severity of nonserious AEs and SAEs (Safety)"
          ]
        },
        "sponsors": { "lead_sponsor": "Exelixis" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "1732",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Sequential Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "XL184-021" },
        "start_date": "September 5, 2017",
        "primary_completion_date": "March 2020",
        "completion_date": "December 2020",
        "study_first_posted": "May 31, 2017",
        "last_update_posted": "August 21, 2019",
        "locations": {
          "location": [
            "Exelixis Clinical Site #53, Gilbert, Arizona, United States",
            "Exelixis Clinical Site #18, Phoenix, Arizona, United States",
            "Exelixis Clinical Site #1, Duarte, California, United States",
            "Exelixis Clinical Site #20, La Jolla, California, United States",
            "Exelixis Clinical Site #46, Los Angeles, California, United States",
            "Exelixis Clinical Site #51, Newport Beach, California, United States",
            "Exelixis Clinical Site #21, Stanford, California, United States",
            "Exelixis Clinical Site #34, Denver, Colorado, United States",
            "Exelixis Clinical Site #50, Denver, Colorado, United States",
            "Exelixis Clinical Site #42, New Haven, Connecticut, United States",
            "Exelixis Clinical Site #48, Washington, District of Columbia, United States",
            "Exelixis Clinical Site #16, Jacksonville, Florida, United States",
            "Exelixis Clinical Site #32, Harvey, Illinois, United States",
            "Exelixis Clinical Site #23, Fairway, Kansas, United States",
            "Exelixis Clinical Site #24, New Orleans, Louisiana, United States",
            "Exelixis Clinical Site #10, Boston, Massachusetts, United States",
            "Exelixis Clinical Site #3, Detroit, Michigan, United States",
            "Exelixis Clinical Site #17, Rochester, Minnesota, United States",
            "Exelixis Clinical Site #43, Kansas City, Missouri, United States",
            "Exelixis Clinical Site #35, Omaha, Nebraska, United States",
            "Exelixis Clinical Site #38, Camden, New Jersey, United States",
            "Exelixis Clinical Site #27, East Brunswick, New Jersey, United States",
            "Exelixis Clinical Site #31, New Brunswick, New Jersey, United States",
            "Exelixis Clinical Site #37, Bronx, New York, United States",
            "Exelixis Clinical Site #40, East Setauket, New York, United States",
            "Exelixis Clinical Site #11, New York, New York, United States",
            "Exelixis Clinical Site #49, Columbus, Ohio, United States",
            "Exelixis Clinical Site #6, Oklahoma City, Oklahoma, United States",
            "Exelixis Clinical Site #45, Portland, Oregon, United States",
            "Exelixis Clinical Site #41, Bethlehem, Pennsylvania, United States",
            "Exelixis Clinical Site #15, Philadelphia, Pennsylvania, United States",
            "Exelixis Clinical Site #13, Dallas, Texas, United States",
            "Exelixis Clinical Site #26, Dallas, Texas, United States",
            "Exelixis Clinical Site #29, Houston, Texas, United States",
            "Exelixis Clinical Site #39, Houston, Texas, United States",
            "Exelixis Clinical Site #44, Houston, Texas, United States",
            "Exelixis Clinical Site #33, Lubbock, Texas, United States",
            "Exelixis Clinical Site #2, Salt Lake City, Utah, United States",
            "Exelixis Clinical Site #30, Blacksburg, Virginia, United States",
            "Exelixis Clinical Site #14, Charlottesville, Virginia, United States",
            "Exelixis Clinical Site #52, Gent, Belgium",
            "Exelixis Clinical Site #54, Leuven, Belgium",
            "Exelixis Clinical Site #8, Villejuif, Cedex, France",
            "Exelixis Clinical Site #7, Paris, France",
            "Exelixis Clinical Site #36, TÃ¼bingen, Germany",
            "Exelixis Clinical Site #47, Rozzano, Milano, Italy",
            "Exelixis Clinical Site #25, Milano, Italy",
            "Exelixis Clinical Site #4, Milano, Italy",
            "Exelixis Clinical Site #12, Nijmegen, Gelderland, Netherlands",
            "Exelixis Clinical Site #28, Barcelona, Spain",
            "Exelixis Clinical Site #9, Barcelona, Spain",
            "Exelixis Clinical Site #22, Madrid, Spain",
            "Exelixis Clinical Site #5, Madrid, Spain",
            "Exelixis Clinical Site #19, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03170960"
      },
      {
        "-rank": "331",
        "nct_id": "NCT03150810",
        "title": "Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",
        "status": {
          "-open": "Y",
          "#text": "Recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Locally Advanced or Metastatic Solid Tumors" },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "BGB-290"
            },
            {
              "-type": "Drug",
              "#text": "Temozolomide"
            },
            {
              "-type": "Drug",
              "#text": "BGB-290"
            },
            {
              "-type": "Drug",
              "#text": "Temozolomide"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE.",
            "Incidence, nature and severity of adverse events as assessed by CTCAE.",
            "Pharmacokinetic (PK) parameters (Cmax) of BGB-290 and TMZ.",
            "Pharmacokinetic (PK) parameters (Tmax) of BGB-290 and TMZ.",
            "Objective response rate (ORR) as assessed using RECIST.",
            "Duration of response (DOR).",
            "Disease control rate (DCR)",
            "Progression free survival (PFS)",
            "Overall survival (OS)"
          ]
        },
        "sponsors": {
          "lead_sponsor": "BeiGene USA, Inc.",
          "collaborator": [
            "Myriad Genetics, Inc.",
            "BeiGene"
          ]
        },
        "gender": "All",
        "min_age": "18 Years",
        "max_age": "99 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "150",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Non-Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "BGB-290-103",
            "2017-001553-14"
          ]
        },
        "start_date": "July 12, 2017",
        "primary_completion_date": "July 1, 2020",
        "completion_date": "August 1, 2020",
        "study_first_posted": "May 12, 2017",
        "last_update_posted": "July 19, 2019",
        "locations": {
          "location": [
            "START Midwest, Grand Rapids, Michigan, United States",
            "Washington University, Saint Louis, Missouri, United States",
            "Mount Sinai - PRIME, New York, New York, United States",
            "Montefiore Medical Center PRIME, New York, New York, United States",
            "Sarah Cannon Research Institute (Tennessee Oncology), Nashville, Tennessee, United States",
            "Mary Crowley Cancer Research Centers, Dallas, Texas, United States",
            "University of Texas- MD Anderson Cancer Center, Houston, Texas, United States",
            "Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia",
            "Saint Vincent's Hospital, Darlinghurst, New South Wales, Australia",
            "Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",
            "Hospital Universitari Vall d'Hebron, Barcelona, Spain",
            "Institut Catalia d'oncologia- l'Hospitalet, Barcelona, Spain",
            "START Madrid-FundaciÃ³n JimÃ©nez DÃ­az, Madrid, Spain",
            "START-Madrid, Madrid, Spain",
            "Hospital ClÃ­nico de Valencia, Valencia, Spain",
            "Sarah Cannon Research Institute UK, London, Greater London, United Kingdom",
            "Sir Bobby Robson Cancer Trials Research Centre, Newcastle, Newcastle Upon Tyne, United Kingdom",
            "Beatson West of Scotland Cancer Centre, Glasgow, Strathclyde, United Kingdom",
            "University College London Hospitals, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT03150810"
      },
      {
        "-rank": "332",
        "nct_id": "NCT02797964",
        "title": "A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "SRA737"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Number of subjects with adverse events as assessed by CTCAE 4.03",
            "Maximum tolerated dose of SRA737",
            "Recommended Phase 2 dose of SRA737",
            "Objective response rate of SRA737"
          ]
        },
        "sponsors": { "lead_sponsor": "Sierra Oncology, Inc." },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": {
          "phase": [
            "Phase 1",
            "Phase 2"
          ]
        },
        "enrollment": "112",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Sequential Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "SRA737-01" },
        "start_date": "July 2016",
        "primary_completion_date": "September 2019",
        "completion_date": "April 2020",
        "study_first_posted": "June 14, 2016",
        "last_update_posted": "March 7, 2019",
        "locations": {
          "location": [
            "Royal Marsden Hospital, Sutton, London, United Kingdom",
            "Belfast City Hospital, Belfast, Northern Ireland, United Kingdom",
            "Oxford University Hospitals, Headington, Oxford, United Kingdom",
            "Velindre Cancer Centre - Cardiff, Cardiff, Whitchurch, United Kingdom",
            "The Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom",
            "Western General Hospital, Edinburgh, United Kingdom",
            "The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom",
            "The Leeds Teaching Hospitals of St James University Hospital, Leeds, United Kingdom",
            "University Hospitals of Leicester, Leicester, United Kingdom",
            "Guy's and St. Thomas, London, United Kingdom",
            "Sarah Cannon Research Institute, London, United Kingdom",
            "University College London Hospitals, London, United Kingdom",
            "The Christie, Manchester, United Kingdom",
            "Freeman Hospital, Newcastle upon Tyne, United Kingdom",
            "Sheffield Teaching Hospitals, Sheffield, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT02797964"
      },
      {
        "-rank": "333",
        "nct_id": "NCT00413075",
        "title": "Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Solid Tumor",
            "Lymphoma"
          ]
        },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "oral belinostat"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort",
            "Determine the pharmacokinetics of oral PXD101 when dosed once or twice daily at various dose levels",
            "Explore anti-tumor activity",
            "Determine the safety, tolerability, and anti-tumor activity of orally administered PXD101 to patients with lymphoma"
          ]
        },
        "sponsors": {
          "lead_sponsor": "Onxeo",
          "collaborator": "Spectrum Pharmaceuticals, Inc"
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "121",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "PXD101-CLN-9" },
        "start_date": "June 2006",
        "primary_completion_date": "August 2011",
        "completion_date": "August 2011",
        "study_first_posted": "December 19, 2006",
        "last_update_posted": "July 8, 2015",
        "locations": {
          "location": [
            "Yale New Haven Hospital, New Haven, Connecticut, United States",
            "Columbia University - Herbert Irving Cancer Center, New York, New York, United States",
            "New York University Cancer Institute, New York, New York, United States",
            "M.D. Anderson Cancer Center, Houston, Texas, United States",
            "Research Facility, Copenhagen, Denmark",
            "Research Facility, London, Surrey, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00413075"
      },
      {
        "-rank": "334",
        "nct_id": "NCT00940225",
        "title": "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies",
        "status": {
          "-open": "N",
          "#text": "Completed"
        },
        "study_results": "No Results Available",
        "conditions": {
          "condition": [
            "Solid Tumors",
            "Cancer"
          ]
        },
        "interventions": {
          "intervention": [
            {
              "-type": "Drug",
              "#text": "XL184"
            },
            {
              "-type": "Drug",
              "#text": "Placebo"
            },
            {
              "-type": "Drug",
              "#text": "XL184"
            },
            {
              "-type": "Drug",
              "#text": "XL184"
            }
          ]
        },
        "outcome_measures": {
          "outcome_measure": [
            "To evaluate the efficacy of XL184 in subjects with advanced solid tumors",
            "Safety and tolerability of XL184 in subjects with advanced solid tumors",
            "To correlate the pathway dysfunction of disease-related genes or proteins such as MET and downstream signaling molecules with clinical outcome",
            "To further characterize the pharmacokinetic (PK) and pharmacodynamic parameters of XL184"
          ]
        },
        "sponsors": { "lead_sponsor": "Exelixis" },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 2" },
        "enrollment": "730",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Allocation: Randomized",
            "Intervention Model: Parallel Assignment",
            "Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": { "other_id": "XL184-203" },
        "start_date": "August 2009",
        "primary_completion_date": "May 2013",
        "completion_date": "June 2014",
        "study_first_posted": "July 15, 2009",
        "last_update_posted": "February 19, 2015",
        "locations": {
          "location": [
            "Pinnacle Oncology of Arizona, Scottsdale, Arizona, United States",
            "University of California Davis Cancer Center, Sacramento, California, United States",
            "University of California, San Francisco, San Francisco, California, United States",
            "Stanford University Medical Center, Stanford, California, United States",
            "Rocky Mountain Cancer Centers, Denver, Colorado, United States",
            "Yale University School of Medicine, New Haven, Connecticut, United States",
            "Florida Cancer Specialists, Fort Meyers, Florida, United States",
            "Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States",
            "Medical College of Georgia, Augusta, Georgia, United States",
            "Central Indiana Cancer Centers, Indianapolis, Indiana, United States",
            "Tulane University Health Sciences Center, New Orleans, Louisiana, United States",
            "Dana Farber Cancer Center, Boston, Massachusetts, United States",
            "University of Michigan Health System, Ann Arbor, Michigan, United States",
            "Wayne State University, Detroit, Michigan, United States",
            "University of Missouri Health Care, Columbia, Missouri, United States",
            "Kansas City Cancer Center, Lee's Summit, Missouri, United States",
            "Midwest Hematology Oncology Consultants, St. Louis, Missouri, United States",
            "Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",
            "NYU Clinical Cancer Center, New York, New York, United States",
            "Memorial Sloan Kettering Cancer Center, New York, New York, United States",
            "Duke University Medical Center, Durham, North Carolina, United States",
            "Ohio State University GYN Oncology, Hilliard, Ohio, United States",
            "University of Oklahoma, Oklahoma City, Oklahoma, United States",
            "Cancer Care Associates, Tulsa, Oklahoma, United States",
            "Northwest Cancer Specialists, Tualatin, Oregon, United States",
            "University of Pennsylvania, Philadelphia, Pennsylvania, United States",
            "Cancer Centers of the Carolinas, ITOR, Greenville, South Carolina, United States",
            "Sarah Cannon Research Institute, Nashville, Tennessee, United States",
            "Texas Oncology - Central Austin Cancer Center, Austin, Texas, United States",
            "Mary Crowley Medical Research Center, Dallas, Texas, United States",
            "University of Texas, M. D., Anderson Cancer Center, Houston, Texas, United States",
            "Tyler Cancer Center, Tyler, Texas, United States",
            "Fairfax Northern Virginia Hematology Oncology, Fairfax, Virginia, United States",
            "University of Washington, Seattle, Washington, United States",
            "One Study Location, Brussels, Belgium",
            "One Study Location, Jette, Belgium",
            "Multiple Study Locations, Leuven, Belgium",
            "Liege, Belgium",
            "One Study Location, Mons, Belgium",
            "One Study Location, Jerusalem, Israel",
            "One Study Location, Tel Aviv, Israel",
            "One Study Location, Tel-Hashomer, Israel",
            "One Study Location, Zerifin, Israel",
            "Multiple Study Locations, Tainan City, Taiwan",
            "Taipei, Taiwan",
            "Taoyuan County, Taiwan",
            "One Study Location, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT00940225"
      },
      {
        "-rank": "335",
        "nct_id": "NCT01772004",
        "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)",
        "status": {
          "-open": "N",
          "#text": "Active, not recruiting"
        },
        "study_results": "No Results Available",
        "conditions": { "condition": "Solid Tumors" },
        "interventions": {
          "intervention": {
            "-type": "Drug",
            "#text": "Avelumab"
          }
        },
        "outcome_measures": {
          "outcome_measure": [
            "Dose Limiting Toxicity",
            "Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) for Efficacy Expansion Cohorts",
            "Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0",
            "Pharmacokinetic parameters: AUC (0-t), AUC (0-infinity), Î»z, Cmax, Tmax, T(1/2) of avelumab",
            "Immune-related Best Overall Response (irBOR) and Best Overall Response (BOR) according to modified Immune-related response criteria (irRC) and RECIST version 1.1, respectively",
            "Immune-related Progression-Free Survival (irPFS) time and Progression-Free Survival (PFS) Time according to modified irRC and RECIST version 1.1 , respectively",
            "Overall Survival Time",
            "Pharmacodynamic profile of avelumab to include serum levels of cytokines",
            "Number of subjects with anti-avelumab antibodies",
            "Level of PD-L1 tumor expression",
            "Unconfirmed response according to RECIST 1.1 per investigator assessment for Primary expansion cohort",
            "Duration of response according to modified irRC and RECIST 1.1 per investigator assessment",
            "Progression Free Survival time according to RECIST 1.1 for Efficacy Expansion Cohorts",
            "Duration of response according to RECIST 1.1 for Efficacy Expansion cohorts",
            "Confirmed BOR as per RECIST 1.1 as adjudicated by an Independent Endpoint Review Committee (IERC) for secondary urothelial carcinoma cohort"
          ]
        },
        "sponsors": {
          "lead_sponsor": "EMD Serono",
          "collaborator": "Merck KGaA, Darmstadt, Germany"
        },
        "gender": "All",
        "min_age": "18 Years",
        "age_groups": {
          "age_group": [
            "Adult",
            "Older Adult"
          ]
        },
        "phases": { "phase": "Phase 1" },
        "enrollment": "1758",
        "funded_bys": { "funded_by": "Industry" },
        "study_types": "Interventional",
        "study_designs": {
          "study_design": [
            "Intervention Model: Single Group Assignment",
            "Masking: None (Open Label)",
            "Primary Purpose: Treatment"
          ]
        },
        "other_ids": {
          "other_id": [
            "EMR 100070-001",
            "2013-002834-19"
          ]
        },
        "start_date": "January 31, 2013",
        "primary_completion_date": "October 31, 2019",
        "completion_date": "October 31, 2019",
        "study_first_posted": "January 21, 2013",
        "last_update_posted": "July 18, 2019",
        "locations": {
          "location": [
            "For Recruiting Locations in the United States, please Contact U.S. Medical Information, Rockland, Massachusetts, United States",
            "Please contact the Communication Center, Leuven, Belgium",
            "Please contact the Communication Center, Praha, Czechia",
            "Please contact the Communication Center, Paris, France",
            "Please contact the Communication Center, Berlin, Germany",
            "Please contact the Communication Center, Budapest, Hungary",
            "Please contact the Communication Center, Seoul, Korea, Republic of",
            "Please contact the Communication Center, Warszawa, Poland",
            "Please contact the Communication Center, Taipei, Taiwan",
            "Please contact the Communication Center, London, United Kingdom"
          ]
        },
        "url": "https://ClinicalTrials.gov/show/NCT01772004"
      }
    ]
  }
}